{
  "drugs": [
    {
      "heading": "Epratuzumab\u2013SN-38",
      "names": [
        "Epratuzumab\u2013SN-38"
      ],
      "phases": [],
      "conditions": [
        "Lymphoma and Leukemia"
      ],
      "targets": [
        "CD22"
      ],
      "payload": [
        "Irinotecan metabolite (SN38)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Immunomedics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMGN-242",
      "names": [
        "C-242 DM4",
        "C242 maytansinoid-4",
        "CANTUZUMAB RAVTANSINE",
        "HUC242-DM4",
        "IMGN242",
        "huC242-DM4",
        "C242 DM4",
        "Cantuzumab Ravtansine",
        "Maytasinoid DM4-d humanised monoclonal  huC242",
        "IMGN-242"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Gastric (stomach) cancers",
        "Neoplasms (Stomach)",
        "Solid Tumors",
        "Gastric cancer (metastatic or locally advanced)",
        "GE Junction Cancer (metastatic or locally advanced)"
      ],
      "targets": [
        "CanAg",
        "CanAg-expressing cancers, including gastric cancer; MUC1 sialylated carbohydrate tumour-associated (CA242, cancer antigen 242)"
      ],
      "payload": [
        "Maytansinoid (DM4)  ravtansine (DM4).",
        "maytansinoid DM4"
      ],
      "linker": [
        "A reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "huC242"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL1742998",
      "locations": [],
      "trials": [],
      "# conditions": 5,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMGN 289",
      "names": [
        "IMGN 289"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "EGFRviii"
      ],
      "payload": [
        "DM1"
      ],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "IMMUNOGEN"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "RG-7636 | Anti-ETBR",
      "names": [
        "RG7636",
        "DEDN6526A",
        "DEDN-6526A",
        "Anti-ETBR",
        "RG-7636"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "melanoma, cutaneous, mucosal and ocular",
        "Unresectable, malignant melanoma",
        "Melanoma"
      ],
      "targets": [
        "Endothelin receptor ETB"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Peptide linker (Seattle Genetics)",
        "Peptide linker (using Seattle Genetics ADC technology)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": "CHEMBL2109282",
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SC16LD6.5",
      "names": [
        "ROVALPITUZUMAB TESIRINE",
        "Rovalpituzumab tesirine",
        "SC 002",
        "SC0002",
        "SC16LD6.5 SC0001-SCX",
        "Rova-T",
        "SC0001",
        "sc0001-SCX",
        "SC16LD6.5",
        "SC-002",
        "SC-16LD6.5"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Small Cell Lung Cancer",
        "Cancer",
        "Recurrent Small Cell Lung Cancer",
        "Cancers, small cell lung (SCLC)",
        "Small Cell Lung Carcinoma"
      ],
      "targets": [
        "DLL3 (delta-like 3) | delta like canonical Notch ligand 3",
        "SC-16 (anti-Fyn3)"
      ],
      "payload": [
        "pyrrolobenzodiazepine (PDB) dimer SCX",
        "D6.5 (DNA damaging agent)"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8).   An average of 2 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa SC16"
      ],
      "Max Phase": "3",
      "developers": [
        "Stemcentrx",
        "AbbVie"
      ],
      "chembl": "CHEMBL3990011",
      "trials": [
        "NCT01901653",
        "NCT03543358",
        "NCT02674568",
        "NCT03086239",
        "NCT03061812",
        "NCT02874664",
        "NCT03000257"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Finland",
        "Croatia",
        "Belarus",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# conditions": 6,
      "# locations": 35,
      "# trials": 7
    },
    {
      "heading": "AGS 16C3F | AGS-16M8F | AGS-16C3F",
      "names": [
        "AGS 16C3F",
        "AGS-16M8F",
        "AGS-16C3F"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Renal Cell Carcinoma / Liver carcinoma / Prostate Cancer",
        "Prostate Cancer",
        "Liver Carcinoma"
      ],
      "targets": [
        "AGS-16/ENPP3  (Ectonucleotide pyrophosphatase/phosphodiesterase family member 3)"
      ],
      "payload": [
        "Monomethyl auristatin\u00a0F (MMAF)"
      ],
      "linker": [
        "Non-cleavable maleimido-caproyl linker"
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Astellas",
        "Agensys"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17551",
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "iratumumab | MDX-060",
      "names": [
        "iratumumab",
        "MDX-060"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Hodgkin's disease",
        "Lymphoma",
        "Non-Hodgkin's lymphoma"
      ],
      "targets": [
        "CD30"
      ],
      "payload": [
        "-"
      ],
      "linker": [
        "-"
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb",
        "Medarex"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "KTN0182A",
      "names": [
        "KTN0182A"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Broad Range of Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Pyrrolobenzodiazepine (PBD)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Kolltan"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "RG7986",
      "names": [
        "RG7986"
      ],
      "phases": [],
      "conditions": [
        "Non-Hodgkin lymphoma"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Genentech",
        "Roche"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EDO-772P/B776",
      "names": [
        "EDO-772P/B776"
      ],
      "phases": [],
      "conditions": [
        "Ovarian cancer"
      ],
      "targets": [
        "A fragment of the cancer antigen 125 (CA125)"
      ],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Mundipharma EDO"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EDO-B278",
      "names": [
        "EDO-B278"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "Human tissue factor"
      ],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Mundipharma EDO"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CD22-4AP",
      "names": [
        "CD22-4AP",
        "TRPH-222",
        "Anti-CD22 -  TRPH-222 ANTI-CD22 ADC TRPH-222 TRPH222"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin\u2019s lymphoma Acute lymphoid leukemia B-cell Lymphoma",
        "Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Marginal Zone",
        "Lymphoma, B-Cell",
        "Non-Hodgkin Lymphoma, Acute Lymphoid Lymphoma",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "targets": [
        "CD22",
        "CD22, a B-cell-restricted sialogycoprotein that is an important modulator of B-cell signaling and survival. CD22 is expressed on nearly all B-cell malignancies and is a validated ADC target."
      ],
      "payload": [
        "Site-specific conjugation of a maytansine payload."
      ],
      "linker": [
        "A 4AP non-cleavable linker."
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "Site-specific modified humanized antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Catalent",
        "Triphase Accelerator Corporation"
      ],
      "ttd": "DQC80I",
      "trials": [
        "NCT03682796"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "# conditions": 9,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "KTN0125",
      "names": [
        "KTN0125"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [],
      "payload": [
        "a thienoindole cytotoxic agent (TEI)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "An anti-ALK monoclonal antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Kolltan"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | RG-7841 | Anti-Ly6E | DLYE5953A",
      "names": [
        "Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841",
        "RG-7841",
        "Anti-Ly6E",
        "DLYE5953A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors Breast Non Small Lung Cancer"
      ],
      "targets": [
        "Lymphocyte antigen 6 complex locus E (LY6E)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Seagen",
        "Roche"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CDX014 | CR014-vcMMAE | CR 014-vcMMAE | CDX-014",
      "names": [
        "CDX014",
        "CR014-vcMMAE",
        "CR 014-vcMMAE",
        "CDX-014"
      ],
      "phases": [
        "Preclinical",
        "Phase 1/2"
      ],
      "conditions": [
        "Kidney cancer, Clear Cell Renal Cell Carcinoma, Papillary Cell Renal Cell Carcinoma, Renal cell carcinoma (RCC)"
      ],
      "targets": [
        "Transmembrane protein T-cell immunoglobulin mucin-1 (TIM-1); HAVCR1 (hepatitis A virus cellular receptor 1; KIM-1"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Celldex"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Hertuzumab Vedotin | Hertuzumab-vcMMAE",
      "names": [
        "Hertuzumab Vedotin",
        "Hertuzumab-vcMMAE"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Breast Cancer and HER2 positive human gastric cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor-2 (HER2)"
      ],
      "payload": [
        "monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "MC-Val-Cit-PAB"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Hertuzumab"
      ],
      "Max Phase": "2",
      "developers": [
        "Rongchang",
        "MabPlex"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "B7-H3 ADC | DS-7300",
      "names": [
        "B7-H3 ADC",
        "DS-7300"
      ],
      "phases": [
        "Preclinical",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Solid Tumors",
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "ttd": "DT8R1L",
      "trials": [
        "NCT05280470"
      ],
      "locations": [
        "Czechia",
        "China",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 2,
      "# locations": 24,
      "# trials": 1
    },
    {
      "heading": "ADCT-502",
      "names": [
        "ADCT-502"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Epidermal growth factor receptor 2 (HER2)-expressing solid tumors"
      ],
      "targets": [
        "HER2 (Human epidermal growth factor receptor 2)"
      ],
      "payload": [
        "Tesirine, a clinically-validated, potent pyrrolobenzodiazepine (PBD-based) dimer toxin (SG3249).   Drug-to-antibody ratio is 1.7"
      ],
      "linker": [
        "A cathepsin B-cleavable valine-alanine linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A engineered version of the humanized anti-HER2 IgG1 trastuzuma"
      ],
      "Max Phase": "1",
      "developers": [
        "ADC Therapeutics"
      ],
      "ttd": "D05CRY",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SGN-CD19B",
      "names": [
        "SGN-CD19B"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma, Diffuse large B-cell lymphoma, Follicular lymphoma (high grade)"
      ],
      "targets": [
        "CD19; a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, expressed on B-cell-derived cancers."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer, SGD-1882"
      ],
      "linker": [
        "A maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker"
      ],
      "domain": [
        "Hematology"
      ],
      "antibody": [
        "hBU12ec"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SC-006 | SC006",
      "names": [
        "SC-006",
        "SC006"
      ],
      "phases": [],
      "conditions": [
        "Colorectal Cancer"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Stemcentrx",
        "AbbVie"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AMG172",
      "names": [
        "AMG172",
        "AMG 172"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Clear Cell Renal Carcinoma",
        "Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Renal Cell Adenocarcinoma",
        "Renal Cell Carcinoma (RCC) | Kidney Cancer"
      ],
      "targets": [
        "CD70 (CD27L); A Type II transmembrane protein and member of the Tumor Necrosis Factor (TNF) family"
      ],
      "payload": [
        "Maytansine DM1"
      ],
      "linker": [
        "Non-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Amgen"
      ],
      "trials": [
        "NCT01497821"
      ],
      "locations": [
        "Germany",
        "France",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "BIIB015 | BIIB-015",
      "names": [
        "BIIB015",
        "BIIB-015"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "CFC1B (Cripto)"
      ],
      "payload": [
        "Maytansinoid derivative, DM4"
      ],
      "linker": [
        "MCC"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Biogen"
      ],
      "chembl": "CHEMBL2109575",
      "trials": [
        "NCT00674947"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "IMGN388 | CNTO 95-DM4 | CNTO 365 | IMGN-388",
      "names": [
        "IMGN388",
        "IMGN-388",
        "CNTO 365",
        "CNTO 95-DM4"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors/endothelial cells"
      ],
      "targets": [
        "alpha-V (?v) integrin"
      ],
      "payload": [
        "DM4"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL2109633",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "hLL1 | CD74-DOX | IMMU-110 | hLL1-DOX | Milatuzumab doxorubicin | MEDI-115",
      "names": [
        "hLL1",
        "IMMU-110",
        "CD74-DOX",
        "hLL1-DOX",
        "Milatuzumab doxorubicin",
        "MEDI-115"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Disease, Hodgkin",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Breast Cancer",
        "Chronic lymphocytic leukemia",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "HER2-Positive Metastatic Breast Cancer",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Peripheral T-cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Hodgkin Disease",
        "B-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "T-Cell Lymphoma",
        "Classical Hodgkin Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "HER2-positive Early Breast Cancer",
        "Large B-Cell Lymphoma",
        "Non-Hodgkin\u2019s lymphoma",
        "Multiple myeloma",
        "Double-Expressor Lymphoma",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Anaplastic Large-Cell Lymphoma",
        "Breast Neoplasms",
        "Stage III Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Lymphoma, T-cell",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "CD74 (major histocompatibility class II invariant chain, MH2)"
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [
        "Hydrazone"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Immunomedics"
      ],
      "trials": [
        "NCT03991884",
        "NCT01920932",
        "NCT03755804",
        "NCT05600686",
        "NCT01992653",
        "NCT06486441",
        "NCT01060904",
        "NCT03274492",
        "NCT04203641",
        "NCT03646123",
        "NCT04914741",
        "NCT02292979",
        "NCT05404945",
        "NCT02605915",
        "NCT06377566",
        "NCT03726879",
        "NCT05113251",
        "NCT01712490",
        "NCT04790903",
        "NCT02505269",
        "NCT05673785",
        "NCT06112379",
        "NCT04569032",
        "NCT06132958",
        "NCT04685616",
        "NCT03677141",
        "NCT01777152",
        "NCT06340568",
        "NCT06047080",
        "NCT02734771",
        "NCT02979522",
        "NCT01534078",
        "NCT04594798",
        "NCT03467373",
        "NCT01309789",
        "NCT01966471",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# conditions": 44,
      "# locations": 54,
      "# trials": 37
    },
    {
      "heading": "RG7450 | Vandortuzumab vedotin | DSTP3086S | RG-7450 | MSTP2109A | DSTP-3086S | Anti-STEAP1 ADC",
      "names": [
        "RG7450",
        "Vandortuzumab vedotin",
        "DSTP3086S",
        "RG-7450",
        "VANDORTUZUMAB VEDOTIN",
        "MSTP2109A",
        "DSTP-3086S",
        "Anti-STEAP1 ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Metastatic castration-resistant Prostate Cancer"
      ],
      "targets": [
        "Anti-six transmembrane epithelial antigen of the prostate 1 (STEAP1); a membrane protein overexpressed in prostate cancer (PRSS24)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": "CHEMBL3833306",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DFRF 4539A | RG 7598 | RG-7598 | RG7598",
      "names": [
        "RG 7598",
        "RG7598",
        "DFRF 4539A",
        "DFRF4539A",
        "RG-7598"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma"
      ],
      "targets": [],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": "CHEMBL2109279",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Vorsetuzumab mafodotin | SGN-75",
      "names": [
        "Vorsetuzumab mafodotin",
        "VORSETUZUMAB MAFODOTIN",
        "SGN-75"
      ],
      "phases": [
        "Phase 1/1",
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "CD70-positive hematologic malignancies",
        "Glioblastoma Multiforme",
        "Non-Hodgkin\u2019s lymphoma (NHL)",
        "renal cell carcinoma (RCC)",
        "Malignant Glioma",
        "Carcinoma, Renal Cell"
      ],
      "targets": [
        "CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)"
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)"
      ],
      "linker": [
        "Maleimidocaproyl\u00a0 Phenylalanine\u00a0(a non-cleavable maleimidocaproyl (mc) linker).   An average of 3-5 cysteinyl"
      ],
      "domain": [
        "Oncology | Hematology | Immunology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Seagen"
      ],
      "chembl": "CHEMBL2108672",
      "trials": [
        "NCT01015911",
        "NCT02590263"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "# conditions": 7,
      "# locations": 2,
      "# trials": 2
    },
    {
      "heading": "PF06688992 | GD3 ADC | PF-06688992",
      "names": [
        "PF06688992",
        "GD3 ADC",
        "PF-06688992"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Melanoma",
        "Multiple myeloma"
      ],
      "targets": [
        "Ganglioside GD3; a surface antigen expressed on many malignant melanoma cells"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Pfizer"
      ],
      "trials": [
        "NCT03159117"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "SGN-CD352a",
      "names": [
        "SGN-CD352a"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma (MM)"
      ],
      "targets": [
        "CD352; SLAMF6 (Signaling Lymphocyte Activation Molecule family member 6), a type 1 membrane protein in the SLAM family of immunoreceptors."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "Protease Cleavable Linker"
      ],
      "domain": [
        "Oncology, Hematology"
      ],
      "antibody": [
        "An anti-CD352 engineered cysteine (EC-mAb) h20F3ec"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AbGn-110",
      "names": [
        "AbGn-110"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Breast cancer Gastric (stomach) cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Biobetter cytotoxic payload"
      ],
      "linker": [
        "Proprietary linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "AbGenomics BV"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AbGn-108",
      "names": [
        "AbGn-108"
      ],
      "phases": [],
      "conditions": [
        "Lung cancer Ovarian cancer"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "AbGenomics BV"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AB-3A4 | AB-3A4-ADC | AB-3A4-vcMMAE | AB-3A4 ADC",
      "names": [
        "AB-3A4",
        "AB-3A4-ADC",
        "AB-3A4-vcMMAE",
        "AB-3A4 ADC"
      ],
      "phases": [],
      "conditions": [
        "Prostate",
        "Triple Negative Breast Cancer (TNBC)",
        "Ovarian cancer"
      ],
      "targets": [
        "KAAG-1 (kidney-associated antigen-1); KAAG1-positive cell lines including, SKOV-3 (ovarian), MDA-MB-231 (TNBC) and PC-3 (prostate)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Alethia"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ALT-Q5",
      "names": [
        "ALT-Q5"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Alteogen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "RG 7600 | DMOT-4039A | DMOT4039A | RG7600",
      "names": [
        "RG 7600",
        "DMOT4039A",
        "RG-7600",
        "DMOT-4039A",
        "RG7600"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "pancreatic tumor",
        "Unresectable pancreatic or platinum-resistant cancer Ovarian tumor"
      ],
      "targets": [
        "mesothelin (MSLN); Unnamed antigen"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease-cleavable peptide linker."
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": "CHEMBL2109281",
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PF-06263507 | A1-mafodotin | PF06263507 | A1-mcMMAF | PF 06263507 | Anti-5T4 monoclonal",
      "names": [
        "Anti-5T4 monoclonal",
        "PF-06263507",
        "A1-mafodotin",
        "A1-mcMMAF",
        "PF 06263507",
        "PF06263507"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Malignant Glioma",
        "Solid tumors"
      ],
      "targets": [
        "5T4"
      ],
      "payload": [
        "Monomethyl auristatin\u00a0F (MMAF)"
      ],
      "linker": [
        "A non-cleavable maleimidocaproyl linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Oxford BioMedica",
        "Pfizer",
        "WYETH"
      ],
      "trials": [
        "NCT02590263"
      ],
      "locations": [
        "Japan"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "PF 06664178 | PF06664178 | PF-06664178 | RN927C",
      "names": [
        "PF 06664178",
        "PF06664178",
        "PF-06664178",
        "RN927C"
      ],
      "phases": [],
      "conditions": [
        "Solid tumors",
        "Pancreatic, lung, ovarian, and triple-negative breast tumor types",
        "Non Small Cell Lung Cancer ovarian cancer, and breast cancer"
      ],
      "targets": [
        "Trop-2, also known as TACSTD2, EGP-1, GA733-1, and M1S1",
        "TROP2; a cell-surface glycoprotein overexpressed in a variety of late stage epithelial carcinomas with low to no expression in normal tissues."
      ],
      "payload": [
        "A proprietary microtubule inhibitor (MTI) linker-payload, PF-06380101 (a Dolastatin 10 analogue) linked at the C-terminus of the antibody heavy chain via an enzymatic process.",
        "PF-06380101, a novel cytotoxic Dolastatin 10 analogue."
      ],
      "linker": [
        "AcLys-VC-PABC; site-specific transglutaminase-mediated conjugation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-Trop-2 hIgG1 antibody."
      ],
      "Max Phase": null,
      "developers": [
        "Rinat",
        "Pfizer",
        "WYETH"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "superseding SGN-75 | SGN-CD70A | SGN CD70 A",
      "names": [
        "superseding SGN-75",
        "SGN-CD70A",
        "SGN CD70 A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Diffuse, Large B-Cell, Lymphoma",
        "Renal Cell Carcinoma",
        "Mantle-Cell Lymphoma",
        "Carcinoma, Renal Cell",
        "hematologic malignancies",
        "Follicular Lymphoma, Grade 3",
        "Renal cell carcinoma/RCC"
      ],
      "targets": [
        "CD70; the ligand for the co-stimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, found on the surfaces of various types of cancer cells."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "A stable, protease-cleavable, peptide-based linker"
      ],
      "domain": [
        "Oncology; Hematology."
      ],
      "antibody": [
        "An engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "trials": [
        "NCT01015911",
        "NCT02216890"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "# conditions": 8,
      "# locations": 2,
      "# trials": 2
    },
    {
      "heading": "DSTA4637S | RG7861 | Anti-S. aureus TAC",
      "names": [
        "DSTA4637S",
        "RG7861",
        "Anti-S. aureus TAC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Healthy Volunteers Staphylococcus aureus infections"
      ],
      "targets": [
        "S. Aureus"
      ],
      "payload": [
        "dmDNA31"
      ],
      "linker": [],
      "domain": [
        "Infectious diseases"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Genentech"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MLN-2704 | MLN2704",
      "names": [
        "MLN-591DM1",
        "MLN-2704",
        "MLN2704"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "targets": [
        "PSMA  (Prostate-specific membrane antigen)"
      ],
      "payload": [
        "Maytansine analog drug maytansinoid-1 (DM1)"
      ],
      "linker": [
        "Disulfide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MLN591"
      ],
      "Max Phase": "2",
      "developers": [
        "Takeda",
        "Millennium"
      ],
      "chembl": "CHEMBL2109556",
      "trials": [
        "NCT00070837",
        "NCT00052000"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "BAY 79-4620 | 3ee9 | BAY 794620 | BAY79-4620",
      "names": [
        "BAY 79-4620",
        "3ee9",
        "BAY 794620",
        "BAY79-4620"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Various solid tumors"
      ],
      "targets": [
        "CA9 (carbonic anhydrase IX, CAIX, MN, G250)"
      ],
      "payload": [
        "Monomethyl  Auristatin E (MMAE)"
      ],
      "linker": [
        "Valine\u2013citrulline (vc)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine | LOP628 | LOP-628 | LOP 628 | Anti-c-kit humanised IgG1/\u03ba -maitansine",
      "names": [
        "Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine",
        "LOP628",
        "LOP-628",
        "LOP 628",
        "Anti-c-kit humanised IgG1/\u03ba -maitansine"
      ],
      "phases": [
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "HER2 Overexpressing Gastric Carcinoma",
        "Papillary thyroid carcinoma",
        "Gastric Cancer",
        "Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia"
      ],
      "targets": [
        "CD117; Mast/stem cell growth factor receptor (SCFR); proto-oncogene c-Kit or tyrosine-protein kinase Kit"
      ],
      "payload": [
        "A maytansine payload"
      ],
      "linker": [
        "Non-cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Novartis"
      ],
      "trials": [
        "NCT04714190",
        "ChiCTR-DND-17012404"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "SGN-CD123A",
      "names": [
        "SGN-CD123A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Acute Myelogenous / Myeloid Leukemia (AML)"
      ],
      "targets": [
        "CD123; also known as IL-3RA (alpha-chain of the interleukin-3 receptor)  This target is frequently observed in leukemic disorders and may contribute to the proliferative advantage of leukemic cells. CD123 is overexpressed in various hematologic malignancies, including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and hairy cell leukemia."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "Protease Cleavable Linker"
      ],
      "domain": [],
      "antibody": [
        "Humanized"
      ],
      "Max Phase": "1",
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SAR428926 | SAR428926 SAR 428926",
      "names": [
        "SAR428926",
        "SAR428926 SAR 428926"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors",
        "Advanced triple negative breast cancer (TNBC)"
      ],
      "targets": [
        "LAMP1; Lysosome-associated membrane protein 1.  This target plays a key role in cell-cell adhesion and migration."
      ],
      "payload": [
        "Maytansinoid DM4; DM4"
      ],
      "linker": [
        "A disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CBT-161 | Anti-cMET ADC",
      "names": [
        "CBT-161",
        "Anti-cMET ADC"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "cMET; Also called tyrosine-protein kinase Met and hepatocyte growth factor receptor (HGFR)"
      ],
      "payload": [
        "Proprietary tubulin-binding, DNA alkylation and other cytotoxic agents"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Sorrento Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-NOTCH3 ADC | PF06650808 | PF-06650808 | Anti-NOTCH3-ADC | PF-6650808",
      "names": [
        "Anti-NOTCH3 ADC",
        "PF06650808",
        "PF-06650808",
        "Anti-NOTCH3-ADC",
        "PF-6650808"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Ovarian cancer",
        "Solid tumors",
        "Non-small  cell  lung  cancer (NSCLC)",
        "Triple negative breast cancer (TNBC)"
      ],
      "targets": [
        "Notch3 (Neurogenic locus notch homolog protein 3)"
      ],
      "payload": [
        "Auristatin-based cytotoxic agent"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AGS 62P1 | AGS62P1",
      "names": [
        "AGS 62P1",
        "AGS62P1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Acute Myelogenous / Myeloid Leukemia (AML)"
      ],
      "targets": [
        "FLT3 (FMS-like tyrosine kinase 3) a member of the class III receptor tyrosine kinase family, which is highly expressed in the blasts of both AML and ALL patients."
      ],
      "payload": [
        "Amberstatin269 | Aurixime"
      ],
      "linker": [
        "Oxime bond to pAF sites"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-FLT3 monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Astellas",
        "Agensys"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADCM-E7974 | NC-6201",
      "names": [
        "ADCM-E7974",
        "NC-6201"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Cetuximab-insensitive KRAS-mutated tumors",
        "Triple Negative Breast cancer (TNBC)"
      ],
      "targets": [
        "EGFR; Epidermal growth factor receptor (EGFR),  a transmembrane tyrosine kinase receptor involved in the proliferation and survival of cancer cells."
      ],
      "payload": [
        "E7974, a synthetic analog of  hemiasterlin (tubulin inhibitor"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "NCAB001 (Same sequence with  Cetuximab)"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "NanoCarrier (Japan)",
        "Eisai"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "NV101 | Doxorubicin-anti-CD99",
      "names": [
        "NV101",
        "Doxorubicin-anti-CD99"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Disease, Hodgkin",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Breast Cancer",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "HER2-Positive Metastatic Breast Cancer",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Peripheral T-cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Hodgkin Disease",
        "B-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "T-Cell Lymphoma",
        "Classical Hodgkin Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "HER2-positive Early Breast Cancer",
        "Large B-Cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Anaplastic Large-Cell Lymphoma",
        "Breast Neoplasms",
        "Stage III Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Ewing Sarcoma",
        "Lymphoma, T-cell",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "CD99; also known as MIC2 or Single-chain type-1 glycoprotein, is a heavily O-glycosylated transmembrane protein. CD99 is xpressed on all leukocytes but highest on thymocytes; found on the cell surface of Ewing's sarcoma and positive in granulosa cell tumors. It is more expressed in malignant gliomas than in the brain. Overexpression results in higher levels of invasiveness and lower rates of survival."
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "NanoValent"
      ],
      "trials": [
        "NCT03991884",
        "NCT01920932",
        "NCT03755804",
        "NCT05600686",
        "NCT01992653",
        "NCT06486441",
        "NCT01060904",
        "NCT03274492",
        "NCT04203641",
        "NCT03646123",
        "NCT04914741",
        "NCT02292979",
        "NCT05404945",
        "NCT02605915",
        "NCT06377566",
        "NCT03726879",
        "NCT05113251",
        "NCT01712490",
        "NCT04790903",
        "NCT02505269",
        "NCT05673785",
        "NCT06112379",
        "NCT04569032",
        "NCT06132958",
        "NCT04685616",
        "NCT03677141",
        "NCT01777152",
        "NCT06340568",
        "NCT06047080",
        "NCT02734771",
        "NCT02979522",
        "NCT01534078",
        "NCT04594798",
        "NCT03467373",
        "NCT01309789",
        "NCT01966471",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# conditions": 42,
      "# locations": 54,
      "# trials": 37
    },
    {
      "heading": "NV103 | Irinotecan-anti-CD99",
      "names": [
        "NV103",
        "Irinotecan-anti-CD99"
      ],
      "phases": [
        "Preclinical",
        "Phase 2"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Gastric Cancer",
        "Neuroendocrine tumors",
        "Gastroesophageal Junction Cancer",
        "Pancreatic Adenocarcinoma"
      ],
      "targets": [
        "CD99; also known as MIC2 or Single-chain type-1 glycoprotein, is a heavily O-glycosylated transmembrane protein. CD99 is xpressed on all leukocytes but highest on thymocytes; found on the cell surface of Ewing's sarcoma and positive in granulosa cell tumors. It is more expressed in malignant gliomas than in the brain. Overexpression results in higher levels of invasiveness and lower rates of survival."
      ],
      "payload": [
        "Irinotecan"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "NanoValent"
      ],
      "trials": [
        "NCT06219941"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Moldova, Republic of",
        "United States of America",
        "Georgia",
        "Malaysia",
        "Republic of Korea",
        "Republic of Moldova",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 16,
      "# trials": 1
    },
    {
      "heading": "NV102 | Doxorubicin-anti-CD19",
      "names": [
        "NV102",
        "Doxorubicin-anti-CD19"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Disease, Hodgkin",
        "And acute lymphoblastic leukemia (ALL)",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Breast Cancer",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "HER2-Positive Metastatic Breast Cancer",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Peripheral T-cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Hodgkin Disease",
        "B-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "T-Cell Lymphoma",
        "Classical Hodgkin Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "HER2-positive Early Breast Cancer",
        "Large B-Cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Anaplastic Large-Cell Lymphoma",
        "Breast Neoplasms",
        "Stage III Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Lymphoma, T-cell",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Acute myeloid leukemia (AML)",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "CD19; a cell surface molecule expressed only by B lymphocytes and follicular dendritic cells of the hematopoietic system. CD19 is the earliest of the B-lineage-restricted antigens to be expressed and is present on most pre-B cells and most non-T-cell acute lymphocytic leukemia cells and B-cell type chronic lymphocytic leukemia cells."
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "NanoValent"
      ],
      "trials": [
        "NCT03991884",
        "NCT01920932",
        "NCT03755804",
        "NCT05600686",
        "NCT01992653",
        "NCT06486441",
        "NCT01060904",
        "NCT03274492",
        "NCT04203641",
        "NCT03646123",
        "NCT04914741",
        "NCT02292979",
        "NCT05404945",
        "NCT02605915",
        "NCT06377566",
        "NCT03726879",
        "NCT05113251",
        "NCT01712490",
        "NCT04790903",
        "NCT02505269",
        "NCT05673785",
        "NCT06112379",
        "NCT04569032",
        "NCT06132958",
        "NCT04685616",
        "NCT03677141",
        "NCT01777152",
        "NCT06340568",
        "NCT06047080",
        "NCT02734771",
        "NCT02979522",
        "NCT01534078",
        "NCT04594798",
        "NCT03467373",
        "NCT01309789",
        "NCT01966471",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# conditions": 43,
      "# locations": 54,
      "# trials": 37
    },
    {
      "heading": "EDC9 | EDC-CD20",
      "names": [
        "EDC9",
        "EDC-CD20"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Diffuse large B cell lymphoma."
      ],
      "targets": [
        "CD20 and sodium-potassium ATPase."
      ],
      "payload": [
        "Rituximab is conjugated to a steroidal glycoside"
      ],
      "linker": [
        "A proprietary long non-cleavable, fexible, stable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Centrose",
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DYS-ADC | EDC-1 | DYS-EDC | EDC1",
      "names": [
        "DYS-ADC",
        "EDC-1",
        "DYS-EDC",
        "EDC1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Thyroid Carcinoma",
        "Pancreatic Cancer",
        "Lymphoma"
      ],
      "targets": [
        "Dysadherin (also known as  FXYD5); a cancer cell membrane-associated glycoprotein that has been recognized as a prognostic indicator of metastasis and/or poor survival in many different cancer types. The presence of dysadherin expression contributes causally to cancer metastasis in a number of ways, including downregulation of E-cadherin-mediated cell adhesion, upregulation of tumor-promoting chemokine production and enhancement of cancer stem-cell properties."
      ],
      "payload": [
        "CEN-106, a novel Na,K-ATPase inhibitor known to induce necrosis in human cancer cell types."
      ],
      "linker": [
        "A proprietary long non-cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-dysadherin antibody (NCC-M53)"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Centrose",
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ASN-004 ASN004 ASN 004 | ASN 004 | ASN-004",
      "names": [
        "ASN 004",
        "ASN-004 ASN004 ASN 004",
        "ASN-004"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors (Breast, Lung, Stomach)",
        "Solid Tumor"
      ],
      "targets": [
        "5T4 (Oncofoetal glycoprotein); TPBG and trophoblast glycoprotein, a 72 kDa glycoprotein member of the LRR family of proteins expressed on trophoblasts, tumor cells, ovarian cuboidal epithelium and embryonic stem cells, and impacts cell adhesion and motility."
      ],
      "payload": [
        "Dolaflexin (auristatin) analog, a microtubule disruptor capable of bystander-effect tumor cell killing.  Drug-to-antibody ratio (DAR): ~15"
      ],
      "linker": [
        "Single-chain homo-dimer  antibody,  Fleximer\u00ae linker  technology; 3 Fleximer chains per antibody."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "scFvFc antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Asana BioSciences"
      ],
      "trials": [
        "NCT04410224"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "MEN 1309 MEN1309 OBT076 | MEN1309 | OBT076",
      "names": [
        "MEN 1309 MEN1309 OBT076",
        "OBT076",
        "MEN1309"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC)",
        "Solid Tumor",
        "Diffuse large B-cell lymphoma (DLBCL) | a type of non-Hodgkin lymphoma - NHL)"
      ],
      "targets": [
        "Ly75/CD205 (a type I transmembrane glycoprotein and a C-type lectin receptor; over-expressed in several solid tumors and non-Hodgking lymphomas (NHL)"
      ],
      "payload": [
        "Maytansinoid toxin (DM4)"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Hematology; Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Oxford BioTherapeutics",
        "Menarini Ricerche"
      ],
      "ttd": "D8DJX0",
      "trials": [
        "NCT04064359"
      ],
      "locations": [
        "Spain",
        "Greece",
        "Belgium",
        "France",
        "United States"
      ],
      "# conditions": 3,
      "# locations": 5,
      "# trials": 1
    },
    {
      "heading": "Anti-HER-3 | anti-HER-3 ADC",
      "names": [
        "Anti-HER-3",
        "anti-HER-3 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Colon cancer",
        "Neuroblastoma.",
        "Prostate cancer,  Ovarian cancer,  Lung cancer,  Head & neck,  Pancreatic Cancer",
        "Stomach Cancer",
        "Breast cancer",
        "Melanoma"
      ],
      "targets": [
        "HER3"
      ],
      "payload": [
        "A duocarmycin derivative"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "EV20, an anti-HER3 monoclonal antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "MediaPharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 6,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MK8109 | Vintafolide | VYNFINIT\u00ae | EC145/MK 8109 | MK 8109 | EC145",
      "names": [
        "MK8109",
        "Vintafolide",
        "VYNFINIT\u00ae",
        "EC145/MK 8109",
        "MK 8109",
        "EC145"
      ],
      "phases": [],
      "conditions": [
        "Platinum-resistant ovarian cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "targets": [
        "Folate Receptor"
      ],
      "payload": [
        "Vinblastine"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Merck Sharp & Dohme",
        "Endocyte"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EC2629",
      "names": [
        "EC2629"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Drug-resistant ovarian cancer",
        "Triple negative breast cancer (TNBC)"
      ],
      "targets": [
        "Folate receptor positive cancer cells; Tumor-associated macrophages (TAMs)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Endocyte"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PF-06647263 | anti-EFNA4-ADC | PF-06647263 EFNA4-ADC",
      "names": [
        "PF-06647263",
        "anti-EFNA4-ADC",
        "PF-06647263 EFNA4-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic Triple Negative Breast Cancer (mTNBC)"
      ],
      "targets": [
        "Ephrin-A4 (EFNA4)"
      ],
      "payload": [
        "Calicheamicin"
      ],
      "linker": [
        "Hydrazone cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hE22"
      ],
      "Max Phase": "1",
      "developers": [
        "Pfizer"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MEDI-547 | MEDI547",
      "names": [
        "MEDI-547",
        "MEDI547"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "EphA2"
      ],
      "payload": [
        "Auristatin MMAF"
      ],
      "linker": [
        "Stable linker maleimidocaproyl (mc)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "MedImmune"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EC1169",
      "names": [
        "EC1169"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic Castrate-resistant Prostate Cancer (mCRPC)."
      ],
      "targets": [
        "PSMA; Prostate-Specific Membrane Antigen"
      ],
      "payload": [
        "Tubulysin B hydrazide (TubBH)"
      ],
      "linker": [
        "A stable, enzyme-cleavable, bioreleasable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Endocyte"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABV176 | ABBV-176 | ABBV176 | ABBV 176",
      "names": [
        "ABBV-176 DC-1630993 h16f",
        "ABV176",
        "Rolinsatamab talirine",
        "ABBV 176",
        "ABBV176",
        "ABBV-176"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced solid tumors",
        "Sold tumors"
      ],
      "targets": [
        "PRLR (prolactin receptor);  a tumor-associated antigen (TAA) overexpressed by a variety of tumor cell types",
        "PRLR (prolactin receptor); a tumor-associated antigen (TAA) overexpressed by a variety of tumor cell types"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PDB) dimers SGD-1882",
        "Auristatin-0101, an auristatin microtubule inhibitor"
      ],
      "linker": [
        "Cleavable maleimidocaproyl type linker  On an average of 2 site-specific drug attachment engineered cysteines (C242, C242')"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-PTK7 monoclonal antibody",
        "Immunoglobulin G1-kappa, anti-PRLR (prolactin receptor)], monoclonal antibody,"
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-CD70 ADC | CD70 ADC | Anti-CD70-ADC | CD70-ADC",
      "names": [
        "anti-CD70 ADC",
        "CD70 ADC",
        "Anti-CD70-ADC",
        "CD70-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Cancer",
        "nasopharyngeal cancers",
        "Renal cell carcinoma (RCC)"
      ],
      "targets": [
        "CD70"
      ],
      "payload": [
        "Ambrx's proprietary drug payloads"
      ],
      "linker": [
        "Site-specific"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CD184-Dasatinib-ADC | CD184-Dasatinib",
      "names": [
        "CD184-Dasatinib-ADC",
        "CD184-Dasatinib"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Chronic diseases"
      ],
      "targets": [
        "CXCR4; Chemokine receptor type 4 (CXCR-4) also known as fusin or CD184; CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12)"
      ],
      "payload": [
        "Dasatinib;  an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity.  Drug-to-antibody ratio (DAR) ~3"
      ],
      "linker": [],
      "domain": [
        "Non-Oncology; Non-Hematology;"
      ],
      "antibody": [
        "anti-CXCR4 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CD163-dexamethasone ADC | anti-CD163-dexamethasone | anti-CD163-dexamethasone ADC | Cymac-001",
      "names": [
        "CD163-dexamethasone ADC",
        "anti-CD163-dexamethasone ADC",
        "anti-CD163-dexamethasone",
        "Cymac-001"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "B-cell Non Hodgkin Lymphoma",
        "Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Small Cell Lung Cancer",
        "Diffuse Large B-cell Lymphoma",
        "Severe and/or chronic inflammatory diseases",
        "B-Cell Lymphoma",
        "Relapsed Cancer",
        "Solid Tumor",
        "ALL",
        "B-cell Acute Lymphoblastic Leukemia",
        "Hodgkin Lymphoma"
      ],
      "targets": [
        "CD-163; a high affinity scavenger receptor for the hemoglobin-haptoglobin complex (in the absence of haptoglobin, with lower affinity, for hemoglobin alone. CD163 has also been shown to mark cells of monocyte/macrophage lineage."
      ],
      "payload": [
        "Synthetic glucocorticoids (GCs) | Dexamethasone  Drug-to-antibody ratio: 4"
      ],
      "linker": [],
      "domain": [
        "Non-Oncology; Non-Hematology; Inflammation;"
      ],
      "antibody": [
        "Anti-CD163"
      ],
      "Max Phase": "3",
      "developers": [
        "Affinicon"
      ],
      "trials": [
        "NCT05180097",
        "NCT03544281",
        "NCT04484623",
        "NCT05922501",
        "NCT04300556",
        "NCT05498220",
        "NCT03061812",
        "NCT05016947",
        "NCT03828292",
        "NCT05991388",
        "NCT04246047"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Israel",
        "Croatia",
        "Belarus",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# conditions": 12,
      "# locations": 35,
      "# trials": 11
    },
    {
      "heading": "CD70-glucocorticoid ADC",
      "names": [
        "CD70-glucocorticoid ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Anti-inflammatory diseases."
      ],
      "targets": [
        "CD70 (also referred to as CD27L), a tumor necrosis factor-related cell-surface ligand, and its receptor, CD27, is expressed on different immune cell populations."
      ],
      "payload": [
        "Glucocorticoids"
      ],
      "linker": [
        "A novel phosphate bridged Cathepsin B sensitive linker designed to enable the targeted delivery of glucocorticoids. This linker expands the scope of potential ADC payloads by allowing an aliphatic alcohol to be a stable, yet cleavable attachment site."
      ],
      "domain": [
        "Non-Oncology; Non-Hematology; Inflammation"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CD184-FK506",
      "names": [
        "CD184-FK506"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Rheumatoid arthritis",
        "Inflammatory  bowel disease",
        "Psoriasis."
      ],
      "targets": [
        "CXCR4; Chemokine receptor type 4 (CXCR-4) also known as fusin or CD184; CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12)"
      ],
      "payload": [
        "FK506,  also known as tacrolimus or fujimycin, an antibiotic with immunosuppressive properties."
      ],
      "linker": [],
      "domain": [
        "Non-Oncology; Non-hematology; Inflammation"
      ],
      "antibody": [
        "anti-CXCR4 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Ambrx"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HKT288 | Maytansine-based ADC HKT-288 | HKT-288 | CDH6-ADC",
      "names": [
        "HKT288",
        "Maytansine-based ADC HKT-288",
        "HKT-288",
        "CDH6-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Epithelial Ovarian cancer",
        "Advanced Solid Tumors",
        "Renal Cell Carcinoma (RCC)"
      ],
      "targets": [
        "Tumor-associated antigen (TAA) CDH6 (CDH-6); Cadherin-6 (cell-cell adhesion molecule)."
      ],
      "payload": [
        "Tubulin-binding maytansinoid DM4 payload. (N2'-Deacetyl-N2'-(4-mercapto-4- methyl-1-oxopentyl)maytansine)"
      ],
      "linker": [
        "sulfo-SPDB (N-succinimidyl-4-(2-pyridyldithio)-2-sulfo butanoate)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-CDH6 IgG1"
      ],
      "Max Phase": "1",
      "developers": [
        "Novartis"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PCA062 PCA-062 | PCA062 | PCA-062",
      "names": [
        "PCA062 PCA-062",
        "PCA062",
        "PCA-062"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "P-cadherin-positive cancers",
        "Esophageal cancer.",
        "Head & neck cancer",
        "Triple negative breast cancer (TNBC)"
      ],
      "targets": [
        "P-cadherin; a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN",
        "Novartis"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ZV203",
      "names": [
        "ZV203"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Breast cancer",
        "Gastric/Stomach cancer"
      ],
      "targets": [
        "HER2; Human epidermal growth factor receptor 2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Concortis"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "c-MET ADC",
      "names": [
        "c-MET ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Non-small cell lung cancer (NSCLC)"
      ],
      "targets": [
        "c-MET; Tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR); involved in cell proliferation, invasion, and angiogenesis."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-c-Met antibody STI-0602"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Concortis"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EP-400",
      "names": [
        "EP-400"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Esperance"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMAB362-vcMMAE",
      "names": [
        "IMAB362-vcMMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Gastric Cancer"
      ],
      "targets": [
        "CLDN18.2; Tight junction protein Claudin 18.2"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Valine\u2013citrulline linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Astellas",
        "Ganymed"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-endosialin-MC-VC-PABC-MMAE",
      "names": [
        "Anti-endosialin-MC-VC-PABC-MMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ewing sarcoma",
        "Neuroblastoma"
      ],
      "targets": [
        "CD248; also known as Endosialin, a member of a novel family of C-type lectin transmembrane receptors which play a role in cell\u2013cell adhesion and host defence. CD248 is expressed in the cell surface of tumor-associated stroma cells, as well as in sarcoma and neuroblastoma cells."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  Drug-to-antibody ratio: 3 - 4"
      ],
      "linker": [
        "A maleimidocaproyl-valine-citrulline linker with a p-aminobenzylcarbamate spacer"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-endosialin"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Genzyme"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HTI-1511",
      "names": [
        "HTI-1511"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid tumors",
        "Colon Cancer",
        "EGFR-positive tumors, including those with KRAS and BRAF mutations",
        "Lung Cancer",
        "Cholangiocarcinoma"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor (EGFR)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Bis-alkylating linker (site specific ThioBridge\u2122 linker technology)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Halozyme"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 5,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMB-202",
      "names": [
        "IMB-202"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "Undisclosed intracellular tumor antigens"
      ],
      "payload": [],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "ImmunoBiochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMB-201",
      "names": [
        "IMB-201"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "Undisclosed intracellular tumor antigens."
      ],
      "payload": [],
      "linker": [
        "Stable (non-cleavable) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "ImmunoBiochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IGN523",
      "names": [
        "IGN523"
      ],
      "phases": [],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)/Acute Myeloid Leukemia(AML)"
      ],
      "targets": [
        "CD98 (gp125)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Igenica"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IGN786",
      "names": [
        "IGN786"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "follicular lymphoma, diffuse large B-cell lymphoma (DLBCL)",
        "Multiple myeloma",
        "Acute myeloid leukemia (AML)",
        "Chronic lymphocytic leukemia (CLL)",
        "Pancreatic cancer."
      ],
      "targets": [
        "SAIL; Surface Antigen In Leukemia | c15orf54"
      ],
      "payload": [
        "Monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "A maleimidocaproyl (mc) linker"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [
        "anti-SAIL"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Igenica"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 5,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LCB14-15nm",
      "names": [
        "LCB14-15nm"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Takeda",
        "Legochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LCB14-17nn",
      "names": [
        "LCB14-17nn"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Mesothelin; a tumour differentiation antigen normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is also highly expressed in several cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown however, recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Legochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-CD37 ADC | LCB14-15xx | NNV019",
      "names": [
        "anti-CD37 ADC",
        "LCB14-15xx",
        "NNV019"
      ],
      "phases": [],
      "conditions": [
        "Various Leukemias"
      ],
      "targets": [
        "CD37; a cell surface glycoprotein.  As a type III transmembrane protein CD37 is present on mature B cells, some T cells, and monocytes that may play a role in ion transport; Also expressed on B-cell lymphomas, B-cell chronic lymphocytic leukemia, and hairy cell leukemia.",
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology",
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Y-Biologics",
        "Nordic Nanovector",
        "Legochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AR-001 | YBK-001 | YBL-001",
      "names": [
        "AR-001",
        "YBK-001",
        "YBL-001"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Y-Biologics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LCB14-19nm",
      "names": [
        "LCB14-19nm"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "EGFRvIII; Epidermal growth factor receptor variant III, a mutated form of EGFR which plays a prominent role in tumorigenesis."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Samsung Medical Center",
        "Legochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LCB14-2nm",
      "names": [
        "LCB14-2nm"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Seasun Biomaterials",
        "Legochem"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110 | Herceptin-LC-LBG-MMAF | LCB14-0110",
      "names": [
        "Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF",
        "LCB14 0110",
        "Herceptin-LC-LBG-MMAF",
        "LCB14-0110"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "(Breast | Stomach)",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "HER2; Human epidermal growth factor 2"
      ],
      "payload": [
        "Monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "LegoChem's proprietary linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Legochem",
        "Shanghai Fosun"
      ],
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 24,
      "# locations": 72,
      "# trials": 20
    },
    {
      "heading": "Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC",
      "names": [
        "Anti-ADAM9-sulfoSPDB-DM4",
        "DGN549",
        "C442",
        "Anti-ADAM9",
        "Anti-ADAM9 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Pancreatic Cancer",
        "ADAM9-expressing tumors",
        "Prostate Cancer"
      ],
      "targets": [
        "ADAM-9; also known as MDC9 or  meltrin-\u03b3; A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein, which enables various roles in a wide range of cellular process. Over-expression of ADAM-9 has been reported in several cancers",
        "ADAM-9; also known as MDC9 or meltrin-\u03b3; A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein, which enables various roles in a wide range of cellular process. Over-expression of ADAM-9 has been reported in several cancers."
      ],
      "payload": [
        "Indolinobenzodiazepine DNA-alkylating monoimine (DGN549)  Drug-to-antibody ratio:  2",
        "Maytansine-derived microtubule  disruptor DM4   Drug-to-antibody ratio of ~3.5"
      ],
      "linker": [
        "Conjugated to engineered cysteine residues via a cleavable peptide linker.",
        "Lysine-linked via a cleavable sulfo-SPDB linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-ADAM9 antibody: AEX6003",
        "Anti-ADAM9 antibody: AEX6003(S442C)"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "IMMUNOGEN",
        "MacroGenics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-TEM-1 | TEM-1-ADC | Anti-TEM-1",
      "names": [
        "anti-TEM-1",
        "TEM-1-ADC",
        "Anti-TEM-1"
      ],
      "phases": [],
      "conditions": [
        "Sarcoma",
        "Neuroblastoma",
        "Melanoma",
        "Colorectal carcinoma"
      ],
      "targets": [
        "CD248; also known as Endosialin, a member of a novel family of C-type lectin transmembrane receptors which play a role in cell\u2013cell adhesion and host defence. CD248 is expressed in the cell surface of tumor-associated stroma cells, as well as in sarcoma and neuroblastoma cells"
      ],
      "payload": [
        "A duocarmycin derivative"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "E.8-3, an anti-TEM-1 monoclonal antibody"
      ],
      "Max Phase": null,
      "developers": [
        "MediaPharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-CD22 Anthracycline-Based | Anti-CD22-NMS249 | anti-CD22-NMS249 | Anti-CD22 Anthracycline-Based ADC",
      "names": [
        "anti-CD22 Anthracycline-Based",
        "Anti-CD22-NMS249",
        "anti-CD22-NMS249",
        "Anti-CD22 Anthracycline-Based ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Non-Hodgkin lymphoma (NHL)"
      ],
      "targets": [
        "CD22; a molecule belonging to the SIGLEC family of lectins, found on the surface of mature B cells and to a lesser extent on some immature B cells"
      ],
      "payload": [
        "A anthracycline analogue (PNU-159682)"
      ],
      "linker": [
        "A protease-cleavable maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl linker (MC-vc-PAB)."
      ],
      "domain": [
        "Oncology; Hematology;"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Genentech"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Azonafide-ADC",
      "names": [
        "Azonafide-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [
        "Azonafide (2-[2\u2032-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de, h]isoquinoline-1,3-dione) is the parent of a new series of anthracene-containing antitumor agents."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Oncolinx"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-MTX3:Nigrin | OMTX503",
      "names": [
        "Anti-MTX3:Nigrin",
        "OMTX503"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "MTX3; a membrane protein of endothelial cells"
      ],
      "payload": [
        "Nigrin B; a plant toxin from Sambucus nigra (bark) and a member of Type 2 RIP family; inhibit ribosomal activity."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-MTX3 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Oncomatryx"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "OMTX705 | Anti-MTX5:Cytolysin ADC",
      "names": [
        "OMTX705",
        "Anti-MTX5:Cytolysin ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Pancreatic cancer"
      ],
      "targets": [
        "MTX5; a membrane glycoprotein of cancer-associated fibroblasts"
      ],
      "payload": [
        "Highly cytotoxic synthetic Cytolysins; A synthetic tetrapeptidic analogues of the natural class tubulysins with a low MW: 780 g/mol"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "OMTX anti-MTX5 humanized mAb"
      ],
      "Max Phase": "1",
      "developers": [
        "Oncomatryx"
      ],
      "trials": [
        "NCT05547321"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "SNG-8023 ADC",
      "names": [
        "SNG-8023 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Liver cancer",
        "Leukemia",
        "Breast cancer"
      ],
      "targets": [
        "ER-alpha36, a novel variant of estrogen receptor-alpha (ER-alpha), is expressed in ER-positive and -negative human breast carcinomas."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ER-alpha36 monoclonal antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Shenogen Pharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-TM4SF1 ADC",
      "names": [
        "Anti-TM4SF1 ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid Cancer",
        "Pancreatic Cancer",
        "Non-small cell lung cancer",
        "Prostate Cancer,  Colon Cancers."
      ],
      "targets": [
        "TM4SF1; Tetraspanin-like protein; Highly expressed on the plasma membranes of many human cancer cells; Also expressed on the endothelial cells lining tumor blood vessels."
      ],
      "payload": [
        "An auristatin cytotoxic agent LP2 (chemical name mc-3377)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-human TM4SF1 monoclonal antibody, v1.10"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Pfizer",
        "Angiex"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TGM-004",
      "names": [
        "TGM-004"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TGM-005",
      "names": [
        "TGM-005"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TGM-001",
      "names": [
        "TGM-001"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TGM-002",
      "names": [
        "TGM-002"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TGM-003",
      "names": [
        "TGM-003"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Targetome SA"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-Prolactin Receptor | Anti-PRLR-ADC | PRLR | REGN2878-DM1",
      "names": [
        "Anti-Prolactin Receptor",
        "Anti-PRLR-ADC",
        "PRLR",
        "REGN2878-DM1"
      ],
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "targets": [
        "Prolactin Receptor (PRLR); a type 1 cytokine receptor"
      ],
      "payload": [
        "Cytotoxic maytansine derivative DM1"
      ],
      "linker": [
        "Non-cleavable SMCC linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "High-affinity function-blocking anti-PRLR IgG1 antibody (REGN2878)"
      ],
      "Max Phase": null,
      "developers": [
        "Regeneron"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HuMAB-5B1-ATAC",
      "names": [
        "HuMAB-5B1-ATAC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Metastatic pancreatic cancer"
      ],
      "targets": [
        "Unknown"
      ],
      "payload": [
        "Amanitin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "MabVax",
        "Heidelberg Pharma",
        "Wilex"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-CD19 ADC | Anti-CD19 ADC | Anti-CD19 ATAC",
      "names": [
        "anti-CD19 ADC",
        "Anti-CD19 ADC",
        "Anti-CD19 ATAC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "B-ALL",
        "Burkitt Lymphoma"
      ],
      "targets": [
        "CD19+; also known  as B-lymphocyte surface antigen B4, B4, CVID; Nalm-6"
      ],
      "payload": [
        "Maleimide Amanitin"
      ],
      "linker": [
        "Site-specific (THIOMAB\u2122). The THIOMAB platform provides one specific site on each heavy chain (Fab region) for drug attachment. As a result, conjugation of a THIOMAB generates a more homogenous ADC product with a primary DAR close to two. The resulting homogeneity of these ADCs leads to a simplified drug profile and improved therapeutic index."
      ],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Wilex",
        "Heidelberg Pharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LY3076226 | ADC LY3076226 | Anti-fibroblast Growth Factor Receptor 3 | Anti-FGFR3 ADC LY3076226",
      "names": [
        "LY3076226",
        "ADC LY3076226",
        "Anti-fibroblast Growth Factor Receptor 3",
        "Anti-FGFR3 ADC LY3076226"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Advanced or metastatic cancer"
      ],
      "targets": [
        "Fibroblast growth factor receptor (FGFR) family; consists of four members\u2014FGFR-1, FGFR-2, FGFR-3, and FGFR-4"
      ],
      "payload": [
        "Microtubule inhibitor, DM4"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-FGFR-3 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Eli Lilly"
      ],
      "trials": [
        "NCT02529553"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "# conditions": 3,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "IMMU-140 | anti-HLA-DR-SN-38 ADC",
      "names": [
        "IMMU-140",
        "anti-HLA-DR-SN-38 ADC"
      ],
      "phases": [],
      "conditions": [
        "Hodgkin lymphoma (HL)",
        "Melanoma",
        "Acute lymphocytic leukemia (ALL)",
        "Diffuse large B-cell lymphoma (DLBCL)",
        "Acute myeloid leukemia (AML)",
        "Chronic lymphocytic leukemia (CLL)",
        "Multiple myeloma (MM)"
      ],
      "targets": [
        "HLA-DR. This target is a member of the MHC class II antigen family expressed on hematologic and solid tumors. Antibodies directed against HLA-DR have demonstrated some clinical success, but toxicities limited development."
      ],
      "payload": [
        "Active metabolite of irinotecan, SN-38"
      ],
      "linker": [],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "Humanized anti-HLA-DR IgG4 antibody (IMMU-114)"
      ],
      "Max Phase": null,
      "developers": [
        "Immunomedics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 7,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MI130004",
      "names": [
        "MI130004"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Selectivity towards cell lines with high HER2 expression (IC50s 0.282 and 0.182 nM against HCC-1954 and SK-BR-3 cell lines)"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "PM050489"
      ],
      "linker": [
        "Linker containing a maleimide group to enable conjugation to Cys residues."
      ],
      "domain": [],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "PharmaMar"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "",
      "names": [],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ovarian, colon, prostate, and pancreatic tumors"
      ],
      "targets": [
        "Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Siamab"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AVID300 | AVID 300",
      "names": [
        "AVID300",
        "AVID 300"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "EGF receptor, EGFR, ErbB-1 and HER1 in humans."
      ],
      "payload": [
        "DM1 (Mertansine, emtansine), a thiol-containing maytansinoid"
      ],
      "linker": [
        "Non-cleavable linker"
      ],
      "domain": [
        "Oncology | Hemtology"
      ],
      "antibody": [
        "Panitumumab (ABX-EGF), a fully human monoclonal antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Formation Biologics (Forbius)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMAB027-vcMMAE",
      "names": [
        "IMAB027-vcMMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "targets": [
        "CLDN6-positive tumors. The transmembrane protein claudin (-CLDN) family play a key role in the maintenance of epithelial and endothelial tight junctions, and possibly as well as cellular signal transduction plays a role in maintaining the cytoskeleton. CLDN6 expressed in a number of different human cancer cells, while expression in normal tissues is limited to the placenta."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE, vedotin)"
      ],
      "linker": [
        "Lysosomally cleavable dipeptide, valine-citrulline (vc)"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "IMAB027"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Astellas",
        "Ganymed"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Satoreotide tetraxetan",
      "names": [
        "Satoreotide tetraxetan"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Tacatuzumab Tetraxetan",
      "names": [
        "Tacatuzumab Tetraxetan"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [
        "Tetraxetan (a chelator for yttrium-90, a radioisotope)"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "Tacatuzumab"
      ],
      "Max Phase": null,
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADCT-701",
      "names": [
        "ADCT-701"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Liver"
      ],
      "targets": [
        "DLK1"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "ADC Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EV20/MMAF",
      "names": [
        "EV20/MMAF"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "HER3"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "MediaPharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMGN779 | IMGN 779",
      "names": [
        "IMGN779",
        "IMGN 779"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML) With FLT3-ITD Mutations"
      ],
      "targets": [
        "CD33 (Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage"
      ],
      "payload": [
        "DGN462 (DNA-alkylating agent consisting of an indolino-benzodiazepine dimer containing a mono-imine moiety)"
      ],
      "linker": [
        "Disulfide linker / Sulfo-SPDB"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Z4681A"
      ],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-GPC2 ADC | D3-GPC2-PBD",
      "names": [
        "anti-GPC2 ADC",
        "D3-GPC2-PBD"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "targets": [
        "GPC2; Glypican 2, also known cerebroglycan, a cell surface protein shown to be preferentially expressed on numerous pediatric cancers"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer, a potent cytotoxic DNA minor groove interstrand crosslinking agent.   Drug-to-antibody ratio: 2.6"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "D3-GPC2-IgG1"
      ],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "VIS705",
      "names": [
        "VIS705"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "P. aeruginosa"
      ],
      "targets": [
        "Pseudomonas aeruginosa, a type of Gram-negative bacterial infection. The antibody targets a core region of lipopolysaccharide present at high density on P. aeruginosa and common across serotypes."
      ],
      "payload": [
        "Anti-microbial cell-killing peptide."
      ],
      "linker": [],
      "domain": [
        "Antibacterials"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Visterra"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMGN-633 | AVE9633",
      "names": [
        "IMGN-633",
        "AVE9633"
      ],
      "phases": [],
      "conditions": [
        "Acute myeloid leukemia (AML)"
      ],
      "targets": [
        "CD33, Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) a transmembrane receptor expressed on cells of myeloid lineage."
      ],
      "payload": [
        "DM4 (N2\u2032- Deacetyl-N2\u2032-(4-mercapto-4-methyl-1-oxopentyl)-maytansine)"
      ],
      "linker": [
        "A disulfide bond"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Humanized mAb, anti-CD33 antigen"
      ],
      "Max Phase": null,
      "developers": [
        "IMMUNOGEN"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB06318",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-CD44v6 | Anti-CD44v6-DM1 | Bivatuzumab mertansine | BIWI-1 | CD44v6-DM1",
      "names": [
        "BIWA-1-DM1",
        "BIWA-4 MERTANSINE",
        "Anti-CD44v6",
        "Anti-CD44v6-DM1",
        "Bivatuzumab mertansine",
        "BIVATUZUMAB MERTANSINE",
        "BIWI-1",
        "CD44v6-DM1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Breast Neoplasms",
        "Squamous cell carcinoma of the head and neck or esophagus"
      ],
      "targets": [
        "CD44v6 | (homing function and Indian blood group system, chondroitin sulfate proteoglycan 8, CSPG8) variant 6 (CD44v6, CD44V6)"
      ],
      "payload": [
        "DM1"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN",
        "Boehringer Ingelheim"
      ],
      "chembl": "CHEMBL2109288",
      "trials": [
        "NCT02254005",
        "NCT02254018"
      ],
      "locations": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 2
    },
    {
      "heading": "UC-961ADC3 | Cirmtuzumab Vedotin | Cirmtuzumab Vedotin UC-961ADC3",
      "names": [
        "UC-961ADC3",
        "Cirmtuzumab Vedotin",
        "Cirmtuzumab Vedotin UC-961ADC3"
      ],
      "phases": [],
      "conditions": [
        "Chronic lymphocytic leukemia (CLL)",
        "Many different solid-tumors",
        "B-cell lymphomas",
        "Acute leukemias"
      ],
      "targets": [
        "Receptor  tyrosine-kinase  like  orphan  receptor  (ROR1), a  member  of  the tyrosine kinase family. (ROR1 expressing cells (e.g. CLL cells, JeKo-1 cells, or solid tumor cells) or ROR1-negative cells (e.g. Ramos and Jurkat cells)."
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Lysine-linker with a drug to antibody ratio of 2.5  The proprietaryby  linker was developed Concortis Biosystems, San Diego, USA."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "UC-961 Cirmtuzumab"
      ],
      "Max Phase": null,
      "developers": [],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GM103",
      "names": [
        "GM103"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Anti-M\u00fcllerian hormone type II receptor (AMHRII)"
      ],
      "payload": [
        "Auristatin derivative"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GamaMabs"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "\u00b9\u00b3\u00b9I-chTNT-1/B mAb | Derlotuximab Biotin",
      "names": [
        "\u00b9\u00b3\u00b9I-chTNT-1/B mAb",
        "Derlotuximab Biotin"
      ],
      "phases": [],
      "conditions": [
        "Recurrent glioblastoma multiforme"
      ],
      "targets": [
        "DNA-histone H1 complex"
      ],
      "payload": [
        "Radio labeled  Iodine | 131 I"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "immunoglobulin G1-kappa, anti-[Homo sapiens DNA/histone 1 (H1) complex], chimeric monoclonal antibody (TNT-1/B monoclonal antibody)"
      ],
      "Max Phase": null,
      "developers": [
        "Peregrine Pharmaceuticals"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DT2219ARL | IND100780 | GTB-1550 | OXS-1550 | DT-2219ARL | GTB-1550 OXS-1550 | DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein",
      "names": [
        "DT2219ARL",
        "IND100780",
        "GTB-1550",
        "OXS-1550",
        "DT-2219ARL",
        "GTB-1550 OXS-1550",
        "DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein"
      ],
      "phases": [
        "Phase 1",
        "Phase 1/2"
      ],
      "conditions": [
        "Lymphoma",
        "Advanced B-cell lymphoid malignancies.  Leukemia",
        "Neoplasms"
      ],
      "targets": [
        "Two targets: CD19 and CD22.  CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development; also expressed on most B-cell mature lymphoma cells and leukemia cells.  CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia; Often co-expressed with CD19 on mature B-cell malignancies such as lymphoma."
      ],
      "payload": [
        "A modified form of diphtheria toxin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "GTB-1550 | OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.  When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload."
      ],
      "Max Phase": "2",
      "developers": [
        "Georgetown Translational (Oxis Biotech)"
      ],
      "trials": [
        "NCT04146610"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "IKS01",
      "names": [
        "IKS01"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Gastric Cancer",
        "Breast Cancer",
        "Solid Tumors",
        "Gastroesophageal-junction Cancer"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Iksuda"
      ],
      "trials": [
        "NCT05872295"
      ],
      "locations": [
        "Australia"
      ],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "IKS02",
      "names": [
        "IKS02"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Iksuda"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IKS03",
      "names": [
        "IKS03"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Iksuda"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IKS04",
      "names": [
        "IKS04"
      ],
      "phases": [],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [],
      "payload": [
        "Femtogenix's sequence-selective DNA-interactive payload molecule"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Iksuda"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "NBE-002 \u2013 ROR-1 | NBE-002 NBE-002 - ROR-1",
      "names": [
        "NBE-002 \u2013 ROR-1",
        "NBE-002 NBE-002 - ROR-1",
        "NBE-002"
      ],
      "phases": [
        "Preclinical",
        "Phase 1/2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC) Lung Cancer CLL - MCL"
      ],
      "targets": [
        "Receptor  tyrosine-kinase  like  orphan  receptor  (ROR1), a  member  of  the tyrosine kinase family. (ROR1 expressing cells (e.g. CLL cells, JeKo-1 cells, or solid tumor cells) or ROR1-negative cells (e.g. Ramos and Jurkat cells)."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "NBE Therapeutics"
      ],
      "ttd": "D79HBK",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "NBE-003",
      "names": [
        "NBE-003"
      ],
      "phases": [],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC) Pancreatic Carcinoma"
      ],
      "targets": [
        "Undisclosed target"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "NBE Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "NBE-001",
      "names": [
        "NBE-001"
      ],
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "targets": [
        "Undisclosed target"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "NBE Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SGN-19A SGN-CD19A hBU12-491 | Denintuzumab mafodotin | hBU12-491 | SGN-19A | SGN-CD19A",
      "names": [
        "DENINTUZUMAB MAFODOTIN",
        "SGN-19A SGN-CD19A hBU12-491",
        "Denintuzumab mafodotin",
        "hBU12-491",
        "SGN-19A",
        "SGN-CD19A"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma",
        "Glioblastoma Multiforme",
        "All ALL and NHL  Acute lymphoblastic leukemia (ALL)  Aggressive non-Hodgkin\u2019s lymphoma (NHL)  Refractory B-lineage non-Hodgkin lymphoma",
        "Malignant Glioma",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse",
        "Burkitt Lymphoma"
      ],
      "targets": [
        "CD19 (B lymphocyte surface antigen B4, Leu-12)"
      ],
      "payload": [
        "Monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "A noncleavable maleimidocaproxyl-valine-citrulline linker.  An average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "IgG1 - kappa  huBU12"
      ],
      "Max Phase": "2",
      "developers": [
        "Seagen"
      ],
      "chembl": "CHEMBL3545371",
      "trials": [
        "NCT01786096",
        "NCT02590263",
        "NCT01786135"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "# conditions": 8,
      "# locations": 2,
      "# trials": 3
    },
    {
      "heading": "Depatuxizumab Mafodotin | ABT-414 | ABT-414 ABT-414/806 Depatux-M",
      "names": [
        "Depatuxizumab Mafodotin",
        "ABT-414",
        "ABT-414 ABT-414/806 Depatux-M",
        "DEPATUXIZUMAB MAFODOTIN"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "non-small-cell lung cancer",
        "Gliosarcoma",
        "Glioblastoma",
        "Glioblastoma Multiforme",
        "Squamous cell tumors",
        "1L and 2L Glioblastoma Multiforme (GBM) and solid tumors",
        "Malignant Glioma",
        "Squamous Cell Tumors",
        "Pediatric Brain Tumors"
      ],
      "targets": [
        "EGFR/EGFRde2-7 (EGFRvIII) | EGFR  (epidermal growth factor receptor, receptor tyrosine-protein  kinase erbB-1, ERBB1, HER1, HER-1, ERBB"
      ],
      "payload": [
        "Monomethyl Aurisatin F (MMAF)"
      ],
      "linker": [
        "A stable noncleavable maleimidocaproyl (mc) linker  on an average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa | Depatuxizumab (ABT-806)"
      ],
      "Max Phase": "3",
      "developers": [
        "AbbVie"
      ],
      "chembl": "CHEMBL3707277",
      "trials": [
        "NCT02573324",
        "NCT02343406",
        "NCT02590263",
        "NCT01741727",
        "NCT01800695"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Ireland",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Finland",
        "Argentina",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "New Zealand",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 9,
      "# locations": 32,
      "# trials": 5
    },
    {
      "heading": "DNIB0600A | Lifastuzumab Vedotin | MNIB2126A  Anti-NaPi2b ADC RG-7599 | RG-7599",
      "names": [
        "DNIB0600A",
        "MNIB2126A  Anti-NaPi2b ADC RG-7599",
        "RG-7599",
        "NAPI3B",
        "LIFASTUZUMAB VEDOTIN",
        "DNIB-0600A",
        "Lifastuzumab Vedotin"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Platinum-resistant ovarian cancer",
        "Non-small-cell lung cancer"
      ],
      "targets": [
        "Phosphate-sodium cotransporter SLC34A2 (solute carrier family 34 sodium phosphate member 2, sodium/phosphate cotransporter 2B, NaPi2b, NaPi3b, NAPI-3B)."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker on an average of 3-4 cysteinyl  (Protease-cleavable peptide linker (vc- MMAE platform; Seattle Genetics)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "TAT211"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "ttd": "D05YYP",
      "chembl": "CHEMBL4297938",
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-MUC16 ADC | DMUC5754A | Sofituzumab vedotin | RG7458",
      "names": [
        "SOFITUZUMAB VEDOTIN",
        "RG-7458",
        "RG7458",
        "Anti-MUC16 ADC",
        "DMUC-5754A",
        "Sofituzumab vedotin",
        "DMUC5754A"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Ovarian Cancer, Pancreatic Cancer",
        "Ovarian cancer, fallopian tube cancer, Pancreatic cancer, Peritoneal cancer"
      ],
      "targets": [
        "Mucin 16 (Mucin 16, MUC-16, cancer antigen 125, CA125)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Roche"
      ],
      "chembl": "CHEMBL3545372",
      "trials": [
        "NCT01335958"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "CDP-671 | CMB-401 | hCTMO1-calicheamicin | hCTMO1-calicheamicin CDP-671",
      "names": [
        "CDP-671",
        "CMB-401",
        "hCTMO1-calicheamicin",
        "hCTMO1-calicheamicin CDP-671"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Monotherapy for the treatment of recurrent platinum-sensitive epithelial ovarian carcinoma (EOC)"
      ],
      "targets": [
        "MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227)"
      ],
      "payload": [
        "Calicheamicin"
      ],
      "linker": [
        "Amide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - nd"
      ],
      "Max Phase": "2",
      "developers": [
        "Pfizer",
        "Celltech",
        "WYETH"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BR96-DOX | SGN-15 | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248",
      "names": [
        "SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin",
        "SGN-15",
        "BMS-182248",
        "BR96-DOX"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Disease, Hodgkin",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Advanced breast cancer",
        "Breast Cancer",
        "Ovarian Neoplasms",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Non-Small Cell Lung Carcinoma",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "HER2-Positive Metastatic Breast Cancer",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Peripheral T-cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Hodgkin Disease",
        "B-Cell Lymphoma",
        "Carcinoma, Non-Small-Cell Lung",
        "Lymphoma, Non Hodgkin",
        "NSCLC",
        "T-Cell Lymphoma",
        "Classical Hodgkin Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Prostate",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "HER2-positive Early Breast Cancer",
        "Large B-Cell Lymphoma",
        "Prostatic Neoplasms",
        "Various leukemias and carcinomas",
        "Double-Expressor Lymphoma",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Anaplastic Large-Cell Lymphoma",
        "Breast Neoplasms",
        "Stage III Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Lymphoma, T-cell",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "Lewis Y (Le(y)) antigen"
      ],
      "payload": [
        "Doxorubicin"
      ],
      "linker": [
        "A hydrazone linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Bristol Myers Squibb",
        "Seagen"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB05818",
      "trials": [
        "NCT03991884",
        "NCT01920932",
        "NCT03755804",
        "NCT05600686",
        "NCT00051584",
        "NCT01992653",
        "NCT06486441",
        "NCT01060904",
        "NCT03274492",
        "NCT04203641",
        "NCT03646123",
        "NCT04914741",
        "NCT02292979",
        "NCT05404945",
        "NCT00051571",
        "NCT02605915",
        "NCT06377566",
        "NCT03726879",
        "NCT05113251",
        "NCT01712490",
        "NCT00031187",
        "NCT04790903",
        "NCT02505269",
        "NCT05673785",
        "NCT06112379",
        "NCT04569032",
        "NCT06132958",
        "NCT04685616",
        "NCT03677141",
        "NCT00086333",
        "NCT01777152",
        "NCT06340568",
        "NCT06047080",
        "NCT02734771",
        "NCT02979522",
        "NCT00028483",
        "NCT01534078",
        "NCT04594798",
        "NCT03467373",
        "NCT01309789",
        "NCT01966471",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# conditions": 49,
      "# locations": 54,
      "# trials": 42
    },
    {
      "heading": "BAY 1187982 | BAY 1187982 BAY1187982 FGFR2-ADC | Aprutumab ixadotin",
      "names": [
        "FGFR2-ADC",
        "Aprutumab ixadotin",
        "BAY1187982",
        "BAY 1187982 BAY1187982 FGFR2-ADC",
        "APRUTUMAB IXADOTIN",
        "BAY 1187982",
        "BAY-1187982"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors (overexpressing FGFR2)"
      ],
      "targets": [
        "FGFR2 (fibroblast growth factor receptor 2, | bacteria-expressed kinase (BEK) | Craniofacial dysostosis 1 (CFD1)| Jackson-Weiss syndrome (JWS) | Keratinocyte growth factor receptor (KGFR); Crouzon syndrome (CEK3) | ECT1 K-SAM | TK14 | TK25 | CD332."
      ],
      "payload": [
        "Auristatin W derivative   on an average of 4 lysyl"
      ],
      "linker": [
        "A noncleavable linker  An average of 4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - lambda (a fully human anti-FGFR2 antibody BAY 1179470)"
      ],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "ttd": "D01MZT",
      "chembl": "CHEMBL4650293",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "EC-mAb | h2H12ec-SGD-1910 | SGN-CD33A | Vadastuximab talirine | h2H12ec-mc-val-ala-SGD-1882",
      "names": [
        "SGN - CD33A",
        "EC-mAb",
        "h2H12ec-SGD-1910",
        "SGN-CD33A",
        "Vadastuximab talirine",
        "SGNCD33A",
        "h2H12ec-mc-val-ala-SGD-1882",
        "VADASTUXIMAB TALIRINE"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia",
        "Myelodysplastic syndromes (MDS)",
        "Ulcerative Colitis (UC)",
        "Acute myeloid leukemia (AML)",
        "Acute Myelogenous Leukemia",
        "Acute Myeloid Leukemia",
        "Gastric Adenocarcinoma"
      ],
      "targets": [
        "CD33 (Sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer SGD-1882"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimidocaproyl type linker.   An average of 2 site-specific drug attachment engineered cysteines (C239, C239')"
      ],
      "domain": [
        "Oncology, Hematoloy, Immunology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Seagen"
      ],
      "chembl": "CHEMBL3990021",
      "trials": [
        "NCT01902329",
        "NCT02326584"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 7,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "Cantuzumab mertansine | huC242-DM1 | SB408075 | SB-408075",
      "names": [
        "SB408075",
        "CANTUZUMAB MERTANSINE",
        "HUC242-DM1",
        "Cantuzumab mertansine",
        "huC242-DM1",
        "HUC-242-DM1",
        "SB-408075"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Pancreatic cancer, biliary cancer, colorectal cancers, gastric cancers, uterine cancers, non-small cell lung cancers (NSCLC), and bladder cancer"
      ],
      "targets": [
        "CanAg (a glycoform of MUC1 (sialylated carbohydrate tumour-associated (CA242, cancer antigen 242)"
      ],
      "payload": [
        "Maytansinoid antimicrotubule agent DM1 | N(sup 2')-deacetyl-N(sup 2')-(3-sulfanylpropanoyl)maytansine"
      ],
      "linker": [
        "A stabel thiopentanoate linker (or reducible SPP (N-succinimidyl 4-(2-pyridyldithio)) linker)   An average of 4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "GlaxoSmithKline"
      ],
      "chembl": "CHEMBL1742997",
      "drugbank": "https://go.drugbank.com/drugs/DB17239",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anetumab Ravtansine | BAY 94-9343",
      "names": [
        "BAY94-9343",
        "BAY 94-9343",
        "BAY-949343",
        "ANETUMAB RAVTANSINE",
        "Anetumab Ravtansine",
        "BAY-94-9343",
        "Anetumab ravtansine"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Oncology",
        "Solid tumors / Malignant pleural mesothelioma",
        "Mesothelioma",
        "Ovarian Neoplasms",
        "Medical Oncology",
        "Pancreatic Cancer",
        "Neoplasms"
      ],
      "targets": [
        "Mesothelin | MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte potentiating factor, MPF, CAK1)"
      ],
      "payload": [
        "Maytansinoid DM4 (microtubule inhibitor)"
      ],
      "linker": [
        "A reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate] on an average of 3 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - lambda; BAY 86-1903"
      ],
      "Max Phase": "2",
      "developers": [
        "Bayer"
      ],
      "ttd": "D0CN9D",
      "chembl": "CHEMBL2109629",
      "drugbank": "https://go.drugbank.com/drugs/DB14809",
      "trials": [
        "NCT02751918",
        "NCT03023722",
        "NCT02639091",
        "NCT02696642",
        "NCT02610140",
        "NCT02485119",
        "NCT03102320",
        "NCT02824042",
        "NCT01439152"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Moldova, Republic of",
        "Finland",
        "Spain",
        "Singapore",
        "Switzerland",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Netherlands",
        "Australia",
        "Russian Federation",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "# conditions": 7,
      "# locations": 18,
      "# trials": 9
    },
    {
      "heading": "SAR 3419 | SAR3419 | Coltuximab Ravtansine",
      "names": [
        "COLTUXIMAB RAVTANSINE",
        "SAR 3419",
        "SAR3419",
        "Coltuximab ravtansine",
        "Coltuximab Ravtansine",
        "SAR-3419"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma (NHL)",
        "Diffuse Large B-Cell Lymphoma (DLBCL)/Acute lymphoblastic leukemia (ALL)",
        "Diffuse Large B-cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "CD19 | B lymphocyte surface antigen B4, Leu-12"
      ],
      "payload": [
        "Maytansine DM4 (microtubule inhibitor)"
      ],
      "linker": [
        "A reducible SPDB/(N-succinimidyl-4-(2-pyridyldithio)butyrate.  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "chembl": "CHEMBL2109286",
      "drugbank": "https://go.drugbank.com/drugs/DB06342",
      "trials": [
        "NCT01472887",
        "NCT01470456"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Israel",
        "Austria",
        "Poland",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Belgium",
        "France",
        "Norway",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 12,
      "# trials": 2
    },
    {
      "heading": "Azintuxizumab Vedotin | ABBV-838 | ABBV-838 ABBV838",
      "names": [
        "Azintuxizumab Vedotin",
        "ABBV-838",
        "AZINTUXIZUMAB VEDOTIN",
        "ABBV-838 ABBV838"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Multiple myeloma (MM) |  Plasma cell myeloma"
      ],
      "targets": [
        "SLAMF7 (SLAM family member 7, CD2 subset 1, CS1, CD2-like receptor-activating cytotoxic cells, CRACC, 19A24, CD319)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.   On an average of 3 cysteinyl"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "chembl": "CHEMBL4297859",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Clivatuzumab Tetraxetan | hPAM4 | hPAM4-DOTA | hPAM4 IgG-DOTA",
      "names": [
        "hPAM4 IgG-DOTA",
        "HPAM4-DOTA",
        "S9S0HY-PAM4",
        "HPAM-4-DOTA",
        "hPAM4",
        "HPAM-4",
        "IgG-DOTA",
        "YTTRIUM (90Y) CLIVATUZUMAB TETRAXETAN",
        "Clivatucyn",
        "90HY-PAM4",
        "hPAM4-DOTA",
        "CLIVATUZUMAB TETRAXETAN",
        "Clivatuzumab Tetraxetan",
        "90Y-HPAM4",
        "HPAM4-CIDE",
        "HPAM-DOTA HY-PAM4",
        "YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN",
        "90Y-HPAMA4",
        "IMMU-107"
      ],
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "targets": [
        "MUC1  (mucin 1) is a glycoprotein with extensive O-linked glycosylation of its extracellular domain."
      ],
      "payload": [
        "Yttrium-90-labeled (90Y)   Chelator tetraxetan (DOTA)"
      ],
      "linker": [
        "Conjugated, on an average of 4 to 7 lysyl, linked to the chelator by their N6."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Clivatuzumab"
      ],
      "Max Phase": "3",
      "developers": [
        "Immunomedics"
      ],
      "chembl": [
        "CHEMBL3301586",
        "CHEMBL2108708"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Epitumomab cituxetan | Anti-MUC1 Therapeutic",
      "names": [
        "Epitumomab cituxetan",
        "Anti-MUC1 Therapeutic",
        "HMFG 1",
        "EPITUMOMAB CITUXETAN"
      ],
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Epithelial ovarian"
      ],
      "targets": [
        "MUC1 (mucin 1, polymorphic epithelial mucin, PEM, episialin, CD227)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "HMFG 1"
      ],
      "Max Phase": "3",
      "chembl": "CHEMBL2108592",
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin",
      "names": [
        "IBRITUMOMAB TIUXETAN",
        "Ibritumomab tiuxetan",
        "ZEVALIN",
        "IDEC-IN2B8",
        "In-111 Zevalin Y-90 Zevalin",
        "IDEC-Y2B8",
        "Zevalin Kit-Indium-111",
        "IDEC-129",
        "IDEC-Y2B8 IDEC-129"
      ],
      "phases": [
        "Phase 4"
      ],
      "conditions": [
        "Non-Hodgkin's lymphoma (NHL)"
      ],
      "targets": [
        "MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)"
      ],
      "payload": [
        "Conjugated with chelator tiuxetan  radiolabelled with Yttrium-90, Y-90 (Therapeutic) and Indium-111, In-111 (Diagnostic)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "4",
      "developers": [
        "Biogen",
        "Schering"
      ],
      "chembl": "CHEMBL1201606",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BESPONSA\u00ae | CMC-544 CMC544 | Inotuzumab ozogamicin | CMC-544",
      "names": [
        "WAY-207294 CMC-544",
        "BESPONSA\u00ae",
        "WAY-207294",
        "CMC-544 CMC544",
        "CMC-544",
        "Besponsa",
        "PF-05208773",
        "INOTUZUMAB OZOGAMICIN",
        "Inotuzumab ozogamicin"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Refractory B Acute Lymphoblastic Leukemia",
        "Acute Lymphocytic Leukemia",
        "Aggressive non-Hodgkin\u2019s lymphoma",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Lymphoma",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Refractory B Lymphoblastic Lymphoma",
        "B cell acute lymphoblastic leukemia (B cell ALL)",
        "B-Cell Lymphoma",
        "ALL",
        "Recurrent B Lymphoblastic Lymphoma",
        "Precursor b-Cell Lymphoblastic Leukemia-Lymphoma",
        "ACUTE LYMPHOBLASTIC LEUKEMIA",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Leukemia",
        "Acute Lymphoblastic Leukemia",
        "B-cell Acute Lymphoblastic Leukemia",
        "Leukemia, Acute Lymphoblastic"
      ],
      "targets": [
        "CD22  (Sialic Acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)"
      ],
      "payload": [
        "N-acetyl- \u03b3\u00a0Calicheamicin"
      ],
      "linker": [
        "Hydrazone (4-(4-acetylphenoxy) butanoic acid)"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "IgG4 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "chembl": "CHEMBL2108611",
      "drugbank": "https://go.drugbank.com/drugs/DB05889",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf",
      "trials": [
        "NCT03991884",
        "NCT01134575",
        "NCT03962465",
        "NCT00868608",
        "NCT04307576",
        "NCT03913559",
        "NCT03677596",
        "NCT01055496",
        "NCT01679119",
        "NCT01564784",
        "NCT05016947",
        "NCT00073749",
        "NCT00724971",
        "NCT01363297",
        "NCT05748171",
        "NCT00867087",
        "NCT05687032",
        "NCT00717925",
        "NCT00299494"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "India",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Hong Kong",
        "Switzerland",
        "Australia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Slovakia",
        "Belgium",
        "Estonia"
      ],
      "# conditions": 19,
      "# locations": 36,
      "# trials": 19
    },
    {
      "heading": "Laprituximab emtansine | IMGN-289 IMGN289 J2898A-SMCC-DM1 | IMGN-289 | IMGN289",
      "names": [
        "Laprituximab emtansine",
        "IMGN-289 IMGN289 J2898A-SMCC-DM1",
        "IMGN-289",
        "IMGN289"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",
        "Non-Hodgkin's Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Diffuse Large B-cell Lymphoma",
        "B-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Richter Syndrome",
        "Lymphoma, Non-Hodgkin",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Non-Hodgkins Lymphoma",
        "Acute Lymphoblastic Leukemia",
        "Large B-Cell Lymphoma",
        "Lymphoma, T-Cell",
        "Double-Expressor Lymphoma",
        "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
        "B-cell Non Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "High-grade B-cell Lymphoma",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "Cancers, head and neck, Cancers, non-small cell lung (NSCLC), Solid tumors (EGFR positive)",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB"
      ],
      "payload": [
        "Maytansinoid DM1"
      ],
      "linker": [
        "A noncleavable succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker.  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "IMMUNOGEN"
      ],
      "trials": [
        "NCT02611323",
        "NCT04182204",
        "NCT03671018",
        "NCT05283720",
        "NCT01209130",
        "NCT05600686",
        "NCT01134575",
        "NCT04404283",
        "NCT01992653",
        "NCT03274492",
        "NCT05171647",
        "NCT05800366",
        "NCT05498220",
        "NCT04914741",
        "NCT01421667",
        "NCT01796171",
        "NCT01290549",
        "NCT01679119",
        "NCT05798156",
        "NCT04679012",
        "NCT04790903",
        "NCT02677155",
        "NCT01470456",
        "NCT01691898",
        "NCT00867087",
        "NCT05991388",
        "NCT02734771",
        "NCT06047080",
        "NCT04594798",
        "NCT02257567",
        "NCT02729896",
        "NCT00299494",
        "NCT02600897",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Finland",
        "Israel",
        "Argentina",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Ukraine",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 29,
      "# locations": 40,
      "# trials": 34
    },
    {
      "heading": "BAY 1129980 | BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer | LYPD3 protein-directed - s - Bayer | Lupartumab amadotin",
      "names": [
        "BAY 1129980",
        "BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer",
        "LYPD3 protein-directed - s - Bayer",
        "Lupartumab amadotin"
      ],
      "phases": [
        "Phase 1",
        "Phase i  i"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "targets": [
        "LYPD3 (LY6/PLAUR domain containing 3, C4.4A )"
      ],
      "payload": [
        "Auristatin W derivative"
      ],
      "linker": [
        "A partially reduced S-cystine sulfurhydryl groups.  On an average of KRN-23"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - lambda"
      ],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "177lu | Lilotomab satetraxetan | lutetium | lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1",
      "names": [
        "177Lu",
        "177Lu-PSMA-617",
        "Lilotomab satetraxetan",
        "Pluvicto\u00ae",
        "lutetium",
        "177lu",
        "Lutetium",
        "177Lu-tetraxetan-HH1",
        "lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1",
        "177Lu-DOTA-HH1",
        "Vipivotide Tetraxetan  177Lu-PSMA-617",
        "LUTETIUM (LU177) LILOTOMAB SATETRAXETAN",
        "Vipivotide Tetraxetan"
      ],
      "phases": [
        "Phase 1",
        "Approved",
        "Phase 1/2"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive  metastatic castration-resistant prostate cancer (mCRPC) who have been  treated with androgen receptor (AR) pathway inhibition and taxane-based  chemotherapy.",
        "Non-Hodgkin's lymphoma (NHL)"
      ],
      "targets": [
        "CD37 (tetraspanin-26, TSPAN26)",
        "Prostate-specific membrane antigen (PSMA), present in the majority of patients with mCRPC"
      ],
      "payload": [
        "conjugated with chelator satetraxetan (DOTA derivative; p-SCN-Bn-DOTA)  radiolabelled with Lutetium-177, Lu-177",
        "A beta-emitting radioisotope (lutetium-177 or 177Lu), branded as EndolucinBeta\u00ae"
      ],
      "linker": [],
      "domain": [
        "Oncology",
        "Oncology Hematology"
      ],
      "antibody": [
        "PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand.",
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Novartis",
        "Nordic Nanovector",
        "Endocyte"
      ],
      "chembl": "CHEMBL4802261",
      "trials": [
        "NCT04786847"
      ],
      "locations": [
        "Australia"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "Debio 1562 | IMGN529 | K7153A-SMCC-DM1 | Naratuximab emtansine | naratuximab emtansine | K7153A",
      "names": [
        "Debio 1562",
        "IMGN529",
        "DEBIO-1562",
        "IMGN 529",
        "K7153A-SMCC-DM1",
        "Naratuximab emtansine",
        "naratuximab emtansine",
        "K7153A",
        "NARATUXIMAB EMTANSINE",
        "IMGN-529"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Lymphoma, diffuse large B cell (DLBCL)",
        "non-Hodgkin\u2019s lymphoma",
        "Chronic lymphocytic leukemia"
      ],
      "targets": [
        "CD37 (tetraspanin-26, TSPAN26)"
      ],
      "payload": [
        "Maytansine DM1 (microtubule inhibitor"
      ],
      "linker": [
        "a succinimidyl-4-(N-maleimidomethyl) cyclohexane-  1-carboxylate (SMCC) linker forming a nonreducible thioether bond.  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "humanized IgG1 antibody K7153A"
      ],
      "Max Phase": "2",
      "developers": [
        "Debiopharm",
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL2109268",
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "RO5541072-000 | DCDT2980S | FCU2803 | RG-7593 | ACD22-VCMMAE | DCDT-2989S | Pinatuzumab vedotin",
      "names": [
        "RO5541072-000",
        "ACD-22-VCMMAE",
        "DCDT-2980S",
        "DCDT2980S",
        "FCU2803",
        "RG-7593",
        "ACD22-VCMMAE",
        "RO-5541072000",
        "DCDT-2989S",
        "FCU-2703",
        "RO-5541072-000",
        "FCU2703",
        "PINATUZUMAB VEDOTIN",
        "ACD-22VCMMAE",
        "Pinatuzumab vedotin"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "B cell lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",
        "Diffuse large B cell lymphoma (DLBCL)",
        "Chronic lymphocytic leukemia (CLL)",
        "Non-Hodgkin's lymphoma (NHL)"
      ],
      "targets": [
        "CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.   An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": "CHEMBL3301585",
      "trials": [
        "NCT01691898",
        "NCT01209130"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "France",
        "Netherlands",
        "United States"
      ],
      "# conditions": 7,
      "# locations": 6,
      "# trials": 2
    },
    {
      "heading": "Polivy\u2122 | ACD79B-VCMMAE | Polatuzumab vedotin | RG-7596 | DCDS4501A | FCU2711 | DCDS-4501A | RO5541077-000",
      "names": [
        "ANTI-CD79B ADC",
        "POLIVY",
        "FCU2711",
        "POLATUZUMAB VEDOTIN PIIQ",
        "DCDS4501A",
        "POLATUZUMAB VEDOTIN",
        "ACD-79B-VCMMAE",
        "ACD-79BVCMMAE",
        "RO-5541077-000",
        "Polivy",
        "ACD79B-VCMMAE",
        "Polatuzumab vedotin",
        "RG7596",
        "RO-5541077000",
        "Polivy\u2122",
        "RG-7596",
        "DCDS-4501A",
        "FCU-2711",
        "RO5541077-000"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Richter's Transformation",
        "Grade 3a Follicular Lymphoma",
        "Non-Hodgkin's Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "B-cell Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Aggressive Non-Hodgkin Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "B-Cell Lymphoma",
        "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma",
        "B-Cell Non-Hodgkin Lymphoma",
        "Marginal Zone Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Large B-cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "Richter Syndrome",
        "Refractory Non-Hodgkin Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "Relapsed Diffuse Large B-cell Lymphoma",
        "Relapsed B-Cell Non-Hodgkin Lymphoma",
        "Non-Hodgkins Lymphoma",
        "Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma (DLBCL) / B-cell malignancies / Chronic lymphocytic leukemia (CLL) / Non-Hodgkin's lymphoma (NHL)",
        "Lymphoma, Follicular",
        "Relapsed Non Hodgkin Lymphoma",
        "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Grade 1 Follicular Lymphoma",
        "Transformed Follic Lymph to Diff Large B-Cell Lymphoma",
        "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "CD79b | immunoglobulin-associated CD79 beta"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.   An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "chembl": "CHEMBL3301582",
      "drugbank": "https://go.drugbank.com/drugs/DB12240",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf",
      "trials": [
        "NCT02611323",
        "NCT06043674",
        "NCT03671018",
        "NCT04182204",
        "NCT05283720",
        "NCT05260957",
        "NCT01992653",
        "NCT03274492",
        "NCT05171647",
        "NCT06071871",
        "NCT05800366",
        "NCT05498220",
        "NCT03533283",
        "NCT05633615",
        "NCT04914741",
        "NCT01290549",
        "NCT05410418",
        "NCT04833114",
        "NCT05798156",
        "NCT05169658",
        "NCT04679012",
        "NCT04790903",
        "NCT03677141",
        "NCT03677154",
        "NCT01691898",
        "NCT06047080",
        "NCT04844866",
        "NCT04594798",
        "NCT02257567",
        "NCT03467373",
        "NCT02729896",
        "NCT04970901",
        "NCT02600897",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Finland",
        "Israel",
        "Argentina",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Ukraine",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 43,
      "# locations": 40,
      "# trials": 34
    },
    {
      "heading": "BL-B029A1 | BL-B029A1 BL B029A1",
      "names": [
        "BL-B029A1",
        "BL-B029A1 BL B029A1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Epithelial Tumor"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Systimmune"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BL-M005A2 | BL M005A2 BL-M005A2",
      "names": [
        "BL-M005A2",
        "BL M005A2 BL-M005A2"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "- Non-small cell lung cancer  (NSCLC)",
        "- Breast cancer"
      ],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Systimmune"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BL-M002A2 | BL M002A2 BL-M002A2",
      "names": [
        "BL-M002A2",
        "BL M002A2 BL-M002A2"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "- Glioma - Lung cancer"
      ],
      "targets": [
        "Unknown"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Systimmune"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AVID100 | AVID 100 anti-EGFR ADC",
      "names": [
        "AVID100",
        "AVID 100 anti-EGFR ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 1/2"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid tumors",
        "Advanced epithelial  carcinomas including tumors resistant to currently approved anti-EGFR therapeutics.  - Solid Tumor,  - Adult Triple Negative Breast Cancer  - Head and Neck Squamous Cell Carcinoma  - Non Small Cell Lung Cancer"
      ],
      "targets": [
        "EGFR"
      ],
      "payload": [
        "Microtubule inhibitor Maytansinoid mertansine (DM1)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-EGFR antibody (MAB100)"
      ],
      "Max Phase": "2",
      "developers": [
        "Formation Biologics (Forbius)"
      ],
      "trials": [
        "NCT06210815"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "HM2-MMAE | ALT-P7 ALT-P7 | ALT-P7",
      "names": [
        "HM2-MMAE",
        "ALT-P7 ALT-P7",
        "ALT-P7"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Advanced or refractory breast cancer which is unresponsive to current standard therapy",
        "HER2-positive breast cancer"
      ],
      "targets": [
        "HER2; Human epidermal growth factor receptor 2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab (biobetter)"
      ],
      "Max Phase": "1",
      "developers": [
        "Alteogen",
        "3SBIO"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17220",
      "trials": [
        "NCT03281824"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "T-DM1 | Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla\u00ae | Trastuzumab Emtansine",
      "names": [
        "trastuzumab emtansine",
        "trastuzumab-emtansine",
        "T-DM1",
        "Trastuzumab-DM1",
        "Kadcyla\u00ae",
        "Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502",
        "TRASTUZUMAB EMTANSINE",
        "Kadcyla",
        "RG-3502",
        "PRO-132365",
        "TRASTUZUMAB-MCC-DM1 T-DM1",
        "ADO-TRASTUZUMAB EMTANSINE",
        "KADCYLA",
        "Trastuzumab Emtansine",
        "Trastuzumab emtansine"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Ovarian Cancer",
        "Non-small Cell Lung Cancer",
        "Synchronous Bilateral Breast Carcinoma",
        "Gastric Cancer",
        "Neoplasia",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Endometrial Cancer",
        "Left Ventricular Function Systolic Dysfunction",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Advanced Unresectable or Metastatic Solid Malignancy",
        "HER2 Amplification",
        "Breast Cancer Female",
        "HER2 Positive Breast Carcinoma",
        "Neoplasms",
        "Pancreas Cancer",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "HER2 Gene Mutation",
        "HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy",
        "HER-2 Positive Breast Cancer",
        "Anatomic Stage IIB Breast Cancer AJCC v8",
        "Cholangiocellular Carcinoma",
        "Tumors",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Invasive Breast Carcinoma",
        "Neoplasm Metastasis",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Urinary Tract Cancers",
        "Inflammatory Breast Cancer",
        "HER2-positive Early Breast Cancer",
        "Multifocal Breast Carcinoma",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "HER2-positive Metastatic Breast Cancer",
        "Metastatic Solid Tumor",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Locally Advanced Breast Cancer",
        "HER2-positive Breast Cancer",
        "Solid Tumors",
        "Metastatic Gastric Adenocarcinoma",
        "Early Breast Cancer",
        "Breast Cancer",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Locally Advanced or Early Breast Cancer",
        "Cancer",
        "Residual Invasive Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Stage IIIC Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Solid Tumor Cancers",
        "HER2 Positive Breast Cancer",
        "Bladder Cancer",
        "Stage IIIA Breast Cancer",
        "HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Recurrent Breast Cancer",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "HER2+ metastatic breast cancer (MBC)",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Gastroesophageal Junction Adenocarcinoma",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "HER2-Positive Primary Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutant Non-small Cell Lung Cancer",
        "Triple Negative Breast Neoplasms",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "Esophageal Adenocarcinoma",
        "Advanced Solid Tumors",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Stage IV Breast Cancer",
        "Anatomic Stage III Breast Cancer AJCC v8"
      ],
      "targets": [
        "HER2/neu proto-oncogene (also called c-erbB-2)  ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Maytansine DM1, a microtubule inhibitor.   N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylmaytansine  on an average of 3-4 lysyl"
      ],
      "linker": [
        "Noncleavable succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "ttd": [
        "D0P4TH",
        "D0UG0K"
      ],
      "chembl": [
        "CHEMBL1743082",
        "CHEMBL2109399"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB05773",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf",
      "trials": [
        "NCT05323955",
        "NCT01976169",
        "NCT02038010",
        "NCT04622319",
        "NCT00932373",
        "NCT02658734",
        "NCT03529110",
        "NCT02073487",
        "NCT02390427",
        "NCT03032107",
        "NCT05673928",
        "NCT00829166",
        "NCT01494662",
        "NCT04486352",
        "NCT00943670",
        "NCT01702571",
        "NCT00934856",
        "NCT06100874",
        "NCT04931342",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT00679211",
        "NCT04632992",
        "NCT00509769",
        "NCT03153163",
        "NCT02605915",
        "NCT04893109",
        "NCT03726879",
        "NCT06126640",
        "NCT06313086",
        "NCT02999672",
        "NCT01120184",
        "NCT00951665",
        "NCT00781612",
        "NCT05113251",
        "NCT01513083",
        "NCT00875979",
        "NCT02924883",
        "NCT02314481",
        "NCT03084939",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT05593094",
        "NCT06324357",
        "NCT01772472",
        "NCT04740918",
        "NCT05650879",
        "NCT04924699",
        "NCT02289833",
        "NCT01419197",
        "NCT00679341",
        "NCT02675829",
        "NCT05415215",
        "NCT01196052",
        "NCT03523585",
        "NCT05755048",
        "NCT04589845",
        "NCT01565200",
        "NCT04457596",
        "NCT04341181",
        "NCT01904903",
        "NCT04733118",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 84,
      "# locations": 72,
      "# trials": 66
    },
    {
      "heading": "TAK-522 | XMT-1522 | XMT1522 TAK-522",
      "names": [
        "TAK-522",
        "XMT-1522",
        "XMT1522 TAK-522"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Nonsmall Cell Lung Cancer",
        "Advanced Breast Cancer",
        "Advanced Gastric Cancer"
      ],
      "targets": [
        "Epidermal growth factor receptor 2  (HER2)"
      ],
      "payload": [
        "Auristatin F-hydroxypropylamide, (AF-HPA) | (MMAF-HPA)  An average drug-to-antibody ration (DAR) of 12"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An engineered novel mAb (HT-19) optimized for ADC; binds to a unique  epitope distinct from trastuzumab or  pertuzumab."
      ],
      "Max Phase": "1",
      "developers": [
        "Takeda",
        "Mersana"
      ],
      "trials": [
        "NCT02952729"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "ARX788 HER2 ADC | ARX788",
      "names": [
        "ARX788 HER2 ADC",
        "ANVATABART OPAFIDOTIN",
        "ARX788 ADC",
        "ANVATABART OPADOTIN",
        "Anvatabart opadotin",
        "ARX 788",
        "ARX-788",
        "ARX788"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Carcinoma",
        "Breast Neoplasms",
        "Triple Negative Breast Cancer",
        "HER2 Positive Metastatic Breast Cancer",
        "Solid Tumors",
        "HER2 Low Breast Carcinoma",
        "Gastric Neoplasm",
        "Hormone-receptor-positive Breast Cancer",
        "Solid Tumors (HER2 over-expressing tumors including breast, gastric, colon, pancreatic and ovarian cancers)"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)  Site-specific conjugation   DAR is 1.9"
      ],
      "linker": [
        "A non-natural amino acid linker para-acetyl-phenylalanine (pAcF)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Engineered IgG1  Modified Trastuzumab with a p-acetylphenylalanine (pAcPhe) residue"
      ],
      "Max Phase": "2",
      "developers": [
        "Ambrx"
      ],
      "chembl": "CHEMBL4297892",
      "drugbank": "https://go.drugbank.com/drugs/DB18290",
      "trials": [
        "NCT04829604",
        "NCT06224673",
        "NCT04983121",
        "NCT03255070"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Australia",
        "France",
        "United States"
      ],
      "# conditions": 9,
      "# locations": 5,
      "# trials": 4
    },
    {
      "heading": "Nano-doxorubicin | MM-302",
      "names": [
        "Nano-doxorubicin",
        "MM-302"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Disease, Hodgkin",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Breast Cancer",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "HER2-Positive Metastatic Breast Cancer",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Peripheral T-cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Hodgkin Disease",
        "B-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "T-Cell Lymphoma",
        "Locally advanced/metastatic HER2-positive breast cancer patients who have received prior treatment with trastuzumab in any setting and who have either progressed or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting.",
        "Classical Hodgkin Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "HER2-positive Early Breast Cancer",
        "Large B-Cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Anaplastic Large-Cell Lymphoma",
        "Breast Neoplasms",
        "Stage III Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Lymphoma, T-cell",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Liposomal doxorubicin (Liposome-encapsulated doxorubicin)"
      ],
      "linker": [
        "PEG-DSPE"
      ],
      "domain": [],
      "antibody": [
        "scFv anti-HER2"
      ],
      "Max Phase": "3",
      "developers": [
        "Merrimack"
      ],
      "trials": [
        "NCT03991884",
        "NCT01920932",
        "NCT03755804",
        "NCT05600686",
        "NCT01992653",
        "NCT06486441",
        "NCT01060904",
        "NCT03274492",
        "NCT04203641",
        "NCT03646123",
        "NCT04914741",
        "NCT02292979",
        "NCT05404945",
        "NCT02605915",
        "NCT06377566",
        "NCT03726879",
        "NCT05113251",
        "NCT01712490",
        "NCT04790903",
        "NCT02505269",
        "NCT05673785",
        "NCT06112379",
        "NCT04569032",
        "NCT06132958",
        "NCT04685616",
        "NCT03677141",
        "NCT01777152",
        "NCT06340568",
        "NCT06047080",
        "NCT02734771",
        "NCT02979522",
        "NCT01534078",
        "NCT04594798",
        "NCT03467373",
        "NCT01309789",
        "NCT01966471",
        "NCT04884035"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# conditions": 42,
      "# locations": 54,
      "# trials": 37
    },
    {
      "heading": "Bstrongximab-ADC",
      "names": [
        "Bstrongximab-ADC"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "CureMeta"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PF-06804103 PF 06804103 Anti-NG-HER2 ADC | Anti-NG-HER2 ADC | PF-06804103",
      "names": [
        "PF-06804103 PF 06804103 Anti-NG-HER2 ADC",
        "PF-06804103",
        "Anti-NG-HER2 ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Breast cancer",
        "Gastric cancers.",
        "(Metastatic) Solid tumors",
        "Breast Neoplasms"
      ],
      "targets": [
        "HER2 (human epidermal growth factor receptor 2)"
      ],
      "payload": [
        "Anti-Trop2 Aur0101"
      ],
      "linker": [
        "Cleavable valine-citrulline- linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Pfizer"
      ],
      "trials": [
        "NCT03284723"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Russian Federation",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 6,
      "# trials": 1
    },
    {
      "heading": "IPH43",
      "names": [
        "IPH43"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "MICA/B, a highly polymorphic ligand of the NK cell activating receptor NKG2D"
      ],
      "payload": [
        "Pyrrolobenzodiazepine dimers (PBDs)"
      ],
      "linker": [],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Innate",
        "AstraZeneca"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anetumab corixetan",
      "names": [
        "Anetumab corixetan"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte-potentiating factor, MPF, CAK1)"
      ],
      "payload": [
        "Chelator corixetan, with anaverage of 0.5 chelator per antibody"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "Immunoglobulin G1-lambda2"
      ],
      "Max Phase": null,
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-3373",
      "names": [
        "ABBV-3373"
      ],
      "phases": [],
      "conditions": [
        "Rheumatoid arthritis (RA)"
      ],
      "targets": [
        "TNF"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Anti-TNF monoclonal antibodies / Antirheumatics"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BDC-1001",
      "names": [
        "TRASTUZUMAB IMBOTOLIMOD",
        "BDC 1001",
        "BDC1001",
        "BDC-1001"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "HER2-positive Colorectal Cancer",
        "Gastric Cancer",
        "Breast Cancer",
        "HER2-positive Solid Tumors",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "HER2-positive Endometrial Cancer",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "HER2-Expressing Solid Tumors, including metastatic breast and gastric cancers.",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "HER2-positive Gastroesophageal Cancer",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "HER2-positive Breast Cancer",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "HER2 ((human epidermal growth factor receptor 2)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Bolt"
      ],
      "ttd": "D1XI9E",
      "chembl": "CHEMBL5095315",
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04278144",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT05954143",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 29,
      "# locations": 72,
      "# trials": 22
    },
    {
      "heading": "RN765C",
      "names": [
        "RN765C"
      ],
      "phases": [],
      "conditions": [
        "Metastatic colorectal cancer, Metastatic non-small cell lung cancer, and  Head and neck cancer"
      ],
      "targets": [
        "Epidermal growth factor receptor (EGFR), a member of the ErbB family of type I receptor tyrosine kinases."
      ],
      "payload": [
        "PF-06380101 (Aur0101), an auristatin microtubule inhibitor (a cytotoxic Dolastatin 10 analogue)"
      ],
      "linker": [
        "AcLys-VC (valine-citruline)-PABC (cleavable linker)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-EGFR hIgG1 antibody,"
      ],
      "Max Phase": null,
      "developers": [
        "Rinat",
        "Pfizer"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "STI-6129 LNDS1001 | LNDS1001 | STI-6129 | CD38-077",
      "names": [
        "STI-6129 LNDS1001",
        "LNDS1001",
        "STI-6129",
        "CD38-077"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Light Chain (AL) Amyloidosis",
        "Advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis",
        "Relapsed or Refractory Multiple Myeloma",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "CD38"
      ],
      "payload": [
        "Duostatin 5.2 (Duo.5.2), a microtubule inhibitor. This is a  A novel cytotoxic payload derived from monomethyl auristatin F (MMAF)"
      ],
      "linker": [
        "A non-polyethylene glycol linker"
      ],
      "domain": [],
      "antibody": [
        "CD38 specific antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Sorrento Therapeutics"
      ],
      "trials": [
        "NCT05308225",
        "NCT05584709",
        "NCT05565807",
        "NCT04316442"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 2,
      "# trials": 4
    },
    {
      "heading": "ZV05-mcMMAF | ZV05-ADC | ZV0501 | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501",
      "names": [
        "ZV05-mcMMAF",
        "ZV05-ADC",
        "ZV0501",
        "5T4-MMAF ADC",
        "5T4-MMAF ADC ZV05-mcMMAF ZV0501"
      ],
      "phases": [],
      "conditions": [
        "Gastric cancers.",
        "RCC",
        "Colorectal cancer",
        "Ovarian cancer,  Pancreatic cancer",
        "NSCLC"
      ],
      "targets": [
        "5T4 also known as TPBG or oncofetal antigen, is an N-glycosylated transmembrane 72 kDa glycoprotein."
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)"
      ],
      "linker": [
        "Proprietary linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ZV05"
      ],
      "Max Phase": null,
      "developers": [
        "Zova Biotherapeutics",
        "Concortis"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 5,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AG02",
      "names": [
        "AG02"
      ],
      "phases": [],
      "conditions": [
        "Mesothelioma"
      ],
      "targets": [
        "CSP-1 (surface protein named -1)"
      ],
      "payload": [
        "Saporin  (Routinely used as a cost-effective payload in ADCs for proof-of-concept (POC) studies)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "human cancer cell surface proteins (CSPs)"
      ],
      "Max Phase": null,
      "developers": [
        "A&G"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-RON-ADC | Zt/g4-DM1",
      "names": [
        "Anti-RON-ADC",
        "Zt/g4-DM1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "RON (a tyrosine kinase (TK) receptor of the Met proto-oncogene family., also known as macrophage stimulating 1 receptor or MST1R)"
      ],
      "payload": [
        "Maytansinoid (DM1)"
      ],
      "linker": [
        "A thioether linker"
      ],
      "domain": [],
      "antibody": [
        "Anti-RON mAb Zt/g4 (IgG1a/\u03ba))"
      ],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SAR 566658 | SAR566658",
      "names": [
        "SAR-566658",
        "SAR 566658",
        "SAR566658",
        "huDS6-DM4"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "ovarian, breast, and other epithelial cancers",
        "Solid tumors",
        "Ca6 positive tumors"
      ],
      "targets": [
        "Sialoglycotope CA6/huDS6 (Mucin 1)"
      ],
      "payload": [
        "Maytansine DM4\u00a0(microtubule inhibitor)"
      ],
      "linker": [
        "SPDB"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "chembl": "CHEMBL2109635",
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "lintuzumab satetraxetan | 225Ac | Actinium",
      "names": [
        "lintuzumab satetraxetan",
        "225Ac",
        "Actinium"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma",
        "Prostate Cancer",
        "Non-small Cell Lung Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)"
      ],
      "payload": [
        "Actinium-225 (Ac 225) radiolabelled to satetraxetan (DOTA derivative); average of 1 or 2 lysyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "CD33"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06147037",
        "NCT04946370"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "AstraZeneca",
        "Fusion Pharmaceuticals Inc"
      ],
      "# conditions": 6,
      "# locations": 2,
      "# trials": 2
    },
    {
      "heading": "Mirzotamab Clezutoclax | ABBV-155",
      "names": [
        "MIRZOTAMAB CLEZUTOCLAX",
        "ABBV155",
        "Mirzotamab Clezutoclax",
        "ABBV-155"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid tumors, advanced or metastatic"
      ],
      "targets": [
        "CD276 (B7H3, B7-H3, B7-related protein 2, B7RP2, B7RP-2, B7 homolog 3, B7 homologue 3)"
      ],
      "payload": [
        "Clezutoclax (an inhibitor of BCL2L1)  Average of 2 cysteinyl"
      ],
      "linker": [
        "A cleavable dipeptide (valine-alanine) linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa | mirzotamab, P01-18-P10-18, huAb13v1, huAb13.1a"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "ttd": "DDE82F",
      "chembl": "CHEMBL4594514",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ST8176AA1",
      "names": [
        "ST8176AA1"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "ErbB2+ solid tumors"
      ],
      "targets": [
        "ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2)"
      ],
      "payload": [
        "ST7464AA1, the active form of the prodrug HDAC (Histone deacetylase) inhibitor ST7612AA1  The average drug/antibody ratio (DAR) was 4.5 as measured by hydrophobic interaction chromatography (HIC)"
      ],
      "linker": [
        "A maleimide-thiol linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab. Trastuzumab was partially reduced with tris [2-carboxyethyl] phosphine (TCEP)."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Alfasigma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE | SGN-CD228A",
      "names": [
        "SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE",
        "SGN-CD228A"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors"
      ],
      "targets": [
        "Melanotransferrin (CD228 MFI2 MELTF), a cell-surfaced glycosylphosphatidylinoitol (GPI)-anchored glycoprotein that belongs to the transferrin family of iron-binding proteins.   CD228 was first described as an oncofetal protein highly expressed on malignant melanoma cells.  In addition to melanoma, CD228 is highly expressed in mesothelioma, non-small cell lung (NSCL), breast, colorectal, and pancreatic carcinomas."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE, vedotin)  Drug to antibody-ratio: 8"
      ],
      "linker": [
        "The payload is conjugated via a \u03b2-glucuronidase-cleavable linker, which incorporates a PEG side chain and self-stabilizing maleimide to achieve homogenous conjugation with decreased plasma clearance and increased preclinical antitumor activity."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hL49, an antibody specific for human CD228."
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "ttd": "DS6BE2",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PEN-221 | BTP-227 | PEN221",
      "names": [
        "PEN-221",
        "BTP-227",
        "PEN221"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Neuroendocrine",
        "Small cell lung cancers"
      ],
      "targets": [
        "Somatostatin receptor 2;  SSTR2"
      ],
      "payload": [
        "DM1 (emtansine), a thiol-containing maytansinoid"
      ],
      "linker": [
        "An optimized cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An SSTR2 targeting ligand"
      ],
      "Max Phase": "2",
      "developers": [
        "Tarveda"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PEN-866 | PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666",
      "names": [
        "PEN-866",
        "PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666"
      ],
      "phases": [
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced solid tumors"
      ],
      "targets": [
        "Heat Shock Protein 90 (HSP90)"
      ],
      "payload": [
        "SN-38 (irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin)"
      ],
      "linker": [
        "An optimized cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Heat Shock Protein 90 (HSP90) Ligand (a chaperone protein)"
      ],
      "Max Phase": "2",
      "developers": [
        "Tarveda"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BT1718 | BT-1718 | BT 1718",
      "names": [
        "BT1718",
        "BT-1718",
        "BT 1718"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Soft tissue sarcoma",
        "Triple negative breast cancer",
        "non-small cell lung cancer"
      ],
      "targets": [
        "Membrane type 1-matrix metalloprotease (MT1-MMP; MMP14)"
      ],
      "payload": [
        "DM1 (emtansine), a thiol-containing maytansinoid"
      ],
      "linker": [
        "A hindered disulfide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A bicyclic peptide"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Bicycle Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Satumomab Penditide | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | OncoScint\u00ae CR/OV | 111In | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide",
      "names": [
        "SATUMOMAB PENDETIDE 111IN",
        "INDIUM IN-111 SATUMOMAB PENDETIDE",
        "ONCOSCINT",
        "INDIUM (111IN) SATUMOMAB PENDETIDE",
        "SATUMOMAB",
        "CYT-103 111 IN",
        "CYT-103",
        "Satumomab Penditide",
        "Satumomab pendetide",
        "INDIUM IN 111 SATUMOMAB PENDETIDE",
        "111In",
        "CYT-099",
        "CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium",
        "satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide",
        "SATUMOMAB PENDETIDE INDIUM IN-111",
        "B72.3",
        "INDIUM IN 111 CYT-103",
        "OncoScint\u00ae CR/OV",
        "MONAB B72.3-GYK-DTPA-111IN",
        "SATUMOMAB PENDETIDE"
      ],
      "phases": [
        "Phase 1",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma",
        "Colorectal cancer Ovarian Cancer",
        "Non-small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "Tumor-associated antigen, T AG-72, which is found in many adenocarcinomas."
      ],
      "payload": [
        "Indium-111"
      ],
      "linker": [
        "DTPA as a linker for the added In-111.   Site-specific conjugation of a linker-chelator to the oxidized oligosaccharide component of the B72.3 molecule (CYT-103)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "B72.3 (CYT-099)"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Knoll (Europe)",
        "Lonza Biologics"
      ],
      "chembl": "CHEMBL1743091",
      "trials": [
        "NCT06147037"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "# conditions": 6,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "DOTA-HUJ-591-GS DOTA-HUJ-591 HuJ591-DOTA | Rosopatamab Tetraxetan",
      "names": [
        "DOTA-HUJ-591-GS DOTA-HUJ-591 HuJ591-DOTA",
        "Rosopatamab Tetraxetan"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Prostate cancer"
      ],
      "targets": [
        "FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)"
      ],
      "payload": [
        "Tetraxetan (DOTA), a chelator for yttrium-90, a radioisotope.  on an average of 3 to 5 lysyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-human prostate-specific membrane antigen."
      ],
      "Max Phase": "2",
      "developers": [],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "OTSA-101-DTPA OTSA101-DTPA-90Y | OTSA-101-DTPA | Tabituximab Barzuxetan | OTSA101-SS01",
      "names": [
        "OTSA-101-DTPA OTSA101-DTPA-90Y",
        "OTSA-101-DTPA",
        "Tabituximab Barzuxetan",
        "OTSA101-SS01"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Synovial Sarcoma"
      ],
      "targets": [
        "FZD10 (frizzled class receptor 10, frizzled family receptor 10, Frizzled-10, CD350), a 7-transmenbrane receptor, member of the Wnt signalling receptor family."
      ],
      "payload": [
        "Barzuxetan, p-SCN-Bn-CHX-A\"-DPTA, a DPTA chelator derivative"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa Tabituximab"
      ],
      "Max Phase": "1",
      "developers": [
        "OncoTherapy Science (Japan)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ASP-1929  RM-1929 Cetuximab-irdye 700dx | RM-1929 | Cetuximab sarotalocan | ASP-1929",
      "names": [
        "CETUXIMAB SAROTALOCAN SODIUM",
        "ASP-1929  RM-1929 Cetuximab-irdye 700dx",
        "Cetuximab-IRDye-700DX",
        "Cetuximab sarotalocan",
        "RM-1929",
        "CETUXIMAB SAROTALOCAN",
        "CETUXIMAB-IRDYE 700DX",
        "ASP-1929"
      ],
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Recurrent Head and Neck Cancer Oesophageal cancer"
      ],
      "targets": [
        "Epidermal growth factor (EGFR)  Anti-[Homo sapiens EGFR (epidermal growth factor receptor, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, ERBB)]"
      ],
      "payload": [
        "IRDye\u00ae 700DX (IR700, LI-COR; Lincoln, Nebraska) near-infrared (690 nm) photosensitizing dye"
      ],
      "linker": [
        "Undisclosed"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Cetuximab"
      ],
      "Max Phase": "3",
      "developers": [
        "Aspyrian",
        "Rakuten Medical"
      ],
      "chembl": "CHEMBL4298088",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Tamrintamab Pamozirine | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Anti-DPEP3 ADC | SC-003",
      "names": [
        "Anti-DPEP3 ADC",
        "Tamrintamab pamozirine",
        "SC-003",
        "Tamrintamab Pamozirine",
        "SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "DPEP3 (dipeptidase 3) also known as MBD3, a glycosylphosphatidylinositol anchored membrane protein from the DPEP family of dipeptidase proteins, which are involved in the hydrolytic metabolism of various dipeptides and some antibiotics containing amide-like linkages."
      ],
      "payload": [
        "A pyrrolobenzodiazepine dimer (PBD) SC-DR002  An average of 2 cysteinyl (Cys215' and Cys215''')"
      ],
      "linker": [
        "Protease-cleavable maleimide linker (LD6.23)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens DPEP3 (dipeptidase 3)], humanized monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Stemcentrx",
        "AbbVie"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17222",
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADCT-301 | ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d | HuMax-TAC-ADC | Camidanlumab tesirine",
      "names": [
        "ADCT-301",
        "ADCT301",
        "CAMIDANLUMAB TESIRINE",
        "ADCT 502",
        "ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d",
        "HuMax-TAC-ADC",
        "ADCT-301 TESIRINE",
        "ADCT 301",
        "Camidanlumab tesirine"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "- Non-Hodgkin's lymphoma (NHL) - Hodgkin lymphoma - Acute lymphocytic leukemia (ALL)  Other potential indications being investigated in clinical studies:  - Burkitt's Lymphoma Chronic  - Lymphocytic Leukemia  - Small Lymphocytic Lymphoma  - Large B-Cell Lymphoma - Diffuse Large B-Cell Lymphoma - Follicular Lymphoma - Mantle-Cell Lymphoma - Marginal Zone Waldenstrom's Macroglobulinaemia Lymphoma, - T-cell Cutaneous Lymphoma,  - Peripheral T-Cell Lymphoma,"
      ],
      "targets": [
        "CD25 (IL2RA - interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine dimer SG3199  On an average of 2 cysteinyl"
      ],
      "linker": [
        "A cleavable, valine-alanine dipeptide (as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "CD25 targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Genmab",
        "ADC Therapeutics"
      ],
      "ttd": "D0LL1N",
      "chembl": "CHEMBL4297871",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-647 | PF-06647020 | Cofetuzumab pelidotin | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020",
      "names": [
        "ABBV-647",
        "PTK7-ADC",
        "Gedatolisib",
        "PF-06647020",
        "PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020",
        "Cofetuzumab pelidotin",
        "COFETUZUMAB PELIDOTIN"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Cancer",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Advanced Solid Tumors, including: - Ovarian Cancer,  - Triple Negative Breast Cancer - Recurrent non-small cell lung cancer (NSCLC)",
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer",
        "Neoplasms"
      ],
      "targets": [
        "Protein Tyrosine Kinase 7 (PTK7) | Colon carcinoma kinase 4 (CCK4).   Functions in developmental biology (Wnt signaling and planar cell polarity)  Expression linked to poor prognosis in patients with TNBC and NSCLC  Enriched on cancer stem cells (CSCs), which may contribute to treatment resistance and relapse."
      ],
      "payload": [
        "Auristatin-0101 microtubule inhibitor payload (Aur0101)"
      ],
      "linker": [
        "Cleavable valine-citrulline linker |  a  cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  An average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa  An anti-[Homo sapiens PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody."
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie",
        "Stemcentrx",
        "Pfizer"
      ],
      "chembl": "CHEMBL3989983",
      "trials": [
        "NCT03243331",
        "NCT02222922",
        "NCT04189614"
      ],
      "locations": [
        "Israel",
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "# conditions": 6,
      "# locations": 6,
      "# trials": 3
    },
    {
      "heading": "RO7032005 | DCDS0780A | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin",
      "names": [
        "RO7032005",
        "DCDS0780A",
        "DCDS0780A DCDS 0780A RO7032005",
        "Iladatuzumab vedotin"
      ],
      "phases": [
        "Phase 1/1",
        "Phase 1"
      ],
      "conditions": [
        "Non-Hodgkin's lymphoma (NHL)"
      ],
      "targets": [
        "CD79B (immunoglobulin-associated CD79 beta)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  On an average of 2 cysteinyl."
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker."
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [
        "IgG1 - kappa Anti-[Homo sapiens CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADC",
      "names": [
        "Ladiratuzumab vedotin",
        "SGN-LIV1A",
        "Anti-LIV-1 ADC",
        "LADIRATUZUMAB VEDOTIN"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase ii i"
      ],
      "conditions": [
        "HER2 Mutations Breast Neoplasms",
        "Triple Negative Breast Neoplasms",
        "- Breast Cancer,  - ERBB2 positive cancers including (potential other indications include melanoma, prostate, ovarian, and uterine cancer)  - Small Cell Lung Cancer,  - Non-small Cell Lung Cancer, - Squamous Non-small Cell Lung Cancer,  - Non-squamous Head and Neck Cancer, - Squamous Cell Carcinoma - Esophageal Squamous Cell - Carcinoma Gastric Adenocarcinoma  - Gastroesophageal Junction Adenocarcinoma",
        "Breast Cancer",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms"
      ],
      "targets": [
        "Zinc transporter LIV-1 (anti-solute carrier family 39 zinc transporter member 6 (SLC39A6) or ZIP6."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  On an average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) (a proteolytically cleavable type linker)  Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody."
      ],
      "Max Phase": "2",
      "developers": [
        "Seagen"
      ],
      "ttd": "DS6B1L",
      "chembl": "CHEMBL4298101",
      "trials": [
        "NCT03424005",
        "NCT01969643",
        "NCT03310957"
      ],
      "locations": [
        "Israel",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "France",
        "United States"
      ],
      "# conditions": 6,
      "# locations": 8,
      "# trials": 3
    },
    {
      "heading": "ASG-15ME | AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | AGS15E | AGS-15vcMMAE | Sirtratumab vedotin | AGS-15E | Ha15-10ac.1vcMMAE",
      "names": [
        "ASG-15ME",
        "AGS15C \u2013SGD-1006",
        "Ha15-10ac12vcMMAE",
        "AGS15E",
        "AGS-15vcMMAE",
        "Sirtratumab vedotin",
        "AGS-15E",
        "Ha15-10ac.1vcMMAE"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Bladder Cancer Metastatic urothelial cancer"
      ],
      "targets": [
        "SLTRK6 (SLIT and NTRK like family member 6, \"SLIT and NTRK-like family, member 6\")"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)   On an average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "IgG2 - kappa anti-[Homo sapiens SLITRK6 (SLIT and NTRK like family member 6)], Homo sapiensmonoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Astellas",
        "Ligand Pharmaceuticals",
        "Seagen",
        "Agensys"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-321 | Serclutamab Talirine | ABBV-321 Anti-Egfr/pbd -  ABBV-321",
      "names": [
        "ABBV-321",
        "SERCLUTAMAB TALIRINE",
        "Serclutamab Talirine",
        "ABBV-321 TALIRINE",
        "ABBV-321 Anti-Egfr/pbd -  ABBV-321"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands."
      ],
      "targets": [
        "EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PDB) dimer SGD-1882 with a fixed DAR of 2.0"
      ],
      "linker": [
        "A cathepsin-cleavable maleimidocaproyl-valine-alanine (MC-Val-Ala) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, affinity-matured humanized antibody (ABT-806 AM1) with a higher affinity for EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)."
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "chembl": "CHEMBL4594392",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Losatuxizumab vedotin | ABBV-221 | ABBV-221 ABBV221",
      "names": [
        "LOSATUXIZUMAB VEDOTIN",
        "ABBV 221",
        "Losatuxizumab vedotin",
        "ABBV-221 ABBV221",
        "ABBV-221"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid tumors (overexpressing EGFR), including: - Head and Neck Squamous Cell Carcinoma  - Non-small Cell Lung Cancer  - Triple Negative Breast Cancer - Colorectal Carcinoma  - Glioblastoma Multiforme"
      ],
      "targets": [
        "EGFR (epidermal growth factor receptor, receptor tyrosine-protein  kinase erbB-1, ERBB1, HER1, HER-1, ERBB) delta 2-7 isoform (delta2-7EGFR, de2-7 EGFR, EGFRvIII)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  On an average of 3 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa affinity-matured ABT-806"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "chembl": "CHEMBL4594515",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CR011 CR011-vcMMAE | Glembatumumab vedotin | CDX-011",
      "names": [
        "GLEMBATUMUMAB VEDOTIN",
        "CDX-011",
        "CR-011-VCMMAE",
        "CR011 CR011-vcMMAE",
        "Glembatumumab vedotin"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Breast cancer (TNBC) Advanced or metastatic melanoma",
        "Unresectable Stage III or Stage IV Melanoma",
        "Metastatic gpNMB Over-expressing Triple Negative Breast Cancer",
        "Breast Cancer"
      ],
      "targets": [
        "GPNMB (glycoprotein transmembrane NMB, hematopoeitic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain"
      ],
      "payload": [
        "Monomethyl Auristatin E\u00a0(MMAE)  On an average of 5 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG2 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Celldex"
      ],
      "chembl": "CHEMBL1743028",
      "drugbank": "https://go.drugbank.com/drugs/DB05996",
      "trials": [
        "NCT01997333",
        "NCT01156753",
        "NCT00704158",
        "NCT00412828"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 9,
      "# trials": 4
    },
    {
      "heading": "BMS-936561 | \u03b1CD70_MED-A | BMS936561 | MDX-1203",
      "names": [
        "BMS-936561",
        "\u03b1CD70_MED-A",
        "BMS936561",
        "MDX-1203"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Renal Cell Carcinoma (RCC) | Non-Hodgkin's lymphoma",
        "Non-hodgkin's Lymphoma"
      ],
      "targets": [
        "CD70 (TNFSF7) | CD70, the ligand for the co-stimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells."
      ],
      "payload": [
        "A prodrug of a CC-1065 (rachelmycin) analogue  duocarmycin"
      ],
      "linker": [
        "Di-peptide"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Medarex"
      ],
      "trials": [
        "NCT00944905"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal | BT-062 | Oxobuthyldithio | Indatuximab Ravtansine | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4",
      "names": [
        "Indatuximab ravtansine",
        "1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal",
        "BT-062",
        "Oxobuthyldithio",
        "BT062 , intravenous administration",
        "INDATUXIMAB RAVTANSINE",
        "BT062",
        "Indatuximab Ravtansine",
        "BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Breast cancer",
        "Multiple Myeloma",
        "Multiple myeloma (MM)",
        "Bladder cancer"
      ],
      "targets": [
        "CD138 | SDC1 (syndecan-1, CD138)"
      ],
      "payload": [
        "Maytansine DM4 (microtubule inhibitor) | [N2'-deacetyl-N2'-(4-mercapto-4-methyl- 1-oxopentyl)-maytansine]"
      ],
      "linker": [
        "A reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate].  An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology, Hematology"
      ],
      "antibody": [
        "IgG4 - kappa - murine/human chimeric form of B-B4 (CD138-specific antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "BioTest",
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL1743031",
      "trials": [
        "NCT01001442",
        "NCT01638936"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "Promiximab duocarmycin",
      "names": [
        "Promiximab duocarmycin"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid tumors - Small cell lung cancer (SCLC)"
      ],
      "targets": [
        "CD56"
      ],
      "payload": [
        "A DNA alkylating duocarmycin analog.  On an average DAR (Drug-to-Antibody Ratio) of about 2.04"
      ],
      "linker": [
        "Conjugated via reduced interchain disulfides.  valine-citrulline-seco"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hIgG1 anti-CD56 antibody promiximab"
      ],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MEDI3726 | ADCT-401 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
      "names": [
        "MEDI3726",
        "ADCT-401",
        "Anti-PSMA/PBD ADC MEDI3726 ADCT-401"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Castration resistant prostate cancer",
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "targets": [
        "An engineered version of the anti-Prostate-specific membrane antigen (PSMA) antibody J591"
      ],
      "payload": [
        "A highly cytotoxic DNA cross- linking pyrrolobenzodiazepine (PBD) dimer tesirine (SG319).   The drug-to-antibody ratio  [DAR] is 1.8"
      ],
      "linker": [
        "A valine-alanine dipeptide linker.  Site specifically conjugated"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized PSMA-specific IgG1 monoclonal antibody J591 engineered to enable site-specific conjugation"
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca",
        "MedImmune",
        "ADC Therapeutics"
      ],
      "trials": [
        "NCT02991911"
      ],
      "locations": [
        "United Kingdom",
        "Switzerland",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "MEDI 4276 | MEDI-4276 | MEDI4276",
      "names": [
        "MEDI 4276",
        "MEDI-4276",
        "MEDI4276"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "HER2 Expressing Breast or Gastric/Stomach Cancers",
        "Breast cancer Gastric cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (HER2; ERBB2)"
      ],
      "payload": [
        "MMETA, a Tubulysin Payload also known as AZ13599185."
      ],
      "linker": [
        "Site-specific conjugation on mc-Lys-MMETA to 2 engineered cysteine residues on the heavy chain via a maleimidocaproyl linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab scFv (Binding to Domain IV of HER2)"
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca",
        "MedImmune"
      ],
      "trials": [
        "NCT02576548"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "BMS-986148 | BMS986148",
      "names": [
        "BMS-986148",
        "BMS986148"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Solid tumors - Lung Cancer (Mesothelioma),  - Ovarian cancer,  - Pancreatic cancer",
        "Advanced Cancer"
      ],
      "targets": [
        "Mesothelin, a GPI-anchored cell surface protein"
      ],
      "payload": [
        "Tubulysin"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A fully human IgG1 anti-mesothelin monoclonal antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb"
      ],
      "trials": [
        "NCT02341625",
        "NCT02884726"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Hong Kong",
        "Korea, Republic of",
        "United Kingdom",
        "Australia",
        "Belgium",
        "Netherlands",
        "Japan",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 10,
      "# trials": 2
    },
    {
      "heading": "AXL-107-MMAE | HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | Enapotamab vedotin | HuMax-AXL-ADC",
      "names": [
        "HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC",
        "AXL-107-MMAE",
        "HUMAX AXL ADC",
        "ENAPOTAMAB VEDOTIN",
        "Enapotamab vedotin",
        "HUMAX-AXL-ADC",
        "HuMax-AXL-ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Sarcoma",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Endometrial Cancer",
        "Thyroid Cancer",
        "Solid tumors including - Ovarian cancer",
        "- Non Small Cell Lung Cancer (NSCLC)",
        "Cervical Cancer",
        "- Cervical cancer",
        "Solid Tumors",
        "- Endometrial cancer",
        "- Thyroid Cancer.",
        "Melanoma"
      ],
      "targets": [
        "AXL (AXL receptor tyrosine kinase, tyrosine-protein kinase receptor UFO), a signaling molecule expressed on many solid cancers and implicated in tumor biology."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  An average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p- aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker  Protease Cleavable Linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa."
      ],
      "Max Phase": "2",
      "developers": [
        "Genmab",
        "Seagen"
      ],
      "ttd": "D0QI1K",
      "chembl": "CHEMBL4297987",
      "drugbank": "https://go.drugbank.com/drugs/DB16156",
      "trials": [
        "NCT02988817"
      ],
      "locations": [
        "Denmark",
        "United Kingdom",
        "Spain",
        "Belgium",
        "Netherlands",
        "United States"
      ],
      "# conditions": 13,
      "# locations": 6,
      "# trials": 1
    },
    {
      "heading": "CX-2029",
      "names": [
        "CX-2029"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Esophageal Cancer",
        "Diffuse Large B Cell Lymphoma",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "- Head and neck cancer - Squamous non-small cell lung cancer - Esophageal carcinoma - Diffuse large B cell lymphoma"
      ],
      "targets": [
        "CD71, a transferrin receptor 1 (TFR1) is a 95-kDa homodimeric transmembrane glycoprotein."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "AbbVie",
        "CytomX"
      ],
      "trials": [
        "NCT03543813"
      ],
      "locations": [
        "Spain",
        "Korea, Republic of",
        "United Kingdom",
        "United States"
      ],
      "# conditions": 6,
      "# locations": 4,
      "# trials": 1
    },
    {
      "heading": "BMS986288 | BMS-986288 BMS986288 | BMS-986288",
      "names": [
        "BMS986288",
        "BMS-986288 BMS986288",
        "BMS-986288"
      ],
      "phases": [
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "targets": [
        "CTLA-4 (CTLA4; cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a protein receptor that functions as an immune checkpoint and downregulates immune responses."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-CTLA-4 Probody.  BMS-986288 is a Probody version of the anti-CTLA-4 antibody ipilimumab (Yervoy\u00ae) (a non-fucosylated version of ipilimumab)"
      ],
      "Max Phase": "2",
      "developers": [
        "Bristol Myers Squibb",
        "CytomX"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CD166 AADC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CX-2009 | CD166 PDC",
      "names": [
        "CX 2009",
        "ANTI-CD166-DM4 CX-2009",
        "PRALUZATAMAB RAVTANSINE",
        "CD166 AADC",
        "Praluzatamab Ravtansine",
        "CX-2009 ADC CX-2009",
        "CX-2009",
        "CD166 PDC"
      ],
      "phases": [
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "CD166-postitive solid tumors"
      ],
      "targets": [
        "CD166 (activated leucocyte cell adhesion molecule, ALCAM)"
      ],
      "payload": [
        "Maytansinoid (DM4; N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine)  On an average of 3-4 lysyl"
      ],
      "linker": [
        "Reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa A recombinant antibody targeting the tumor-associated antigen (TAA) CD166"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "CytomX"
      ],
      "chembl": "CHEMBL4297736",
      "drugbank": "https://go.drugbank.com/drugs/DB16090",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38 | hMN14-SN-38 | Labetuzumab govitecan | IMMU-130 | Labetuzumab-SN-38 IMMU-130",
      "names": [
        "LABETUZUMAB GOVITECAN",
        "hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38",
        "hMN14-SN-38",
        "Labetuzumab govitecan",
        "Labetuzumab-SN-38 IMMU-130",
        "IMMU-130",
        "ANTI-CEACAM5-SN 38"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer",
        "Solid tumors - Colorectal cancer/CRC"
      ],
      "targets": [
        "CEACAM4, Carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e"
      ],
      "payload": [
        "Camptothecin analog (SN38) Irinotecan metabolite 7-ethyl-10 hydroxycamptothecin (active metabolite of irinotecan (CPT-11, camptothecin-11))"
      ],
      "linker": [
        "Lysine;  a maleimide-type cleavable linker (carbonate group, 4-aminobenzyl alcohol and cathepsine-B-cleavable dipeptide Phe-Lys) and containing a triazoline group and a spacer PEG (n=8)   An average of 6 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Immunomedics"
      ],
      "chembl": "CHEMBL3544923",
      "trials": [
        "NCT01270698"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "Epratuzumab Tesirine | ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249 | hLL2-cys-PBD | ADCT-602 | ADCT 602 ADCT602 ADCT-602",
      "names": [
        "Epratuzumab Tesirine",
        "ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249",
        "hLL2-cys-PBD",
        "ADCT-602",
        "ADCT 602 ADCT602 ADCT-602"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Refractory B Acute Lymphoblastic Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "CD22 Positive",
        "Clinical inducation includes:  - Follicular  lymphoma  (FL) - marginal  zone  lymphoma  (MZL) - Mantle cell lymphoma (MCL) - Difuse large B-cell lymphoma (DLBCL) - small lymphocytic lymphoma  (SLL) - chronic  lymphocytic  leukemia  (CLL)",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "Philadelphia Chromosome Positive"
      ],
      "targets": [
        "CD22;  a type-I transmembrane sialoglycoprotein with expression restricted to the B-cell lineage"
      ],
      "payload": [
        "A Pyrrolobenzodiazepine (PBD) dimer toxin.  Antibody to drug ratio (DAR) is 1.7."
      ],
      "linker": [
        "The agent is stochastically conjugated via a cathepsin-cleavable valine-alanine (val-ala) peptide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-CD22 monoclonal antibody epratuzumab (hLL2)  Derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2)"
      ],
      "Max Phase": "2",
      "developers": [
        "ADC Therapeutics"
      ],
      "trials": [
        "NCT03698552"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 6,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "OBI-999 Anti-Globo H ADC | Anti-Globo H ADC | OBI-999",
      "names": [
        "OBI-999 Anti-Globo H ADC",
        "Anti-Globo H ADC",
        "OBI-999"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Solid tumors"
      ],
      "targets": [
        "Globo H, an antigen expressed in epithelial cancers"
      ],
      "payload": [],
      "linker": [
        "Site-specific ThioBridge"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "OBI Pharma"
      ],
      "ttd": "D2H6NI",
      "drugbank": "https://go.drugbank.com/drugs/DB17356",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "3A4-PL1601",
      "names": [
        "3A4-PL1601"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Advanced solid tumors with high unmet medical needs, including:  - platinum resistant ovarian cancer - triple negative breast cancer."
      ],
      "targets": [
        "KAAG1 (kidney-associated antigen 1), an 84 amino acid protein encoded by the reverse strand of a housekeeping gene called DCDC2."
      ],
      "payload": [
        "PL1601 (which contains Hydraspace, a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199)."
      ],
      "linker": [
        "Site-specifically conjugated using GlycoConnect technology"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "humanized monoclonal antibody 3A4, a humanized antibody against human KAAG1."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "ADC Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "5F9vcMMAE | Indusatumab Vedotin | TAK-264 | TAK264 | MLN-0264 | MLN 0264 | MLN0264",
      "names": [
        "5F9vcMMAE",
        "Indusatumab Vedotin",
        "TAK-264",
        "INDUSATUMAB VEDOTIN",
        "TAK264",
        "MLN-0264",
        "MLN 0264",
        "MLN0264"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid tumors | Pancreatic Adenocarcinoma",
        "Advanced Gastrointestinal Malignancies",
        "gastrointestinal tumors",
        "solid tumor"
      ],
      "targets": [
        "Guanylyl cyclase C (GCC) / GUCY2C (guanylate cyclase 2C, guanylate cyclase C, GC-C, heat-stable enterotoxin receptor, hSTAR, intestinal guanylate cyclase"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  An average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa;   MLN2045; 5F9"
      ],
      "Max Phase": "2",
      "developers": [
        "Takeda",
        "Millennium"
      ],
      "chembl": "CHEMBL4298045",
      "trials": [
        "NCT01577758"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "TAK-164 TAK164 Anti-GCC ADC Anti-GCC | TAK-164",
      "names": [
        "TAK-164 TAK164 Anti-GCC ADC Anti-GCC",
        "TAK-164"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "- Advanced Gastrointestinal Malignancies",
        "Solid tumors - Gastrointestinal Neoplasms",
        "- Esophageal, Stomach, Pancreas, Colon Neoplasms",
        "- Malignant Tumors of Digestive Organ"
      ],
      "targets": [
        "The extracellular domain of guanylyl cyclase C (GCC; GUCY2C)).  GCC is a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain. This receptor is overexpressed on the surface of certain tumor cells."
      ],
      "payload": [
        "An indolino-benzodiazepine (IGN) dimer; a DNA alkylator DGN549 (also known as IGN-P1)"
      ],
      "linker": [
        "Peptide-linked  A central substituted phenyl spacer"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-GCC antibody.  A full-length, fully human IgG1 antibody (mAb) directed towards the extracellular domain of guanylyl cyclase C (GCC)."
      ],
      "Max Phase": "2",
      "developers": [
        "Takeda",
        "Millennium"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 4,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TR1801-ADC | TR1801-ADC MT-8633 | MT-8633",
      "names": [
        "TR1801-ADC",
        "TR1801-ADC MT-8633",
        "MT-8633"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific",
        "Lung, colorectal, and gastric cancers",
        "Sold tumors"
      ],
      "targets": [
        "c-Met, also known as hepatocyte growth factor receptor (HGFR), a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) toxin-linker tesirine (SG3249)"
      ],
      "linker": [
        "Cleavable (Val\u2010Ala)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized, IgG2 monoclonal antibody, hD12; nonagonistic cMet targeting antibody."
      ],
      "Max Phase": "1",
      "developers": [
        "Open Innovation Partners",
        "AstraZeneca",
        "MedImmune",
        "Tanabe Research Laboratories USA"
      ],
      "ttd": "DU6H8Z",
      "trials": [
        "NCT03859752"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "JBH492",
      "names": [
        "JBH492"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non-Hodgkins Lymphoma",
        "Non-hodgkins lymphoma Chronic lymphocytic leukemia"
      ],
      "targets": [
        "CCR7 (CC-chemokine receptor 7)"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Novartis"
      ],
      "ttd": "DQVR30",
      "trials": [
        "NCT04240704"
      ],
      "locations": [
        "Singapore",
        "Israel",
        "Finland",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "Japan"
      ],
      "# conditions": 3,
      "# locations": 7,
      "# trials": 1
    },
    {
      "heading": "NJH395 anti-HER2 ISAC NJH395 | NJH395",
      "names": [
        "NJH395 anti-HER2 ISAC NJH395",
        "NJH395"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "NON-breast HER2+ Malignancies",
        "Non-breast HER2-positive advanced malignancies"
      ],
      "targets": [
        "Antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "payload": [
        "Toll-like receptor (TLR) 7 and TLR8"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-HER2"
      ],
      "Max Phase": "1",
      "developers": [
        "Novartis"
      ],
      "ttd": "DEX8D5",
      "trials": [
        "NCT03696771"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Japan",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 4,
      "# trials": 1
    },
    {
      "heading": "FS-1502 | FS-1502 Trastuzumab Monomethyl Auristatin F",
      "names": [
        "FS-1502",
        "FS-1502 Trastuzumab Monomethyl Auristatin F"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "Patients with metastatic, HER2 positive metastatic breast cancer",
        "Metastatic Breast Cancer",
        "HER2-positive Early Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "HER2/neu"
      ],
      "payload": [
        "Monomethyl Auristatin F"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "3",
      "developers": [
        "Shanghai Fosun"
      ],
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT00679341",
        "NCT03523585",
        "NCT05755048",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 24,
      "# locations": 72,
      "# trials": 21
    },
    {
      "heading": "F0002-ADC | CD30-MCC-DM1 | F0002-ADC CD30-MCC-DM1",
      "names": [
        "F0002-ADC",
        "CD30-MCC-DM1",
        "F0002-ADC CD30-MCC-DM1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Refractory or Recurrent CD30+ Hematologic Malignancies"
      ],
      "targets": [
        "CD30, also known as TNFRSF8, is a 120kD transmembrane protein of the tumor necrosis factor (TNF-) family and a known tumor marker found on many different types of lymphomas"
      ],
      "payload": [
        "DM1 or Mertansine, a thiol-containing maytansinoid"
      ],
      "linker": [
        "Stable SMCC linker"
      ],
      "domain": [
        "Hematology"
      ],
      "antibody": [
        "CD30 targeting antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "trials": [
        "NCT03894150"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "CC-99712 \u2013 Anti-BCMA ADC | CC-99712",
      "names": [
        "ISPECTAMAB DEBOTANSINE",
        "Ispectamab Debotansine \u2013 BMS-986352 \u2013 CC-99712",
        "Ispectamab debotansine",
        "CC-99712 \u2013 Anti-BCMA ADC",
        "SP8919",
        "BMS-986352",
        "CC-99712"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Relapsed and refractory (r/r) multiple myeloma (MM)",
        "Multiple Myeloma",
        "Multiple myeloma (MM)"
      ],
      "targets": [
        "TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)",
        "B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17)"
      ],
      "payload": [
        "Debotansine, conjugated at C-4 of four specific phenylalanine residues with N2'-deacetylmaytansine (p-azidomethyl-L-phenyalanine or pAMF)"
      ],
      "linker": [
        "Noncleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Humanized monoclonal antibody; Immunoglobulin G1-kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "Sutro Biopharma",
        "Celgene",
        "Bristol Myers Squibb"
      ],
      "ttd": "DH5BX2",
      "chembl": "CHEMBL5095127",
      "drugbank": "https://go.drugbank.com/drugs/DB18456",
      "trials": [
        "NCT04036461"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "France",
        "United States"
      ],
      "# conditions": 3,
      "# locations": 5,
      "# trials": 1
    },
    {
      "heading": "Ab1-18Hr1 | AbGn-107",
      "names": [
        "Ab1-18Hr1",
        "AbGn-107"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors - Colorectal cancer - Pancreatic cancer - Stomach / gastric cancers - Biliary cancer"
      ],
      "targets": [
        "Transferrin receptor protein 1 (CD71) glycotope."
      ],
      "payload": [
        "Tubulin inhibitor DM4"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 AG7 targeting CD71"
      ],
      "Max Phase": "1",
      "developers": [
        "AbGenomics BV"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SHR-A1201",
      "names": [
        "SHR-A1201"
      ],
      "phases": [],
      "conditions": [
        "Solid tumors HER-2 positive recurrent metastatic breast cancer"
      ],
      "targets": [
        "HER2/neu"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Jiangsu HengRui Medicine"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SHR-A1403 | HTI-1066 | HTI-1066 SHR-A1403",
      "names": [
        "SHR-A1403",
        "HTI-1066",
        "HTI-1066 SHR-A1403"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid tumors:  - Liver cancer - Stomach cancer - Colorectal cancer,  - Lung cancer - Breast cancers.",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "c-Met; a tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), a receptor tyrosine kinase (RTK) that is important in tumor growth, metastasis, and angiogenesis of many human malignancies."
      ],
      "payload": [
        "Undisclosed proprietary payload"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-c-Met antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Jiangsu HengRui Medicine"
      ],
      "trials": [
        "NCT03856541"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "AMG 224 | AMG 224 anti-BCMA\u2013MCC\u2013DM1",
      "names": [
        "AMG 224",
        "AMG 224 anti-BCMA\u2013MCC\u2013DM1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Relapsed or Refractory (r/r)Multiple Myeloma"
      ],
      "targets": [
        "BCMA; B-cell maturation antigen which belongs to the tumor necrosis factor receptor family and is expressed on late B-cells and plasma cells."
      ],
      "payload": [
        "DM1 is a semi-synthetic derivative of the ansamycin antibiotic maytansine conjugated to MCC."
      ],
      "linker": [
        "MCC is the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate conjugated to lysine residues in the antibody"
      ],
      "domain": [
        "Oncology Hematology"
      ],
      "antibody": [
        "anti-human BCMA IgG1 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Amgen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GQ1001 | GQ1001 \u2013 HER2",
      "names": [
        "GQ1001",
        "GQ1001 \u2013 HER2"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Cancer - Any cancer",
        "HER2-Positive Advanced Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive solid tumors",
        "HER2-Positive Advanced Solid Tumor",
        "Advanced/ Metastatic Her-2 Positive Breast Cancer",
        "HER2-positive Biliary Tract Cancer",
        "HER2-Positive Salivary Gland Carcinomas"
      ],
      "targets": [
        "HER2+ tumors"
      ],
      "payload": [
        "DM1 [N2\u2019-deacetyl-N2\u2019-(3-mercapto-1-oxopropyl)-maytansine], a synthetic derivative of the microtubule-targeted agent maytansine"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "2",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "ttd": "DSOE74",
      "trials": [
        "NCT05575804",
        "NCT04450732",
        "ACTRN12620000592943"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "# conditions": 8,
      "# locations": 3,
      "# trials": 3
    },
    {
      "heading": "GQ1003 \u2013 TROP2",
      "names": [
        "GQ1003 \u2013 TROP2"
      ],
      "phases": [],
      "conditions": [
        "NSCLC, TNBC and other Solid Tumors"
      ],
      "targets": [
        "TROP2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GQ1005 \u2013 HER2",
      "names": [
        "GQ1005 \u2013 HER2"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "HER2 Expressing or Mutated Advanced Malignant Solid Tumors",
        "Low/medium Breast Cancer, Gastric or Gastroesophageal Junction Cancers and other HER2 expressing Solid Tumors"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "trials": [
        "NCT06154343"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "GC1007",
      "names": [
        "GC1007"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GC1009",
      "names": [
        "GC1009"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GQ1014",
      "names": [
        "GQ1014"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GQ1015",
      "names": [
        "GQ1015"
      ],
      "phases": [],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GQ1017",
      "names": [
        "GQ1017"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GQ1018",
      "names": [
        "GQ1018"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [],
      "targets": [
        "Undisclosed"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "RC-48 RC 480-ADC RC48 | RC-48 | Aidixi\u00ae | Disitamab Vedotin | RC48 | \u7231\u5730\u5e0c\u00ae | RC 480-ADC",
      "names": [
        "RC-48 RC 480-ADC RC48",
        "RC-48",
        "Aidixi\u00ae",
        "Disitamab vedotin",
        "Disitamab Vedotin",
        "RC48",
        "\u7231\u5730\u5e0c\u00ae",
        "RC 480-ADC",
        "DISITAMAB VEDOTIN"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Approved"
      ],
      "conditions": [
        "HER2-positive",
        "Advanced Gastroesophageal Adenocarcinoma",
        "Non-small Cell Lung Cancer",
        "Non-muscle Invasive Bladder Cancer",
        "Phase II)  HER2 Expressing Non-Small Cell Lung Cancer (China",
        "Gastric Cancer",
        "Breast Cancer",
        "Advanced Melanoma",
        "Advanced Cancer",
        "Non Small Cell Lung Cancer",
        "Ovarian Neoplasms",
        "Gynecological Malignancy",
        "Salivary Gland Tumors",
        "Biliary Tract Cancer",
        "HER2 Low Breast Neoplasms",
        "UTUC",
        "Urothelial Carcinoma",
        "Non-Muscle Invasive Bladder Cancer",
        "Phase I / II)  HER-2 Expressing Gastric Cancer (Worldwide",
        "Endometrial Neoplasms",
        "Carcinoma",
        "Melanoma, Stage II",
        "Gastroesophageal Junction Adenocarcinoma",
        "HER2",
        "Carcinoma, Non-Small-Cell Lung",
        "HER2 Overexpressing Gastric Carcinoma",
        "Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance",
        "Capecitabine",
        "Cervical Cancer",
        "High-risk Non-muscle Invasive Bladder Cancer",
        "HER2 Positive Breast Neoplasms",
        "Solid Tumors Advanced Breast Cancer  ___  HER2-Expressing Gastric Cancer -Launched in China in June 2021)  HER2- Expressing Urothelial Carcinoma (China",
        "HER2-expressing",
        "Triple Negative Breast Neoplasms",
        "Registration Trial/ Phase III)  HER2- Expressing Urothelial Carcinoma (Worldwide",
        "Metastatic Breast Cancer",
        "Upper Tract Urothelial Carcinoma",
        "Advanced Breast Cancer",
        "Solid Tumor",
        "Muscle Invasive Bladder Carcinoma",
        "HER2-positive Advanced Breast With Liver Metastases",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Phase III)  HER2 Low-to-Non Expressing Urothelial Cancer (China",
        "NMIBC",
        "HER2 Positive Breast Carcinoma",
        "Stomach Neoplasms",
        "Bladder Cancer",
        "Breast Diseases",
        "Colorectal Cancer",
        "Castration-resistant Prostate Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Breast Neoplasms",
        "HER2-positive Breast Cancer",
        "Solid Tumors",
        "HER2-expressing locally advanced or metastatic malignant solid tumor",
        "Phase II)  HER2 Expressing Biliary Tract Cancer (China",
        "HER2-Positive Solid Tumors",
        "Phase I)"
      ],
      "targets": [
        "Epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE) https://adc.expert/2Jmq1pT"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.  On an average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "RemeGen",
        "MabPlex"
      ],
      "chembl": "CHEMBL5095273",
      "drugbank": "https://go.drugbank.com/drugs/DB17208",
      "trials": [
        "NCT05331326",
        "NCT06074484",
        "NCT05601401",
        "NCT04965519",
        "NCT04879329",
        "NCT03052634",
        "NCT06157892",
        "NCT06389006",
        "NCT04280341",
        "NCT04073602",
        "NCT05016973",
        "NCT06178159",
        "NCT06105008",
        "NCT02881138",
        "NCT06221748",
        "NCT05917158",
        "NCT06003231",
        "NCT05955209",
        "NCT03500380",
        "NCT05940896",
        "NCT05785325",
        "NCT04264936",
        "NCT05302284",
        "NCT06227156",
        "NCT04311034",
        "NCT03809013",
        "NCT03507166",
        "NCT05980481",
        "NCT05943379",
        "NCT05135715",
        "NCT05911295",
        "NCT06178601",
        "NCT05297552",
        "NCT06227117",
        "NCT06378242",
        "NCT06155396",
        "NCT04714190",
        "NCT05957757",
        "NCT04329429",
        "NCT05356351",
        "NCT05514158",
        "NCT05403242",
        "NCT05996952",
        "NCT06155383",
        "NCT04400695",
        "NCT05417230",
        "NCT02881190",
        "ChiCTR2200055827",
        "NCT05745740",
        "NCT03556345"
      ],
      "locations": [
        "Canada",
        "Chile",
        "Israel",
        "Singapore",
        "China",
        "Argentina",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Belgium",
        "Japan",
        "United States"
      ],
      "# conditions": 58,
      "# locations": 13,
      "# trials": 50
    },
    {
      "heading": "RC108",
      "names": [
        "RC108"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Digestive Cancer",
        "Solid tumors",
        "Solid Tumor"
      ],
      "targets": [
        "c-MET"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "RemeGen",
        "MabPlex"
      ],
      "trials": [
        "NCT04617314",
        "NCT05628857"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "ADCT-901",
      "names": [
        "ADCT-901"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Advanced solid tumors with high unmet medical needs, including:  - platinum resistant ovarian cancer - triple negative breast cancer."
      ],
      "targets": [
        "KAAG1 (kidney-associated antigen 1), an 84 amino acid protein encoded by the reverse strand of a housekeeping gene called DCDC2."
      ],
      "payload": [
        "SG3199, a pyrrolobenzodiazepine (PBD)-dimer cytotoxin."
      ],
      "linker": [
        "A cathepsin-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "humanized monoclonal antibody 3A4.  3A4 is a humanized antibody against human KAAG1."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "ADC Therapeutics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "XB002 ICON-2 Tissue Factor ADC | ICON-2 Tissue Factor ADC  XB002",
      "names": [
        "XB002 ICON-2 Tissue Factor ADC",
        "ICON-2 Tissue Factor ADC  XB002"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Esophageal SCC",
        "Metastatic Castration-resistant Prostate Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Endometrial Cancer",
        "Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Non Small Cell Lung Cancer",
        "Tissue Factor-Expressing Solid Tumors",
        "Pancreatic Cancer",
        "Solid tumors",
        "SCCHN"
      ],
      "targets": [
        "Tissue Factor (TF) is a 47-kDa membrane-bound cell surface receptor. It is also known as thromboplastin, coagulation factor III (fIII) or CD142. TF is highly expressed on tumor cells and in the tumor microenvironment, and overexpression, while not oncogenic itself, facilitates angiogenesis, metastasis and other processes important to tumor development and progression."
      ],
      "payload": [
        "Microtubule disrupting agent monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease cleavable valine-citrulline (vc) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Human tissue factor specific antibody (TF-011)"
      ],
      "Max Phase": "1",
      "developers": [
        "Exelixis",
        "Iconic",
        "Zymeworks"
      ],
      "trials": [
        "NCT04925284"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "# conditions": 12,
      "# locations": 9,
      "# trials": 1
    },
    {
      "heading": "MRG004A",
      "names": [
        "MRG004A"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Solid Tumors"
      ],
      "targets": [
        "Tissue Factor (TF) is a 47-kDa membrane-bound cell surface receptor. It is also known as thromboplastin, coagulation factor III (fIII) or CD142. TF is highly expressed on tumor cells and in the tumor"
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Lepu Biopharma",
        "Shanghai Miracogen"
      ],
      "trials": [
        "NCT04843709"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "REGN3124-PBD",
      "names": [
        "REGN3124-PBD"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Glioblastoma Multiforme (GBM)"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor variant III (EGFRvIII)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PBD) dimer"
      ],
      "linker": [
        "Tesirine (SG3249) linker payload A cathepsin B-cleavable valine-alanine linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "REGN3124"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Regeneron"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CLDN18.2 ADC | SOT102 | SO-N102",
      "names": [
        "CLDN18.2 ADC",
        "SOT102",
        "SO-N102"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Solid Tumors Gastric cancer Pancreatic cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Gastric and pancreatic adenocarcinoma  MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 100000004864   MedDRA version: 21.1 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864"
      ],
      "targets": [
        "Claudin 18.2"
      ],
      "payload": [
        "DAR-2 PNU-159682, an anthracycline derivative."
      ],
      "linker": [
        "Site Specific Non-cleavable Amide/Peptide Linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Proprietary monoclonal antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "SOTIO Bio"
      ],
      "trials": [
        "EUCTR2021-005873-25-ES",
        "NCT05525286"
      ],
      "locations": [
        "Czechia",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 5,
      "# trials": 2
    },
    {
      "heading": "DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA | DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148",
      "names": [
        "DHES0815A",
        "anti-HER2/PBD-monoamide anti-HER2/PBD-MA",
        "DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA",
        "RG6148"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Relapsed or refractory Acute Myeloid Leukemia."
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2)"
      ],
      "payload": [
        "DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA)"
      ],
      "linker": [
        "Disulfide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "THIOMAB humanized IgG1 anti-HER2 monoclonal antibody (hu7C2), which binds domain 1 of the HER2 ECD"
      ],
      "Max Phase": "1",
      "developers": [
        "Genentech",
        "Roche"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Loncastuximab tesirine | ADCT-402 | ADCT-402 RB4v1.2-SG-3249 | Zynlonta",
      "names": [
        "Loncastuximab tesirine",
        "ADCT-402 RB4v1.2-SG-3249",
        "Zynlonta",
        "ADCT-402 TESIRINE",
        "LONCASTUXIMAB TESIRINE",
        "ZYNLONTA",
        "ADCT-402"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 1/2",
        "Phase 4"
      ],
      "conditions": [
        "B-cell Non Hodgkin Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Diffuse large B cell lymphoma (DLBCL) and Lymphoma, mantle cell lymphoma  Relapsed/refractory (R/R) B-cell lineage non-Hodgkin lymphoma.",
        "Relapsed B-Cell Non-Hodgkin Lymphoma",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "B-Cell Non-Hodgkin Lymphoma",
        "Double-Expressor Lymphoma"
      ],
      "targets": [
        "CD19 (B lymphocyte surface antigen B4, Leu-12)"
      ],
      "payload": [
        "SG3199 / Pyrrolobenzodiazepine (PDB) dimer SCX  Average of two molecules of tesirine"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)   On an average of 2 cysteinyl"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "Immunoglobulin G1, anti-human CD19 | immunoglobulin G1-kappa, anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "ADC Therapeutics"
      ],
      "ttd": [
        "D0HV4B",
        "D8L5PA"
      ],
      "chembl": "CHEMBL4297778",
      "drugbank": "https://go.drugbank.com/drugs/DB16222",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf",
      "trials": [
        "NCT05600686",
        "NCT05991388",
        "NCT04970901"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "# conditions": 9,
      "# locations": 6,
      "# trials": 3
    },
    {
      "heading": "Tivdak | HuMax\u00ae-TF-ADC | TF-011-MMAE  HuMax-TF-ADC | Tisotumab Vedotin",
      "names": [
        "Tisotumab Vedotin",
        "HuMax-TF-ADC",
        "TF-011-MMAE",
        "GCT1015-04",
        "IGG1-1015-011-1006",
        "Tisotumab vedotin",
        "Tivdak",
        "TISOTUMAB VEDOTIN TFTV",
        "TIVDAK",
        "HuMax\u00ae-TF-ADC",
        "TISOTUMAB VEDOTIN",
        "TF-011-MMAE  HuMax-TF-ADC"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Solid Tumor  Cervical Cancer",
        "Lung Cancer (NSCLC)",
        "Ovarian Cancer",
        "Prostate Cancer",
        "MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Solid Malignancies",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Second- or Third-Line Recurrent or Metastatic Cervical Cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Esophagus Cancer",
        "Colorectal Neoplasms",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Lung Cancer(NSCLC)",
        "Therapeutic area: Diseases [C] - Neoplasms [C04]",
        "Lung Cancer, Nonsmall Cell",
        "Cervix Cancer",
        "Peritoneal Cancer",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the head and neck (SCCHN)                   MedDRA version: 20.0                 Level: PT                 Classification code 10060862                 Term: Prostate cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: HLT                 Classification code 10014742                 Term: Endometrial neoplasms malignant                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10008342                 Term: Cervix carcinoma                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10023774                 Term: Large cell lung cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10062878                 Term: Gastrooesophageal cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10005003                 Term: Bladder cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: SOC",
        "Carcinoma, Non-Small-Cell Lung",
        "Cervical Cancer",
        "Exocrine Pancreatic Cancer",
        "Fallopian Tube Cancer",
        "Ovary Cancer",
        "Recurrent or stage IVB cervical cancer  MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "recurrent or stage IVB cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "recurrent or metastatic cervical cancer  MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Bladder Cancer",
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)  MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10080244 Term: Peritoneal cancer index System Organ Class: 10022891 - Investigations",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (non-small cell lung cancer [NSCLC]  MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)                   MedDRA version: 20.0                 Level: PT                 Classification code 10033128                 Term: Ovarian cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10016180                 Term: Fallopian tube cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10080244                 Term: Peritoneal cancer index                 System Organ Class: 10022891 - Investigations",
        "Endometrium Cancer",
        "Prostate Cancer (CRPC)",
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), esophagus or lung (non-small cell lung cancer [NSCLC])  MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
      ],
      "targets": [
        "Tissue Factor (TF), coagulation factor III (thromboplastin) also known as CD142, a protein encoded by the F3 gene present in subendothelial tissue and leukocytes."
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker on an average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Genmab",
        "Seagen"
      ],
      "chembl": "CHEMBL4297841",
      "drugbank": "https://go.drugbank.com/drugs/DB16732",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf",
      "trials": [
        "NCT03245736",
        "EUCTR2016-004743-37-BE",
        "NCT02001623",
        "EUCTR2017-003413-25-DK",
        "EUCTR2017-003413-25-DE",
        "NCT03438396",
        "CTIS2023-508832-68-00",
        "EUCTR2013-001074-15-GB",
        "EUCTR2015-001120-29-DK",
        "NCT03485209",
        "EUCTR2019-001655-39-ES",
        "EUCTR2017-004758-40-DK",
        "EUCTR2019-001219-22-ES",
        "NCT02552121",
        "EUCTR2017-003413-25-IT",
        "EUCTR2019-001219-22-IE",
        "EUCTR2017-003413-25-CZ",
        "NCT03657043",
        "NCT05866354",
        "NCT04697628",
        "NCT03786081"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Germany",
        "Greece",
        "France",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Finland",
        "Israel",
        "Argentina",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "Ukraine",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Belgium",
        "Estonia"
      ],
      "# conditions": 35,
      "# locations": 36,
      "# trials": 21
    },
    {
      "heading": "SGN-PDL1V",
      "names": [
        "SGN-PDL1V"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Non-small cell lung cancer (NSCLC) Head and neck squamous cell carcinomas (HNSCC)"
      ],
      "targets": [
        "T cell checkpoint ligand, PD-(L)1. PD-(L)1 is a target with limited normal tissue expression and clinically validated expression across a variety of malignancies, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinomas (HNSCC)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease-cleavable peptide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-PD-L1 antibody"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Ifinatamab Deruxtecan \u2013 DS-7300a | DS-7300a | MABX-9001a",
      "names": [
        "MABX-9001a",
        "DS7300A",
        "IFINATAMAB DERUXTECAN",
        "DS 7300A",
        "DS-7300a",
        "MABX-9001A CYSTEINYL-DERUXTECAN",
        "Ifinatamab Deruxtecan \u2013 DS-7300a",
        "DS-7300A"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Advanced Solid and Malignant Tumors",
        "Small Cell Lung Cancer",
        "Extensive-stage Small-cell Lung Cancer",
        "Extensive Stage-small Cell Lung Cancer"
      ],
      "targets": [
        "B7-H3 (CD276), a type I transmembrane protein belonging to the B7 family which includes immune checkpoint molecules CTLA-4 ligands and PD-L1. B7-H3 is highly expressed in various types of solid tumors with low expression in normal  (healthy) tissues. Several studies have reported that B7-H3 overexpression is associated with poor prognosis in several types of cancers"
      ],
      "payload": [
        "Deruxtecan (an exatecan derivative, DXd, that is a potent DNA topoisomerase I inhibitor) conjugated, on an average of 4 cysteinyl"
      ],
      "linker": [
        "A thioether, an enzymatically cleavable peptide-based linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti\u2013B7-H3 IgG1 monoclonal antibody (MABX-9001a)"
      ],
      "Max Phase": "3",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "chembl": "CHEMBL5095331",
      "trials": [
        "NCT06362252",
        "NCT05280470",
        "NCT06203210"
      ],
      "locations": [
        "Czechia",
        "China",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 4,
      "# locations": 24,
      "# trials": 3
    },
    {
      "heading": "Anti-ROR2 ADC | BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC | BA3021 | Ozuriftamab Vedotin | CAB-ROR2-ADC",
      "names": [
        "OZURIFTAMAB VEDOTIN",
        "Ozuriftamab vedotin",
        "Anti-ROR2 ADC",
        "BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC",
        "BA3021",
        "CAB-ROR2-ADC (BA-3021)",
        "Ozuriftamab Vedotin",
        "CAB-ROR2-ADC",
        "BA-3021"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Metastatic Squamous Cell Carcinoma of the Head and Neck",
        "Advanced solid tumors including non-small cell lung cancer (NSCLC), triple negative breast cancer and soft tissue sarcoma.",
        "Head and Neck Cancer",
        "Triple Negative Breast Cancer",
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Metastatic Cancer",
        "Non Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Melanoma"
      ],
      "targets": [
        "Ror2, also known as receptor tyrosine kinase-like orphan receptor 2, is a membrane- bound RTK that is activated by non-canonical Wnt signaling through its association with the Wnt5A glycoprotein during normal bone and cartilage development."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE); vedotin, on an average of 4 cysteinyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "BioAtla"
      ],
      "ttd": [
        "D08RWO",
        "D82BZH"
      ],
      "chembl": "CHEMBL5095285",
      "trials": [
        "NCT03504488",
        "NCT05271604"
      ],
      "locations": [
        "Italy",
        "Hong Kong",
        "Germany",
        "Poland",
        "Spain",
        "Greece",
        "Taiwan",
        "United States"
      ],
      "# conditions": 9,
      "# locations": 8,
      "# trials": 2
    },
    {
      "heading": "CAB-Axl-ADC | CAB-anti-Axl-ADC | Mecbotamab Vedotin | CAB-anti-Axl-ADC BA3011 | BA3011",
      "names": [
        "CAB-anti-Axl-ADC",
        "CAB-Axl-ADC",
        "Mecbotamab vedotin",
        "BA-3011",
        "Mecbotamab Vedotin",
        "CAB-AXL-ADC",
        "MECBOTAMAB VEDOTIN",
        "CAB-anti-Axl-ADC BA3011",
        "BA3011"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer",
        "Colon cancer,  melanoma,  CML, Esophageal, Liver Cancer AML, NSCLC, Breast, Ovarian Cancer",
        "Myxofibrosarcoma",
        "Solid tumors Pancreatic cancer",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "targets": [
        "AXL, a TAM family receptor tyrosine kinase and oncogene involved in the stimulation of cell proliferation. (AXL receptor tyrosine kinase, ARK, JTK11, Tyro7, UFO) [Homo sapiens]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE) (Vedotin)"
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker on an average of 4 cysteinyl"
      ],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [
        "IgG1 - kappa CAB-Axl antibodies"
      ],
      "Max Phase": "2",
      "developers": [
        "Sinobioway Biomedicine",
        "BioAtla"
      ],
      "ttd": [
        "D00OON",
        "DYI4L2"
      ],
      "chembl": "CHEMBL5095312",
      "drugbank": "https://go.drugbank.com/drugs/DB17442",
      "trials": [
        "NCT03425279",
        "NCT04681131"
      ],
      "locations": [
        "Italy",
        "Hong Kong",
        "Germany",
        "Poland",
        "Spain",
        "Greece",
        "Taiwan",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 8,
      "# trials": 2
    },
    {
      "heading": "SBT6050 | Pertuzumab Zuvotolimod",
      "names": [
        "SBT6050",
        "PERTUZUMAB ZUVOTOLIMOD",
        "SBT 6050",
        "Pertuzumab Zuvotolimod"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Solid tumors HER2-Expressing Tumors",
        "Breast Neoplasms",
        "Brain Metastases",
        "HER2-Positive Metastatic Breast Cancer",
        "Left Ventricular Function Systolic Dysfunction",
        "Breast Cancer; HER2-positive; Metastatic",
        "Metastatic Breast Cancer",
        "HER2-positive Early Breast Cancer",
        "Advanced Breast Cancer",
        "HER2-positive Breast Cancer",
        "Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Neoplasm Metastasis",
        "Recurrent Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens]"
      ],
      "payload": [
        "Analogue of motolimod (an agonist for the toll-like receptor 8, TLR8) on an average of 4 cysteinyl"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340); humanized monoclonal antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "Silverback"
      ],
      "ttd": "DUA7P2",
      "chembl": "CHEMBL5095143",
      "trials": [
        "NCT02131064",
        "NCT05323955",
        "NCT02390427",
        "NCT04784715",
        "NCT04538742",
        "NCT02605915",
        "NCT02073487",
        "NCT03726879",
        "NCT00781612",
        "NCT01120184",
        "NCT00934856",
        "NCT05113251",
        "NCT00943670",
        "NCT01904903",
        "NCT05954143",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "North Macedonia",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "New Zealand",
        "United States",
        "Norway",
        "Canada",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 17,
      "# locations": 53,
      "# trials": 16
    },
    {
      "heading": "OG1953 | KSI 301 | Tarcocimab Tedromer | KSI301 | KSI-301",
      "names": [
        "OG1953",
        "KSI 301",
        "Tarcocimab Tedromer",
        "KSI301",
        "KSI-301",
        "OG-1953",
        "TARCOCIMAB TEDROMER"
      ],
      "phases": [
        "Phase 3"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion",
        "Wet Age-related Macular Degeneration",
        "Age-related macular degeneration (AMD), neovascular (wet) Diabetic macular edema"
      ],
      "targets": [
        "VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)(humanized)"
      ],
      "payload": [
        "The biopolymer tedromer on an average of 2 cysteinyl"
      ],
      "linker": [],
      "domain": [
        "Ophthalmology Immunology;"
      ],
      "antibody": [
        "The Humanized monoclonal antibody tarcocimab conjugated via a linker to a nonaantennary dendrimer with phosphorylcholine polymer end groups"
      ],
      "Max Phase": "3",
      "developers": [
        "Kodiak Sciences"
      ],
      "chembl": "CHEMBL5095154",
      "trials": [
        "NCT04964089",
        "NCT04592419"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Slovakia",
        "Israel",
        "Germany",
        "Poland",
        "Spain",
        "Latvia",
        "Hungary",
        "France",
        "Puerto Rico",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 12,
      "# trials": 2
    },
    {
      "heading": "BAY 2635190 | Trastuzumab Corixetan | BAY-2635190 | BAY2635190",
      "names": [
        "Trastuzumab Corixetan",
        "BAY 2635190",
        "BAY-2635190",
        "BAY2635190",
        "TRASTUZUMAB CORIXETAN"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Radiolabeled; Corixetan; Octadentate 3,2-HOPO chelator (BAY 1903150)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab conjugated to the chelator group corixetan on an average of 0.5 lysyl per antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "Bayer"
      ],
      "chembl": "CHEMBL5095155",
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 23,
      "# locations": 72,
      "# trials": 20
    },
    {
      "heading": "AEX4089DC1 | AEX4089DC1 Anti-B7-H3 ADC | Anti-B7-H3 ADC | MGC018 | Vobramitamab Duocarmazine",
      "names": [
        "VOBRAMITAMAB DUOCARMAZINE",
        "AEX4089DC1",
        "MGC 018",
        "AEX4089DC1 Anti-B7-H3 ADC",
        "MGC018",
        "Anti-B7-H3 ADC",
        "MGC-018",
        "Vobramitamab Duocarmazine",
        "Vobramitamab duocarmazine"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Malignant Melanoma",
        "Hepatocellular Cancer",
        "Renal Cell Carcinoma",
        "Epithelial Ovarian Cancer",
        "Pancreatic Ductal Carcinoma",
        "Castration-Resistant Prostatic Cancer",
        "Solid tumors Non-small cell lung cancer (NSCLC) Melanoma Metastatic prostate cancer Triple-negative breast cancer (TNBC) Head and neck squamous cell carcinoma (HNSCC)",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "B7-H3 (CD276), an immune checkpoint member of the B7 and CD28 families; Induced on antigen-presenting cells and plays an important role in the inhibition of T-cell function; highly overexpressed on a wide range of human solid cancers; Often correlates with both negative prognosis and poor clinical outcome in patients."
      ],
      "payload": [
        "A synthetic duocarmycin analogs.  (pro-drug seco-duocarmycin-p-hydroxybenzamide-azaindole (seco- DUBA) with an average of 2.7 cysteines"
      ],
      "linker": [
        "A cleavable N-[2-(2 maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl- p-aminobenzyloxycarbonyl-N-[2-(2-hydroxyethoxy)ethyl]- N-[2-(methylamino)ethyl]carbamoyl linker  A duocarmycin-based, linker-drug; valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MacroGenics proprietary B7-H3 antibody (humanized B7-H3 mAb)"
      ],
      "Max Phase": "2",
      "developers": [
        "MacroGenics"
      ],
      "ttd": "DDP74J",
      "chembl": "CHEMBL4594576",
      "drugbank": "https://go.drugbank.com/drugs/DB18871",
      "trials": [
        "NCT05293496"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 8,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "PSMA-TTC PSMA targeted thorium-227 | PSMA-TTC | BAY-2315497 | Pelgifatamab Corixetan",
      "names": [
        "BAY2315497 Injection",
        "PSMA-TTC",
        "PSMA-TTC PSMA targeted thorium-227",
        "BAY-2315497",
        "Pelgifatamab Corixetan"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic prostate cancer",
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "targets": [
        "FOLH1 (folate hydrolase, prostate-specific membrane antigen, PSMA) [Homo sapiens]"
      ],
      "payload": [
        "Chelator corixetan conjugated on an average of 1 lysine (0.8 chelator per antibody)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "1",
      "developers": [
        "Bayer"
      ],
      "trials": [
        "NCT03724747"
      ],
      "locations": [
        "United Kingdom",
        "Finland",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "WT1-RTA | Grisnilimab setaritox",
      "names": [
        "WT1-RTA",
        "Grisnilimab setaritox"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Graft-versus-host disease (GvHD)"
      ],
      "targets": [
        "[CD7 (CD7 antigen (p41),GP40, LEU-9, TP41, Tp40)"
      ],
      "payload": [
        "An aglycosylated ricin toxin A (RTA), known as ricinus communis ricin A, conjugated on an average of 1.6 lysyl"
      ],
      "linker": [],
      "domain": [
        "Immunology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "Xenikos"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SPV-T3a-RTA | Dafsolimab Setaritox",
      "names": [
        "SPV-T3a-RTA",
        "Dafsolimab Setaritox"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Graft-versus-host disease (GvHD)"
      ],
      "targets": [
        "CD3E (CD3 epsilon, Leu-4)]"
      ],
      "payload": [
        "An aglycosylated ricin toxin A (RTA), known as ricinus communis ricin A, conjugated on an average of 1.6 lysyl"
      ],
      "linker": [],
      "domain": [
        "Immunology"
      ],
      "antibody": [
        "Immunoglobulin G2B-kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Xenikos"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Mipasetamab Uzoptirine | ADCT-601",
      "names": [
        "Mipasetamab Uzoptirine",
        "ADCT-601",
        "MIPASETAMAB UZOPTIRINE"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors (eg, lung, breast, prostate, pancreas, glioma, and esophageal) and Hematological malignancies (eg, acute and chronic myeloid leukemia)."
      ],
      "targets": [
        "AXL (AXL receptor tyrosine kinase, ARK, JTK11, Tyro7, UFO)"
      ],
      "payload": [
        "Pyrrolobenzodiazepine (PDB) dimer SG3199 on an average of 2 glycoengineered CH2 N84.4"
      ],
      "linker": [
        "A cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "1",
      "developers": [
        "ADC Therapeutics"
      ],
      "chembl": "CHEMBL5095300",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Zalsenertant Tetraxetan | Lutetium Lu 177 Zalsenertant Tetraxetan",
      "names": [
        "Zalsenertant Tetraxetan",
        "Lutetium Lu 177 Zalsenertant Tetraxetan"
      ],
      "phases": [],
      "conditions": [
        "Ductal pancreatic adenocarcinoma"
      ],
      "targets": [],
      "payload": [
        "Neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227)  Beta-emitting radioisotope lutetium Lu 177"
      ],
      "linker": [
        "Chelating agent, dodecanetetraacetic acid (DOTA)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Pivekimab Sunirine | IMGN-632 | MGN 632 | IMGN 632 | IMGN632",
      "names": [
        "Pivekimab Sunirine",
        "IMGN-632",
        "MGN 632",
        "IMGN 632",
        "IMGN632",
        "PIVEKIMAB SUNIRINE"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory/relapsed acute myeloid leukemia (AML)  Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).",
        "Refractory Acute Myeloid Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia",
        "Myeloproliferative Neoplasm",
        "Mixed Phenotype Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Myelodysplastic/Myeloproliferative Neoplasm"
      ],
      "targets": [
        "CD123 | The alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells."
      ],
      "payload": [
        "DNA mono-alkylating payload of the indolinobenzodiazepine pseudodimer (IGN) class of cytotoxic compounds (sulfonated DGN462).  Site-specific, via engineered cysteines  2 payload molecules are attached per antibody  The payload alkylates DNA without cross-linking"
      ],
      "linker": [
        "Peptide, stable in circulation, cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-CD123 antibody G4723A"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL4297991",
      "drugbank": "https://go.drugbank.com/drugs/DB17337",
      "trials": [
        "NCT06034470",
        "NCT04086264",
        "NCT05320380",
        "NCT03386513"
      ],
      "locations": [
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "France",
        "United States"
      ],
      "# conditions": 15,
      "# locations": 6,
      "# trials": 4
    },
    {
      "heading": "IMGC936",
      "names": [
        "IMGC936",
        "IMGC 936",
        "IZELTABART TAPATANSINE",
        "IMGC-936"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Multiple solid tumor types - non-small cell lung cancer, - gastric,  - pancreatic,  - triple-negative breast - colorectal)",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "ADAM9, a cell surface protein that belongs to the ADAM (a disintegrin and metalloproteinase) family of proteases, which have been implicated in cytokine and growth factor shedding and cell migration. Dysregulation of ADAM9 has been implicated in tumor progression and metastasis, as well as pathological neovascularization."
      ],
      "payload": [
        "DM21C, a next-generation maytansinoid microtubule-disrupting payload with greater stability and bystander activity than other DM compounds. DM21C is linked to the antibody by site-specific conjugation to two engineered cysteines (DAR=2)"
      ],
      "linker": [
        "A stable tripeptide linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MGA021: a high-affinity humanized anti-ADAM9 with YTE mutation"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN",
        "MacroGenics"
      ],
      "ttd": "DA4O8C",
      "chembl": "CHEMBL5095346",
      "trials": [
        "NCT04622774"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "IMGN151",
      "names": [
        "IMGN151"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "High Grade Serous Adenocarcinoma of Ovary",
        "Endometrial Cancer",
        "Tumors with a broad range of FR\u03b1-expression including: - ovarian cancer - endometrial cancer - triple-negative breast cancer - non-small cell lung cancer"
      ],
      "targets": [
        "Folate Receptor alpha (FR\u03b1)"
      ],
      "payload": [
        "Maytansinoid derivative DM21.  The average drug per antibody ratio is 3.5."
      ],
      "linker": [
        "Stable cleavable peptide linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A bivalent, biparatopic antibody targeting two independent epitopes of FR\u03b1."
      ],
      "Max Phase": "1",
      "developers": [
        "IMMUNOGEN"
      ],
      "trials": [
        "NCT05527184"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 5,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "PRO1184",
      "names": [
        "Rinatabart Sesutecan",
        "PRO1184",
        "Rina-S"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Locally advanced and/or metastatic solid tumors Ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma",
        "Primary Peritoneal Carcinoma",
        "Endometrial Cancer",
        "Non-small Cell Lung Cancer",
        "High Grade Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor-positive/Her2 Negative Breast Cancer",
        "Mesothelioma",
        "Breast Adenocarcinoma",
        "Ovarian, lung, and breast cancers"
      ],
      "targets": [
        "Folate receptor alpha",
        "Folate receptor alpha (FOLR1), a glycosyl phosphatidylinositol anchored membrane protein."
      ],
      "payload": [
        "Exatecan payload",
        "Exatecan, a topoisomerase 1 inhibitor."
      ],
      "linker": [
        "ProfoundBio's novel, proprietary hydrophilic linker.",
        "A cleavable, hydrophilic linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A folate receptor alpha-directed antibody",
        "A human monoclonal antibody that selectively binds to FOLR1"
      ],
      "Max Phase": "2",
      "developers": [
        "ProfoundBio"
      ],
      "trials": [
        "NCT05579366"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "# conditions": 12,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "PRO1160",
      "names": [
        "PRO1160"
      ],
      "phases": [],
      "conditions": [
        "Multiple hematologic malignancies"
      ],
      "targets": [
        "CD70, an antigen that is aberrantly overexpressed in multiple hematologic malignancies and carcinomas with limited normal tissue expression."
      ],
      "payload": [
        "Exatecan, a topoisomerase 1 inhibitor"
      ],
      "linker": [
        "A cleavable, hydrophilic linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Human monoclonal antibody that selectively binds to CD70"
      ],
      "Max Phase": null,
      "developers": [
        "ProfoundBio"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ETx-22",
      "names": [
        "ETx-22"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Bladder and triple negative breast cancer (TNBC) as well as malignancies with medium and low nectin-4 expression levels, including ovarian, head and neck and lung cancer"
      ],
      "targets": [
        "Nectin-4, a protein located on the surface of cells that is highly expressed in bladder cancer and triple negative breast cancer as well as ovarian cancer and head and neck cancer."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Emergence"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HS-20089",
      "names": [
        "HS-20089"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Endometrial Cancer",
        "Advanced Solid tumors",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "B7-H4"
      ],
      "payload": [
        "Undisclosed Payload, DAR = 6"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Shanghai Hansoh Biomedical"
      ],
      "trials": [
        "NCT06336707",
        "NCT05263479",
        "NCT06014190"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 7,
      "# locations": 1,
      "# trials": 3
    },
    {
      "heading": "AZD8205",
      "names": [
        "AZD8205"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Breast Cancer",
        "Including breast, ovarian, endometrial, and cholangiocarcinoma.",
        "Biliary Tract Carcinoma"
      ],
      "targets": [
        "B7-H4; This target has been associated with decreased inflammatory CD4+ T-cell responses and a correlation between B7-H4-expressing tumor-associated macrophages and FoxP3+ regulatory T cells (Tregs) within the tumor microenvironment. Since B7-H4 is expressed on tumor cells and tumor-associated macrophages in various cancer types, therapeutic blockade of B7-H4 could favorably alter the tumor microenvironment allowing for antigen-specific clearance tumor cells.  B7-H4 has limited expression in normal tissues, but is overexpressed in solid tumors, including breast, ovarian, endometrial, and cholangiocarcinoma, and is a potential target for tumor immunotherapy."
      ],
      "payload": [
        "A novel topoisomerase 1 inhibitor (TOP1i)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Antibody against B7-H4"
      ],
      "Max Phase": "2",
      "developers": [
        "AstraZeneca"
      ],
      "ttd": "DD10IZ",
      "trials": [
        "NCT05123482"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Thailand",
        "Hungary",
        "China",
        "Japan",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Belgium",
        "Netherlands",
        "United States"
      ],
      "# conditions": 6,
      "# locations": 15,
      "# trials": 1
    },
    {
      "heading": "SGN-B7H4V",
      "names": [
        "SGN-B7H4V"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Breast cancer Ovarian cancer Endometrial tumors."
      ],
      "targets": [
        "B7-H4, a member of the B7 family of immune checkpoint ligands. B7-H4 expression is elevated on a variety of solid tumors including breast, ovarian, and endometrial tumors."
      ],
      "payload": [
        "Microtubule disrupting agent monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Protease-cleavable peptide linker, valine-citrulline"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Fully human IgG1 anti-B7-H4 monoclonal antibody (mAb)"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TORL-2-307-ADC",
      "names": [
        "TORL-2-307-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Pancreas Cancer",
        "- Advanced Solid Tumor - Gastric Cancer - Pancreas Cancer - Gastroesophageal Junction Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Gastric Cancer",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "CLDN 18.2.  The Claudin 18.2 or CLDN18 protein is an isoform of claudin18, a member of the tight junction protein family and a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer.   CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors."
      ],
      "payload": [
        "MMAE (Monomethyl auristatin E, a synthetic antineoplastic)."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Translational Research in Oncology",
        "TORL Biotherapeutics"
      ],
      "trials": [
        "NCT05156866"
      ],
      "locations": [
        "Korea, Republic of",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "Anti-CD269-ADC | Anti-CD269-amanitin-ADC | Anti-BCMA | HDP-101 | Anti-BCMA-ATAC | anti-BCMA-ADC",
      "names": [
        "Anti-CD269-ADC",
        "Anti-CD269-amanitin-ADC",
        "Anti-BCMA",
        "HDP-101",
        "Anti-BCMA-ATAC",
        "anti-BCMA-ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "- Non Hodgkin Lymphoma (B-cell) - Plasma Cell Disorder",
        "- Multiple Myeloma (MM)"
      ],
      "targets": [
        "CD269; also known as B cell maturation antigen (BCMA); a member of the TNF-receptor superfamily that is preferentially expressed in mature B lymphocytes. CD269 promotes B cell survival and plays a role in the regulation of humoral immunity."
      ],
      "payload": [
        "Amanitin (amatoxin family); a small bicyclic peptide naturally occurring in the death cap mushroom.  DAR = 2"
      ],
      "linker": [
        "Cleavable linker / Site specific"
      ],
      "domain": [
        "Oncology; Hematology"
      ],
      "antibody": [
        "anti-CD269 mAb"
      ],
      "Max Phase": "2",
      "developers": [
        "Heidelberg Pharma"
      ],
      "trials": [
        "NCT03763370"
      ],
      "locations": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "MGTA-117 \u2013 Amanitin ADC",
      "names": [
        "MGTA-117 \u2013 Amanitin ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "targets": [
        "CD117 (c-Kit)"
      ],
      "payload": [
        "Amanitin"
      ],
      "linker": [],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Heidelberg Pharma",
        "Magenta"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "A166 ADC | A166 ADC A166 anti-HER2 ADC A166",
      "names": [
        "A166 ADC",
        "A166 ADC A166 anti-HER2 ADC A166",
        "A166"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Bile Duct Cancer",
        "Prostate Cancer",
        "Colo-rectal Cancer",
        "Primary Peritoneal Carcinoma",
        "Mucoepidermoid Carcinoma",
        "Head and Neck Cancer",
        "Recurrent Breast Cancer",
        "Liver Cancer",
        "Recurrent Renal Cell Cancer",
        "Mouth Cancer",
        "Recurrent Prostate Cancer",
        "Urologic Cancer",
        "Palate Cancer",
        "Cholangiocarcinoma",
        "Tongue Cancer",
        "Lip Cancer Stage I",
        "Mucinous Breast Cancer Recurrent",
        "Larynx Cancer",
        "Head and Neck Carcinoma",
        "Salivary Gland Carcinoma",
        "Rectal Cancer",
        "Recurrent Ovarian Carcinoma",
        "HER2 Positive Gastric Cancer",
        "HER-2 Gene Amplification",
        "Cervical Cancer",
        "Skin Cancer",
        "Salivary Gland Cancer",
        "Salivary Gland Neoplasms",
        "Rectal Cancer Stage III",
        "Rectal Cancer Stage I",
        "Recurrent Colon Cancer",
        "Rare Diseases",
        "Lung Cancer",
        "Solid Tumor",
        "Recurrent Gastric Cancer",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Mucinous Adenocarcinoma Gastric",
        "Breast Neoplasm Malignant Primary",
        "Tonsil Cancer",
        "HER2 Gene Mutation",
        "HER2-positive Breast Cancer",
        "Rectal Cancer Stage II",
        "Salivary Gland Tumor",
        "Relapsed/refractory cancers expressing HER2 Antigen or having amplified HER2 Gene.  Breast cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "payload": [
        "Auristatin-based payload"
      ],
      "linker": [
        "A site-specific conjugation and cleavable Val-Cit linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-HER2 antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "KLUS"
      ],
      "ttd": "DD94ZN",
      "drugbank": "https://go.drugbank.com/drugs/DB17413",
      "trials": [
        "NCT03602079"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 45,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "SKB315",
      "names": [
        "SKB315"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "targets": [
        "CLDN 18.2.  The Claudin 18.2 or CLDN18 protein is an isoform of claudin18, a member of the tight junction protein family and a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer.   CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors."
      ],
      "payload": [
        "A topoisomerase I inhibitor"
      ],
      "linker": [
        "A site-specific conjugation and highly stable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A anti-Claudin 18.2 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "KLUS"
      ],
      "ttd": "D56AJO",
      "trials": [
        "NCT05367635"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "SKB264 ADC",
      "names": [
        "SKB264",
        "SKB264 ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Endometrial Cancer",
        "Epithelial Ovarian Cancer",
        "Small-Cell Lung Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies, including:  - Ovarian epithelial cancer - Gastric adenocarcinoma - Pancreatic adenocarcinoma - Triple negative breast cancer - Bladder cancer",
        "Endometrial Carcinoma",
        "Gastric Adenocarcinoma"
      ],
      "targets": [
        "TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on several types of solid tumors."
      ],
      "payload": [
        "A proprietary cytotoxic, belotecan-derived payload. Belotecan (Camtobell\u00ae; CKD602) is a novel camptothecin derivative antitumor agent."
      ],
      "linker": [
        "via site-specific conjugation and highly stable linker; Average DAR (Drug Antibody Ratio) of 7.4."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "3",
      "developers": [
        "KLUS"
      ],
      "ttd": "DOS62C",
      "trials": [
        "NCT06132958",
        "NCT06074588",
        "NCT04152499"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Taiwan",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "Chile",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 12,
      "# locations": 33,
      "# trials": 3
    },
    {
      "heading": "AMG-595 | AMG595",
      "names": [
        "AMG-595",
        "AMG595"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Glioma (GBM) / Brain cancer"
      ],
      "targets": [
        "EGFRviii"
      ],
      "payload": [
        "Maytansine DM1"
      ],
      "linker": [
        "Non-cleavable linker; Hetero-bifunctional linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-EGFRvIII antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Amgen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DS-9606a | DS-9606-a",
      "names": [
        "DS-9606a",
        "DS-9606-a"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "- Advanced Cancer - Metastatic Cancer - Ovarian Cancer - Germ Cell Tumor"
      ],
      "targets": [
        "Undisclosed"
      ],
      "payload": [
        "Undisclosed"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "YL201",
      "names": [
        "YL201"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "Undisclosed"
      ],
      "payload": [
        "Undisclosed"
      ],
      "linker": [
        "Tumor Microenvironment Activable Linker (TMALIN)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "MediLink"
      ],
      "trials": [
        "NCT06057922",
        "NCT05434234"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 2
    },
    {
      "heading": "BB-1705",
      "names": [
        "BB-1705"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid tumors",
        "Solid Tumor"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor (EGFR)"
      ],
      "payload": [
        "Eribulin,  a fully synthetic, structurally simplified, macrocyclic ketone analogue of the marine natural product halichondrin B, produced from the marine sponge Halichondria okadai. Eribulin\u2019s anti-tumor activity is mediated by the inhibition of microtubule elongation and mitotic spindle formation, which results in apoptosis.  DAR = 2"
      ],
      "linker": [
        "REsidue-SPEcific Conjugation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An Anti-EGFR antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Bliss (Hangzhou)"
      ],
      "trials": [
        "NCT05217693"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "J6M0-mcMMAF | Blenrep\u00ae | Belantamab mafodotin | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | GSK2857916",
      "names": [
        "J6M0-mcMMAF",
        "BELANTAMAB",
        "GSK-2857916",
        "Blenrep\u00ae",
        "Belantamab mafodotin",
        "BELANTAMAB MAFODOTIN BLMF",
        "GSK2857916  2857916 GSK '916 J6M0-mcMMAF",
        "BELANTAMAB MAFODOTIN",
        "Blenrep",
        "GSK2857916"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 1/2",
        "Phase 4"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Glioblastoma Multiforme",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864",
        "Malignant Glioma",
        "Relapsed Cancer",
        "Multiple myeloma (BTD and PRIME)",
        "Health Condition 1: -  Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs Health Condition 3: D758- Other specified diseases of bloodand blood-forming organs"
      ],
      "targets": [
        "TNFRSF17 (TNF receptor superfamily member 17, tumor necrosis factor receptor superfamily, member 17, B cell maturation antigen, BCMA, BCM, TNFRSF13A, CD269)."
      ],
      "payload": [
        "Monomethyl Auristatin F (MMAF)   An average of 4 cysteinyl"
      ],
      "linker": [
        "A noncleavable maleimidocaproyl (mc) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Humanized monoclonal antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "GlaxoSmithKline",
        "Seagen"
      ],
      "ttd": "D52NZX",
      "chembl": "CHEMBL4298209",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf",
      "trials": [
        "CTRI/2022/05/042713",
        "NCT03544281",
        "EUCTR2017-004810-25-DE",
        "NCT02064387",
        "NCT05922501",
        "EUCTR2018-002816-29-DE",
        "NCT05064358",
        "NCT02590263",
        "NCT04822337",
        "NCT03763370",
        "NCT03525678",
        "NCT04177823",
        "NCT03828292",
        "NCT04484623",
        "NCT04246047"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "China",
        "Ireland",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Israel",
        "Republic of Korea",
        "Argentina",
        "Taiwan",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "United States of America",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 9,
      "# locations": 30,
      "# trials": 15
    },
    {
      "heading": "RC118",
      "names": [
        "RC118"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Solid Tumors including gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer.",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "Claudin 18.2, also known as CLDN18.2, is an isoform of claudin 18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, including gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer.   Claudin 18.2 is involved in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE), a potent tubulin binder with a half maximal inhibitory concentration (IC50) in the subnanomolar range,"
      ],
      "linker": [
        "Cathepsin cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-CLDN18.2 antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Biocytogen",
        "MabPlex",
        "RemeGen"
      ],
      "ttd": "D5R8YF",
      "drugbank": "https://go.drugbank.com/drugs/DB18428",
      "trials": [
        "NCT06038396",
        "NCT05205850"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "SYS6002 | CRB-701",
      "names": [
        "SYS6002",
        "CRB-701"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Advanced solid tumors, focusing\u00a0on urothelial cancer and other Nectin-4-positive solid tumors potentially including lung, breast and prostate cancer.",
        "Solid Tumor, Adult"
      ],
      "targets": [
        "Nectin-4"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Neticin-4 targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Corbus"
      ],
      "trials": [
        "NCT06265727"
      ],
      "locations": [
        "Spain",
        "United States",
        "United Kingdom",
        "Turkey"
      ],
      "# conditions": 2,
      "# locations": 4,
      "# trials": 1
    },
    {
      "heading": "PYX-201",
      "names": [
        "PYX-201"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors, including breast, head and neck, lung, and thyroid cancer."
      ],
      "targets": [
        "Fibronectin extra-domain B (ED-B)"
      ],
      "payload": [
        "Auristatin"
      ],
      "linker": [
        "A cathepsin B-cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Human IgG1 anti-fibronectin extra-domain B monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Pyxis Oncology"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18382",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti 5T4 ADC SYD1875 | SYD1875",
      "names": [
        "SYD1875",
        "Anti 5T4 ADC SYD1875"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors",
        "Solid Tumor"
      ],
      "targets": [
        "5T4, a 72 kD, heavily N-glycosylated proteins with several leucine-rich repeats which are often associated with protein-protein interactions. The protein is expressed by many different cancers but rarely in normal adult tissues."
      ],
      "payload": [
        "Duocarmycin analogues  http://www.adcreview.com/duocarmycin-analogues/"
      ],
      "linker": [
        "Cleavable valine-citrulline-seco (vc-seco)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "humanized IgG1 5T4 oncofetal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Byondis"
      ],
      "trials": [
        "NCT04202705"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "BYON3521 | BYON3521 ADC",
      "names": [
        "BYON3521",
        "BYON3521 ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors",
        "Solid Tumor"
      ],
      "targets": [
        "c-MET, also known as tyrosine-protein kinase MET [Mesenchymal Epithelial Transition] factor or HGFR [Hepatocyte Growth Factor Receptor]), is a proto-oncogene active in normal cell division, growth and differentiation."
      ],
      "payload": [
        "A DNA-alkylating duocarmycin analog.   Duocarmycin hydroxybenzamide azaindole (DUBA), is rapidly degraded in the plasma, potentially increasing the maximum tolerated doses.  http://www.adcreview.com/duocarmycin-analogues/"
      ],
      "linker": [
        "Cleavable valine-citrulline-seco (vc-seco)  A cleavable linker-drug called valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA or SYD980)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized IgG1 c-MET-targeting monoclonal antibody, SYD2884."
      ],
      "Max Phase": "1",
      "developers": [
        "Byondis"
      ],
      "trials": [
        "NCT05323045"
      ],
      "locations": [
        "Italy",
        "United Kingdom",
        "Belgium",
        "Netherlands"
      ],
      "# conditions": 2,
      "# locations": 4,
      "# trials": 1
    },
    {
      "heading": "BYON4413 ADC | BYON4413 BYON4413 ADC",
      "names": [
        "BYON4413 ADC",
        "BYON4413 BYON4413 ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Relapsed / Refractory AML",
        "Relapsed / Refractory MDS"
      ],
      "targets": [
        "Directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed on many hemato-oncological malignancies."
      ],
      "payload": [
        "A DNA-alkylating duocarmycin analog  Duocarmycin hydroxybenzamide azaindole (DUBA), is rapidly degraded in the plasma, potentially increasing the maximum tolerated doses.  http://www.adcreview.com/duocarmycin-analogues/"
      ],
      "linker": [
        "Cleavable valine-citrulline-seco (vc-seco)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Byondis"
      ],
      "trials": [
        "NCT06359002"
      ],
      "locations": [
        "Spain",
        "Belgium",
        "Netherlands"
      ],
      "# conditions": 2,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "PSMA-ADC",
      "names": [
        "PSMA-ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Prostate cancer and Glioblastoma Multiforme (GBM)"
      ],
      "targets": [
        "FOLH1 (folate hydrolase, prostate specific membrane antigen, PSMA)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Progenics Pharmaceuticals"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Anti-CD74-ADC | STRO-001",
      "names": [
        "Anti-CD74-ADC",
        "STRO-001"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "B Cells--Tumors",
        "Follicular Lymphoma",
        "Multiple Myeloma",
        "Mantle cell lymphoma",
        "Indolent Lymphoma",
        "Non Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Multiple myeloma (MM),  Diffuse large B-cell lymphoma",
        "B-cell Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "targets": [
        "CD74; a type II transmembrane glycoprotein involved in the formation and transport of MHC class II protein. CD74 is rapidly internalized and highly expressed in many B-cell malignancies with limited expression in normal tissues."
      ],
      "payload": [
        "Maytansoid  A drug-antibody ratio (DAR) of 2"
      ],
      "linker": [
        "A non-cleavable dibenzocyclooctyne (DBCO) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "a p-azido-methyl-phenylalanine (pAMF)-containing anti-CD74 aglycosylated human IgG1 antibody (SP7219)"
      ],
      "Max Phase": "1",
      "developers": [
        "Sutro Biopharma"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17224",
      "trials": [
        "NCT03424603"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 10,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "SYD985 | Trastuzumab vc-seco-DUBA | Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole | Trastuzumab duocarmazine | SYD 985",
      "names": [
        "SYD985",
        "TRASTUZUMAB DUOCARMAZINE",
        "Trastuzumab vc-seco-DUBA",
        "Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole",
        "Trastuzumab duocarmazine",
        "SYD-985",
        "SYD 985"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Endometrial Cancer",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Solid Tumor",
        "Breast Cancer Female",
        "Solid tumors (HER2-expressing breast cancer) - Breast cancer - Uterine Serous Carcinoma (USC)",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Solid Tumors",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Duocarmycin / Seco-DUBA"
      ],
      "linker": [
        "A cleavable linker N-[2-(2 maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl- p-aminobenzyloxycarbonyl-N-[2-(2-hydroxyethoxy)ethyl]- N-[2-(methylamino)ethyl]carbamoyl   An average of 2 or 4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Byondis",
        "Synthon Pharmaceuticals Durham, NC"
      ],
      "ttd": [
        "D0HL5N",
        "DI0ED3"
      ],
      "chembl": "CHEMBL4298178",
      "drugbank": "https://go.drugbank.com/drugs/DB16342",
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT03262935",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT04205630",
        "NCT04235101",
        "NCT00679341",
        "NCT02277717",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Dominican Republic",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Norway",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 27,
      "# locations": 58,
      "# trials": 24
    },
    {
      "heading": "BAT8007",
      "names": [
        "BAT8007"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "Nectin-4, a tumor-associated antigen found on the surface of solid tumor cells/"
      ],
      "payload": [
        "A small molecule topoisomerase I inhibitor and high DAR."
      ],
      "linker": [
        "Proprietary ADC linker-payload with a cleavable but systemically stable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-Nectin4"
      ],
      "Max Phase": "1",
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-319",
      "names": [
        "ABBV-319"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "CD19, a marker essential for B-cell proliferation and has high expression across B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL)."
      ],
      "payload": [
        "A proprietary glucocorticosteroid / glucocorticoid receptor modulators [GRMs]) payload"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An optimized high-affinity immunoglobulin G1 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-400",
      "names": [
        "ABBV-400"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid tumors including squamous and non squamous non-small cell lung cancer, gastric cancer, gastroesophageal adenocarcinoma, head and neck cancer squamous cell carcinoma, colorectal cancer, renal cell carcinoma."
      ],
      "targets": [
        "c-Met (hepatocyte growth factor receptor; HGFR), a receptor tyrosine kinase over-expressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis."
      ],
      "payload": [
        "An undisclosed topoisomerase inhibitor"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-706",
      "names": [
        "ABBV-706"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Recurrent or refractory solid tumors including small cell lung cancer (SCLC), high grade central nervous system tumors like grade-4 glioblastoma (GBM), grade-3 oligodendroglioma, grade 3/4 astrocytoma, neuroendocrine carcinomas like neuroendocrine prostate cancer (NEPC), gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), large cell neuroendocrine carcinoma (LCNEC), and SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)."
      ],
      "targets": [
        "Seizure-related homolog 6 (SEZ6)."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18710",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "GMF-1A3 | GMF-1A3-MMAE",
      "names": [
        "GMF-1A3",
        "GMF-1A3-MMAE"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Breast cancer"
      ],
      "targets": [
        "Amphiregulin ( (AREG) , a key proliferative effector of estrogen receptor signaling in breast cancer and other malignancies.   Amphiregulin is a single-pass transmembrane protein proteolytically processed by TACE/ADAM17 to release the soluble EGFR ligand, leaving a residual transmembrane stalk that is subsequently internalized."
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TH1902 | Sudocetaxel Zendusortide",
      "names": [
        "TH1902",
        "Sudocetaxel Zendusortide"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Solid Malignancies",
        "Urothelial Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Advanced or Metastatic Non-Small-Cell Lung Cancer",
        "Prostatic Neoplasms, Castration-Resistant",
        "Neoplasm Metastasis",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Ureteral Cancer",
        "Prostatic Cancer, Castration-Resistant",
        "Lung Cancer",
        "Solid Tumor",
        "Non-Small Cell Lung Cancer",
        "Bladder Cancer",
        "Locally Advanced or Metastatic Unresectable Urothelial Cancer",
        "Resectable Non-Small-Cell Lung Cancer",
        "Breast Neoplasms",
        "Androgen-Resistant Prostatic Neoplasms"
      ],
      "targets": [
        "Sortilin (SORT1) receptor.  A novel receptor that is highly expressed in many types of cancer and is associated with poor prognosis and decreased survival"
      ],
      "payload": [
        "Docetaxel (2:1 ratio),"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [],
      "antibody": [
        "TH19P01, a proprietary, sortilin-targeting peptide"
      ],
      "Max Phase": "3",
      "developers": [
        "Theratechnologies"
      ],
      "trials": [
        "NCT05089734",
        "NCT05633667",
        "NCT00934856",
        "NCT02131064",
        "NCT03337698",
        "NCT00051571",
        "NCT02605915",
        "NCT04527991",
        "NCT00781612",
        "NCT06074588",
        "NCT04794699",
        "NCT04880863",
        "NCT04381832",
        "NCT00679341",
        "NCT05006794",
        "NCT03474107",
        "NCT00132379",
        "NCT01120184",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Puerto Rico",
        "Thailand",
        "Italy",
        "Israel",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Norway",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 23,
      "# locations": 53,
      "# trials": 19
    },
    {
      "heading": "XMT-1536 | Upifitamab Rilsodotin | UpRi | XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin | XMT1536",
      "names": [
        "Upifitamab rilsodotin",
        "XMT-1536",
        "Upifitamab Rilsodotin",
        "UpRi",
        "XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin",
        "XMT1536"
      ],
      "phases": [
        "Preclinical",
        "Phase 3"
      ],
      "conditions": [
        "NSCLC",
        "Solid tumors",
        "Ovarian cancer"
      ],
      "targets": [
        "NaPi2b; Sodium-dependent phosphate transport protein 2B is involved in actively transporting phosphate into cells via Na+ co-transport. NaPi2b is highly expressed in 75 to 90% of both non-squamous NSCLC and epithelial ovarian cancer."
      ],
      "payload": [
        "A proprietary auristatin payload (3 to 5 flexible polymers PHF-BA-EG2-MI-AF-HPA-Ala, each comprising maleimide (MI) bioconjugation linkers and 3 to 4 auristatin F- hydroxypropylamide-L-alanine (AF-HPA-Ala), with a drug to antibody ratio (DASR) of 12:1 to 15:1"
      ],
      "linker": [
        "Thioether bond (Protease cleavable)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "3",
      "developers": [
        "Mersana"
      ],
      "ttd": "D0QFD2",
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "M9346A-sulfo-SPDB-DM4 | Mirvetuximab Soravtansine | IMGN853 | IMGN-853 | Elahere | Anti-FOLR1 monoclonal -maytansinoid",
      "names": [
        "MIRVETUXIMAB SORAVTANSINE-GYNX",
        "M9346A-sulfo-SPDB-DM4",
        "MIRVETUXIMAB SORAVTANSINE",
        "Mirvetuximab Soravtansine",
        "Mirvetuximab soravtansine",
        "ELAHERE",
        "IMGN853",
        "IMGN-853",
        "MIRVETUXIMAB SORAVTANSINE GYNX",
        "Elahere",
        "Anti-FOLR1 monoclonal -maytansinoid"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Folate Receptor-Alpha Positive",
        "Ovarian tumor",
        "non-small cell lung cancer (NSCLC) and other solid tumor",
        "Tumors",
        "Endometrial Cancer",
        "BRCA1 Gene Mutation",
        "Peritoneal Cancer",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Folate Receptor Alpha Positive",
        "BRCA2 Gene Mutation",
        "Fallopian Tube Cancer",
        "Ovary Cancer",
        "Recurrent Ovarian Cancer",
        "Recurrent Primary Peritoneal Carcinoma",
        "High Grade Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma",
        "Recurrent Uterine Serous Carcinoma",
        "Recurrent Uterine Carcinosarcoma",
        "Solid Tumors",
        "Platinum Resistant Ovarian Cancer"
      ],
      "targets": [
        "Folate receptor 1 (FR\u03b1/ Folate Receptor \u03b1, FOLRI 1)"
      ],
      "payload": [
        "Maytansinoid DM4  (N2'- Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine"
      ],
      "linker": [
        "N-Succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate linker (Sulfo-SPDB).  Linker specifically designed to counteract multi-drug resistance"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa M9346A anti- FR\u03b1 antibody"
      ],
      "Max Phase": "Approved",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL3545132",
      "drugbank": "https://go.drugbank.com/drugs/DB12489",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf",
      "trials": [
        "NCT04296890",
        "NCT03552471",
        "NCT05622890",
        "NCT02631876",
        "NCT03835819",
        "NCT05456685",
        "NCT06390995",
        "NCT05041257",
        "NCT03832361",
        "NCT02606305",
        "NCT04209855",
        "NCT04274426",
        "NCT05445778",
        "NCT05887609",
        "NCT06365853",
        "NCT01609556"
      ],
      "locations": [
        "Czechia",
        "Bosnia and Herzegovina",
        "China",
        "Ireland",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Georgia",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# conditions": 26,
      "# locations": 27,
      "# trials": 16
    },
    {
      "heading": "Basiliximab Sarotalocan",
      "names": [
        "BASILIXIMAB SAROTALOCAN",
        "Basiliximab Sarotalocan"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "Anti-[Homo sapiens IL2RA (interleukin 2 receptor subunit alpha; IL-2RA, TAC, p55, CD25)]"
      ],
      "payload": [
        "IRDye 700DX (IR700) near-infrared photosensitizing dye Conjugated on an average of 2 or 3 lysyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens IL2RA (interleukin 2 receptor subunit alpha; IL-2RA, TAC, p55, CD25)], chimeric monoclonal antibody"
      ],
      "Max Phase": "2",
      "chembl": "CHEMBL5314724",
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Maridebart cafraglutide",
      "names": [
        "MARIDEBART CAFRAGLUTIDE",
        "Maridebart cafraglutide"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "Glucagon-like peptide 1 (GLP-1) receptor GIPR (gastric inhibitory polypeptide receptor)"
      ],
      "payload": [
        "Two identical glucagon-like peptide 1 (GLP-1) analogues"
      ],
      "linker": [
        "A fused 18-mer linker (diglycyl- tris(tetraglycyl-seryl)- lysinamide"
      ],
      "domain": [],
      "antibody": [
        "Immunoglobulin G1-kappa, anti-[Homo sapiens GIPR (gastric inhibitory polypeptide receptor)], Homo sapiens monoclonal antibody"
      ],
      "Max Phase": "2",
      "chembl": "CHEMBL5314751",
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Oberotatug Ravtansine",
      "names": [
        "OBEROTATUG RAVTANSINE",
        "Oberotatug Ravtansine"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "LY75 (human lymphocyte antigen 75, C-type lectin domain family 13 member B, CLEC13B, DEC-205, CD205)]"
      ],
      "payload": [
        "maytansinoid DM4 [N2'- deacetyl-N2'-(4-mercapto-4- methyl-1-oxopentyl)-maytansine]"
      ],
      "linker": [
        "A reducible SPDB linker [N- succinimidyl 4-(2-pyridyldithio)butanoate]"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A human immunoglobulin G1-kappa, anti-[Homo sapiens LY75 (human lymphocyte antigen 75, C-type lectin domain family 13 member B, CLEC13B, DEC-205, CD205)]"
      ],
      "Max Phase": "2",
      "chembl": "CHEMBL5314757",
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Puxitatug samrotecan",
      "names": [
        "Puxitatug samrotecan",
        "PUXITATUG SAMROTECAN"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [],
      "targets": [
        "VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)"
      ],
      "payload": [
        "A  topoisomerase I inhibitor"
      ],
      "linker": [],
      "domain": [],
      "antibody": [
        "immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)], Homo sapiens monoclonal antibody"
      ],
      "Max Phase": "2",
      "chembl": "CHEMBL5314766",
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Trastuzumab Botidotin",
      "names": [
        "A 166",
        "A-166",
        "TRASTUZUMAB BOTIDOTIN",
        "Trastuzumab Botidotin"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "Duostatin-5 (Duo-5) with a drug-antibody ratio (DAR) of 2"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An immunoglobulin G1-kappa, anti-ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody"
      ],
      "Max Phase": "3",
      "chembl": "CHEMBL5314782",
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "developers": [
        "RemeGen"
      ],
      "# conditions": 23,
      "# locations": 72,
      "# trials": 20
    },
    {
      "heading": "REGN5093 \u2013 M114",
      "names": [
        "REGN5093-M114",
        "REGN5093 \u2013 M114"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Advanced NSCLC",
        "MET Overexpressing Advanced Cancer"
      ],
      "targets": [
        "Two different epitopes of Mesenchymal Epithelial Transition Factor (MET)"
      ],
      "payload": [
        "M24 (maytansine derivative) with a drug to antibody ratio of about 3.2."
      ],
      "linker": [
        "M114, a protease cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "REGN5093, a 1+1 asymmetric bispecific antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Regeneron"
      ],
      "trials": [
        "NCT04982224"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "M1231",
      "names": [
        "M1231"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Metastatic Solid Tumors Esophageal Cancer Non-Small Cell Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "Esophageal Cancer"
      ],
      "targets": [
        "EGFR (Epidermal growth factor receptor, a protein that is present on the surface of both normal cells and cancer cells and is involved in cell growth) and MUC1 (a glycoprotein involved in the metastasis and invasion of multiple tumor types)"
      ],
      "payload": [
        "Hemiasterlin derivative, conjugates using Sutro's proprietary fixed-point coupling technology attach to specific amino acid sites of the antibody with with a drug-to-antibody ratio (DAR) of about 4."
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Sutro Biopharma"
      ],
      "trials": [
        "NCT04695847"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "DS-8201 | DS-8201a | Trastuzumab deruxtecan | ENHERTU\u00ae",
      "names": [
        "DS-8201",
        "DS-8201A",
        "FAM-TRASTUZUMAB DERUXTECAN-NXKI",
        "DS-8201a",
        "ENHERTU\u00ae",
        "TRASTUZUMAB DERUXTECAN NXKI",
        "TRASTUZUMAB DERUXTECAN",
        "Enhertu",
        "TRASTUZUMAB DERUXTECAN-NXKI",
        "Trastuzumab deruxtecan",
        "Trastuzumab-Deruxtecan (T-DXd)"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen     MedDRA version: 21.1 Level: LLT Classification code 10071114 Term: Metastatic gastric adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Neoplasm, Gastrointestinal",
        "Gastric Cancer",
        "Advanced Cancer",
        "Solid tumors (including Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer)",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Adenocarcinoma - GEJ",
        "Advanced Colorectal Cancer",
        "Stage IIA Breast Cancer",
        "Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)",
        "Recurrent Glioblastoma",
        "Invasive Breast Cancer",
        "Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Inflammatory Breast Cancer Stage III",
        "Left Ventricular Function Systolic Dysfunction",
        "Early-stage Breast Cancer",
        "Gastroesophageal-junction Cancer",
        "HER2 Amplification",
        "Breast Cancer Female",
        "Esophageal Cancer",
        "HER2 Gene Mutation",
        "Metastatic Cancer",
        "Adenocarcinoma, Gastric",
        "Malignant Neoplasm of Breast",
        "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Advanced Solid Malignancies",
        "Adenocarcinoma Gastric Stage IV With Metastases",
        "Breast Tumors",
        "BREAST CANCER",
        "Gastric Cancer, Adenocarcinoma",
        "Neoplasm Metastasis",
        "HER2-positive Early Breast Cancer",
        "Non-small Cell Lung Carcinoma",
        "HER2-positive Metastatic Breast Cancer",
        "Neoplasm, Breast",
        "Advanced or Metastatic Breast Cancer",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Locally Advanced Breast Cancer",
        "HER2-positive Breast Cancer",
        "Chemotherapy-induced Alopecia",
        "Stage III Breast Cancer",
        "Metastatic Gastric Adenocarcinoma",
        "Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864",
        "HER2-over-expressing or HER2-mutated unresectable and/or metastatic non-squamous NSCLC",
        "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer",
        "Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast",
        "Breast Cancer",
        "Brain Cancer",
        "HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Locally Advanced or Early Breast Cancer",
        "Residual Invasive Breast Cancer",
        "HER-2 Protein Overexpression",
        "Stage II Breast Cancer",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Metastatic Breast Cancer",
        "Leptomeningeal Metastasis",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Colorectal Neoplasm",
        "Gastrooesophageal Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Advanced Solid Tumor",
        "Recurrent Breast Cancer",
        "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "HER2-mutant Non-Small Cell Lung Cancer",
        "Breast Cancer Stage IV",
        "HER2 Low Breast Adenocarcinoma",
        "Biliary Tract Cancer",
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Gastroesophageal Junction Adenocarcinoma",
        "HER2-Positive Primary Breast Cancer",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutant Non-small Cell Lung Cancer",
        "Triple Negative Breast Neoplasms",
        "Non-Small Cell Lung Cancer",
        "Stage IIB Breast Cancer",
        "Esophageal Adenocarcinoma",
        "Advanced Solid Tumors",
        "Glioblastoma",
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
        "Her2-positive, unresectable and/or metastatic breast cancer.",
        "Gastric Adenocarcinoma",
        "HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine- protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)"
      ],
      "payload": [
        "A topoisomerase I inhibitor payload, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative).  Average drug-to-antibody ratio 7 - 8"
      ],
      "linker": [
        "A tetrapeptide linker, Gly-Phe-Leu-Gly (GFLG).  An average of 8 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "AstraZeneca",
        "DAIICHI SANKYO"
      ],
      "ttd": "D06BHB",
      "chembl": "CHEMBL4297844",
      "drugbank": "https://go.drugbank.com/drugs/DB14962",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf",
      "trials": [
        "NCT05744375",
        "NCT05323955",
        "NCT03384940",
        "NCT04622319",
        "NCT03334617",
        "NCT04873362",
        "NCT04420598",
        "NCT03329690",
        "NCT03742102",
        "NCT04752059",
        "NCT04014075",
        "NCT04784715",
        "EUCTR2019-001512-34-BE",
        "NCT04986579",
        "NCT01772472",
        "NCT03383692",
        "NCT06048718",
        "NCT03424005",
        "NCT04494425",
        "EUCTR2019-004531-22-FR",
        "NCT04704934",
        "NCT06271837",
        "NCT02390427",
        "EUCTR2018-000221-31-BE",
        "NCT03529110",
        "NCT05274048",
        "NCT04644237",
        "NCT06058988",
        "NCT04553770",
        "NCT06100874",
        "NCT05480384",
        "NCT00928330",
        "NCT04556773",
        "NCT05795101",
        "NCT04744831",
        "NCT05704829",
        "NCT02605915",
        "NCT05417594",
        "NCT03726879",
        "NCT05113251",
        "NCT05034887",
        "NCT03368196",
        "NCT06467357",
        "NCT04989816",
        "JPRN-jRCT2080223860",
        "NCT04639219",
        "NCT00679341",
        "NCT04686305",
        "NCT05982678",
        "EUCTR2020-001574-29-BE",
        "EUCTR2020-001574-29-PL",
        "NCT04538742",
        "NCT02073487",
        "NCT04739761",
        "EUCTR2018-000764-29-GB",
        "EUCTR2020-003427-42-NL",
        "NCT04132960",
        "NCT01969643",
        "NCT06174987",
        "NCT04539938",
        "NCT05950945",
        "NCT04042701",
        "NCT05980481",
        "NCT06324357",
        "NCT03366428",
        "NCT06429761",
        "NCT03523585",
        "NCT05048797",
        "EUCTR2018-000764-29-PL",
        "NCT02564900",
        "NCT01904903",
        "NCT05765851",
        "NCT03505710",
        "NCT06172127",
        "NCT05246514",
        "NCT02131064",
        "EUCTR2019-002991-15-ES",
        "NCT05965479",
        "NCT00781612",
        "EUCTR2019-004531-22-PL",
        "NCT03734029",
        "EUCTR2018-000221-31-CZ",
        "NCT04379596",
        "EUCTR2020-003427-42-FR",
        "NCT05633979",
        "NCT04482309",
        "NCT03248492",
        "NCT05650879",
        "NCT06244485",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "Turkiye",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Czech Republic",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "North America",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Europe",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 91,
      "# locations": 64,
      "# trials": 90
    },
    {
      "heading": "BL-B01D1",
      "names": [
        "BL-B01D1"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Metastatic gastrointestinal tumors and other solid tumor"
      ],
      "targets": [
        "EGFR and HER3, members of the human epidermal growth factor receptor (ErbB) family."
      ],
      "payload": [
        "A topoisomerase I inhibitor agent (Ed-04), which is a derivative of the alkaloid camptothecin conjugates to the cysteine site of the antibody with a Drug to Antibody Ratio (DAR) between 7.5 and 8."
      ],
      "linker": [
        "A cathepsin B cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Izalontamab, bispecific antibody against EGFR/HER3 (SI-B001)"
      ],
      "Max Phase": "1",
      "developers": [
        "Systimmune",
        "Sichuan Baili"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BAT8001",
      "names": [
        "BAT8001"
      ],
      "phases": [
        "Phase 3"
      ],
      "conditions": [
        "HER2-positive stomach cancer and breast cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "A maytansine derivative"
      ],
      "linker": [
        "A novel uncleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab"
      ],
      "Max Phase": "3",
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BAT8003",
      "names": [
        "BAT8003"
      ],
      "phases": [
        "Phase 1  i"
      ],
      "conditions": [
        "Advanced Solid Cancer Triple-negative-breast-cancer"
      ],
      "targets": [
        "Trophoblast cell surface antigen 2 (TROP2)"
      ],
      "payload": [
        "A potent cytotoxic maytansine derivative."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMMU-132 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38 | hRS7-SN38 | Trodelvy | hRS7-SN-38-ADC",
      "names": [
        "IMMU-132",
        "hRS7-[CL-SN-38] hrS7-SN-38",
        "Sacituzumab govitecan",
        "HRS7-SN38",
        "SACITUZUMAB GOVITECAN",
        "hRS7-SN-38",
        "hRS7-SN38",
        "TRODELVY",
        "Trodelvy",
        "hRS7-SN-38-ADC",
        "sacituzumab govitecan",
        "Sacituzumab govetican",
        "SACITUZUMAB GOVITECAN HZIY"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Residual Cancer",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Triple-negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Solid Malignancies",
        "NSCLC Stage IV",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Renal Cell Cancer",
        "Endometrial Cancer",
        "Urinary Bladder Neoplasms",
        "Invasive Breast Cancer",
        "Metastatic Solid tumor",
        "Head and Neck Cancers- Squamous Cell",
        "Prostatic Cancer, Castration-Resistant",
        "PR-Negative Breast Cancer",
        "Mesotheliomas Pleural",
        "Solid Tumor",
        "Breast Cancer Female",
        "Locally Advanced or Metastatic Unresectable Urothelial Cancer",
        "Esophageal Cancer",
        "Locally Advanced or Metastatic Urothelial Carcinoma",
        "Human Epidermal Growth Factor 2 Low Breast Cancer",
        "HR+/HER2- Metastatic Breast Cancer",
        "Endometrial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Advanced or Metastatic Solid Tumor",
        "Recurrent Breast Carcinoma",
        "Metastatic Urothelial Cancer",
        "Esophagogastric Adenocarcinoma",
        "Small Cell Lung Cancer",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Urothelial Carcinoma",
        "Mesothelioma; Pleura",
        "Her 2 Positive Breast Cancer",
        "Advanced or Metastatic Non-Small-Cell Lung Cancer",
        "Invasive Breast Carcinoma",
        "Liver Failure",
        "Glioblastoma Multiforme",
        "Triple Negative Breast Cancer",
        "Triple-Negative Breast Cancer",
        "Metastatic HER2 Negative Breast Carcinoma",
        "epithelial cancers | bladder, colorectal, head and neck, kidney, NSCLC, SCLC, ovary, pancreas, prostate, gastrointestina",
        "HER2-negative Breast Cancer",
        "Muscle Invasive Bladder Carcinoma",
        "Pancreatic Cancer",
        "Metastatic Solid Tumor",
        "PD-L1 Positive",
        "Stage II Bladder Cancer AJCC v8",
        "Breast Cancer Metastatic",
        "Gland",
        "Chemotherapy-induced Alopecia",
        "Stage III Breast Cancer",
        "Prostate Cancer",
        "Urothelial Cancer",
        "Breast Cancer",
        "ER-Negative Breast Cancer",
        "Cancer",
        "Circulating Tumor DNA",
        "Esophageal Squamous Cell Carcinoma",
        "Brain Metastases, Adult",
        "Carcinoma, Non-Small-Cell Lung",
        "Stage IIIB Breast Cancer",
        "Thymoma",
        "Mesothelioma",
        "PD-L1 Negative",
        "Hormone-receptor-positive Breast Cancer",
        "Ovarian Carcinoma",
        "Stage IIIC Breast Cancer",
        "Differentiated Thyroid Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Urothelial Bladder Carcinoma",
        "Bladder Cancer",
        "Stage IIIA Breast Cancer",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Salivary Gland Cancers",
        "Advanced Solid Tumor",
        "Hepatocellular Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastrointestinal Cancer",
        "Hormone-refractory Prostate Cancer",
        "Triple-Negative Breast Carcinoma",
        "Locally Advanced or Unresectable Metastatic Breast Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Thymic Carcinoma",
        "Prostatic Neoplasms, Castration-Resistant",
        "Cervical Cancer",
        "Unresectable Breast Carcinoma",
        "Stage IIIA Bladder Cancer AJCC v8",
        "Solid Tumor, Adult",
        "Ovarian Epithelial Cancer",
        "Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "HR-Positive Breast Cancer",
        "Anaplastic Thyroid Cancer",
        "Advanced Solid Tumors",
        "Muscle-Invasive Bladder Carcinoma",
        "Stage IV Breast Cancer",
        "Resectable Non-Small-Cell Lung Cancer",
        "Glioblastoma",
        "Carcinoma Breast Stage IV",
        "Metastatic Triple-Negative Breast Cancer",
        "Androgen-Resistant Prostatic Neoplasms",
        "Localized Muscle Invasive Bladder Urothelial Carcinoma"
      ],
      "targets": [
        "TACSTD2 | tumor-associated calcium signal transducer 2) or EGP1 | M1S1, Gastrointestinal tumor-associated antigen GA7331, Pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2"
      ],
      "payload": [
        "Camptothecin analog (SN38) Irinotecan metabolite 7-ethyl-10 hydroxycamptothecin"
      ],
      "linker": [
        "Carbonate"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa"
      ],
      "Max Phase": "Approved",
      "developers": [
        "GILEAD",
        "Immunomedics"
      ],
      "ttd": "D8LAE2",
      "chembl": "CHEMBL3545262",
      "drugbank": "https://go.drugbank.com/drugs/DB12893",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf",
      "trials": [
        "NCT05101096",
        "NCT06133517",
        "NCT05089734",
        "NCT05633667",
        "NCT04639986",
        "NCT05382286",
        "NCT06486441",
        "NCT05097599",
        "NCT06028932",
        "NCT04434040",
        "NCT06248515",
        "NCT04454437",
        "NCT05675579",
        "NCT06100874",
        "NCT06235216",
        "NCT05520723",
        "NCT04448886",
        "NCT04039230",
        "NCT05581589",
        "NCT05382299",
        "NCT04863885",
        "NCT05186974",
        "NCT06081244",
        "NCT03337698",
        "NCT04468061",
        "NCT05633654",
        "NCT03971409",
        "NCT05884320",
        "NCT06065371",
        "NCT04527991",
        "NCT01631552",
        "NCT06123468",
        "NCT04230109",
        "NCT05838521",
        "NCT04595565",
        "NCT06167317",
        "NCT03725761",
        "NCT06238921",
        "NCT05119907",
        "NCT05552001",
        "NCT03964727",
        "NCT03901339",
        "NCT03995706",
        "NCT04794699",
        "NCT06329869",
        "NCT03869190",
        "NCT04251416",
        "NCT05327530",
        "NCT04617522",
        "NCT04381832",
        "NCT04986579",
        "NCT04143711",
        "NCT03547973",
        "NCT02574455",
        "NCT04724018",
        "NCT05113966",
        "NCT06477419",
        "NCT03424005",
        "NCT05006794",
        "NCT06401824",
        "NCT05609968",
        "NCT05840211",
        "NCT04647916",
        "NCT04958785",
        "NCT05143229",
        "NCT05833867",
        "NCT06263543"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Georgia",
        "Argentina",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Estonia"
      ],
      "# conditions": 104,
      "# locations": 46,
      "# trials": 67
    },
    {
      "heading": "GQ1010",
      "names": [
        "GQ1010"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "targets": [
        "Trophoblast cell surface antigen 2 (TROP2)"
      ],
      "payload": [
        "Next generation camptothecin analogue"
      ],
      "linker": [
        "A stable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "GeneQuantum (Suzhou, China)",
        "Pyramid Biosciences"
      ],
      "trials": [
        "NCT06384807"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "ZB131-MMAE | ZB131-DXd | ZB131 | ZB131  ZB131-MMAE  ZB131-DXd",
      "names": [
        "ZB131-MMAE",
        "ZB131-DXd",
        "ZB131",
        "ZB131  ZB131-MMAE  ZB131-DXd"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Adult Pancreatic Ductal",
        "Solid Tumors",
        "Adenocarcinoma Ovarian Serous Adenocarcinoma Biliary Cancer Metastatic  Ovarian Serous Cystadenocarcinoma"
      ],
      "targets": [
        "Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, including ovarian cancer."
      ],
      "payload": [
        "ZB131-MMAE (ZB131 conjugated to monomethyl auristatin E) with drug-to-antibody ratio (DAR) of 3 \u2013 4   ZB131-DXd (ZB131 conjugated to deruxtecan) with DAR of 7 \u2013 8"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ZB131, an antibody directed against CSP."
      ],
      "Max Phase": "2",
      "developers": [
        "ZielBio"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 3,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BB-1701 | HER2-Targeting ADC",
      "names": [
        "BB-1701",
        "HER2-Targeting ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Locally advanced/metastatic HER2 positive solid tumors  - Breast cancer,  - Gastric/gastroesophageal junction cancer, - Bladder cancer - Colon cancer",
        "Breast Cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "Eribulin, a fully synthetic, structurally simplified, macrocyclic ketone analogue of the marine natural product halichondrin B, produced from the marine sponge Halichondria okadai. Eribulin\u2019s anti-tumor activity is mediated by the inhibition of microtubule elongation and mitotic spindle formation, which results in apoptosis."
      ],
      "linker": [
        "REsidue-SPEcific Conjugation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-HER2 Antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "Bliss (Hangzhou)",
        "Eisai"
      ],
      "ttd": "D56ECJ",
      "drugbank": "https://go.drugbank.com/drugs/DB17443",
      "trials": [
        "NCT06188559"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "TQB2103",
      "names": [
        "TQB2103"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "claudin18.2 positive human gastric and pancreatic cancer",
        "Advanced Malignant Neoplasm"
      ],
      "targets": [
        "Claudin18.2"
      ],
      "payload": [
        "A small-molecule toxin"
      ],
      "linker": [
        "An enzymatically cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A proprietary claudin18.2-targeted monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Sino Biopharmaceutical"
      ],
      "trials": [
        "NCT05867563"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302",
      "names": [
        "LM-302",
        "LM-302 BMS-986476 TPX-4589",
        "BMS-986476",
        "TPX-4589"
      ],
      "phases": [
        "Phase 2"
      ],
      "conditions": [
        "Gastrointestinal cancer, including gastric, gastroesophageal junction and pancreatic cancer"
      ],
      "targets": [
        "Claudin 18.2.  CLDN18.2 expression is associated with tumor pathogenesis, proliferation, and metastasis, making it a promising target for cancer therapies."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Ant0-Claudin 18.2 antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "LaNova",
        "Turning Point therapeutics"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18604",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CMG901",
      "names": [
        "CMG901"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid tumors that express the cell surface protein Claudin 18.2, including gastric cancers.",
        "Gastric Cancer",
        "Gastric cancer, Gastroesophageal junction cancer",
        "Gastroesophageal Junction Cancer",
        "Pancreatic Adenocarcinoma"
      ],
      "targets": [
        "Claudin 18.2 | Claudin 18.2 a transmembrane protein, also known as CLDN18.2, is an isoform of claudin 18, a member of the tight junction protein family. It is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer.[1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A antibody targeting Claudin 18.2 /CLDN18.2"
      ],
      "Max Phase": "2",
      "developers": [
        "Lepu Biopharma",
        "AstraZeneca",
        "KYM Biosciences",
        "Keymed Biosciences"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18619",
      "trials": [
        "NCT06219941",
        "JPRN-jRCT2031230569"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Moldova, Republic of",
        "United States of America",
        "Georgia",
        "Malaysia",
        "Republic of Korea",
        "Republic of Moldova",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 16,
      "# trials": 2
    },
    {
      "heading": "ABBV-011",
      "names": [
        "ABBV-011"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "targets": [
        "Seizure-related homolog 6 (SEZ6), a surface-expressed SCLC target with broad expression in small cell lung cancer (SCLC) and minimal normal, healthy, tissue expression."
      ],
      "payload": [
        "Calicheamicin-based ADC  A novel calicheamicin linker drug, LD19.10, that lacks the acid-labile DMH found in previous calicheamicin ADCs"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "SC17, an antibody targeting SEZ6 that is rapidly internalized upon receptor binding."
      ],
      "Max Phase": "1",
      "developers": [
        "AbbVie"
      ],
      "ttd": "D4J9HV",
      "drugbank": "https://go.drugbank.com/drugs/DB18622",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DB-1303 | DB-1303 BNT323 | BNT323",
      "names": [
        "DB-1303",
        "DB-1303 BNT323",
        "BNT323"
      ],
      "phases": [
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Endometrial Cancer",
        "Advanced/unresectable, recurrent, or metastatic HER2-expressing malignant solid tumors.  Endometrial carcinoma"
      ],
      "targets": [
        "HER2 (human epidermal growth factor receptor 2)."
      ],
      "payload": [
        "A  proprietary topoisomerase I inhibitor P1003"
      ],
      "linker": [
        "An enzymatically cleavable peptide-linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-HER2 antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "Duality Biologics"
      ],
      "trials": [
        "NCT06340568"
      ],
      "locations": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "DB-1311",
      "names": [
        "DB-1311"
      ],
      "phases": [],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Duality Biologics"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056 | XMT-2056",
      "names": [
        "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056",
        "XMT-2056"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [],
      "targets": [
        "Directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)."
      ],
      "payload": [
        "An agonist for the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173)"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "HT-19, a monoclonal antibody  linked to a payload composed of an"
      ],
      "Max Phase": "1",
      "developers": [
        "GlaxoSmithKline",
        "Mersana"
      ],
      "ttd": "D7AT3H",
      "drugbank": "https://go.drugbank.com/drugs/DB18230",
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC | ABT-700-vcMMAE | Telisotuzumab Vedotin | ABBV 399 | ABBV-399 | Teliso-V",
      "names": [
        "ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC",
        "ABT-700-vcMMAE",
        "PR-1420682",
        "Telisotuzumab Vedotin",
        "ABBV 399",
        "ABBV-399",
        "TELISOTUZUMAB VEDOTIN",
        "ABT-700-VCMMAE",
        "Teliso-V",
        "ABT-399"
      ],
      "phases": [
        "Phase 1/1",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Solid Tumors (c-Met expressing Non Small Cell Lung Cancer / NSCLC)",
        "Non-small Cell Lung Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Advanced Solid Tumors Cancer",
        "Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Non Small Cell Lung Cancer"
      ],
      "targets": [
        "c-MET (Met proto-oncogene, Hepatocyte growth factor (HGF) receptor, HGFR, Scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)  On an average of 3-4 lysyl"
      ],
      "linker": [
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa  ABT-700"
      ],
      "Max Phase": "3",
      "developers": [
        "AbbVie"
      ],
      "chembl": "CHEMBL3990032",
      "trials": [
        "NCT03539536",
        "EUCTR2018-001772-38-IE",
        "NCT04928846",
        "EUCTR2018-001772-38-HU",
        "NCT02099058"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "South Africa",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Chile",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Slovakia",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 6,
      "# locations": 40,
      "# trials": 5
    },
    {
      "heading": "Lorvotuzumab mertansine | IMGN-901 | BB-10901 IMGN901 huN901-DM1 IMGN-901 | huN901-DM1",
      "names": [
        "Lorvotuzumab mertansine",
        "IMGN-901",
        "huN901-DM1",
        "HUN901-DM1, BB-10901",
        "BB-10901 IMGN901 huN901-DM1 IMGN-901",
        "LORVOTUZUMAB MERTANSINE"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "multiple myeloma",
        "Ovarian Cancer",
        "Multiple Myeloma",
        "Small Cell Lung Cancer",
        "Synovial sarcoma.",
        "Independent Children's  Oncology Group study trials in children with: Relapsed or refractory Wilms tumor",
        "Small-cell lung cancer (SCLC)",
        "malignant peripheral nerve sheath tumor (MPNST)",
        "Leukemia",
        "rhabdomyosarcoma",
        "Merkel Cell Carcinoma",
        "SCLC",
        "pleuropulmonary blastoma",
        "neuroblastoma"
      ],
      "targets": [
        "CD56 | NCAM1 (neural cell adhesion molecule 1, CD56, NCAM-1)"
      ],
      "payload": [
        "Maytansine DM1 (microtubule inhibitor)"
      ],
      "linker": [
        "A thiopentanoate linker (or reducible SPP (N-succinimidyl 4-(2-pyridyldithio)) linker)   An average of 3-4 lysyl"
      ],
      "domain": [
        "Oncology | Hematology"
      ],
      "antibody": [
        "A humanized version of the murine monoclonal antibody N901  IgG1 - kappa"
      ],
      "Max Phase": "2",
      "developers": [
        "IMMUNOGEN"
      ],
      "chembl": "CHEMBL1743037",
      "trials": [
        "NCT02420873",
        "NCT00065429",
        "NCT00991562",
        "NCT00346385",
        "NCT00346255"
      ],
      "locations": [
        "United Kingdom",
        "Argentina",
        "United States"
      ],
      "# conditions": 14,
      "# locations": 3,
      "# trials": 5
    },
    {
      "heading": "U3-1402 U3-1402A Anti-HER3 | HER3 ADC | Patritumab Deruxtecan | U3-1402",
      "names": [
        "U31402",
        "Patritumab Deruxtecan",
        "Patritumab deruxtecan",
        "U3-1402 U3-1402A Anti-HER3",
        "HER3-DXd (FL-DP)",
        "U3-1402",
        "U3-1402A",
        "PATRITUMAB DERUXTECAN",
        "U3 1402",
        "HER3-DXd (CTM-1 Lyo-DP)",
        "HER3 ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Non-small cell lung (NSCLC) and breast cancer",
        "Solid Tumor, Adult",
        "Metastatic Breast Cancer",
        "Breast Cancer",
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Solid tumors"
      ],
      "targets": [
        "HER3-positive (human epidermal growth factor receptor HER3 (ErbB3)."
      ],
      "payload": [
        "Deruxtecan, DX-8951 derivative (DXd, topoisomerase I inhibitor), a camptothecin derivative  On an average of 8 cysteinyl"
      ],
      "linker": [
        "Peptide cleavable linker ( a tetrapeptide-based cleavable linker)  The antibody is covalently conjugated, via cysteine residues, through a tumor selective cleavable linker to the payload."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa  Patritumab, also known as AMG 888 and U3-1287"
      ],
      "Max Phase": "3",
      "developers": [
        "Amgen",
        "DAIICHI SANKYO"
      ],
      "ttd": "DX5A8D",
      "chembl": "CHEMBL4594611",
      "trials": [
        "NCT03260491",
        "NCT02980341",
        "NCT04965766",
        "NCT05865990",
        "NCT04610528"
      ],
      "locations": [
        "Austria",
        "Japan",
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "France",
        "Netherlands",
        "United States"
      ],
      "# conditions": 7,
      "# locations": 8,
      "# trials": 5
    },
    {
      "heading": "TROP2 ADC | Datopotamab deruxtecan | DS-1062 DS1062 DS-1062A Anti-TRP2/dxd | DS-1062",
      "names": [
        "DS-1062a",
        "Dato-DXd",
        "ADC DS-1062A",
        "DS-1062",
        "DS-1062A",
        "DATOPOTAMAB DERUXTECAN",
        "DS1062",
        "Datopotamab deruxtecan",
        "DS-1062 DS1062 DS-1062A Anti-TRP2/dxd",
        "TROP2 ADC"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Prostate Cancer",
        "unresectable advanced NSCLC",
        "Additional Indications Below for Module 4 and 5",
        "Non-small Cell Lung Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy  MedDRA version: 23.0 Level: PT Classification code 10083232 Term: HER2 negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Gastric Cancer",
        "Breast Cancer",
        "Urothelial Cancer",
        "Hormone Receptor Positive Tumor",
        "Biliary Cancer",
        "Biliary Tract Cancer",
        "C349",
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Endometrial Cancer",
        "Advanced Solid Malignancies",
        "Carcinoma, Non-Small-Cell Lung",
        "Stage I-III triple-negative breast cancer with residual invasive disease after neoadjuvant therapy.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "HER2 Negative Breast Carcinoma",
        "Cervical Cancer",
        "NSCLC",
        "Triple Negative Breast Neoplasms",
        "Triple Negative Breast Cancer",
        "Breast Neoplasm",
        "Advanced Breast Cancer",
        "HER2-negative Breast Cancer",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Breast Cancer Female",
        "Colorectal Cancer",
        "ER-negative Breast Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Small Cell Lung Cancer Only in Module 5",
        "Metastatic Lung Cancer",
        "Solid Tumors",
        "Triple-negative Breast Cancer",
        "various Advanced/Metastatic solid tumour types  - Endometrial Cancer  - Gastric Cancer  - Ovarian Cancer - Metastatic castration-resistant prostate cancer - Colorectal cancer  MedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Advanced Solid Tumor",
        "C349 Bronchus or lung, unspecified  Bronchus or lung, unspecified",
        "ER Positive Breast Cancer",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "targets": [
        "TACSTD also known as tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)"
      ],
      "payload": [
        "A topoisomerase I inhibitor payload  With an average of 4 cysteinyl"
      ],
      "linker": [
        "A tetrapeptide-based linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized anti-TROP2 monoclonal antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "AstraZeneca",
        "DAIICHI SANKYO"
      ],
      "ttd": "DP41HV",
      "chembl": "CHEMBL4297939",
      "trials": [
        "NCT06103864",
        "NCT05687266",
        "NCT05594095",
        "NCT06176261",
        "NCT04644068",
        "NCT04484142",
        "EUCTR2020-005620-12-ES",
        "NCT04940325",
        "NCT05489211",
        "NCT05417594",
        "NCT05749588",
        "EUCTR2022-002680-30-DE",
        "NCT03742102",
        "NCT05104866",
        "PER-062-22",
        "NCT06112379",
        "NCT04656652",
        "NCT05374512",
        "NCT05824325",
        "EUCTR2022-000776-19-PL",
        "NCT05629585",
        "NCT06244485",
        "EUCTR2018-000764-29-PL",
        "NCT05460273"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Argentina",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "United Kindgdom",
        "Philippines",
        "Korea South",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Hungaria",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# conditions": 42,
      "# locations": 42,
      "# trials": 24
    },
    {
      "heading": "SAR408701 SAR 408701 SAR-408701 | Tusamitamab Ravtansine | SAR408701 | SAR-408701 | SAR 408701",
      "names": [
        "SAR408701 SAR 408701 SAR-408701",
        "Tusamitamab Ravtansine",
        "SAR-408701",
        "Tusamitamab ravtansine",
        "SAR408701",
        "MAYTANSIN-LOADED ANTI-CEACAM5 MAB",
        "TUSAMITAMAB RAVTANSINE",
        "SAR 408701"
      ],
      "phases": [
        "Phase 3",
        "Phase 1/2"
      ],
      "conditions": [
        "Stomach",
        "Solid Tumors",
        "Solid tumors CRC",
        "NSCLC",
        "Adenocarcinoma"
      ],
      "targets": [
        "CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5 | CEA | CD66e [Homo sapiens]"
      ],
      "payload": [
        "Maytansinoid DM4 on an average of 3-4 lysyl"
      ],
      "linker": [
        "SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "CEACAM5 targeting antibody"
      ],
      "Max Phase": "3",
      "developers": [
        "IMMUNOGEN",
        "Sanofi"
      ],
      "ttd": [
        "D05TBQ",
        "D2D6NJ"
      ],
      "chembl": "CHEMBL4298098",
      "drugbank": "https://go.drugbank.com/drugs/DB17448",
      "locations": [],
      "trials": [],
      "# conditions": 5,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202",
      "names": [
        "MORAb-202 MORAb-003-VCP-eribulin",
        "MORAb-202",
        "FARLETUZUMAB ECTERIBUL",
        "FARLETUZUMAB ECTERIBULIN",
        "Farletuzumab ecteribulin",
        "Farletuzumab Ecteribulin",
        "MORAB-202"
      ],
      "phases": [
        "Preclinical",
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Platinum-sensitive solid tumors:  - Ovarian Cancer",
        "- Triple-negative Breast Cancer (TNBC)",
        "- Non-small cell lung (NSCLC)",
        "- Gastric cancer",
        "Neoplasms, Ovarian",
        "Metastatic Breast Cancer",
        "- Endometrial Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "Breast Cancer",
        "Solid Tumor",
        "Chemotherapy-induced Alopecia"
      ],
      "targets": [
        "Folate receptor alpha (FRA)"
      ],
      "payload": [
        "The microtubule-targeting agent (MTA), eribulin, a derivative of the macrocyclic polyether natural product halichondrin B.   Conjugated on an average drug-to-antibody ratio of 4.0."
      ],
      "linker": [
        "Cathepsin-cleavable linker   A reduced interchain disulfide bonds to maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl linker - designed to be cleaved by cathepsin B, a lysosomal cysteine protease."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "The humanized anti-human folate receptor alpha (FRA) antibody farletuzumab."
      ],
      "Max Phase": "3",
      "developers": [
        "Morphotek",
        "Eisai"
      ],
      "chembl": "CHEMBL4802212",
      "drugbank": "https://go.drugbank.com/drugs/DB18857",
      "trials": [
        "NCT05613088",
        "NCT05104866",
        "NCT03734029",
        "NCT03901339",
        "NCT04300556",
        "NCT05577715",
        "NCT04986579",
        "NCT02574455"
      ],
      "locations": [
        "China",
        "Sweden",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 11,
      "# locations": 28,
      "# trials": 8
    },
    {
      "heading": "LM-305",
      "names": [
        "LM-305"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Multiple myeloma"
      ],
      "targets": [
        "G protein-coupled receptor, class C, group 5, member D (GPRC5D)  GPRC5D (G protein-coupled receptor, class C, group 5, member D) is a member of the G protein-coupled receptors (GPCRs) family. As a novel GPCR drug target, GPRC5D is an orphan receptor with no endogenous ligand found. GPRC5D is mainly expressed in malignant bone marrow plasma cells and hair follicles, while in normal tissues, little or no expression is observed. Studies have shown that GPRC5D is specifically highly expressed in patients with multiple myeloma (MM) in a BCMA-independent manner Therefore, GPRC5D has attracted great attention as a key new target in the treatment of MM."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A protease-degradable linker"
      ],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [
        "anti-GPRC5D antibody."
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ATG-022",
      "names": [
        "ATG-022"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors Gastric cancer Pancreatic cancer"
      ],
      "targets": [
        "Claudin 18.2  (CLDN18.2)   Claudins are cell adhesion molecules normally expressed within the tight junctions between cells to form a barrier that regulates cell permeability. In cancer, Claudins are expressed at the cell surface due to changes in cell polarity. The Claudin 18.2 isoform is overexpressed in various primary malignant tumors including gastric, esophageal and pancreatic cancers."
      ],
      "payload": [
        "The antimitotic agent, monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "A valine-citrulline (vc-) type linker (mc-vc-PABC-MMAE)  This ADC includes a maleimidocaproyl (mc) spacer, a protease-sensitive dipeptide, valine-citrulline (vc), a self-immolative spacer, para-amino benzyloxycarbonyl (PABC)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IMAB362, an antibody targeting CLDN18.2."
      ],
      "Max Phase": "1",
      "developers": [
        "Antengene"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CPO301",
      "names": [
        "CPO301"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Cancer, Lung",
        "Cancer",
        "Advanced Solid Tumors  Treatment of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) patients refractory to relapsed/refractory to or are ineligible EGFR-targeted therapies, such as 3rd-generation EGFR inhibitors including osimertinib.    - EGFR C797S Mutation Non-small Cell Lung Cancer, - EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer, - EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma"
      ],
      "targets": [
        "Epidermal Growth Factor Receptor (EGFR) C797S + EGFR T790M + EGFR-Ex19del ( C797S + Epidermal Growth Factor Receptor T790M + EGFR exon 19 deletion)."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "CSPC Pharmaceutical Group"
      ],
      "trials": [
        "NCT05948865"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "# conditions": 3,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "W0101 | W0101 W-0101 | Lonigutamab Ugodotin | W-0101",
      "names": [
        "W0101",
        "W0101 W-0101",
        "Lonigutamab Ugodotin",
        "W-0101"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Advanced or metastatic solid tumors, including:  - squamous non-small-cell lung cancer (sqNSCLC) - head-and-neck cancer - ER+ HER2- invasive breast cancer."
      ],
      "targets": [
        "Insulin-like growth factor type 1 receptor (IGF-1R)/IGF1R; CD221) [Homo sapiens]"
      ],
      "payload": [
        "Conjugated with dolastatin/auristatin derivative (ugodotin) derivative on an average of 4 cysteinyl"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "hz208F2-4"
      ],
      "Max Phase": "2",
      "developers": [
        "Pierre Fabre",
        "Roche"
      ],
      "trials": [
        "NCT03316638"
      ],
      "locations": [
        "Spain",
        "France"
      ],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "Trastuzumab rezetecan SHR-A1811 | Trastuzumab rezetecan | SHR-A1811",
      "names": [
        "SHR A1811",
        "Trastuzumab rezetecan SHR-A1811",
        "Trastuzumab rezetecan",
        "TRASTUZUMAB REZETECAN",
        "SHR-A1811"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Triple-Negative Breast Cancer (TNBC)",
        "Gastric Cancer",
        "Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Hormone Receptor Negative Tumor",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Breast cancer Gastric cancer,  Colorectal cancer, and  NSCLC",
        "Breast Tumors",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Early-stage Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Neoplasm",
        "HER2-negative Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Locally Advanced Breast Cancer",
        "HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy",
        "HER2-positive Breast Cancer",
        "Triple-negative Breast Cancer",
        "Recurrent Breast Cancer"
      ],
      "targets": [
        "Human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "payload": [
        "SHR9265, a novel topoisomerase I inhibitor payload.  Rezetecan (SHR9265) is a delicately selected exatecan derivative (a camptothecin derivative) with a better liposolubility and cellular permeability.  SHR-A1811 has a drug-to-antibody ratio (DAR) of 5.7,"
      ],
      "linker": [
        "A stable and cleavable linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab  A humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)"
      ],
      "Max Phase": "3",
      "developers": [
        "Luzsana Biotechnology"
      ],
      "chembl": "CHEMBL5314712",
      "trials": [
        "NCT05323955",
        "NCT05594095",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT05582499",
        "NCT03726879",
        "NCT06126640",
        "NCT00781612",
        "NCT05113251",
        "NCT05749588",
        "NCT06123494",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT05824325",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# conditions": 36,
      "# locations": 72,
      "# trials": 26
    },
    {
      "heading": "cMET-ADC MYTX-011 | MYTX-011",
      "names": [
        "cMET-ADC MYTX-011",
        "MYTX-011"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Advanced Non-Small Cell Non-Squamous Lung Cancer",
        "Locally advanced, recurrent or metastatic NSCLC",
        "NSCLC Stage IV",
        "Advanced Non-Small Cell Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "NSCLC Stage IIIB"
      ],
      "targets": [
        "cMET (mesenchymal-epithelial transition factor), which belongs to the MET family, is a type of receptor tyrosine kinase that is expressed on the surfaces of various epithelial cells.  cMET is also known as tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR).  As a type of proto-oncogene, abnormal activation of c-Met can promote the development and progression of a variety of cancers including liver, lung, colon, breast, pancreatic, ovarian, prostate, and gastric carcinomas, as well as cancers of the nervous system such as glioblastoma."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)  Drug-to-antibody ratio (DAR) = 2"
      ],
      "linker": [
        "Val-Cit (Valine\u2013citrulline/vc) linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized IgG1 pH-dependent anti-cMET antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Mythic Therapeutics"
      ],
      "trials": [
        "NCT05652868"
      ],
      "locations": [
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "# conditions": 8,
      "# locations": 6,
      "# trials": 1
    },
    {
      "heading": "DP303c",
      "names": [
        "DP303c"
      ],
      "phases": [
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "HER2-positive advanced solid tumors.",
        "HER2-positive Breast Cancer"
      ],
      "targets": [
        "HER2"
      ],
      "payload": [
        "A monomethyl auristatin E (MMAE) with an average drug-to-antibody ratio (DAR) of 2.0.  The two MMAE molecules are attached site-specifically through transamidation to residue Q295 in the antibody heavy chain\u2019s constant region."
      ],
      "linker": [
        "A cleavable linker (LND1002, manufactured by Levena)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A HER2-targeting antibody (DP001)"
      ],
      "Max Phase": "3",
      "developers": [
        "CSPC Pharmaceutical Group"
      ],
      "trials": [
        "NCT06313086"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "PR-1498487-MMAE PR-1498487 PAB-MMAE | ABBV-085 | Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085 | PR-1498487-MMAE | Samrotamab vedotin",
      "names": [
        "SAMROTAMAB VEDOTIN",
        "PR-1498487 PAB-MMAE",
        "ADC ABBV-085",
        "ABBV085",
        "PR-1498487-MMAE PR-1498487 PAB-MMAE",
        "ABBV-085",
        "ABBV 085",
        "Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085",
        "PR-1498487-MMAE",
        "Samrotamab vedotin"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Solid tumors in which huLRRC15 is expressed in the tumor stromal microenvironment.",
        "Carcinoma of the Breast",
        "Undifferentiated Pleomorphic Sarcoma",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "targets": [
        "LRRC15 (leucine-rich repeat-containing protein 15, leucine-rich repeat induced by beta-amyloid homolog); LIB [1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)   On an average of 2 cysteinyl."
      ],
      "linker": [
        "Cleavable maleimidocaproyl-valyl-citrullinyl-p- aminobenzyloxycarbonyl (mc-val-cit-PABC)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Immunoglobulin G1-kappa  Humanized and chimeric monoclonal antibody.  IgG1 - kappa anti-LRRC15-targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "chembl": "CHEMBL4594513",
      "trials": [
        "NCT02565758"
      ],
      "locations": [
        "Spain",
        "France",
        "United States"
      ],
      "# conditions": 5,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "JS108",
      "names": [
        "JS108"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "targets": [
        "TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is highly expressed on several types of solid tumors"
      ],
      "payload": [
        "Tub196"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-Trop2 mAb"
      ],
      "Max Phase": "1",
      "developers": [
        "Shanghai Junshi"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "anti-PSMA ADC | ARX517 | ARX517-PSMA-ADC",
      "names": [
        "anti-PSMA ADC",
        "ARX517",
        "PSMA ADC",
        "ARX517-PSMA-ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Prostate Cancer",
        "GBM",
        "Gliosarcoma"
      ],
      "targets": [
        "PSMA; Prostrate-specific membrane antigen"
      ],
      "payload": [
        "AS269 /  pAF-AS269, a proprietary microtubule inhibitor drug payload   The payload AS269 is conjugated to the synthetic amino acids para-acetylphenylalanine (pAF) in a humanized mAb."
      ],
      "linker": [
        "Site-specific Non-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A fully humanized anti-PSMA mAb"
      ],
      "Max Phase": "2",
      "developers": [
        "Progenics Pharmaceuticals",
        "Ambrx"
      ],
      "ttd": "D08VJC",
      "trials": [
        "NCT01695044",
        "NCT02020135",
        "NCT01856933",
        "NCT01414296",
        "NCT01414283",
        "NCT04662580"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 6
    },
    {
      "heading": "EO-3021 also known as SYSA1801",
      "names": [
        "EO-3021 also known as SYSA1801"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Gastrointestinal Neoplasms",
        "Stomach Neoplasm",
        "Oncology",
        "Pancreas Neoplasm",
        "Digestive System Neoplasm",
        "Neoplasms by Site",
        "Neoplasms"
      ],
      "targets": [
        "Claudin 18.2 | Claudin 18.2 a transmembrane protein, also known as CLDN18.2, is an isoform of claudin 18, a member of the tight junction protein family. It is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer, non-small-cell lung cancer (NSCLC), and pancreatic cancer.[1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)   A drug-to-antibody ratio (DAR) of 2"
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [],
      "antibody": [
        "A antibody targeting Claudin 18.2 /CLDN18.2"
      ],
      "Max Phase": "1",
      "developers": [
        "Elevation Oncology",
        "CSPC Pharmaceutical Group"
      ],
      "trials": [
        "NCT05980416"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "# conditions": 7,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "CUSP06",
      "names": [
        "CUSP06"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumor",
        "Ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma."
      ],
      "targets": [
        "Cadherin-6 (CDH6) Cadherin-6 (CDH6) is a class II Cadherin (CDH)"
      ],
      "payload": [
        "An exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor).  The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies.  A drug-to-antibody ratio (DAR) of 8  In preclinical data, this linker/payload has been shown to have a stronger \"bystander effect\" than competitor ADCs."
      ],
      "linker": [
        "A protease-cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A proprietary antibody with high CDH6 binding affinity"
      ],
      "Max Phase": "1",
      "developers": [
        "OnCusp Therapeutics"
      ],
      "trials": [
        "NCT06234423"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "BAT8006",
      "names": [
        "BAT8006"
      ],
      "phases": [],
      "conditions": [
        "Ovarian, lung, breast cancer"
      ],
      "targets": [
        "Folate-Receptor-\u03b1 (FR\u03b1)"
      ],
      "payload": [
        "A small molecule topoisomerase I inhibitor"
      ],
      "linker": [
        "Bio-Thera's proprietary ADC linker-payload combination.  A systemically stable and cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-FR\u03b1 antibody"
      ],
      "Max Phase": null,
      "developers": [
        "Bio thera Solutions"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADRX-0706",
      "names": [
        "ADRX-0706"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Solid Tumors"
      ],
      "targets": [
        "Nectin-4, a cell surface adhesion protein over-expressed in multiple human cancers and associated with poor disease prognosis."
      ],
      "payload": [
        "A novel tubulin inhibitor payload  A drug-antibody ratio of eight (DAR 8)."
      ],
      "linker": [
        "A proprietary conjugation technology"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "anti-Nectin-4 antibody."
      ],
      "Max Phase": "1",
      "developers": [
        "Adcentrx"
      ],
      "trials": [
        "NCT06036121"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "BRY812",
      "names": [
        "BRY812"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced malignant tumors"
      ],
      "targets": [
        "LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "1",
      "developers": [
        "BioRay"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Raludotatug Deruxtecan  DS-6000a R-DXd | DS-6000a R-DXd | Raludotatug Deruxtecan",
      "names": [
        "Raludotatug Deruxtecan  DS-6000a R-DXd",
        "DS-6000A",
        "DS-6000a R-DXd",
        "DS-6000",
        "DS 6000A",
        "DS6000A",
        "Raludotatug Deruxtecan",
        "RALUDOTATUG DERUXTECAN"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Solid Cancer",
        "Renal Cell Carcinoma Ovarian Tumor"
      ],
      "targets": [
        "CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation."
      ],
      "payload": [
        "Deruxtecan   MAAA-1181a (DXd), the cytotoxic DNA topoisomerase I inhibitor derivative of exatecan, with potential antineoplastic activity."
      ],
      "linker": [
        "An enzymatically cleavable tetrapeptide-based linker."
      ],
      "domain": [
        "Onclology"
      ],
      "antibody": [
        "A monoclonal antibody against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6)"
      ],
      "Max Phase": "3",
      "ttd": "DISJ28",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "chembl": "CHEMBL5095329",
      "trials": [
        "NCT06161025"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Taiwan",
        "Japan"
      ],
      "# conditions": 2,
      "# locations": 4,
      "# trials": 1
    },
    {
      "heading": "SGN-CEACAM5C",
      "names": [
        "SGN-CEACAM5C"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Colorectal Neoplasms Carcinoma,  Non-Small-Cell Lung Cancer, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma,"
      ],
      "targets": [
        "CEACAM5C is a Cell adhesion molecule.   Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e, is a member of the carcinoembryonic antigen (CEA) gene family.  It has limited expression in normal. healthy, adult tissues, but is overexpressed in carcinomas of the gastrointestinal tract, the genitourinary and respiratory systems, and breast cancer."
      ],
      "payload": [
        "Topoisomerase I inhibitor payloads."
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-CEACAM5 antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HLX43",
      "names": [
        "HLX43"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "targets": [
        "PDL-1"
      ],
      "payload": [
        "camptothecin payload with an drug-antibody ratio (DAR) of 8"
      ],
      "linker": [
        "A cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An anti-PD-L1 humanized IgG1 monoclonal antibody"
      ],
      "Max Phase": "1",
      "developers": [
        "Shanghai Henlius"
      ],
      "trials": [
        "NCT06115642"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "HBM9033",
      "names": [
        "HBM9033"
      ],
      "phases": [],
      "conditions": [
        "solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers"
      ],
      "targets": [
        "human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors."
      ],
      "payload": [],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Pfizer",
        "Nona Bioscience"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SGN-B6A",
      "names": [
        "SGN-B6A"
      ],
      "phases": [
        "Phase 1",
        "Phase 3"
      ],
      "conditions": [
        "Lung Cancer (NSCLC), Pancreatic, pharyngeal, and bladder carcinomas"
      ],
      "targets": [
        "Integrin beta-6 (ITGB6) | The integrins are a large family of cell surface receptors with diverse roles in cellular adhesion, motility, and cytokinesis. Functional integrins exist as heterodimers consisting of single alpha and beta chains. Within this family, integrin beta-6 (which dimerizes exclusively with isoform alpha-v) is of particular note for its role in cancer. Integrin beta-6 is overexpressed in numerous solid tumors. [1]"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE). T"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "An antibody is specific for integrin beta-6 which does not bind other alpha-v family members."
      ],
      "Max Phase": "3",
      "developers": [
        "Pfizer",
        "Seagen"
      ],
      "ttd": "DJYD13",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "STRO-002 STRO 002 SP8193 | Luveltamab Tazevibulin \u2013 S\u03a4RO-002 \u2013 Luvelta",
      "names": [
        "Luveltamab Tazevibulin \u2013 S\u03a4RO-002 \u2013 Luvelta",
        "LUVELTAMAB TAZEVIBULIN",
        "STRO-002",
        "SP-8193",
        "Luveltamab tazevibulin",
        "STRO-002 STRO 002 SP8193",
        "SP8193"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Endometrial Carcinoma Fallopian tube Primary peritoneal carcinoma (PPC)",
        "Ovarian Cancer",
        "Endometrioid Adenocarcinoma",
        "Primary Peritoneal Carcinoma",
        "Platinum-resistant Ovarian Cancer",
        "Ovary Cancer",
        "Endometrial Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Neoplasm Malignant",
        "Solid Tumors",
        "Ovarian Carcinoma"
      ],
      "targets": [
        "FolR\u03b1/FOLR1 (Folate receptor alpha, folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18) [Homo sapiens], is overexpressed in platinum-resistant ovarian cancer and other solid tumors."
      ],
      "payload": [
        "A tubulin-targeting 3-aminophenyl hemiasterlin payload, SC209, which has potent cytotoxic activity and is a weak substrate for efflux pumps."
      ],
      "linker": [
        "The SC239 drug-linker is conjugated via a protease cleavable valine citrulline p-aminobenzyl carbamate linker functionalized with dibenzocyclooctyne (DBCO)."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-FolRa human IgG1 antibody (SP8166)  on an average of 4 p-azidomethyl-L-phenyalanine (pAMF)"
      ],
      "Max Phase": "3",
      "developers": [
        "Sutro Biopharma"
      ],
      "ttd": "D10GPJ",
      "chembl": "CHEMBL5095133",
      "drugbank": "https://go.drugbank.com/drugs/DB17563",
      "trials": [
        "NCT06238687",
        "NCT05870748",
        "NCT03748186",
        "NCT05200364"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Israel",
        "China",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "United States"
      ],
      "# conditions": 13,
      "# locations": 8,
      "# trials": 4
    },
    {
      "heading": "OBI-992 | BSI-992",
      "names": [
        "OBI-992",
        "BSI-992"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 1/2"
      ],
      "conditions": [
        "Non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and gastric cancer (GC), Several other cancers are also potential targets.",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "Human trophoblast cell-surface antigen 2 (TROP2)"
      ],
      "payload": [
        "A potent topoisomerase I inhibitor payload"
      ],
      "linker": [
        "A differentiated hydrophilic, enzyme-cleavable linker that is stable in circulation"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "TROP2 targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "OBI Pharma",
        "Biosion (China)"
      ],
      "trials": [
        "NCT06480240"
      ],
      "locations": [
        "United States"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "STRO-003",
      "names": [
        "STRO-003"
      ],
      "phases": [],
      "conditions": [
        "Lung cancer Breast cancer"
      ],
      "targets": [
        "Receptor tyrosine kinase ROR1   Receptor tyrosine kinase ROR1 plays an essential role in embryogenesis and is overexpressed in many types of malignant tumors."
      ],
      "payload": [
        "A next-generation exatecan class of payloads, known for their ability to inhibit topoisomerase-1 (TOPO-1) and cause DNA disruption.  DASR = 8.0"
      ],
      "linker": [
        "\u03b2-Glucuronidase-cleavable linkers"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": null,
      "developers": [
        "Sutro Biopharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "STRO-004",
      "names": [
        "STRO-004"
      ],
      "phases": [],
      "conditions": [
        "Multiple solid tumor indications including HNSCC, breast and  lung cancer"
      ],
      "targets": [
        "Tissue Factor (TF)  Tissue Factor is expressed in the subendothelium. When endothelium is  damaged, tissue factor combines with circulating factor VII to activate factor  X. Activated factor X initiates  the coagulation cascade"
      ],
      "payload": [
        "Potent exatecan payload, broadly active against solid tumor indications \u2013 Potent topoisomerase I inhibitor (nM) \u2013 Strong bystander activity,  \u2013 Limited susceptibility to efflux by drug pumps  Conjugation at sites optimized for stability in circulation, tumor specific payload release \u2013 Homogeneous DAR4, no DAR distribution"
      ],
      "linker": [
        "Optimized linker, designed for tumor-selective payload release \u2013 Hydrophilic linker supporting improved solubility and PK \u2013 PEG chain further enhances solubility, supporting high DAR \u2013 Stable in circulation \u2013 Efficiently cleaved by \u03b2-glucuronidase enzyme"
      ],
      "domain": [
        "Oncology / Hematology"
      ],
      "antibody": [
        "A TF-targeting antibody"
      ],
      "Max Phase": null,
      "developers": [
        "Sutro Biopharma"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "VLS-101 MK-2140 | VLS-101 | Zilovertamab vedotin | MK-2140",
      "names": [
        "VLS-101 MK-2140",
        "Zilovertamab vedotin",
        "MK-2140",
        "VLS-101"
      ],
      "phases": [
        "Phase 2/3",
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "- Chronic Lymphocytic Leukemia  - Mantle Cell Lymphoma Follicular  - Lymphoma Marginal Zone - Lymphoma Diffuse Large B-cell  - Lymphoma Richter Transformation - Lymphoma Burkitt Lymphoma  - Lymphoplasmacytoid Lymphoma  - T-cell Non-Hodgkin Lymphoma  - Acute Lymphoid Leukemia Acute  - Myeloid Leukemia Waldenstrom Macroglobulinemia"
      ],
      "targets": [
        "Receptor tyrosine kinase-like orphan receptor 1 (ROR1)"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE),  an anti-microtubule cytotoxin, with an average of 4 cysteinyl"
      ],
      "linker": [
        "A proteolytically maleimidocaproyl-valyl-citrullinyl-p- aminobenzyloxycarbonyl (mc-val-cit-PABC) type cleavable linker"
      ],
      "domain": [
        "Hematology Oncology"
      ],
      "antibody": [
        "A humanized monoclonal antibody recognizing extracellular ROR1"
      ],
      "Max Phase": "3",
      "developers": [
        "VelosBio",
        "Merck KGaA, Darmstadt, Germany",
        "Merck Sharp & Dohme"
      ],
      "ttd": [
        "D1CG5M",
        "D3YJZ7"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18457",
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BHV-1500",
      "names": [
        "BHV-1500"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "targets": [
        "CD30 is a member of the tumor necrosis factor receptor superfamily, which is characteristically expressed in certain hematopoietic malignancies, including Hodgkin lymphoma, among others."
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE, vedotin)"
      ],
      "linker": [],
      "domain": [
        "Oncology/Hematology"
      ],
      "antibody": [],
      "Max Phase": "Preclinical",
      "developers": [
        "Biohaven"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BHV-1510",
      "names": [
        "BHV-1510"
      ],
      "phases": [
        "Preclinical"
      ],
      "conditions": [
        "Solid tumors"
      ],
      "targets": [
        "Trophoblast cell-surface antigen 2 (Trop-2; also known as epithelial glycoprotein-1, gastrointestinal antigen 733-1, membrane component surface marker-1, and tumor-associated calcium signal transducer-2).   Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. Trop-2 is an ideal candidate for targeted therapeutics due to it being a transmembrane protein with an extracellular domain over-expressed on a wide variety of tumors as well as its upregulated expression relative to normal cells."
      ],
      "payload": [
        "Proprietary potential best-in-class Topolx, site-specifically conjugated via Enzymatic (non-cysteine) with a drug to antibody-ratio of 4."
      ],
      "linker": [
        "Proprietary highly stable (irreversible) and protease cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Sacituzumab, an antitrophoblast cell-surface antigen 2 (Trop-2) IgG1 kappa antibody."
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Biohaven"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AMT-562",
      "names": [
        "AMT-562"
      ],
      "phases": [
        "Phase 1"
      ],
      "conditions": [
        "Advanced solid tumors"
      ],
      "targets": [
        "HER3, a unique member of the EGFR family of tyrosine kinases, which is broadly expressed in several cancers, including breast, lung, pancreatic, colorectal, gastric, prostate, and bladder cancers and is often associated with poor patient outcomes and therapeutic resistance. [1]"
      ],
      "payload": [
        "Site specifically conjugated to exatecan.  Drug to Antibody-ratio is 8.0"
      ],
      "linker": [
        "A via valine-alanine cleavable linker and a modified self-immolative PABC spacer (T800)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "A humanized HER-3 targeted monoclonal antibody (Ab562)"
      ],
      "Max Phase": "1",
      "developers": [
        "Multitude"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "RC88",
      "names": [
        "RC88"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Mesothelioma Bile Duct Carcinoma Pancreatic cancer Lung Adenocarcinoma Ovarian Cancer other Solid Tumors",
        "Solid Tumor"
      ],
      "targets": [
        "Mesothelin (MSLN)"
      ],
      "payload": [
        "Mmicrotubule inhibitor monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Cleavable linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "MSLN-targeting antibody"
      ],
      "Max Phase": "2",
      "developers": [
        "RemeGen",
        "MabPlex"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18697",
      "trials": [
        "NCT04175847"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "9MW2821",
      "names": [
        "9MW2821"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Solid Tumors metastatic esophageal squamous cell carcinoma"
      ],
      "targets": [
        "Nectin-4;  Nectin cell adhesion protein 4 (Nectin-4) is overexpressed in multiple human malignancies. Such aberrant expression is correlated with cancer progression and poor prognostic."
      ],
      "payload": [
        "Monomethyl auristatin E"
      ],
      "linker": [],
      "domain": [
        "Oncology"
      ],
      "antibody": [],
      "Max Phase": "2",
      "developers": [
        "Mabwell (Shanghai)"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HER3-ADC | Elevation Oncology \u2013 Proof of Concept ADC",
      "names": [
        "HER3-ADC",
        "Elevation Oncology \u2013 Proof of Concept ADC"
      ],
      "phases": [
        "Preclinical",
        "Phase 1"
      ],
      "conditions": [
        "HER3-expressing solid tumors",
        "Advanced Solid Tumor"
      ],
      "targets": [
        "HER3 (ERBB3) , which is expressed on the cell surface of breast cancer, EGFR-mutated non-small cell lung cancer and other solid tumor"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE), a potent anti-cancer microtubule-targeting agent"
      ],
      "linker": [
        "A cleavable valine-citrulline linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "seribantumab, a fully human IgG2 anti-HER3 mAb"
      ],
      "Max Phase": "1",
      "developers": [
        "Elevation Oncology"
      ],
      "trials": [
        "NCT06298058"
      ],
      "locations": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "WAY-CMA-676 | Gemtuzumab ozogamicin | CMA-676 | CDP-771 | hP67.6-calicheamicin | Mylotarg\u00ae",
      "names": [
        "L01XC05",
        "WAY-CMA-676",
        "Gemtuzumab ozogamicin",
        "GEMTUZUMAB OZOGAMICIN RECOMBINANT",
        "CMA-676",
        "Mylotarg",
        "GEMTUZUMAB OZOGAMICIN",
        "CDP-771",
        "CMC-676",
        "hP67.6-calicheamicin",
        "Mylotarg\u00ae"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Infusions, Intravenous",
        "Leukemia, Myeloid",
        "Leukemia, Myelocytic, Acute",
        "Refractory Acute Myeloid Leukemia",
        "Relapsed AML (Acute myeloid leukemia) | CD33 positive",
        "Leukemia, Myeloid, Acute",
        "Acute Myeloid Leukaemia",
        "Leukemia",
        "Pharmacokinetics",
        "Myelodysplastic Syndrome",
        "Leukaemia  Cancer  Leukaemia",
        "Myelodysplastic Syndromes",
        "Safety",
        "Acute Myeloid Leukemia",
        "Acute Myelogenous Leukemia",
        "ECG",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "targets": [
        "CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)"
      ],
      "payload": [
        "Calicheamicin (N-acetyl-\u03b3 calicheamicin 1,2-dimethyl hydrazine dichloride)"
      ],
      "linker": [
        "Covalent linkage (condensation) of a bifunctional linker, 4-(4-acetylphenoxy)butanoic acid (AcBut linker)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG4 - kappa /  hP67.6 (produced from a murine antibody (mP67.6) by complementarity-determining region (CDR) grafting. The resulting humanized hP67.6 antibody is an IgG4 that contains sequences derived from the murine antibody in the antigen-binding region only, thereby reducing the potential for human antimouse antibody (HAMA) responses."
      ],
      "Max Phase": "Approved",
      "developers": [
        "Pfizer",
        "WYETH"
      ],
      "chembl": "CHEMBL1201506",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf",
      "trials": [
        "NCT00003673",
        "NCT04849910",
        "NCT00962767",
        "NCT04385290",
        "NCT03727750",
        "NCT03737955",
        "NCT04070768",
        "NCT02724163",
        "NCT00860639",
        "NCT04207190",
        "NCT00017589",
        "NCT00003131",
        "NCT00882102",
        "NCT05955261",
        "NCT00044733",
        "NCT05183035",
        "NCT03531918",
        "NCT05904106",
        "NCT00037596",
        "NCT00766116",
        "NCT00037583",
        "NCT06448013",
        "NCT05558124",
        "NCT00233909",
        "NCT00304447",
        "NCT03374332",
        "ISRCTN17161961",
        "NCT03839446"
      ],
      "locations": [
        "Czechia",
        "Sweden",
        "Ireland",
        "Denmark",
        "Germany",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Austria",
        "Hungary",
        "Netherlands",
        "New Zealand",
        "United States",
        "Canada",
        "Norway",
        "Wales",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Switzerland",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 17,
      "# locations": 24,
      "# trials": 28
    },
    {
      "heading": "SGN35 | Brentuximab vedotin | Adcetris\u00ae | SGN-35 cAC10-Val-Cit-MMAE",
      "names": [
        "SGN35",
        "CAC10",
        "Brentuximab vedotin",
        "CAC10-VCMMAE",
        "Adcetris",
        "SGN-35",
        "CAC10-VCMMAE(4)",
        "BRENTUXIMAB VEDOTIN BRENTUXIMAB",
        "CAC10-1006(4)",
        "MONOCLONAL  SGN-30",
        "SGN 30",
        "Adcetris\u00ae",
        "BRENTUXIMAB VEDOTIN",
        "CAC-10",
        "ADCETRIS",
        "SGN-35 cAC10-Val-Cit-MMAE"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma",
        "Non-small Cell Lung Cancer",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Disease: Lymphoma (Hodgkin's)  Cancer  Hodgkin lymphoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Anaplastic Large-cell Lymphoma",
        "Subtopic: Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma, Adult",
        "Hodgkin Disease",
        "Skin Lymphoma",
        "Refractory Follicular Lymphoma",
        "NK/T Cell Lymphoma Nos",
        "Melanoma",
        "Anemia, Refractory, With Excess of Blasts",
        "Lymphoma, B-Cell",
        "CLASSICAL HODGKIN LYMPHOMA",
        "Cutaneous T Cell Lymphoma",
        "Neoplasms",
        "Diffuse Large B-cell-lymphoma",
        "Hodgkin's Lymphoma",
        "Lymphoma, Primary Cutaneous Anaplastic Large Cell",
        "Disease, Hodgkin",
        "Leukemia, Lymphoblastic,Acute",
        "Cutaneous Lymphomas",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Diffuse Cutaneous Systemic Sclerosis",
        "Sezary Syndrome",
        "Acute Lymphoid Leukemia",
        "Non-Hodgkin Lymphoma (NHL)",
        "Mycosis Fungoides",
        "S\u00e9zary Syndrome",
        "Lymphoma, T-Cell, Cutaneous",
        "Non-Hodgkin's Disease",
        "Cutaneous Lymphoma",
        "Safety",
        "Lymphoma, T-Cell",
        "Clinical Efficacy",
        "Stage III Childhood Hodgkin Lymphoma",
        "Carcinomas",
        "Solid Tumors",
        "Mast Cell Leukemia",
        "Diffuse Large B-Cell Lymphoma",
        "Lymphoma, NK-cell",
        "Myelodysplastic Syndromes",
        "Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Classical Hodgkin Lymphoma",
        "Germ Cell Cancer",
        "Lymphoma, Large-Cell, Anaplastic",
        "dcSSc",
        "Lymphomatoid Papulosis",
        "Lymphoma, T-cell",
        "Systemic Mastocytosis",
        "Recurrent Hodgkin Lymphoma",
        "Topic: National Cancer Research Network",
        "Anaplastic Large Cell Lymphoma (ALCL)",
        "Leukemia, Acute Myeloid",
        "Lymphoma, T-Cell, Peripheral",
        "Scleroderma",
        "Enteropathy Associated T-cell Lymphoma",
        "Diffuse Large B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Peripheral T Cell Lymphoma",
        "Cutaneous T-cell Lymphoma (CTCL)",
        "Relapsed or Refractory Hodgkin Lymphoma",
        "T-Cell Lymphoma",
        "Lymphoma, Non-Hodgkin",
        "Relapsed or Refractory Anaplastic Large-cell Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Graft vs. Host Disease",
        "Anaplastic Large-Cell Lymphoma",
        "Hodgkin Lymphoma (HL)",
        "Hematologic Disorder",
        "Cutaneous T-Cell Lymphoma",
        "Aggressive Systemic Mastocytosis",
        "Acute Myeloid Leukemia",
        "Lymphatic Diseases"
      ],
      "targets": [
        "TNFRSF8 (tumor necrosis factor receptor (TNFR) superfamily member 8, KI-1, CD30)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)"
      ],
      "linker": [
        "Valine-citrulline (protease-cleavable)"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "IgG1 - kappa (cAC10)"
      ],
      "Max Phase": "Approved",
      "developers": [
        "Takeda",
        "Seagen"
      ],
      "chembl": "CHEMBL1742994",
      "drugbank": "https://go.drugbank.com/drugs/DB08870",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125388s106lbl.pdf",
      "trials": [
        "NCT01874054",
        "NCT01026233",
        "NCT01421667",
        "NCT03217643",
        "NCT01396070",
        "NCT02280785",
        "NCT06186986",
        "NCT01700751",
        "NCT01578499",
        "NCT01777152",
        "NCT02227199",
        "NCT02734771",
        "NCT01868451",
        "NCT05414500",
        "NCT04609566",
        "NCT05922904",
        "NCT05180097",
        "NCT01716806",
        "NCT01920932",
        "NCT01492088",
        "NCT02684292",
        "NCT05404945",
        "NCT06120504",
        "NCT01578967",
        "NCT01026415",
        "NCT05313243",
        "NCT04569032",
        "NCT01100502",
        "NCT01534078",
        "NCT00947856",
        "NCT02927769",
        "NCT03755804",
        "NCT01990534",
        "NCT02164006",
        "NCT02686346",
        "NCT05442554",
        "NCT00848926",
        "NCT02243436",
        "NCT06377566",
        "ISRCTN77650947",
        "NCT01712490",
        "NCT03264131",
        "NCT00430846",
        "NCT05673785",
        "NCT02567851",
        "NCT01807598",
        "NCT01461538",
        "NCT03587844",
        "NCT02979522",
        "NCT06254495",
        "NCT03222492",
        "NCT01352520",
        "NCT02616965",
        "NCT02822586",
        "NCT01909934",
        "NCT01309789",
        "NCT01851200",
        "NCT04404283",
        "NCT01596218",
        "NCT05357794",
        "NCT01060904",
        "NCT03646123",
        "NCT02292979",
        "NCT02467946",
        "NCT00866047",
        "NCT01508312",
        "NCT05149768",
        "NCT03198689",
        "NCT02505269",
        "NCT04685616",
        "NCT02581631",
        "NCT04587687",
        "NCT01950364",
        "NCT05316246",
        "NCT02572167",
        "NCT02939014",
        "NCT02086604",
        "NCT02429375"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Lithuania",
        "China",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# conditions": 82,
      "# locations": 38,
      "# trials": 78
    },
    {
      "heading": "MRG003",
      "names": [
        "MRG003"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Recurrent or Metastatic Nasopharyngeal Carcinoma",
        "Advanced or Metastatic Biliary Tract Cancer",
        "EGFR-positive refractory: - Advanced squamous cell carcinomas of the head and neck (SCCHN),  - Nasopharyngeal carcinoma (NPC),  - Colorectal cancer (CRC).",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "targets": [
        "EGFR-positive Cancers"
      ],
      "payload": [
        "Monomethyl auristatin E (MMAE)"
      ],
      "linker": [
        "Valine-citrulline linker."
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Anti-epidermal growth factor receptor (EGFR) humanized immunoglobulin G1 monoclonal antibody."
      ],
      "Max Phase": "3",
      "developers": [
        "Lepu Biopharma",
        "Shanghai Miracogen"
      ],
      "trials": [
        "NCT04868344",
        "NCT05688605",
        "NCT05126719",
        "NCT04838964",
        "NCT05751512"
      ],
      "locations": [
        "China"
      ],
      "# conditions": 5,
      "# locations": 1,
      "# trials": 5
    },
    {
      "heading": "TAA013",
      "names": [
        "TAA013"
      ],
      "phases": [
        "Phase 3"
      ],
      "conditions": [],
      "targets": [
        "Human epidermal growth factor 2 (HER2)"
      ],
      "payload": [
        "DM1 (Maytansine)  DAR: 3.5"
      ],
      "linker": [
        "Lysine-SMCC"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "Trastuzumab (IgG1)"
      ],
      "Max Phase": "3",
      "developers": [
        "TOT Biopharm"
      ],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ZW49 HER2 x HER2 Bispecific | ZW49 | Zanidatamab Zovodotin",
      "names": [
        "ZW49 HER2 x HER2 Bispecific",
        "ZW49",
        "Zanidatamab zovodotin",
        "Zanidatamab Zovodotin"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Solid tumors  Locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents.  - Gastric cancer - Breast cancer",
        "Metastatic Solid Tumors",
        "Esophageal Cancer"
      ],
      "targets": [
        "ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340) [Homo sapiens] biparatopic"
      ],
      "payload": [
        "A novel, proprietary, N-acyl sulfonamide auristatin cytotoxin designed to take advantage of the enhanced antibody-HER2 internalization of ZW25. | Conjugated  on an average of 2-3 cysteinyl"
      ],
      "linker": [
        "A proprietary cleavable, 1-maleimido-3,6,9-trioxadodecan-12-oyl-valyl-citrullyl linker"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "ZW25;  an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab.  ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent e\ufb00ector function."
      ],
      "Max Phase": "2",
      "developers": [
        "BeiGene",
        "Zymeworks"
      ],
      "ttd": "DH09QZ",
      "drugbank": "https://go.drugbank.com/drugs/DB15472",
      "trials": [
        "NCT04695847"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "# conditions": 4,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "ABBV-154",
      "names": [
        "ABBV-154"
      ],
      "ttd": "D2AQW7",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MRG002",
      "names": [
        "MRG002",
        "TRASTUZUMAB--VCMMAE",
        "TRASTUZUMAB VEDOTIN",
        "MRG-002",
        "MRG 002"
      ],
      "ttd": "DM7WY2",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "developers": [
        "Shanghai Miracogen"
      ],
      "chembl": "CHEMBL5315030",
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT04742153",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT05754853",
        "NCT05338957",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT04924699",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Advanced or Metastatic Urothelium Cancer",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Advanced Malignant Solid Tumors",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Advanced or Metastatic Breast Cancer",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 26,
      "# locations": 72,
      "# trials": 24
    },
    {
      "heading": "PSMA ADC therapeutic",
      "names": [
        "PSMA ADC therapeutic"
      ],
      "ttd": "D0A7LL",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "Progenics Pharmaceuticals"
      ],
      "trials": [
        "NCT01695044",
        "NCT02020135",
        "NCT01856933",
        "NCT01414296",
        "NCT01414283"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Prostate Cancer",
        "GBM",
        "Gliosarcoma"
      ],
      "locations": [
        "United States"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 5
    },
    {
      "heading": "Milatuzumab-doxorubicin",
      "names": [
        "Milatuzumab-doxorubicin"
      ],
      "ttd": "D0Y6BO",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 1/2"
      ],
      "Max Phase": "3",
      "developers": [
        "Immunomedics"
      ],
      "trials": [
        "NCT03991884",
        "NCT01920932",
        "NCT03755804",
        "NCT05600686",
        "NCT01992653",
        "NCT06486441",
        "NCT01060904",
        "NCT03274492",
        "NCT04203641",
        "NCT03646123",
        "NCT04914741",
        "NCT02292979",
        "NCT05404945",
        "NCT02605915",
        "NCT06377566",
        "NCT03726879",
        "NCT05113251",
        "NCT01712490",
        "NCT04790903",
        "NCT02505269",
        "NCT05673785",
        "NCT06112379",
        "NCT04569032",
        "NCT06132958",
        "NCT04685616",
        "NCT03677141",
        "NCT01777152",
        "NCT06340568",
        "NCT06047080",
        "NCT02734771",
        "NCT02979522",
        "NCT01534078",
        "NCT04594798",
        "NCT03467373",
        "NCT01309789",
        "NCT01966471",
        "NCT04884035"
      ],
      "conditions": [
        "Disease, Hodgkin",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Lymphoma, NK-cell",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Breast Cancer",
        "Hodgkin Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "Lymphoma",
        "Non-Hodgkin Lymphoma",
        "HER2-Positive Metastatic Breast Cancer",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "B-cell Non-Hodgkin Lymphoma",
        "Endometrial Cancer",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Peripheral T-cell Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma",
        "Refractory B Lymphoblastic Lymphoma",
        "Hodgkin Disease",
        "B-Cell Lymphoma",
        "Lymphoma, Non Hodgkin",
        "T-Cell Lymphoma",
        "Classical Hodgkin Lymphoma",
        "Recurrent B Lymphoblastic Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Lymphoma, B-Cell",
        "HER2-positive Early Breast Cancer",
        "Large B-Cell Lymphoma",
        "Double-Expressor Lymphoma",
        "Lymphoma, Large-Cell, Anaplastic",
        "Pancreas Cancer",
        "Anaplastic Large-Cell Lymphoma",
        "Breast Neoplasms",
        "Stage III Childhood Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Lymphoma, T-cell",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "DLBCL",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 41,
      "# locations": 54,
      "# trials": 37
    },
    {
      "heading": "XMT-1592",
      "names": [
        "XMT-1592"
      ],
      "ttd": "DDL79K",
      "phases": [
        "Phase 1/2"
      ],
      "Max Phase": "2",
      "developers": [
        "Mersana"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CX2029",
      "names": [
        "CX2029"
      ],
      "ttd": "DZ1F3N",
      "phases": [
        "Phase 1/2"
      ],
      "Max Phase": "2",
      "developers": [
        "CytomX"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "FOR46",
      "names": [
        "FOR46"
      ],
      "ttd": "D48ZBO",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "Fortis Therapeutics"
      ],
      "trials": [
        "NCT03575819",
        "NCT05011188",
        "NCT03650491"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Metastatic Castration-resistant Prostate Cancer",
        "Prostate Cancer",
        "Multiple Myeloma With Failed Remission",
        "Prostate Cancer Metastatic",
        "Multiple Myeloma in Relapse"
      ],
      "locations": [
        "United States"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 6,
      "# locations": 1,
      "# trials": 3
    },
    {
      "heading": "INBRX-109",
      "names": [
        "INBRX-109"
      ],
      "ttd": "D56ERU",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Inhibrx"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ABBV-CX-2029",
      "names": [
        "ABBV-CX-2029"
      ],
      "ttd": "D58AMF",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "AbbVie",
        "CytomX"
      ],
      "trials": [
        "NCT03543813"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Solid Tumor, Adult",
        "Diffuse Large B Cell Lymphoma",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer"
      ],
      "locations": [
        "Spain",
        "Korea, Republic of",
        "United Kingdom",
        "United States"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 5,
      "# locations": 4,
      "# trials": 1
    },
    {
      "heading": "TAK-500",
      "names": [
        "TAK-500"
      ],
      "ttd": "D9ICV2",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Takeda"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SGN-CD30C",
      "names": [
        "SGN-CD30C"
      ],
      "ttd": "DDG8W9",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Seagen"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "MEDI2228",
      "names": [
        "MEDI2228"
      ],
      "ttd": "DG80IS",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "AstraZeneca"
      ],
      "trials": [
        "NCT03489525"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "locations": [
        "Spain",
        "Australia",
        "Greece",
        "France",
        "United States"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 5,
      "# trials": 1
    },
    {
      "heading": "DS-6157",
      "names": [
        "DS-6157"
      ],
      "ttd": "DJ4X7D",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "DAIICHI SANKYO"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CLT030",
      "names": [
        "CLT030"
      ],
      "ttd": "DW01LJ",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Cellerant Therapeutics"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-1013",
      "names": [
        "ADC-1013"
      ],
      "ttd": "D0C5LJ",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "developers": [
        "Alligator Bioscience AB"
      ],
      "trials": [
        "NCT02379741",
        "EUCTR2020-005182-14-FR"
      ],
      "conditions": [
        "Solid Tumors",
        "Neoplasms",
        "Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "locations": [
        "Sweden",
        "United Kingdom",
        "France",
        "Denmark"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 4,
      "# trials": 2
    },
    {
      "heading": "Glypican3-ADC",
      "names": [
        "Glypican3-ADC"
      ],
      "ttd": "D0YP8F",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Bristol Myers Squibb"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CA9-ADC",
      "names": [
        "CA9-ADC"
      ],
      "ttd": "D01BUS",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "MorphoSys AG"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-1001",
      "names": [
        "ADC-1001"
      ],
      "ttd": "D01NGB",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Alligator Bioscience AB"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-3680",
      "names": [
        "ADC-3680"
      ],
      "ttd": "D02JND",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "Argenta Discovery Ltd"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "d-trastuzumab",
      "names": [
        "d-trastuzumab"
      ],
      "ttd": "D0C2CP",
      "phases": [
        "Preclinical",
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "developers": [
        "IATRICa Inc"
      ],
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 23,
      "# locations": 72,
      "# trials": 20
    },
    {
      "heading": "ADC-1012",
      "names": [
        "ADC-1012"
      ],
      "ttd": "D0G0AQ",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Alligator Bioscience AB"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Maclizumab",
      "names": [
        "Maclizumab"
      ],
      "ttd": "D0J5EQ",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Cytoguide ApS"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-7828",
      "names": [
        "ADC-7828"
      ],
      "ttd": "D0K2MT",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Argenta Discovery Ltd"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CD79-targeted immunotoxins",
      "names": [
        "CD79-targeted immunotoxins"
      ],
      "ttd": "D0M7EP",
      "phases": [
        "Preclinical",
        "Phase 2"
      ],
      "Max Phase": "2",
      "developers": [
        "Genentech"
      ],
      "trials": [
        "NCT00071539"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "locations": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "ADC-5510",
      "names": [
        "ADC-5510"
      ],
      "ttd": "D0TA3V",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Adolor Corp"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-9971",
      "names": [
        "ADC-9971"
      ],
      "ttd": "D0U3YW",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Argenta Discovery Ltd"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "OP-06",
      "names": [
        "OP-06"
      ],
      "ttd": "D0WM5H",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Onco-Pharmakon Inc"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DSTA-4637S",
      "names": [
        "DSTA-4637S"
      ],
      "ttd": "D1A5GK",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "developers": [
        "Genentech"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BAY 2315497",
      "names": [
        "BAY 2315497"
      ],
      "ttd": "DENO78",
      "phases": [
        "Phase 3"
      ],
      "Max Phase": "3",
      "developers": [
        "Progenics Pharmaceuticals"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-03",
      "names": [
        "ADC-03"
      ],
      "ttd": "D0AN9V",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Almac Discovery"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADC-01",
      "names": [
        "ADC-01"
      ],
      "ttd": "DRJU35",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Almac Discovery"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "YH012",
      "names": [
        "YH012"
      ],
      "ttd": "DKHL40",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Biocytogen"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "YH013",
      "names": [
        "YH013"
      ],
      "ttd": "D0AM9O",
      "phases": [
        "Preclinical"
      ],
      "Max Phase": "Preclinical",
      "developers": [
        "Biocytogen"
      ],
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "90Y-CYT-356 | CYT-356-90Y | YTTRIUM Y 90 CAPROMAB PENDETIDE | CYT-356 90Y | ONCOLTAD | CYT-356-Y-90",
      "names": [
        "90Y-CYT-356",
        "CYT-356-90Y",
        "INDIUM (111IN) CAPROMAB PENDETIDE",
        "PROSTASCINT",
        "(SUP 111)IN-CAPROMAB PENDETIDE",
        "YTTRIUM Y 90 CAPROMAB PENDETIDE",
        "CYT-356 90Y",
        "INDIUM IN 111 CAPROMAB PENDETIDE",
        "CYT-356",
        "CAPROMAB PENDETIDE",
        "7E11-C5.3",
        "INDIUM IN-111 CAPROMAB PENDETIDE",
        "ONCOLTAD",
        "CYT-356-Y-90",
        "CYT-351",
        "ProstaScint"
      ],
      "chembl": [
        "CHEMBL2109552",
        "CHEMBL1201579",
        "CHEMBL2108800"
      ],
      "phases": [
        "Phase 2",
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Altumomab pentetate | HYBRI-CEAKER | INDIUM IN 111 ALTUMOMAB PENTETATE | ZCE025 | ZCE-025 | ALTUMOMAB | MAB-35 | ALTUMOMAB PENTETATE",
      "names": [
        "Altumomab pentetate",
        "HYBRI-CEAKER",
        "INDIUM IN 111 ALTUMOMAB PENTETATE",
        "ZCE025",
        "ZCE-025",
        "ALTUMOMAB",
        "MAB-35",
        "ALTUMOMAB PENTETATE"
      ],
      "chembl": "CHEMBL2109040",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BEVACIZUMAB GAMMA",
      "names": [
        "BEVACIZUMAB GAMMA"
      ],
      "chembl": "CHEMBL5314727",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT03424005",
        "NCT03337698",
        "NCT06039202",
        "NCT05489211",
        "NCT02606305",
        "NCT06336707",
        "NCT03786081",
        "NCT04486352",
        "NCT05647122",
        "NCT05445778",
        "NCT04931342",
        "NCT05464030",
        "NCT05200364"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Gastric Cancer",
        "Urothelial Cancer",
        "Breast Cancer",
        "Advanced Solid Tumours",
        "Colorectal Neoplasms",
        "Carcinoma Non-small Cell Lung",
        "Biliary Tract Cancer",
        "Endometrial Cancer",
        "Peritoneal Cancer",
        "Head and Neck Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Cervical Cancer",
        "Ovarian Carcinoma",
        "Fallopian Tube Cancer",
        "Ovary Cancer",
        "Colorectal Cancer",
        "Advanced Solid Tumors",
        "Metastatic Castration-resistant Prostate Cancer",
        "Primary Peritoneal Cancer",
        "Metastatic Colorectal Cancer",
        "Epithelial Ovarian Cancer"
      ],
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Denmark",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "developers": [
        "Merck KGaA, Darmstadt, Germany",
        "EMD Serono"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 23,
      "# locations": 24,
      "# trials": 13
    },
    {
      "heading": "IODINE I 131 DERLOTUXIMAB BIOTIN | IODINE (131I) DERLOTUXIMAB BIOTIN | Cotara | IODINE I-131 DERLOTUXIMAB BIOTIN",
      "names": [
        "IODINE I 131 DERLOTUXIMAB BIOTIN",
        "IODINE (131I) DERLOTUXIMAB BIOTIN",
        "Cotara",
        "IODINE I-131 DERLOTUXIMAB BIOTIN"
      ],
      "chembl": "CHEMBL3544924",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "OPELKIBART ELMANITIN",
      "names": [
        "OPELKIBART ELMANITIN"
      ],
      "chembl": "CHEMBL5314859",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SP-8166 | SP8166 | LUVELTAMAB TAZIDE",
      "names": [
        "SP-8166",
        "SP8166",
        "LUVELTAMAB TAZIDE"
      ],
      "chembl": "CHEMBL5095134",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT05870748"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Platinum-resistant Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Israel",
        "Korea, Republic of",
        "Australia",
        "United States"
      ],
      "developers": [
        "Sutro Biopharma",
        "GOG Foundation"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 5,
      "# locations": 6,
      "# trials": 1
    },
    {
      "heading": "DELPACIBART ETEDESIRAN",
      "names": [
        "DELPACIBART ETEDESIRAN"
      ],
      "chembl": "CHEMBL5314669",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "111INDIUM-ZEVALIN | INDIUM IN 111 IBRITUMOMAB TIUXETAN | IBRITUMOMAB TIUXETAN IN-111 | ZEVALIN INDIUM IN-111 | ZEVALIN IN-111",
      "names": [
        "111INDIUM-ZEVALIN",
        "INDIUM IN 111 IBRITUMOMAB TIUXETAN",
        "IBRITUMOMAB TIUXETAN IN-111",
        "ZEVALIN INDIUM IN-111",
        "ZEVALIN IN-111"
      ],
      "chembl": "CHEMBL2108610",
      "phases": [
        "Phase -1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "90Y-DOTA-HMN14 | YTTRIUM Y 90 LABETUZUMAB TETRAXETAN",
      "names": [
        "90Y-DOTA-HMN14",
        "YTTRIUM Y 90 LABETUZUMAB TETRAXETAN"
      ],
      "chembl": "CHEMBL2108668",
      "phases": [
        "Phase -1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ZIRCONIUM Zr 89 CREFMIRLIMAB BERDOXAM | ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM",
      "names": [
        "ZIRCONIUM Zr 89 CREFMIRLIMAB BERDOXAM",
        "ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM"
      ],
      "chembl": "CHEMBL5314651",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Taplitumomab paptox | TAPLITUMOMAB PAPTOX",
      "names": [
        "Taplitumomab paptox",
        "TAPLITUMOMAB PAPTOX"
      ],
      "chembl": "CHEMBL2107890",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ANTI-MELANOMA MAB FRAGMENTS | Tecnemab K1",
      "names": [
        "ANTI-MELANOMA MAB FRAGMENTS",
        "Tecnemab K1"
      ],
      "chembl": "CHEMBL5315106",
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Nacolomab tafenatox | NACOLOMAB TAFENATOX",
      "names": [
        "Nacolomab tafenatox",
        "NACOLOMAB TAFENATOX"
      ],
      "chembl": "CHEMBL2108151",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TELIMOMAB ARITOX | Telimomab aritox | T101 | T-101",
      "names": [
        "TELIMOMAB ARITOX",
        "T-101",
        "T101",
        "Telimomab aritox"
      ],
      "chembl": "CHEMBL2108790",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05600686"
      ],
      "conditions": [
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "Double-Expressor Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "ADC Therapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "KSA-INTERLEUKIN-2 | HUKS-IL2 | EMD-273066 | TUCOTUZUMAB CELMOLEUKIN | EMD 273066",
      "names": [
        "KSA-INTERLEUKIN-2",
        "HUKS-IL2",
        "EMD-273066",
        "TUCOTUZUMAB CELMOLEUKIN",
        "EMD 273066"
      ],
      "chembl": "CHEMBL2108660",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ADALIMUMAB FOSIMDESONIDE",
      "names": [
        "ADALIMUMAB FOSIMDESONIDE"
      ],
      "chembl": "CHEMBL5314652",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BICIROMAB BRALLOBARBITAL | T2G1S | FIBRISCINT | Biciromab brallobarbital",
      "names": [
        "BICIROMAB BRALLOBARBITAL",
        "T2G1S",
        "FIBRISCINT",
        "Biciromab brallobarbital"
      ],
      "chembl": "CHEMBL2109283",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IZALONTAMAB BRENGITECAN",
      "names": [
        "IZALONTAMAB BRENGITECAN"
      ],
      "chembl": "CHEMBL5314841",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "90Y IBRITUMOMAB TIUXETAN | YTTRIUM Y 90 IBRITUMOMAB TIUXETAN | IBRITUMOMAB TIUXETAN YTTRIUM Y-90 | (90)Y-IBRITUMOMAB TIUXETAN | 90Y-IBRITUMOMAB | IBRITUMOMAB TIUXETAN Y-90 | YTTRIUM Y-90 IBRITUMOMAB TIUXETAN",
      "names": [
        "90Y IBRITUMOMAB TIUXETAN",
        "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN",
        "IBRITUMOMAB TIUXETAN YTTRIUM Y-90",
        "(90)Y-IBRITUMOMAB TIUXETAN",
        "90Y-IBRITUMOMAB",
        "IBRITUMOMAB TIUXETAN Y-90",
        "YTTRIUM Y-90 IBRITUMOMAB TIUXETAN"
      ],
      "chembl": "CHEMBL2108667",
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DORLIMOMAB ARITOX | Dorlimomab aritox | ST-1 4197X-RA | MDX-RA",
      "names": [
        "DORLIMOMAB ARITOX",
        "Dorlimomab aritox",
        "ST-1 4197X-RA",
        "MDX-RA"
      ],
      "chembl": "CHEMBL2109124",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "PNU-214936 | ABR-214936 | ANATUMOMAB MAFENATOX | Anatumomab mafenatox | ANYARA",
      "names": [
        "PNU-214936",
        "ABR-214936",
        "ANATUMOMAB MAFENATOX",
        "Naptumomab estafenatox",
        "NAPTUMOMAB ESTAFENATOX",
        "ANYARA TTS CD3",
        "ANYARA",
        "Anatumomab mafenatox",
        "TTS CD3",
        "ABR-217620",
        "TTS-CD3"
      ],
      "chembl": [
        "CHEMBL2108248",
        "CHEMBL1743045"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT04880863",
        "NCT03983954",
        "NCT00420888",
        "NCT00132379",
        "NCT00056537"
      ],
      "conditions": [
        "NSCL2 Gene Mutation",
        "Ovarian Cancer",
        "Non-Small-Cell Lung Carcinoma",
        "Prostate Cancer",
        "GastroEsophageal Cancer",
        "Non-small Cell Lung Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Cancer",
        "Renal Cell Carcinoma",
        "Endometrial Cancer",
        "Carcinoma, Non-Small-Cell Lung",
        "Mesothelioma",
        "NSCLC",
        "Melanoma",
        "ER+ Breast Cancer",
        "Cervical Squamous Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "HER2-negative Breast Cancer",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer Metastatic"
      ],
      "locations": [
        "Israel",
        "Ukraine",
        "Denmark",
        "United States",
        "United Kingdom",
        "Bulgaria",
        "Russian Federation",
        "Norway",
        "Romania"
      ],
      "developers": [
        "Active Biotech AB"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 23,
      "# locations": 9,
      "# trials": 5
    },
    {
      "heading": "IMCIROMAB PENTETATE | MYOSCINT INDIUM IN-111 | IMCIROMAB | INDIUM IN 111 IMCIROMAB PENTETATE | INDIUM IN-111 IMCIROMAB PENTETATE | INDIUM IN-111 MYOSCINT | INDIUM (111IN) IMCIROMAB",
      "names": [
        "IMCIROMAB PENTETATE",
        "MYOSCINT INDIUM IN-111",
        "IMCIROMAB",
        "INDIUM IN 111 IMCIROMAB PENTETATE",
        "INDIUM IN-111 IMCIROMAB PENTETATE",
        "INDIUM IN-111 MYOSCINT",
        "INDIUM (111IN) IMCIROMAB"
      ],
      "chembl": "CHEMBL2109038",
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "names": [
        "Enfortumab",
        "ASG-22ME",
        "AGS-22ME",
        "AGS-22MSE",
        "AGS-22CE",
        "ENFORTUMAB VEDOTIN EJFV",
        "PADCEV EJFV",
        "ASG-22CE",
        "AGS-22M",
        "ASG-22MSE",
        "ENFORTUMAB VEDOTIN",
        "Enfortumab Vedotin",
        "Padcev",
        "AGS-22M6E",
        "Enfortumab vedotin"
      ],
      "phases": [
        "Phase 3",
        "Phase 1",
        "Phase 2",
        "Approved",
        "Phase 4"
      ],
      "conditions": [
        "Gene Product Sequence Variation",
        "Bladder, breast, lung, pancreas cancer and solid tumor",
        "Urothelial Cancer",
        "Unresectable Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Urothelial Carcinoma",
        "Cancer",
        "Advanced or Metastatic Solid Malignancies",
        "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation",
        "Urinary Bladder Neoplasms",
        "Urologic Neoplasms",
        "Unresectable Bladder Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Urethral Neoplasms",
        "Malignant Renal Pelvis Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Renal Pelvis and Ureter Urothelial Carcinoma",
        "Gene Abnormality",
        "Renal Pelvis Neoplasms",
        "Metastatic Urothelial Cancer (Solid Tumors)",
        "Ureteral Cancer",
        "Bladder Squamous Cell Carcinoma",
        "Lung Cancer",
        "Bladder Cancer",
        "Malignant Urethral Neoplasm",
        "Malignant Ureter Neoplasm",
        "Urachal Adenocarcinoma",
        "Carcinoma, Transitional Cell",
        "Ureteral Neoplasms",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Locally Advanced Urothelial Carcinoma",
        "Locally Advanced Bladder Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Bladder Adenocarcinoma"
      ],
      "targets": [
        "Cell Surface Protein Nectin 4 (PVRL4 / poliovirus receptor-related 4, nectin-4, nectin 4, PPR4, LNIR)",
        "Nectin 4 (PVRL4, Poliovirus receptor-related 4, nectin-4, nectin 4, PPR4, LNIR)"
      ],
      "payload": [
        "Monomethyl Auristatin E (MMAE)",
        "Monomethyl Auristatin E \u00a0(MMAE)"
      ],
      "linker": [
        "Valine\u2013citrulline",
        "A cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker   on an average of 3-4 cysteinyl"
      ],
      "domain": [
        "Oncology"
      ],
      "antibody": [
        "AGS-22C3 or AGSM6"
      ],
      "developers": [
        "Astellas",
        "Seagen"
      ],
      "ttd": [
        "DORB45",
        "DAG87H"
      ],
      "heading": "Enfortumab | ASG-22ME | AGS-22ME | AGS-22CE | ASG-22CE | AGS-22M | ASG-22MSE | Enfortumab Vedotin | Padcev | AGS-22M6E | Enfortumab vedotin",
      "chembl": "CHEMBL3301589",
      "Max Phase": "Approved",
      "drugbank": "https://go.drugbank.com/drugs/DB13007",
      "fda_label": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s007lbl.pdf",
      "trials": [
        "NCT05756569",
        "NCT04887870",
        "NCT03869190",
        "NCT03288545",
        "NCT03192501",
        "NCT04878029",
        "NCT05775471",
        "NCT03474107",
        "NCT03219333",
        "NCT04724018"
      ],
      "locations": [
        "China",
        "Denmark",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Argentina",
        "Austria",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# conditions": 34,
      "# locations": 22,
      "# trials": 10
    },
    {
      "heading": "LMB-1",
      "names": [
        "LMB-1"
      ],
      "chembl": "CHEMBL2109306",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Citatuzumab bogatox | CITATUZUMAB BOGATOX | VB6-845",
      "names": [
        "Citatuzumab bogatox",
        "CITATUZUMAB BOGATOX",
        "VB6-845"
      ],
      "chembl": "CHEMBL1743000",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Moxetumomab pasudotox | Lumoxiti | HA-22 | HA22 | MOXETUMOMAB PASUDOTOX | CAT-8015 | MOXETUMOMAB PASUDOTOX TDFK",
      "names": [
        "Moxetumomab pasudotox",
        "Lumoxiti",
        "HA-22",
        "HA22",
        "MOXETUMOMAB PASUDOTOX",
        "CAT-8015",
        "MOXETUMOMAB PASUDOTOX TDFK"
      ],
      "chembl": "CHEMBL1743043",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3",
        "Phase 4"
      ],
      "Max Phase": "4",
      "trials": [
        "NCT01030536",
        "NCT00586924",
        "NCT01829711",
        "NCT00659425"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Hairy Cell Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Non-Hodgkin's Lymphoma",
        "Leukemia, Hairy Cell"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Israel",
        "Ireland",
        "Germany",
        "Poland",
        "United Kingdom",
        "Spain",
        "Serbia",
        "Belgium",
        "France",
        "Norway",
        "United States"
      ],
      "developers": [
        "MedImmune"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 6,
      "# locations": 14,
      "# trials": 4
    },
    {
      "heading": "LMB-7",
      "names": [
        "LMB-7"
      ],
      "chembl": "CHEMBL2109307",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Proxinium, Vicinium | Vicineum | VB4-845 | XD60E5X7FI | PROXINIUM | OPORTUZUMAB MONATOX | VICINIUM | 4D5MOCB-ETA",
      "names": [
        "Proxinium, Vicinium",
        "Vicineum",
        "VB4-845",
        "XD60E5X7FI",
        "PROXINIUM",
        "OPORTUZUMAB MONATOX",
        "VICINIUM",
        "4D5MOCB-ETA"
      ],
      "chembl": "CHEMBL1743052",
      "phases": [
        "Phase 3"
      ],
      "Max Phase": "3",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ALEMTUZUMAB BETA",
      "names": [
        "ALEMTUZUMAB BETA"
      ],
      "chembl": "CHEMBL5314722",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DINUTUXIMAB BETA | Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)",
      "names": [
        "DINUTUXIMAB BETA",
        "Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)"
      ],
      "chembl": "CHEMBL5315068",
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BETALUTIN | TETULOMAB TETRAXETAN LU-177 | (SUP 177)LU-TETULOMAB | 177LU-TETULOMAB | 177LU-TETRAXETAN-TETULOMAB",
      "names": [
        "TETULOMAB TETRAXETAN LU-177",
        "BETALUTIN",
        "(SUP 177)LU-TETULOMAB",
        "177LU-TETULOMAB",
        "177LU-TETRAXETAN-TETULOMAB"
      ],
      "chembl": "CHEMBL4297907",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT01796171"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "Sweden",
        "Ireland",
        "Denmark",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Croatia",
        "Austria",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "developers": [
        "Nordic Nanovector"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 24,
      "# trials": 1
    },
    {
      "heading": "SIGVOTATUG VEDOTIN",
      "names": [
        "SIGVOTATUG VEDOTIN"
      ],
      "chembl": "CHEMBL5314879",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "2F35K89X9W | 90Y-EPRATUZUMAB | S9S0Y-DOTA-HLL2 | 90Y-DOTA-HLL2 | YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN | Y-90-DOTA-HLL2 | (SUP 90)Y-DOTA-HLL2",
      "names": [
        "2F35K89X9W",
        "90Y-EPRATUZUMAB",
        "S9S0Y-DOTA-HLL2",
        "90Y-DOTA-HLL2",
        "YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN",
        "Y-90-DOTA-HLL2",
        "(SUP 90)Y-DOTA-HLL2"
      ],
      "chembl": "CHEMBL2108666",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ORTHOZYME CD 5 PLUS | ZOLIMOMAB ARITOX | XOMA ZYME H 65 | H-65RTA | ZX-CD5 | H-65-RTA | H65-RTA",
      "names": [
        "ORTHOZYME CD 5 PLUS",
        "ZOLIMOMAB ARITOX",
        "XOMA ZYME H 65",
        "H-65RTA",
        "ZX-CD5",
        "H-65-RTA",
        "H65-RTA"
      ],
      "chembl": "CHEMBL2108785",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CERGUTUZUMAB AMUNALEUKIN | RG-7813 | RO-6895882 | RO6895882 | RG7813",
      "names": [
        "CERGUTUZUMAB AMUNALEUKIN",
        "RG-7813",
        "RO-6895882",
        "RO6895882",
        "RG7813"
      ],
      "chembl": "CHEMBL3990018",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "VERLUMA | Nofetumomab merpentan 99Tc | TECHNETIUM (99MTC) NOFETUMOMAB MERPENTAN | NOFETUMOMAB MERPENTAN 99TC | TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN",
      "names": [
        "VERLUMA",
        "Nofetumomab merpentan 99Tc",
        "TECHNETIUM (99MTC) NOFETUMOMAB MERPENTAN",
        "NOFETUMOMAB MERPENTAN 99TC",
        "TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN"
      ],
      "chembl": "CHEMBL2109287",
      "phases": [
        "Phase 4"
      ],
      "Max Phase": "4",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "HAFP-31 | YTTRIUM Y 90 TACATUZUMAB TETRAXETAN | YTTRIUM (90Y) TACATUZUMAB TETRAXETAN | AFP-CIDE",
      "names": [
        "HAFP-31",
        "YTTRIUM Y 90 TACATUZUMAB TETRAXETAN",
        "YTTRIUM (90Y) TACATUZUMAB TETRAXETAN",
        "AFP-CIDE"
      ],
      "chembl": "CHEMBL2108669",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "CMD-193",
      "names": [
        "CMD-193"
      ],
      "chembl": "CHEMBL2109504",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "SP-8893 | ISPECTAMAB TAZIDE",
      "names": [
        "SP-8893",
        "ISPECTAMAB TAZIDE"
      ],
      "chembl": "CHEMBL5314684",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LMB-2",
      "names": [
        "LMB-2"
      ],
      "chembl": "CHEMBL2109367",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "TRASTUZUMAB BRENGITECAN",
      "names": [
        "TRASTUZUMAB BRENGITECAN"
      ],
      "chembl": "CHEMBL5314886",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT05323955",
        "NCT02390427",
        "NCT02073487",
        "NCT06100874",
        "NCT00928330",
        "NCT01969643",
        "NCT04873362",
        "NCT02131064",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT05113251",
        "NCT04784715",
        "NCT05980481",
        "NCT04379596",
        "NCT01772472",
        "NCT00679341",
        "NCT03523585",
        "NCT01904903",
        "NCT01966471"
      ],
      "conditions": [
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Gastric Cancer",
        "Breast Cancer",
        "Locally Advanced or Early Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "Brain Metastases",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer; HER2-positive; Metastatic",
        "Neoplasm Metastasis",
        "Hormone Receptor Positive Breast Neoplasms",
        "HER2 Positive Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "Left Ventricular Function Systolic Dysfunction",
        "Triple Negative Breast Neoplasms",
        "HER2-positive Early Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Positive Breast Cancer",
        "Breast Cancer Female",
        "Breast Neoplasms",
        "Breast Cancer Metastatic",
        "Recurrent Breast Cancer"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "developers": [
        "RemeGen"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 23,
      "# locations": 72,
      "# trials": 20
    },
    {
      "heading": "LMB-9 | B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38",
      "names": [
        "LMB-9",
        "B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38"
      ],
      "chembl": "CHEMBL2109503",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ASG-5ME",
      "names": [
        "ASG-5ME"
      ],
      "chembl": "CHEMBL2109574",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT01166490"
      ],
      "conditions": [
        "Pancreatic Neoplasms",
        "Gastric Neoplasms"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Seagen",
        "Agensys"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "SACITUZUMAB TIRUMOTECAN",
      "names": [
        "SACITUZUMAB TIRUMOTECAN"
      ],
      "chembl": "CHEMBL5314875",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT06132958",
        "NCT06074588"
      ],
      "conditions": [
        "Endometrial Cancer",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "developers": [
        "GOG Foundation",
        "Merck Sharp & Dohme"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 54,
      "# trials": 2
    },
    {
      "heading": "BEZETABART DEBOTANSINE",
      "names": [
        "BEZETABART DEBOTANSINE"
      ],
      "chembl": "CHEMBL5314812",
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "ARX-788 MAB | ANVATABART PACTIL | ARX788 mAb",
      "names": [
        "ARX-788 MAB",
        "ANVATABART PACTIL",
        "ARX788 mAb"
      ],
      "chembl": "CHEMBL5314616",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT04829604",
        "NCT06224673",
        "NCT03255070"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Carcinoma",
        "Breast Neoplasms",
        "Triple Negative Breast Cancer",
        "HER2 Positive Metastatic Breast Cancer",
        "HER2 Low Breast Carcinoma",
        "Solid Tumors",
        "Gastric Neoplasm",
        "Hormone-receptor-positive Breast Cancer"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Australia",
        "France",
        "United States"
      ],
      "developers": [
        "Ambrx"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 8,
      "# locations": 5,
      "# trials": 3
    },
    {
      "heading": "HUMY9-6 | AVE-9633",
      "names": [
        "HUMY9-6",
        "AVE-9633"
      ],
      "chembl": "CHEMBL2109266",
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DP-303c",
      "names": [
        "DP-303c"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17212",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "DCLL-9718S",
      "names": [
        "DCLL-9718S"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17392",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "BVX-001",
      "names": [
        "BVX-001"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18733",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "IMMU-114",
      "names": [
        "IMMU-114"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18458",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197  vaccine",
      "names": [
        "Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197  vaccine"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB10061",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AOC-1020",
      "names": [
        "AOC-1020"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18621",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AOC 1001",
      "names": [
        "AOC 1001"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18620",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Tositumomab I-131",
      "names": [
        "Tositumomab I-131"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB17991",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "LMB-100",
      "names": [
        "LMB-100"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18591",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Zenocutuzumab",
      "names": [
        "Zenocutuzumab"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB15559",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "Mitazalimab",
      "names": [
        "Mitazalimab"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB15225",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "EUCTR2020-005182-14-FR"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "locations": [
        "France"
      ],
      "developers": [
        "Alligator Bioscience AB"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "Nendratareotide uzatansine",
      "names": [
        "Nendratareotide uzatansine"
      ],
      "drugbank": "https://go.drugbank.com/drugs/DB18351",
      "phases": [],
      "Max Phase": null,
      "conditions": [],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "locations": [],
      "trials": [],
      "developers": [],
      "# conditions": 0,
      "# locations": 0,
      "# trials": 0
    },
    {
      "heading": "AGS67E",
      "names": [
        "AGS67E"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT02175433"
      ],
      "conditions": [
        "Relapsed Lymphoid Malignancy",
        "Refractory Lymphoid Malignancy"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "Astellas"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "AGX101",
      "names": [
        "AGX101"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06440005"
      ],
      "conditions": [
        "Pancreas Cancer",
        "Cancer",
        "Locally Advanced Carcinoma",
        "Triple Negative Breast Cancer",
        "Advanced Cancer",
        "Metastatic Solid Tumor",
        "Pancreatic Adenocarcinoma"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Angiex"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 7,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "AMT-151",
      "names": [
        "AMT-151"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05498597"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Endometrioid Adenocarcinoma",
        "Advanced Cancer",
        "Lung Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Advanced Carcinoma",
        "Endometrial Cancer",
        "Endometrial Endometrioid Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Ovarian Carcinoma",
        "Triple Negative Breast Cancer",
        "Ovarian Epithelial Cancer",
        "Ovarian Clear Cell Carcinoma",
        "Malignant Pleural Mesothelioma",
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "China",
        "Australia"
      ],
      "developers": [
        "Multitude"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 19,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "AZD9592",
      "names": [
        "AZD9592"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05647122"
      ],
      "conditions": [
        "Head and Neck Neoplasms",
        "Colorectal Neoplasms",
        "Carcinoma Non-small Cell Lung",
        "Advanced Solid Tumours"
      ],
      "locations": [
        "Canada",
        "Italy",
        "China",
        "Malaysia",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "Japan",
        "United States"
      ],
      "developers": [
        "AstraZeneca"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 11,
      "# trials": 1
    },
    {
      "heading": "BAT8009 for Injection | BAT8009",
      "names": [
        "BAT8009 for Injection",
        "BAT8009"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05405621"
      ],
      "conditions": [
        "Locally Advanced/Metastatic Solid Tumours"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Bio thera Solutions"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "BB-1709",
      "names": [
        "BB-1709"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06241898"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Bliss (Hangzhou)"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "BG-C9074",
      "names": [
        "BG-C9074"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06233942"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [
        "Australia"
      ],
      "developers": [
        "BeiGene"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "BGB-C354",
      "names": [
        "BGB-C354"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06422520"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [],
      "developers": [
        "BeiGene"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "BIO-106",
      "names": [
        "BIO-106"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05320588"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Cancer",
        "Oncology"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "BiOneCure Therapeutics Inc"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "B003",
      "names": [
        "B003"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT03953833"
      ],
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Shanghai Pharmaceuticals Holding"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "CA102N",
      "names": [
        "CA102N"
      ],
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06039202"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "locations": [],
      "developers": [
        "Holy Stone Healthcare Co., Ltd"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "CS5001",
      "names": [
        "CS5001"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05279300"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Lymphoma"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "developers": [
        "CStone Pharmaceuticals"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "FDA018-ADC",
      "names": [
        "FDA018-ADC"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05174637"
      ],
      "conditions": [
        "Advanced/ Metastatic Solid Tumors"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "FDA022 Monoclonal -  for injection Phase Ib | FDA022 | FDA022 Monoclonal -  for injection Phase Ia",
      "names": [
        "FDA022 Monoclonal -  for injection Phase Ib",
        "FDA022",
        "FDA022-BB05",
        "FDA022 Monoclonal -  for injection Phase Ia"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05564858",
        "NCT06413615"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "DXC006",
      "names": [
        "DXC006"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06224855"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Hematological Malignancies"
      ],
      "locations": [],
      "developers": [
        "Hangzhou DAC Biotechnology Co., Ltd"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "EBC-129",
      "names": [
        "EBC-129"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05701527"
      ],
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "locations": [
        "Singapore",
        "United States"
      ],
      "developers": [
        "EDDC (Experimental Drug Development Centre), A*STAR Research Entities"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "FZ-AD004",
      "names": [
        "FZ-AD004"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05914545"
      ],
      "conditions": [
        "Advanced and Metastatic Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Fudan-Zhangjiang"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "HLX42",
      "names": [
        "HLX42"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06210815"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Shanghai Henlius"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "HS-20093 (Phase Ib: Dose expansion) | HS-20093 | HS-20093 (Phase Ia: Dose escalation)",
      "names": [
        "HS-20093 (Phase Ib: Dose expansion)",
        "HS-20093",
        "HS-20093 (Phase Ia: Dose escalation)"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06464055",
        "NCT06112704",
        "NCT05276609"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Malignant Solid Tumors"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Shanghai Hansoh Biomedical"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 3
    },
    {
      "heading": "HS-20105",
      "names": [
        "HS-20105"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06144723"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [],
      "developers": [
        "Shanghai Hansoh Biomedical"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "JSKN003",
      "names": [
        "JSKN003"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05494918"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "locations": [
        "Australia"
      ],
      "developers": [
        "Alphamab Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "KM501",
      "names": [
        "KM501"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05804864"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Xuanzhu Biopharm"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "L-DOS47",
      "names": [
        "L-DOS47"
      ],
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "Max Phase": "3",
      "trials": [
        "NCT02340208",
        "NCT04203641",
        "EUCTR2010-020729-42-PL"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Pancreas Cancer",
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer  MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
      ],
      "locations": [
        "Poland",
        "United States"
      ],
      "developers": [
        "Pharm-Olam International",
        "Helix BioPharma"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 2,
      "# trials": 3
    },
    {
      "heading": "LCB84",
      "names": [
        "LCB84"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05941507"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "AntibodyChem Biosciences",
        "Legochem"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "LY4052031",
      "names": [
        "LY4052031"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06465069"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Prostate Cancer",
        "Recurrent Solid Tumor",
        "Esophageal Cancer",
        "Renal Pelvis Cancer",
        "Non-small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Urinary Bladder Neoplasm",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Solid Tumor",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Eli Lilly",
        "Loxo Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 14,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "LY4101174",
      "names": [
        "LY4101174"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06238479"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Prostate Cancer",
        "Recurrent Solid Tumor",
        "Esophageal Cancer",
        "Renal Pelvis Cancer",
        "Non-small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Urinary Bladder Neoplasm",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Solid Tumor",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "Australia",
        "Japan",
        "United States"
      ],
      "developers": [
        "Eli Lilly",
        "Loxo Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 14,
      "# locations": 3,
      "# trials": 1
    },
    {
      "heading": "LY4170156",
      "names": [
        "LY4170156"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06400472"
      ],
      "conditions": [
        "Pancreatic Neoplasm",
        "Endometrial Neoplasms",
        "Triple Negative Breast Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Uterine Cervical Neoplasms",
        "Ovarian Neoplasms",
        "Colorectal Neoplasms"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Eli Lilly",
        "Loxo Oncology"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 7,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "M9140",
      "names": [
        "M9140"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05464030"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Denmark",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "developers": [
        "Merck KGaA, Darmstadt, Germany",
        "EMD Serono"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 24,
      "# trials": 1
    },
    {
      "heading": "ORM-5029",
      "names": [
        "ORM-5029"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05511844"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER-2 Gene Amplification",
        "HER2 Gene Mutation",
        "HER-2 Protein Overexpression"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Orum Therapeutics USA, Inc"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "PBI-410",
      "names": [
        "PBI-410"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06384807"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Biohaven"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "SIBP-A13 | SIBP-A13 formulation for injection",
      "names": [
        "SIBP-A13",
        "SIBP-A13 formulation for injection"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06298058"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "locations": [],
      "developers": [
        "Shanghai Institute Of Biological Products"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 0,
      "# trials": 1
    },
    {
      "heading": "TAC-001",
      "names": [
        "TAC-001"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT05399654"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "developers": [
        "Tallac Therapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "TAK-853",
      "names": [
        "TAK-853"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06390995"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumors"
      ],
      "locations": [
        "Japan"
      ],
      "developers": [
        "Takeda"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "TORL-1-23",
      "names": [
        "TORL-1-23"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05103683"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Endometrial Cancer",
        "NSCLC",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Translational Research in Oncology",
        "TORL Biotherapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 4,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "TORL-3-600",
      "names": [
        "TORL-3-600"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT05948826"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "developers": [
        "Translational Research in Oncology",
        "TORL Biotherapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 2,
      "# trials": 1
    },
    {
      "heading": "TORL-4-500",
      "names": [
        "TORL-4-500"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06005740"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Advanced Solid Tumor"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Translational Research in Oncology",
        "TORL Biotherapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "TQB2102 | TQB2102 for injection | TQB2102 injection",
      "names": [
        "TQB2102",
        "TQB2102 for injection",
        "TQB2102 injection"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06431490",
        "NCT05735496",
        "NCT06115902",
        "NCT06198751",
        "NCT06452706"
      ],
      "conditions": [
        "Advanced Cancer",
        "Breast Cancer",
        "Biliary Tract Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Chiatai Tianqing"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 5
    },
    {
      "heading": "TUB-040",
      "names": [
        "TUB-040"
      ],
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06303505"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Tubulis"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 2,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "VIP943",
      "names": [
        "VIP943"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06034275"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "B-cell Acute Lymphoblastic Leukemia",
        "High-risk Myelodysplastic Syndrome"
      ],
      "locations": [
        "United States"
      ],
      "developers": [
        "Vincerx Pharma, Inc"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 3,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "WTX212A | WTX212A injection",
      "names": [
        "WTX212A",
        "WTX212A injection"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT06106152"
      ],
      "conditions": [
        "Advanced Lung Cancer"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "Westlake Therapeutics"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 1,
      "# locations": 1,
      "# trials": 1
    },
    {
      "heading": "YL202 should be intravenously infused | YL202",
      "names": [
        "YL202 should be intravenously infused",
        "YL202"
      ],
      "phases": [
        "Phase 2"
      ],
      "Max Phase": "2",
      "trials": [
        "NCT06439771",
        "NCT06107686"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer",
        "Locally Advanced or Metastatic Solid Tumors",
        "HNSCC",
        "Breast Cancer",
        "NSCLC"
      ],
      "locations": [
        "China"
      ],
      "developers": [
        "MediLink"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 5,
      "# locations": 1,
      "# trials": 2
    },
    {
      "heading": "AMG 595",
      "names": [
        "AMG 595"
      ],
      "phases": [
        "Phase 1"
      ],
      "Max Phase": "1",
      "trials": [
        "NCT01475006"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Advanced Malignant Glioma",
        "Anaplastic Astrocytomas"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "developers": [
        "Amgen"
      ],
      "targets": [],
      "payload": [],
      "linker": [],
      "domain": [],
      "antibody": [],
      "# conditions": 3,
      "# locations": 2,
      "# trials": 1
    }
  ],
  "orgs": [
    {
      "heading": "3SBIO",
      "names": [
        "3SBIO"
      ],
      "HQ City": "Shenyang",
      "HQ Country": "China",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "http://www.3sbio.com/",
      "Acquisition": "-",
      "drugs": [
        "HM2-MMAE | ALT-P7 ALT-P7 | ALT-P7"
      ],
      "co-developers": [
        "Alteogen"
      ],
      "# co-developers": 1,
      "locations": [
        "Korea, Republic of"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "A&G",
      "names": [
        "A&G Pharmaceuticals",
        "A&G",
        "A&G Pharmaceutical Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05627960"
      ],
      "co-developers": [],
      "drugs": [
        "AG02"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ADC Therapeutics",
      "names": [
        "ADC Therapeutics SA",
        "ADC Therapeutics S.A",
        "ADC Therapeutics Murray Hill, NJ",
        "ADC Terapeutics",
        "ADC Therapeutics America, Inc",
        "ADC Therapeutics",
        "ADC Therapeutics in collaboration with MedImmune"
      ],
      "HQ City": "Lausanne",
      "HQ Country": "Switzerland",
      "Founding Year": "2011",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://adctherapeutics.com",
      "Acquisition": "-",
      "ttd": [
        "D05CRY",
        "D0HV4B",
        "D0LL1N",
        "D8L5PA"
      ],
      "co-developers": [
        "Genmab",
        "Regeneron",
        "MedImmune",
        "AstraZeneca"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf"
      ],
      "trials": [
        "NCT03698552",
        "NCT05600686",
        "NCT05991388",
        "NCT04970901"
      ],
      "drugs": [
        "ADCT-901",
        "ADCT-701",
        "Loncastuximab tesirine | ADCT-402 | ADCT-402 RB4v1.2-SG-3249 | Zynlonta",
        "ADCT-301 | ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d | HuMax-TAC-ADC | Camidanlumab tesirine",
        "ADCT-502",
        "TELIMOMAB ARITOX | Telimomab aritox | T101 | T-101",
        "MEDI3726 | ADCT-401 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
        "Epratuzumab Tesirine | ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249 | hLL2-cys-PBD | ADCT-602 | ADCT 602 ADCT602 ADCT-602",
        "3A4-PL1601",
        "Mipasetamab Uzoptirine | ADCT-601"
      ],
      "# co-developers": 4,
      "locations": [
        "Italy",
        "Czechia",
        "Switzerland",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "# locations": 7,
      "# drugs": 10,
      "# Preclinical drugs": 3,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AGO Research",
      "names": [
        "AGO Research",
        "AGO Research GmbH"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04274426"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ALX Oncology",
      "names": [
        "ALX Oncology"
      ],
      "HQ City": "Burlingame",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.alxoncology.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AbGenomics BV",
      "names": [
        "Taiwan Branch",
        "AbGenomics International",
        "AbGenomics BV"
      ],
      "HQ City": "Oss",
      "HQ Country": "Netherlands",
      "Founding Year": "2009",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.abgenomics.com",
      "Acquisition": "-",
      "drugs": [
        "AbGn-108",
        "Ab1-18Hr1 | AbGn-107",
        "AbGn-110"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AbbVie",
      "names": [
        "Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University",
        "AbbVie",
        "AbbVie Stemcentrx LLC",
        "Stemcentrx (now part of AbbVie)",
        "CytomX and AbbVie",
        "AbbVie (prior sponsor, Abbott)",
        "AbbVie Deutschland GmbH & Co. KG",
        "Abbvie",
        "AbbVie, Inc"
      ],
      "HQ City": "North Chicago",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.abbvie.com",
      "Acquisition": "-",
      "ttd": [
        "D2AQW7",
        "D4J9HV",
        "D58AMF",
        "DDE82F"
      ],
      "co-developers": [
        "Genmab",
        "Stemcentrx",
        "CytomX",
        "Roche",
        "Genentech",
        "EuPAL",
        "Pfizer",
        "Radiation Therapy Oncology Group"
      ],
      "trials": [
        "NCT05283720",
        "NCT03539536",
        "NCT02573324",
        "NCT03543358",
        "NCT02674568",
        "NCT03086239",
        "NCT01741727",
        "EUCTR2018-001772-38-HU",
        "NCT02565758",
        "NCT04070768",
        "NCT04928846",
        "NCT02343406",
        "NCT05016947",
        "NCT05955261",
        "NCT05183035",
        "NCT02590263",
        "NCT05904106",
        "NCT01800695",
        "NCT02099058",
        "EUCTR2018-001772-38-IE",
        "NCT04189614",
        "NCT03061812",
        "NCT03000257"
      ],
      "drugs": [
        "ABBV-154",
        "ABBV-647 | PF-06647020 | Cofetuzumab pelidotin | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020",
        "Azintuxizumab Vedotin | ABBV-838 | ABBV-838 ABBV838",
        "Tamrintamab Pamozirine | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Anti-DPEP3 ADC | SC-003",
        "ABBV-321 | Serclutamab Talirine | ABBV-321 Anti-Egfr/pbd -  ABBV-321",
        "ABV176 | ABBV-176 | ABBV176 | ABBV 176",
        "ABBV-011",
        "PR-1498487-MMAE PR-1498487 PAB-MMAE | ABBV-085 | Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085 | PR-1498487-MMAE | Samrotamab vedotin",
        "Mirzotamab Clezutoclax | ABBV-155",
        "ABBV-3373",
        "Losatuxizumab vedotin | ABBV-221 | ABBV-221 ABBV221",
        "ABBV-CX-2029",
        "SC16LD6.5",
        "ABBV-319",
        "ABBV-400",
        "Depatuxizumab Mafodotin | ABT-414 | ABT-414 ABT-414/806 Depatux-M",
        "ABBV-706",
        "CX-2029",
        "ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC | ABT-700-vcMMAE | Telisotuzumab Vedotin | ABBV 399 | ABBV-399 | Teliso-V",
        "SC-006 | SC006"
      ],
      "# co-developers": 8,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "South Africa",
        "Israel",
        "Finland",
        "Argentina",
        "Croatia",
        "Austria",
        "Belarus",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Chile",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# locations": 47,
      "# drugs": 20,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 7,
      "# Phase 2 drugs": 8,
      "# Phase 3 drugs": 3,
      "# Phase 4 drugs": 0,
      "# trials": 23,
      "# Phase 1 trials": 9,
      "# Phase 2 trials": 8,
      "# Phase 3 trials": 6,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Abbott Diabetes Care",
      "names": [
        "Abbott Diabetes Care"
      ],
      "HQ City": "Alameda",
      "HQ Country": "United States",
      "Founding Year": "1888",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.abbott.com/diabetes-care.html",
      "Acquisition": "-",
      "trials": [
        "NCT01432275"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Acepodia Biotech",
      "names": [
        "Acepodia Biotech",
        "Acepodia Biotech, Inc"
      ],
      "HQ City": "Milpitas",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.acepodia.com",
      "Acquisition": "-",
      "trials": [
        "NCT05653271",
        "NCT06415487"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Actinium",
      "names": [
        "Actinium"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1971",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.actiniumpharma.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Active Biotech AB",
      "names": [
        "Active Biotech AB"
      ],
      "HQ City": "Lund",
      "HQ Country": "Sweden",
      "Founding Year": "1983",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.activebiotech.com/",
      "Acquisition": "-",
      "trials": [
        "NCT00420888",
        "NCT00056537",
        "NCT00132379"
      ],
      "co-developers": [],
      "drugs": [
        "PNU-214936 | ABR-214936 | ANATUMOMAB MAFENATOX | Anatumomab mafenatox | ANYARA"
      ],
      "# co-developers": 0,
      "locations": [
        "Israel",
        "Ukraine",
        "Denmark",
        "United States",
        "United Kingdom",
        "Bulgaria",
        "Russian Federation",
        "Norway",
        "Romania"
      ],
      "# locations": 9,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Adcentrx",
      "names": [
        "Adcentrx Therapeutics",
        "Adcentrx"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06036121"
      ],
      "co-developers": [],
      "drugs": [
        "ADRX-0706"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Adimab",
      "names": [
        "Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab",
        "Adimab"
      ],
      "HQ City": "Lebanon",
      "HQ Country": "United States",
      "Founding Year": "2007",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.adimab.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Adolor Corp",
      "names": [
        "Adolor Corp"
      ],
      "HQ City": "Exton",
      "HQ Country": "United States",
      "Founding Year": "1994",
      "Public/Private": "-",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Cubist Pharmaceuticals in 2011",
      "ttd": [
        "D0TA3V"
      ],
      "co-developers": [],
      "drugs": [
        "ADC-5510"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Affinicon",
      "names": [
        "Affinicon"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "CD163-dexamethasone ADC | anti-CD163-dexamethasone | anti-CD163-dexamethasone ADC | Cymac-001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Israel",
        "Croatia",
        "Belarus",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# locations": 35,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Agensys",
      "names": [
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Agensys and Seattle Genetics",
        "Agensys, Inc",
        "Agensys"
      ],
      "HQ City": "Santa Monica",
      "HQ Country": "United States",
      "Founding Year": "1996",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Astellas in 2007",
      "trials": [
        "NCT01166490"
      ],
      "co-developers": [
        "Astellas",
        "Ligand Pharmaceuticals",
        "Seagen"
      ],
      "drugs": [
        "AGS 62P1 | AGS62P1",
        "ASG-15ME | AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | AGS15E | AGS-15vcMMAE | Sirtratumab vedotin | AGS-15E | Ha15-10ac.1vcMMAE",
        "AGS 16C3F | AGS-16M8F | AGS-16C3F",
        "ASG-5ME"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Aivita Biomedical",
      "names": [
        "Aivita Biomedical, Inc",
        "Aivita Biomedical"
      ],
      "HQ City": "Irvine",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://aivitabiomedical.com",
      "Acquisition": "-",
      "trials": [
        "NCT04690387",
        "NCT05100641",
        "NCT05007496",
        "NCT03743298"
      ],
      "co-developers": [
        "PT AIVITA Biomedika Indonesia"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alaunos Therapeutics",
      "names": [
        "Alaunos Therapeutics"
      ],
      "HQ City": "Houston",
      "HQ Country": "United States",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.alaunos.com",
      "Acquisition": "-",
      "trials": [
        "NCT00815607"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alethia",
      "names": [
        "Alethia",
        "Alethia Biotherapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "AB-3A4 | AB-3A4-ADC | AB-3A4-vcMMAE | AB-3A4 ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alfasigma",
      "names": [
        "Alfasigma"
      ],
      "HQ City": "Bologna",
      "HQ Country": "Italy",
      "Founding Year": "1948",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.alfasigma.com/",
      "Acquisition": "-",
      "drugs": [
        "ST8176AA1"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alliance Foundation Trials",
      "names": [
        "Alliance Foundation Trials",
        "Alliance for Clinical Trials in Oncology",
        "Alliance Foundation Trials, LLC"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.alliancefoundationtrials.org",
      "Acquisition": "-",
      "trials": [
        "NCT05633654",
        "NCT04486352",
        "NCT04457596"
      ],
      "co-developers": [
        "NSABP Foundation",
        "Genentech",
        "Eli Lilly",
        "Seagen",
        "GILEAD",
        "Pfizer"
      ],
      "drugs": [],
      "# co-developers": 6,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alligator Bioscience AB",
      "names": [
        "Alligator Bioscience AB"
      ],
      "HQ City": "Lund",
      "HQ Country": "Sweden",
      "Founding Year": "2001",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.alligatorbioscience.com",
      "Acquisition": "-",
      "ttd": [
        "D0C5LJ",
        "D01NGB",
        "D0G0AQ"
      ],
      "co-developers": [],
      "trials": [
        "NCT02379741",
        "EUCTR2020-005182-14-FR"
      ],
      "drugs": [
        "Mitazalimab",
        "ADC-1013",
        "ADC-1001",
        "ADC-1012"
      ],
      "# co-developers": 0,
      "locations": [
        "Sweden",
        "United Kingdom",
        "France",
        "Denmark"
      ],
      "# locations": 4,
      "# drugs": 4,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Almac Discovery",
      "names": [
        "Almac Discovery"
      ],
      "HQ City": "Craigavon",
      "HQ Country": "UK",
      "Founding Year": "2001",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.almacgroup.com",
      "Acquisition": "-",
      "ttd": [
        "D0AN9V",
        "DRJU35"
      ],
      "co-developers": [],
      "drugs": [
        "ADC-03",
        "ADC-01"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alphamab Oncology",
      "names": [
        "Alphamab Oncology",
        "Alphamab (Australia) Co Pty Ltd"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2011",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.alphamaboncology.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05494918"
      ],
      "co-developers": [],
      "drugs": [
        "JSKN003"
      ],
      "# co-developers": 0,
      "locations": [
        "Australia"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alteogen",
      "names": [
        "Alteogen",
        "Alteogen, Inc"
      ],
      "HQ City": "Daejeon",
      "HQ Country": "South Korea",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.alteogen.com",
      "Acquisition": "-",
      "trials": [
        "NCT03281824"
      ],
      "co-developers": [
        "3SBIO"
      ],
      "drugs": [
        "ALT-Q5",
        "HM2-MMAE | ALT-P7 ALT-P7 | ALT-P7"
      ],
      "# co-developers": 1,
      "locations": [
        "Korea, Republic of"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Alzamend Neuro",
      "names": [
        "Alzamend Neuro",
        "Alzamend Neuro, Inc"
      ],
      "HQ City": "Tampa",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.alzamend.com",
      "Acquisition": "-",
      "trials": [
        "NCT05834296"
      ],
      "co-developers": [
        "bioRASI, LLC"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Ambrx",
      "names": [
        "Merck & Co and Ambrx",
        "Ambrx, Inc",
        "Ambrx"
      ],
      "HQ City": "La Jolla",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.ambrx.com",
      "Acquisition": "-",
      "trials": [
        "NCT04829604",
        "NCT04662580",
        "NCT06224673",
        "NCT03255070"
      ],
      "co-developers": [
        "Progenics Pharmaceuticals",
        "Johnson & Johnson"
      ],
      "drugs": [
        "ARX-788 MAB | ANVATABART PACTIL | ARX788 mAb",
        "anti-PSMA ADC | ARX517 | ARX517-PSMA-ADC",
        "CD70-glucocorticoid ADC",
        "anti-CD70 ADC | CD70 ADC | Anti-CD70-ADC | CD70-ADC",
        "CD184-FK506",
        "ARX788 HER2 ADC | ARX788",
        "CD184-Dasatinib-ADC | CD184-Dasatinib"
      ],
      "# co-developers": 2,
      "locations": [
        "China",
        "Korea, Republic of",
        "Australia",
        "France",
        "United States"
      ],
      "# locations": 5,
      "# drugs": 7,
      "# Preclinical drugs": 4,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Amgen",
      "names": [
        "Daiichi Sankyo The antibody part is developed in collaboration with Amgen",
        "Amgen",
        "Amgen, Inc",
        "Daiichi Sankyo  The antibody part is developed in collaboration with Amgen"
      ],
      "HQ City": "Thousand Oaks",
      "HQ Country": "United States",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.amgen.com",
      "Acquisition": "-",
      "trials": [
        "NCT01475006",
        "NCT01497821",
        "NCT04307576",
        "NCT04822337"
      ],
      "co-developers": [
        "DAIICHI SANKYO",
        "Servier",
        "GlaxoSmithKline",
        "Nova Laboratories Limited",
        "NordForsk",
        "Pfizer"
      ],
      "drugs": [
        "AMG-595 | AMG595",
        "AMG172",
        "U3-1402 U3-1402A Anti-HER3 | HER3 ADC | Patritumab Deruxtecan | U3-1402",
        "AMG 224 | AMG 224 anti-BCMA\u2013MCC\u2013DM1",
        "AMG 595"
      ],
      "# co-developers": 6,
      "locations": [
        "Austria",
        "Spain",
        "Japan",
        "Korea, Republic of",
        "Germany",
        "Australia",
        "Taiwan",
        "France",
        "Netherlands",
        "United States"
      ],
      "# locations": 10,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Amphera BV",
      "names": [
        "Amphera BV"
      ],
      "HQ City": "Leiden",
      "HQ Country": "Netherlands",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.amphera.nl",
      "Acquisition": "-",
      "trials": [
        "NCT03610360"
      ],
      "co-developers": [
        "TMC Pharma"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Amsterdam UMC",
      "names": [
        "Amsterdam UMC"
      ],
      "HQ City": "Amsterdam",
      "HQ Country": "Netherlands",
      "Founding Year": "-",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.amsterdamumc.org",
      "Acquisition": "-",
      "trials": [
        "NL-OMON56595"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Angiex",
      "names": [
        "The Center for Vascular Biology Research and the Departments of Angiex",
        "Angiex",
        "Angiex, Inc",
        "The Center for Vascular Biology Research and the Departments of  Angiex"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.angiex.com",
      "Acquisition": "-",
      "trials": [
        "NCT06440005"
      ],
      "co-developers": [
        "Pfizer"
      ],
      "drugs": [
        "Anti-TM4SF1 ADC",
        "AGX101"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Antengene",
      "names": [
        "Antengene",
        "Antengene Corporation (Antengene Biologics)",
        "Antengene Corporation ( Antengene Biologics)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2017",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.antengene.com/",
      "Acquisition": "-",
      "drugs": [
        "ATG-022"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AntibodyChem Biosciences",
      "names": [
        "AntibodyChem Biosciences",
        "AntibodyChem Biosciences, Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05941507"
      ],
      "co-developers": [
        "Legochem"
      ],
      "drugs": [
        "LCB84"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Apices Soluciones S.L",
      "names": [
        "Apices Soluciones S.L"
      ],
      "HQ City": "Madrid",
      "HQ Country": "Spain",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.apices.es",
      "Acquisition": "-",
      "trials": [
        "NCT06133517"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Arcus",
      "names": [
        "Arcus",
        "Arcus Biosciences, Inc"
      ],
      "HQ City": "Hayward",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.arcusbio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04381832",
        "NCT05633667"
      ],
      "co-developers": [
        "GILEAD"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Argenta Discovery Ltd",
      "names": [
        "Argenta Discovery Ltd"
      ],
      "HQ City": "Harlow",
      "HQ Country": "UK",
      "Founding Year": "2000",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.argentadiscovery.com",
      "Acquisition": "-",
      "ttd": [
        "D02JND",
        "D0K2MT",
        "D0U3YW"
      ],
      "co-developers": [],
      "drugs": [
        "ADC-3680",
        "ADC-7828",
        "ADC-9971"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Array BioPharma",
      "names": [
        "Array BioPharma"
      ],
      "HQ City": "Boulder",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Pfizer in 2019",
      "trials": [
        "NCT03971409"
      ],
      "co-developers": [
        "GILEAD",
        "Pfizer"
      ],
      "drugs": [],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Arterica",
      "names": [
        "Arterica",
        "Arterica, Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "ACTRN12620000773932"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Artiva",
      "names": [
        "Artiva"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.artivabio.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Asana BioSciences",
      "names": [
        "Asana Biosciences",
        "Asana BioSciences"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ASN-004 ASN004 ASN 004 | ASN 004 | ASN-004"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Aspyrian",
      "names": [
        "Aspyrian",
        "Rakuten Medical (Aspyrian Therapeutics)"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ASP-1929  RM-1929 Cetuximab-irdye 700dx | RM-1929 | Cetuximab sarotalocan | ASP-1929"
      ],
      "co-developers": [
        "Rakuten Medical"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Astellas",
      "names": [
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Astellas Northbrook, IL Seattle Genetics Bothell, WA",
        "Astellas Pharma Inc",
        "Astellas Pharma (Agensys)",
        "Astellas Pharma Global Development, Inc",
        "Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas",
        "Astellas",
        "Astellas (Ganymed Pharmaceuticals)"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2005",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.astellas.com",
      "Acquisition": "-",
      "ttd": [
        "DORB45",
        "DAG87H"
      ],
      "co-developers": [
        "Roche",
        "Agensys",
        "Seagen",
        "Merck Sharp & Dohme",
        "Ganymed",
        "GILEAD",
        "Ligand Pharmaceuticals"
      ],
      "trials": [
        "NCT02171143",
        "NCT02150070",
        "NCT05756569",
        "NCT02125435",
        "NCT03869190",
        "NCT03288545",
        "NCT02175433",
        "NCT02140125",
        "NCT03474107",
        "NCT03219333",
        "NCT02052375"
      ],
      "drugs": [
        "ASG-15ME | AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | AGS15E | AGS-15vcMMAE | Sirtratumab vedotin | AGS-15E | Ha15-10ac.1vcMMAE",
        "AGS 62P1 | AGS62P1",
        "IMAB362-vcMMAE",
        "Enfortumab | ASG-22ME | AGS-22ME | AGS-22CE | ASG-22CE | AGS-22M | ASG-22MSE | Enfortumab Vedotin | Padcev | AGS-22M6E | Enfortumab vedotin",
        "AGS 16C3F | AGS-16M8F | AGS-16C3F",
        "IMAB027-vcMMAE",
        "AGS67E"
      ],
      "# co-developers": 7,
      "locations": [
        "China",
        "Denmark",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Argentina",
        "Austria",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 22,
      "# drugs": 7,
      "# Preclinical drugs": 2,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 11,
      "# Phase 1 trials": 6,
      "# Phase 2 trials": 4,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "AstraZeneca",
      "names": [
        "AstraZeneca",
        "LaNova AstraZeneca",
        "ASTRAZENECA AB",
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca",
        "Innate Pharma in collaboration with AstraZeneca",
        "Daiichi Sankyo and AstraZeneca",
        "AstraZeneca AB",
        "AstraZeneca UK Limited"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United Kingdom",
      "Founding Year": "1999",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.astrazeneca.com",
      "Acquisition": "-",
      "ttd": [
        "DP41HV",
        "DD10IZ",
        "DG80IS"
      ],
      "co-developers": [
        "ADC Therapeutics",
        "Innate",
        "Fusion Pharmaceuticals Inc",
        "Eisai",
        "DAIICHI SANKYO",
        "NSABP Foundation",
        "KYM Biosciences",
        "MedImmune",
        "NeoTX Therapeutics Ltd",
        "Keymed Biosciences",
        "Lepu Biopharma",
        "Open Innovation Partners",
        "Tanabe Research Laboratories USA",
        "Natera",
        "Merck Sharp & Dohme",
        "GILEAD",
        "Paxman Coolers Limited"
      ],
      "trials": [
        "NCT03505710",
        "NCT05744375",
        "NCT06103864",
        "NCT05687266",
        "NCT03384940",
        "NCT04538742",
        "NCT04622319",
        "NCT03529110",
        "NCT04644237",
        "NCT06058988",
        "NCT05123482",
        "NCT04739761",
        "NCT04644068",
        "EUCTR2018-000764-29-GB",
        "NCT05246514",
        "NCT03334617",
        "EUCTR2020-001574-29-PL",
        "NCT05480384",
        "NCT04556773",
        "NCT05795101",
        "EUCTR2021-005223-21-IT",
        "NCT06219941",
        "NCT04744831",
        "NCT06174987",
        "NCT05489211",
        "NCT03329690",
        "NCT05704829",
        "NCT05417594",
        "NCT03983954",
        "EUCTR2020-005620-12-ES",
        "NCT05965479",
        "NCT06106945",
        "NCT05113251",
        "NCT05647122",
        "EUCTR2019-004531-22-PL",
        "NCT03368196",
        "NCT06467357",
        "NCT06147037",
        "EUCTR2022-002680-30-DE",
        "NCT03742102",
        "NCT04989816",
        "NCT05104866",
        "NCT03734029",
        "NCT05950945",
        "PER-062-22",
        "NCT04042701",
        "NCT04014075",
        "NCT04784715",
        "NCT06112379",
        "NCT04379596",
        "NCT04986579",
        "NCT05797168",
        "NCT04639219",
        "NCT03383692",
        "NCT04482309",
        "NCT03248492",
        "NCT03366428",
        "NCT05374512",
        "EUCTR2022-000776-19-PL",
        "NCT05629585",
        "NCT06429761",
        "NCT04494425",
        "NCT04686305",
        "EUCTR2019-004531-22-FR",
        "NCT03523585",
        "NCT05048797",
        "EUCTR2018-000764-29-PL",
        "NCT04704934",
        "NCT00198380",
        "NCT06271837",
        "NCT05982678",
        "NCT02564900",
        "EUCTR2020-001574-29-BE",
        "NCT05702229",
        "NCT05460273",
        "NCT05765851"
      ],
      "drugs": [
        "CMG901",
        "LM-305",
        "MEDI2228",
        "AZD9592",
        "MEDI 4276 | MEDI-4276 | MEDI4276",
        "DS-8201 | DS-8201a | Trastuzumab deruxtecan | ENHERTU\u00ae",
        "TROP2 ADC | Datopotamab deruxtecan | DS-1062 DS1062 DS-1062A Anti-TRP2/dxd | DS-1062",
        "IPH43",
        "AZD8205",
        "MEDI3726 | ADCT-401 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
        "TR1801-ADC | TR1801-ADC MT-8633 | MT-8633",
        "lintuzumab satetraxetan | 225Ac | Actinium"
      ],
      "# co-developers": 17,
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "Moldova, Republic of",
        "North Macedonia",
        "Turkiye",
        "China",
        "Bosnia and Herzegovina",
        "Republic of Moldova",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "North America",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "United States of America",
        "Ukraine",
        "Portugal",
        "United Kindgdom",
        "Philippines",
        "Korea South",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Hungaria",
        "Switzerland",
        "Europe",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Republic of Korea",
        "Australia",
        "Serbia",
        "Belgium",
        "Spain",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 12,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 6,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 76,
      "# Phase 1 trials": 11,
      "# Phase 2 trials": 34,
      "# Phase 3 trials": 29,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Bayer",
      "names": [
        "Bayer HealthCare Pharmaceuticals",
        "Bayer HealthCare",
        "Bayer Pharmaceuticals Whippany, NJ",
        "Bayer AG",
        "Bayer",
        "Bayer HealthCare Pharmaceuticals in association with ImmunoGen Inc",
        "Bayer HealthCare Pharmaceuticals in association with  ImmunoGen Inc"
      ],
      "HQ City": "Leverkusen",
      "HQ Country": "Germany",
      "Founding Year": "1863",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.bayer.com",
      "Acquisition": "-",
      "ttd": [
        "D0CN9D"
      ],
      "co-developers": [
        "IMMUNOGEN",
        "MorphoSys AG"
      ],
      "trials": [
        "NCT02751918",
        "NCT03724747",
        "NCT03023722",
        "NCT02639091",
        "NCT02696642",
        "NCT02610140",
        "NCT02485119",
        "NCT03102320",
        "NCT02824042",
        "NCT01439152",
        "NCT04147819",
        "NCT02581878"
      ],
      "drugs": [
        "BAY 1129980 | BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer | LYPD3 protein-directed - s - Bayer | Lupartumab amadotin",
        "BAY 1187982 | BAY 1187982 BAY1187982 FGFR2-ADC | Aprutumab ixadotin",
        "PSMA-TTC PSMA targeted thorium-227 | PSMA-TTC | BAY-2315497 | Pelgifatamab Corixetan",
        "BAY 2635190 | Trastuzumab Corixetan | BAY-2635190 | BAY2635190",
        "Anetumab Ravtansine | BAY 94-9343",
        "BAY 79-4620 | 3ee9 | BAY 794620 | BAY79-4620"
      ],
      "# co-developers": 2,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "Moldova, Republic of",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 73,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 12,
      "# Phase 1 trials": 10,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BeiGene",
      "names": [
        "BeiGene",
        "Zymeworks In collaboration with BeiGene"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.beigene.com",
      "Acquisition": "-",
      "trials": [
        "NCT05316246",
        "NCT05957757",
        "NCT05350917",
        "NCT06233942",
        "NCT06422520"
      ],
      "co-developers": [
        "Jiangsu HengRui Medicine",
        "Takeda",
        "RemeGen",
        "Zymeworks"
      ],
      "drugs": [
        "BGB-C354",
        "BG-C9074",
        "ZW49 HER2 x HER2 Bispecific | ZW49 | Zanidatamab Zovodotin"
      ],
      "# co-developers": 4,
      "locations": [
        "Australia",
        "Canada",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BiOneCure Therapeutics Inc",
      "names": [
        "BiOneCure Therapeutics Inc"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05320588"
      ],
      "co-developers": [],
      "drugs": [
        "BIO-106"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bicycle Therapeutics",
      "names": [
        "Bicycle Therapeutics"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United Kingdom",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC Platform Technology Technology",
      "Website URL": "https://bicycletherapeutics.com/",
      "Acquisition": "-",
      "drugs": [
        "BT1718 | BT-1718 | BT 1718"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bio thera Solutions",
      "names": [
        "Bio-Thera Solutions, Ltd",
        "Bio-Thera Solutions (Guangzhou, China)",
        "Bio-Thera Solutions",
        "Bio thera Solutions"
      ],
      "HQ City": "Guangzhou",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.biother\u0430\u0441olutions.com",
      "Acquisition": "-",
      "trials": [
        "NCT05405621"
      ],
      "co-developers": [],
      "drugs": [
        "BAT8006",
        "BAT8009 for Injection | BAT8009",
        "BAT8001",
        "BAT8007",
        "BAT8003"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioAtla",
      "names": [
        "BioAtlaSan Diego, CA",
        "BioAtla San Diego, CA",
        "BioAtla in collaboration with Sinobioway Biomedicine",
        "BioAlta",
        "BioAtla",
        "BioAtla, Inc"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2007",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.bioatla.com",
      "Acquisition": "-",
      "ttd": [
        "D00OON",
        "D08RWO",
        "D82BZH",
        "DYI4L2"
      ],
      "co-developers": [
        "Sinobioway Biomedicine"
      ],
      "trials": [
        "NCT03504488",
        "NCT03425279",
        "NCT04681131",
        "NCT05271604"
      ],
      "drugs": [
        "Anti-ROR2 ADC | BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC | BA3021 | Ozuriftamab Vedotin | CAB-ROR2-ADC",
        "CAB-Axl-ADC | CAB-anti-Axl-ADC | Mecbotamab Vedotin | CAB-anti-Axl-ADC BA3011 | BA3011"
      ],
      "# co-developers": 1,
      "locations": [
        "Italy",
        "Hong Kong",
        "Germany",
        "Poland",
        "Spain",
        "Greece",
        "Taiwan",
        "United States"
      ],
      "# locations": 8,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 4,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioNTech",
      "names": [
        "BioNTech SE",
        "BioNTech"
      ],
      "HQ City": "Mainz",
      "HQ Country": "Germany",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://biontech.de",
      "Acquisition": "-",
      "trials": [
        "NCT06340568"
      ],
      "co-developers": [
        "Duality Biologics"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioRay",
      "names": [
        "BioRay",
        "BioRay Pharmaceutical Co"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "BRY812"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "BioTest",
      "names": [
        "BioTest",
        "Biotest Pharmaceuticals Corporation",
        "Biotest"
      ],
      "HQ City": "Dreieich",
      "HQ Country": "Germany",
      "Founding Year": "-",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.biotest.com",
      "Acquisition": "-",
      "trials": [
        "NCT01001442",
        "NCT01638936"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "drugs": [
        "1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal | BT-062 | Oxobuthyldithio | Indatuximab Ravtansine | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biocytogen",
      "names": [
        "Biocytogen"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "2009",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.biocytogen.com",
      "Acquisition": "-",
      "ttd": [
        "D5R8YF",
        "DKHL40",
        "D0AM9O"
      ],
      "co-developers": [
        "RemeGen",
        "MabPlex"
      ],
      "drugs": [
        "YH013",
        "RC118",
        "YH012"
      ],
      "# co-developers": 2,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biogen",
      "names": [
        "Biogen Schering AG  Spectrum Pharmaceuticals",
        "Biogen"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1978",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.biogen.com",
      "Acquisition": "-",
      "trials": [
        "NCT00674947"
      ],
      "co-developers": [
        "Schering"
      ],
      "drugs": [
        "Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin",
        "BIIB015 | BIIB-015"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 1,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biohaven",
      "names": [
        "Biohaven Therapeutics Ltd",
        "Biohaven"
      ],
      "HQ City": "New Haven",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.biohavenpharma.com",
      "Acquisition": "Acquired by Pfizer in 2022",
      "trials": [
        "NCT06384807"
      ],
      "co-developers": [],
      "drugs": [
        "BHV-1500",
        "PBI-410",
        "BHV-1510"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Biosion (China)",
      "names": [
        "Biosion (China)",
        "OBI Pharma (ex-China) and  Biosion (China)"
      ],
      "HQ City": "Nanjing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.biosion.com",
      "Acquisition": "-",
      "drugs": [
        "OBI-992 | BSI-992"
      ],
      "co-developers": [
        "OBI Pharma"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bliss (Hangzhou)",
      "names": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd",
        "Bliss (Hangzhou)",
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China) in collaboration with Eisai & Co, Ltd",
        "Bliss Biopharmaceutical"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "ttd": [
        "D56ECJ"
      ],
      "co-developers": [
        "Eisai"
      ],
      "trials": [
        "NCT05217693",
        "NCT06241898",
        "NCT06188559"
      ],
      "drugs": [
        "BB-1701 | HER2-Targeting ADC",
        "BB-1705",
        "BB-1709"
      ],
      "# co-developers": 1,
      "locations": [
        "China",
        "Japan",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Boehringer Ingelheim",
      "names": [
        "Boehringer Ingelheim"
      ],
      "HQ City": "Ingelheim am Rhein",
      "HQ Country": "Germany",
      "Founding Year": "1885",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer, ADC Platform Technology",
      "Website URL": "https://www.boehringer-ingelheim.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02254005",
        "NCT02254018",
        "NCT06324357"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "drugs": [
        "Anti-CD44v6 | Anti-CD44v6-DM1 | Bivatuzumab mertansine | BIWI-1 | CD44v6-DM1"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bolt",
      "names": [
        "Bolt",
        "Bolt Biotherapeutics",
        "Bolt Biotherapeutics, Inc"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.boltbio.com/",
      "Acquisition": "-",
      "ttd": [
        "D1XI9E"
      ],
      "co-developers": [
        "Bristol Myers Squibb",
        "Roche"
      ],
      "trials": [
        "NCT05954143",
        "NCT04278144"
      ],
      "drugs": [
        "BDC-1001"
      ],
      "# co-developers": 2,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Bristol Myers Squibb",
      "names": [
        "Bristol Myers Squibb In collaboration with CytomX",
        "BMS",
        "Seattle Genetics (Licensed from  Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "Bristol Myers Squibb  In collaboration with CytomX",
        "Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "Bristol-Myers Squibb",
        "Bristol-Myers Squibb Princeton, NJ",
        "Bristol-Myers Squibb (Celgene) Sutro Biopharma",
        "Bristol Myers Squibb",
        "Bristol-Myers Squibb (BMS)"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1887",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.bms.com",
      "Acquisition": "-",
      "ttd": [
        "DH5BX2",
        "D0YP8F"
      ],
      "co-developers": [
        "Celgene",
        "Eisai",
        "CytomX",
        "Sutro Biopharma",
        "Seagen",
        "Bolt",
        "GILEAD",
        "Medarex"
      ],
      "trials": [
        "NCT05613088",
        "NCT01716806",
        "NCT04863885",
        "NCT02927769",
        "NCT02572167",
        "NCT04300556",
        "NCT02884726",
        "NCT05577715",
        "NCT02341625",
        "NCT02581631",
        "NCT04278144",
        "NCT00944905",
        "NCT03646123"
      ],
      "drugs": [
        "Glypican3-ADC",
        "BMS986288 | BMS-986288 BMS986288 | BMS-986288",
        "CC-99712 \u2013 Anti-BCMA ADC | CC-99712",
        "BMS-986148 | BMS986148",
        "BR96-DOX | SGN-15 | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248",
        "iratumumab | MDX-060"
      ],
      "# co-developers": 8,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# locations": 54,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 13,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 11,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Byondis",
      "names": [
        "Byondis",
        "Byondis B.V"
      ],
      "HQ City": "Nijmegen",
      "HQ Country": "Netherlands",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.byondis.com",
      "Acquisition": "-",
      "ttd": [
        "DI0ED3"
      ],
      "co-developers": [
        "Synthon Pharmaceuticals Durham, NC"
      ],
      "trials": [
        "NCT05323045",
        "NCT02277717",
        "NCT06359002",
        "NCT03262935",
        "NCT04202705",
        "NCT04205630",
        "NCT04235101"
      ],
      "drugs": [
        "BYON4413 ADC | BYON4413 BYON4413 ADC",
        "Anti 5T4 ADC SYD1875 | SYD1875",
        "BYON3521 | BYON3521 ADC",
        "SYD985 | Trastuzumab vc-seco-DUBA | Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole | Trastuzumab duocarmazine | SYD 985"
      ],
      "# co-developers": 1,
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Dominican Republic",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Norway",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 58,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 7,
      "# Phase 1 trials": 5,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CSPC Pharmaceutical Group",
      "names": [
        "CSPC Megalith Biopharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group Limited",
        "CSPC ZhongQi Pharmaceutical Technology Co., Ltd",
        "CSPC ZhongQi Pharmaceutical Technology Co",
        "CSPC Pharmaceutical Group",
        "CSPC ZhongQi Pharmaceutical",
        "CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd"
      ],
      "HQ City": "Shijiazhuang",
      "HQ Country": "China",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.cspc.com.cn",
      "Acquisition": "-",
      "trials": [
        "NCT06265727",
        "NCT06313086",
        "NCT04146610"
      ],
      "co-developers": [
        "Elevation Oncology",
        "Corbus"
      ],
      "drugs": [
        "CPO301",
        "EO-3021 also known as SYSA1801",
        "DP303c"
      ],
      "# co-developers": 2,
      "locations": [
        "China",
        "Canada",
        "Japan",
        "United States"
      ],
      "# locations": 4,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CStone Pharmaceuticals",
      "names": [
        "CStone Pharmaceuticals"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.cstonepharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05279300"
      ],
      "co-developers": [],
      "drugs": [
        "CS5001"
      ],
      "# co-developers": 0,
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cambridge Antibody Technology",
      "names": [
        "Cambridge Antibody Technology"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United Kingdom",
      "Founding Year": "1989",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by AstraZeneca in 2006",
      "trials": [
        "NCT00586924"
      ],
      "co-developers": [
        "MedImmune"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Caris Life Sciences",
      "names": [
        "Caris Life Sciences"
      ],
      "HQ City": "Irving",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.carislifesciences.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Catalent",
      "names": [
        "Catalent Pharma Solutions and Triphase Accelerator Corporation",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience",
        "Catalent"
      ],
      "HQ City": "Somerset",
      "HQ Country": "United States",
      "Founding Year": "2007",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://www.catalent.com/",
      "Acquisition": "-",
      "drugs": [
        "CD22-4AP"
      ],
      "co-developers": [
        "Triphase Accelerator Corporation"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Celgene",
      "names": [
        "Celgene",
        "Celgene in collaboration with Sutro",
        "Celgene Corporation",
        "Bristol-Myers Squibb (Celgene) Sutro Biopharma"
      ],
      "HQ City": "Summit",
      "HQ Country": "United States",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.celgene.com/",
      "Acquisition": "Acquired by Bristol-Myers Squibb in 2019",
      "trials": [
        "NCT04884035",
        "NCT02073487",
        "NCT02616965",
        "NCT02086604",
        "NCT04036461",
        "NCT00766116"
      ],
      "co-developers": [
        "Novartis",
        "Sutro Biopharma",
        "Bristol Myers Squibb",
        "Seagen",
        "Pfizer"
      ],
      "drugs": [
        "CC-99712 \u2013 Anti-BCMA ADC | CC-99712"
      ],
      "# co-developers": 5,
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "France",
        "United States"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Celldex",
      "names": [
        "Celldex Therapeutics",
        "Celldex Therapeutics, Inc",
        "Celldex"
      ],
      "HQ City": "Hampton",
      "HQ Country": "United States",
      "Founding Year": "1983",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.celldex.com",
      "Acquisition": "-",
      "trials": [
        "NCT01997333",
        "NCT01156753"
      ],
      "co-developers": [],
      "drugs": [
        "CDX014 | CR014-vcMMAE | CR 014-vcMMAE | CDX-014",
        "CR011 CR011-vcMMAE | Glembatumumab vedotin | CDX-011"
      ],
      "# co-developers": 0,
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "# locations": 9,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cellerant Therapeutics",
      "names": [
        "Cellerant Therapeutics"
      ],
      "HQ City": "San Carlos",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.cellerant.com/",
      "Acquisition": "-",
      "ttd": [
        "DW01LJ"
      ],
      "co-developers": [],
      "drugs": [
        "CLT030"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Celltech",
      "names": [
        "Celltech"
      ],
      "HQ City": "Slough",
      "HQ Country": "United Kingdom",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "-",
      "Acquisition": "Acquired by UCB in 2004",
      "drugs": [
        "CDP-671 | CMB-401 | hCTMO1-calicheamicin | hCTMO1-calicheamicin CDP-671"
      ],
      "co-developers": [
        "Pfizer",
        "WYETH"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Centrose",
      "names": [
        "Centrose",
        "Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)"
      ],
      "HQ City": "Madison",
      "HQ Country": "United States",
      "Founding Year": "2004",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.centrose.com",
      "Acquisition": "-",
      "drugs": [
        "DYS-ADC | EDC-1 | DYS-EDC | EDC1",
        "EDC9 | EDC-CD20"
      ],
      "co-developers": [
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Chiatai Tianqing",
      "names": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd",
        "Chiatai Tianqing",
        "Chia Tai Tianqing Pharmaceutical Group Co., Ltd"
      ],
      "HQ City": "Nanjing",
      "HQ Country": "China",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.ctgpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06431490",
        "NCT05735496",
        "NCT05867563",
        "NCT06115902",
        "NCT06198751",
        "NCT06452706"
      ],
      "co-developers": [],
      "drugs": [
        "TQB2102 | TQB2102 for injection | TQB2102 injection"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Chiron Pharma",
      "names": [
        "Chiron Pharma"
      ],
      "HQ City": "Emeryville",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Novartis in 2006",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Chugai",
      "names": [
        "Chugai",
        "Chugai Pharmaceutical"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "1925",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.chugai-pharm.co.jp",
      "Acquisition": "-",
      "trials": [
        "NCT00860639",
        "NCT03726879"
      ],
      "co-developers": [
        "Roche"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Clovis Oncology",
      "names": [
        "Clovis Oncology",
        "Clovis Oncology, Inc"
      ],
      "HQ City": "Boulder",
      "HQ Country": "United States",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.clovisoncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT03552471"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Coherent Biopharma",
      "names": [
        "Coherent Biopharma"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Concortis",
      "names": [
        "Concortis Biotherapeutics (a subsidiary of Sorrento Therapeutics)",
        "Concortis Biotherapeutics",
        "Concortis"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Platform Technology",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ZV203",
        "c-MET ADC",
        "ZV05-mcMMAF | ZV05-ADC | ZV0501 | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501"
      ],
      "co-developers": [
        "Zova Biotherapeutics"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Conjugate Light (Australia) Pty Ltd",
      "names": [
        "Conjugate Light (Australia) Pty Ltd"
      ],
      "HQ City": "Melbourne",
      "HQ Country": "Australia",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "ACTRN12620000592943"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Conjupro Biotherapeutics",
      "names": [
        "Conjupro Biotherapeutics, Inc",
        "Conjupro Biotherapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05948865"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Corbus",
      "names": [
        "Corbus Pharmaceuticals CSPC Megalith Biopharmaceutical, a subsidiary of CSPC Pharmaceutical Group",
        "Corbus Pharmaceuticals Inc",
        "Corbus"
      ],
      "HQ City": "Norwood",
      "HQ Country": "United States",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.corbuspharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06265727"
      ],
      "co-developers": [
        "CSPC Pharmaceutical Group"
      ],
      "drugs": [
        "SYS6002 | CRB-701"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "United States",
        "United Kingdom",
        "Turkey"
      ],
      "# locations": 4,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CuraGen Corporation",
      "names": [
        "CuraGen Corporation"
      ],
      "HQ City": "Branford",
      "HQ Country": "United States",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Celldex Therapeutics in 2009",
      "trials": [
        "NCT00704158",
        "NCT00412828"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CureMeta",
      "names": [
        "CureMeta"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.curemeta.com/",
      "Acquisition": "-",
      "drugs": [
        "Bstrongximab-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cytogen",
      "names": [
        "Cytogen"
      ],
      "HQ City": "Princeton",
      "HQ Country": "United States",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by EUSA Pharma in 2008",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Cytoguide ApS",
      "names": [
        "Cytoguide ApS"
      ],
      "HQ City": "Copenhagen",
      "HQ Country": "Denmark",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.cytoguide.com/",
      "Acquisition": "-",
      "ttd": [
        "D0J5EQ"
      ],
      "co-developers": [],
      "drugs": [
        "Maclizumab"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "CytomX",
      "names": [
        "Bristol Myers Squibb In collaboration with CytomX",
        "CytomX Therapeutics South San Francisco, CA",
        "Bristol Myers Squibb  In collaboration with CytomX",
        "CytomX Therapeutics",
        "CytomX and AbbVie",
        "CytomX",
        "CytomX Therapeutics ImmunoGen (Originator)"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.cytomx.com",
      "Acquisition": "-",
      "ttd": [
        "DZ1F3N",
        "D58AMF"
      ],
      "co-developers": [
        "IMMUNOGEN",
        "Bristol Myers Squibb",
        "AbbVie"
      ],
      "trials": [
        "NCT03543813"
      ],
      "drugs": [
        "CX2029",
        "BMS986288 | BMS-986288 BMS986288 | BMS-986288",
        "ABBV-CX-2029",
        "CD166 AADC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CX-2009 | CD166 PDC",
        "CX-2029"
      ],
      "# co-developers": 3,
      "locations": [
        "Spain",
        "Korea, Republic of",
        "United Kingdom",
        "United States"
      ],
      "# locations": 4,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 5,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "DAIICHI SANKYO",
      "names": [
        "Daiichi Sankyo The antibody part is developed in collaboration with Amgen",
        "DAIICHI SANKYO",
        "DAIICHI SANKYO Co.,Ltd",
        "Daiichi Sankyo Inc",
        "Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company",
        "Daiichi Sankyo Basking Ridge, NJ",
        "Daiichi Sankyo  The antibody part is developed in collaboration with Amgen",
        "Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd.)",
        "Daiichi Sankyo Company, Limited",
        "Daiichi Sankyo Co., Ltd",
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo",
        "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company",
        "Daiichi Sankyo",
        "Daiichi Sankyo, Inc",
        "Daiichi Sankyo Company",
        "Daiichi Sankyo and AstraZeneca"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2005",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.daiichisankyo.com",
      "Acquisition": "-",
      "ttd": [
        "D06BHB",
        "DISJ28",
        "DJ4X7D",
        "DT8R1L",
        "DX5A8D"
      ],
      "co-developers": [
        "Translational Research in Oncology",
        "AstraZeneca",
        "Amgen",
        "Eisai",
        "NSABP Foundation",
        "UNICANCER",
        "Merck Sharp & Dohme",
        "MedSIR",
        "GILEAD",
        "Paxman Coolers Limited"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf"
      ],
      "trials": [
        "NCT03505710",
        "NCT06103864",
        "NCT03384940",
        "NCT04622319",
        "NCT04538742",
        "EUCTR2018-000221-31-BE",
        "NCT03529110",
        "NCT04644237",
        "NCT04739761",
        "NCT06176261",
        "NCT04553770",
        "NCT05246514",
        "EUCTR2020-003427-42-NL",
        "NCT04132960",
        "NCT04556773",
        "NCT05795101",
        "NCT04420598",
        "NCT06161025",
        "NCT04484142",
        "NCT06174987",
        "NCT04744831",
        "NCT03329690",
        "NCT04940325",
        "NCT05489211",
        "NCT05113251",
        "NCT05034887",
        "NCT03368196",
        "NCT06467357",
        "NCT04989816",
        "NCT05104866",
        "NCT03734029",
        "NCT05950945",
        "NCT04752059",
        "NCT04042701",
        "NCT04014075",
        "NCT06362252",
        "NCT02980341",
        "NCT06112379",
        "NCT06203210",
        "NCT04784715",
        "NCT04379596",
        "EUCTR2020-003427-42-FR",
        "EUCTR2018-000221-31-CZ",
        "EUCTR2019-001512-34-BE",
        "NCT04986579",
        "NCT05633979",
        "NCT05865990",
        "NCT04610528",
        "NCT03383692",
        "NCT06048718",
        "NCT03248492",
        "NCT04639219",
        "NCT03366428",
        "NCT05374512",
        "NCT04482309",
        "NCT04656652",
        "NCT05629585",
        "NCT06244485",
        "NCT04494425",
        "JPRN-jRCT2080223860",
        "NCT03260491",
        "NCT05280470",
        "NCT03523585",
        "NCT04686305",
        "NCT05048797",
        "NCT04704934",
        "NCT06271837",
        "NCT05982678",
        "NCT04965766",
        "NCT02564900",
        "NCT05460273",
        "NCT05765851"
      ],
      "drugs": [
        "Ifinatamab Deruxtecan \u2013 DS-7300a | DS-7300a | MABX-9001a",
        "Raludotatug Deruxtecan  DS-6000a R-DXd | DS-6000a R-DXd | Raludotatug Deruxtecan",
        "DS-6157",
        "DS-8201 | DS-8201a | Trastuzumab deruxtecan | ENHERTU\u00ae",
        "U3-1402 U3-1402A Anti-HER3 | HER3 ADC | Patritumab Deruxtecan | U3-1402",
        "TROP2 ADC | Datopotamab deruxtecan | DS-1062 DS1062 DS-1062A Anti-TRP2/dxd | DS-1062",
        "B7-H3 ADC | DS-7300",
        "DS-9606a | DS-9606-a"
      ],
      "# co-developers": 10,
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "Turkiye",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "North America",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "United Kindgdom",
        "Portugal",
        "Philippines",
        "Korea South",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Hungaria",
        "Switzerland",
        "Europe",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 68,
      "# drugs": 8,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 4,
      "# Phase 4 drugs": 0,
      "# trials": 72,
      "# Phase 1 trials": 12,
      "# Phase 2 trials": 33,
      "# Phase 3 trials": 26,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Debiopharm",
      "names": [
        "Debiopharm",
        "ImmunoGen Debiopharm Internaltional",
        "ImmunoGen  Debiopharm Internaltional"
      ],
      "HQ City": "Lausanne",
      "HQ Country": "Switzerland",
      "Founding Year": "1980",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.debiopharm.com/",
      "Acquisition": "-",
      "drugs": [
        "Debio 1562 | IMGN529 | K7153A-SMCC-DM1 | Naratuximab emtansine | naratuximab emtansine | K7153A"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Dendreon",
      "names": [
        "Dendreon"
      ],
      "HQ City": "Seattle",
      "HQ Country": "United States",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Sanpower Group in 2017",
      "trials": [
        "NCT06100705"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Dizal",
      "names": [
        "Dizal"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.dizalpharma.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Dragonfly",
      "names": [
        "Dragonfly",
        "Dragonfly Therapeutics"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.dragonflyimmune.com",
      "Acquisition": "-",
      "trials": [
        "NCT04143711"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Duality Biologics",
      "names": [
        "Duality Biologics in collaboration with BioNTech",
        "Duality Biologics",
        "Duality Biologics in collaboration with BionTech",
        "DualityBio Inc"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.dualitybio.com",
      "Acquisition": "-",
      "trials": [
        "NCT06340568"
      ],
      "co-developers": [
        "BioNTech"
      ],
      "drugs": [
        "DB-1311",
        "DB-1303 | DB-1303 BNT323 | BNT323"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "EDDC (Experimental Drug Development Centre), A*STAR Research Entities",
      "names": [
        "EDDC (Experimental Drug Development Centre), A*STAR Research Entities"
      ],
      "HQ City": "Singapore",
      "HQ Country": "Singapore",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.a-star.edu.sg/eddc",
      "Acquisition": "-",
      "trials": [
        "NCT05701527"
      ],
      "co-developers": [],
      "drugs": [
        "EBC-129"
      ],
      "# co-developers": 0,
      "locations": [
        "Singapore",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "EMD Serono",
      "names": [
        "EMD Serono Research & Development Institute, Inc",
        "EMD Serono"
      ],
      "HQ City": "Rockland",
      "HQ Country": "United States",
      "Founding Year": "1919",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.emdserono.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05327530",
        "NCT04695847",
        "NCT05464030"
      ],
      "co-developers": [
        "GILEAD",
        "Merck KGaA, Darmstadt, Germany",
        "Nektar Therapeutics"
      ],
      "drugs": [
        "BEVACIZUMAB GAMMA",
        "M9140"
      ],
      "# co-developers": 3,
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Denmark",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 24,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Eisai",
      "names": [
        "Morphotek\u00ae, a subsidiary of Eisai Eisai Co Bristol Myers Squibb",
        "NanoCarrier Co.,Ltd (Japan) and Eisai",
        "Eisai",
        "Eisai Inc",
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China) in collaboration with Eisai & Co, Ltd",
        "Morphotek\u00c2\u00ae (a subsidiary of Eisai)"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "1941",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.eisai.com",
      "Acquisition": "-",
      "trials": [
        "NCT05613088",
        "NCT04300556",
        "NCT05577715",
        "NCT04986579",
        "NCT00882102",
        "NCT06188559"
      ],
      "co-developers": [
        "AstraZeneca",
        "DAIICHI SANKYO",
        "Bliss (Hangzhou)",
        "NanoCarrier (Japan)",
        "Bristol Myers Squibb",
        "Morphotek",
        "GILEAD",
        "Paxman Coolers Limited"
      ],
      "drugs": [
        "BB-1701 | HER2-Targeting ADC",
        "ADCM-E7974 | NC-6201",
        "MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202"
      ],
      "# co-developers": 8,
      "locations": [
        "China",
        "Sweden",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 28,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 6,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Elevation Oncology",
      "names": [
        "Elevation Oncology"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.elevationoncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT05980416"
      ],
      "co-developers": [
        "CSPC Pharmaceutical Group"
      ],
      "drugs": [
        "HER3-ADC | Elevation Oncology \u2013 Proof of Concept ADC",
        "EO-3021 also known as SYSA1801"
      ],
      "# co-developers": 1,
      "locations": [
        "Japan",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Eli Lilly",
      "names": [
        "Eli Lilly",
        "Eli Lilly and Company"
      ],
      "HQ City": "Indianapolis",
      "HQ Country": "United States",
      "Founding Year": "1876",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.lilly.com",
      "Acquisition": "-",
      "trials": [
        "NCT06400472",
        "NCT06465069",
        "NCT02529553",
        "NCT04486352",
        "NCT06238479"
      ],
      "co-developers": [
        "Alliance Foundation Trials",
        "Loxo Oncology",
        "Pfizer",
        "Genentech"
      ],
      "drugs": [
        "LY3076226 | ADC LY3076226 | Anti-fibroblast Growth Factor Receptor 3 | Anti-FGFR3 ADC LY3076226",
        "LY4101174",
        "LY4052031",
        "LY4170156"
      ],
      "# co-developers": 4,
      "locations": [
        "Japan",
        "Canada",
        "Australia",
        "United States"
      ],
      "# locations": 4,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Emergence",
      "names": [
        "Emergence",
        "Emergence Therapeutics"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.emergencebio.com/",
      "Acquisition": "-",
      "drugs": [
        "ETx-22"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Endocyte",
      "names": [
        "Endocyte, Merck",
        "Endocyte (now part of Novartis) Advanced Accelerator Applications",
        "Endocyte"
      ],
      "HQ City": "West Lafayette",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Novartis in 2018",
      "drugs": [
        "EC1169",
        "MK8109 | Vintafolide | VYNFINIT\u00ae | EC145/MK 8109 | MK 8109 | EC145",
        "EC2629",
        "177lu | Lilotomab satetraxetan | lutetium | lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1"
      ],
      "co-developers": [
        "Novartis",
        "Nordic Nanovector",
        "Merck Sharp & Dohme"
      ],
      "# co-developers": 3,
      "locations": [
        "Australia"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 1,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Enliven",
      "names": [
        "Enliven Therapeutics",
        "Enliven"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05650879"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Enzon",
      "names": [
        "Enzon",
        "Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)"
      ],
      "HQ City": "Piscataway",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology technology",
      "Website URL": "-",
      "Acquisition": "Divested its specialty pharmaceutical business in 2012",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Esperance",
      "names": [
        "Esperance Pharmaceuticals",
        "Esperance"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.esperancepharma.com/",
      "Acquisition": "-",
      "drugs": [
        "EP-400"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "EuPAL",
      "names": [
        "EuPAL"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05183035"
      ],
      "co-developers": [
        "Genentech",
        "AbbVie",
        "Roche"
      ],
      "drugs": [],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Exelixis",
      "names": [
        "Exelixis"
      ],
      "HQ City": "Alameda",
      "HQ Country": "United States",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.exelixis.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04878029",
        "NCT04925284"
      ],
      "co-developers": [
        "Iconic",
        "Zymeworks"
      ],
      "drugs": [
        "XB002 ICON-2 Tissue Factor ADC | ICON-2 Tissue Factor ADC  XB002"
      ],
      "# co-developers": 2,
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "# locations": 9,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Formation Biologics (Forbius)",
      "names": [
        "Formation Biologics",
        "Formation Biologics (Forbius)",
        "Forbius"
      ],
      "HQ City": "Toronto",
      "HQ Country": "Canada",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.forbius.com",
      "Acquisition": "-",
      "drugs": [
        "AVID100 | AVID 100 anti-EGFR ADC",
        "AVID300 | AVID 300"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Fortis Therapeutics",
      "names": [
        "Fortis Therapeutics, Inc",
        "Fortis Therapeutics"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://fortistx.com/",
      "Acquisition": "-",
      "ttd": [
        "D48ZBO"
      ],
      "co-developers": [],
      "trials": [
        "NCT03575819",
        "NCT05011188",
        "NCT03650491"
      ],
      "drugs": [
        "FOR46"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Fudan-Zhangjiang",
      "names": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd",
        "Fudan-Zhangjiang",
        "Fudan-Zhangjiang Bio-Pharmaceutica"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "-",
      "Acquisition": "Need clarification on company name",
      "trials": [
        "NCT03894150",
        "NCT06413615",
        "NCT05564858",
        "NCT05174637",
        "NCT05914545"
      ],
      "co-developers": [],
      "drugs": [
        "FDA018-ADC",
        "FDA022 Monoclonal -  for injection Phase Ib | FDA022 | FDA022 Monoclonal -  for injection Phase Ia",
        "FZ-AD004",
        "F0002-ADC | CD30-MCC-DM1 | F0002-ADC CD30-MCC-DM1"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Fusion Pharmaceuticals Inc",
      "names": [
        "Fusion Pharmaceuticals Inc"
      ],
      "HQ City": "Hamilton",
      "HQ Country": "Canada",
      "Founding Year": "2014",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://fusionpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06147037"
      ],
      "co-developers": [
        "AstraZeneca"
      ],
      "drugs": [
        "lintuzumab satetraxetan | 225Ac | Actinium"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "G1 Therapeutics",
      "names": [
        "G1 Therapeutics, Inc",
        "G1 Therapeutics"
      ],
      "HQ City": "Research Triangle Park",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.g1therapeutics.com",
      "Acquisition": "-",
      "trials": [
        "NCT05113966"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GILEAD",
      "names": [
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics",
        "Kite, A Gilead Company",
        "Gilead Sciences",
        "Gilead Sciences (previously Immunomedics)",
        "Gilead Sciences, Inc.",
        "Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas",
        "GILEAD",
        "Gilead"
      ],
      "HQ City": "Foster City",
      "HQ Country": "United States",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.gilead.com",
      "Acquisition": "-",
      "ttd": [
        "D8LAE2"
      ],
      "co-developers": [
        "Novartis",
        "Alliance Foundation Trials",
        "UNICANCER",
        "Varian Inc",
        "EMD Serono",
        "MFAR",
        "Merck KGaA, Darmstadt, Germany",
        "Arcus",
        "Nektar Therapeutics",
        "Eisai",
        "NSABP Foundation",
        "Roche",
        "Array BioPharma",
        "Seagen",
        "Merck Sharp & Dohme",
        "MedSIR",
        "Pfizer",
        "Paxman Coolers Limited",
        "AstraZeneca",
        "DAIICHI SANKYO",
        "GOG Foundation",
        "Bristol Myers Squibb",
        "Immunomedics",
        "Strata Oncology",
        "Astellas"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf"
      ],
      "trials": [
        "NCT05101096",
        "NCT05089734",
        "NCT01270698",
        "NCT05633667",
        "NCT04639986",
        "NCT05382286",
        "NCT06486441",
        "NCT05097599",
        "NCT06028932",
        "NCT06248515",
        "NCT04454437",
        "NCT01826877",
        "NCT05675579",
        "NCT06100874",
        "NCT04448886",
        "NCT05382299",
        "NCT06235216",
        "NCT05520723",
        "NCT05581589",
        "NCT04863885",
        "NCT05186974",
        "NCT06081244",
        "NCT04468061",
        "NCT05633654",
        "NCT03971409",
        "NCT05884320",
        "NCT06065371",
        "NCT04527991",
        "NCT01631552",
        "NCT06123468",
        "NCT04230109",
        "NCT05838521",
        "NCT04595565",
        "NCT06167317",
        "NCT05119907",
        "NCT03725761",
        "NCT06238921",
        "NCT05552001",
        "NCT03964727",
        "NCT03901339",
        "NCT03995706",
        "NCT06329869",
        "NCT03869190",
        "NCT04251416",
        "NCT05327530",
        "NCT04617522",
        "NCT04381832",
        "NCT04986579",
        "NCT03547973",
        "NCT02574455",
        "NCT04724018",
        "NCT06477419",
        "NCT03424005",
        "NCT05006794",
        "NCT06401824",
        "NCT05609968",
        "NCT05840211",
        "NCT04647916",
        "NCT04958785",
        "NCT05143229",
        "NCT05833867",
        "NCT06263543"
      ],
      "drugs": [
        "IMMU-132 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38 | hRS7-SN38 | Trodelvy | hRS7-SN-38-ADC"
      ],
      "# co-developers": 25,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Georgia",
        "Argentina",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Estonia"
      ],
      "# locations": 46,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 62,
      "# Phase 1 trials": 10,
      "# Phase 2 trials": 39,
      "# Phase 3 trials": 13,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GOG Foundation",
      "names": [
        "GOG Foundation"
      ],
      "HQ City": "Philadelphia",
      "HQ Country": "United States",
      "Founding Year": "1970",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://gog.org/",
      "Acquisition": "-",
      "trials": [
        "NCT06132958",
        "NCT06486441",
        "NCT05445778",
        "NCT05870748",
        "NCT04931342",
        "NCT03786081"
      ],
      "co-developers": [
        "Genmab",
        "IMMUNOGEN",
        "Roche",
        "Sutro Biopharma",
        "Seagen",
        "Merck Sharp & Dohme",
        "GILEAD"
      ],
      "drugs": [
        "SP-8166 | SP8166 | LUVELTAMAB TAZIDE",
        "SACITUZUMAB TIRUMOTECAN"
      ],
      "# co-developers": 7,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# locations": 54,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 4,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GWT-TUD GmbH",
      "names": [
        "GWT-TUD GmbH"
      ],
      "HQ City": "Dresden",
      "HQ Country": "Germany",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.gwt-tud.de",
      "Acquisition": "-",
      "trials": [
        "NCT04833114"
      ],
      "co-developers": [
        "Roche"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GamaMabs",
      "names": [
        "GamaMabs"
      ],
      "HQ City": "Toulouse",
      "HQ Country": "France",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.gamamabs.com/",
      "Acquisition": "-",
      "drugs": [
        "GM103"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Ganymed",
      "names": [
        "Ganymed",
        "Ganymed Pharmaceuticals",
        "Astellas (Ganymed Pharmaceuticals)"
      ],
      "HQ City": "Mainz",
      "HQ Country": "Germany",
      "Founding Year": "2001",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Astellas Pharma in 2016",
      "drugs": [
        "IMAB362-vcMMAE",
        "IMAB027-vcMMAE"
      ],
      "co-developers": [
        "Astellas"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GeneQuantum (Suzhou, China)",
      "names": [
        "GeneQuantum (Suzhou, China)",
        "GeneQuantum Healthcare (Suzhou) Co., Ltd",
        "Pyramid Biosciences GeneQuantum Healthcare (Suzhou) Co",
        "GeneQuantum Healthcare (Suzhou, China)",
        "GeneQuantum Healthcare"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.genequantum.com",
      "Acquisition": "-",
      "ttd": [
        "DSOE74"
      ],
      "co-developers": [
        "Pyramid Biosciences"
      ],
      "trials": [
        "NCT06464055",
        "NCT06154343",
        "NCT05575804",
        "NCT04450732"
      ],
      "drugs": [
        "GQ1017",
        "GC1007",
        "GQ1014",
        "GC1009",
        "GQ1010",
        "GQ1018",
        "GQ1015",
        "GQ1001 | GQ1001 \u2013 HER2",
        "GQ1003 \u2013 TROP2",
        "GQ1005 \u2013 HER2"
      ],
      "# co-developers": 1,
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 10,
      "# Preclinical drugs": 4,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genentech",
      "names": [
        "Genentech and Nerviano Medical Sciences",
        "Roche-Genentech",
        "Genentech, Inc",
        "Genentech F. Hoffmann-La Roche",
        "Genentech",
        "Genentech Roche In collaboration with ImmunoGen",
        "Genentech Roche  In collaboration with ImmunoGen",
        "Genentech Inc. (South San Francisco, CA, USA)",
        "Genentech Inc",
        "GenentechSouth San Francisco, CA"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "1976",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.gene.com",
      "Acquisition": "Acquired by Roche in 2009",
      "ttd": [
        "D0P4TH",
        "D0UG0K",
        "D05YYP",
        "D0M7EP",
        "D1A5GK"
      ],
      "co-developers": [
        "AbbVie",
        "Alliance Foundation Trials",
        "Istari Oncology",
        "Roche",
        "Eli Lilly",
        "Seagen",
        "EuPAL",
        "Pfizer"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf"
      ],
      "trials": [
        "NCT06043674",
        "NCT01209130",
        "NCT05260957",
        "NCT02390427",
        "NCT00932373",
        "NCT05673928",
        "NCT01992653",
        "NCT04486352",
        "NCT04434040",
        "NCT00943670",
        "NCT05800366",
        "NCT05498220",
        "NCT05633615",
        "NCT00928330",
        "NCT00679211",
        "NCT04632992",
        "NCT00509769",
        "NCT01290549",
        "NCT04893109",
        "NCT00781612",
        "NCT01120184",
        "NCT05410418",
        "NCT00951665",
        "NCT04160494",
        "NCT05169658",
        "NCT04679012",
        "NCT05183035",
        "NCT01691898",
        "NCT02675829",
        "NCT04594798",
        "NCT01904903",
        "NCT01335958"
      ],
      "drugs": [
        "DNIB0600A | Lifastuzumab Vedotin | MNIB2126A  Anti-NaPi2b ADC RG-7599 | RG-7599",
        "anti-CD22 Anthracycline-Based | Anti-CD22-NMS249 | anti-CD22-NMS249 | Anti-CD22 Anthracycline-Based ADC",
        "CD79-targeted immunotoxins",
        "DSTA-4637S",
        "DSTA4637S | RG7861 | Anti-S. aureus TAC",
        "RO5541072-000 | DCDT2980S | FCU2803 | RG-7593 | ACD22-VCMMAE | DCDT-2989S | Pinatuzumab vedotin",
        "Polivy\u2122 | ACD79B-VCMMAE | Polatuzumab vedotin | RG-7596 | DCDS4501A | FCU2711 | DCDS-4501A | RO5541077-000",
        "RG 7600 | DMOT-4039A | DMOT4039A | RG7600",
        "DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA | DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148",
        "RG7986",
        "RO7032005 | DCDS0780A | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin",
        "Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | RG-7841 | Anti-Ly6E | DLYE5953A",
        "RG7450 | Vandortuzumab vedotin | DSTP3086S | RG-7450 | MSTP2109A | DSTP-3086S | Anti-STEAP1 ADC",
        "RG-7636 | Anti-ETBR",
        "DFRF 4539A | RG 7598 | RG-7598 | RG7598",
        "T-DM1 | Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla\u00ae | Trastuzumab Emtansine"
      ],
      "# co-developers": 8,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "Lithuania",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 73,
      "# drugs": 16,
      "# Preclinical drugs": 1,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 8,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 32,
      "# Phase 1 trials": 7,
      "# Phase 2 trials": 23,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genitope Corporation",
      "names": [
        "Genitope Corporation"
      ],
      "HQ City": "Redwood City",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Genitope Pharmaceuticals in 2008",
      "trials": [
        "NCT00071955"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genmab",
      "names": [
        "Genmab",
        "Co-developed by Genmab and Seattle Genetics",
        "Genmab in collaboration with Seattle Genetics",
        "GenmabPrinceton, NJSeattle GeneticsBothell, WA",
        "Genmab A/S"
      ],
      "HQ City": "Copenhagen",
      "HQ Country": "Denmark",
      "Founding Year": "1999",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.genmab.com",
      "Acquisition": "-",
      "ttd": [
        "D0QI1K"
      ],
      "co-developers": [
        "AbbVie",
        "GOG Foundation",
        "Seagen",
        "Merck Sharp & Dohme",
        "ADC Therapeutics"
      ],
      "trials": [
        "NCT05283720",
        "EUCTR2017-003413-25-IT",
        "EUCTR2013-001074-15-GB",
        "EUCTR2015-001120-29-DK",
        "NCT03245736",
        "EUCTR2016-004743-37-BE",
        "CTIS2023-508832-68-00",
        "EUCTR2019-001655-39-ES",
        "NCT02001623",
        "EUCTR2017-004758-40-DK",
        "EUCTR2017-003413-25-DK",
        "EUCTR2017-003413-25-CZ",
        "NCT02988817",
        "NCT03657043",
        "EUCTR2017-003413-25-DE",
        "NCT02552121",
        "NCT03438396",
        "NCT03786081"
      ],
      "drugs": [
        "ADCT-301 | ADCT-301 HuMax-TAC-ADC \u201cCami-T\u201d | HuMax-TAC-ADC | Camidanlumab tesirine",
        "Tivdak | HuMax\u00ae-TF-ADC | TF-011-MMAE  HuMax-TF-ADC | Tisotumab Vedotin",
        "AXL-107-MMAE | HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | Enapotamab vedotin | HuMax-AXL-ADC"
      ],
      "# co-developers": 5,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Germany",
        "Greece",
        "France",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Finland",
        "Israel",
        "Argentina",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "Ukraine",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Belgium",
        "Estonia"
      ],
      "# locations": 36,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 18,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 8,
      "# Phase 3 trials": 10,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genta",
      "names": [
        "Genta Incorporated",
        "Genta"
      ],
      "HQ City": "Berkeley Heights",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Genasense in 2009",
      "trials": [
        "NCT00017589"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Genzyme",
      "names": [
        "Genzyme"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sanofi.com/",
      "Acquisition": "Acquired by Sanofi in 2011",
      "drugs": [
        "Anti-endosialin-MC-VC-PABC-MMAE"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Georgetown Translational (Oxis Biotech)",
      "names": [
        "Georgetown Translational (Oxis Biotech)",
        "GT Biopharma.  Previously known as  Oxis Biotech (Georgetown Translational Pharmaceuticals)"
      ],
      "HQ City": "Los Angeles",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oxisbiotech.com/",
      "Acquisition": "-",
      "drugs": [
        "DT2219ARL | IND100780 | GTB-1550 | OXS-1550 | DT-2219ARL | GTB-1550 OXS-1550 | DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "GlaxoSmithKline",
      "names": [
        "GlaxoSmithKline LLC",
        "GlaxoSmithKline (GSK) Co-developer: Seattle Genetics",
        "GlaxoSmithKline",
        "GlaxoSmithKline Research  Development Limited",
        "GlaxoSmithKline (GSK)",
        "GlaxoSmithKline Research Development Limited",
        "GlaxoSmithKline  (GSK) Co-developer: Seattle Genetics",
        "Glaxo Wellcome",
        "GlaxoSmithKline Research & Development Ltd"
      ],
      "HQ City": "Brentford",
      "HQ Country": "UK",
      "Founding Year": "2000",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.gsk.com",
      "Acquisition": "-",
      "ttd": [
        "D7AT3H"
      ],
      "co-developers": [
        "Amgen",
        "Novartis",
        "IMMUNOGEN",
        "Sanofi",
        "Roche",
        "Mersana",
        "Seagen",
        "Pfizer"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf"
      ],
      "trials": [
        "NCT01224821",
        "NCT02064387",
        "NCT05922501",
        "NCT00856297",
        "NCT05064358",
        "NCT04177823",
        "NCT04484623",
        "NCT04246047",
        "CTRI/2022/05/042713",
        "NCT00861744",
        "EUCTR2017-004810-25-DE",
        "NCT00322049",
        "EUCTR2018-002816-29-DE",
        "NCT00002163",
        "NCT04822337",
        "NCT03763370",
        "NCT03828292",
        "NCT00891176",
        "NCT03544281",
        "NCT00624819",
        "NCT04341181",
        "NCT03525678"
      ],
      "drugs": [
        "Cantuzumab mertansine | huC242-DM1 | SB408075 | SB-408075",
        "J6M0-mcMMAF | Blenrep\u00ae | Belantamab mafodotin | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | GSK2857916",
        "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056 | XMT-2056"
      ],
      "# co-developers": 8,
      "locations": [
        "Mexico",
        "Czechia",
        "China",
        "Ireland",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Israel",
        "Republic of Korea",
        "Argentina",
        "Taiwan",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "United States of America",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 30,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 22,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 10,
      "# Phase 3 trials": 8,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Halozyme",
      "names": [
        "Halozyme"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://www.halozyme.com/",
      "Acquisition": "-",
      "drugs": [
        "HTI-1511"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Hangzhou DAC Biotechnology Co., Ltd",
      "names": [
        "Hangzhou DAC Biotechnology Co., Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.dacbio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06224855"
      ],
      "co-developers": [],
      "drugs": [
        "DXC006"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Hangzhou Zhongmei Huadong",
      "names": [
        "Hangzhou Zhongmei Huadong",
        "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05622890"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Heading Medicine",
      "names": [
        "Heading Medicine"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Heidelberg Pharma",
      "names": [
        "Magenta Therapeutics in collaboration with Heidelberg Pharma (Originator Harvard University)",
        "Heidelberg Pharma",
        "Heidelberg Pharma in collaboration with Heading Medicine Co. Ltd",
        "Heidelberg Pharma in collaboration with MabVax"
      ],
      "HQ City": "Ladenburg",
      "HQ Country": "Germany",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.heidelberg-pharma.com",
      "Acquisition": "-",
      "drugs": [
        "Anti-CD269-ADC | Anti-CD269-amanitin-ADC | Anti-BCMA | HDP-101 | Anti-BCMA-ATAC | anti-BCMA-ADC",
        "HuMAB-5B1-ATAC",
        "anti-CD19 ADC | Anti-CD19 ADC | Anti-CD19 ATAC",
        "MGTA-117 \u2013 Amanitin ADC"
      ],
      "co-developers": [
        "MabVax",
        "Wilex",
        "Magenta"
      ],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 4,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Helix BioPharma",
      "names": [
        "Helix BioPharma Corporation",
        "Helix BioPharma Corp",
        "Helix BioPharma"
      ],
      "HQ City": "Aurora",
      "HQ Country": "Canada",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.helixbiopharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02340208",
        "NCT04203641",
        "EUCTR2010-020729-42-PL"
      ],
      "co-developers": [
        "Pharm-Olam International",
        "Theradex"
      ],
      "drugs": [
        "L-DOS47"
      ],
      "# co-developers": 2,
      "locations": [
        "Poland",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Holy Stone Healthcare Co., Ltd",
      "names": [
        "Holy Stone Healthcare Co., Ltd"
      ],
      "HQ City": "Taipei",
      "HQ Country": "Taiwan",
      "Founding Year": "1991",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.holystonehealth.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06039202"
      ],
      "co-developers": [],
      "drugs": [
        "CA102N"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "IATRICa Inc",
      "names": [
        "IATRICa Inc"
      ],
      "HQ City": "Sunnyvale",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://iatrica.com/",
      "Acquisition": "-",
      "ttd": [
        "D0C2CP"
      ],
      "co-developers": [],
      "drugs": [
        "d-trastuzumab"
      ],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ICON plc",
      "names": [
        "ICON plc"
      ],
      "HQ City": "Dublin",
      "HQ Country": "Ireland",
      "Founding Year": "1990",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.iconplc.com",
      "Acquisition": "-",
      "trials": [
        "NCT04844866"
      ],
      "co-developers": [
        "Miltenyi Biomedicine GmbH"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "IDEAYA",
      "names": [
        "IDEAYA Biosciences",
        "IDEAYA"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.ideayabio.com",
      "Acquisition": "-",
      "trials": [
        "NCT04794699"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "IMMUNOGEN",
      "names": [
        "ImmunoGen Debiopharm Internaltional",
        "ImmunoGen  Debiopharm Internaltional",
        "Macrogenics and ImmunoGen",
        "Immunogen",
        "IMMUNOGEN",
        "ImmunoGen and MorphoSys",
        "ImmungoGen",
        "CytomX Therapeutics ImmunoGen (Originator)",
        "ImmunoGen",
        "ImmunogGen and Novartis",
        "ImmunoGen, Inc",
        "ImmunoGen (previously also Sanofi)",
        "ImmunoGen (Cambridge MA USA)"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.immunogen.com",
      "Acquisition": "-",
      "ttd": [
        "DA4O8C"
      ],
      "co-developers": [
        "Boehringer Ingelheim",
        "Novartis",
        "MacroGenics",
        "CytomX",
        "GlaxoSmithKline",
        "Sanofi",
        "GOG Foundation",
        "BioTest",
        "Debiopharm",
        "Clovis Oncology",
        "Merck Sharp & Dohme",
        "MorphoSys AG",
        "Bayer"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf"
      ],
      "trials": [
        "NCT04296890",
        "NCT03835819",
        "NCT05041257",
        "NCT04086264",
        "NCT02610140",
        "NCT04622774",
        "NCT04209855",
        "NCT00346385",
        "NCT05445778",
        "NCT06034470",
        "NCT00346255",
        "NCT03552471",
        "NCT02631876",
        "NCT03386513",
        "NCT02606305",
        "NCT00991562",
        "NCT05456685",
        "NCT02420873",
        "NCT03832361",
        "NCT00065429",
        "NCT03102320",
        "NCT05527184",
        "NCT05887609",
        "NCT06365853",
        "NCT01609556"
      ],
      "drugs": [
        "Anti-CD44v6 | Anti-CD44v6-DM1 | Bivatuzumab mertansine | BIWI-1 | CD44v6-DM1",
        "M9346A-sulfo-SPDB-DM4 | Mirvetuximab Soravtansine | IMGN853 | IMGN-853 | Elahere | Anti-FOLR1 monoclonal -maytansinoid",
        "SAR 3419 | SAR3419 | Coltuximab Ravtansine",
        "IMGN151",
        "SAR408701 SAR 408701 SAR-408701 | Tusamitamab Ravtansine | SAR408701 | SAR-408701 | SAR 408701",
        "IMGN-242",
        "Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC",
        "Laprituximab emtansine | IMGN-289 IMGN289 J2898A-SMCC-DM1 | IMGN-289 | IMGN289",
        "CD166 AADC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CX-2009 | CD166 PDC",
        "IMGN779 | IMGN 779",
        "IMGC936",
        "IMGN 289",
        "IMGN388 | CNTO 95-DM4 | CNTO 365 | IMGN-388",
        "PCA062 PCA-062 | PCA062 | PCA-062",
        "Pivekimab Sunirine | IMGN-632 | MGN 632 | IMGN 632 | IMGN632",
        "SAR 566658 | SAR566658",
        "1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal | BT-062 | Oxobuthyldithio | Indatuximab Ravtansine | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4",
        "Lorvotuzumab mertansine | IMGN-901 | BB-10901 IMGN901 huN901-DM1 IMGN-901 | huN901-DM1",
        "SAR428926 | SAR428926 SAR 428926",
        "IMGN-633 | AVE9633",
        "Cantuzumab mertansine | huC242-DM1 | SB408075 | SB-408075",
        "Debio 1562 | IMGN529 | K7153A-SMCC-DM1 | Naratuximab emtansine | naratuximab emtansine | K7153A"
      ],
      "# co-developers": 13,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "Bosnia and Herzegovina",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Israel",
        "Finland",
        "Georgia",
        "Argentina",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# locations": 46,
      "# drugs": 22,
      "# Preclinical drugs": 1,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 6,
      "# Phase 2 drugs": 10,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 25,
      "# Phase 1 trials": 8,
      "# Phase 2 trials": 13,
      "# Phase 3 trials": 4,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Iconic",
      "names": [
        "Iconic Therapeutics in collaboration with Zymeworks",
        "Iconic",
        "Iconic Therapeutics, Inc",
        "Iconic Therapeutics  in collaboration with Zymeworks"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.iconictx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT01485588",
        "NCT02358889",
        "NCT02771340"
      ],
      "co-developers": [
        "Exelixis",
        "Zymeworks"
      ],
      "drugs": [
        "XB002 ICON-2 Tissue Factor ADC | ICON-2 Tissue Factor ADC  XB002"
      ],
      "# co-developers": 2,
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "# locations": 9,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Igenica",
      "names": [
        "Igenica Biotherapeutics",
        "Igenica"
      ],
      "HQ City": "Burlingame",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Xencor in 2015",
      "drugs": [
        "IGN523",
        "IGN786"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Iksuda",
      "names": [
        "Iksuda (Glythera)",
        "Iksuda",
        "Iksuda Therapeutics (formerly known as Glythera)",
        "Iksuda Therapeutics Ltd"
      ],
      "HQ City": "Newcastle upon Tyne",
      "HQ Country": "United Kingdom",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.iksuda.com",
      "Acquisition": "-",
      "trials": [
        "NCT05872295"
      ],
      "co-developers": [],
      "drugs": [
        "IKS03",
        "IKS02",
        "IKS04",
        "IKS01"
      ],
      "# co-developers": 0,
      "locations": [
        "Australia"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Immune Tolerance Network (ITN)",
      "names": [
        "Immune Tolerance Network (ITN)"
      ],
      "HQ City": "-",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.immunetolerance.org",
      "Acquisition": "-",
      "trials": [
        "NCT03222492"
      ],
      "co-developers": [
        "Seagen",
        "PPD"
      ],
      "drugs": [],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ImmunityBio",
      "names": [
        "ImmunityBio"
      ],
      "HQ City": "Culver City",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.immunitybio.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ImmunoBiochem",
      "names": [
        "ImmunoBiochem"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "IMB-202",
        "IMB-201"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Immunomedics",
      "names": [
        "Gilead Sciences (previously Immunomedics)",
        "Immunomedics",
        "Immunmedics"
      ],
      "HQ City": "Morris Plains",
      "HQ Country": "United States",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Gilead Sciences in 2020",
      "ttd": [
        "D0Y6BO"
      ],
      "co-developers": [
        "GILEAD"
      ],
      "drugs": [
        "IMMU-140 | anti-HLA-DR-SN-38 ADC",
        "hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38 | hMN14-SN-38 | Labetuzumab govitecan | IMMU-130 | Labetuzumab-SN-38 IMMU-130",
        "Epratuzumab\u2013SN-38",
        "IMMU-132 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38 | hRS7-SN38 | Trodelvy | hRS7-SN-38-ADC",
        "Milatuzumab-doxorubicin",
        "hLL1 | CD74-DOX | IMMU-110 | hLL1-DOX | Milatuzumab doxorubicin | MEDI-115",
        "Clivatuzumab Tetraxetan | hPAM4 | hPAM4-DOTA | hPAM4 IgG-DOTA"
      ],
      "# co-developers": 1,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Estonia",
        "Vietnam"
      ],
      "# locations": 59,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 3,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Inhibrx",
      "names": [
        "Inhibrx"
      ],
      "HQ City": "La Jolla",
      "HQ Country": "United States",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.inhibrx.com/",
      "Acquisition": "-",
      "ttd": [
        "D56ERU"
      ],
      "co-developers": [],
      "drugs": [
        "INBRX-109"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Innate",
      "names": [
        "Innate",
        "Innate Pharma in collaboration with AstraZeneca"
      ],
      "HQ City": "Marseille",
      "HQ Country": "France",
      "Founding Year": "1999",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.innate-pharma.com/",
      "Acquisition": "-",
      "drugs": [
        "IPH43"
      ],
      "co-developers": [
        "AstraZeneca"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Innovent",
      "names": [
        "Innovent"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2011",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.innoventbio.com",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Istari Oncology",
      "names": [
        "Istari Oncology",
        "Istari Oncology, Inc"
      ],
      "HQ City": "Durham",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.istarioncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT04160494"
      ],
      "co-developers": [
        "Genentech"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Jazz Pharmaceuticals",
      "names": [
        "Jazz Pharmaceuticals"
      ],
      "HQ City": "Dublin",
      "HQ Country": "Ireland",
      "Founding Year": "2003",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.jazzpharma.com",
      "Acquisition": "-",
      "trials": [
        "NCT05558124"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Jiangsu HengRui Medicine",
      "names": [
        "Jiangsu Hengrui Pharmaceutical Co., Ltd",
        "Jiangsu HengRui Medicine",
        "Jiangsu HengRui Medicine Co., Ltd",
        "Jiangsu Hengrui Medicine Co. in collaboration with Beijing Shijitan Hospital",
        "Jiangsu Hengrui Medicine Co"
      ],
      "HQ City": "Lianyungang",
      "HQ Country": "China",
      "Founding Year": "1970",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.hrs.com.cn",
      "Acquisition": "-",
      "trials": [
        "NCT03856541",
        "NCT06126640",
        "NCT05350917",
        "NCT06123494"
      ],
      "co-developers": [
        "BeiGene",
        "RemeGen"
      ],
      "drugs": [
        "SHR-A1403 | HTI-1066 | HTI-1066 SHR-A1403",
        "SHR-A1201"
      ],
      "# co-developers": 2,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Johnson & Johnson",
      "names": [
        "Johnson & Johnson"
      ],
      "HQ City": "New Brunswick",
      "HQ Country": "United States",
      "Founding Year": "1886",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer, ADC Platform Technology technology",
      "Website URL": "https://www.jnj.com",
      "Acquisition": "-",
      "trials": [
        "NCT04662580"
      ],
      "co-developers": [
        "Ambrx"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "KLUS",
      "names": [
        "KLUS Pharma, a subsidiary of Kelun Pharmaceuticals (Sichuan Chengdu, China)",
        "KLUS Pharma",
        "Klus Pharma, the US subsidiary of China-based Kelun-Biotech",
        "KLUS",
        "Klus Pharma",
        "Klus Pharma Inc"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "ttd": [
        "DD94ZN",
        "DOS62C",
        "D56AJO"
      ],
      "co-developers": [],
      "trials": [
        "NCT03602079",
        "NCT04152499"
      ],
      "drugs": [
        "SKB315",
        "A166 ADC | A166 ADC A166 anti-HER2 ADC A166",
        "SKB264 ADC"
      ],
      "# co-developers": 0,
      "locations": [
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Taiwan",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "Chile",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 33,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "KYM Biosciences",
      "names": [
        "KYM Biosciences",
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.kymbiosciences.com/",
      "Acquisition": "-",
      "drugs": [
        "CMG901"
      ],
      "co-developers": [
        "Lepu Biopharma",
        "AstraZeneca",
        "Keymed Biosciences"
      ],
      "# co-developers": 3,
      "locations": [
        "Canada",
        "Singapore",
        "Moldova, Republic of",
        "United States of America",
        "Georgia",
        "Malaysia",
        "Republic of Korea",
        "Republic of Moldova",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "# locations": 16,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kanisa",
      "names": [
        "Kanisa Pharmaceuticals",
        "Kanisa"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT00233909"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Keymed Biosciences",
      "names": [
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca",
        "Keymed Biosciences"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.keymedbio.com/",
      "Acquisition": "-",
      "drugs": [
        "CMG901"
      ],
      "co-developers": [
        "Lepu Biopharma",
        "AstraZeneca",
        "KYM Biosciences"
      ],
      "# co-developers": 3,
      "locations": [
        "Canada",
        "Singapore",
        "Moldova, Republic of",
        "United States of America",
        "Georgia",
        "Malaysia",
        "Republic of Korea",
        "Republic of Moldova",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "# locations": 16,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kirilys Therapeutics",
      "names": [
        "Kirilys Therapeutics Inc",
        "Kirilys Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04410224"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Knoll (Europe)",
      "names": [
        "Knoll (Europe)",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe)  Manufacturer: Lonza Biologics",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe) Manufacturer: Lonza Biologics"
      ],
      "HQ City": "Ludwigshafen",
      "HQ Country": "Germany",
      "Founding Year": "1886",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.knoll.basf.com/",
      "Acquisition": "Acquired by BASF in 1990",
      "drugs": [
        "Satumomab Penditide | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | OncoScint\u00ae CR/OV | 111In | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide"
      ],
      "co-developers": [
        "Lonza Biologics"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kodiak Sciences",
      "names": [
        "Kodiak Sciences",
        "Kodiak Sciences Inc"
      ],
      "HQ City": "Palo Alto",
      "HQ Country": "United States",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.kodiak.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04964089",
        "NCT04592419"
      ],
      "co-developers": [],
      "drugs": [
        "OG1953 | KSI 301 | Tarcocimab Tedromer | KSI301 | KSI-301"
      ],
      "# co-developers": 0,
      "locations": [
        "Italy",
        "Czechia",
        "Slovakia",
        "Israel",
        "Germany",
        "Poland",
        "Spain",
        "Latvia",
        "Hungary",
        "France",
        "Puerto Rico",
        "United States"
      ],
      "# locations": 12,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kolltan",
      "names": [
        "Kolltan",
        "Kolltan Pharmaceuticals"
      ],
      "HQ City": "New Haven",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Celldex Therapeutics in 2016",
      "drugs": [
        "KTN0182A",
        "KTN0125"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kura Oncology",
      "names": [
        "Kura Oncology, Inc",
        "Kura Oncology"
      ],
      "HQ City": "La Jolla",
      "HQ Country": "United States",
      "Founding Year": "2014",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://kuraoncology.com",
      "Acquisition": "-",
      "trials": [
        "NCT06448013"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Kyowa Kirin",
      "names": [
        "Kyowa Kirin",
        "Kyowa Kirin, Inc"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "1949",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.kyowakirin.com",
      "Acquisition": "-",
      "trials": [
        "NCT05414500"
      ],
      "co-developers": [
        "Seagen"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "LaNova",
      "names": [
        "LaNova BMS (ex-China excl. Korea) Turning Point therapeutics (now part of BMS)",
        "LaNova"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.lanovabio.com/",
      "Acquisition": "-",
      "drugs": [
        "LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302"
      ],
      "co-developers": [
        "Turning Point therapeutics"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Legochem",
      "names": [
        "LegoChem Biosciences and Nordic Nanovector",
        "LegoChem Biosciences and Gree Cross",
        "LigaChem Biosciences, Inc",
        "Legochem Biosciences and Fosun Pharma",
        "LegoChem Biosciences and Takeda",
        "Legochem",
        "LegoChem Biosiences and Samsung Medical Center",
        "LegoChem Biosciences and Seasun Biomaterials",
        "LegoChem Biosciences and Y-Biologics"
      ],
      "HQ City": "Daejeon",
      "HQ Country": "South Korea",
      "Founding Year": "2002",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Platform Technology",
      "Website URL": "https://www.legochembio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05941507"
      ],
      "co-developers": [
        "AntibodyChem Biosciences",
        "Seasun Biomaterials",
        "Y-Biologics",
        "Takeda",
        "Samsung Medical Center",
        "Nordic Nanovector",
        "Shanghai Fosun"
      ],
      "drugs": [
        "LCB14-19nm",
        "LCB14-15nm",
        "LCB84",
        "LCB14-17nn",
        "Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110 | Herceptin-LC-LBG-MMAF | LCB14-0110",
        "anti-CD37 ADC | LCB14-15xx | NNV019",
        "LCB14-2nm"
      ],
      "# co-developers": 7,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Lepu Biopharma",
      "names": [
        "Shanghai Miracogen, a fully owned subsidiary of Lepu Biopharma",
        "Shanghai Miracogen in partnership with Lepu Biopharma",
        "Lepu Biopharma",
        "KYM Biosciences (A joint venture of Keymed Biosciences and Lepu Biopharma) AstraZeneca",
        "Shanghai Miracogen  in partnership with Lepu Biopharma"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.lepubiopharma.com",
      "Acquisition": "-",
      "drugs": [
        "MRG004A",
        "CMG901",
        "MRG003"
      ],
      "co-developers": [
        "AstraZeneca",
        "KYM Biosciences",
        "Shanghai Miracogen",
        "Keymed Biosciences"
      ],
      "# co-developers": 4,
      "locations": [
        "Canada",
        "Singapore",
        "Moldova, Republic of",
        "United States of America",
        "China",
        "Georgia",
        "Malaysia",
        "Republic of Korea",
        "Republic of Moldova",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "# locations": 17,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Ligand Pharmaceuticals",
      "names": [
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Ligand Pharmaceuticals",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics Co-developed by Astellas"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://www.ligand.com/",
      "Acquisition": "-",
      "drugs": [
        "ASG-15ME | AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | AGS15E | AGS-15vcMMAE | Sirtratumab vedotin | AGS-15E | Ha15-10ac.1vcMMAE"
      ],
      "co-developers": [
        "Astellas",
        "Seagen",
        "Agensys"
      ],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Lisata Therapeutics",
      "names": [
        "Lisata Therapeutics, Inc",
        "Lisata Therapeutics"
      ],
      "HQ City": "Basking Ridge",
      "HQ Country": "United States",
      "Founding Year": "1980",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://lisatatx.com",
      "Acquisition": "-",
      "trials": [
        "NCT00012064"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Lonza Biologics",
      "names": [
        "Lonza Biologics",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe)  Manufacturer: Lonza Biologics",
        "Cytogen Corporation (Primary) Chiron Theraoeutics (Europe) Knoll Pharmaceuticals (Europe) Manufacturer: Lonza Biologics"
      ],
      "HQ City": "Visp",
      "HQ Country": "Switzerland",
      "Founding Year": "1897",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://www.lonza.com/",
      "Acquisition": "-",
      "drugs": [
        "Satumomab Penditide | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | OncoScint\u00ae CR/OV | 111In | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide"
      ],
      "co-developers": [
        "Knoll (Europe)"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Loxo Oncology",
      "names": [
        "Loxo Oncology, Inc",
        "Loxo Oncology"
      ],
      "HQ City": "Stamford",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Eli Lilly in 2019",
      "trials": [
        "NCT06400472",
        "NCT06465069",
        "NCT06238479"
      ],
      "co-developers": [
        "Eli Lilly"
      ],
      "drugs": [
        "LY4101174",
        "LY4052031",
        "LY4170156"
      ],
      "# co-developers": 1,
      "locations": [
        "Australia",
        "Japan",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 3,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Luzsana Biotechnology",
      "names": [
        "Luzsana Biotechnology"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.luzsana.com/",
      "Acquisition": "-",
      "drugs": [
        "Trastuzumab rezetecan SHR-A1811 | Trastuzumab rezetecan | SHR-A1811"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MBrace Therapeutics",
      "names": [
        "MBrace Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06014658"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MFAR",
      "names": [
        "MFAR"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06235216"
      ],
      "co-developers": [
        "GILEAD"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MabPlex",
      "names": [
        "Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)",
        "MabPlex (Yantai, China)",
        "MabPlex"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "CDMO",
      "Website URL": "https://www.mabplexinc.com",
      "Acquisition": "-",
      "drugs": [
        "RC-48 RC 480-ADC RC48 | RC-48 | Aidixi\u00ae | Disitamab Vedotin | RC48 | \u7231\u5730\u5e0c\u00ae | RC 480-ADC",
        "RC118",
        "RC108",
        "Hertuzumab Vedotin | Hertuzumab-vcMMAE",
        "RC88"
      ],
      "co-developers": [
        "Rongchang",
        "Biocytogen",
        "RemeGen"
      ],
      "# co-developers": 3,
      "locations": [
        "Canada",
        "Chile",
        "Israel",
        "Singapore",
        "China",
        "Argentina",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Belgium",
        "Japan",
        "United States"
      ],
      "# locations": 13,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MabVax",
      "names": [
        "MabVax",
        "Heidelberg Pharma in collaboration with MabVax"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2006",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.mabvax.com/",
      "Acquisition": "-",
      "drugs": [
        "HuMAB-5B1-ATAC"
      ],
      "co-developers": [
        "Wilex",
        "Heidelberg Pharma"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mabwell (Shanghai)",
      "names": [
        "Mabwell (Shanghai) Bioscience Co., Ltd",
        "Mabwell (Shanghai)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2016",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.mabwell.com/",
      "Acquisition": "-",
      "drugs": [
        "9MW2821"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MacroGenics",
      "names": [
        "50 co-development between MacroGenics and Immunogen",
        "MacroGenics",
        "Macrogenics and ImmunoGen"
      ],
      "HQ City": "Rockville",
      "HQ Country": "United States",
      "Founding Year": "2000",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.macrogenics.com",
      "Acquisition": "-",
      "ttd": [
        "DDP74J",
        "DA4O8C"
      ],
      "co-developers": [
        "IMMUNOGEN"
      ],
      "trials": [
        "NCT04622774",
        "NCT05293496"
      ],
      "drugs": [
        "IMGC936",
        "Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC",
        "AEX4089DC1 | AEX4089DC1 Anti-B7-H3 ADC | Anti-B7-H3 ADC | MGC018 | Vobramitamab Duocarmazine"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Magenta",
      "names": [
        "Magenta Therapeutics in collaboration with Heidelberg Pharma (Originator Harvard University)",
        "Magenta"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.magentatx.com/",
      "Acquisition": "-",
      "drugs": [
        "MGTA-117 \u2013 Amanitin ADC"
      ],
      "co-developers": [
        "Heidelberg Pharma"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MedImmune",
      "names": [
        "MedImmune LLC",
        "MedImmune",
        "Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune",
        "Medimmune",
        "ADC Therapeutics in collaboration with MedImmune"
      ],
      "HQ City": "Gaithersburg",
      "HQ Country": "United States",
      "Founding Year": "1988",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by AstraZeneca in 2007",
      "trials": [
        "NCT03489525",
        "NCT01030536",
        "NCT00077493",
        "NCT02991911",
        "NCT00586924",
        "NCT00659425",
        "NCT00126646",
        "NCT01829711",
        "NCT02576548"
      ],
      "co-developers": [
        "AstraZeneca",
        "Open Innovation Partners",
        "Tanabe Research Laboratories USA",
        "Cambridge Antibody Technology",
        "ADC Therapeutics"
      ],
      "drugs": [
        "MEDI-547 | MEDI547",
        "MEDI 4276 | MEDI-4276 | MEDI4276",
        "Moxetumomab pasudotox | Lumoxiti | HA-22 | HA22 | MOXETUMOMAB PASUDOTOX | CAT-8015 | MOXETUMOMAB PASUDOTOX TDFK",
        "MEDI3726 | ADCT-401 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401",
        "TR1801-ADC | TR1801-ADC MT-8633 | MT-8633"
      ],
      "# co-developers": 5,
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Israel",
        "Switzerland",
        "Ireland",
        "Germany",
        "Poland",
        "United Kingdom",
        "Spain",
        "Serbia",
        "Belgium",
        "France",
        "Norway",
        "United States"
      ],
      "# locations": 15,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 1,
      "# trials": 9,
      "# Phase 1 trials": 7,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MedSIR",
      "names": [
        "MedSIR"
      ],
      "HQ City": "Barcelona",
      "HQ Country": "Spain",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.medsir.org",
      "Acquisition": "-",
      "trials": [
        "NCT04420598",
        "NCT06172127",
        "NCT05865990",
        "NCT04733118",
        "NCT06048718",
        "NCT05520723"
      ],
      "co-developers": [
        "GILEAD",
        "DAIICHI SANKYO",
        "Roche"
      ],
      "drugs": [],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 6,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Medarex",
      "names": [
        "Medarex",
        "Medarex Bristol-Myers Squibb"
      ],
      "HQ City": "Princeton",
      "HQ Country": "United States",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Bristol-Myers Squibb in 2009",
      "drugs": [
        "iratumumab | MDX-060",
        "BMS-936561 | \u03b1CD70_MED-A | BMS936561 | MDX-1203"
      ],
      "co-developers": [
        "Bristol Myers Squibb"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MediLink",
      "names": [
        "MediLink",
        "MediLink Therapeutics (Suzhou) Co., Ltd",
        "MediLink (Suzhou)"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06439771",
        "NCT06107686",
        "NCT06057922",
        "NCT05434234"
      ],
      "co-developers": [],
      "drugs": [
        "YL202 should be intravenously infused | YL202",
        "YL201"
      ],
      "# co-developers": 0,
      "locations": [
        "China",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MediaPharma",
      "names": [
        "MediaPharma",
        "MediaPharma S.r.l",
        "Mediapharma"
      ],
      "HQ City": "L'Aquila",
      "HQ Country": "Italy",
      "Founding Year": "2010",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "EV20/MMAF",
        "Anti-HER-3 | anti-HER-3 ADC",
        "anti-TEM-1 | TEM-1-ADC | Anti-TEM-1"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Medivation",
      "names": [
        "Medivation",
        "Medivation, Inc",
        "Medivation, Inc."
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Pfizer in 2016",
      "trials": [
        "NCT00377715"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Menarini Ricerche",
      "names": [
        "Co-developed by Menarini Ricerche and Oxford BioTherapeutics",
        "Menarini Ricerche"
      ],
      "HQ City": "Florence",
      "HQ Country": "Italy",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.menarini.com/",
      "Acquisition": "-",
      "drugs": [
        "MEN 1309 MEN1309 OBT076 | MEN1309 | OBT076"
      ],
      "co-developers": [
        "Oxford BioTherapeutics"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "Greece",
        "Belgium",
        "France",
        "United States"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Merck KGaA, Darmstadt, Germany",
      "names": [
        "Merck",
        "Merck KGaA, Darmstadt, Germany",
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics"
      ],
      "HQ City": "Darmstadt",
      "HQ Country": "Germany",
      "Founding Year": "1668",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.merckgroup.com/",
      "Acquisition": "-",
      "ttd": [
        "D3YJZ7"
      ],
      "co-developers": [
        "Nektar Therapeutics",
        "VelosBio",
        "EMD Serono",
        "Merck Sharp & Dohme",
        "GILEAD"
      ],
      "trials": [
        "NCT05327530",
        "NCT03547973",
        "NCT04695847",
        "NCT05464030"
      ],
      "drugs": [
        "VLS-101 MK-2140 | VLS-101 | Zilovertamab vedotin | MK-2140",
        "BEVACIZUMAB GAMMA",
        "M9140"
      ],
      "# co-developers": 5,
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Denmark",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 24,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Merck Sharp & Dohme",
      "names": [
        "Merck",
        "MSD",
        "Merck Sharp & Dohme LLC",
        "Merck Sharp & Dohme"
      ],
      "HQ City": "Kenilworth",
      "HQ Country": "United States",
      "Founding Year": "1891",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.msd.com",
      "Acquisition": "-",
      "ttd": [
        "D3YJZ7"
      ],
      "co-developers": [
        "Genmab",
        "AstraZeneca",
        "DAIICHI SANKYO",
        "Endocyte",
        "IMMUNOGEN",
        "VelosBio",
        "GOG Foundation",
        "Merck KGaA, Darmstadt, Germany",
        "RemeGen",
        "Seagen",
        "Strata Oncology",
        "Astellas",
        "Pfizer",
        "GILEAD"
      ],
      "trials": [
        "NCT05180097",
        "NCT03835819",
        "NCT05756569",
        "NCT03032107",
        "NCT05382286",
        "NCT05097599",
        "NCT04879329",
        "NCT02684292",
        "NCT04448886",
        "NCT05404945",
        "NCT05186974",
        "NCT06081244",
        "NCT06161025",
        "NCT04468061",
        "NCT05775471",
        "NCT04946370",
        "NCT06074588",
        "NCT02677155",
        "NCT04042701",
        "NCT06362252",
        "NCT05313243",
        "NCT03288545",
        "NCT06203210",
        "NCT06132958",
        "NCT05911295",
        "NCT03310957",
        "NCT00777608",
        "NCT05280470",
        "NCT05609968",
        "NCT04609566",
        "NCT05922904",
        "NCT03786081"
      ],
      "drugs": [
        "VLS-101 MK-2140 | VLS-101 | Zilovertamab vedotin | MK-2140",
        "MK8109 | Vintafolide | VYNFINIT\u00ae | EC145/MK 8109 | MK 8109 | EC145",
        "SACITUZUMAB TIRUMOTECAN"
      ],
      "# co-developers": 14,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# locations": 54,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 32,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 21,
      "# Phase 3 trials": 8,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Merrimack",
      "names": [
        "Merrimack",
        "Merrimack Pharmaceuticals, Inc"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.merrimack.com/",
      "Acquisition": "-",
      "drugs": [
        "Nano-doxorubicin | MM-302"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# locations": 54,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mersana",
      "names": [
        "Mersana Therapeutics in collaboration with Takeda.  Antibody development: Adimab",
        "Mersana Therapeutics",
        "Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab",
        "Mersana",
        "Mersana Therapeutics Cambridge, MA"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2001",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.mersana.com",
      "Acquisition": "-",
      "ttd": [
        "D0QFD2",
        "DDL79K"
      ],
      "co-developers": [
        "Takeda",
        "GlaxoSmithKline"
      ],
      "trials": [
        "NCT02952729"
      ],
      "drugs": [
        "TAK-522 | XMT-1522 | XMT1522 TAK-522",
        "XMT-1536 | Upifitamab Rilsodotin | UpRi | XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin | XMT1536",
        "XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056 | XMT-2056",
        "XMT-1592"
      ],
      "# co-developers": 2,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MethylGene",
      "names": [
        "MethylGene Inc.",
        "MethylGene Inc",
        "MethylGene"
      ],
      "HQ City": "Montreal",
      "HQ Country": "Canada",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Mirati Therapeutics in 2013",
      "trials": [
        "NCT02429375"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Millennium",
      "names": [
        "Takeda (listed as Millennium Pharmaceuticals) ImmunoGen",
        "Millennium",
        "Millennium Pharmaceuticals",
        "Millennium: The Takeda Oncology Company",
        "Millennium Pharmaceuticals, Inc"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Takeda in 2008",
      "trials": [
        "NCT00947856",
        "NCT01990534",
        "NCT00052000",
        "NCT01492088",
        "NCT02686346",
        "NCT01060904",
        "NCT02292979",
        "NCT01026233",
        "NCT00848926",
        "NCT02467946",
        "NCT02280785",
        "NCT02243436",
        "NCT01577758",
        "NCT00070837",
        "NCT00866047",
        "NCT01026415",
        "NCT01100502",
        "NCT02567851",
        "NCT01578499",
        "NCT01777152",
        "NCT01950364",
        "NCT01309789",
        "NCT01851200"
      ],
      "co-developers": [
        "Takeda",
        "Seagen",
        "Samsung Medical Center"
      ],
      "drugs": [
        "5F9vcMMAE | Indusatumab Vedotin | TAK-264 | TAK264 | MLN-0264 | MLN 0264 | MLN0264",
        "TAK-164 TAK164 Anti-GCC ADC Anti-GCC | TAK-164",
        "MLN-2704 | MLN2704"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 23,
      "# Phase 1 trials": 7,
      "# Phase 2 trials": 12,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Miltenyi Biomedicine GmbH",
      "names": [
        "Miltenyi Biomedicine GmbH"
      ],
      "HQ City": "Bergisch Gladbach",
      "HQ Country": "Germany",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.miltenyibiotec.com",
      "Acquisition": "-",
      "trials": [
        "NCT04844866"
      ],
      "co-developers": [
        "ICON plc"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Minghui Pharmaceutical (Hangzhou) Ltd",
      "names": [
        "Minghui Pharmaceutical (Hangzhou) Ltd",
        "Minghui Pharmaceutical Pty Ltd"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06373406",
        "NCT05652855"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mirati Therapeutics",
      "names": [
        "Mirati Therapeutics",
        "Mirati Therapeutics Inc.",
        "Mirati Therapeutics Inc"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.mirati.com",
      "Acquisition": "-",
      "trials": [
        "NCT04887870"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "MorphoSys AG",
      "names": [
        "MorphoSys AG"
      ],
      "HQ City": "Planegg",
      "HQ Country": "Germany",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.morphosys.com/",
      "Acquisition": "-",
      "ttd": [
        "D01BUS"
      ],
      "co-developers": [
        "IMMUNOGEN",
        "Bayer"
      ],
      "trials": [
        "NCT03102320"
      ],
      "drugs": [
        "CA9-ADC"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Morphotek",
      "names": [
        "Morphotek",
        "Morphotek\u00ae, a subsidiary of Eisai Eisai Co Bristol Myers Squibb",
        "Morphotek\u00c2\u00ae (a subsidiary of Eisai)"
      ],
      "HQ City": "Exton",
      "HQ Country": "United States",
      "Founding Year": "2000",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.morphotek.com/",
      "Acquisition": "Acquired by Eisai in 2007",
      "drugs": [
        "MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202"
      ],
      "co-developers": [
        "Eisai"
      ],
      "# co-developers": 1,
      "locations": [
        "China",
        "Sweden",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 28,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Multitude",
      "names": [
        "Multitude Therapeutics Inc",
        "Multitude Therapeutics (Australia) Pty Ltd",
        "Multitude"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05498597"
      ],
      "co-developers": [],
      "drugs": [
        "AMT-562",
        "AMT-151"
      ],
      "# co-developers": 0,
      "locations": [
        "China",
        "Australia"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mundipharma EDO",
      "names": [
        "Mundipharma EDO GmbH",
        "Mundipharma EDO"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "UK",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.mundipharma.com",
      "Acquisition": "-",
      "drugs": [
        "EDO-B278",
        "EDO-772P/B776"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Mythic Therapeutics",
      "names": [
        "Mythic Therapeutics,,",
        "Mythic Therapeutics,",
        "Mythic Therapeutics"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.mythictx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05652868"
      ],
      "co-developers": [],
      "drugs": [
        "cMET-ADC MYTX-011 | MYTX-011"
      ],
      "# co-developers": 0,
      "locations": [
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "# locations": 6,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NBE Therapeutics",
      "names": [
        "NBE Therapeutics",
        "NBE Therapeutics GmbH",
        "NBE-Therapeutics"
      ],
      "HQ City": "Basel",
      "HQ Country": "Switzerland",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.nbe-therapeutics.com",
      "Acquisition": "-",
      "ttd": [
        "D79HBK"
      ],
      "co-developers": [],
      "drugs": [
        "NBE-002 \u2013 ROR-1 | NBE-002 NBE-002 - ROR-1",
        "NBE-003",
        "NBE-001"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NSABP Foundation",
      "names": [
        "NSABP Foundation Inc",
        "NSABP Foundation Inc.",
        "NSABP Foundation"
      ],
      "HQ City": "-",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.nsabp.org",
      "Acquisition": "-",
      "trials": [
        "NCT05633654",
        "NCT04622319",
        "NCT01772472"
      ],
      "co-developers": [
        "AstraZeneca",
        "DAIICHI SANKYO",
        "Alliance Foundation Trials",
        "Roche",
        "GILEAD"
      ],
      "drugs": [],
      "# co-developers": 5,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NanoCarrier (Japan)",
      "names": [
        "NanoCarrier (Japan)",
        "NanoCarrier Co.,Ltd (Japan) and Eisai"
      ],
      "HQ City": "Chiba",
      "HQ Country": "Japan",
      "Founding Year": "1996",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://www.nanocarrier.co.jp/",
      "Acquisition": "-",
      "drugs": [
        "ADCM-E7974 | NC-6201"
      ],
      "co-developers": [
        "Eisai"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NanoValent",
      "names": [
        "NanoValent Pharmaceuticals",
        "NanoValent"
      ],
      "HQ City": "Waltham",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.nanovalent.com",
      "Acquisition": "-",
      "drugs": [
        "NV101 | Doxorubicin-anti-CD99",
        "NV102 | Doxorubicin-anti-CD19",
        "NV103 | Irinotecan-anti-CD99"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Moldova, Republic of",
        "China",
        "Bosnia and Herzegovina",
        "Republic of Moldova",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Georgia",
        "Republic of Korea",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "United States of America",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "# locations": 58,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Natera",
      "names": [
        "Natera, Inc.",
        "Natera, Inc",
        "Natera"
      ],
      "HQ City": "Austin",
      "HQ Country": "United States",
      "Founding Year": "2004",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.natera.com",
      "Acquisition": "-",
      "trials": [
        "NCT05965479"
      ],
      "co-developers": [
        "AstraZeneca"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nektar Therapeutics",
      "names": [
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics",
        "Nektar Therapeutics"
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "1990",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology technology",
      "Website URL": "https://www.nektar.com",
      "Acquisition": "-",
      "trials": [
        "NCT05327530"
      ],
      "co-developers": [
        "GILEAD",
        "Merck KGaA, Darmstadt, Germany",
        "EMD Serono"
      ],
      "drugs": [],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NeoTX Therapeutics Ltd",
      "names": [
        "NeoTX Therapeutics Ltd"
      ],
      "HQ City": "Jerusalem",
      "HQ Country": "Israel",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.neotx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03983954",
        "NCT04880863"
      ],
      "co-developers": [
        "Translational Drug Development",
        "AstraZeneca"
      ],
      "drugs": [],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nerviano Medical Sciences",
      "names": [
        "Nerviano Medical Sciences"
      ],
      "HQ City": "Nerviano",
      "HQ Country": "Italy",
      "Founding Year": "1963",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.nervianoms.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Neuronix Ltd",
      "names": [
        "Neuronix Ltd"
      ],
      "HQ City": "Yokneam",
      "HQ Country": "Israel",
      "Founding Year": "2009",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.neuronixmedical.com/",
      "Acquisition": "-",
      "trials": [
        "NCT01825317"
      ],
      "co-developers": [
        "company: K The Power"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nona Bioscience",
      "names": [
        "Nona Bioscience and Pfizer",
        "Nona Bioscience"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.nonabio.com/",
      "Acquisition": "-",
      "drugs": [
        "HBM9033"
      ],
      "co-developers": [
        "Pfizer"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NordForsk",
      "names": [
        "NordForsk"
      ],
      "HQ City": "Oslo",
      "HQ Country": "Norway",
      "Founding Year": "2005",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.nordforsk.org/",
      "Acquisition": "-",
      "trials": [
        "NCT04307576"
      ],
      "co-developers": [
        "Nova Laboratories Limited",
        "Pfizer",
        "Amgen",
        "Servier"
      ],
      "drugs": [],
      "# co-developers": 4,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nordic Nanovector",
      "names": [
        "LegoChem Biosciences and Nordic Nanovector",
        "Nordic Nanovector ASA",
        "Nordic Nanovector"
      ],
      "HQ City": "Oslo",
      "HQ Country": "Norway",
      "Founding Year": "2009",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.nordicnanovector.com",
      "Acquisition": "-",
      "trials": [
        "NCT01796171"
      ],
      "co-developers": [
        "Endocyte",
        "Y-Biologics",
        "Novartis",
        "Legochem"
      ],
      "drugs": [
        "BETALUTIN | TETULOMAB TETRAXETAN LU-177 | (SUP 177)LU-TETULOMAB | 177LU-TETULOMAB | 177LU-TETRAXETAN-TETULOMAB",
        "anti-CD37 ADC | LCB14-15xx | NNV019",
        "177lu | Lilotomab satetraxetan | lutetium | lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1"
      ],
      "# co-developers": 4,
      "locations": [
        "Czechia",
        "Singapore",
        "Sweden",
        "Ireland",
        "Denmark",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Croatia",
        "Austria",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 24,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Nova Laboratories Limited",
      "names": [
        "Nova Laboratories Limited"
      ],
      "HQ City": "Leicester",
      "HQ Country": "United Kingdom",
      "Founding Year": "1984",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.novalabs.co.uk/",
      "Acquisition": "-",
      "trials": [
        "NCT04307576"
      ],
      "co-developers": [
        "Amgen",
        "Pfizer",
        "Servier",
        "NordForsk"
      ],
      "drugs": [],
      "# co-developers": 4,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Novartis",
      "names": [
        "Novartis",
        "Novartis and ImmunoGen",
        "ImmunogGen and Novartis",
        "Novartis Vaccines",
        "Endocyte (now part of Novartis) Advanced Accelerator Applications",
        "Novartis Pharmaceuticals"
      ],
      "HQ City": "Basel",
      "HQ Country": "Switzerland",
      "Founding Year": "1996",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.novartis.com",
      "Acquisition": "-",
      "ttd": [
        "DEX8D5",
        "DQVR30"
      ],
      "co-developers": [
        "Celgene",
        "Endocyte",
        "IMMUNOGEN",
        "GlaxoSmithKline",
        "GILEAD",
        "Pfizer",
        "Nordic Nanovector"
      ],
      "trials": [
        "NCT03696771",
        "NCT01125527",
        "NCT02038010",
        "NCT00856297",
        "NCT02073487",
        "NCT04240704",
        "NCT05143229",
        "NCT04385290"
      ],
      "drugs": [
        "Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine | LOP628 | LOP-628 | LOP 628 | Anti-c-kit humanised IgG1/\u03ba -maitansine",
        "PCA062 PCA-062 | PCA062 | PCA-062",
        "NJH395 anti-HER2 ISAC NJH395 | NJH395",
        "JBH492",
        "177lu | Lilotomab satetraxetan | lutetium | lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1",
        "HKT288 | Maytansine-based ADC HKT-288 | HKT-288 | CDH6-ADC"
      ],
      "# co-developers": 7,
      "locations": [
        "Italy",
        "Singapore",
        "Finland",
        "Israel",
        "China",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Japan",
        "United States"
      ],
      "# locations": 11,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 8,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Novavax",
      "names": [
        "Novavax"
      ],
      "HQ City": "Gaithersburg",
      "HQ Country": "United States",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.novavax.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05135273"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "NovoCure Ltd",
      "names": [
        "NovoCure Ltd"
      ],
      "HQ City": "St. Helier",
      "HQ Country": "Jersey",
      "Founding Year": "2000",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.novocure.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05764954"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "OBI Pharma",
      "names": [
        "OBI Pharma (ex-China) and Biosion (China)",
        "OBI Pharma, Inc",
        "OBI Pharma (ex-China) and  Biosion (China)",
        "OBI Pharma",
        "Oncomatryx"
      ],
      "HQ City": "Taipei",
      "HQ Country": "Taiwan",
      "Founding Year": "2002",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.obipharma.com",
      "Acquisition": "-",
      "ttd": [
        "D2H6NI"
      ],
      "co-developers": [
        "Biosion (China)"
      ],
      "trials": [
        "NCT06480240"
      ],
      "drugs": [
        "OBI-992 | BSI-992",
        "OBI-999 Anti-Globo H ADC | Anti-Globo H ADC | OBI-999"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "OnCusp Therapeutics",
      "names": [
        "OnCusp Therapeutics",
        "OnCusp Therapeutics, Inc"
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oncusptx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06234423"
      ],
      "co-developers": [],
      "drugs": [
        "CUSP06"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Onco-Pharmakon Inc",
      "names": [
        "Onco-Pharmakon Inc"
      ],
      "HQ City": "Montreal",
      "HQ Country": "Canada",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://onco-pharmakon.com/",
      "Acquisition": "-",
      "ttd": [
        "D0WM5H"
      ],
      "co-developers": [],
      "drugs": [
        "OP-06"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "OncoTherapy Science (Japan)",
      "names": [
        "OncoTherapy Science (Japan)",
        "OncoTherapy Science (Japan) Centre Leon Berard"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2001",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oncotherapy.co.jp/",
      "Acquisition": "-",
      "drugs": [
        "OTSA-101-DTPA OTSA101-DTPA-90Y | OTSA-101-DTPA | Tabituximab Barzuxetan | OTSA101-SS01"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oncolinx",
      "names": [
        "Oncolinx"
      ],
      "HQ City": "Boston",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://www.oncolinx.com/",
      "Acquisition": "-",
      "drugs": [
        "Azonafide-ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oncomatryx",
      "names": [
        "Oncomatryx Biopharma S.L",
        "Oncomatryx",
        "Oncomatryx Biopharma"
      ],
      "HQ City": "Bilbao",
      "HQ Country": "Spain",
      "Founding Year": "2011",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05547321"
      ],
      "co-developers": [],
      "drugs": [
        "Anti-MTX3:Nigrin | OMTX503",
        "OMTX705 | Anti-MTX5:Cytolysin ADC"
      ],
      "# co-developers": 0,
      "locations": [
        "Spain",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Open Innovation Partners",
      "names": [
        "Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune",
        "Open Innovation Partners",
        "Open Innovation Partners, Inc"
      ],
      "HQ City": "Boston",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://openinnovationpartners.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03859752"
      ],
      "co-developers": [
        "AstraZeneca",
        "MedImmune",
        "Tanabe Research Laboratories USA"
      ],
      "drugs": [
        "TR1801-ADC | TR1801-ADC MT-8633 | MT-8633"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Orano Med LLC",
      "names": [
        "Orano Med LLC"
      ],
      "HQ City": "Rockville",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "https://www.oranomed.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05283330"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Orum Therapeutics USA, Inc",
      "names": [
        "Orum Therapeutics USA, Inc"
      ],
      "HQ City": "San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.orumtx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05511844"
      ],
      "co-developers": [],
      "drugs": [
        "ORM-5029"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oxford BioMedica",
      "names": [
        "Oxford BioMedica"
      ],
      "HQ City": "Oxford",
      "HQ Country": "United Kingdom",
      "Founding Year": "1995",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Viral Vector Platform",
      "Website URL": "https://www.oxfordbiomedica.co.uk/",
      "Acquisition": "-",
      "drugs": [
        "PF-06263507 | A1-mafodotin | PF06263507 | A1-mcMMAF | PF 06263507 | Anti-5T4 monoclonal"
      ],
      "co-developers": [
        "Pfizer",
        "WYETH"
      ],
      "# co-developers": 2,
      "locations": [
        "Japan"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Oxford BioTherapeutics",
      "names": [
        "Oxford BioTherapeutics",
        "Co-developed by Menarini Ricerche and Oxford BioTherapeutics",
        "Oxford BioTherapeutics Ltd"
      ],
      "HQ City": "Oxford",
      "HQ Country": "United Kingdom",
      "Founding Year": "2004",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.oxfordbiotherapeutics.com/",
      "Acquisition": "-",
      "ttd": [
        "D8DJX0"
      ],
      "co-developers": [
        "Menarini Ricerche"
      ],
      "trials": [
        "NCT04064359"
      ],
      "drugs": [
        "MEN 1309 MEN1309 OBT076 | MEN1309 | OBT076"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "Greece",
        "Belgium",
        "France",
        "United States"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PPD",
      "names": [
        "PPD"
      ],
      "HQ City": "Wilmington",
      "HQ Country": "United States",
      "Founding Year": "1985",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.ppd.com/",
      "Acquisition": "Acquired by Thermo Fisher Scientific in 2021",
      "trials": [
        "NCT03222492"
      ],
      "co-developers": [
        "Immune Tolerance Network (ITN)",
        "Seagen"
      ],
      "drugs": [],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PT AIVITA Biomedika Indonesia",
      "names": [
        "PT AIVITA Biomedika Indonesia"
      ],
      "HQ City": "Jakarta",
      "HQ Country": "Indonesia",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04690387",
        "NCT05007496"
      ],
      "co-developers": [
        "Aivita Biomedical"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PT. Prodia Stem Cell Indonesia",
      "names": [
        "PT. Prodia Stem Cell Indonesia"
      ],
      "HQ City": "Jakarta",
      "HQ Country": "Indonesia",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05261750"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Palleos Healthcare GmbH",
      "names": [
        "Palleos Healthcare GmbH"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05425550"
      ],
      "co-developers": [
        "mobile Health AG"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Paxman Coolers Limited",
      "names": [
        "Paxman Coolers Limited"
      ],
      "HQ City": "Huddersfield",
      "HQ Country": "United Kingdom",
      "Founding Year": "1969",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://paxmanscalpcooling.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04986579"
      ],
      "co-developers": [
        "AstraZeneca",
        "GILEAD",
        "DAIICHI SANKYO",
        "Eisai"
      ],
      "drugs": [],
      "# co-developers": 4,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Peregrine Pharmaceuticals",
      "names": [
        "Peregrine Pharmaceuticals, Inc",
        "Peregrine Pharmaceuticals"
      ],
      "HQ City": "Tustin",
      "HQ Country": "United States",
      "Founding Year": "1981",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.peregrineinc.com/",
      "Acquisition": "-",
      "drugs": [
        "\u00b9\u00b3\u00b9I-chTNT-1/B mAb | Derlotuximab Biotin"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pfizer",
      "names": [
        "Nona Bioscience and Pfizer",
        "Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University",
        "Seagen (Pfizer)",
        "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc",
        "Pfizer (Wyeth)",
        "Wyeth is now a wholly owned subsidiary of Pfizer",
        "Pfizer",
        "Pfizer (Wyeth Pharmaceuticals)"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1849",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.pfizer.com",
      "Acquisition": "-",
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf"
      ],
      "co-developers": [
        "AbbVie",
        "Novartis",
        "Alliance Foundation Trials",
        "GlaxoSmithKline",
        "Nona Bioscience",
        "Eli Lilly",
        "Rinat",
        "Amgen",
        "Roche",
        "Array BioPharma",
        "Seagen",
        "Merck Sharp & Dohme",
        "NordForsk",
        "Stemcentrx",
        "GILEAD",
        "Celgene",
        "UCB Pharma",
        "Genentech",
        "WYETH",
        "Servier",
        "Oxford BioMedica",
        "Angiex",
        "Nova Laboratories Limited",
        "Strata Oncology",
        "Celltech"
      ],
      "trials": [
        "NCT00003673",
        "NCT03991884",
        "NCT04341181",
        "NCT01976169",
        "NCT01134575",
        "NCT03962465",
        "NCT02312037",
        "NCT02222922",
        "NCT00962767",
        "NCT05097599",
        "NCT00868608",
        "NCT04486352",
        "NCT04307576",
        "NCT04385290",
        "NCT04039230",
        "NCT03727750",
        "NCT03737955",
        "NCT03913559",
        "NCT04070768",
        "NCT03677596",
        "NCT02724163",
        "NCT01055496",
        "NCT04207190",
        "NCT03971409",
        "NCT01679119",
        "NCT00003131",
        "NCT01026038",
        "NCT01564784",
        "NCT00148824",
        "NCT00743652",
        "NCT00073749",
        "NCT00724971",
        "NCT01363297",
        "NCT00044733",
        "NCT05748171",
        "NCT03531918",
        "NCT00037596",
        "NCT03159117",
        "NCT00867087",
        "NCT00766116",
        "NCT05687032",
        "NCT01562990",
        "NCT00037583",
        "NCT01847781",
        "NCT00717925",
        "NCT00304447",
        "NCT03284723",
        "NCT03374332",
        "NCT00299494",
        "NCT03839446",
        "NCT04189614"
      ],
      "drugs": [
        "BESPONSA\u00ae | CMC-544 CMC544 | Inotuzumab ozogamicin | CMC-544",
        "SGN-B6A",
        "CDP-671 | CMB-401 | hCTMO1-calicheamicin | hCTMO1-calicheamicin CDP-671",
        "PF 06664178 | PF06664178 | PF-06664178 | RN927C",
        "ABBV-647 | PF-06647020 | Cofetuzumab pelidotin | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020",
        "PF-06647263 | anti-EFNA4-ADC | PF-06647263 EFNA4-ADC",
        "HBM9033",
        "Anti-TM4SF1 ADC",
        "PF06688992 | GD3 ADC | PF-06688992",
        "RN765C",
        "WAY-CMA-676 | Gemtuzumab ozogamicin | CMA-676 | CDP-771 | hP67.6-calicheamicin | Mylotarg\u00ae",
        "PF-06804103 PF 06804103 Anti-NG-HER2 ADC | Anti-NG-HER2 ADC | PF-06804103",
        "PF-06263507 | A1-mafodotin | PF06263507 | A1-mcMMAF | PF 06263507 | Anti-5T4 monoclonal",
        "Anti-NOTCH3 ADC | PF06650808 | PF-06650808 | Anti-NOTCH3-ADC | PF-6650808"
      ],
      "# co-developers": 25,
      "locations": [
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "India",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Wales",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Hong Kong",
        "Switzerland",
        "Australia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Slovakia",
        "Belgium",
        "Estonia"
      ],
      "# locations": 39,
      "# drugs": 14,
      "# Preclinical drugs": 1,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 51,
      "# Phase 1 trials": 13,
      "# Phase 2 trials": 27,
      "# Phase 3 trials": 6,
      "# Phase 4 trials": 4
    },
    {
      "heading": "Pharm-Olam International",
      "names": [
        "Pharm-Olam International"
      ],
      "HQ City": "Houston",
      "HQ Country": "United States",
      "Founding Year": "1994",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.pharm-olam.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02340208"
      ],
      "co-developers": [
        "Helix BioPharma"
      ],
      "drugs": [
        "L-DOS47"
      ],
      "# co-developers": 1,
      "locations": [
        "Poland",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "PharmaMar",
      "names": [
        "PharmaMar"
      ],
      "HQ City": "Madrid",
      "HQ Country": "Spain",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://pharmamar.com/",
      "Acquisition": "-",
      "drugs": [
        "MI130004"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pheon Therapeutics",
      "names": [
        "Pheon Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06457997"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pierre Fabre",
      "names": [
        "Pierre Fabre Medicament",
        "Pierre Fabre In collaboration with Roche",
        "Pierre Fabre"
      ],
      "HQ City": "Castres",
      "HQ Country": "France",
      "Founding Year": "1961",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.pierre-fabre.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03316638"
      ],
      "co-developers": [
        "Roche"
      ],
      "drugs": [
        "W0101 | W0101 W-0101 | Lonigutamab Ugodotin | W-0101"
      ],
      "# co-developers": 1,
      "locations": [
        "Spain",
        "France"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Precision Life Sciences Group",
      "names": [
        "Precision Life Sciences Group"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT02049489",
        "NCT01280552"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Prima BioMed Ltd",
      "names": [
        "Prima BioMed Ltd"
      ],
      "HQ City": "Sydney",
      "HQ Country": "Australia",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.primabiomed.com.au/",
      "Acquisition": "-",
      "trials": [
        "NCT01068509",
        "NCT01617629"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ProfoundBio",
      "names": [
        "ProfoundBio US Co",
        "ProfoundBio"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.profoundbio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05579366"
      ],
      "co-developers": [],
      "drugs": [
        "PRO1184",
        "PRO1160"
      ],
      "# co-developers": 0,
      "locations": [
        "China",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Progenics Pharmaceuticals",
      "names": [
        "Progenics Pharmaceuticals New York, NY",
        "Progenics Pharmaceuticals, Inc. (Tarrytown NY USA)",
        "Progenics Pharmaceuticals",
        "Progenics pharmaceuticals",
        "Progenics Pharmaceuticals, Inc"
      ],
      "HQ City": "New York City",
      "HQ Country": "United States",
      "Founding Year": "1986",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Lantheus in 2019",
      "ttd": [
        "D08VJC",
        "D0A7LL",
        "DENO78"
      ],
      "co-developers": [
        "Ambrx"
      ],
      "trials": [
        "NCT01695044",
        "NCT02020135",
        "NCT01856933",
        "NCT01414296",
        "NCT01414283"
      ],
      "drugs": [
        "anti-PSMA ADC | ARX517 | ARX517-PSMA-ADC",
        "PSMA ADC therapeutic",
        "PSMA-ADC",
        "BAY 2315497"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Puma Biotechnology, Inc",
      "names": [
        "Puma Biotechnology, Inc"
      ],
      "HQ City": "Los Angeles",
      "HQ Country": "United States",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.pumabiotechnology.com/",
      "Acquisition": "-",
      "trials": [
        "NCT01494662",
        "NCT05274048"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pyramid Biosciences",
      "names": [
        "Pyramid Biosciences",
        "Pyramid Biosciences GeneQuantum Healthcare (Suzhou) Co"
      ],
      "HQ City": "Boston",
      "HQ Country": "United States",
      "Founding Year": "2018",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://pyramidbio.com/",
      "Acquisition": "-",
      "drugs": [
        "GQ1010"
      ],
      "co-developers": [
        "GeneQuantum (Suzhou, China)"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Pyxis Oncology",
      "names": [
        "Pyxis Oncology"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2018",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.pyxisoncology.com/",
      "Acquisition": "-",
      "drugs": [
        "PYX-201"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Radiation Therapy Oncology Group",
      "names": [
        "Radiation Therapy Oncology Group"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.rtog.org/",
      "Acquisition": "-",
      "trials": [
        "NCT02573324"
      ],
      "co-developers": [
        "AbbVie"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Rakuten Medical",
      "names": [
        "Rakuten Medical (Aspyrian Therapeutics)",
        "Rakuten Medical"
      ],
      "HQ City": "Tokyo",
      "HQ Country": "Japan",
      "Founding Year": "2005",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.rakuten-med.com/",
      "Acquisition": "-",
      "drugs": [
        "ASP-1929  RM-1929 Cetuximab-irdye 700dx | RM-1929 | Cetuximab sarotalocan | ASP-1929"
      ],
      "co-developers": [
        "Aspyrian"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Redwood Bioscience",
      "names": [
        "Redwood Bioscience.",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience",
        "Redwood Bioscience"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Catalent in 2014",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Regeneron",
      "names": [
        "Regenron",
        "Regeneron",
        "Regeneron Pharmaceuticals",
        "Regeneron Pharmaceuticals, Tarrytown, NY"
      ],
      "HQ City": "Tarrytown",
      "HQ Country": "United States",
      "Founding Year": "1988",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.regeneron.com",
      "Acquisition": "-",
      "trials": [
        "NCT04982224",
        "NCT05991388"
      ],
      "co-developers": [
        "ADC Therapeutics"
      ],
      "drugs": [
        "REGN3124-PBD",
        "REGN5093 \u2013 M114",
        "Anti-Prolactin Receptor | Anti-PRLR-ADC | PRLR | REGN2878-DM1"
      ],
      "# co-developers": 1,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "RemeGen",
      "names": [
        "Remegen Biosciences (Shandong China), Yantai Rongchang Biological Engineering (manufactured by MabPlex)",
        "RemeGen",
        "RemeGen Co., Ltd"
      ],
      "HQ City": "Yantai",
      "HQ Country": "China",
      "Founding Year": "2008",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.remegen.com",
      "Acquisition": "-",
      "trials": [
        "NCT04617314",
        "NCT04965519",
        "NCT06157892",
        "NCT03052634",
        "NCT06389006",
        "NCT04280341",
        "NCT04073602",
        "NCT06038396",
        "NCT06178159",
        "NCT06105008",
        "NCT02881138",
        "NCT06221748",
        "NCT03500380",
        "NCT05940896",
        "NCT05628857",
        "NCT06227156",
        "NCT04311034",
        "NCT03809013",
        "NCT05745740",
        "NCT03507166",
        "NCT05980481",
        "NCT05943379",
        "NCT05135715",
        "NCT05911295",
        "NCT05297552",
        "NCT06227117",
        "NCT06378242",
        "NCT06155396",
        "NCT04714190",
        "NCT05957757",
        "NCT04329429",
        "NCT05514158",
        "NCT05996952",
        "NCT06155383",
        "NCT04400695",
        "NCT05205850",
        "NCT05350917",
        "NCT02881190",
        "NCT04175847",
        "NCT05302284",
        "NCT03556345"
      ],
      "co-developers": [
        "Jiangsu HengRui Medicine",
        "BeiGene",
        "Seagen",
        "Merck Sharp & Dohme",
        "Biocytogen",
        "MabPlex"
      ],
      "drugs": [
        "Trastuzumab Botidotin",
        "RC-48 RC 480-ADC RC48 | RC-48 | Aidixi\u00ae | Disitamab Vedotin | RC48 | \u7231\u5730\u5e0c\u00ae | RC 480-ADC",
        "RC118",
        "RC108",
        "TRASTUZUMAB BRENGITECAN",
        "RC88"
      ],
      "# co-developers": 6,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 41,
      "# Phase 1 trials": 6,
      "# Phase 2 trials": 28,
      "# Phase 3 trials": 7,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Rinat",
      "names": [
        "Rinat"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2001",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.rinatcorp.com/",
      "Acquisition": "Acquired by Pfizer in 2006",
      "drugs": [
        "RN765C",
        "PF 06664178 | PF06664178 | PF-06664178 | RN927C"
      ],
      "co-developers": [
        "Pfizer",
        "WYETH"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Roche",
      "names": [
        "Roche (in collaboration with Seattle Genetic)",
        "Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)",
        "Roche-Genentech",
        "Genentech F. Hoffmann-La Roche",
        "Roche",
        "Genentech Roche In collaboration with ImmunoGen",
        "Roche Pharma AG",
        "Genentech Roche  In collaboration with ImmunoGen",
        "F. Hoffmann-La Roche (Roche)",
        "Hoffmann-La Roche",
        "Roche, F. Hoffmann-La Roche (Roche)",
        "Roche, F. Hoffmann-La Roche Ltd. (Basel, Switzerland)",
        "Pierre Fabre In collaboration with Roche",
        "Roche, F. Hoffmann-La Roche"
      ],
      "HQ City": "Basel",
      "HQ Country": "Switzerland",
      "Founding Year": "1896",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.roche.com",
      "Acquisition": "-",
      "trials": [
        "NCT02611323",
        "NCT04182204",
        "NCT03671018",
        "NCT02658734",
        "NCT00829166",
        "NCT06172127",
        "NCT03274492",
        "NCT05171647",
        "NCT00934856",
        "NCT01702571",
        "NCT06071871",
        "NCT04931342",
        "NCT03533283",
        "NCT04914741",
        "NCT04873362",
        "NCT02131064",
        "NCT04487756",
        "NCT03337698",
        "NCT03153163",
        "NCT02605915",
        "NCT03726879",
        "NCT00781612",
        "NCT02999672",
        "NCT01966471",
        "NCT04833114",
        "NCT01513083",
        "NCT00875979",
        "NCT05798156",
        "NCT02924883",
        "NCT02314481",
        "NCT04790903",
        "NCT03084939",
        "NCT05183035",
        "NCT03869190",
        "NCT03677141",
        "NCT03677154",
        "NCT01772472",
        "NCT04740918",
        "NCT05954143",
        "NCT05535244",
        "NCT02289833",
        "NCT06047080",
        "NCT01419197",
        "NCT00679341",
        "NCT03424005",
        "NCT05415215",
        "NCT01196052",
        "NCT04589845",
        "NCT02257567",
        "NCT03467373",
        "NCT02729896",
        "NCT01565200",
        "NCT04341181",
        "NCT01120184",
        "NCT04733118",
        "NCT02600897"
      ],
      "co-developers": [
        "AbbVie",
        "EuPAL",
        "Bolt",
        "NSABP Foundation",
        "Chugai",
        "GlaxoSmithKline",
        "GOG Foundation",
        "Pierre Fabre",
        "Genentech",
        "Seagen",
        "MedSIR",
        "Astellas",
        "Pfizer",
        "GWT-TUD GmbH",
        "GILEAD"
      ],
      "drugs": [
        "DNIB0600A | Lifastuzumab Vedotin | MNIB2126A  Anti-NaPi2b ADC RG-7599 | RG-7599",
        "W0101 | W0101 W-0101 | Lonigutamab Ugodotin | W-0101",
        "RO5541072-000 | DCDT2980S | FCU2803 | RG-7593 | ACD22-VCMMAE | DCDT-2989S | Pinatuzumab vedotin",
        "Anti-MUC16 ADC | DMUC5754A | Sofituzumab vedotin | RG7458",
        "Polivy\u2122 | ACD79B-VCMMAE | Polatuzumab vedotin | RG-7596 | DCDS4501A | FCU2711 | DCDS-4501A | RO5541077-000",
        "RG 7600 | DMOT-4039A | DMOT4039A | RG7600",
        "DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA | DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148",
        "RG7986",
        "RO7032005 | DCDS0780A | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin",
        "Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | RG-7841 | Anti-Ly6E | DLYE5953A",
        "RG7450 | Vandortuzumab vedotin | DSTP3086S | RG-7450 | MSTP2109A | DSTP-3086S | Anti-STEAP1 ADC",
        "RG-7636 | Anti-ETBR",
        "DFRF 4539A | RG 7598 | RG-7598 | RG7598",
        "T-DM1 | Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla\u00ae | Trastuzumab Emtansine"
      ],
      "# co-developers": 15,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "Lithuania",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Finland",
        "Israel",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 73,
      "# drugs": 14,
      "# Preclinical drugs": 0,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 6,
      "# Phase 2 drugs": 5,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 56,
      "# Phase 1 trials": 5,
      "# Phase 2 trials": 32,
      "# Phase 3 trials": 18,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Rongchang",
      "names": [
        "Rongchang",
        "Yantai Rongchang Biological Engineering",
        "Rongchang Pharmaceuticals"
      ],
      "HQ City": "Chongqing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "Hertuzumab Vedotin | Hertuzumab-vcMMAE"
      ],
      "co-developers": [
        "MabPlex"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "SICHUAN BIOKIN",
      "names": [
        "SICHUAN BIOKIN",
        "Baili-Bio (Chengdu) (Sichuan Biokin)"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "SOTIO Bio",
      "names": [
        "SOTIO Biotech a.s",
        "SOTIO a.s",
        "SOTIO Bio"
      ],
      "HQ City": "Prague",
      "HQ Country": "Czech Republic",
      "Founding Year": "2010",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.sotio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04834544",
        "EUCTR2021-005873-25-ES",
        "NCT05525286"
      ],
      "co-developers": [],
      "drugs": [
        "CLDN18.2 ADC | SOT102 | SO-N102"
      ],
      "# co-developers": 0,
      "locations": [
        "Czechia",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "# locations": 5,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Samsung Medical Center",
      "names": [
        "Samsung Medical Center",
        "LegoChem Biosiences and Samsung Medical Center"
      ],
      "HQ City": "Seoul",
      "HQ Country": "South Korea",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.samsunghospital.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02280785"
      ],
      "co-developers": [
        "Millennium",
        "Legochem"
      ],
      "drugs": [
        "LCB14-19nm"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sanofi",
      "names": [
        "ImmunoGen (previously also Sanofi)",
        "Sanofi Pasteur, a Sanofi Company",
        "Sanofi"
      ],
      "HQ City": "Paris",
      "HQ Country": "France",
      "Founding Year": "2004",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.sanofi.com",
      "Acquisition": "-",
      "ttd": [
        "D05TBQ",
        "D2D6NJ"
      ],
      "co-developers": [
        "IMMUNOGEN",
        "GlaxoSmithKline"
      ],
      "trials": [
        "NCT01444781",
        "NCT04142242",
        "NCT06397768",
        "NCT05922501",
        "NCT01472887",
        "NCT01983540",
        "NCT00772070",
        "NCT02610348",
        "NCT01470456",
        "NCT00654901",
        "NCT00258856"
      ],
      "drugs": [
        "SAR 3419 | SAR3419 | Coltuximab Ravtansine",
        "SAR408701 SAR 408701 SAR-408701 | Tusamitamab Ravtansine | SAR408701 | SAR-408701 | SAR 408701",
        "SAR 566658 | SAR566658",
        "SAR428926 | SAR428926 SAR 428926"
      ],
      "# co-developers": 2,
      "locations": [
        "Italy",
        "Czechia",
        "Israel",
        "Austria",
        "Poland",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Belgium",
        "France",
        "Norway",
        "United States"
      ],
      "# locations": 12,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 11,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 5,
      "# Phase 3 trials": 5,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Schering",
      "names": [
        "Biogen Schering AG  Spectrum Pharmaceuticals",
        "Schering"
      ],
      "HQ City": "Berlin",
      "HQ Country": "Germany",
      "Founding Year": "1885",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.bayer.com/",
      "Acquisition": "Acquired by Bayer in 2006",
      "drugs": [
        "Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin"
      ],
      "co-developers": [
        "Biogen"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 1,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Seagen",
      "names": [
        "Seattle Genetics",
        "Astellas Northbrook, IL Seattle Genetics Bothell, WA",
        "Genmab in collaboration with Seattle Genetics",
        "GenmabPrinceton, NJSeattle GeneticsBothell, WA",
        "GlaxoSmithKline  (GSK) Co-developer: Seattle Genetics",
        "Agensys, Inc. Seattle Genetics, Inc",
        "Roche (in collaboration with Seattle Genetic)",
        "Seattle Genetics (Licensed from  Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "Seagen Sanofi",
        "Seagen (Pfizer)",
        "Seattle Genetics, Inc",
        "Seattle genetics",
        "Seagen",
        "Originated by Agensys, Ligand Pharmaceuticals and Seattle Genetics   Co-developed by Astellas",
        "Seattle genetics, Inc. (Bothell WA USA)",
        "Seattle Genetics (Licensed from Bristol-Myers Squibb (BMS) with technology licensed from Enzon)",
        "SEAGEN INC",
        "Seagen Inc",
        "Seagen, Inc"
      ],
      "HQ City": "Bothell",
      "HQ Country": "United States",
      "Founding Year": "1998",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.seagen.com",
      "Acquisition": "Acquired by Pfizer in 2023",
      "ttd": [
        "D0QI1K",
        "DDG8W9",
        "DJYD13",
        "DS6BE2",
        "DORB45",
        "DS6B1L"
      ],
      "co-developers": [
        "Millennium",
        "Alliance Foundation Trials",
        "GlaxoSmithKline",
        "Ligand Pharmaceuticals",
        "Teva",
        "Kyowa Kirin",
        "Roche",
        "Merck Sharp & Dohme",
        "Pfizer",
        "GILEAD",
        "Celgene",
        "PPD",
        "Takeda",
        "GOG Foundation",
        "Agensys",
        "Genentech",
        "Immune Tolerance Network (ITN)",
        "Genmab",
        "Bristol Myers Squibb",
        "RemeGen",
        "Astellas"
      ],
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125388s106lbl.pdf",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s007lbl.pdf"
      ],
      "trials": [
        "NCT05323955",
        "NCT00051584",
        "NCT01874054",
        "NCT01026233",
        "NCT01421667",
        "NCT01396070",
        "NCT00051571",
        "NCT01700751",
        "NCT00031187",
        "NCT03485209",
        "NCT03288545",
        "NCT01578499",
        "NCT01777152",
        "NCT02552121",
        "NCT02227199",
        "NCT02734771",
        "EUCTR2019-001219-22-IE",
        "NCT01868451",
        "NCT03424005",
        "NCT05414500",
        "NCT04457596",
        "NCT04609566",
        "NCT05922904",
        "NCT04697628",
        "NCT05180097",
        "NCT01716806",
        "NCT01920932",
        "NCT05756569",
        "NCT05673928",
        "NCT02001623",
        "NCT01166490",
        "NCT06120504",
        "NCT01578967",
        "NCT01026415",
        "NCT04569032",
        "NCT01100502",
        "NCT00079755",
        "NCT02326584",
        "NCT01534078",
        "NCT03474107",
        "NCT03657043",
        "NCT03245736",
        "NCT02216890",
        "NCT03786081",
        "NCT00947856",
        "NCT02927769",
        "NCT03755804",
        "NCT04879329",
        "NCT03438396",
        "NCT01969643",
        "NCT00848926",
        "NCT06377566",
        "NCT05775471",
        "NCT06003231",
        "NCT04539938",
        "NCT01712490",
        "NCT03264131",
        "NCT00430846",
        "NCT05911295",
        "NCT00086333",
        "NCT01807598",
        "EUCTR2019-001219-22-ES",
        "NCT01461538",
        "NCT03587844",
        "NCT06254495",
        "NCT03222492",
        "NCT01352520",
        "NCT02616965",
        "NCT02822586",
        "NCT03219333",
        "NCT01309789",
        "NCT04404283",
        "NCT01596218",
        "NCT05357794",
        "NCT01060904",
        "NCT06157892",
        "NCT03646123",
        "NCT01902329",
        "NCT01786135",
        "NCT00866047",
        "NCT01508312",
        "NCT05149768",
        "NCT03198689",
        "NCT02505269",
        "NCT04685616",
        "NCT02581631",
        "NCT01786096",
        "NCT04587687",
        "NCT03310957",
        "NCT00028483",
        "NCT01015911",
        "NCT02572167",
        "NCT02086604"
      ],
      "drugs": [
        "SGN-B7H4V",
        "SGN-CEACAM5C",
        "Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADC",
        "SGN-CD352a",
        "AXL-107-MMAE | HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | Enapotamab vedotin | HuMax-AXL-ADC",
        "SGN35 | Brentuximab vedotin | Adcetris\u00ae | SGN-35 cAC10-Val-Cit-MMAE",
        "BR96-DOX | SGN-15 | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248",
        "SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE | SGN-CD228A",
        "EC-mAb | h2H12ec-SGD-1910 | SGN-CD33A | Vadastuximab talirine | h2H12ec-mc-val-ala-SGD-1882",
        "SGN-PDL1V",
        "SGN-CD30C",
        "Tivdak | HuMax\u00ae-TF-ADC | TF-011-MMAE  HuMax-TF-ADC | Tisotumab Vedotin",
        "SGN-19A SGN-CD19A hBU12-491 | Denintuzumab mafodotin | hBU12-491 | SGN-19A | SGN-CD19A",
        "SGN-B6A",
        "Enfortumab | ASG-22ME | AGS-22ME | AGS-22CE | ASG-22CE | AGS-22M | ASG-22MSE | Enfortumab Vedotin | Padcev | AGS-22M6E | Enfortumab vedotin",
        "SGN-CD19B",
        "ASG-5ME",
        "ASG-15ME | AGS15C \u2013SGD-1006 | Ha15-10ac12vcMMAE | AGS15E | AGS-15vcMMAE | Sirtratumab vedotin | AGS-15E | Ha15-10ac.1vcMMAE",
        "Vorsetuzumab mafodotin | SGN-75",
        "superseding SGN-75 | SGN-CD70A | SGN CD70 A",
        "J6M0-mcMMAF | Blenrep\u00ae | Belantamab mafodotin | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | GSK2857916",
        "Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | RG-7841 | Anti-Ly6E | DLYE5953A"
      ],
      "# co-developers": 21,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Puerto Rico",
        "Czech Republic",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Georgia",
        "Republic of Korea",
        "Argentina",
        "El Salvador",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "United States of America",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam"
      ],
      "# locations": 61,
      "# drugs": 22,
      "# Preclinical drugs": 1,
      "# Approved drugs": 4,
      "# Phase 1 drugs": 10,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 3,
      "# Phase 4 drugs": 0,
      "# trials": 93,
      "# Phase 1 trials": 21,
      "# Phase 2 trials": 58,
      "# Phase 3 trials": 12,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Seasun Biomaterials",
      "names": [
        "LegoChem Biosciences and Seasun Biomaterials",
        "Seasun Biomaterials"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2014",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.seasunbio.com/",
      "Acquisition": "-",
      "drugs": [
        "LCB14-2nm"
      ],
      "co-developers": [
        "Legochem"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Servier",
      "names": [
        "Servier"
      ],
      "HQ City": "Suresnes",
      "HQ Country": "France",
      "Founding Year": "1954",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://servier.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04307576"
      ],
      "co-developers": [
        "Nova Laboratories Limited",
        "Pfizer",
        "Amgen",
        "NordForsk"
      ],
      "drugs": [],
      "# co-developers": 4,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Fosun",
      "names": [
        "Fosun",
        "Legochem Biosciences and Fosun Pharma",
        "Shanghai Fosun Pharmaceutical Development Co, Ltd",
        "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd",
        "Shanghai Fosun"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.fosunpharma.com",
      "Acquisition": "-",
      "trials": [
        "NCT05755048"
      ],
      "co-developers": [
        "Legochem"
      ],
      "drugs": [
        "FS-1502 | FS-1502 Trastuzumab Monomethyl Auristatin F",
        "Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110 | Herceptin-LC-LBG-MMAF | LCB14-0110"
      ],
      "# co-developers": 1,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Hansoh Biomedical",
      "names": [
        "Hansoh BioMedical R&D Company",
        "Shanghai Hansoh Biomedical Co., Ltd",
        "Shanghai Hansoh Biomedical",
        "Hansoh (Shanghai)",
        "Hansoh BioMedical R&D Company ( Shanghai Hansoh Biomedical Co., Ltd"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2004",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.hansohbio.com",
      "Acquisition": "-",
      "trials": [
        "NCT06144723",
        "NCT05263479",
        "NCT06336707",
        "NCT06014190",
        "NCT06112704",
        "NCT05276609"
      ],
      "co-developers": [],
      "drugs": [
        "HS-20093 (Phase Ib: Dose expansion) | HS-20093 | HS-20093 (Phase Ia: Dose escalation)",
        "HS-20105",
        "HS-20089"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 3,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 6,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 3,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Henlius",
      "names": [
        "Shanghai Henlius Biotech",
        "Shanghai Henlius"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.henlius.com",
      "Acquisition": "-",
      "trials": [
        "NCT06115642",
        "NCT06210815"
      ],
      "co-developers": [],
      "drugs": [
        "HLX43",
        "HLX42"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 2,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Institute Of Biological Products",
      "names": [
        "Shanghai Institute Of Biological Products"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06298058"
      ],
      "co-developers": [],
      "drugs": [
        "SIBP-A13 | SIBP-A13 formulation for injection"
      ],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Junshi",
      "names": [
        "Shanghai Junshi Bioscience Co., Ltd",
        "Shanghai Junshi"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2012",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.junshipharma.com/",
      "Acquisition": "-",
      "drugs": [
        "JS108"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Miracogen",
      "names": [
        "Shanghai Miracogen, a fully owned subsidiary of Lepu Biopharma",
        "Shanghai Miracogen in partnership with Lepu Biopharma",
        "Shanghai Miracogen  in partnership with Lepu Biopharma",
        "Shanghai Miracogen Inc",
        "Miracogen",
        "Shanghai Miracogen"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.miracogen.com",
      "Acquisition": "-",
      "ttd": [
        "DM7WY2"
      ],
      "co-developers": [
        "Lepu Biopharma"
      ],
      "trials": [
        "NCT05754853",
        "NCT04868344",
        "NCT04843709",
        "NCT05688605",
        "NCT05338957",
        "NCT04742153",
        "NCT05126719",
        "NCT04838964",
        "NCT05751512",
        "NCT04924699"
      ],
      "drugs": [
        "MRG004A",
        "MRG003",
        "MRG002"
      ],
      "# co-developers": 1,
      "locations": [
        "Mexico",
        "Kenya",
        "Indonesia",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Costa Rica",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "United Arab Emirates",
        "Czech Republic",
        "Puerto Rico",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Finland",
        "Dominican Republic",
        "Georgia",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Venezuela",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Estonia",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 72,
      "# drugs": 3,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 10,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 6,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shanghai Pharmaceuticals Holding",
      "names": [
        "Shanghai Pharmaceuticals Holding Co., Ltd",
        "Shanghai Pharmaceuticals Holding"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sphchina.com/",
      "Acquisition": "-",
      "trials": [
        "NCT03953833"
      ],
      "co-developers": [],
      "drugs": [
        "B003"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shattuck Labs",
      "names": [
        "Shattuck Labs"
      ],
      "HQ City": "Austin",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.shattucklabs.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Shenogen Pharma",
      "names": [
        "Shenogen Pharma Group",
        "Shenogen Pharma"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "SNG-8023 ADC"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Siamab",
      "names": [
        "Siamab",
        "Siamab Therapeutics"
      ],
      "HQ City": "Newton",
      "HQ Country": "United States",
      "Founding Year": "2012",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.siamab.com/",
      "Acquisition": "-",
      "drugs": [
        ""
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sichuan Baili",
      "names": [
        "Sichuan Baili",
        "SystImmune, Inc in collaboration with Sichuan Baili Pharmaceutical Co"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "BL-B01D1"
      ],
      "co-developers": [
        "Systimmune"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sichuan Kelun",
      "names": [
        "Sichuan Kelun Pharmaceutical Research Institute Co., Ltd",
        "Sichuan Kelun"
      ],
      "HQ City": "Chengdu",
      "HQ Country": "China",
      "Founding Year": "1992",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "http://www.kelunpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05367635"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Silverback",
      "names": [
        "Silverback",
        "Silverback Therapeutics"
      ],
      "HQ City": "Seattle",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://silverbacktx.com/",
      "Acquisition": "-",
      "ttd": [
        "DUA7P2"
      ],
      "co-developers": [],
      "drugs": [
        "SBT6050 | Pertuzumab Zuvotolimod"
      ],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "North Macedonia",
        "Czechia",
        "Singapore",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "New Zealand",
        "United States",
        "Norway",
        "Canada",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 53,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sino Biopharmaceutical",
      "names": [
        "Sino Biopharmaceutical"
      ],
      "HQ City": "Hong Kong",
      "HQ Country": "China",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sinobiopharm.com/",
      "Acquisition": "-",
      "drugs": [
        "TQB2103"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sinobioway Biomedicine",
      "names": [
        "BioAtla in collaboration with Sinobioway Biomedicine",
        "Sinobioway Biomedicine"
      ],
      "HQ City": "Beijing",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "CAB-Axl-ADC | CAB-anti-Axl-ADC | Mecbotamab Vedotin | CAB-anti-Axl-ADC BA3011 | BA3011"
      ],
      "co-developers": [
        "BioAtla"
      ],
      "# co-developers": 1,
      "locations": [
        "Italy",
        "Hong Kong",
        "Germany",
        "Poland",
        "Spain",
        "Greece",
        "Taiwan",
        "United States"
      ],
      "# locations": 8,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sorrento Therapeutics",
      "names": [
        "Sorrento Therapeutics",
        "Sorrento Therapeutics, Inc"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2006",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.sorrentotherapeutics.com",
      "Acquisition": "-",
      "trials": [
        "NCT05308225",
        "NCT05584709",
        "NCT04316442"
      ],
      "co-developers": [],
      "drugs": [
        "CBT-161 | Anti-cMET ADC",
        "STI-6129 LNDS1001 | LNDS1001 | STI-6129 | CD38-077"
      ],
      "# co-developers": 0,
      "locations": [
        "China",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Spectrum Pharmaceuticals",
      "names": [
        "Spectrum Pharmaceuticals"
      ],
      "HQ City": "Henderson",
      "HQ Country": "United States",
      "Founding Year": "1987",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.sppirx.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Spirogen",
      "names": [
        "Spirogen"
      ],
      "HQ City": "London",
      "HQ Country": "United Kingdom",
      "Founding Year": "1995",
      "Public/Private": "-",
      "Established/Startup": "Established",
      "Specialty": "ADC Platform Technology Technology",
      "Website URL": "https://www.spirogen.com/",
      "Acquisition": "Acquired by AstraZeneca in 2013",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Stemcentrx",
      "names": [
        "Stem CentRx",
        "Pfizer Stemcentrx (now AbbVie) In collaboration with Indiana University",
        "Stemcentrx (now part of AbbVie)",
        "AbbVie Stemcentrx LLC",
        "Stemcentrx"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "-",
      "Acquisition": "Acquired by AbbVie in 2016",
      "trials": [
        "NCT01901653",
        "NCT02874664"
      ],
      "co-developers": [
        "Pfizer",
        "AbbVie"
      ],
      "drugs": [
        "SC-006 | SC006",
        "ABBV-647 | PF-06647020 | Cofetuzumab pelidotin | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020",
        "Tamrintamab Pamozirine | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Anti-DPEP3 ADC | SC-003",
        "SC16LD6.5"
      ],
      "# co-developers": 2,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Finland",
        "Croatia",
        "Belarus",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# locations": 36,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Strata Oncology",
      "names": [
        "Strata Oncology"
      ],
      "HQ City": "Ann Arbor",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.strataoncology.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05097599"
      ],
      "co-developers": [
        "GILEAD",
        "Pfizer",
        "Merck Sharp & Dohme"
      ],
      "drugs": [],
      "# co-developers": 3,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Sutro Biopharma",
      "names": [
        "Sutro Biopharma, Inc",
        "SUTRO",
        "EMD Serono Merck KGaA, Darmstadt, Germany Sutro Biopharma",
        "Sutro Biopharma",
        "Bristol-Myers Squibb (Celgene) Sutro Biopharma",
        "Celgene in collaboration with Sutro"
      ],
      "HQ City": "South San Francisco",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.sutrobio.com",
      "Acquisition": "-",
      "ttd": [
        "D10GPJ"
      ],
      "co-developers": [
        "Tasly Pharmaceutical Group Co., Ltd",
        "Celgene",
        "Bristol Myers Squibb",
        "GOG Foundation"
      ],
      "trials": [
        "NCT06238687",
        "NCT03748186",
        "NCT05870748",
        "NCT03424603",
        "NCT05200364"
      ],
      "drugs": [
        "SP-8166 | SP8166 | LUVELTAMAB TAZIDE",
        "CC-99712 \u2013 Anti-BCMA ADC | CC-99712",
        "Anti-CD74-ADC | STRO-001",
        "STRO-004",
        "STRO-003",
        "M1231",
        "STRO-002 STRO 002 SP8193 | Luveltamab Tazevibulin \u2013 S\u03a4RO-002 \u2013 Luvelta"
      ],
      "# co-developers": 4,
      "locations": [
        "Canada",
        "Italy",
        "Singapore",
        "Israel",
        "China",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "France",
        "United States"
      ],
      "# locations": 10,
      "# drugs": 7,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 3,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Suzhou Zanrong Pharma",
      "names": [
        "Suzhou Zanrong Pharma Limited",
        "Suzhou Zanrong Pharma"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05593094"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Synthon Pharmaceuticals Durham, NC",
      "names": [
        "Synthon Pharmaceuticals Durham, NC"
      ],
      "HQ City": "Durham",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "Acquired by Synthon Holding B.V. in 2015",
      "ttd": [
        "D0HL5N"
      ],
      "co-developers": [
        "Byondis"
      ],
      "drugs": [
        "SYD985 | Trastuzumab vc-seco-DUBA | Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole | Trastuzumab duocarmazine | SYD 985"
      ],
      "# co-developers": 1,
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Saudi Arabia",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Dominican Republic",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Norway",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium",
        "Vietnam",
        "Uganda"
      ],
      "# locations": 58,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Systimmune",
      "names": [
        "Systimmune",
        "SystImmune, Inc in collaboration with Sichuan Baili Pharmaceutical Co"
      ],
      "HQ City": "Bothell",
      "HQ Country": "United States",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.systimmune.com",
      "Acquisition": "-",
      "drugs": [
        "BL-B01D1",
        "BL-B029A1 | BL-B029A1 BL B029A1",
        "BL-M005A2 | BL M005A2 BL-M005A2",
        "BL-M002A2 | BL M002A2 BL-M002A2"
      ],
      "co-developers": [
        "Sichuan Baili"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 4,
      "# Preclinical drugs": 3,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TG Therapeutics, Inc",
      "names": [
        "TG Therapeutics, Inc"
      ],
      "HQ City": "New York",
      "HQ Country": "United States",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.tgtherapeutics.com/",
      "Acquisition": "-",
      "trials": [
        "NCT02164006"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TMC Pharma",
      "names": [
        "TMC Pharma"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT03610360"
      ],
      "co-developers": [
        "Amphera BV"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TORL Biotherapeutics",
      "names": [
        "TORL Biotherapeutics, LLC",
        "TORL Biotherapeutics"
      ],
      "HQ City": "Irvine",
      "HQ Country": "United States",
      "Founding Year": "2021",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.torlbio.com",
      "Acquisition": "-",
      "trials": [
        "NCT05948826",
        "NCT06005740",
        "NCT05156866",
        "NCT05103683"
      ],
      "co-developers": [
        "Translational Research in Oncology"
      ],
      "drugs": [
        "TORL-3-600",
        "TORL-1-23",
        "TORL-4-500",
        "TORL-2-307-ADC"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "Korea, Republic of",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 4,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "TOT Biopharm",
      "names": [
        "TOT Biopharm"
      ],
      "HQ City": "Suzhou",
      "HQ Country": "China",
      "Founding Year": "2010",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.totbiopharm.com/",
      "Acquisition": "-",
      "drugs": [
        "TAA013"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Takeda",
      "names": [
        "Mersana Therapeutics in collaboration with Takeda.  Antibody development: Adimab",
        "Millennium",
        "Takeda (listed as Millennium Pharmaceuticals) ImmunoGen",
        "Mersana Therapeutics in collaboration with Takeda. Antibody development: Adimab",
        "Takeda",
        "LegoChem Biosciences and Takeda",
        "Millennium: The Takeda Oncology Company",
        "Takeda Development Center Americas, Inc",
        "Takeda Pharmaceutical Co. Ltd. (Osaka Japan)"
      ],
      "HQ City": "Osaka",
      "HQ Country": "Japan",
      "Founding Year": "1781",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "https://www.takeda.com",
      "Acquisition": "-",
      "ttd": [
        "D9ICV2"
      ],
      "co-developers": [
        "Millennium",
        "Mersana",
        "BeiGene",
        "Legochem",
        "Seagen"
      ],
      "trials": [
        "NCT05442554",
        "NCT05316246",
        "NCT01712490",
        "NCT02979522",
        "NCT06390995",
        "NCT03217643",
        "NCT02467946",
        "NCT02939014",
        "NCT05673785",
        "NCT04685616",
        "NCT01909934",
        "NCT06186986"
      ],
      "drugs": [
        "5F9vcMMAE | Indusatumab Vedotin | TAK-264 | TAK264 | MLN-0264 | MLN 0264 | MLN0264",
        "TAK-500",
        "LCB14-15nm",
        "TAK-522 | XMT-1522 | XMT1522 TAK-522",
        "TAK-164 TAK164 Anti-GCC ADC Anti-GCC | TAK-164",
        "TAK-853",
        "SGN35 | Brentuximab vedotin | Adcetris\u00ae | SGN-35 cAC10-Val-Cit-MMAE",
        "MLN-2704 | MLN2704"
      ],
      "# co-developers": 5,
      "locations": [
        "Mexico",
        "Czechia",
        "Lithuania",
        "China",
        "Ireland",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Israel",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "# locations": 38,
      "# drugs": 8,
      "# Preclinical drugs": 0,
      "# Approved drugs": 1,
      "# Phase 1 drugs": 2,
      "# Phase 2 drugs": 4,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 12,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 7,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 2
    },
    {
      "heading": "Tallac Therapeutics",
      "names": [
        "Tallac Therapeutics"
      ],
      "HQ City": "Burlingame",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://tallactherapeutics.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05399654"
      ],
      "co-developers": [],
      "drugs": [
        "TAC-001"
      ],
      "# co-developers": 0,
      "locations": [
        "Australia",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tanabe Research Laboratories USA",
      "names": [
        "Tanabe Research Laboratories USA in collaboration with Open Innovation Partners and MedImmune",
        "Tanabe Research Laboratories",
        "Tanabe Research Laboratories USA"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.tanabe-usa.com/",
      "Acquisition": "-",
      "ttd": [
        "DU6H8Z"
      ],
      "co-developers": [
        "Open Innovation Partners",
        "AstraZeneca",
        "MedImmune"
      ],
      "drugs": [
        "TR1801-ADC | TR1801-ADC MT-8633 | MT-8633"
      ],
      "# co-developers": 3,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Targetome SA",
      "names": [
        "Targetome SA",
        "Targetome SA, a spin-off from the University of Li\u00c3\u00a8ge (ULg), Belgium.",
        "Targetome SA, a spin-off from the University of Li\u00e8ge (ULg), Belgium",
        "Targetome SA, a spin-off from the University of Li\u00c3\u00a8ge (ULg), Belgium.,",
        "Targetome SA, a spin-off from the University of Li\u00c3\u00a8ge (ULg), Belgium"
      ],
      "HQ City": "Li\u00e8ge",
      "HQ Country": "Belgium",
      "Founding Year": "2015",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.targetome.com",
      "Acquisition": "-",
      "drugs": [
        "TGM-004",
        "TGM-002",
        "TGM-003",
        "TGM-005",
        "TGM-001"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 5,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tarveda",
      "names": [
        "Tarveda Therapeutics",
        "Tarveda"
      ],
      "HQ City": "Watertown",
      "HQ Country": "United States",
      "Founding Year": "2011",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "Acquired by Centrose in 2022",
      "drugs": [
        "PEN-866 | PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666",
        "PEN-221 | BTP-227 | PEN221"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tasly Pharmaceutical Group Co., Ltd",
      "names": [
        "Tasly Pharmaceutical Group Co., Ltd"
      ],
      "HQ City": "Tianjin",
      "HQ Country": "China",
      "Founding Year": "1994",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "http://www.tasly.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06238687"
      ],
      "co-developers": [
        "Sutro Biopharma"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Telix Pharmaceuticals",
      "names": [
        "Telix Pharmaceuticals",
        "Telix Pharmaceuticals (Innovations) Pty Limited"
      ],
      "HQ City": "Melbourne",
      "HQ Country": "Australia",
      "Founding Year": "2015",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.telixpharma.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04786847"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Teva",
      "names": [
        "Teva Branded Pharmaceutical Products R&D, Inc",
        "Teva Pharmaceuticals USA",
        "Teva"
      ],
      "HQ City": "Petah Tikva",
      "HQ Country": "Israel",
      "Founding Year": "1901",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.tevapharm.com/",
      "Acquisition": "-",
      "trials": [
        "NCT00071539",
        "NCT03755804"
      ],
      "co-developers": [
        "Seagen"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 2,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 2,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Theradex",
      "names": [
        "Theradex"
      ],
      "HQ City": "Princeton",
      "HQ Country": "United States",
      "Founding Year": "1983",
      "Public/Private": "Private",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.theradex.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04203641"
      ],
      "co-developers": [
        "Helix BioPharma"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Theratechnologies",
      "names": [
        "Theratechnologies"
      ],
      "HQ City": "Montreal",
      "HQ Country": "Canada",
      "Founding Year": "1993",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.theratech.com/",
      "Acquisition": "-",
      "drugs": [
        "TH1902 | Sudocetaxel Zendusortide"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "North Macedonia",
        "China",
        "Bosnia and Herzegovina",
        "Sweden",
        "Ireland",
        "Denmark",
        "Panama",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Puerto Rico",
        "Thailand",
        "Italy",
        "Israel",
        "Georgia",
        "Argentina",
        "Slovenia",
        "El Salvador",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Norway",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "# locations": 53,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Translational Drug Development",
      "names": [
        "Translational Drug Development"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT04880863"
      ],
      "co-developers": [
        "NeoTX Therapeutics Ltd"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Translational Research in Oncology",
      "names": [
        "Translational Research in Oncology",
        "Translational Research in Oncology-U.S"
      ],
      "HQ City": "Omaha",
      "HQ Country": "United States",
      "Founding Year": "2003",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC platform technology",
      "Website URL": "https://www.trio-cancer.org",
      "Acquisition": "-",
      "trials": [
        "NCT05156866",
        "NCT04553770",
        "NCT05103683",
        "NCT05948826",
        "NCT06005740"
      ],
      "co-developers": [
        "TORL Biotherapeutics",
        "DAIICHI SANKYO"
      ],
      "drugs": [
        "TORL-3-600",
        "TORL-1-23",
        "TORL-4-500",
        "TORL-2-307-ADC"
      ],
      "# co-developers": 2,
      "locations": [
        "Canada",
        "Korea, Republic of",
        "United States"
      ],
      "# locations": 3,
      "# drugs": 4,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 4,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 5,
      "# Phase 1 trials": 4,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Triphase Accelerator Corporation",
      "names": [
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience,",
        "Triphase Accelerator",
        "Catalent Pharma Solutions and Triphase Accelerator Corporation",
        "Triphase Accelerator Corporation, in collaboration with Catalent. The drug was originally developed by Catalent Biologics\u00e2\u20ac\u2122 subsidiary Redwood Bioscience",
        "Triphase Accelerator Corporation",
        "Triphase Research and Development III Corp"
      ],
      "HQ City": "Toronto",
      "HQ Country": "Canada",
      "Founding Year": "2011",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://triphaseco.com/",
      "Acquisition": "-",
      "ttd": [
        "DQC80I"
      ],
      "co-developers": [
        "Catalent"
      ],
      "trials": [
        "NCT03682796"
      ],
      "drugs": [
        "CD22-4AP"
      ],
      "# co-developers": 1,
      "locations": [
        "Canada",
        "United States"
      ],
      "# locations": 2,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Tubulis",
      "names": [
        "Tubulis",
        "Tubulis GmbH"
      ],
      "HQ City": "Munich",
      "HQ Country": "Germany",
      "Founding Year": "2019",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "ADC Platform Technology",
      "Website URL": "https://tubulis.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06303505"
      ],
      "co-developers": [],
      "drugs": [
        "TUB-040"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Turning Point therapeutics",
      "names": [
        "LaNova BMS (ex-China excl. Korea) Turning Point therapeutics (now part of BMS)",
        "Turning Point therapeutics"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2013",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.tptherapeutics.com/",
      "Acquisition": "Acquired by Bristol Myers Squibb in 2021",
      "drugs": [
        "LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302"
      ],
      "co-developers": [
        "LaNova"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "UCB Pharma",
      "names": [
        "UCB Pharma",
        "UCB Pharma SA"
      ],
      "HQ City": "Brussels",
      "HQ Country": "Belgium",
      "Founding Year": "1928",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.ucb.com/",
      "Acquisition": "-",
      "trials": [
        "NCT00867087",
        "NCT01590966",
        "NCT01363297",
        "NCT01055496",
        "NCT00868608",
        "NCT01564784",
        "NCT00299494",
        "NCT00356408"
      ],
      "co-developers": [
        "Pfizer"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 8,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 4,
      "# Phase 3 trials": 3,
      "# Phase 4 trials": 0
    },
    {
      "heading": "UNICANCER",
      "names": [
        "UNICANCER"
      ],
      "HQ City": "Paris",
      "HQ Country": "France",
      "Founding Year": "1964",
      "Public/Private": "Non-Profit",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.unicancer.fr/",
      "Acquisition": "-",
      "trials": [
        "NCT04132960",
        "NCT05552001",
        "NCT04595565"
      ],
      "co-developers": [
        "GILEAD",
        "DAIICHI SANKYO"
      ],
      "drugs": [],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 3,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 2,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Varian Inc",
      "names": [
        "Varian Inc"
      ],
      "HQ City": "Palo Alto",
      "HQ Country": "United States",
      "Founding Year": "1948",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://www.varian.com/",
      "Acquisition": "Acquired by Siemens Healthineers in 2021",
      "trials": [
        "NCT05833867"
      ],
      "co-developers": [
        "GILEAD"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "VelosBio",
      "names": [
        "Merck & Co (VelosBio)",
        "VelosBio"
      ],
      "HQ City": "San Diego",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://velosbio.com/",
      "Acquisition": "Acquired by Merck & Co. in 2020",
      "ttd": [
        "D1CG5M"
      ],
      "co-developers": [
        "Merck KGaA, Darmstadt, Germany",
        "Merck Sharp & Dohme"
      ],
      "drugs": [
        "VLS-101 MK-2140 | VLS-101 | Zilovertamab vedotin | MK-2140"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 1,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Veru Inc.",
      "names": [
        "Veru Inc."
      ],
      "HQ City": "Miami",
      "HQ Country": "United States",
      "Founding Year": "1996",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "-",
      "Website URL": "https://verupharma.com/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Vincerx Pharma, Inc",
      "names": [
        "Vincerx Pharma, Inc"
      ],
      "HQ City": "Palo Alto",
      "HQ Country": "United States",
      "Founding Year": "2017",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://vincerx.com/",
      "Acquisition": "-",
      "trials": [
        "NCT06034275"
      ],
      "co-developers": [],
      "drugs": [
        "VIP943"
      ],
      "# co-developers": 0,
      "locations": [
        "United States"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Visterra",
      "names": [
        "Visterra"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2008",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.visterrainc.com/",
      "Acquisition": "Acquired by Otsuka Pharmaceutical in 2018",
      "drugs": [
        "VIS705"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 1,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Vor Biopharma",
      "names": [
        "Vor Biopharma"
      ],
      "HQ City": "Cambridge",
      "HQ Country": "United States",
      "Founding Year": "2016",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.vorbio.com/",
      "Acquisition": "-",
      "trials": [
        "NCT04849910"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "WYETH",
      "names": [
        "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc",
        "Pfizer (Wyeth)",
        "WYETH",
        "Wyeth is now a wholly owned subsidiary of Pfizer",
        "Pfizer (Wyeth Pharmaceuticals)"
      ],
      "HQ City": "Madison",
      "HQ Country": "United States",
      "Founding Year": "1926",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Antibody developer",
      "Website URL": "-",
      "Acquisition": "Acquired by Pfizer in 2009",
      "fda_label": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf",
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf"
      ],
      "co-developers": [
        "Rinat",
        "Pfizer",
        "Celltech",
        "Oxford BioMedica"
      ],
      "trials": [
        "NCT00037583",
        "NCT01134575",
        "NCT00044733",
        "NCT00717925",
        "NCT00962767",
        "NCT00304447",
        "NCT00037596",
        "NCT00148824"
      ],
      "drugs": [
        "BESPONSA\u00ae | CMC-544 CMC544 | Inotuzumab ozogamicin | CMC-544",
        "CDP-671 | CMB-401 | hCTMO1-calicheamicin | hCTMO1-calicheamicin CDP-671",
        "PF 06664178 | PF06664178 | PF-06664178 | RN927C",
        "WAY-CMA-676 | Gemtuzumab ozogamicin | CMA-676 | CDP-771 | hP67.6-calicheamicin | Mylotarg\u00ae",
        "PF-06263507 | A1-mafodotin | PF06263507 | A1-mcMMAF | PF 06263507 | Anti-5T4 monoclonal",
        "Anti-NOTCH3 ADC | PF06650808 | PF-06650808 | Anti-NOTCH3-ADC | PF-6650808"
      ],
      "# co-developers": 4,
      "locations": [
        "Czechia",
        "Singapore",
        "Lithuania",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "India",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "New Zealand",
        "Wales",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Hong Kong",
        "Switzerland",
        "Australia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Slovakia",
        "Belgium",
        "Estonia"
      ],
      "# locations": 38,
      "# drugs": 6,
      "# Preclinical drugs": 0,
      "# Approved drugs": 2,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 2,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 8,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 5,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 1
    },
    {
      "heading": "Westlake Therapeutics",
      "names": [
        "Westlake Therapeutics"
      ],
      "HQ City": "-",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06106152"
      ],
      "co-developers": [],
      "drugs": [
        "WTX212A | WTX212A injection"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Wilex",
      "names": [
        "Wilex"
      ],
      "HQ City": "Munich",
      "HQ Country": "Germany",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "HuMAB-5B1-ATAC",
        "anti-CD19 ADC | Anti-CD19 ADC | Anti-CD19 ATAC"
      ],
      "co-developers": [
        "MabVax",
        "Heidelberg Pharma"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Wisconsin Alumni Research Foundation - WARF",
      "names": [
        "Centrose (Originator: Wisconsin Alumni Research Foundation - WARF)",
        "Wisconsin Alumni Research Foundation - WARF"
      ],
      "HQ City": "Madison",
      "HQ Country": "United States",
      "Founding Year": "1925",
      "Public/Private": "Non-profit",
      "Established/Startup": "Established",
      "Specialty": "Unclear",
      "Website URL": "https://www.warf.org",
      "Acquisition": "-",
      "drugs": [
        "DYS-ADC | EDC-1 | DYS-EDC | EDC1",
        "EDC9 | EDC-CD20"
      ],
      "co-developers": [
        "Centrose"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 2,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Xadcera",
      "names": [
        "Xadcera"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Xenikos",
      "names": [
        "Xenikos"
      ],
      "HQ City": "Nijmegen",
      "HQ Country": "Netherlands",
      "Founding Year": "2006",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.xenikos.com",
      "Acquisition": "-",
      "drugs": [
        "SPV-T3a-RTA | Dafsolimab Setaritox",
        "WT1-RTA | Grisnilimab setaritox"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 2,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Xuanzhu Biopharm",
      "names": [
        "Xuanzhu Biopharm",
        "Xuanzhu Biopharmaceutical Co., Ltd"
      ],
      "HQ City": "-",
      "HQ Country": "China",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05804864"
      ],
      "co-developers": [],
      "drugs": [
        "KM501"
      ],
      "# co-developers": 0,
      "locations": [
        "China"
      ],
      "# locations": 1,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Y-Biologics",
      "names": [
        "LegoChem Biosciences and Y-Biologics",
        "Y-Biologics"
      ],
      "HQ City": "-",
      "HQ Country": "South Korea",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://ybiologics.com/en/",
      "Acquisition": "-",
      "drugs": [
        "anti-CD37 ADC | LCB14-15xx | NNV019",
        "AR-001 | YBK-001 | YBL-001"
      ],
      "co-developers": [
        "Nordic Nanovector",
        "Legochem"
      ],
      "# co-developers": 2,
      "locations": [],
      "# locations": 0,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zai Lab (Shanghai)",
      "names": [
        "Zai Lab (Shanghai) Co., Ltd",
        "Zai Lab (Shanghai)"
      ],
      "HQ City": "Shanghai",
      "HQ Country": "China",
      "Founding Year": "2014",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "-",
      "Website URL": "https://www.zailaboratory.com/",
      "Acquisition": "-",
      "trials": [
        "NCT05866354"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 1,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zhejiang ACEA Pharmaceutical Co. Ltd",
      "names": [
        "Zhejiang ACEA Pharmaceutical Co. Ltd"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05565807"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zhejiang Medicine",
      "names": [
        "Zhejiang Medicine",
        "Zhejiang Medicine Co"
      ],
      "HQ City": "Shaoxing",
      "HQ Country": "China",
      "Founding Year": "1997",
      "Public/Private": "Public",
      "Established/Startup": "Established",
      "Specialty": "API & Intermediates, Human/Animal Nutrition",
      "Website URL": "https://www.zmc.top/en/",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "ZielBio",
      "names": [
        "ZielBio, Inc",
        "ZielBio"
      ],
      "HQ City": "Charlottesville",
      "HQ Country": "United States",
      "Founding Year": "-",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Antibody Developer",
      "Website URL": "https://www.zielbio.com",
      "Acquisition": "-",
      "drugs": [
        "ZB131-MMAE | ZB131-DXd | ZB131 | ZB131  ZB131-MMAE  ZB131-DXd"
      ],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zionexa",
      "names": [
        "Zionexa"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT06195709"
      ],
      "co-developers": [],
      "drugs": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 1,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zova Biotherapeutics",
      "names": [
        "Zova Biotherapeutics",
        "Zova Biotherapeutics (Zova Bio)"
      ],
      "HQ City": "Hangzhou",
      "HQ Country": "China",
      "Founding Year": "2020",
      "Public/Private": "Private",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [
        "ZV05-mcMMAF | ZV05-ADC | ZV0501 | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501"
      ],
      "co-developers": [
        "Concortis"
      ],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 1,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "Zymeworks",
      "names": [
        "Iconic Therapeutics in collaboration with Zymeworks",
        "Iconic Therapeutics  in collaboration with Zymeworks",
        "Zymeworks",
        "Zymeworks In collaboration with BeiGene"
      ],
      "HQ City": "Vancouver",
      "HQ Country": "Canada",
      "Founding Year": "2003",
      "Public/Private": "Public",
      "Established/Startup": "Startup",
      "Specialty": "Unclear",
      "Website URL": "https://www.zymeworks.com",
      "Acquisition": "-",
      "ttd": [
        "DH09QZ"
      ],
      "co-developers": [
        "Exelixis",
        "Iconic",
        "BeiGene"
      ],
      "drugs": [
        "XB002 ICON-2 Tissue Factor ADC | ICON-2 Tissue Factor ADC  XB002",
        "ZW49 HER2 x HER2 Bispecific | ZW49 | Zanidatamab Zovodotin"
      ],
      "# co-developers": 3,
      "locations": [
        "Italy",
        "Canada",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "# locations": 10,
      "# drugs": 2,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 1,
      "# Phase 2 drugs": 1,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "bioRASI, LLC",
      "names": [
        "bioRASI, LLC"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05834296"
      ],
      "co-developers": [
        "Alzamend Neuro"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 1,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "company: K The Power",
      "names": [
        "company: K The Power"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT01825317"
      ],
      "co-developers": [
        "Neuronix Ltd"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "mobile Health AG",
      "names": [
        "mobile Health AG"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "trials": [
        "NCT05425550"
      ],
      "co-developers": [
        "Palleos Healthcare GmbH"
      ],
      "drugs": [],
      "# co-developers": 1,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 1,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    },
    {
      "heading": "pharmaand GmbH",
      "names": [
        "pharmaand GmbH"
      ],
      "HQ City": "-",
      "HQ Country": "-",
      "Founding Year": "-",
      "Public/Private": "-",
      "Established/Startup": "-",
      "Specialty": "-",
      "Website URL": "-",
      "Acquisition": "-",
      "drugs": [],
      "co-developers": [],
      "# co-developers": 0,
      "locations": [],
      "# locations": 0,
      "# drugs": 0,
      "# Preclinical drugs": 0,
      "# Approved drugs": 0,
      "# Phase 1 drugs": 0,
      "# Phase 2 drugs": 0,
      "# Phase 3 drugs": 0,
      "# Phase 4 drugs": 0,
      "# trials": 0,
      "# Phase 1 trials": 0,
      "# Phase 2 trials": 0,
      "# Phase 3 trials": 0,
      "# Phase 4 trials": 0
    }
  ],
  "trials": [
    {
      "id": "NCT05174637",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FDA018-ADC",
        "Drug: FDA018-ADC",
        "FDA018-Antibody-drug Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 78,
      "conditions": [
        "Advanced/ Metastatic Solid Tumors"
      ],
      "Start Date": "2021-10-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT03489525",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)",
        "Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)",
        "Dose Expansion, MEDI2228, ADC (antibody drug conjugate)",
        "Dose Escalation, MEDI2228, ADC (antibody drug conjugate)"
      ],
      "locations": [
        "Spain",
        "Australia",
        "Greece",
        "France",
        "United States"
      ],
      "enrollment": 107,
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "Start Date": "2018-03-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT04829604",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Ambrx, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "antibody drug conjugate (ADC)",
        "ARX788"
      ],
      "locations": [
        "Australia",
        "Korea, Republic of",
        "France",
        "United States"
      ],
      "enrollment": 71,
      "conditions": [
        "HER2 Positive Metastatic Breast Cancer"
      ],
      "Start Date": "2021-10-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT05156866",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "Drug: TORL-2-307-ADC",
        "TORL-2-307-ADC"
      ],
      "locations": [
        "Korea, Republic of",
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "Gastric Cancer",
        "Advanced Solid Tumor",
        "Pancreas Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": "2021-01-12",
      "Max Phase": "1"
    },
    {
      "id": "NCT01414283",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 52,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2008-10-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01414296",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 10,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2009-01-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01695044",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 119,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2012-09-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04681131",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "PD-1 inhibitor",
        "Biological: CAB-AXL-ADC",
        "Biological: PD-1 inhibitor",
        "CAB-AXL-ADC",
        "BA3011"
      ],
      "locations": [
        "Italy",
        "Hong Kong",
        "Poland",
        "Germany",
        "Greece",
        "Taiwan",
        "Spain",
        "United States"
      ],
      "enrollment": 240,
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "Start Date": "2020-08-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT04329429",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 57,
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": "2020-03-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT04073602",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 19,
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": "2019-08-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT04132960",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "UNICANCER"
      ],
      "collaborators": [
        "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company"
      ],
      "interventions": [
        "DS-8201a"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 186,
      "conditions": [
        "Breast Tumors"
      ],
      "Start Date": "2019-10-21",
      "Max Phase": "2"
    },
    {
      "id": "NCT02988817",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Genmab"
      ],
      "collaborators": [],
      "interventions": [
        "Enapotamab vedotin (HuMax-AXL-ADC)",
        "Biological: Enapotamab vedotin (HuMax-AXL-ADC)"
      ],
      "locations": [
        "Denmark",
        "United Kingdom",
        "Spain",
        "Belgium",
        "Netherlands",
        "United States"
      ],
      "enrollment": 306,
      "conditions": [
        "Ovarian Cancer",
        "Sarcoma",
        "Non Small Cell Lung Cancer (NSCLC)",
        "Endometrial Cancer",
        "Thyroid Cancer",
        "Solid Tumors",
        "Cervical Cancer",
        "Melanoma"
      ],
      "Start Date": "2016-01-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT03504488",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Biological: CAB-ROR2-ADC",
        "PD-1 inhibitor",
        "Biological: PD-1 inhibitor",
        "BA3021",
        "CAB-ROR2-ADC"
      ],
      "locations": [
        "Italy",
        "Hong Kong",
        "Poland",
        "Germany",
        "Greece",
        "Taiwan",
        "Spain",
        "United States"
      ],
      "enrollment": 420,
      "conditions": [
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma"
      ],
      "Start Date": "2018-06-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT05205850",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC118-ADC",
        "RC118 for injection",
        "Drug: RC118-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 135,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2021-11-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT06014658",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MBrace Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "Antibody-Drug Conjugate",
        "Drug: Antibody-Drug Conjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 90,
      "conditions": [
        "Cancer"
      ],
      "Start Date": "2023-01-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT02020135",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Progenics Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 9,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2013-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04695847",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "EMD Serono Research & Development Institute, Inc."
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "interventions": [
        "Bispecific antibody drug conjugate (ADC)",
        "M1231"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 23,
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Metastatic Solid Tumors",
        "Esophageal Cancer"
      ],
      "Start Date": "2021-01-13",
      "Max Phase": "1"
    },
    {
      "id": "NCT03255070",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Ambrx, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "antibody drug conjugate (ADC)",
        "ARX788"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": 106,
      "conditions": [
        "Gastric Neoplasm",
        "Solid Tumors",
        "Breast Neoplasms"
      ],
      "Start Date": "2018-03-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT04240704",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Novartis Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "JBH492"
      ],
      "locations": [
        "Singapore",
        "Israel",
        "Finland",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "Japan"
      ],
      "enrollment": 25,
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non-Hodgkins Lymphoma"
      ],
      "Start Date": "2020-09-07",
      "Max Phase": "1"
    },
    {
      "id": "NCT03425279",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Biological: PD-1 inhibitor",
        "PD-1 inhibitor",
        "CAB-AXL-ADC",
        "Biological: CAB-AXL-ADC"
      ],
      "locations": [
        "Hong Kong",
        "Taiwan",
        "United States"
      ],
      "enrollment": 300,
      "conditions": [
        "Myxofibrosarcoma",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "Start Date": "2018-01-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT04064359",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Oxford BioTherapeutics Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: OBT076, a CD205-directed antibody-drug conjugate",
        "MEN1309",
        "OBT076, a CD205-directed antibody-drug conjugate"
      ],
      "locations": [
        "Spain",
        "Greece",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 200,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2019-07-25",
      "Max Phase": "1"
    },
    {
      "id": "NCT02001623",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "TIVDAK",
        "Tisotumab Vedotin (HuMax-TF-ADC)",
        "Drug: Tisotumab Vedotin (HuMax-TF-ADC)"
      ],
      "locations": [
        "Sweden",
        "Denmark",
        "United Kingdom",
        "Belgium",
        "United States"
      ],
      "enrollment": 195,
      "conditions": [
        "Cervix Cancer",
        "Ovary Cancer",
        "Prostate Cancer (CRPC)",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "Bladder Cancer",
        "Esophagus Cancer",
        "Endometrium Cancer",
        "Lung Cancer(NSCLC)"
      ],
      "Start Date": "2013-11-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT04617314",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC108 for injection",
        "RC108"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 32,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2021-03-10",
      "Max Phase": "1"
    },
    {
      "id": "NCT05564858",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia",
        "Drug: FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib",
        "FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia",
        "FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib",
        "FDA022-BB05"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 107,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2022-09-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT06440005",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Angiex, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ADC",
        "AGX101"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 80,
      "conditions": [
        "Pancreas Cancer",
        "Cancer",
        "Locally Advanced Carcinoma",
        "Triple Negative Breast Cancer",
        "Advanced Cancer",
        "Metastatic Solid Tumor",
        "Pancreatic Adenocarcinoma"
      ],
      "Start Date": "2024-05-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05011188",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Rahul Aggarwal"
      ],
      "collaborators": [
        "Fortis Therapeutics, Inc."
      ],
      "interventions": [
        "Antibody-Drug Conjugate (ADC)",
        "FOR46",
        "XTANDI",
        "Enzalutamide",
        "anti-CD46 antibody conjugate",
        "Pegfilgrastim",
        "G-CSF"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer",
        "Prostate Cancer"
      ],
      "Start Date": "2022-01-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT05996952",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "West China Hospital"
      ],
      "collaborators": [
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 77,
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "Start Date": "2023-03-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT06234423",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "OnCusp Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "CUSP06"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 180,
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumor"
      ],
      "Start Date": "2024-02-09",
      "Max Phase": "1"
    },
    {
      "id": "NCT04316442",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Sorrento Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129",
        "anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 60,
      "conditions": [
        "Light Chain (AL) Amyloidosis"
      ],
      "Start Date": "2021-04-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04662580",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Ambrx, Inc."
      ],
      "collaborators": [
        "Johnson & Johnson"
      ],
      "interventions": [
        "ARX517"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 262,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2021-07-27",
      "Max Phase": "1"
    },
    {
      "id": "NCT06457997",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pheon Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "PHN-010"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 273,
      "conditions": [
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Colon Cancer",
        "Advanced Cancer",
        "Lung Cancer",
        "Cervical Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-07-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04152499",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Klus Pharma Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SKB264"
      ],
      "locations": [
        "Canada",
        "China",
        "Korea, Republic of",
        "Turkey",
        "United States"
      ],
      "enrollment": 1300,
      "conditions": [
        "Urothelial Carcinoma",
        "Epithelial Ovarian Cancer",
        "Small-Cell Lung Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Endometrial Carcinoma",
        "Gastric Adenocarcinoma"
      ],
      "Start Date": "2020-02-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT04400695",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Xeloda",
        "Navelbine",
        "Paclitaxel Injection",
        "Docetaxel Injection",
        "Drug: Vinorelbine Tartrate Injection",
        "RC48-ADC",
        "Drug: Capecitabine Tablets",
        "Drug: Paclitaxel Injection",
        "Vinorelbine Tartrate Injection",
        "Capecitabine Tablets",
        "RC48",
        "Drug: RC48-ADC",
        "Drug: Docetaxel Injection",
        "Taxol",
        "Taxotere"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 366,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2020-04-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT05103683",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "TORL-1-23"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 90,
      "conditions": [
        "Ovarian Cancer",
        "Endometrial Cancer",
        "NSCLC",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2021-11-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT05217693",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "BB-1705"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 288,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2022-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05308225",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Sorrento Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 72,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2023-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04610528",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "SOLTI Breast Cancer Research Group"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "U3 1402",
        "Patritumab Deruxtecan"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 80,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2020-12-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT06198751",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "7.5 mg/kg of TQB2102 for injection",
        "6.0 mg/kg of TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 104,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2024-02-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT05297552",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: JS001",
        "JS001",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 40,
      "conditions": [
        "Muscle Invasive Bladder Carcinoma"
      ],
      "Start Date": "2022-03-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT04202705",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD1875"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "enrollment": 31,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2020-02-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT05323045",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "BYON3521"
      ],
      "locations": [
        "Italy",
        "United Kingdom",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 31,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2022-03-21",
      "Max Phase": "1"
    },
    {
      "id": "NCT05514158",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC48-ADC injection",
        "RC98 injection",
        "RC48-ADC",
        "Drug: RC98",
        "Drug: RC48-ADC",
        "RC98"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 24,
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": "2022-04-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT05135715",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 50,
      "conditions": [
        "HER2-positive",
        "Advanced Melanoma",
        "Melanoma, Stage II"
      ],
      "Start Date": "2021-11-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT05941507",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "LigaChem Biosciences, Inc."
      ],
      "collaborators": [
        "AntibodyChem Biosciences, Inc."
      ],
      "interventions": [
        "Anti-PD-1 monoclonal antibody",
        "LCB84"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 300,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2023-10-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT02874664",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Stemcentrx"
      ],
      "collaborators": [],
      "interventions": [
        "SC16LD6.5",
        "Rovalpituzumab Tesirine"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 46,
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "Start Date": "2016-09-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05527184",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN151"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 227,
      "conditions": [
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "High Grade Serous Adenocarcinoma of Ovary"
      ],
      "Start Date": "2023-01-11",
      "Max Phase": "1"
    },
    {
      "id": "NCT02881138",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd.",
        "RemeGen"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 24,
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": "2016-03-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03366428",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a",
        "Experimental product"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 51,
      "conditions": [
        "Malignant Neoplasm of Breast"
      ],
      "Start Date": "2017-12-26",
      "Max Phase": "1"
    },
    {
      "id": "NCT02552121",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc.",
        "Genmab"
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "Drug: Tisotumab vedotin (HuMax-TF-ADC)",
        "Tisotumab vedotin (HuMax-TF-ADC)"
      ],
      "locations": [
        "Belgium",
        "Denmark",
        "United Kingdom",
        "Hungary",
        "United States"
      ],
      "enrollment": 33,
      "conditions": [
        "Lung Cancer (NSCLC)",
        "Cervix Cancer",
        "Ovary Cancer",
        "Bladder Cancer",
        "Esophagus Cancer",
        "Endometrium Cancer",
        "Prostate Cancer (CRPC)"
      ],
      "Start Date": "2015-09-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT02674568",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab tesirine",
        "SC16LD6.5"
      ],
      "locations": [],
      "enrollment": 342,
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": "2016-01-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT05745740",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC48-ADC",
        "Pyrotinib",
        "Drug: RC48-ADC",
        "DV",
        "Drug: Pyrotinib"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 26,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2023-02-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT06210815",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Henlius Biotech"
      ],
      "collaborators": [],
      "interventions": [
        "HLX42",
        "Anti-EGFR ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 42,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2024-03-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT05565807",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Zhejiang ACEA Pharmaceutical Co. Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 84,
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "Start Date": "2023-02-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT06005740",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "TORL-4-500"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "Hepatocellular Carcinoma",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-12-04",
      "Max Phase": "1"
    },
    {
      "id": "NCT04965519",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 120,
      "conditions": [
        "Gynecological Malignancy"
      ],
      "Start Date": "2021-07-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT02881190",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd.",
        "RemeGen"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 57,
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": "2015-12-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT06452706",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 42,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2024-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06431490",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 103,
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": "2024-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06038396",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "Toripalimab",
        "RC118",
        "RC118 for injection",
        "Toripalimab for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 64,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-08-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT03507166",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd.",
        "RemeGen"
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 43,
      "conditions": [
        "Advanced Cancer",
        "Urothelial Carcinoma"
      ],
      "Start Date": "2017-12-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT03556345",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 127,
      "conditions": [
        "HER2 Overexpressing Gastric Carcinoma",
        "Gastric Cancer"
      ],
      "Start Date": "2018-01-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT05367635",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sichuan Kelun Pharmaceutical Research Institute Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "SKB315 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 206,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2022-03-16",
      "Max Phase": "1"
    },
    {
      "id": "NCT05460273",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Datopotamab Deruxtecan (Dato-DXd)",
        "DS-1062a"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 119,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2022-07-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT05525286",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "SOTIO Biotech a.s."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: SOT102",
        "SOT102"
      ],
      "locations": [
        "Czechia",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 160,
      "conditions": [
        "Pancreatic Cancer"
      ],
      "Start Date": "2021-07-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT05652855",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Minghui Pharmaceutical Pty Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "MHB088C for Injection"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 48,
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": "2023-01-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT03809013",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Drug: RC48-ADC",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 64,
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": "2019-01-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT01807598",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jason Robert Gotlib"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris",
        "SGN-35",
        "anti-CD30 antibody-drug conjugate",
        "anti-CD30 ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 10,
      "conditions": [
        "Mast Cell Leukemia",
        "Aggressive Systemic Mastocytosis",
        "Systemic Mastocytosis"
      ],
      "Start Date": "2013-09-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06384807",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Biohaven Therapeutics Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "GQ1010",
        "PBI-410",
        "BHV1510"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 170,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2024-04-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT05320588",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "BiOneCure Therapeutics Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BIO-106",
        "Keytruda",
        "Pembrolizumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 332,
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Cancer",
        "Oncology"
      ],
      "Start Date": "2022-03-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT06115642",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Henlius Biotech"
      ],
      "collaborators": [],
      "interventions": [
        "HLX43",
        "Anti-PD-L1 ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 36,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-11-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT06115902",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 150,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-11-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT03052634",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC 2.5 mg/kg (HER2 Positive)",
        "Drug: RC48-ADC 2.0 mg/kg (HER2 Positive)",
        "Drug: RC48-ADC 2.0 mg/kg (HER2 Low Expression)",
        "RC48-ADC 1.5 mg/kg (HER2 Positive)",
        "RC48-ADC 2.0 mg/kg (HER2 Positive)",
        "RC48-ADC 2.5 mg/kg (HER2 Positive)",
        "RC48-ADC 2.0 mg/kg (HER2 Low Expression)",
        "Drug: RC48-ADC 1.5 mg/kg (HER2 Positive)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 112,
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "Start Date": "2016-12-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT02277717",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985 (trastuzumab vc-seco-DUBA)"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 185,
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": "2014-10-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03748186",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STRO-002"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": 160,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Endometrioid Adenocarcinoma",
        "Primary Peritoneal Carcinoma",
        "Ovary Cancer",
        "Endometrial Cancer",
        "Ovarian Carcinoma"
      ],
      "Start Date": "2019-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05652868",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Mythic Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "MYTX-011"
      ],
      "locations": [
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "enrollment": 150,
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Advanced Non-Small Cell Non-Squamous Lung Cancer",
        "NSCLC Stage IV",
        "Advanced Non-Small Cell Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "NSCLC Stage IIIB"
      ],
      "Start Date": "2023-03-23",
      "Max Phase": "1"
    },
    {
      "id": "NCT04280341",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Peking University"
      ],
      "collaborators": [
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "Biological: RC48-ADC in combinaton with JS001",
        "RC48-ADC in combinaton with JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 50,
      "conditions": [
        "HER2-Positive Solid Tumors"
      ],
      "Start Date": "2019-12-30",
      "Max Phase": "1"
    },
    {
      "id": "NCT00031187",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc.",
        "Seattle Genetics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Taxotere (docetaxel)",
        "Drug: Taxotere (docetaxel)",
        "SGN-15 (cBR96-doxorubicin immunoconjugate)",
        "Drug: SGN-15 (cBR96-doxorubicin immunoconjugate)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 160,
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "Start Date": "2000-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03248492",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "Experimental product"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 253,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2017-08-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT03505710",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "Trastuzumab deruxtecan",
        "Experimental product"
      ],
      "locations": [
        "Netherlands",
        "Spain",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 181,
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2018-05-21",
      "Max Phase": "2"
    },
    {
      "id": "NCT03725761",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Wisconsin, Madison"
      ],
      "collaborators": [
        "Gilead Sciences",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 31,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2018-10-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT01432275",
      "phases": [],
      "sponsor": [
        "Abbott Diabetes Care"
      ],
      "collaborators": [],
      "interventions": [
        "Abbott FreeStyle InsuLinx",
        "Device: ADC blood glucose meter with insulin calculator active",
        "Lifescan Verio Pro or",
        "Device: Comparator blood glucose meter",
        "Comparator blood glucose meter",
        "Device: ADC blood glucose meter",
        "ADC blood glucose meter with insulin calculator active",
        "Roche Accu-Chek Aviva Nano",
        "Bayer Contour USB",
        "Abbott Freestyle InsuLinx",
        "ADC blood glucose meter"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": 179,
      "conditions": [
        "Diabetes Mellitus"
      ],
      "Start Date": "2011-09-01",
      "Max Phase": null
    },
    {
      "id": "NCT06265727",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Corbus Pharmaceuticals Inc."
      ],
      "collaborators": [
        "CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd."
      ],
      "interventions": [
        "CRB-701"
      ],
      "locations": [
        "Spain",
        "United States",
        "United Kingdom",
        "Turkey"
      ],
      "enrollment": 420,
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "Start Date": "2024-04-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06263543",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Reshma L. Mahtani, D.O."
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 75,
      "conditions": [
        "Metastatic Breast Cancer",
        "Human Epidermal Growth Factor 2 Low Breast Cancer",
        "Advanced Breast Cancer",
        "Breast Cancer",
        "Hormone-receptor-positive Breast Cancer"
      ],
      "Start Date": "2024-06-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT06155396",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Zimberelimab",
        "Disitamab Vedotin \uff08RC48-ADC)",
        "Disitamab Vedotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 116,
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": "2024-01-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT05584709",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sorrento Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STI-6129",
        "Anti-CD38 antibody drug conjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 34,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-03-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00126646",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "immunotoxin therapy",
        "antibody-drug conjugate therapy",
        "Drug: BL22 immunotoxin",
        "Procedure: immunotoxin therapy",
        "Procedure: antibody-drug conjugate therapy",
        "BL22 immunotoxin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "Start Date": "2005-02-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT05980481",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "Oxaliplatin injection",
        "Drug: Toripalimab",
        "Drug: Oxaliplatin injection",
        "Toripalimab",
        "Disitamab Vedotin",
        "RC48-ADC",
        "Trastuzumab",
        "Capecitabine Tablets",
        "Drug: Capecitabine",
        "Oxaliplatin",
        "Capecitabine",
        "Trastuzumab Injection",
        "Drug: RC48-ADC",
        "Drug: Herceptin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 130,
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": "2023-01-07",
      "Max Phase": "3"
    },
    {
      "id": "NCT05943379",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: RC48-ADC in Combination with gemcitabine",
        "RC48-ADC in Combination with gemcitabine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 85,
      "conditions": [
        "NMIBC"
      ],
      "Start Date": "2023-03-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT04868344",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG003"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 61,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2018-05-09",
      "Max Phase": "1"
    },
    {
      "id": "NCT06224855",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hangzhou DAC Biotechnology Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "DXC006",
        "Recombinant Humanized Antibody-drug conjugate"
      ],
      "locations": [],
      "enrollment": 110,
      "conditions": [
        "Advanced Solid Tumors",
        "Hematological Malignancies"
      ],
      "Start Date": "2024-01-24",
      "Max Phase": "1"
    },
    {
      "id": "NCT05914545",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FZ-AD004-Antibody-drug Conjugate",
        "FZ-AD004"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 121,
      "conditions": [
        "Advanced and Metastatic Solid Tumor"
      ],
      "Start Date": "2023-06-12",
      "Max Phase": "1"
    },
    {
      "id": "NCT03682796",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Triphase Research and Development III Corp."
      ],
      "collaborators": [],
      "interventions": [
        "TRPH-222"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 32,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma",
        "Lymphoma, Marginal Zone",
        "Lymphoma, B-Cell",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": "2018-10-15",
      "Max Phase": "1"
    },
    {
      "id": "NCT03368196",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a"
      ],
      "locations": [
        "Taiwan"
      ],
      "enrollment": 12,
      "conditions": [
        "Neoplasm, Breast",
        "Adenocarcinoma, Gastric"
      ],
      "Start Date": "2018-04-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT03650491",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fortis Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "FOR46"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 31,
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma",
        "Multiple Myeloma With Failed Remission"
      ],
      "Start Date": "2019-04-03",
      "Max Phase": "1"
    },
    {
      "id": "NCT03575819",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fortis Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "FOR46"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 56,
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "Start Date": "2019-02-04",
      "Max Phase": "1"
    },
    {
      "id": "NCT05866354",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Zai Lab (Shanghai) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Tisotumab Vedotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 19,
      "conditions": [
        "Solid Malignancies"
      ],
      "Start Date": "2023-06-16",
      "Max Phase": "1"
    },
    {
      "id": "NCT03384940",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Italy",
        "United Kingdom",
        "Spain",
        "Japan",
        "United States"
      ],
      "enrollment": 86,
      "conditions": [
        "Colorectal Neoplasm"
      ],
      "Start Date": "2018-02-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT05464030",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "EMD Serono Research & Development Institute, Inc."
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "interventions": [
        "M9140",
        "Bevacizumab",
        "Capecitabine"
      ],
      "locations": [
        "Spain",
        "Japan",
        "United States"
      ],
      "enrollment": 180,
      "conditions": [
        "Colorectal Cancer"
      ],
      "Start Date": "2022-08-04",
      "Max Phase": "1"
    },
    {
      "id": "NCT05797168",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "AZD5305",
        "AZD5335"
      ],
      "locations": [
        "Canada",
        "Israel",
        "China",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "enrollment": 150,
      "conditions": [
        "Ovarian Cancer",
        "Lung Adenocarcinoma"
      ],
      "Start Date": "2023-06-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT03500380",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: Lapatinib",
        "RC48-ADC",
        "RC48",
        "Lapatinib",
        "Drug: RC48-ADC",
        "Capecitabine",
        "Drug: Capecitabine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 301,
      "conditions": [
        "Breast Diseases",
        "Breast Neoplasms",
        "HER2-positive Breast Cancer",
        "Capecitabine",
        "HER2-positive Advanced Breast With Liver Metastases",
        "HER2 Positive Breast Carcinoma"
      ],
      "Start Date": "2018-04-24",
      "Max Phase": "3"
    },
    {
      "id": "NCT05302284",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Drug: Carboplatin",
        "JS001",
        "Drug: Toripalimab",
        "Toripalimab",
        "Drug: Gemcitabine",
        "Disitamab Vedotin",
        "Gemcitabine",
        "RC48-ADC",
        "Carboplatin",
        "Cisplatin",
        "Drug: RC48-ADC",
        "Drug: Cisplatin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 452,
      "conditions": [
        "HER2-expressing",
        "Urothelial Carcinoma"
      ],
      "Start Date": "2022-03-21",
      "Max Phase": "3"
    },
    {
      "id": "NCT06105008",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "Toripalimab",
        "Disitamab Vedotin",
        "RC48-ADC, DV"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 80,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2024-12-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT05751512",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Cetuximab injection",
        "MRG003",
        "Methotrexate Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 180,
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "Start Date": "2023-03-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT04965766",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gustave Roussy, Cancer Campus, Grand Paris"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "HER3-DXd",
        "U3-1402"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 170,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2021-05-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT03602079",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Klus Pharma Inc."
      ],
      "collaborators": [],
      "interventions": [
        "A166"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 49,
      "conditions": [
        "Bile Duct Cancer",
        "Prostate Cancer",
        "Colo-rectal Cancer",
        "Primary Peritoneal Carcinoma",
        "Mucoepidermoid Carcinoma",
        "Head and Neck Cancer",
        "Recurrent Breast Cancer",
        "Liver Cancer",
        "Recurrent Renal Cell Cancer",
        "Mouth Cancer",
        "Recurrent Prostate Cancer",
        "Urologic Cancer",
        "Palate Cancer",
        "Cholangiocarcinoma",
        "Tongue Cancer",
        "Lip Cancer Stage I",
        "Mucinous Breast Cancer Recurrent",
        "Larynx Cancer",
        "Head and Neck Carcinoma",
        "Salivary Gland Carcinoma",
        "Rectal Cancer",
        "Recurrent Ovarian Carcinoma",
        "HER2 Positive Gastric Cancer",
        "Cervical Cancer",
        "HER-2 Gene Amplification",
        "Skin Cancer",
        "Salivary Gland Cancer",
        "Salivary Gland Neoplasms",
        "Rectal Cancer Stage III",
        "Rectal Cancer Stage I",
        "Recurrent Colon Cancer",
        "Rare Diseases",
        "Lung Cancer",
        "Solid Tumor",
        "Recurrent Gastric Cancer",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Mucinous Adenocarcinoma Gastric",
        "Breast Neoplasm Malignant Primary",
        "Tonsil Cancer",
        "HER2 Gene Mutation",
        "HER2-positive Breast Cancer",
        "Rectal Cancer Stage II",
        "Salivary Gland Tumor"
      ],
      "Start Date": "2018-07-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT04925284",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Exelixis"
      ],
      "collaborators": [],
      "interventions": [
        "Nivolumab",
        "XB002"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 573,
      "conditions": [
        "Esophageal SCC",
        "Metastatic Castration-resistant Prostate Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "Endometrial Cancer",
        "Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Non Small Cell Lung Cancer",
        "Tissue Factor-Expressing Solid Tumors",
        "Pancreatic Cancer",
        "SCCHN"
      ],
      "Start Date": "2021-06-07",
      "Max Phase": "1"
    },
    {
      "id": "NCT06238479",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [
        "Loxo Oncology, Inc."
      ],
      "interventions": [
        "LY4101174"
      ],
      "locations": [
        "Australia",
        "Japan",
        "United States"
      ],
      "enrollment": 280,
      "conditions": [
        "Ovarian Cancer",
        "Prostate Cancer",
        "Recurrent Solid Tumor",
        "Esophageal Cancer",
        "Renal Pelvis Cancer",
        "Non-small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Urinary Bladder Neoplasm",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Solid Tumor",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-03-05",
      "Max Phase": "1"
    },
    {
      "id": "NCT01497821",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Amgen"
      ],
      "collaborators": [],
      "interventions": [
        "AMG 172"
      ],
      "locations": [
        "Germany",
        "France",
        "United States"
      ],
      "enrollment": 37,
      "conditions": [
        "Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Clear Cell Renal Carcinoma",
        "Renal Cell Adenocarcinoma"
      ],
      "Start Date": "2012-01-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03734029",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "Paclitaxel",
        "Eribulin",
        "Drug: Trastuzumab deruxtecan (DS-8201a)",
        "Drug: Gemcitabine",
        "Gemcitabine",
        "Nab-paclitaxel",
        "Drug: Paclitaxel",
        "Trastuzumab deruxtecan (DS-8201a)",
        "Capecitabine",
        "Drug: Nab-paclitaxel",
        "Drug: Capecitabine",
        "Drug: Eribulin"
      ],
      "locations": [
        "China",
        "Sweden",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Austria",
        "Taiwan",
        "Hungary",
        "United States",
        "Canada",
        "Portugal",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Belgium"
      ],
      "enrollment": 557,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2018-06-11",
      "Max Phase": "3"
    },
    {
      "id": "NCT04924699",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG002",
        "Trastuzumab Emtansine for Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 350,
      "conditions": [
        "Advanced Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2021-06-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT06224673",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Laura Huppert, MD, BA"
      ],
      "collaborators": [
        "Ambrx, Inc."
      ],
      "interventions": [
        "Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788",
        "Biological Sample Collection",
        "Specimen Collection",
        "Biospecimen Collection",
        "Computed Tomography (CT)",
        "PET/CT",
        "Anvatabart Opadotin",
        "CT Scan",
        "Antibody-drug Conjugate ARX788",
        "ARX788"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Hormone-receptor-positive Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "HER2 Low Breast Carcinoma",
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2024-07-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT03677596",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "inotuzumab ozogamicin-dose level 2",
        "Inotuzumab ozogamicin-dose level 1",
        "Besponsa"
      ],
      "locations": [
        "Singapore",
        "Hungary",
        "Poland",
        "India",
        "Turkey",
        "Spain",
        "Taiwan",
        "United States"
      ],
      "enrollment": 102,
      "conditions": [
        "ACUTE LYMPHOBLASTIC LEUKEMIA",
        "Precursor b-Cell Lymphoblastic Leukemia-Lymphoma",
        "Leukemia"
      ],
      "Start Date": "2019-07-01",
      "Max Phase": "4"
    },
    {
      "id": "NCT05126719",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Docetaxel injection",
        "MRG003",
        "Capecitabine tablets"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 238,
      "conditions": [
        "Recurrent or Metastatic Nasopharyngeal Carcinoma"
      ],
      "Start Date": "2021-08-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT04838964",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG003"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 80,
      "conditions": [
        "Advanced or Metastatic Biliary Tract Cancer"
      ],
      "Start Date": "2021-04-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT06048718",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "DS-8021a, ENHERTU",
        "Trastuzumab-Deruxtecan (T-DXd)"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 27,
      "conditions": [
        "Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2024-06-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT04843709",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG004A"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "enrollment": 181,
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": "2021-07-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT05688605",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG003+HX008"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 18,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2022-06-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT04742153",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG002"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 66,
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "Start Date": "2021-05-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05293496",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MacroGenics"
      ],
      "collaborators": [],
      "interventions": [
        "MGD019",
        "lorigerlimab",
        "MGC018",
        "vobramitamab duocarmazine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 278,
      "conditions": [
        "Malignant Melanoma",
        "Hepatocellular Cancer",
        "Renal Cell Carcinoma",
        "Epithelial Ovarian Cancer",
        "Pancreatic Ductal Carcinoma",
        "Castration-Resistant Prostatic Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2022-04-19",
      "Max Phase": "1"
    },
    {
      "id": "NCT04940325",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gustave Roussy, Cancer Campus, Grand Paris"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "DS-1062a"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 100,
      "conditions": [
        "Metastatic Lung Cancer"
      ],
      "Start Date": "2021-05-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT04235101",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "(vic-)trastuzumab duocarmazine + Zejula",
        "SYD985 + Niraparib"
      ],
      "locations": [
        "United Kingdom",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 32,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2020-06-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT02564900",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a (DP)",
        "DS-8201a (DP2)",
        "DS-8201a (DP1)"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "enrollment": 292,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2015-09-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04714190",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection",
        "Irinotecan Hydrochloride Injection",
        "Drug: Paclitaxel injection",
        "CAMPTO",
        "Drug: Irinotecan Hydrochloride Injection",
        "Aitan",
        "RC48-ADC",
        "Drug: Apatinib Mesylate Tablets",
        "Apatinib Mesylate Tablets",
        "Paclitaxel injection",
        "Drug: RC48-ADC",
        "Taxol"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 351,
      "conditions": [
        "HER2 Overexpressing Gastric Carcinoma",
        "Gastric Cancer"
      ],
      "Start Date": "2021-01-15",
      "Max Phase": "3"
    },
    {
      "id": "NCT04300556",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Eisai Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "MORAb-202",
        "Prednisolone",
        "Farletuzumab ecteribulin",
        "Dexamethasone",
        "Prednisone"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "France",
        "United States"
      ],
      "enrollment": 142,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2020-08-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT01439152",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY94-9343 (2.2 mg/kg)",
        "BAY94-9343 (1.8 mg/kg)",
        "BAY94-9343",
        "BAY94-9343 (Expansion)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 148,
      "conditions": [
        "Oncology"
      ],
      "Start Date": "2011-09-07",
      "Max Phase": "1"
    },
    {
      "id": "NCT05338957",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MRG002+HX008"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 30,
      "conditions": [
        "Advanced Malignant Solid Tumors"
      ],
      "Start Date": "2022-08-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT05872295",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Iksuda Therapeutics Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "IKS014"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 165,
      "conditions": [
        "Gastric Cancer",
        "Breast Cancer",
        "Gastroesophageal-junction Cancer"
      ],
      "Start Date": "2023-09-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT05754853",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Miracogen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel Injection",
        "Docetaxel Injection",
        "MRG002",
        "Gemcitabine Hydrochloride for Injection",
        "Pemetrexed Disodium Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 290,
      "conditions": [
        "Advanced or Metastatic Urothelium Cancer"
      ],
      "Start Date": "2023-04-06",
      "Max Phase": "3"
    },
    {
      "id": "NCT04311034",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 37,
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "Start Date": "2018-09-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT05865990",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "HER3-DXd",
        "Patritumab deruxtecan"
      ],
      "locations": [
        "Spain",
        "Austria"
      ],
      "enrollment": 60,
      "conditions": [
        "Advanced Non-Small Cell Squamous Lung Cancer",
        "Metastatic Breast Cancer",
        "Solid Tumor, Adult"
      ],
      "Start Date": "2023-11-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT05950945",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab Deruxtecan",
        "DS-8201a (trastuzumab derextecan)",
        "T-DXd",
        "Enhertu\u00ae"
      ],
      "locations": [
        "Brazil",
        "United States"
      ],
      "enrollment": 250,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-12-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT05280470",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Ifinatamab Deruxtecan (I-DXd)",
        "DS-7300a"
      ],
      "locations": [
        "China",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 187,
      "conditions": [
        "Extensive-stage Small-cell Lung Cancer"
      ],
      "Start Date": "2022-03-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT05276609",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Hansoh Biomedical Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20093 (Phase Ib: Dose expansion)",
        "HS-20093 (Phase Ia: Dose escalation)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 177,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2021-11-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT05800366",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jennifer Crombie, MD"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Prednisolone, Methylprednisolone",
        "RO7082859",
        "Rituxan",
        "Hydroxydaunomycin",
        "Polatuzumab",
        "Cytophosphane, Cytoxan",
        "Cyclophosphamide",
        "Glofitamab",
        "Doxorubicin Hydrochloride",
        "Polatuzumab vedotin, DCDS4501S, RG7596",
        "Rituximab",
        "Prednisone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 40,
      "conditions": [
        "Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": "2023-04-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT06465069",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [
        "Loxo Oncology, Inc."
      ],
      "interventions": [
        "LY4052031"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 220,
      "conditions": [
        "Ovarian Cancer",
        "Prostate Cancer",
        "Recurrent Solid Tumor",
        "Esophageal Cancer",
        "Renal Pelvis Cancer",
        "Non-small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Urinary Bladder Neoplasm",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Solid Tumor",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04887870",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Mirati Therapeutics Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Nivolumab",
        "Pembrolizumab",
        "Ipilimumab",
        "Enfortumab Vedotin-Ejfv",
        "OPDIVO",
        "YERVOY",
        "Sitravatinib",
        "PADCEV",
        "KEYTRUDA",
        "MGCD516"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 55,
      "conditions": [
        "Advanced or Metastatic Solid Malignancies"
      ],
      "Start Date": "2021-06-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT03894150",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "F0002-ADC",
        "Drug: F0002-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 45,
      "conditions": [
        "Refractory or Recurrent CD30+ Hematologic Malignancies"
      ],
      "Start Date": "2019-03-26",
      "Max Phase": "1"
    },
    {
      "id": "NCT05748171",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Besponsa",
        "ALLR3",
        "R3",
        "Inotuzumab ozogamicin"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Finland",
        "Spain",
        "Switzerland",
        "Israel",
        "Hungary",
        "Sweden",
        "Germany",
        "Denmark",
        "Poland",
        "Austria",
        "Slovakia",
        "Greece",
        "Belgium",
        "France",
        "Netherlands",
        "Norway"
      ],
      "enrollment": 100,
      "conditions": [
        "ACUTE LYMPHOBLASTIC LEUKEMIA"
      ],
      "Start Date": "2023-05-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT04410224",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Kirilys Therapeutics Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASN004"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 19,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2022-04-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT03383692",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a",
        "Norvir",
        "Orungal",
        "Ritonavir",
        "Sporanox",
        "Itraconazole"
      ],
      "locations": [
        "Korea, Republic of",
        "Taiwan",
        "Japan"
      ],
      "enrollment": 40,
      "conditions": [
        "Neoplasm Metastasis"
      ],
      "Start Date": "2018-01-12",
      "Max Phase": "1"
    },
    {
      "id": "NCT06112704",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20093"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 220,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-02-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT02565758",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "ABBV-085"
      ],
      "locations": [
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 85,
      "conditions": [
        "Carcinoma of the Breast",
        "Advanced Solid Tumors",
        "Undifferentiated Pleomorphic Sarcoma",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "Start Date": "2015-09-18",
      "Max Phase": "1"
    },
    {
      "id": "NCT00052000",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MLN2704 (DM1 conjugated monoclonal antibody MLN591)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 29,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2002-11-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00070837",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MLN2704 (DM1 conjugated monoclonal antibody MLN591)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 46,
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "Start Date": "2003-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04042701",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "AstraZeneca UK Limited"
      ],
      "interventions": [
        "Pembrolizumab",
        "Trastuzumab deruxtecan (DS-8201a)"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "France",
        "United States"
      ],
      "enrollment": 115,
      "conditions": [
        "Non-small Cell Lung Carcinoma",
        "Breast Cancer"
      ],
      "Start Date": "2020-02-10",
      "Max Phase": "1"
    },
    {
      "id": "NCT05410418",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Washington University School of Medicine"
      ],
      "collaborators": [
        "Genentech, Inc.",
        "Institute for Follicular Lymphoma"
      ],
      "interventions": [
        "RO5541077",
        "BTCT4465A",
        "Polatuzumab vedotin",
        "DCDS4501A",
        "Mosunetuzumab",
        "RO7030816"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 34,
      "conditions": [
        "Follicular Lymphoma",
        "Lymphoma, Follicular"
      ],
      "Start Date": "2022-10-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT00258856",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Polysaccharide Diphtheria Conjugate Vaccine",
        "Menactra\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 234,
      "conditions": [
        "Meningococcal Infection",
        "Meningitis"
      ],
      "Start Date": "2006-01-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06203210",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Amrubicin",
        "Lurbinectedin",
        "Topotecan",
        "Ifinatamab deruxtecan",
        "I-DXd"
      ],
      "locations": [
        "Czechia",
        "China",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 468,
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": "2024-05-21",
      "Max Phase": "3"
    },
    {
      "id": "NCT04142242",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Blood sample",
        "Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine",
        "MenACYW Conjugate vaccine",
        "MenQuadfi"
      ],
      "locations": [
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 471,
      "conditions": [
        "Meningococcal Infection (Healthy Volunteers)"
      ],
      "Start Date": "2019-10-04",
      "Max Phase": "3"
    },
    {
      "id": "NCT01856933",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Heinrich Elinzano, MD"
      ],
      "collaborators": [
        "Progenics Pharmaceuticals, Inc.",
        "University of Texas",
        "Rhode Island Hospital"
      ],
      "interventions": [
        "Drug: PSMA ADC",
        "PSMA ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 6,
      "conditions": [
        "Glioblastoma Multiforme",
        "GBM",
        "Gliosarcoma"
      ],
      "Start Date": "2013-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03953833",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Pharmaceuticals Holding Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003."
      ],
      "locations": [
        "China"
      ],
      "enrollment": 30,
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": "2019-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05887609",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Colorado, Denver"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "IMGN853",
        "Olaparib",
        "MIRV",
        "Mirvetuximab Soravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 53,
      "conditions": [
        "Ovary Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2023-10-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT06132958",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [
        "European Network for Gynaecological Oncological Trial groups(ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Paclitaxel",
        "Sacituzumab tirumotecan",
        "TAXOL\u00ae",
        "SKB264 MK-2870",
        "ADRIAMYCIN\u00ae",
        "Doxorubicin"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "Sweden",
        "Ireland",
        "Denmark",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Finland",
        "Israel",
        "Argentina",
        "Austria",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "Chile",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 710,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2023-12-06",
      "Max Phase": "3"
    },
    {
      "id": "NCT05755048",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)",
        "Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 314,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-03-28",
      "Max Phase": "3"
    },
    {
      "id": "NCT06244485",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [],
      "interventions": [
        "DS-8201a",
        "T-DXd",
        "Dato-DXd",
        "ENHERTU",
        "DS-1062a",
        "Valemetostat tosylate",
        "DS-3201b"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "enrollment": 210,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-02-16",
      "Max Phase": "1"
    },
    {
      "id": "NCT04205630",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985",
        "(vic-)trastuzumab duocarmazine",
        "Trastuzumab vc-seco-DUBA"
      ],
      "locations": [
        "Singapore",
        "Ukraine",
        "Poland",
        "Korea, Republic of",
        "Serbia",
        "Russian Federation",
        "United States"
      ],
      "enrollment": 64,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2020-05-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT00071955",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genitope Corporation"
      ],
      "collaborators": [],
      "interventions": [
        "autologous immunoglobulin idiotype-KLH conjugate vaccine",
        "sargramostim"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": null,
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": "2003-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01577758",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MLN0264"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 41,
      "conditions": [
        "Advanced Gastrointestinal Malignancies"
      ],
      "Start Date": "2012-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03529110",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "T-DM1",
        "DS-8201a",
        "Ado-trastuzumab emtansine (T-DM1)",
        "Drug: Ado-trastuzumab emtansine (T-DM1)",
        "Drug: Trastuzumab deruxtecan (T-DXd)",
        "Trastuzumab deruxtecan (T-DXd)"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Hong Kong",
        "Italy",
        "Belgium",
        "China",
        "France",
        "Korea, Republic of",
        "United Kingdom",
        "Germany",
        "Australia",
        "Taiwan",
        "Spain",
        "Japan",
        "United States"
      ],
      "enrollment": 524,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2018-04-13",
      "Max Phase": "3"
    },
    {
      "id": "NCT04175847",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC88 for Injection",
        "RC88"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 200,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2020-04-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT00856297",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Novartis Vaccines"
      ],
      "collaborators": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier",
        "MenACWY-CRM conjugate vaccine",
        "Licensed comparator"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 389,
      "conditions": [
        "Meningococcal Meningitis"
      ],
      "Start Date": "2009-02-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT01396070",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Youn Kim"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "Adcetris"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Mycosis Fungoides",
        "Cutaneous T-cell Lymphoma (CTCL)",
        "Sezary Syndrome",
        "Cutaneous Lymphoma",
        "Non-Hodgkin Lymphoma (NHL)"
      ],
      "Start Date": "2011-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04878029",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Emory University"
      ],
      "collaborators": [
        "Exelixis",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Questionnaire Administration",
        "Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E",
        "Cabozantinib S-malate",
        "Cometriq",
        "Anti-Nectin 4 ADC ASG-22CE",
        "Cabometyx",
        "ASG-22CE",
        "Enfortumab Vedotin",
        "Enfortumab Vedotin-ejfv",
        "Padcev",
        "BMS-907351",
        "XL-184",
        "AGS 22ME",
        "XL184",
        "Quality-of-Life Assessment",
        "AGS-22M6E",
        "Quality of Life Assessment"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 32,
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation",
        "Metastatic Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma"
      ],
      "Start Date": "2021-07-23",
      "Max Phase": "1"
    },
    {
      "id": "NCT01631552",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Sacituzumab Govitecan-hziy (SG)",
        "IMMU-132",
        "hRS7-SN38"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 515,
      "conditions": [
        "Hormone-refractory Prostate Cancer",
        "Small Cell Lung Cancer",
        "Esophageal Cancer",
        "Glioblastoma Multiforme",
        "Non-small Cell Lung Cancer",
        "Urinary Bladder Neoplasms",
        "Endometrial Cancer",
        "Head and Neck Cancers- Squamous Cell",
        "Triple Negative Breast Cancer",
        "Ovarian Epithelial Cancer",
        "Carcinoma Breast Stage IV",
        "Hepatocellular Carcinoma",
        "Pancreatic Cancer",
        "Cervical Cancer",
        "Gastric Adenocarcinoma",
        "Renal Cell Cancer"
      ],
      "Start Date": "2012-12-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT03424603",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "STRO-001"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "B Cells--Tumors",
        "Follicular Lymphoma",
        "Multiple Myeloma",
        "Indolent Lymphoma",
        "Non Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "B-cell Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "Start Date": "2018-02-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT06107686",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL202 should be intravenously infused"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 200,
      "conditions": [
        "NSCLC",
        "Breast Cancer",
        "Locally Advanced or Metastatic Solid Tumors",
        "HNSCC"
      ],
      "Start Date": "2023-12-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT06057922",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL201 for Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 640,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-09-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT05991388",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "University of Birmingham"
      ],
      "collaborators": [
        "ADC Therapeutics SA",
        "Fight Kids Cancer",
        "Regeneron Pharmaceuticals",
        "Cancer Research UK"
      ],
      "interventions": [
        "Loncastuximab tesirine",
        "Etoposide Phosphate",
        "CAR T-cells (TBC)",
        "Odronextamab",
        "Ifosfamide",
        "REGN-1979",
        "Carboplatin",
        "Etoposide",
        "Rituximab",
        "Dexamethasone",
        "ADCT-402"
      ],
      "locations": [],
      "enrollment": 210,
      "conditions": [
        "B-cell Non Hodgkin Lymphoma"
      ],
      "Start Date": "2024-05-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05434234",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL201"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "enrollment": 196,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2022-05-25",
      "Max Phase": "1"
    },
    {
      "id": "NCT00148824",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "French National Agency for Research on AIDS and Viral Hepatitis"
      ],
      "collaborators": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "interventions": [
        "7-valent pneumococcal conjugate vaccine (vaccine)",
        "23-valent pneumococcal conjugate vaccine (vaccine)"
      ],
      "locations": [],
      "enrollment": 212,
      "conditions": [
        "HIV Infections"
      ],
      "Start Date": "2003-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04494425",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo"
      ],
      "interventions": [
        "Paclitaxel",
        "DS-8201a; T-DXd",
        "Nab-Paclitaxel",
        "Trastuzumab deruxtecan",
        "Capecitabine"
      ],
      "locations": [
        "Mexico",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Saudi Arabia",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 866,
      "conditions": [
        "Advanced or Metastatic Breast Cancer"
      ],
      "Start Date": "2020-07-24",
      "Max Phase": "3"
    },
    {
      "id": "NCT04622774",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "MacroGenics"
      ],
      "interventions": [
        "IMGC936"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "enrollment": 56,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2020-10-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT02952729",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Mersana Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "XMT-1522"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 120,
      "conditions": [
        "Advanced Nonsmall Cell Lung Cancer",
        "Advanced Breast Cancer",
        "Advanced Gastric Cancer"
      ],
      "Start Date": "2016-11-21",
      "Max Phase": "1"
    },
    {
      "id": "NCT03386513",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN632"
      ],
      "locations": [
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 179,
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Myeloproliferative Neoplasm"
      ],
      "Start Date": "2018-01-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT02567851",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Birmingham"
      ],
      "collaborators": [
        "Leukaemia Lymphoma Research",
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "Adcetris"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": 38,
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": "2014-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05143229",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Kansas Medical Center"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Novartis Pharmaceuticals"
      ],
      "interventions": [
        "Alpelisib",
        "Piqray",
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2022-03-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT01026038",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "13-valent pneumococcal conjugate vaccine"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 263,
      "conditions": [
        "13-valent Pneumococcal Vaccine",
        "Antibody Response",
        "Immunization",
        "Safety"
      ],
      "Start Date": "2010-04-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT00743652",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "13-valent Pneumococcal Conjugate Vaccine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 373,
      "conditions": [
        "13-valent Pneumococcal Vaccine",
        "Pneumococcal Disease"
      ],
      "Start Date": "2009-01-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT04587687",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Joseph Tuscano"
      ],
      "collaborators": [
        "Seagen Inc.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Levact",
        "Bendamustine Hydrochloride",
        "Bendamustin Hydrochloride",
        "Adcetris",
        "Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35",
        "SyB L-0501",
        "SGN-35",
        "Brentuximab Vedotin",
        "Bendeka",
        "Treanda",
        "Anti-CD30 Antibody-Drug Conjugate SGN-35",
        "Cytostasan Hydrochloride",
        "ADC SGN-35",
        "cAC10-vcMMAE",
        "Ribomustin",
        "Anti-CD30 Monoclonal Antibody-MMAE SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 23,
      "conditions": [
        "Refractory Follicular Lymphoma",
        "Recurrent Follicular Lymphoma"
      ],
      "Start Date": "2020-12-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT05200364",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Bevacizumab",
        "Avastin",
        "STRO-002"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 58,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Ovary Cancer",
        "Ovarian Carcinoma"
      ],
      "Start Date": "2022-03-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT03316638",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Pierre Fabre Medicament"
      ],
      "collaborators": [],
      "interventions": [
        "W0101 - Cohort A1",
        "W0101 - Cohort A2",
        "Expansion Phase",
        "W0101 - Expansion Phase",
        "Dose escalation Phase"
      ],
      "locations": [
        "Spain",
        "France"
      ],
      "enrollment": 316,
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": "2017-11-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT06235216",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Grupo Espanol de Tumores Neuroendocrinos"
      ],
      "collaborators": [
        "MFAR",
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 42,
      "conditions": [
        "Anaplastic Thyroid Cancer",
        "Differentiated Thyroid Cancer"
      ],
      "Start Date": "2024-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05613088",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Eisai Inc."
      ],
      "interventions": [
        "Pegylated Liposomal Doxorubicin (PLD)",
        "BMS-986445",
        "Paclitaxel",
        "MORAb-202",
        "Hycamtin",
        "Bendalis",
        "Topotecan",
        "Caelyx",
        "Farletuzumab Ecteribulin"
      ],
      "locations": [
        "Italy",
        "Chile",
        "Israel",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium",
        "Japan",
        "United States"
      ],
      "enrollment": 90,
      "conditions": [
        "Neoplasms, Ovarian"
      ],
      "Start Date": "2023-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04036461",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Celgene"
      ],
      "collaborators": [],
      "interventions": [
        "GSI (Gamma secretase inhibitor)",
        "BMS-986405",
        "CC-99712"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 160,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2019-08-26",
      "Max Phase": "1"
    },
    {
      "id": "NCT01847781",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Karolinska University Hospital"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Prevenar13"
      ],
      "locations": [
        "Sweden"
      ],
      "enrollment": 20,
      "conditions": [
        "IgG Deficiency"
      ],
      "Start Date": "2013-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05405621",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bio-Thera Solutions"
      ],
      "collaborators": [],
      "interventions": [
        "BAT8009 for Injection",
        "Recombinant Humanized Anti-B7H3 Monoclonal Antibody-Exatecan Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 48,
      "conditions": [
        "Locally Advanced/Metastatic Solid Tumours"
      ],
      "Start Date": "2022-08-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT06188559",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Eisai Inc."
      ],
      "collaborators": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "interventions": [
        "BB-1701"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "enrollment": 135,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2024-04-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT05629585",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "SWOG Clinical Trials Partnerships"
      ],
      "interventions": [
        "Pembrolizumab",
        "Dato-DXd",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Durvalumab",
        "Capecitabine",
        "XELODA\u00ae, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord",
        "MEDI4736",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "China",
        "Japan",
        "Sweden",
        "Germany",
        "Denmark",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Greece",
        "Belgium",
        "France",
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 1075,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2022-11-28",
      "Max Phase": "3"
    },
    {
      "id": "NCT03281824",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alteogen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ALT-P7 (HM2-MMAE)"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "enrollment": 27,
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": "2018-01-11",
      "Max Phase": "1"
    },
    {
      "id": "NCT01475006",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Amgen"
      ],
      "collaborators": [],
      "interventions": [
        "AMG 595"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": 32,
      "conditions": [
        "Glioblastoma Multiforme",
        "Advanced Malignant Glioma",
        "Anaplastic Astrocytomas"
      ],
      "Start Date": "2012-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05838521",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": "2023-06-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT04647916",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "SWOG Cancer Research Network"
      ],
      "collaborators": [
        "Gilead Sciences",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "IMMU-132",
        "Sacituzumab Govitecan-hziy",
        "Sacituzumab Govitecan",
        "Trodelvy",
        "hRS7-SN38 Antibody Drug Conjugate",
        "RS7-SN38"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 44,
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic HER2 Negative Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma"
      ],
      "Start Date": "2021-06-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT05980416",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Elevation Oncology"
      ],
      "collaborators": [],
      "interventions": [
        "EO-3021"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "enrollment": 120,
      "conditions": [
        "Gastrointestinal Neoplasms",
        "Stomach Neoplasm",
        "Pancreas Neoplasm",
        "Digestive System Neoplasm",
        "Neoplasms by Site",
        "Neoplasms"
      ],
      "Start Date": "2023-08-10",
      "Max Phase": "1"
    },
    {
      "id": "NCT04982224",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Regeneron Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "REGN5093-M114",
        "Cemiplimab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 237,
      "conditions": [
        "Advanced NSCLC"
      ],
      "Start Date": "2021-11-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT04644068",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "Dato-DXd",
        "Carboplatin",
        "Camizestrant",
        "AZD5305",
        "T- Dxd"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "China",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Russian Federation",
        "Hungary",
        "Japan",
        "United States"
      ],
      "enrollment": 804,
      "conditions": [
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Additional Indications Below for Module 4 and 5",
        "Non-small Cell Lung Cancer",
        "Endometrial Cancer",
        "Small Cell Lung Cancer Only in Module 5",
        "Cervical Cancer",
        "Gastric Cancer",
        "Breast Cancer",
        "Bladder Cancer",
        "Pancreatic Cancer",
        "Biliary Cancer"
      ],
      "Start Date": "2020-11-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT05940896",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab vedotin",
        "RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 24,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2023-06-29",
      "Max Phase": "1"
    },
    {
      "id": "NCT04251416",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Endometrial Carcinoma"
      ],
      "Start Date": "2020-03-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT04039230",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Talazoparib",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 75,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2019-10-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT04450732",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "GQ1001"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "enrollment": 96,
      "conditions": [
        "HER2-positive Biliary Tract Cancer",
        "HER2-positive Breast Cancer",
        "HER2-Positive Salivary Gland Carcinomas",
        "HER2-Positive Advanced Solid Tumor"
      ],
      "Start Date": "2020-07-07",
      "Max Phase": "1"
    },
    {
      "id": "NCT05948826",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TORL Biotherapeutics, LLC"
      ],
      "collaborators": [
        "Translational Research in Oncology"
      ],
      "interventions": [
        "TORL-3-600"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "Colorectal Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-09-29",
      "Max Phase": "1"
    },
    {
      "id": "NCT01270698",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "IMMU-130",
        "hMN14-SN38"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 26,
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "Start Date": "2011-05-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02529553",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [],
      "interventions": [
        "LY3076226"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "Start Date": "2015-09-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04278144",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Bolt Biotherapeutics, Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "Nivolumab",
        "Opdivo",
        "BDC-1001"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 390,
      "conditions": [
        "HER2-positive Colorectal Cancer",
        "HER2-positive Gastroesophageal Cancer",
        "HER2-positive Endometrial Cancer",
        "HER2-positive Breast Cancer",
        "HER2-positive Solid Tumors"
      ],
      "Start Date": "2020-02-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT05399654",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Tallac Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "TAC-001"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": 200,
      "conditions": [
        "Advanced or Metastatic Solid Tumors"
      ],
      "Start Date": "2022-06-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT06154343",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "GQ1005"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 150,
      "conditions": [
        "HER2 Expressing or Mutated Advanced Malignant Solid Tumors"
      ],
      "Start Date": "2022-11-23",
      "Max Phase": "1"
    },
    {
      "id": "NCT05489211",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "AZD2936",
        "Volrustomig",
        "Leucovorin LV",
        "Prednisolone",
        "MEDI5752",
        "IMFINZI",
        "Avastin",
        "5-Fluorouracil",
        "Carboplatin",
        "Capecitabine",
        "Folinic acid",
        "Rilvegostomig",
        "Bevacizumab",
        "Datopotamab deruxtecan (Dato-DXd)",
        "Xeloda",
        "Paraplatin",
        "DS-1062a",
        "Prednisone/ prednisolone",
        "Adrucil",
        "Durvalumab",
        "AZD5305",
        "Saruparib",
        "MEDI4736"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Switzerland",
        "China",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Taiwan",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 531,
      "conditions": [
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Endometrial Cancer",
        "Gastric Cancer",
        "Urothelial Cancer",
        "Biliary Tract Cancer"
      ],
      "Start Date": "2022-09-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT06238687",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Tasly Pharmaceutical Group Co., Ltd"
      ],
      "collaborators": [
        "Sutro Biopharma, Inc."
      ],
      "interventions": [
        "STRO-002"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 132,
      "conditions": [
        "Neoplasm Malignant"
      ],
      "Start Date": "2023-11-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT06373406",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Minghui Pharmaceutical (Hangzhou) Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "MHB036C"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 200,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-05-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT06036121",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Adcentrx Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "ADRX-0706"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 114,
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": "2023-09-26",
      "Max Phase": "1"
    },
    {
      "id": "NCT03159117",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "GD3 ADC",
        "PF-06688992"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 7,
      "conditions": [
        "Melanoma"
      ],
      "Start Date": "2017-05-16",
      "Max Phase": "1"
    },
    {
      "id": "NCT04538742",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited"
      ],
      "interventions": [
        "Tucatinib",
        "Paclitaxel",
        "Durvalumab",
        "ONT-380",
        "Trastuzumab deruxtecan",
        "DS-8201a, T-DXd",
        "Pertuzumab",
        "MEDI4736"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "India",
        "Turkey",
        "Spain",
        "Australia",
        "Russian Federation",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 245,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2020-12-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT06106152",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Second Affiliated Hospital, School of Medicine, Zhejiang University"
      ],
      "collaborators": [
        "Westlake Therapeutics"
      ],
      "interventions": [
        "PD -1/PD-L1antibody",
        "autologous red blood cell PD-1 inhibitor conjugate",
        "PD -1/PD-L1 monoclonal antibody",
        "WTX212A injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 20,
      "conditions": [
        "Advanced Lung Cancer"
      ],
      "Start Date": "2023-12-05",
      "Max Phase": "1"
    },
    {
      "id": "NCT03260491",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [],
      "interventions": [
        "HER3-DXd (FL-DP)",
        "HER3-DXd (CTM-3 Lyo-DP)",
        "HER3-DXd (CTM-1 Lyo-DP)"
      ],
      "locations": [
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "Netherlands",
        "Japan",
        "United States"
      ],
      "enrollment": 309,
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "Start Date": "2017-10-30",
      "Max Phase": "1"
    },
    {
      "id": "NCT06480240",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "OBI Pharma, Inc"
      ],
      "collaborators": [],
      "interventions": [
        "OBI-992"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 117,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-06-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT06413615",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "FDA022-BB05"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 150,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-05-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT02606305",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Pegylated Liposomal Doxorubicin",
        "Pembrolizumab",
        "Bevacizumab",
        "Mirvetuximab soravtansine",
        "IMGN853",
        "Carboplatin"
      ],
      "locations": [
        "Spain",
        "Canada",
        "Belgium",
        "United States"
      ],
      "enrollment": 264,
      "conditions": [
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": "2016-03-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT06362252",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Atezolizumab",
        "Carboplatin",
        "Etoposide",
        "Ifinatamab deruxtecan",
        "I-DXd"
      ],
      "locations": [],
      "enrollment": 149,
      "conditions": [
        "Extensive Stage-small Cell Lung Cancer"
      ],
      "Start Date": "2024-06-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT04434040",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Genentech, Inc.",
        "Stand Up To Cancer"
      ],
      "interventions": [
        "Tecentriq",
        "Atezolizumab",
        "Sacituzumab govitecan",
        "Trodelvy, IMMU-132"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 40,
      "conditions": [
        "Breast Cancer",
        "Residual Cancer",
        "Triple Negative Breast Cancer",
        "Circulating Tumor DNA"
      ],
      "Start Date": "2020-07-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT06074588",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Pemetrexed",
        "Sacituzumab tirumotecan",
        "ALIMTA\u00ae",
        "SKB264, MK-2870",
        "Docetaxel",
        "TAXOTERE\u00ae"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Hong Kong",
        "Thailand",
        "Chile",
        "Israel",
        "China",
        "Malaysia",
        "Korea, Republic of",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "enrollment": 556,
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "Start Date": "2023-11-12",
      "Max Phase": "3"
    },
    {
      "id": "NCT04189614",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Cofetuzumab Pelidotin",
        "ABBV-647"
      ],
      "locations": [
        "Israel",
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "enrollment": 65,
      "conditions": [
        "Cancer",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "Start Date": "2020-02-13",
      "Max Phase": "1"
    },
    {
      "id": "NCT04724018",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Enfortumab vedotin-ejfv (EV)",
        "Padcev",
        "Trodelvy",
        "Sacituzumab Govitecan (SG)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Bladder Cancer",
        "Urothelial Cancer",
        "Metastatic Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter"
      ],
      "Start Date": "2021-05-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT02822586",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Virginia Commonwealth University"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris",
        "total skin electron beam",
        "TSEB Therapy",
        "TSEB"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 5,
      "conditions": [
        "Mycosis Fungoides",
        "S\u00e9zary Syndrome"
      ],
      "Start Date": "2016-12-19",
      "Max Phase": "1"
    },
    {
      "id": "NCT02631876",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "Gynecologic Oncology Group"
      ],
      "interventions": [
        "Pegylated liposomal doxorubicin",
        "Paclitaxel",
        "Topotecan",
        "Mirvetuximab soravtansine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Switzerland",
        "Russian Federation",
        "Bosnia and Herzegovina",
        "Ireland",
        "United Kingdom",
        "Spain",
        "Serbia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 366,
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal Carcinoma"
      ],
      "Start Date": "2016-03-02",
      "Max Phase": "3"
    },
    {
      "id": "NCT05498597",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Multitude Therapeutics Inc."
      ],
      "collaborators": [
        "Tigermed Consulting Co., Ltd"
      ],
      "interventions": [
        "AMT-151"
      ],
      "locations": [
        "China",
        "Australia"
      ],
      "enrollment": 30,
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Endometrioid Adenocarcinoma",
        "Advanced Cancer",
        "Lung Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Advanced Carcinoma",
        "Endometrial Cancer",
        "Endometrial Endometrioid Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Ovarian Carcinoma",
        "Triple Negative Breast Cancer",
        "Ovarian Epithelial Cancer",
        "Ovarian Clear Cell Carcinoma",
        "Malignant Pleural Mesothelioma",
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-01-25",
      "Max Phase": "1"
    },
    {
      "id": "NCT05374512",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Paclitaxel",
        "Dato-DXd",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Nab-paclitaxel",
        "Eribulin mesylate",
        "Carboplatin",
        "Capecitabine"
      ],
      "locations": [
        "Mexico",
        "Singapore",
        "China",
        "India",
        "Germany",
        "France",
        "Italy",
        "Thailand",
        "Belgium",
        "Argentina",
        "Hungary",
        "Taiwan",
        "United States",
        "Canada",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "South Africa"
      ],
      "enrollment": 600,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2022-05-16",
      "Max Phase": "3"
    },
    {
      "id": "NCT05775471",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jonsson Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Seagen Inc."
      ],
      "interventions": [
        "Keytruda",
        "Biospecimen Collected",
        "Enfortumab Vedotin",
        "Bx",
        "AGS 22ME",
        "Specimen Collection",
        "BIOPSY_TYPE",
        "Anti-Nectin 4 ADC ASG-22CE",
        "Biopsy",
        "Lambrolizumab",
        "Biological Sample Collection",
        "Ureteronephrectomy",
        "MR Urography",
        "Nephroureterectomy",
        "ASG-22CE",
        "SCH 900475",
        "Padcev",
        "AGS-22M6E",
        "Pembrolizumab",
        "MK-3475",
        "Enfortumab Vedotin-ejfv",
        "Biospecimen Collection",
        "Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E",
        "Magnetic Resonance Urography"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 21,
      "conditions": [
        "Renal Pelvis and Ureter Urothelial Carcinoma"
      ],
      "Start Date": "2024-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05701527",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "EDDC (Experimental Drug Development Centre), A*STAR Research Entities"
      ],
      "collaborators": [
        "Parexel"
      ],
      "interventions": [
        "Pembrolizumab",
        "EBC-129"
      ],
      "locations": [
        "Singapore",
        "United States"
      ],
      "enrollment": 84,
      "conditions": [
        "Advanced Solid Tumours"
      ],
      "Start Date": "2023-04-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT03696771",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Novartis Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "NJH395"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Japan",
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "NON-breast HER2+ Malignancies"
      ],
      "Start Date": "2018-12-27",
      "Max Phase": "1"
    },
    {
      "id": "NCT06028932",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "IMMU-132",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Ovarian Carcinoma"
      ],
      "Start Date": "2024-01-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT03023722",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Bayer"
      ],
      "interventions": [
        "anetumab ravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Pancreatic Cancer"
      ],
      "Start Date": "2017-05-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT04595565",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "German Breast Group"
      ],
      "collaborators": [
        "Austrian Breast & Colorectal Cancer Study Group",
        "Spanish Breast Cancer Research Group (GEICAM)",
        "UNICANCER",
        "Gilead Sciences",
        "ETOP IBCSG Partners Foundation",
        "Cancer Trials Ireland"
      ],
      "interventions": [
        "Xeloda",
        "Paraplatin",
        "Platinol",
        "Sacituzumab govitecan",
        "Capecitabine",
        "Trodelvy",
        "Cisplatin",
        "Carboplatin"
      ],
      "locations": [
        "Spain",
        "Switzerland",
        "Ireland",
        "Germany",
        "Austria",
        "Belgium",
        "France"
      ],
      "enrollment": 1332,
      "conditions": [
        "Triple Negative Breast Cancer",
        "HER2-negative Breast Cancer"
      ],
      "Start Date": "2020-10-28",
      "Max Phase": "3"
    },
    {
      "id": "NCT05445778",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "GOG Foundation"
      ],
      "interventions": [
        "Mirvetuximab soravtansine plus Bevacizumab",
        "MIRV",
        "Bevacizumab"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Israel",
        "Philippines",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "United States"
      ],
      "enrollment": 418,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2022-12-27",
      "Max Phase": "3"
    },
    {
      "id": "NCT05271604",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "BioAtla, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "PD-1 inhibitor",
        "Ozuriftamab Vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 80,
      "conditions": [
        "Metastatic Squamous Cell Carcinoma of the Head and Neck",
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Metastatic Cancer",
        "Head and Neck Cancer",
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "Start Date": "2022-12-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT03543813",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "CytomX Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "CX-2029"
      ],
      "locations": [
        "Spain",
        "Korea, Republic of",
        "United Kingdom",
        "United States"
      ],
      "enrollment": 133,
      "conditions": [
        "Esophageal Cancer",
        "Solid Tumor, Adult",
        "Diffuse Large B Cell Lymphoma",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer"
      ],
      "Start Date": "2018-06-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT06298058",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Institute Of Biological Products"
      ],
      "collaborators": [
        "Shanghai Pulmonary Hospital, Shanghai, China"
      ],
      "interventions": [
        "Her3-ADC",
        "SIBP-A13 formulation for injection"
      ],
      "locations": [],
      "enrollment": 144,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-03-12",
      "Max Phase": "1"
    },
    {
      "id": "NCT05867563",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2103 for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 71,
      "conditions": [
        "Advanced Malignant Neoplasm"
      ],
      "Start Date": "2023-07-04",
      "Max Phase": "1"
    },
    {
      "id": "NCT03245736",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "TIVDAK",
        "Tisotumab Vedotin"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": 5,
      "conditions": [
        "Lung Cancer, Nonsmall Cell",
        "Prostate Cancer",
        "Cervix Cancer",
        "Ovary Cancer",
        "Esophagus Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Bladder Cancer",
        "Endometrium Cancer"
      ],
      "Start Date": "2017-08-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT05798156",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Institut f\u00fcr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest"
      ],
      "collaborators": [
        "Charite University, Berlin, Germany",
        "Roche Pharma AG",
        "Zentrum f\u00fcr Klinische Studien Leipzig",
        "Hoffmann-La Roche",
        "University of Salzburg",
        "Arbeitsgemeinschaft medikamentoese Tumortherapie"
      ],
      "interventions": [
        "Obinutuzumab",
        "Rituximab",
        "Glofitamab",
        "Polatuzumab vedotin"
      ],
      "locations": [
        "Austria",
        "Germany"
      ],
      "enrollment": 80,
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": "2023-03-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT05653271",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Acepodia Biotech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Cyclophosphamide",
        "ACE1831",
        "Fludarabine"
      ],
      "locations": [
        "Taiwan",
        "United States"
      ],
      "enrollment": 42,
      "conditions": [
        "Follicular Lymphoma",
        "Non Hodgkin Lymphoma",
        "Primary Mediastinal Large B Cell Lymphoma",
        "B-cell Lymphoma",
        "Marginal Zone Lymphoma",
        "DLBCL"
      ],
      "Start Date": "2023-01-21",
      "Max Phase": "1"
    },
    {
      "id": "NCT02099058",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Nivolumab",
        "Telisotuzumab vedotin",
        "Osimertinib",
        "ABBV-399",
        "Erlotinib"
      ],
      "locations": [
        "Italy",
        "Finland",
        "Japan",
        "Korea, Republic of",
        "Taiwan",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 237,
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "Start Date": "2014-01-15",
      "Max Phase": "1"
    },
    {
      "id": "NCT00674947",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Biogen"
      ],
      "collaborators": [],
      "interventions": [
        "BIIB015"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 55,
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": "2008-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05965479",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Southampton"
      ],
      "collaborators": [
        "AstraZeneca",
        "Natera, Inc."
      ],
      "interventions": [
        "Enhertu",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": 25,
      "conditions": [
        "Gastrooesophageal Cancer"
      ],
      "Start Date": "2024-04-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT00624819",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Prevenar",
        "GSK1024805A",
        "Synflorix",
        "Infanrix hexa",
        "Varilrix",
        "Havrix"
      ],
      "locations": [
        "Poland"
      ],
      "enrollment": 524,
      "conditions": [
        "Infections, Streptococcal",
        "Streptococcus Pneumoniae Vaccines"
      ],
      "Start Date": "2008-03-03",
      "Max Phase": "3"
    },
    {
      "id": "NCT06100874",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Adrienne G. Waks"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Herceptin Hylecta",
        "Sacituzumab Govitecan",
        "Trastuzumab",
        "Trodelvy",
        "Trastuzumab and Hyaluronidase-oysk",
        "Herceptin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 40,
      "conditions": [
        "Breast Cancer Female",
        "Her 2 Positive Breast Cancer",
        "Breast Cancer Metastatic"
      ],
      "Start Date": "2023-11-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT02073487",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Methodist Hospital Research Institute"
      ],
      "collaborators": [
        "Celgene Corporation",
        "Novartis"
      ],
      "interventions": [
        "trastuzumab emtansine",
        "tykerb",
        "T-DM1",
        "Paclitaxel",
        "Taxol",
        "Kadcyla",
        "Trastuzumab",
        "Lapatinib",
        "Pertuzumab",
        "Herceptin",
        "nab-paclitaxel",
        "Perjeta",
        "Abraxane"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 32,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2014-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03737955",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "CDP-771",
        "Mylotarg",
        "Gemtuzumab Ozogamicin",
        "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
        "Quality-of-Life Assessment"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2018-11-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT05622890",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "MIRV",
        "Mirvetuximab Soravtansine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 35,
      "conditions": [
        "Fallopian Tube Cancer",
        "Epithelial Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2022-08-18",
      "Max Phase": "3"
    },
    {
      "id": "NCT04143711",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Dragonfly Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "Nab paclitaxel",
        "Nivolumab",
        "DF1001",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "Denmark",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 378,
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "Start Date": "2019-11-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT06176261",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sarah Sammons, MD"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Datopotamab Deruxtecan",
        "DS-1062; DS-1062a, Dato-DXd"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 58,
      "conditions": [
        "ER-negative Breast Cancer",
        "HER2 Negative Breast Carcinoma",
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "Breast Cancer Female",
        "ER Positive Breast Cancer",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "Start Date": "2023-12-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT01125527",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Novartis Vaccines"
      ],
      "collaborators": [],
      "interventions": [
        "Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)",
        "Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 700,
      "conditions": [
        "Haemophilus Influenzae Type b (Hib) Infection"
      ],
      "Start Date": "2009-08-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT01060904",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "vinblastine",
        "bleomycin",
        "SGN-35",
        "brentuximab vedotin",
        "dacarbazine",
        "doxorubicin"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 51,
      "conditions": [
        "Disease, Hodgkin"
      ],
      "Start Date": "2010-01-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02485119",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY94-9343"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 12,
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": "2015-08-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT05123482",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: AZD8205 and AZD2936 (Rilvegostomig)",
        "Drug: AZD8205",
        "AZD8205 and AZD2936 (Rilvegostomig)",
        "AZD8205"
      ],
      "locations": [
        "Canada",
        "Thailand",
        "Italy",
        "Belgium",
        "China",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Hungary",
        "Netherlands",
        "Japan",
        "United States"
      ],
      "enrollment": 340,
      "conditions": [
        "Breast Cancer",
        "Endometrial Cancer",
        "Biliary Tract Carcinoma",
        "Ovarian Cancer"
      ],
      "Start Date": "2021-10-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT04296890",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "MIRV",
        "Mirvetuximab Soravtansine"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Israel",
        "Ireland",
        "Germany",
        "Poland",
        "Bulgaria",
        "Spain",
        "Australia",
        "Belgium",
        "United States"
      ],
      "enrollment": 106,
      "conditions": [
        "Fallopian Tube Cancer",
        "Epithelial Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2020-07-23",
      "Max Phase": "3"
    },
    {
      "id": "NCT04014075",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Drug: Trastuzumab deruxtecan",
        "DS-8201a",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Italy",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 79,
      "conditions": [
        "Adenocarcinoma Gastric Stage IV With Metastases",
        "Adenocarcinoma - GEJ"
      ],
      "Start Date": "2019-08-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT06415487",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Acepodia Biotech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "ACE2016",
        "Fludarabine",
        "Pembrolizumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Metastatic Solid Tumor",
        "Locally Advanced Solid Tumor"
      ],
      "Start Date": "2024-05-31",
      "Max Phase": "1"
    },
    {
      "id": "NCT03835819",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Pembrolizumab",
        "Keytruda",
        "Mirvetuximab soravtansine",
        "IMGN853",
        "Elahere"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2020-01-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT05547321",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Oncomatryx Biopharma S.L."
      ],
      "collaborators": [],
      "interventions": [
        "OMTX705",
        "Pembrolizumab",
        "Keytruda (trademark)",
        "NA at this moment"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": 120,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2022-10-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT04822337",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Wake Forest University Health Sciences"
      ],
      "collaborators": [
        "Amgen",
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2021-05-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT02980341",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Patritumab Deruxtecan",
        "U3-1402"
      ],
      "locations": [
        "Japan",
        "United States"
      ],
      "enrollment": 184,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2016-11-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT06219941",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "CMG901",
        "LV",
        "Irinotecan",
        "AZD0901",
        "Leucovorin",
        "Nanoliposomal Irinotecan",
        "Gemcitabine",
        "ONIVYDE",
        "5-Fluorouracil",
        "l-leucovorin",
        "Gemzar",
        "5-FU",
        "Camptosar",
        "I-LV"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Moldova, Republic of",
        "Georgia",
        "Malaysia",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "enrollment": 123,
      "conditions": [
        "Gastric Cancer",
        "Pancreatic Adenocarcinoma",
        "Gastroesophageal Junction Cancer"
      ],
      "Start Date": "2023-12-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05735496",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "TQB2102 injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 71,
      "conditions": [
        "Advanced Cancer"
      ],
      "Start Date": "2023-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04556773",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Capivasertib",
        "Paclitaxel",
        "Anastrozole",
        "Fulvestrant",
        "Taxol A",
        "AZD5363",
        "Durvalumab",
        "Trastuzumab deruxtecan",
        "DS-8201a, T-DXd",
        "Capecitabine",
        "Anastrozol",
        "MEDI4736"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Mexico",
        "Korea, Republic of",
        "Taiwan",
        "Australia",
        "Russian Federation",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 138,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2020-12-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT06233942",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "BeiGene"
      ],
      "collaborators": [],
      "interventions": [
        "Tislelizumab",
        "BG-C9074"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 150,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-04-12",
      "Max Phase": "1"
    },
    {
      "id": "NCT00947856",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "Adcetris"
      ],
      "locations": [
        "France",
        "United States"
      ],
      "enrollment": 110,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2009-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06359002",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "BYON4413"
      ],
      "locations": [
        "Spain",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 100,
      "conditions": [
        "Relapsed / Refractory AML",
        "Relapsed / Refractory MDS"
      ],
      "Start Date": "2024-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT06336707",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "Cisplatin / carboplatin",
        "Bevacizumab",
        "Adebrelimab",
        "HS-20089"
      ],
      "locations": [],
      "enrollment": 1048,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2024-04-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT06003231",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "RC48, RC48-ADC",
        "disitamab vedotin"
      ],
      "locations": [
        "Canada",
        "Australia",
        "United States"
      ],
      "enrollment": 160,
      "conditions": [
        "Endometrial Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Squamous Cell of Head and Neck",
        "Ovarian Neoplasms"
      ],
      "Start Date": "2023-11-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT06422520",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "BeiGene"
      ],
      "collaborators": [],
      "interventions": [
        "BGB-C354",
        "Tislelizumab"
      ],
      "locations": [],
      "enrollment": 62,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-06-24",
      "Max Phase": "1"
    },
    {
      "id": "NCT01472887",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi"
      ],
      "collaborators": [],
      "interventions": [
        "SAR3419"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Israel",
        "Poland",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 61,
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": "2012-01-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06112379",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "LYNPARZA\u00ae",
        "Paclitaxel",
        "Dato-DXd",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Olaparib",
        "Epirubicin",
        "Durvalumab",
        "Cyclophosphamide",
        "Carboplatin",
        "Capecitabine",
        "XELODA\u00ae, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord",
        "Doxorubicin",
        "MEDI4736",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Singapore",
        "China",
        "Bulgaria",
        "India",
        "Germany",
        "France",
        "Italy",
        "Thailand",
        "Austria",
        "Hungary",
        "Taiwan",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam"
      ],
      "enrollment": 1728,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-11-14",
      "Max Phase": "3"
    },
    {
      "id": "NCT01470456",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi"
      ],
      "collaborators": [],
      "interventions": [
        "SAR3419",
        "rituximab"
      ],
      "locations": [
        "Austria",
        "France",
        "Norway"
      ],
      "enrollment": 50,
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2011-11-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05804864",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Xuanzhu Biopharmaceutical Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "KM501"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 96,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2023-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT06303505",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Tubulis GmbH"
      ],
      "collaborators": [],
      "interventions": [
        "TUB-040"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 100,
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Ovarian Cancer"
      ],
      "Start Date": "2024-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04246047",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: Belantamab mafodotin",
        "Bortezomib",
        "Drug: Bortezomib",
        "Belantamab mafodotin",
        "Daratumumab",
        "Drug: Daratumumab",
        "Dexamethasone",
        "Drug: Dexamethasone"
      ],
      "locations": [
        "Czechia",
        "China",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "New Zealand",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 571,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2020-01-27",
      "Max Phase": "3"
    },
    {
      "id": "NCT05535244",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Cevostamab",
        "Tocilizumab"
      ],
      "locations": [
        "Italy",
        "Israel",
        "Germany",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 90,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2022-10-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT00891176",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "PrevenarTM",
        "InfanrixTM IPV",
        "NeisVac-CTM",
        "InfanrixTM hexa",
        "Pneumococcal conjugate vaccine GSK1024850A",
        "MenitorixTM",
        "InfanrixTM IPV/Hib",
        "InfanrixTM penta",
        "MeningitecTM"
      ],
      "locations": [
        "Spain",
        "Poland",
        "Germany"
      ],
      "enrollment": 582,
      "conditions": [
        "Neisseria Meningitidis",
        "Haemophilus Influenzae Type b"
      ],
      "Start Date": "2009-05-14",
      "Max Phase": "3"
    },
    {
      "id": "NCT06103864",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "Paclitaxel",
        "Dato-DXd",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Gemcitabine",
        "Durvalumab",
        "Nab-paclitaxel",
        "Carboplatin",
        "MEDI4736"
      ],
      "locations": [
        "Mexico",
        "Singapore",
        "China",
        "India",
        "Germany",
        "France",
        "Italy",
        "Thailand",
        "Argentina",
        "Taiwan",
        "United States",
        "Canada",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "South Africa",
        "Vietnam"
      ],
      "enrollment": 625,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-11-23",
      "Max Phase": "3"
    },
    {
      "id": "NCT06147037",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fusion Pharmaceuticals Inc."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "[225Ac]-FPI-2068",
        "FPI-2053",
        "[111In]-FPI-2107"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 110,
      "conditions": [
        "Metastatic Colorectal Carcinoma",
        "Non-small Cell Lung Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-07-31",
      "Max Phase": "1"
    },
    {
      "id": "NCT06429761",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab deruxtecan"
      ],
      "locations": [],
      "enrollment": 100,
      "conditions": [
        "BREAST CANCER"
      ],
      "Start Date": "2024-09-30",
      "Max Phase": "4"
    },
    {
      "id": "NCT05104866",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Vinorelbine",
        "Eribulin Mesylate",
        "Eribulin",
        "Dato-DXd",
        "Datopotamab deruxtecan (Dato-DXd, DS-1062a)",
        "Gemcitabine",
        "Capecitabine"
      ],
      "locations": [
        "China",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Belgium",
        "Argentina",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Spain",
        "South Africa"
      ],
      "enrollment": 732,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2021-10-18",
      "Max Phase": "3"
    },
    {
      "id": "NCT05609968",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "MK-3475",
        "Keytruda\u00ae",
        "Sacituzumab Govitecan",
        "Trodelvy\u00ae"
      ],
      "locations": [
        "Lithuania",
        "China",
        "Germany",
        "Greece",
        "Italy",
        "Thailand",
        "Israel",
        "Taiwan",
        "United States",
        "Canada",
        "Chile",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Australia",
        "Estonia"
      ],
      "enrollment": 614,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": "2023-02-06",
      "Max Phase": "3"
    },
    {
      "id": "NCT03724747",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY2315497 Injection",
        "Darolutamide(BAY1841788)"
      ],
      "locations": [
        "United Kingdom",
        "Finland",
        "United States"
      ],
      "enrollment": 63,
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "Start Date": "2018-12-18",
      "Max Phase": "1"
    },
    {
      "id": "NCT02884726",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [],
      "interventions": [
        "BMS-986148"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 8,
      "conditions": [
        "Advanced Cancer"
      ],
      "Start Date": "2016-10-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT03856541",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Jiangsu HengRui Medicine Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "SHR-A1403",
        "HTI-1066"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 9,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2019-02-13",
      "Max Phase": "1"
    },
    {
      "id": "NCT05687266",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Pembrolizumab",
        "Pemetrexed",
        "Paclitaxel",
        "Dato-DXd",
        "Durvalumab",
        "Cisplatin",
        "Carboplatin",
        "Datopotamab deruxtecan",
        "MEDI4736, Imfinzi"
      ],
      "locations": [
        "Mexico",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Austria",
        "Hungary",
        "Taiwan",
        "United States",
        "Canada",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Vietnam"
      ],
      "enrollment": 1280,
      "conditions": [
        "NSCLC"
      ],
      "Start Date": "2022-12-29",
      "Max Phase": "3"
    },
    {
      "id": "NCT01100502",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Adcetris",
        "brentuximab vedotin",
        "placebo",
        "SGN-35"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Hungary",
        "Germany",
        "Poland",
        "United States",
        "United Kingdom",
        "Bulgaria",
        "Spain",
        "Serbia",
        "Russian Federation",
        "France",
        "Romania"
      ],
      "enrollment": 329,
      "conditions": [
        "Disease, Hodgkin"
      ],
      "Start Date": "2010-04-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT05456685",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "MIRV",
        "Carboplatin",
        "Mirvetuximab soravtansine"
      ],
      "locations": [
        "Canada",
        "Georgia",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 114,
      "conditions": [
        "High Grade Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "Start Date": "2022-09-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT00848926",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 102,
      "conditions": [
        "Disease, Hodgkin"
      ],
      "Start Date": "2009-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04879329",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "pembrolizumab",
        "disitamab vedotin",
        "KEYTRUDA\u00ae",
        "RC48-ADC"
      ],
      "locations": [
        "Canada",
        "Chile",
        "Israel",
        "Argentina",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "Japan",
        "United States"
      ],
      "enrollment": 332,
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": "2022-05-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT03828292",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Bortezomib",
        "Belantamab mafodotin",
        "Pomalidomide",
        "Dexamethasone"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 15,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2019-03-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT05922501",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "GlaxoSmithKline",
        "Sanofi"
      ],
      "interventions": [
        "Isatuximab",
        "SAR650984",
        "Belantamab mafodotin",
        "Pomalidomide",
        "Dexamethasone",
        "GSK2857916"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Multiple Myeloma",
        "Refractory Multiple Myeloma",
        "Relapsed Cancer"
      ],
      "Start Date": "2024-06-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT04147819",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY2701439"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": 14,
      "conditions": [
        "Cancers With HER2 Expression"
      ],
      "Start Date": "2020-07-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT06014190",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20089"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 460,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Endometrial Cancer"
      ],
      "Start Date": "2023-12-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT06227117",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Toripalimab \uff0812weeks\uff09",
        "JS001",
        "Toripalimab \uff0818weeks\uff09",
        "Disitamab Vedotin Injection \uff0812 weeks\uff09",
        "DV,RC48-ADC",
        "Epirubicin",
        "Sequential Epirubicin",
        "CTX, cyclophosphamide",
        "Sequential CTX",
        "Carboplatin",
        "Disitamab Vedotin Injection \uff0818 weeks\uff09"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 120,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-07-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT05425550",
      "phases": [],
      "sponsor": [
        "Palleos Healthcare GmbH"
      ],
      "collaborators": [
        "mobile Health AG"
      ],
      "interventions": [
        "medidux\u2122 app"
      ],
      "locations": [
        "Switzerland"
      ],
      "enrollment": 585,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2022-08-29",
      "Max Phase": null
    },
    {
      "id": "NCT01874054",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin",
        "bendamustine",
        "Adcetris; SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 55,
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": "2013-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06397768",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "534",
        "Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine",
        "Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine",
        "RSVt vaccine",
        "Varicella virus vaccine",
        "Pentacel\u00ae",
        "Streptococcus pneumoniae vaccine",
        "Vaxelis\u00ae",
        "Measles, mumps, and rubella vaccine",
        "Rotavirus vaccine",
        "Placebo",
        "RECOMBIVAX HB\u00ae or alternate monovalent hepatitis B vaccine",
        "RotaTeq\u00ae",
        "PREVNAR 20\u00ae",
        "M-M-R\u00ae II",
        "Hepatitis B vaccine",
        "VARIVAX\u00ae"
      ],
      "locations": [
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 2226,
      "conditions": [
        "RSV Immunization"
      ],
      "Start Date": "2024-05-13",
      "Max Phase": "3"
    },
    {
      "id": "NCT01026415",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "ketoconazole",
        "midazolam",
        "SGN-35",
        "brentuximab vedotin",
        "rifampin",
        "ADCETRIS; SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 73,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Carcinomas",
        "Neoplasms",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2009-12-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT06161025",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pegylated Liposomal Doxorubicin",
        "PLD",
        "Paclitaxel",
        "DS-6000a",
        "Gemcitabine",
        "Topotecan",
        "R-DXd"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Taiwan",
        "Japan"
      ],
      "enrollment": 650,
      "conditions": [
        "Solid Cancer"
      ],
      "Start Date": "2024-02-27",
      "Max Phase": "3"
    },
    {
      "id": "NCT01712490",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "vinblastine",
        "bleomycin",
        "SGN-35",
        "DTIC",
        "brentuximab vedotin",
        "ADCETRIS\u00ae",
        "dacarbazine",
        "doxorubicin",
        "Adriamycin"
      ],
      "locations": [
        "Czechia",
        "Denmark",
        "Russian Federation",
        "France",
        "Italy",
        "Belgium",
        "Hungary",
        "Taiwan",
        "Norway",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "South Africa"
      ],
      "enrollment": 1334,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2012-11-09",
      "Max Phase": "3"
    },
    {
      "id": "NCT06178159",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "Toripalimab",
        "DV,RC48-ADC",
        "Disitamab Vedotin Injection",
        "Pertuzumab Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 80,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-11-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT01224821",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab"
      ],
      "locations": [],
      "enrollment": 47,
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "Start Date": "1995-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05169658",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "949142-50-1",
        "RG-7828",
        "ADC DCDS4501A",
        "polatuzumab vedotin-piiq",
        "Gazyva",
        "Ro 5541077-000",
        "BTCT4465A",
        "DCDS4501A",
        "R7159",
        "1905409-39-3",
        "huMAB(CD20)",
        "Polatuzumab Vedotin",
        "Mosunetuzumab",
        "Obinutuzumab",
        "RO5072759",
        "Polivy",
        "BTCT 4465A",
        "RG 7828",
        "Mosunetuzumab-axgb",
        "GA-101",
        "RO-5072759",
        "Lunsumio",
        "Antibody-Drug Conjugate DCDS4501A",
        "RG7596",
        "RO7030816",
        "BTCT-4465A",
        "RO 5072759",
        "FCU 2711",
        "1313206-42-6",
        "Anti-CD20 Monoclonal Antibody R7159",
        "CD20/CD3 BiMAb BTCT4465A",
        "Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A",
        "RG7828",
        "GA101"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 42,
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Grade 3a Follicular Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Grade 1 Follicular Lymphoma",
        "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Marginal Zone Lymphoma",
        "Grade 2 Follicular Lymphoma"
      ],
      "Start Date": "2022-03-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT02572167",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "nivolumab",
        "BMS-936558, OPDIVO",
        "brentuximab vedotin",
        "SGN-35, ADCETRIS"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 93,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2015-10-31",
      "Max Phase": "2"
    },
    {
      "id": "NCT03657043",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab"
      ],
      "interventions": [
        "TIVDAK",
        "tisotumab vedotin"
      ],
      "locations": [
        "Italy",
        "Ireland",
        "Denmark",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 98,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2019-03-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT03544281",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [
        "Iqvia Pty Ltd"
      ],
      "interventions": [
        "Bortezomib",
        "Belantamab mafodotin",
        "Dexamethasone",
        "Lenalidomide"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Spain",
        "Australia",
        "United States"
      ],
      "enrollment": 153,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2018-09-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT02724163",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University of Birmingham"
      ],
      "collaborators": [
        "Pfizer",
        "National Cancer Institute, France",
        "Cancer Research UK",
        "Assistance Publique - H\u00f4pitaux de Paris"
      ],
      "interventions": [
        "Fludarabine",
        "Liposomal daunorubicin",
        "Gemtuzumab ozogamicin",
        "Mitoxantrone",
        "Busulfan",
        "Mylotarg",
        "Cyclophosphamide",
        "Cytarabine"
      ],
      "locations": [
        "Switzerland",
        "Ireland",
        "United Kingdom",
        "Australia",
        "France",
        "New Zealand"
      ],
      "enrollment": 700,
      "conditions": [
        "Acute Myeloid Leukaemia"
      ],
      "Start Date": "2016-04-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05948865",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Conjupro Biotherapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SYS6010",
        "CPO301"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 102,
      "conditions": [
        "Cancer, Lung",
        "Cancer"
      ],
      "Start Date": "2023-06-06",
      "Max Phase": "1"
    },
    {
      "id": "NCT03474107",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "ASG-22ME",
        "Paclitaxel",
        "ASG-22CE",
        "Enfortumab Vedotin",
        "Vinflunine",
        "Docetaxel"
      ],
      "locations": [
        "Denmark",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Argentina",
        "Austria",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 608,
      "conditions": [
        "Bladder Cancer",
        "Ureteral Cancer",
        "Urothelial Cancer"
      ],
      "Start Date": "2018-06-27",
      "Max Phase": "3"
    },
    {
      "id": "NCT04484623",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Bortezomib",
        "Belantamab mafodotin",
        "Pomalidomide",
        "Dexamethasone"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "Czechia",
        "Israel",
        "China",
        "Japan",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Australia",
        "Greece",
        "Russian Federation",
        "France",
        "New Zealand",
        "United States"
      ],
      "enrollment": 357,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2020-10-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT00322049",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "U.S. Army Medical Research and Development Command"
      ],
      "collaborators": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine",
        "Tetravalent live attenuated dengue vaccine"
      ],
      "locations": [
        "Thailand"
      ],
      "enrollment": 51,
      "conditions": [
        "Dengue"
      ],
      "Start Date": "2004-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03262935",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Byondis B.V."
      ],
      "collaborators": [],
      "interventions": [
        "SYD985",
        "Trastuzumab vc-seco-DUBA",
        "Trastuzumab (T)",
        "Physician's choice",
        "Eribulin (Eri)",
        "Capecitabine (Cap)",
        "(vic-)trastuzumab duocarmazine",
        "Lapatinib (Lap)",
        "Vinorelbine (Vino)"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Singapore",
        "Sweden",
        "Denmark",
        "United Kingdom",
        "Spain",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 437,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2017-12-15",
      "Max Phase": "3"
    },
    {
      "id": "NCT03523585",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca",
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "T-DXd",
        "Investigator's Choice Comparative Therapy",
        "Trastuzumab",
        "Lapatinib",
        "Trastuzumab deruxtecan",
        "Capecitabine"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "Czechia",
        "Israel",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Australia",
        "Greece",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 608,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2018-08-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT04639986",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Xeloda",
        "IMMU-132",
        "Halaven",
        "Sacituzumab Govitecan-hziy",
        "Eribulin Mesylate Injection",
        "Navelbine",
        "GS-0132",
        "Gemcitabine Injection",
        "Trodelvy\u2122",
        "Gemzar",
        "Capecitabine Oral Product",
        "Vinorelbine injection"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "Taiwan"
      ],
      "enrollment": 331,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2020-11-23",
      "Max Phase": "3"
    },
    {
      "id": "NCT04487756",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Instituto Oncol\u00f3gico Dr Rosell",
        "Instituto Oncologico Dr Rosell"
      ],
      "collaborators": [
        "Roche Pharma AG",
        "Fundacion Clinic per a la Recerca Biom\u00e9dica"
      ],
      "interventions": [
        "Carboplatino (Teva/Accord/Pharmacia)",
        "Drug: Atezolizumab 1200 mg in 20 ML Injection",
        "Drug: Carboplatin",
        "Atezolizumab 1200 mg in 20 ML Injection",
        "Tecentriq",
        "Biological: ADC Vaccine",
        "Carboplatin",
        "Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine",
        "ADC Vaccine"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 20,
      "conditions": [
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "Start Date": "2020-07-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT02326584",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Standard dose cytarabine for induction",
        "vadastuximab talirine",
        "High dose cytarabine for consolidation",
        "Daunorubicin",
        "SGN-CD33A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 116,
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": "2014-12-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05647122",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "5-Fluorouracil (5-FU)",
        "AZD9592",
        "Bevacizumab",
        "Leucovorin",
        "Osimertinib"
      ],
      "locations": [
        "Canada",
        "Italy",
        "China",
        "Malaysia",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 162,
      "conditions": [
        "Head and Neck Neoplasms",
        "Colorectal Neoplasms",
        "Carcinoma Non-small Cell Lung",
        "Advanced Solid Tumours"
      ],
      "Start Date": "2022-12-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT05279300",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "CStone Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "CS5001"
      ],
      "locations": [
        "China",
        "Australia",
        "United States"
      ],
      "enrollment": 156,
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Lymphoma"
      ],
      "Start Date": "2022-03-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT06400472",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Eli Lilly and Company"
      ],
      "collaborators": [
        "Loxo Oncology, Inc."
      ],
      "interventions": [
        "LY4170156"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 220,
      "conditions": [
        "Pancreatic Neoplasm",
        "Endometrial Neoplasms",
        "Triple Negative Breast Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Uterine Cervical Neoplasms",
        "Ovarian Neoplasms",
        "Colorectal Neoplasms"
      ],
      "Start Date": "2024-05-06",
      "Max Phase": "1"
    },
    {
      "id": "NCT04381832",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Arcus Biosciences, Inc."
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Zimberelimab",
        "SG",
        "AB122",
        "AB680",
        "Xtandi",
        "Trodelvy",
        "Etrumadenant",
        "Enzalutamide",
        "Docetaxel",
        "Quemliclustat",
        "AB928",
        "Taxotere"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 173,
      "conditions": [
        "Androgen-Resistant Prostatic Neoplasms",
        "Castration Resistant Prostatic Neoplasms",
        "Prostatic Cancer, Castration-Resistant",
        "Prostatic Neoplasms, Castration-Resistant"
      ],
      "Start Date": "2020-07-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT05954143",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bolt Biotherapeutics, Inc."
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Pertuzumab",
        "Perjeta\u00ae",
        "BDC-1001"
      ],
      "locations": [
        "Spain",
        "Italy",
        "United States"
      ],
      "enrollment": 66,
      "conditions": [
        "HER2-positive Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2023-11-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT04786847",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Telix Pharmaceuticals (Innovations) Pty Limited"
      ],
      "collaborators": [],
      "interventions": [
        "177Lu-DOTA-TLX591"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 30,
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "Start Date": "2022-01-30",
      "Max Phase": "1"
    },
    {
      "id": "NCT05327530",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "EMD Serono Research & Development Institute, Inc."
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics"
      ],
      "interventions": [
        "M6223",
        "IMMU-132",
        "Avelumab",
        "NKTR-255",
        "MSB0010718C",
        "GS-0132",
        "Sacituzumab Govitecan",
        "Trodelvy\u2122"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "Denmark",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Greece",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 252,
      "conditions": [
        "Locally Advanced or Metastatic Urothelial Carcinoma"
      ],
      "Start Date": "2022-08-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT05149768",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Lawson Health Research Institute"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "ADCETRIS, SGN-35",
        "Brentuximab vedotin"
      ],
      "locations": [
        "Canada"
      ],
      "enrollment": 11,
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "Start Date": "2024-02-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT01969643",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-LIV1A",
        "LV",
        "Trastuzumab",
        "Herceptin",
        "ladiratuzumab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 290,
      "conditions": [
        "Hormone Receptor Positive Breast Neoplasms",
        "Triple Negative Breast Neoplasms",
        "HER2 Mutations Breast Neoplasms",
        "HER2 Positive Breast Neoplasms"
      ],
      "Start Date": "2013-10-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT01826877",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Jonsson Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Kite, A Gilead Company"
      ],
      "interventions": [
        "autologous dendritic cells",
        "DC-AdGMCAIX",
        "ADC",
        "dendritic cells transduced with AdGMCA9 expressing GM-CSF-carbonic anhydrase IX fusion protein",
        "therapeutic autologous dendritic cells",
        "AdGMCAIX-transduced autologous dendritic cells",
        "laboratory biomarker analysis"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 12,
      "conditions": [
        "Recurrent Renal Cell Cancer",
        "Stage IV Renal Cell Cancer",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "Start Date": "2013-01-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT06043674",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Christine Ryan"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Obinutuzumab",
        "Atezolizumab",
        "RO5072759, GA101, GAZYVA, GAZYVARO",
        "Actemra",
        "Tecentriq",
        "Glofitamab",
        "RO7082859",
        "Polatuzumab Vedotin",
        "Tocilizumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 66,
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Richter's Transformation"
      ],
      "Start Date": "2024-01-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT05494918",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alphamab (Australia) Co Pty Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "anti-Her2 ADC JSKN003",
        "JSKN003"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 45,
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Solid Tumors"
      ],
      "Start Date": "2022-09-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT01026233",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "Germany",
        "United States"
      ],
      "enrollment": 52,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2010-01-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05577715",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Eisai Inc."
      ],
      "interventions": [
        "BMS-986445",
        "Farletuzumab Ecteribulin",
        "MORAb-202"
      ],
      "locations": [
        "Chile",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": "2022-11-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT05870748",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Sutro Biopharma, Inc."
      ],
      "collaborators": [
        "Asia-Pacific Gynecologic Oncology Trials Group (APGOT)",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Paclitaxel",
        "Neulasta",
        "Gemcitabine",
        "STRO-002",
        "Pegylated liposomal doxorubicin",
        "Topotecan",
        "Luveltamab tazevibulin",
        "Luvelta",
        "Pegfilgrastim"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Israel",
        "Korea, Republic of",
        "Australia",
        "United States"
      ],
      "enrollment": 600,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Platinum-resistant Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Epithelial Ovarian Cancer"
      ],
      "Start Date": "2023-07-12",
      "Max Phase": "3"
    },
    {
      "id": "NCT01716806",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "bendamustine",
        "Adcetris; SGN-35",
        "brentuximab vedotin",
        "dacarbazine",
        "nivolumab"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 131,
      "conditions": [
        "Peripheral T Cell Lymphoma",
        "Hodgkin Disease"
      ],
      "Start Date": "2012-10-31",
      "Max Phase": "2"
    },
    {
      "id": "NCT03525678",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "",
        "Belantamab mafodotin frozen liquid",
        "Belantamab mafodotin lyophilized powder"
      ],
      "locations": [
        "Canada",
        "Italy",
        "France",
        "United Kingdom",
        "Germany",
        "Australia",
        "Spain",
        "United States"
      ],
      "enrollment": 221,
      "conditions": [
        "",
        "Multiple Myeloma"
      ],
      "Start Date": "2018-03-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT00866047",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 58,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2009-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05581589",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "IMMU-132",
        "Radical Cystectomy",
        "Sacituzumab Govitecan-hziy",
        "Complete Cystectomy",
        "Lymphadenectomy",
        "Sacituzumab Govitecan",
        "Lymph Node Excision",
        "Lymph Node Dissection",
        "Trodelvy",
        "hRS7-SN38 Antibody Drug Conjugate",
        "RS7-SN38",
        "excision of the lymph node"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Stage IIIA Bladder Cancer AJCC v8",
        "Stage II Bladder Cancer AJCC v8",
        "Muscle Invasive Bladder Carcinoma"
      ],
      "Start Date": "2023-06-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT05756569",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Emory University"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Merck Sharp & Dohme LLC",
        "Astellas Pharma Inc",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Magnetic Resonance Imaging",
        "Magnetic Resonance Imaging Scan",
        "Keytruda",
        "CAT Scan",
        "Biospecimen Collected",
        "Enfortumab Vedotin",
        "MR Imaging",
        "AGS 22ME",
        "Computed Tomography",
        "Computerized Tomography",
        "tomography",
        "NMR Imaging",
        "CAT",
        "Specimen Collection",
        "CT",
        "Anti-Nectin 4 ADC ASG-22CE",
        "Computed Axial Tomography",
        "MR",
        "Lambrolizumab",
        "Biological Sample Collection",
        "CT Scan",
        "MRI",
        "Questionnaire Administration",
        "NMRI",
        "Nuclear Magnetic Resonance Imaging",
        "ASG-22CE",
        "Padcev",
        "Magnetic Resonance",
        "Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance",
        "AGS-22M6E",
        "Pembrolizumab",
        "Computerized Axial Tomography",
        "MRI Scan",
        "MK-3475",
        "Enfortumab Vedotin-ejfv",
        "Biospecimen Collection",
        "Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E",
        "SCH 900475"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "Urachal Adenocarcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Unresectable Bladder Carcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Stage III Bladder Cancer AJCC v8",
        "Malignant Renal Pelvis Neoplasm",
        "Locally Advanced Bladder Carcinoma",
        "Malignant Ureter Neoplasm",
        "Malignant Urethral Neoplasm",
        "Metastatic Bladder Carcinoma",
        "Bladder Adenocarcinoma"
      ],
      "Start Date": "2023-09-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT02038010",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Northwestern University"
      ],
      "collaborators": [
        "Novartis",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "PI3K inhibitor BYL719",
        "T-DM1",
        "Kadcyla",
        "ado-trastuzumab emtansine",
        "trastuzumab-DM1",
        "trastuzumab-MCC-DM1 antibody-drug conjugate",
        "pharmacological study",
        "BYL719",
        "trastuzumab-MCC-DM1",
        "phosphoinositide 3-kinase inhibitor BYL719",
        "laboratory biomarker analysis",
        "pharmacological studies"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 17,
      "conditions": [
        "Stage IV Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Recurrent Breast Cancer",
        "HER2-positive Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIA Breast Cancer"
      ],
      "Start Date": "2014-05-21",
      "Max Phase": "1"
    },
    {
      "id": "NCT06241898",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bliss Biopharmaceutical (Hangzhou) Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "BB-1709"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 300,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2023-10-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05064358",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin"
      ],
      "locations": [
        "Mexico",
        "Ireland",
        "India",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Argentina",
        "Taiwan",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia"
      ],
      "enrollment": 177,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2022-03-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT00430846",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 45,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Disease, Hodgkin",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2006-11-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01902329",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "HMA",
        "SGN-CD33A",
        "vadastuximab talirine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 195,
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Promyelocytic Leukemia",
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": "2013-07-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05313243",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Brentuximab vedotin",
        "Adcetris",
        "Keytruda"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 43,
      "conditions": [
        "T-Cell Lymphoma"
      ],
      "Start Date": "2023-07-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT03198689",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Lawson Health Research Institute"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "ADCETRIS, SGN-35",
        "Brentuximab Vedotin"
      ],
      "locations": [
        "Canada"
      ],
      "enrollment": 11,
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "Start Date": "2019-05-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT02064387",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "GSK2857916"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "United States"
      ],
      "enrollment": 79,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2014-07-29",
      "Max Phase": "1"
    },
    {
      "id": "NCT05633615",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "SWOG Cancer Research Network"
      ],
      "collaborators": [
        "Genentech, Inc.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "RG-7828",
        "Cyclophosphamide",
        "PET Scan",
        "CART-19",
        "polatuzumab vedotin-piiq",
        "Fludarabine",
        "proton magnetic resonance spectroscopic imaging",
        "Genoxal",
        "Cycloblastin",
        "Cyclophosphamid monohydrate",
        "Tisagenlecleucel",
        "JCAR 017",
        "PT",
        "CYCLO-cell",
        "Observation",
        "Patient Observation",
        "RG 7828",
        "RO7030816",
        "BTCT-4465A",
        "Computerized Axial Tomography",
        "Positron Emission Tomography",
        "Cyclophosphan",
        "KTE-C19",
        "Medical Imaging, Positron Emission Tomography",
        "Cyclophosphanum",
        "tomography",
        "ADC DCDS4501A",
        "CART19",
        "Specimen Collection",
        "Ro 5541077-000",
        "Cytophosphan",
        "Syklofosfamid",
        "CT Scan",
        "Mosunetuzumab",
        "Clafen",
        "RG7596",
        "Carloxan",
        "Fluradosa",
        "Cyclophosphamide Monohydrate",
        "Cyclophospham",
        "Cytoxan",
        "Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A",
        "CAT Scan",
        "Computed Axial Tomography",
        "Biospecimen Collection",
        "Ciclofosfamide",
        "Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017",
        "CP monohydrate",
        "Computed Tomography",
        "Computerized Tomography",
        "Cyclostin",
        "Positron-Emission Tomography",
        "CT",
        "JCAR017",
        "2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate",
        "CTL019",
        "Ledoxina",
        "BTCT 4465A",
        "Cycloblastine",
        "Antibody-Drug Conjugate DCDS4501A",
        "Watchful Waiting",
        "Cicloxal",
        "Yescarta",
        "Fosfaseron",
        "FCU 2711",
        "CTX",
        "Axicabtagene Ciloleucel",
        "Genuxal",
        "CD20/CD3 BiMAb BTCT4465A",
        "Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017",
        "deferred therapy",
        "RG7828",
        "Breyanzi",
        "Active Surveillance",
        "Positron Emission Tomography Scan",
        "Biospecimen Collected",
        "CAT",
        "KTE C19",
        "Cyclophosphamidum",
        "(-)-Cyclophosphamide",
        "KTE-C19 CAR",
        "Lisocabtagene Maraleucel",
        "BTCT4465A",
        "DCDS4501A",
        "Revimmune",
        "Kymriah",
        "Neosar",
        "Cytophosphane",
        "Biological Sample Collection",
        "Polatuzumab Vedotin",
        "Polivy",
        "Ciclofosfamida",
        "Claphene",
        "PET",
        "Tisagenlecleucel-T",
        "Cyclophosphane",
        "CTL019 T-cells",
        "Mitoxan",
        "Cyclostine",
        "Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017",
        "WR- 138719",
        "expectant management"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 396,
      "conditions": [
        "Grade 3b Follicular Lymphoma",
        "Primary Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Transformed Follic Lymph to Diff Large B-Cell Lymphoma",
        "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2023-06-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT06439771",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MediLink Therapeutics (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "YL202 should be intravenously infused"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 180,
      "conditions": [
        "Locally Advanced or Metastatic Breast Cancer"
      ],
      "Start Date": "2024-04-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT04686305",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pemetrexed",
        "T-DXd",
        "Volrustomig",
        "Durvalumab",
        "DS-8201a, Trastuzumab deruxtecan",
        "Other Name: AZD2936",
        "Cisplatin",
        "Carboplatin",
        "Rilvegostomig",
        "MEDI4736",
        "Other Name: MEDI5752"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Thailand",
        "Singapore",
        "Israel",
        "Malaysia",
        "Philippines",
        "Poland",
        "Korea, Republic of",
        "Taiwan",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 248,
      "conditions": [
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2021-03-09",
      "Max Phase": "1"
    },
    {
      "id": "NCT01309789",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "prednisone",
        "SGN-35",
        "brentuximab vedotin",
        "vincristine",
        "cyclophosphamide",
        "doxorubicin"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": 39,
      "conditions": [
        "Lymphoma, NK-cell",
        "Lymphoma, T-cell",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2011-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02581878",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY1862864"
      ],
      "locations": [
        "United Kingdom",
        "Sweden"
      ],
      "enrollment": 21,
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "Start Date": "2015-11-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT01015911",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-75"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 58,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Carcinoma, Renal Cell"
      ],
      "Start Date": "2009-11-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00772070",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune\u00ae)",
        "Menomune\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 173,
      "conditions": [
        "Neisseria Meningitidis",
        "Meningococcemia",
        "Meningitis"
      ],
      "Start Date": "2003-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05628857",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC108"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 240,
      "conditions": [
        "Digestive Cancer"
      ],
      "Start Date": "2022-11-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT05911295",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "disitamab vedotin",
        "pembrolizumab",
        "cisplatin",
        "carboplatin",
        "Gemzar",
        "RC48, RC48-ADC",
        "gemcitabine",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "enrollment": 700,
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": "2023-09-22",
      "Max Phase": "3"
    },
    {
      "id": "NCT01796171",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Nordic Nanovector"
      ],
      "collaborators": [
        "ICON Clinical Research"
      ],
      "interventions": [
        "15 MBq/kg Betalutin",
        "100 mg/m2 lilotomab",
        "20 MBq/kg Betalutin",
        "40 mg lilotomab",
        "10 MBq/kg Betalutin",
        "60 mg/m2 lilotomab",
        "12.5 mBq/kg Betalutin",
        "Rituximab"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "Sweden",
        "Ireland",
        "Denmark",
        "France",
        "Italy",
        "Finland",
        "Israel",
        "Croatia",
        "Austria",
        "Hungary",
        "Netherlands",
        "Norway",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 191,
      "conditions": [
        "Follicular Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2012-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05511844",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Orum Therapeutics USA, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ORM-5029"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 87,
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER-2 Gene Amplification",
        "HER2 Gene Mutation",
        "HER-2 Protein Overexpression"
      ],
      "Start Date": "2022-10-03",
      "Max Phase": "1"
    },
    {
      "id": "NCT03438396",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab",
        "Belgian Gynaecological Oncology Group",
        "Gynecologic Oncology Group",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)"
      ],
      "interventions": [
        "TIVDAK",
        "tisotumab vedotin"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Sweden",
        "Germany",
        "Denmark",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 102,
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": "2018-06-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT01909934",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [
        "Takeda Development Center Americas, Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "Czechia",
        "Hungary",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Croatia",
        "Turkey",
        "Spain",
        "Belgium",
        "Romania"
      ],
      "enrollment": 50,
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": "2014-01-30",
      "Max Phase": "4"
    },
    {
      "id": "NCT05764954",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "NovoCure Ltd."
      ],
      "interventions": [
        "NovoTTF-200T System"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "Adenocarcinoma of Lung"
      ],
      "Start Date": "2023-08-04",
      "Max Phase": "1"
    },
    {
      "id": "NCT06157892",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "tucatinib",
        "RC48, RC48-ADC",
        "disitamab vedotin",
        "TUKYSA, ONT-380, ARRY-380"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 198,
      "conditions": [
        "Breast Neoplasms",
        "HER2 Low Breast Neoplasms",
        "Triple Negative Breast Neoplasms",
        "Gastroesophageal Junction Adenocarcinoma",
        "Stomach Neoplasms",
        "HER2 Positive Breast Neoplasms"
      ],
      "Start Date": "2024-05-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT01777152",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "prednisone",
        "Adcetris; SGN-35",
        "brentuximab vedotin",
        "vincristine",
        "cyclophosphamide",
        "doxorubicin"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Israel",
        "Hungary",
        "Germany",
        "Denmark",
        "Poland",
        "United States",
        "United Kingdom",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "Romania"
      ],
      "enrollment": 452,
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "T-Cell Lymphoma",
        "Anaplastic Large-Cell Lymphoma"
      ],
      "Start Date": "2013-01-31",
      "Max Phase": "3"
    },
    {
      "id": "NCT01166490",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Agensys, Inc."
      ],
      "interventions": [
        "ASG-5ME"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 51,
      "conditions": [
        "Pancreatic Neoplasms",
        "Gastric Neoplasms"
      ],
      "Start Date": "2010-07-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT06464055",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "phase II",
        "Dose Escalation",
        "Dose Expansion2",
        "Dose Expansion1"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 220,
      "conditions": [
        "Advanced Malignant Solid Tumors"
      ],
      "Start Date": "2024-05-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT06365853",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Lubricating Eye Drops",
        "MIRV",
        "Mirvetuximab Soravtansine",
        "IMGN853",
        "Brimonidine tartrate ophthalmic solution eye drops",
        "Prednisolone acetate ophthalmic suspension 1% eye drops"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Ireland",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 100,
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Folate Receptor-Alpha Positive"
      ],
      "Start Date": "2024-06-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT05041257",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "MIRV",
        "Mirvetuximab soravtansine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Ireland",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 79,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2021-08-31",
      "Max Phase": "2"
    },
    {
      "id": "NCT00198380",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Intergroupe Francophone de Cancerologie Thoracique"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Gefitinib"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 90,
      "conditions": [
        "Pneumonic-type Adenocarcinoma (P-ADC)",
        "Lung Adenocarcinoma With Bronchiolo-alveolar Feature"
      ],
      "Start Date": "2005-04-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06144723",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hansoh BioMedical R&D Company"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20105"
      ],
      "locations": [],
      "enrollment": 402,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2024-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01997333",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Celldex Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "CDX-011",
        "Capecitabine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 327,
      "conditions": [
        "Metastatic gpNMB Over-expressing Triple Negative Breast Cancer"
      ],
      "Start Date": "2013-11-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04209855",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [
        "Gynecologic Oncology Group",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)"
      ],
      "interventions": [
        "MIRV",
        "Paclitaxel",
        "Mirvetuximab Soravtansine",
        "Topotecan",
        "Pegylated liposomal doxorubicin",
        "IMGN853"
      ],
      "locations": [
        "Czechia",
        "China",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "enrollment": 453,
      "conditions": [
        "Fallopian Tube Cancer",
        "Epithelial Ovarian Cancer",
        "Peritoneal Cancer"
      ],
      "Start Date": "2019-12-31",
      "Max Phase": "3"
    },
    {
      "id": "NCT06039202",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Holy Stone Healthcare Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Bevacizumab",
        "Nim-HA cinjugate",
        "TAS-102",
        "Trifluridine/tipiracil",
        "CA102N"
      ],
      "locations": [],
      "enrollment": 100,
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "Start Date": "2024-01-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01421667",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin",
        "rituximab",
        "Adcetris; SGN-35"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 176,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, B-Cell",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, T-Cell"
      ],
      "Start Date": "2011-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01461538",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin",
        "Adcetris; SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 84,
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Lymphoid Leukemia",
        "Anemia, Refractory, With Excess of Blasts",
        "Solid Tumors"
      ],
      "Start Date": "2011-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05135273",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "National Institute of Allergy and Infectious Diseases (NIAID)"
      ],
      "collaborators": [
        "Malaria Research and Training Center, Bamako, Mali",
        "Novavax"
      ],
      "interventions": [
        "Verorab Rabies Vaccine",
        "Pfs230D1-EPA/Matrix-M Vaccine"
      ],
      "locations": [
        "Mali"
      ],
      "enrollment": 80,
      "conditions": [
        "Malaria,Falciparum"
      ],
      "Start Date": "2021-10-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT04177823",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Belantamab mafodotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 6,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2019-12-09",
      "Max Phase": "1"
    },
    {
      "id": "NCT05263479",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Shanghai Hansoh Biomedical Co., Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "HS-20089 (Phase Ib: Dose expansion)",
        "HS-20089 (Phase Ia\uff1aDose escalation )"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 177,
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "Start Date": "2022-01-05",
      "Max Phase": "1"
    },
    {
      "id": "NCT01950364",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin and rifampicin",
        "brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "Spain",
        "Belgium",
        "Lithuania"
      ],
      "enrollment": 20,
      "conditions": [
        "Anaplastic Large-cell Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2013-11-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01786096",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-CD19A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 92,
      "conditions": [
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma",
        "Burkitt Lymphoma"
      ],
      "Start Date": "2013-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02216890",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-CD70A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 38,
      "conditions": [
        "Renal Cell Carcinoma",
        "Mantle-Cell Lymphoma",
        "Follicular Lymphoma, Grade 3",
        "Diffuse, Large B-Cell, Lymphoma"
      ],
      "Start Date": "2014-08-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04207190",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Roswell Park Cancer Institute"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "BMN 673",
        "Talzenna",
        "Questionnaire Administration",
        "BMN-673",
        "gemtuzumab",
        "CDP-771",
        "WAY-CMA-676",
        "Talazoparib Tosylate",
        "CMA-676",
        "hP67.6-Calicheamicin",
        "Mylotarg",
        "Gemtuzumab Ozogamicin",
        "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
        "Talazoparib",
        "Quality-of-Life Assessment",
        "Quality of Life Assessment"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Refractory Acute Myeloid Leukemia",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "Start Date": "2020-10-23",
      "Max Phase": "1"
    },
    {
      "id": "NCT05575804",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "collaborators": [
        "GeneQuantum Healthcare (Suzhou) Co., Ltd."
      ],
      "interventions": [
        "GQ1001+pyrotinib",
        "pyrotinib+capecitabine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 75,
      "conditions": [
        "Advanced/ Metastatic Her-2 Positive Breast Cancer"
      ],
      "Start Date": "2022-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03219333",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Astellas Pharma Inc"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "ASG-22ME",
        "ASG-22CE",
        "Enfortumab vedotin"
      ],
      "locations": [
        "Italy",
        "Japan",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 219,
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Renal Pelvis Neoplasms",
        "Ureteral Neoplasms",
        "Urologic Neoplasms",
        "Urinary Bladder Neoplasms",
        "Urothelial Cancer",
        "Urethral Neoplasms"
      ],
      "Start Date": "2017-10-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT04086264",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Azacitidine",
        "IMGN632",
        "Vidaza",
        "Venetoclax",
        "Venclexta",
        "CD123-targeted ADC",
        "Decitabine",
        "Venclyxto"
      ],
      "locations": [
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 218,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2019-11-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT06106945",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "AZD0305"
      ],
      "locations": [
        "Canada",
        "China",
        "Germany",
        "Spain",
        "Australia",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 84,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2023-12-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT02227199",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Seagen Inc.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "MJF-9325",
        "Holoxan",
        "Adcetris",
        "Ribocarbo",
        "Z 4942",
        "Ifoxan",
        "MJF 9325",
        "IFX",
        "VP-16",
        "Holoxane",
        "cAC10-vcMMAE",
        "Ifolem",
        "Ifomide",
        "Ifosfamidum",
        "Carbotec",
        "Tronoxal",
        "Asta Z 4942",
        "Iphosphamide",
        "Naxamide",
        "Carbosol",
        "Displata",
        "Toposar",
        "Ifomida",
        "VP 16-213",
        "Carboplatin Hexal",
        "Carboplatino",
        "VP-16-213",
        "Anti-CD30 Antibody-Drug Conjugate SGN-35",
        "Carboplat",
        "Isoendoxan",
        "Carboplatin",
        "Blastocarb",
        "Laboratory Biomarker Analysis",
        "Lastet",
        "Iphosphamid",
        "Paraplatin AQ",
        "Carbosin",
        "Z-4942",
        "SGN-35",
        "Iso-Endoxan",
        "Ercar",
        "Paraplatine",
        "Asta Z-4942",
        "IFO",
        "Ifosfamide",
        "IFO-Cell",
        "Cyfos",
        "Anti-CD30 Monoclonal Antibody-MMAE SGN-35",
        "JM-8",
        "Nealorin",
        "Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35",
        "Novoplatinum",
        "Paraplatin",
        "Platinwas",
        "EPEG",
        "Vepesid",
        "Ifex",
        "Brentuximab Vedotin",
        "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
        "Isophosphamide",
        "Mitoxana",
        "ADC SGN-35",
        "Etoposide",
        "CBDCA",
        "Seromida"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 45,
      "conditions": [
        "Recurrent Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma"
      ],
      "Start Date": "2014-10-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT06340568",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "BioNTech SE"
      ],
      "collaborators": [
        "DualityBio Inc."
      ],
      "interventions": [
        "BNT323/DB-1303",
        "Doxorubicin",
        "Paclitaxel"
      ],
      "locations": [],
      "enrollment": 468,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2024-08-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT06034275",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Vincerx Pharma, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "VIP943"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Acute Myeloid Leukemia",
        "B-cell Acute Lymphoblastic Leukemia",
        "High-risk Myelodysplastic Syndrome"
      ],
      "Start Date": "2023-09-13",
      "Max Phase": "1"
    },
    {
      "id": "NCT06195709",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Institut Curie"
      ],
      "collaborators": [
        "Zionexa"
      ],
      "interventions": [
        "Endocrine therapy combined with the local treatment of FES-negative lesions",
        "Standardized chemotherapy regimen",
        "Endocrine therapy",
        "Standardized endocrine therapy regimen",
        "Chemotherapy"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 300,
      "conditions": [
        "Breast Carcinoma"
      ],
      "Start Date": "2024-05-27",
      "Max Phase": "3"
    },
    {
      "id": "NCT03698552",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "ADC Therapeutics S.A.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "ADCT-602 (CN); hLL2-cys-PBD (SY); ADCT602 (CN); ADCT 602 (CN); hLL2-cys-SG3249 (SY); ; ADC ADCT-602",
        "ADCT-602"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 65,
      "conditions": [
        "Refractory B Acute Lymphoblastic Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "CD22 Positive",
        "Blasts 5 Percent or More of Bone Marrow Nucleated Cells",
        "Philadelphia Chromosome Positive"
      ],
      "Start Date": "2018-08-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT06034470",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fred Hutchinson Cancer Center"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Bone Marrow Aspiration",
        "Biopsy, Bone Marrow",
        "Ara-C",
        "Antibody-drug Conjugate IMGN632",
        "Fludarabine",
        "Colony-Stimulating Factor 3",
        "Cytarabine",
        "Granulocyte Colony-Stimulating Factor",
        "Pluripoietin",
        "Anti-CD123 ADC IMGN632",
        "Biopsy of Bone Marrow",
        "IMGN 632",
        "Gated Heart Pool Scan",
        "Synchronized Multigated Acquisition Scanning",
        "Erpalfa",
        "Starasid",
        "4-DMDR",
        "WR-28453",
        "MUGA Scan",
        "Radionuclide Ventriculogram Scan",
        "Pivekimab Sunirine",
        "RNVG",
        "Arabinosylcytosine",
        "MUGA",
        "Specimen Collection",
        "Aracytin",
        "4-Demethoxydaunorubicin",
        "Arabine",
        "Arabinofuranosylcytosine",
        "Udicil",
        "U-19920",
        "4-Demethoxydaunomycin",
        "SYMA Scanning",
        "Radionuclide Ventriculography",
        "Fluradosa",
        ".beta.-Cytosine arabinoside",
        "Granulocyte Colony Stimulating Factor",
        "Gated Blood Pool Imaging",
        "Cytarabinum",
        "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-",
        "Biospecimen Collection",
        "Multi-Gated Acquisition Scan",
        "CD123-targeted ADC IMGN632",
        "ARA-cell",
        "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-",
        "Beta-Cytosine Arabinoside",
        "Multigated Acquisition Scan",
        "G-CSF",
        "Bone Marrow Biopsy",
        "Idarubicin",
        "1-.beta.-D-Arabinofuranosylcytosine",
        "CHX-3311",
        "Alexan",
        "CSF3",
        "1-Beta-D-arabinofuranosylcytosine",
        "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "1.beta.-D-Arabinofuranosylcytosine",
        "Blood Pool Scan",
        "IMGN-632",
        "G CSF",
        "Aracytine",
        "Cytosar",
        "Equilibrium Radionuclide Angiography",
        "U 19920",
        "IMGN632",
        "Biospecimen Collected",
        "Tarabine PFS",
        "EC",
        "Cytosine-.beta.-arabinoside",
        "Cytosine-beta-arabinoside",
        "Echocardiography",
        "Biological Sample Collection",
        "Colony Stimulating Factor 3",
        "Aracytidine",
        "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "Cytosine Arabinoside",
        "Cytarbel",
        "Colony-Stimulating Factor (Granulocyte)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Mixed Phenotype Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Myelodysplastic/Myeloproliferative Neoplasm"
      ],
      "Start Date": "2023-12-18",
      "Max Phase": "1"
    },
    {
      "id": "NCT01983540",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine",
        "DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine",
        "Infanrix hexa + Prevenar + Rotarix vaccine"
      ],
      "locations": [
        "Colombia",
        "Costa Rica"
      ],
      "enrollment": 558,
      "conditions": [
        "Whooping Cough",
        "Tetanus",
        "Poliomyelitis",
        "Haemophilus Influenzae Type b",
        "Diphtheria",
        "Hepatitis B"
      ],
      "Start Date": "2013-10-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT02610348",
      "phases": [],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines",
        "DTaP-HB-IPV and Pneumococcal polysaccharide vaccines"
      ],
      "locations": [
        "Thailand"
      ],
      "enrollment": 122,
      "conditions": [
        "Hepatitis B"
      ],
      "Start Date": "2015-11-01",
      "Max Phase": null
    },
    {
      "id": "NCT02573324",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [
        "Radiation Therapy Oncology Group"
      ],
      "interventions": [
        "Radiation",
        "Placebo for ABT-414",
        "Depatuxizumab mafodotin",
        "Temozolomide",
        "ABT-414"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Ireland",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Taiwan",
        "Netherlands",
        "New Zealand",
        "United States",
        "Canada",
        "Portugal",
        "United Kingdom",
        "Colombia",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 691,
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "Start Date": "2015-01-04",
      "Max Phase": "3"
    },
    {
      "id": "NCT04946370",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Weill Medical College of Cornell University"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "United States Department of Defense"
      ],
      "interventions": [
        "Pembrolizumab",
        "225Ac-J591",
        "68Ga-PSMA-HBED-CC",
        "68Ga-PSMA-11",
        "Androgen receptor pathway inhibitor"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 76,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2021-08-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT00654901",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)",
        "DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)",
        "DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)",
        "Infanrix Hexa\u2122"
      ],
      "locations": [
        "Mexico"
      ],
      "enrollment": 881,
      "conditions": [
        "Tetanus",
        "Poliomyelitis",
        "Diphtheria",
        "Hepatitis B",
        "Pertussis",
        "Haemophilus Influenzae Type B Infection"
      ],
      "Start Date": "2008-03-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT01786135",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-CD19A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 64,
      "conditions": [
        "Precursor B-cell Lymphoblastic Leukemia-Lymphoma",
        "Lymphoma, Mantle-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Large B-Cell, Diffuse",
        "Burkitt Lymphoma"
      ],
      "Start Date": "2013-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03786081",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Genmab",
        "Merck Sharp & Dohme LLC",
        "Belgian Gynaecological Oncology Group",
        "GOG Foundation",
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)"
      ],
      "interventions": [
        "Pembrolizumab",
        "Paraplatin",
        "Tisotumab Vedotin",
        "Bevacizumab",
        "Avastin",
        "Carboplatin",
        "TIVDAK",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Ireland",
        "Denmark",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Belgium",
        "Netherlands",
        "United States"
      ],
      "enrollment": 214,
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": "2019-02-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT03284723",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "PF-06804103",
        "PF-06804103 + Palbociclib +Letrozole"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Russian Federation",
        "United States"
      ],
      "enrollment": 95,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2017-11-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01590966",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University Hospital, Ghent"
      ],
      "collaborators": [
        "UCB Pharma SA"
      ],
      "interventions": [
        "administration of Cimzia\u00ae",
        "Immunoscintigraphy with radiolabeled Cimzia\u00ae."
      ],
      "locations": [
        "Belgium"
      ],
      "enrollment": 41,
      "conditions": [
        "Rheumatoid Arthritis",
        "Axial and Peripheral Spondyloarthritis"
      ],
      "Start Date": "2012-10-18",
      "Max Phase": "3"
    },
    {
      "id": "NCT03288545",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Seagen Inc."
      ],
      "interventions": [
        "ASG-22ME",
        "Keytruda",
        "pembrolizumab",
        "cisplatin",
        "ASG-22CE",
        "enfortumab vedotin (EV)",
        "carboplatin",
        "PADCEV",
        "gemcitabine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "France",
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 348,
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Renal Pelvis Neoplasms",
        "Ureteral Neoplasms",
        "Urologic Neoplasms",
        "Urinary Bladder Neoplasms",
        "Urothelial Cancer",
        "Urethral Neoplasms"
      ],
      "Start Date": "2017-10-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT01990534",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab Vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "Thailand",
        "Czechia",
        "Malaysia",
        "Germany",
        "Poland",
        "Turkey",
        "Spain"
      ],
      "enrollment": 60,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2014-03-14",
      "Max Phase": "4"
    },
    {
      "id": "NCT05350917",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The First Affiliated Hospital of Zhengzhou University"
      ],
      "collaborators": [
        "BeiGene",
        "Jiangsu Hengrui Pharmaceutical Co., Ltd.",
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "DisitamabVedotin",
        "Tislelizumab",
        "Pyrotinib maleate"
      ],
      "locations": [],
      "enrollment": 20,
      "conditions": [
        "HER2-positive or Mutated Advanced Colorectal Cancer"
      ],
      "Start Date": "2022-06-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT02222922",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "PF-06647020 combined with Avelumab",
        "PF-06647020 Q3W",
        "PF-06647020 Q2W",
        "fluconazole"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": 138,
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": "2014-10-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT00861744",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "collaborators": [],
      "interventions": [
        "Prevnar\u00ae",
        "Varivax\u00ae",
        "GSK Biological's investigational vaccine 209762",
        "M-M-R\u00ae II (Merck and Co)",
        "Havrix\u00ae"
      ],
      "locations": [
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 1259,
      "conditions": [
        "Measles-Mumps-Rubella Vaccine",
        "Rubella",
        "Mumps",
        "Measles"
      ],
      "Start Date": "2009-06-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT06123494",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Jiangsu HengRui Medicine Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan",
        "SHR-A1811"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 360,
      "conditions": [
        "HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": "2024-01-09",
      "Max Phase": "3"
    },
    {
      "id": "NCT00012064",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Lisata Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "therapeutic autologous dendritic cells"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 56,
      "conditions": [
        "Melanoma (Skin)"
      ],
      "Start Date": "2000-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01444781",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Sanofi Pasteur, a Sanofi Company"
      ],
      "collaborators": [],
      "interventions": [
        "Prevenar\u2122",
        "DTaP-IPV-Hep B-PRP~T combined vaccine",
        "DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide",
        "DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide",
        "DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine",
        "DTaP-IPV-Hep B-PRP~T vaccine",
        "Infanrix hexa\u2122"
      ],
      "locations": [
        "Colombia",
        "Costa Rica"
      ],
      "enrollment": 1106,
      "conditions": [
        "Whooping Cough",
        "Tetanus",
        "Poliomyelitis",
        "Diphtheria",
        "Hepatitis B"
      ],
      "Start Date": "2011-09-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05702229",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Volrustomig",
        "AZD0901",
        "XELOX",
        "FOLFOX",
        "AZD7789",
        "5-Fluorouracil",
        "Capecitabine",
        "Rilvegostomig"
      ],
      "locations": [
        "China",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "enrollment": 240,
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": "2023-01-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT02343406",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [
        "European Organisation for Research and Treatment of Cancer - EORTC"
      ],
      "interventions": [
        "TMZ",
        "Depatuxizumab mafodotin",
        "Temozolomide",
        "ABT-414",
        "Gleostine",
        "Lomustine"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Ireland",
        "Germany",
        "France",
        "Italy",
        "Finland",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 266,
      "conditions": [
        "Glioblastoma"
      ],
      "Start Date": "2015-02-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT00051571",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-15",
        "Docetaxel"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 60,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": null,
      "Max Phase": "2"
    },
    {
      "id": "NCT06065371",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Henry Ford Health System"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Xeloda",
        "Sacituzumab govetican",
        "Trodelvy",
        "Capecitabine"
      ],
      "locations": [],
      "enrollment": 20,
      "conditions": [
        "Gastrointestinal Cancer"
      ],
      "Start Date": "2024-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02340208",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Helix BioPharma Corporation"
      ],
      "collaborators": [
        "Pharm-Olam International"
      ],
      "interventions": [
        "L-DOS47"
      ],
      "locations": [
        "Poland"
      ],
      "enrollment": 76,
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2012-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04592419",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Kodiak Sciences Inc"
      ],
      "collaborators": [],
      "interventions": [
        "Sham Procedure",
        "Aflibercept",
        "KSI-301",
        "Eylea"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Slovakia",
        "Israel",
        "Germany",
        "Poland",
        "Spain",
        "Latvia",
        "Hungary",
        "France",
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 568,
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "Start Date": "2020-09-25",
      "Max Phase": "3"
    },
    {
      "id": "NCT00356408",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "UCB Pharma"
      ],
      "collaborators": [],
      "interventions": [
        "CZP",
        "Cimzia",
        "CDP870",
        "Certolizumab pegol"
      ],
      "locations": [
        "Germany",
        "Canada",
        "United States"
      ],
      "enrollment": 106,
      "conditions": [
        "Crohn's Disease"
      ],
      "Start Date": "2007-01-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05579366",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "ProfoundBio US Co."
      ],
      "collaborators": [],
      "interventions": [
        "PRO1184",
        "PRO1184 intravenous infusion of PRO1184"
      ],
      "locations": [
        "China",
        "United States"
      ],
      "enrollment": 374,
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Endometrial Cancer",
        "Non-small Cell Lung Cancer",
        "High Grade Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor-positive/Her2 Negative Breast Cancer",
        "Mesothelioma",
        "Breast Adenocarcinoma"
      ],
      "Start Date": "2022-12-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT02677155",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Oslo University Hospital"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Norwegian Cancer Society"
      ],
      "interventions": [
        "Sagramostim",
        "Pembrolizumab",
        "GM-CSF",
        "Autologous dendritic cells",
        "Mabthera",
        "Radiotherapy",
        "Anti-PD1",
        "Rituximab"
      ],
      "locations": [
        "Norway"
      ],
      "enrollment": 10,
      "conditions": [
        "Follicular Lymphoma"
      ],
      "Start Date": "2016-01-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04203641",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Helix BioPharma Corporation"
      ],
      "collaborators": [
        "Theradex"
      ],
      "interventions": [
        "L-DOS47",
        "Doxorubicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Pancreas Cancer"
      ],
      "Start Date": "2019-12-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT05283330",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Orano Med LLC"
      ],
      "collaborators": [],
      "interventions": [
        "\u00b2\u00b9\u00b2Pb-DOTAM-GRPR1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Cutaneous Melanoma",
        "NSCLC",
        "Prostate Cancer Metastatic",
        "Colon Cancer",
        "Breast Cancer",
        "Cervical Cancer"
      ],
      "Start Date": "2022-12-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT04964089",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Kodiak Sciences Inc"
      ],
      "collaborators": [],
      "interventions": [
        "Sham Procedure",
        "Aflibercept",
        "KSI-301",
        "Eylea"
      ],
      "locations": [
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 557,
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "Start Date": "2021-06-23",
      "Max Phase": "3"
    },
    {
      "id": "NCT05600686",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Joseph Tuscano"
      ],
      "collaborators": [
        "ADC Therapeutics S.A.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "1, 2-Dehydrocortisone",
        "Prednilonga",
        "Cyclophosphamide",
        "VP-16",
        "Prednicort",
        "rituximab-abbs",
        "Paracort",
        "Genoxal",
        "Cycloblastin",
        "Cyclophosphamid monohydrate",
        "Zynlonta",
        "VP 16-213",
        "Econosone",
        "Adriablastin",
        "Prednisone",
        "CYCLO-cell",
        "SK-Prednisone",
        "ABP 798",
        "Rituximab Biosimilar SAIT101",
        "RTXM83",
        "Prednicen-M",
        "Prednitone",
        "Riabni",
        "Loncastuximab Tesirine",
        "Hydroxydaunomycin",
        "Perrigo Prednisone",
        "Rayos",
        "Cyclophosphan",
        "Predniment",
        "Lastet",
        "Adasone",
        "Cyclophosphanum",
        "Rituximab Biosimilar GB241",
        "Rituximab ARRX",
        "Predicorten",
        ".delta.1-Cortisone",
        "IDEC-C2B8 Monoclonal Antibody",
        "Hydroxyldaunorubicin",
        "Predicor",
        "MabThera",
        "Prednisonum",
        "PRED",
        "Cytophosphan",
        "Rituximab Biosimilar ABP 798",
        "Syklofosfamid",
        "Dacortin",
        "Vincrystine",
        "C2B8 Monoclonal Antibody",
        "Prednisone Intensol",
        "PF-05280586",
        "Clafen",
        "Rituximab Biosimilar JHL1101",
        "Carloxan",
        "Anti-CD19 PBD-conjugate ADCT-402",
        "Rituximab",
        "Doxorubicin",
        "Deltacortene",
        "Lisacort",
        "Cyclophosphamide Monohydrate",
        "VP16",
        "Cyclophospham",
        "Cytoxan",
        "Hydroxyl Daunorubicin",
        "Etoposide",
        "Rituximab Biosimilar RTXM83",
        "Ciclofosfamide",
        "CT-P10",
        "Ofisolona",
        "VCR",
        "Loncastuximab Tesirine-lpyl",
        "Rituximab Biosimilar PF-05280586",
        "Orasone",
        "IDEC-102",
        "CP monohydrate",
        "Decortisyl",
        "Cyclostin",
        "ADCT-402",
        "Toposar",
        "Servisone",
        "2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate",
        "Panafcort",
        "Deltison",
        "VP 16",
        "Rituximab-arrx",
        "Rituximab-pvvr",
        "Truxima",
        "Rituximab Biosimilar IBI301",
        "Ledoxina",
        "Cycloblastine",
        "Deltasone",
        "Metacortandracin",
        "EPEG",
        "rituximab biosimilar TQB2303",
        "Cicloxal",
        "Decorton",
        "Vepesid",
        "Vincristine",
        "Fosfaseron",
        "ADC ADCT-402",
        "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
        "CTX",
        "Delta-Dome",
        "Genuxal",
        "Delta 1-Cortisone",
        "Panasol-S",
        "IDEC-C2B8",
        "Deltacortisone",
        "Rituximab ABBS",
        "BI 695500",
        "Deltra",
        "Cyclophosphamidum",
        "DeCortin",
        "Monoclonal Antibody IDEC-C2B8",
        "(-)-Cyclophosphamide",
        "Rituxan",
        "VP-16-213",
        "Revimmune",
        "Neosar",
        "Prednidib",
        "Cytophosphane",
        "Rituximab Biosimilar BI 695500",
        "Cortancyl",
        "Rituximab Biosimilar CT-P10",
        "Leurocristine",
        "Ruxience",
        "Ciclofosfamida",
        "Claphene",
        "Rituximab Biosimilar SIBP-02",
        "Chimeric Anti-CD20 Antibody",
        "Deltadehydrocortisone",
        "Cyclophosphane",
        "Mitoxan",
        "Meprosona-F",
        "Cyclostine",
        "Meticorten",
        "Promifen",
        "WR- 138719",
        "Rituximab PVVR"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "Double-Expressor Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements"
      ],
      "Start Date": "2023-05-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT05627960",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "A&G Pharmaceutical Inc."
      ],
      "collaborators": [
        "University of Maryland Greenebaum Cancer Center"
      ],
      "interventions": [
        "AG-01 Compound"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 77,
      "conditions": [
        "Hormone-Resistant Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Mesothelioma"
      ],
      "Start Date": "2022-02-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT01825317",
      "phases": [],
      "sponsor": [
        "Neuronix Ltd"
      ],
      "collaborators": [
        "company: K The Power",
        "Chungnam National University Hospital"
      ],
      "interventions": [
        "Sham device",
        "Control device",
        "NICE",
        "NeuroAD"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "enrollment": 32,
      "conditions": [
        "Alzheimer's Disease"
      ],
      "Start Date": "2013-03-01",
      "Max Phase": null
    },
    {
      "id": "NCT01280552",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Precision Life Sciences Group"
      ],
      "collaborators": [],
      "interventions": [
        "ICT-107",
        "Placebo DC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 124,
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "Start Date": "2011-01-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05261750",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "PT. Prodia Stem Cell Indonesia"
      ],
      "collaborators": [],
      "interventions": [
        "Allo-Dendritic-Secretome Adjuvant Therapy",
        "Auto-Dendritic Adjuvant Therapy"
      ],
      "locations": [
        "Indonesia"
      ],
      "enrollment": 15,
      "conditions": [
        "Nasopharyngeal Cancer"
      ],
      "Start Date": "2022-04-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT03743298",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "AV-MEL-1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Metastatic Melanoma"
      ],
      "Start Date": "2021-04-21",
      "Max Phase": "1"
    },
    {
      "id": "NCT00377715",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Medivation, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Dimebon",
        "Placebo"
      ],
      "locations": [
        "Russian Federation"
      ],
      "enrollment": 183,
      "conditions": [
        "Alzheimer's Disease"
      ],
      "Start Date": "2005-09-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00777608",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Donepezil 5 - 10 mg",
        "Comparator: Placebo 5-10 mg",
        "Donepezil 10 mg",
        "Comparator: Placebo 5mg (run in)"
      ],
      "locations": [],
      "enrollment": 106,
      "conditions": [
        "Alzheimer's Disease"
      ],
      "Start Date": "2008-12-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02049489",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Precision Life Sciences Group"
      ],
      "collaborators": [],
      "interventions": [
        "ICT-121 DC vaccine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "Start Date": "2013-12-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03531918",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Fred Hutchinson Cancer Center"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Dihydroxyanthracenedione Dihydrochloride",
        "Cladribina",
        "Cytosar",
        "WAY-CMA-676",
        "2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-",
        "U 19920",
        "CL 232315",
        "Gemtuzumab Ozogamicin",
        "Tarabine PFS",
        "CDP-771",
        "Beta-cytosine Arabinoside",
        "DHAQ",
        "rhG-CSF",
        "Ara-C",
        "Onkotrone",
        "Arabinosylcytosine",
        "Mitroxone",
        "Recombinant Granulocyte Colony-Stimulating Factor",
        "Neotalem",
        "Aracytin",
        "Cytosine-.beta.-arabinoside",
        "Cytosine-beta-arabinoside",
        "Arabine",
        "Arabinofuranosylcytosine",
        "Udicil",
        "Leustat",
        "Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody",
        "Cytarabine",
        "Laboratory Biomarker Analysis",
        "Recombinant Colony-Stimulating Factor 3",
        "Mitoxantrone Dihydrochloride",
        "2CDA",
        "Leustatin",
        "CdA",
        "Leustatine",
        "ARA-cell",
        "U-19920",
        "DHAD",
        "gemtuzumab",
        "Aracytidine",
        "RWJ-26251",
        "1-.beta.-D-Arabinofuranosylcytosine",
        "CHX-3311",
        "1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        "Alexan",
        "hP67.6-Calicheamicin",
        "Novantrone",
        "1-Beta-D-arabinofuranosylcytosine",
        "Cladribine",
        "Cytosine Arabinoside",
        "1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone",
        ".beta.-Cytosine arabinoside",
        "Erpalfa",
        "1.beta.-D-Arabinofuranosylcytosine",
        "Starasid",
        "CMA-676",
        "Cytarabinum",
        "Mitoxantrone Hydrochloride",
        "Cytarbel",
        "Mylotarg",
        "143011-72-7",
        "Mitoxantroni Hydrochloridum",
        "Mitozantrone Hydrochloride",
        "2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-",
        "WR-28453",
        "Pralifan",
        "Aracytine",
        "2-CdA"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 66,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2018-09-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT04690387",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [
        "National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",
        "Indonesia Ministry of Health",
        "PT AIVITA Biomedika Indonesia"
      ],
      "interventions": [
        "GM-CSF",
        "AV-COVID-19"
      ],
      "locations": [
        "Indonesia"
      ],
      "enrollment": 27,
      "conditions": [
        "COVID-19"
      ],
      "Start Date": "2020-12-07",
      "Max Phase": "1"
    },
    {
      "id": "NCT00086333",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-15, Docetaxel"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Non-Small Cell Lung Carcinoma"
      ],
      "Start Date": "2004-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT02771340",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Iconic Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "human Immuno-conjugate 1",
        "ICON-1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 10,
      "conditions": [
        "Choroid Neoplasm",
        "Uveal Melanoma"
      ],
      "Start Date": "2016-05-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01068509",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Prima BioMed Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "Cvac"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": 63,
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "Start Date": "2010-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05100641",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Autologous monocytes",
        "AV-GBM-1"
      ],
      "locations": [],
      "enrollment": 672,
      "conditions": [
        "Primary Glioblastoma"
      ],
      "Start Date": "2024-01-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT04834544",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Peking University Third Hospital"
      ],
      "collaborators": [
        "SOTIO a.s."
      ],
      "interventions": [
        "DCVAC/OvCa",
        "Placebo"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 75,
      "conditions": [
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Carcinoma",
        "Epithelial Ovarian Carcinoma"
      ],
      "Start Date": "2021-04-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT01617629",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Prima BioMed Ltd"
      ],
      "collaborators": [],
      "interventions": [
        "MUC1 Dendritic Cell Vaccine (Cvac)"
      ],
      "locations": [
        "Australia",
        "United States"
      ],
      "enrollment": 9,
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "Start Date": "2011-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04160494",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Darell Bigner"
      ],
      "collaborators": [
        "Istari Oncology, Inc.",
        "Genentech, Inc.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Atezolizumab (1200 mg every three weeks)",
        "D2C7-IT (6920 ng/mL via convection-enhanced delivery)",
        "D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)",
        "Tecentriq"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Malignant Glioma"
      ],
      "Start Date": "2020-02-25",
      "Max Phase": "1"
    },
    {
      "id": "NCT03543358",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "rovalpituzumab tesirine",
        "SC16LD6.5"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 3,
      "conditions": [
        "Cancer"
      ],
      "Start Date": "2018-09-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT03610360",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Amphera BV"
      ],
      "collaborators": [
        "TMC Pharma"
      ],
      "interventions": [
        "MesoPher"
      ],
      "locations": [
        "Italy",
        "United Kingdom",
        "Belgium",
        "France",
        "Netherlands"
      ],
      "enrollment": 176,
      "conditions": [
        "Mesothelioma"
      ],
      "Start Date": "2018-06-21",
      "Max Phase": "3"
    },
    {
      "id": "NCT05007496",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Aivita Biomedical, Inc."
      ],
      "collaborators": [
        "Kariadi Hospital",
        "PT AIVITA Biomedika Indonesia",
        "Central Army Hospital RSPAD Gatot Soebroto"
      ],
      "interventions": [
        "AV-COVID-19"
      ],
      "locations": [
        "Indonesia"
      ],
      "enrollment": 145,
      "conditions": [
        "COVID-19"
      ],
      "Start Date": "2021-04-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT00815607",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alaunos Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "INXN-3001",
        "INXN-1001"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 12,
      "conditions": [
        "Melanoma"
      ],
      "Start Date": "2009-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04744831",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "T-DXd",
        "Drug: DS-8201a 6.4 mg/kg Q3W",
        "Drug: DS-8201a 5.4 mg/kg Q3W",
        "DS-8201a 5.4 mg/kg Q3W",
        "DS-8201a 6.4 mg/kg Q3W"
      ],
      "locations": [
        "Italy",
        "Belgium",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 122,
      "conditions": [
        "Advanced Colorectal Cancer"
      ],
      "Start Date": "2021-01-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT02358889",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Iconic Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Sham injection",
        "human Immuno-conjugate 1",
        "ranibizumab",
        "Lucentis\u00ae",
        "hI-con1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 88,
      "conditions": [
        "Choroidal Neovascularization",
        "Age-related Macular Degeneration"
      ],
      "Start Date": "2015-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00420888",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Active Biotech AB"
      ],
      "collaborators": [],
      "interventions": [
        "naptumomab estafenatox",
        "Referon-A",
        "ABR-217620/naptumomab estafenatox",
        "IFN-alpha"
      ],
      "locations": [
        "Ukraine",
        "United Kingdom",
        "Bulgaria",
        "Russian Federation",
        "Romania"
      ],
      "enrollment": 526,
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "Start Date": "2007-01-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT06477419",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan-hziy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 33,
      "conditions": [
        "Mesothelioma; Pleura",
        "Mesotheliomas Pleural",
        "Mesothelioma"
      ],
      "Start Date": "2024-06-21",
      "Max Phase": "2"
    },
    {
      "id": "NCT06390995",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "TAK-853",
        "Mirvetuximab Soravtansine"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 25,
      "conditions": [
        "Ovarian Cancer",
        "Solid Tumors"
      ],
      "Start Date": "2024-05-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT06378242",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "RC48",
        "Disitamab Vedotin for injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 24,
      "conditions": [
        "High-risk Non-muscle Invasive Bladder Cancer"
      ],
      "Start Date": "2024-04-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT06329869",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "National Taiwan University Hospital"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan"
      ],
      "locations": [],
      "enrollment": 35,
      "conditions": [
        "Esophageal Squamous Cell Carcinoma"
      ],
      "Start Date": "2024-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06248515",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Georgetown University"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan-hziy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Thymic Carcinoma",
        "Thymoma"
      ],
      "Start Date": "2024-04-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT06238921",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Zimberelimab",
        "Stereotactic Radiation",
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 31,
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2024-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06227156",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Disitamab Vedotin Injection",
        "DV,RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 40,
      "conditions": [
        "Castration-resistant Prostate Cancer"
      ],
      "Start Date": "2024-04-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT06174987",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "T-DXd",
        "DS8201a"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "Start Date": "2024-01-05",
      "Max Phase": "3"
    },
    {
      "id": "NCT06167317",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "IMMU-132",
        "GS-0201",
        "GS-0132",
        "Sacituzumab Govitecan",
        "Trodelvy\u2122"
      ],
      "locations": [
        "Israel",
        "United States"
      ],
      "enrollment": 254,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2024-01-09",
      "Max Phase": "1"
    },
    {
      "id": "NCT06133517",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fundaci\u00f3n para el Progreso de la Oncolog\u00eda en Cantabria"
      ],
      "collaborators": [
        "Apices Soluciones S.L."
      ],
      "interventions": [
        "Zimberelimab",
        "Domvanalimab",
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 70,
      "conditions": [
        "Urothelial Bladder Carcinoma"
      ],
      "Start Date": "2024-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06123468",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Institut f\u00fcr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "Austria",
        "Germany"
      ],
      "enrollment": 56,
      "conditions": [
        "Esophagogastric Adenocarcinoma"
      ],
      "Start Date": "2024-04-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT05884320",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Salivary Gland Cancers",
        "Gland"
      ],
      "Start Date": "2023-07-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT05833867",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Omar Mian"
      ],
      "collaborators": [
        "Varian Inc",
        "Gilead Sciences"
      ],
      "interventions": [
        "TRODELVY",
        "Adaptive Radiotherapy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma",
        "Localized Muscle Invasive Bladder Urothelial Carcinoma"
      ],
      "Start Date": "2024-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05552001",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "UNICANCER"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "trodelvy",
        "Sacituzumab govitecan"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 96,
      "conditions": [
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2023-10-05",
      "Max Phase": "3"
    },
    {
      "id": "NCT05260957",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Lazaros Lekakis"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "RO5541077",
        "CAR-T Cell Therapy",
        "Polivy",
        "BTCT4465A",
        "Polatuzumab",
        "Chimeric antigen receptor T-Cell Therapy",
        "Polatuzumab Vedotin",
        "Mosunetuzumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 40,
      "conditions": [
        "Refractory Non-Hodgkin Lymphoma",
        "Aggressive Non-Hodgkin Lymphoma",
        "Relapsed Non Hodgkin Lymphoma"
      ],
      "Start Date": "2022-12-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT05119907",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "GS-0132",
        "IMMU-132",
        "Trodelvy\u2122",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 300,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2021-10-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT05113966",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "G1 Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "CDK 4/6 inhibitor",
        "IMMU-132",
        "Sacituzumab Govitecan-hziy",
        "G1T28",
        "Trodelvy",
        "Trilaciclib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2021-11-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT05101096",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "GS-0132",
        "IMMU-132",
        "Trodelvy\u2122",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 143,
      "conditions": [
        "Metastatic Urothelial Cancer",
        "Metastatic Triple-Negative Breast Cancer",
        "HR+/HER2- Metastatic Breast Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2021-10-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT04617522",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "France",
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Advanced or Metastatic Solid Tumor",
        "Liver Failure"
      ],
      "Start Date": "2021-04-06",
      "Max Phase": "1"
    },
    {
      "id": "NCT04454437",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "GS-0132",
        "IMMU-132",
        "Trodelvy\u2122",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 80,
      "conditions": [
        "Metastatic Triple-negative Breast Cancer"
      ],
      "Start Date": "2020-10-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT03995706",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "The University of Texas Health Science Center at San Antonio"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 26,
      "conditions": [
        "Glioblastoma"
      ],
      "Start Date": "2019-07-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT03964727",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "IMMU-132",
        "GS-0132",
        "Sacituzumab Govitecan-hziy"
      ],
      "locations": [
        "Canada",
        "Hong Kong",
        "Taiwan",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 165,
      "conditions": [
        "Metastatic Solid Tumor"
      ],
      "Start Date": "2019-10-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT03832361",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Alessandro Santin"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "IMGN853",
        "mirvetuximab soravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2020-07-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT03677154",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Mosunetuzumab Intravenous (IV)",
        "Polatuzumab Vedotin",
        "Mosunetuzumab Subcutaneous (SC)",
        "Tocilizumab"
      ],
      "locations": [
        "Israel",
        "Poland",
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "United States"
      ],
      "enrollment": 188,
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": "2019-05-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT03329690",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Standard of Care",
        "DS-8201a",
        "Physician's Choice",
        "Experimental product"
      ],
      "locations": [
        "Korea, Republic of",
        "Japan"
      ],
      "enrollment": 233,
      "conditions": [
        "Neoplasm, Gastrointestinal"
      ],
      "Start Date": "2017-11-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT03086239",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab tesirine"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 29,
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": "2017-04-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT02991911",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "MEDI3726 & Enzalutamide Combo",
        "MEDI3726 Pre-Chemo",
        "MEDI3726 Post-Chemo"
      ],
      "locations": [
        "United Kingdom",
        "Switzerland",
        "United States"
      ],
      "enrollment": 33,
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "Start Date": "2017-01-06",
      "Max Phase": "1"
    },
    {
      "id": "NCT02576548",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "MEDI4276"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 47,
      "conditions": [
        "HER2 Expressing Breast or Gastric/Stomach Cancers"
      ],
      "Start Date": "2015-09-23",
      "Max Phase": "1"
    },
    {
      "id": "NCT06401824",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Maastricht University Medical Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab",
        "sacituzumab govitecan; zirabev"
      ],
      "locations": [
        "Netherlands"
      ],
      "enrollment": 25,
      "conditions": [
        "Brain Metastases, Adult",
        "NSCLC Stage IV"
      ],
      "Start Date": "2024-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT02175433",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "AGS67E"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 71,
      "conditions": [
        "Relapsed Lymphoid Malignancy",
        "Refractory Lymphoid Malignancy"
      ],
      "Start Date": "2014-10-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT02171143",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASP2409",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 58,
      "conditions": [
        "Rheumatoid Arthritis",
        "Pharmacokinetics of ASP2409"
      ],
      "Start Date": "2012-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02150070",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASP2408",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 32,
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Healthy Subjects"
      ],
      "Start Date": "2011-08-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02140125",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Inc"
      ],
      "collaborators": [],
      "interventions": [
        "ASP2408",
        "Placebo"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 24,
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Healthy"
      ],
      "Start Date": "2012-08-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02125435",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASP2408",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 65,
      "conditions": [
        "Pharmacokinetics of ASP2408",
        "Healthy Subjects"
      ],
      "Start Date": "2011-01-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02052375",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Astellas Pharma Global Development, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "ASP2408",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Rheumatoid Arthritis",
        "Pharmacokinetics of ASP2408"
      ],
      "Start Date": "2012-06-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01901653",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Stemcentrx"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab tesirine (SC16LD6.5)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 82,
      "conditions": [
        "Recurrent Small Cell Lung Cancer"
      ],
      "Start Date": "2013-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01741727",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie (prior sponsor, Abbott)"
      ],
      "collaborators": [],
      "interventions": [
        "ABT-414"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 57,
      "conditions": [
        "Squamous Cell Tumors"
      ],
      "Start Date": "2012-10-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01638936",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Biotest Pharmaceuticals Corporation"
      ],
      "collaborators": [
        "Biotest"
      ],
      "interventions": [
        "Indatuximab Ravtansine",
        "BT062 , intravenous administration"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 64,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2012-07-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT01485588",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Iconic Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "hI-con1\u2122 150\u00b5l",
        "hI-con1\u2122 300\u00b5l",
        "hI-con1\u2122 60\u00b5l"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "Start Date": "2010-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01335958",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "DMUC5754A"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 77,
      "conditions": [
        "Ovarian Cancer, Pancreatic Cancer"
      ],
      "Start Date": "2011-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01001442",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Biotest Pharmaceuticals Corporation"
      ],
      "collaborators": [
        "Biotest"
      ],
      "interventions": [
        "BT062",
        "Indatuximab ravtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 35,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2010-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00944905",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [],
      "interventions": [
        "MDX-1203"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 46,
      "conditions": [
        "Renal Cell Carcinoma",
        "Non-hodgkin's Lymphoma"
      ],
      "Start Date": "2009-07-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00071539",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Teva Branded Pharmaceutical Products R&D, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "TP38",
        "immunotoxin",
        "TP-38"
      ],
      "locations": [],
      "enrollment": 56,
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "Start Date": "2003-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00056537",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Active Biotech AB"
      ],
      "collaborators": [],
      "interventions": [
        "ABR-217620",
        "CD3; 5T4FabV18-SEA/E-120; naptumomab estafenatox; Anyara"
      ],
      "locations": [
        "United States",
        "United Kingdom",
        "Norway"
      ],
      "enrollment": 44,
      "conditions": [
        "Renal Cell Carcinoma",
        "Pancreatic Cancer",
        "Non-Small-Cell Lung Carcinoma"
      ],
      "Start Date": "2003-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03000257",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Budigalimab",
        "Rovalpituzumab Tesirine",
        "ABBV-181",
        "Venetoclax"
      ],
      "locations": [
        "Canada",
        "Finland",
        "France",
        "Taiwan",
        "Austria",
        "Australia",
        "Belgium",
        "Spain",
        "Japan",
        "United States"
      ],
      "enrollment": 182,
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "Start Date": "2016-12-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT05520723",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Sacituzumab govitecan",
        "Filgrastim",
        "Imodium",
        "Neupogen",
        "Trodelvy",
        "Loperamide",
        "Granulocyte Colony-Stimulating Factor"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 50,
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2023-02-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT06271837",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "Trastuzumab deruxtecan",
        "T-DXd"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 50,
      "conditions": [
        "Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)"
      ],
      "Start Date": "2024-02-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT06172127",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "T-DXd",
        "Pertuzumab-Trastuzumab FDC SC",
        "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection",
        "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection",
        "Trastuzumab deruxtecan",
        "PHESGO"
      ],
      "locations": [],
      "enrollment": 165,
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": "2024-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06071871",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Obinutuzumab",
        "Columvi",
        "Polivy",
        "Polatuzumab vedotin",
        "Gazyvaro",
        "Glofitamab"
      ],
      "locations": [],
      "enrollment": 99,
      "conditions": [
        "Large B-cell Lymphoma"
      ],
      "Start Date": "2024-04-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT06058988",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "T-DXd"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Recurrent Glioblastoma",
        "Glioblastoma",
        "Metastatic Cancer",
        "Leptomeningeal Metastasis",
        "Brain Cancer"
      ],
      "Start Date": "2023-09-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT05982678",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Netherlands Cancer Institute"
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Netherlands"
      ],
      "enrollment": 72,
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": "2024-05-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT05957757",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RenJi Hospital"
      ],
      "collaborators": [
        "BeiGene",
        "RemeGen Co., Ltd."
      ],
      "interventions": [
        "Disitamab Vedotin",
        "RC48",
        "Tislelizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 20,
      "conditions": [
        "HER2",
        "Non-Muscle Invasive Bladder Cancer"
      ],
      "Start Date": "2023-08-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT05795101",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Filipa Lynce, MD"
      ],
      "collaborators": [
        "Daiichi Sankyo",
        "AstraZeneca"
      ],
      "interventions": [
        "Enhertu",
        "Trastuzumab deruxtecan",
        "Durvalumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 63,
      "conditions": [
        "Invasive Breast Cancer",
        "Inflammatory Breast Cancer Stage III",
        "HER2-positive Breast Cancer",
        "Breast Cancer",
        "HER2 Low Breast Adenocarcinoma"
      ],
      "Start Date": "2023-05-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT05765851",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a (trastuzumab derextecan)",
        "T-DXd",
        "DS-1103a",
        "Enhertu\u00ae"
      ],
      "locations": [
        "Spain",
        "Canada",
        "France",
        "United States"
      ],
      "enrollment": 78,
      "conditions": [
        "Breast Cancer",
        "Advanced Solid Tumor"
      ],
      "Start Date": "2023-05-30",
      "Max Phase": "1"
    },
    {
      "id": "NCT05744375",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Spanish Breast Cancer Research Group"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Enhertu",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 41,
      "conditions": [
        "Locally Advanced Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2023-09-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT05704829",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "West German Study Group"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Chemotherapy+T+P",
        "Standard-of-Care",
        "Trastuzumab deruxtecan",
        "ENHERTU"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": 402,
      "conditions": [
        "HER2-positive Early Breast Cancer"
      ],
      "Start Date": "2023-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05633979",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Valemetostat",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 37,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-02-09",
      "Max Phase": "1"
    },
    {
      "id": "NCT05246514",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab deruxtecan",
        "T-DXd, DS-8201a"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 72,
      "conditions": [
        "HER2-mutant Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2022-07-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05034887",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "National Cancer Center Hospital East"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "Trastuzumab Deruxtecan (T-DXd)"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 37,
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": "2022-01-31",
      "Max Phase": "2"
    },
    {
      "id": "NCT01829711",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "Moxetumomab pasudotox",
        "IV Bag Protectant for Moxetumomab pasudotox"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Israel",
        "Ireland",
        "Germany",
        "Poland",
        "United Kingdom",
        "Spain",
        "Serbia",
        "Belgium",
        "France",
        "Norway",
        "United States"
      ],
      "enrollment": 80,
      "conditions": [
        "Leukemia, Hairy Cell"
      ],
      "Start Date": "2013-04-29",
      "Max Phase": "3"
    },
    {
      "id": "NCT04989816",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "Trastuzumab Deruxtecan",
        "DS8201a; AZD4552; T-DXd"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 95,
      "conditions": [
        "Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "Start Date": "2021-08-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT04986579",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "AstraZeneca",
        "Gilead Sciences",
        "Eisai Inc.",
        "Daiichi Sankyo",
        "Paxman Coolers Limited"
      ],
      "interventions": [
        "Paxman Scalp Cooling System",
        "Eribulin",
        "Halaven",
        "Sacituzumab govitecan",
        "IMMU-132",
        "DS-8201a",
        "Enhertu",
        "Trastuzumab deruxtecan",
        "Trodelvy",
        "Scalp Cooling Cap"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 120,
      "conditions": [
        "Chemotherapy-induced Alopecia",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2021-10-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT04970901",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ADC Therapeutics S.A."
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Loncastuximab Tesirine",
        "Glofitamab",
        "ZYNLONTA",
        "Polatuzumab Vedotin",
        "Mosunetuzumab",
        "ADCT-402"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 200,
      "conditions": [
        "Relapsed B-Cell Non-Hodgkin Lymphoma",
        "B-Cell Non-Hodgkin Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2022-06-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT04784715",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "DS-8201a; T-DXd",
        "Trastuzumab",
        "Taxane",
        "Trastuzumab deruxtecan",
        "Placebo",
        "Pertuzumab"
      ],
      "locations": [
        "Mexico",
        "China",
        "Sweden",
        "Denmark",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Hungary",
        "Taiwan",
        "United States",
        "Canada",
        "Philippines",
        "Peru",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Saudi Arabia",
        "Belgium"
      ],
      "enrollment": 1157,
      "conditions": [
        "Breast Cancer; HER2-positive; Metastatic"
      ],
      "Start Date": "2021-04-26",
      "Max Phase": "3"
    },
    {
      "id": "NCT04752059",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Medical University of Vienna"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Ds8201a",
        "Enhertu",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Austria"
      ],
      "enrollment": 15,
      "conditions": [
        "Breast Cancer Stage IV"
      ],
      "Start Date": "2020-07-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT04739761",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Trastuzumab Deruxtecan",
        "fam-trastuzumab deruxtecan-nxki"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Finland",
        "Switzerland",
        "Japan",
        "Portugal",
        "Sweden",
        "Ireland",
        "Denmark",
        "Germany",
        "Poland",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "Norway",
        "Netherlands",
        "United States"
      ],
      "enrollment": 506,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2021-06-22",
      "Max Phase": "3"
    },
    {
      "id": "NCT04644237",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Japan",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 152,
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2021-03-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT04639219",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a (T-DXd)",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Denmark",
        "Korea, Republic of",
        "Spain",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 102,
      "conditions": [
        "Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast"
      ],
      "Start Date": "2020-12-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT04482309",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd."
      ],
      "interventions": [
        "DS-8201a",
        "Trastuzumab deruxtecan",
        "T-DXd"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Thailand",
        "Czechia",
        "Japan",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "India",
        "Spain",
        "Australia",
        "Russian Federation",
        "Belgium",
        "Netherlands",
        "United States"
      ],
      "enrollment": 468,
      "conditions": [
        "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer",
        "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer"
      ],
      "Start Date": "2020-08-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT04420598",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "(DS-8201a)",
        "Trastuzumab deruxtecan"
      ],
      "locations": [
        "Spain",
        "Portugal"
      ],
      "enrollment": 41,
      "conditions": [
        "Leptomeningeal Metastasis",
        "Advanced Breast Cancer",
        "HER2-positive Breast Cancer",
        "Brain Metastases"
      ],
      "Start Date": "2020-05-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT01030536",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [],
      "interventions": [
        "CAT-8015 40 mcg/kg",
        "CAT-8015 30 mcg/kg",
        "CAT-8015 20 mcg/kg",
        "CAT-8015 60 mcg/kg",
        "CAT-8015 50 mcg/kg"
      ],
      "locations": [
        "Poland",
        "United States"
      ],
      "enrollment": 23,
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2010-02-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT00659425",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "CAT-8015 (Moxetumomab Pasudotox)"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 57,
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Non-Hodgkin's Lymphoma"
      ],
      "Start Date": "2008-09-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00586924",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "collaborators": [
        "Cambridge Antibody Technology"
      ],
      "interventions": [
        "Moxetumomab Pasudotox (CAT 8015)",
        "CAT 8015 (Moxetumomab Pasudotox)"
      ],
      "locations": [
        "Poland",
        "United States"
      ],
      "enrollment": 49,
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "Start Date": "2007-05-10",
      "Max Phase": "1"
    },
    {
      "id": "NCT06448013",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Kura Oncology, Inc."
      ],
      "interventions": [
        "Ziftomenib",
        "GDC-0199",
        "Gemtuzumab ozogamicin",
        "Mylotarg",
        "Venetoclax",
        "Gemtuzumab",
        "ABT-199"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 22,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2024-11-29",
      "Max Phase": "1"
    },
    {
      "id": "NCT06254495",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-35C"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 170,
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Large-Cell, Anaplastic",
        "Lymphoma, T-Cell, Peripheral",
        "Hodgkin Disease"
      ],
      "Start Date": "2024-05-31",
      "Max Phase": "1"
    },
    {
      "id": "NCT06186986",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University Medical Center Groningen"
      ],
      "collaborators": [
        "Takeda"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "89ZR-Brentuximab"
      ],
      "locations": [],
      "enrollment": 20,
      "conditions": [
        "Diffuse Large B-cell-lymphoma"
      ],
      "Start Date": "2024-01-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT06120504",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-35T"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": 110,
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, T-Cell, Peripheral",
        "Hodgkin Disease",
        "Lymphoma, T-Cell, Cutaneous",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Large-Cell, Anaplastic"
      ],
      "Start Date": "2024-02-29",
      "Max Phase": "1"
    },
    {
      "id": "NCT05442554",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 10,
      "conditions": [
        "T-Cell Lymphoma"
      ],
      "Start Date": "2023-07-20",
      "Max Phase": "4"
    },
    {
      "id": "NCT05414500",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Alabama at Birmingham"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Kyowa Kirin, Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Mogamulizumab"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 10,
      "conditions": [
        "Cutaneous T Cell Lymphoma",
        "Mycosis Fungoides"
      ],
      "Start Date": "2023-05-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05357794",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Adcetris",
        "Brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Mycosis Fungoides"
      ],
      "Start Date": "2022-10-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05316246",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanghai Zhongshan Hospital"
      ],
      "collaborators": [
        "BeiGene",
        "Takeda"
      ],
      "interventions": [
        "Brentuximab Vedotin in Combination with Tislelizumab"
      ],
      "locations": [],
      "enrollment": 40,
      "conditions": [
        "NK/T Cell Lymphoma Nos"
      ],
      "Start Date": "2022-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04849910",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Vor Biopharma"
      ],
      "collaborators": [],
      "interventions": [
        "VOR33",
        "gemtuzumab ozogamicin",
        "Mylotarg"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Leukemia, Myeloid, Acute",
        "Myelodysplastic Syndromes"
      ],
      "Start Date": "2021-12-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT01156753",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Celldex Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "\"Investigator's Choice\" chemotherapy",
        "CDX-011"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 120,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2010-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04070768",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "John Quigley"
      ],
      "collaborators": [
        "AbbVie",
        "Pfizer"
      ],
      "interventions": [
        "Gemtuzumab Ozogamicin",
        "GO",
        "Venetoclax"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2019-09-06",
      "Max Phase": "1"
    },
    {
      "id": "NCT00704158",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "CuraGen Corporation"
      ],
      "collaborators": [],
      "interventions": [
        "CR011-vcMMAE"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 42,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2008-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03727750",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Gemtuzumab Ozogamicin"
      ],
      "locations": [
        "Canada",
        "Poland",
        "United Kingdom",
        "Spain",
        "Hungary",
        "United States"
      ],
      "enrollment": 51,
      "conditions": [
        "Pharmacokinetics",
        "ECG",
        "Safety"
      ],
      "Start Date": "2019-07-03",
      "Max Phase": "4"
    },
    {
      "id": "NCT03671018",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Mosunetuzumab (IV)",
        "BTCT4465A",
        "Polatuzumab vedotin",
        "Rituximab",
        "Mosunetuzumab (SC)",
        "Tocilizumab"
      ],
      "locations": [
        "Canada",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 422,
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2018-09-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT03587844",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "brentuximab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 58,
      "conditions": [
        "Sezary Syndrome",
        "Mycosis Fungoides",
        "Lymphomatoid Papulosis"
      ],
      "Start Date": "2018-07-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT00412828",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "CuraGen Corporation"
      ],
      "collaborators": [],
      "interventions": [
        "CR011-vcMMAE"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 117,
      "conditions": [
        "Unresectable Stage III or Stage IV Melanoma"
      ],
      "Start Date": "2006-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03374332",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Brown University"
      ],
      "collaborators": [
        "The Miriam Hospital",
        "Pfizer",
        "Rhode Island Hospital"
      ],
      "interventions": [
        "Gemtuzumab Ozogamicin (GO)",
        "Donor Leukocytes",
        "Mylotarg"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 11,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2019-12-31",
      "Max Phase": "2"
    },
    {
      "id": "NCT03264131",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "CHEP"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 16,
      "conditions": [
        "Lymphoma",
        "Lymphatic Diseases",
        "Adult T-Cell Leukemia/Lymphoma"
      ],
      "Start Date": "2018-10-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT03222492",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "National Institute of Allergy and Infectious Diseases (NIAID)"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Rho Federal Systems Division, Inc.",
        "Immune Tolerance Network (ITN)",
        "PPD"
      ],
      "interventions": [
        "Placebo for brentuximab vedotin",
        "Brentuximab Vedotin",
        "Adcetris\u00ae",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 17,
      "conditions": [
        "dcSSc",
        "Diffuse Cutaneous Systemic Sclerosis",
        "Scleroderma"
      ],
      "Start Date": "2017-09-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT03217643",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Imagine Institute"
      ],
      "collaborators": [
        "Takeda"
      ],
      "interventions": [
        "Brentuximab Vedotin"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 14,
      "conditions": [
        "Enteropathy Associated T-cell Lymphoma"
      ],
      "Start Date": "2018-02-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT05834296",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Alzamend Neuro, Inc."
      ],
      "collaborators": [
        "bioRASI, LLC"
      ],
      "interventions": [
        "ALZN002 (autologous DCs pulsed with E22W mutant peptide).",
        "Placebo"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Alzheimer Disease"
      ],
      "Start Date": "2023-07-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT02939014",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab Vedotin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 39,
      "conditions": [
        "Lymphoma, Large-Cell, Anaplastic",
        "Hodgkin Disease"
      ],
      "Start Date": "2016-11-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT02611323",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Venetoclax"
      ],
      "locations": [
        "Australia",
        "Italy",
        "United States"
      ],
      "enrollment": 133,
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "Start Date": "2016-03-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT02280785",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Samsung Medical Center"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris"
      ],
      "locations": [
        "Korea, Republic of"
      ],
      "enrollment": 33,
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2014-11-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT02164006",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "TG Therapeutics, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "brentuximab vedotin: Adcetris",
        "TGR-1202 + brentuximab vedotin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 16,
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "Start Date": "2014-06-11",
      "Max Phase": "1"
    },
    {
      "id": "NCT01851200",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fondazione Michelangelo"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc.",
        "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"
      ],
      "interventions": [
        "Adcetris",
        "Brentuximab Vedotin",
        "SGN-35"
      ],
      "locations": [
        "Italy"
      ],
      "enrollment": 9,
      "conditions": [
        "Germ Cell Cancer"
      ],
      "Start Date": "2013-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01700751",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Washington University School of Medicine"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "brentuximab vedotin",
        "Adcetris"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 17,
      "conditions": [
        "Leukemia, Lymphoblastic,Acute",
        "Leukemia, Acute Myeloid",
        "Myelodysplastic Syndromes"
      ],
      "Start Date": "2013-02-25",
      "Max Phase": "1"
    },
    {
      "id": "NCT01691898",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "DCDT2980S",
        "MabThera/Rituxan",
        "Pinatuzumab Vedotin",
        "DCDS4501A",
        "GA101, Gazyva, Gazyvaro",
        "Polatuzumab Vedotin",
        "Rituximab"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 231,
      "conditions": [
        "Follicular Lymphoma",
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2012-09-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT01596218",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Dana-Farber Cancer Institute"
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 35,
      "conditions": [
        "Graft vs. Host Disease"
      ],
      "Start Date": "2012-07-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01578967",
      "phases": [],
      "sponsor": [
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Adcetris",
        "Brentuximab vedotin",
        "ABVD",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 41,
      "conditions": [
        "Hodgkin Lymphoma, Adult"
      ],
      "Start Date": "2012-04-01",
      "Max Phase": null
    },
    {
      "id": "NCT01508312",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "H\u00f4pitaux Universitaires Henri Mondor, France"
      ],
      "interventions": [
        "brentuximab vedotin (SGN-35)",
        "Brentuximab Vedotin (SGN-35)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 46,
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "Start Date": "2012-01-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT01492088",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35",
        "ADCETRIS"
      ],
      "locations": [
        "Mexico",
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Relapsed or Refractory Hodgkin Lymphoma",
        "Relapsed or Refractory Anaplastic Large-cell Lymphoma"
      ],
      "Start Date": "2012-04-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT01352520",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Brentuximab vedotin",
        "SGN-35"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 79,
      "conditions": [
        "CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma",
        "Lymphoma",
        "Mycosis Fungoides",
        "Lymphomatoid Papulosis",
        "Hematologic Disorder",
        "Cutaneous Lymphomas",
        "Skin Lymphoma",
        "Lymphoma, Primary Cutaneous Anaplastic Large Cell"
      ],
      "Start Date": "2011-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01290549",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab Vedotin",
        "Rituximab",
        "DCDS4501A"
      ],
      "locations": [
        "Canada",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 95,
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non-Hodgkins Lymphoma"
      ],
      "Start Date": "2011-03-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT01209130",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "rituximab",
        "DCDT2980S"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 91,
      "conditions": [
        "Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia"
      ],
      "Start Date": "2010-10-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00962767",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Arm A",
        "gemtuzumab ozogamicin",
        "Arm B",
        "ATRA plus 6-MP and MTX"
      ],
      "locations": [],
      "enrollment": 168,
      "conditions": [
        "Leukemia, Myelocytic, Acute"
      ],
      "Start Date": "2002-05-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT00860639",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Nantes University Hospital"
      ],
      "collaborators": [
        "Chugai Pharmaceutical",
        "French Innovative Leukemia Organisation"
      ],
      "interventions": [
        "gemtuzumab ozogamycin",
        "gemtuzumab ozogamycin (MYLOTARG \u00ae)"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 327,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2007-10-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT00304447",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Mylotarg"
      ],
      "locations": [],
      "enrollment": 30,
      "conditions": [
        "Infusions, Intravenous",
        "Leukemia, Myelocytic, Acute"
      ],
      "Start Date": "2002-04-01",
      "Max Phase": "4"
    },
    {
      "id": "NCT00233909",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Kanisa Pharmaceuticals"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "Zosuquidar"
      ],
      "locations": [],
      "enrollment": 55,
      "conditions": [
        "Leukemia, Myeloid"
      ],
      "Start Date": "2005-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00003673",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "chemotherapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 55,
      "conditions": [
        "Leukemia"
      ],
      "Start Date": "1998-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00003131",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "chemotherapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 55,
      "conditions": [
        "Leukemia"
      ],
      "Start Date": "1997-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00079755",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "SGN-30 (anti-CD30 mAb)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 80,
      "conditions": [
        "Anaplastic Large-Cell Lymphoma"
      ],
      "Start Date": "2004-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00017589",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genta Incorporated"
      ],
      "collaborators": [],
      "interventions": [
        "gemtuzumab ozogamicin",
        "oblimersen sodium"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": null,
      "conditions": [
        "Leukemia"
      ],
      "Start Date": "2000-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00044733",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Mylotarg (gemtuzumab ozogamicin) Injection"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 38,
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": "2000-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00037583",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Gemtuzumab Ozogamicin"
      ],
      "locations": [],
      "enrollment": 69,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": null,
      "Max Phase": "2"
    },
    {
      "id": "NCT05687032",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Besponsa",
        "inotuzumab ozogamicin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 44,
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2023-02-24",
      "Max Phase": "4"
    },
    {
      "id": "NCT02423928",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alden Cancer Therapy II"
      ],
      "collaborators": [
        "Haukeland University Hospital",
        "Norwegian Radium Hospital"
      ],
      "interventions": [
        "Sendoxan",
        "Yervoy",
        "ipilimumab",
        "Cyclophosphamide",
        "ACT2001",
        "Dendritic cell based cryoimmunotherapy"
      ],
      "locations": [
        "Norway"
      ],
      "enrollment": 18,
      "conditions": [
        "Prostate Cancer"
      ],
      "Start Date": "2015-05-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04553770",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jonsson Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Daiichi Sankyo Co., Ltd.",
        "Translational Research in Oncology-U.S"
      ],
      "interventions": [
        "DS-8201",
        "DS-8201a",
        "Arimidex",
        "Anastrozole",
        "WHO 10516",
        "Fam-trastuzumab Deruxtecan-nxki",
        "Enhertu",
        "Anastrazole",
        "ICI D1033",
        "ZD-1033",
        "Trastuzumab Deruxtecan",
        "ICI-D1033",
        "Therapeutic Conventional Surgery"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 88,
      "conditions": [
        "Invasive Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Stage III Breast Cancer",
        "Early-stage Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIB Breast Cancer"
      ],
      "Start Date": "2020-10-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT03983954",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "NeoTX Therapeutics Ltd."
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)",
        "Obinutuzumab pretreatment (Gazyva\u00ae) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)"
      ],
      "locations": [
        "Israel"
      ],
      "enrollment": 60,
      "conditions": [
        "NSCL2 Gene Mutation",
        "Ovarian Cancer",
        "Prostate Cancer",
        "GastroEsophageal Cancer",
        "Hepatocellular Carcinoma",
        "Urothelial Cancer",
        "Renal Cell Carcinoma",
        "Endometrial Cancer",
        "Mesothelioma",
        "NSCLC",
        "Melanoma",
        "ER+ Breast Cancer",
        "Cervical Squamous Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "HER2-negative Breast Cancer",
        "Bladder Cancer",
        "Pancreatic Adenocarcinoma",
        "Colorectal Cancer Metastatic"
      ],
      "Start Date": "2019-10-10",
      "Max Phase": "1"
    },
    {
      "id": "NCT00346385",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BB-10901",
        "IMGN901"
      ],
      "locations": [
        "United Kingdom",
        "United States"
      ],
      "enrollment": 97,
      "conditions": [
        "Ovarian Cancer",
        "SCLC",
        "Merkel Cell Carcinoma"
      ],
      "Start Date": "2002-03-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00346255",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BB-10901",
        "IMGN901"
      ],
      "locations": [
        "Argentina",
        "United States"
      ],
      "enrollment": 37,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2005-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00065429",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BB-10901"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 64,
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": "2003-04-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01363297",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "CMC-544",
        "Inotuzumab Ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 72,
      "conditions": [
        "Acute Lymphocytic Leukemia"
      ],
      "Start Date": "2011-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00868608",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin",
        "Inotuzumab Ozogamicin (CMC-544)"
      ],
      "locations": [
        "Hong Kong",
        "Singapore",
        "Hungary",
        "Korea, Republic of",
        "Germany",
        "Belgium",
        "Netherlands",
        "Japan",
        "United States"
      ],
      "enrollment": 81,
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": "2009-07-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT00717925",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Inotuzumab Ozogamicin (CMC-544)"
      ],
      "locations": [],
      "enrollment": 13,
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2007-03-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT06155383",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "Toripalimab",
        "Disitamab Vedotin",
        "RC48",
        "Capecitabine",
        "oxaliplatin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 90,
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": "2023-11-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT00073749",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Inotuzumab ozogamicin [CMC-544]"
      ],
      "locations": [
        "Switzerland",
        "Germany",
        "United Kingdom",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 79,
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2003-08-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT05089734",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Sacituzumab Govitecan-hziy (SG)",
        "Docetaxel",
        "IMMU-132",
        "GS-0132"
      ],
      "locations": [
        "Mexico",
        "Germany",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Israel",
        "Austria",
        "Netherlands",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 603,
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2021-11-17",
      "Max Phase": "3"
    },
    {
      "id": "NCT05006794",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "sacituzumab govitecan-hziy",
        "GS-9716",
        "Docetaxel"
      ],
      "locations": [
        "Israel",
        "United States"
      ],
      "enrollment": 195,
      "conditions": [
        "Solid Malignancies"
      ],
      "Start Date": "2021-09-15",
      "Max Phase": "1"
    },
    {
      "id": "NCT01134575",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "interventions": [
        "Rituximab",
        "CMC-544 (Inotuzumab Ozogamycin)",
        "rituxan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 90,
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2010-06-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT00867087",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin (CMC-544)",
        "rituximab",
        "cmc-544"
      ],
      "locations": [
        "Singapore",
        "Korea, Republic of",
        "United Kingdom",
        "Germany",
        "France",
        "United States"
      ],
      "enrollment": 64,
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2009-06-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT00724971",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "Inotuzumab Ozogamicin (CMC-544)",
        "Rituximab (Rituxan)"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 10,
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2008-07-04",
      "Max Phase": "1"
    },
    {
      "id": "NCT06221748",
      "phases": [
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel Injection",
        "Cadonilimab Injection",
        "DV,RC48",
        "AK104, Cadonilimab Injection",
        "Disitamab Vedotin Injection"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 90,
      "conditions": [
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": "2024-02-22",
      "Max Phase": "3"
    },
    {
      "id": "NCT06081244",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "West German Study Group"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "Trodelvy",
        "Keytruda",
        "Sacituzumab govitecan"
      ],
      "locations": [],
      "enrollment": 348,
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2024-04-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00299494",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin",
        "CMC-544",
        "Rituximab"
      ],
      "locations": [
        "Italy",
        "Hong Kong",
        "Switzerland",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 119,
      "conditions": [
        "B-Cell Lymphoma"
      ],
      "Start Date": "2006-05-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT05675579",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "(IMMU-132) Immunomedics",
        "KEYTRUDA\u00ae",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-05-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT05480384",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Brown University"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "Nivolumab",
        "OPDIVO",
        "Trastuzumab deruxtecan",
        "ENHERTU"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "Esophageal Adenocarcinoma",
        "Gastroesophageal-junction Cancer",
        "HER-2 Protein Overexpression",
        "Esophageal Cancer"
      ],
      "Start Date": "2023-07-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT02590263",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Temozolomide",
        "ABT-414",
        "Depatuxizumab",
        "Mafodotin",
        "Whole Brain Radiation"
      ],
      "locations": [
        "Japan"
      ],
      "enrollment": 53,
      "conditions": [
        "Glioblastoma Multiforme",
        "Malignant Glioma"
      ],
      "Start Date": "2015-08-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT05186974",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Sacituzumab Govitecan-hziy (SG)",
        "IMMU-132",
        "Paraplatin\u00ae",
        "GS-0132",
        "Cisplatin",
        "Carboplatin",
        "Platinol\u00ae",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Canada",
        "Hong Kong",
        "Italy",
        "Malaysia",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 193,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2022-05-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT04863885",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "collaborators": [
        "Bristol-Myers Squibb",
        "Gilead Sciences"
      ],
      "interventions": [
        "Nivolumab",
        "Ipilimumab",
        "Yervoy",
        "Sacituzumab govitecan",
        "Opdivo",
        "Trodelvy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 46,
      "conditions": [
        "Metastatic Urothelial Carcinoma"
      ],
      "Start Date": "2021-04-30",
      "Max Phase": "2"
    },
    {
      "id": "NCT04794699",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "IDEAYA Biosciences"
      ],
      "collaborators": [],
      "interventions": [
        "IDE397",
        "Paclitaxel",
        "Sacituzumab govitecan",
        "Docetaxel"
      ],
      "locations": [
        "Germany",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 180,
      "conditions": [
        "Solid Tumor"
      ],
      "Start Date": "2021-04-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT01800695",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Whole Brain Radiation",
        "Depatuxizumab Mafodotin",
        "ABT-414",
        "Temozolomide"
      ],
      "locations": [],
      "enrollment": 202,
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "Start Date": "2013-04-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT04527991",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Taxol\u00ae",
        "IMMU-132",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "GS-0132",
        "Taxotere\u00ae",
        "Vinflunine",
        "Trodelvy\u2122",
        "Javlor \u00ae",
        "Docetaxel"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Ireland",
        "Bulgaria",
        "Germany",
        "Greece",
        "France",
        "Puerto Rico",
        "Italy",
        "Israel",
        "Georgia",
        "Croatia",
        "Austria",
        "Taiwan",
        "United States",
        "Canada",
        "Portugal",
        "United Kingdom",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 696,
      "conditions": [
        "Locally Advanced or Metastatic Unresectable Urothelial Cancer"
      ],
      "Start Date": "2021-01-13",
      "Max Phase": "3"
    },
    {
      "id": "NCT04468061",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "IMMU-132",
        "Keytruda",
        "Sacituzumab Govitecan",
        "Trodelvy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 110,
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer",
        "PD-L1 Negative"
      ],
      "Start Date": "2020-07-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT04448886",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Ana C Garrido-Castro, MD"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "TRODELVY",
        "Keytruda",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 110,
      "conditions": [
        "HR-Positive Breast Cancer",
        "Invasive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2020-09-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT04230109",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Gilead Sciences"
      ],
      "interventions": [
        "Pembrolizumab",
        "IMMU-132",
        "Sacituzumab Govitecan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 260,
      "conditions": [
        "Invasive Breast Cancer",
        "Triple Negative Breast Cancer",
        "PR-Negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER-Negative Breast Cancer"
      ],
      "Start Date": "2020-07-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT06467357",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo"
      ],
      "interventions": [
        "Gemcitabine",
        "Durvalumab",
        "DS-8201a; T-DXd",
        "Ventana PD-L1 SP263 assay",
        "Trastuzumab deruxtecan",
        "Cisplatin",
        "Rilvegostomig",
        "Agilent HercepTest\u2122 mAb pharmDx"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Japan",
        "Germany",
        "Korea, Republic of",
        "Taiwan",
        "Austria",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 620,
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": "2024-06-26",
      "Max Phase": "3"
    },
    {
      "id": "NCT03533283",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Atezolizumab",
        "Actemra",
        "Glofitamab",
        "RO7082859",
        "89Zr-Df-IAB22M2C",
        "Polatuzumab Vedotin",
        "Tocilizumab"
      ],
      "locations": [
        "Italy",
        "Israel",
        "Denmark",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 280,
      "conditions": [
        "Non-Hodgkins Lymphoma"
      ],
      "Start Date": "2018-05-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT03310957",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "SGN-LIV1A",
        "LV",
        "ladiratuzumab vedotin",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Spain",
        "Korea, Republic of",
        "Germany",
        "United States"
      ],
      "enrollment": 186,
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "Start Date": "2018-02-27",
      "Max Phase": "2"
    },
    {
      "id": "NCT00132379",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Active Biotech AB"
      ],
      "collaborators": [],
      "interventions": [
        "ABR-217620",
        "CD3; 5T4FabV18-SEA/E-120; naptumomab estafenatox; Anyara",
        "docetaxel",
        "Taxotere"
      ],
      "locations": [
        "Russian Federation",
        "Denmark",
        "United States"
      ],
      "enrollment": 13,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": "2005-11-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02696642",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "France",
        "Moldova, Republic of"
      ],
      "enrollment": 54,
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": "2016-04-14",
      "Max Phase": "1"
    },
    {
      "id": "NCT05417594",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Datopotamab Deruxtecan (Dato-DXd)",
        "Trastuzumab Deruxtecan (T-DXd)",
        "Temozolomide",
        "AZD9574",
        "[11C]AZ1419 3391"
      ],
      "locations": [
        "Sweden",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "United States"
      ],
      "enrollment": 490,
      "conditions": [
        "Advanced Solid Malignancies"
      ],
      "Start Date": "2022-08-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT02610140",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [
        "ImmunoGen and MorphoSys"
      ],
      "interventions": [
        "Anetumab ravtansine (BAY94-9343)",
        "Vinorelbine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Finland",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Australia",
        "Russian Federation",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 248,
      "conditions": [
        "Mesothelioma"
      ],
      "Start Date": "2015-12-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT04880863",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "NeoTX Therapeutics Ltd."
      ],
      "collaborators": [
        "Translational Drug Development"
      ],
      "interventions": [
        "Obinutuzumab",
        "Gazyva",
        "Anyara",
        "NAP (Naptumomab estafenatox)",
        "ABR-217620",
        "Docetaxel",
        "Taxotere"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 38,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2021-10-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT04609566",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "pembrolizumab",
        "brentuximab vedotin",
        "ADCETRIS",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 140,
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "Start Date": "2021-01-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT04539938",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "tucatinib",
        "T-DXd, Enhertu, DS-8201",
        "trastuzumab deruxtecan",
        "TUKYSA, ARRY-380, ONT-380"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "HER2 Positive Breast Cancer"
      ],
      "Start Date": "2020-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01609556",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "IMGN853",
        "Mirvetuximab soravtansine"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": 206,
      "conditions": [
        "Tumors"
      ],
      "Start Date": "2012-06-28",
      "Max Phase": "1"
    },
    {
      "id": "NCT02729896",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Atezolizumab [TECENTRIQ]"
      ],
      "locations": [
        "Germany",
        "Poland",
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": "2016-11-09",
      "Max Phase": "2"
    },
    {
      "id": "NCT02684292",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Merck Sharp & Dohme LLC"
      ],
      "collaborators": [],
      "interventions": [
        "pembrolizumab",
        "brentuximab vedotin",
        "MK-3475",
        "ADCETRIS\u00ae",
        "KEYTRUDA\u00ae"
      ],
      "locations": [],
      "enrollment": 304,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2016-05-23",
      "Max Phase": "3"
    },
    {
      "id": "NCT02600897",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Lenalidomide"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "United States"
      ],
      "enrollment": 114,
      "conditions": [
        "Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2016-03-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT02581631",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Nivolumab",
        "Brentuximab Vedotin"
      ],
      "locations": [
        "Canada",
        "Italy",
        "United Kingdom",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 145,
      "conditions": [
        "Non-Hodgkin's Disease"
      ],
      "Start Date": "2016-02-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT05171647",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab vedotin",
        "Mosunetuzumab",
        "Gemcitabine",
        "Oxaliplatin",
        "Rituximab",
        "Tocilizumab"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Mexico",
        "Thailand",
        "Israel",
        "China",
        "Japan",
        "Argentina",
        "Peru",
        "Korea, Republic of",
        "Turkey",
        "Russian Federation",
        "New Zealand",
        "United States"
      ],
      "enrollment": 222,
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2022-04-25",
      "Max Phase": "3"
    },
    {
      "id": "NCT05097599",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Strata Oncology"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Pfizer",
        "Gilead Sciences"
      ],
      "interventions": [
        "lorlatinib",
        "encorafenib + binimetinib",
        "sacituzumab govitecan",
        "axitinib",
        "talazoparib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 700,
      "conditions": [
        "Advanced Solid Tumor",
        "Cancer"
      ],
      "Start Date": "2021-11-19",
      "Max Phase": "2"
    },
    {
      "id": "NCT02429375",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "MethylGene Inc."
      ],
      "interventions": [
        "Mocetinostat Plus Brentuximab Vedotin",
        "SGN-35",
        "MGCD0103"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 7,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2015-04-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT04958785",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Taxol\u00ae",
        "Magrolimab",
        "Paclitaxel",
        "Sacituzumab Govitecan-hziy",
        "GS-0132",
        "Trodelvy\u00ae",
        "Nab-Paclitaxel",
        "GS-4721",
        "Abraxane"
      ],
      "locations": [
        "Hong Kong",
        "Korea, Republic of",
        "United Kingdom",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "enrollment": 92,
      "conditions": [
        "Triple-Negative Breast Cancer"
      ],
      "Start Date": "2021-12-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT02086604",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Washington University School of Medicine"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Celgene"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris\u00ae",
        "Revlimid\u00ae",
        "Lenalidomide"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 37,
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": "2014-09-18",
      "Max Phase": "1"
    },
    {
      "id": "NCT04733118",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "MedSIR"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Trastuzumab and Pertuzumab (FDC SC) and T-DM1",
        "Phesgo",
        "Kadcyla",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Italy",
        "Germany",
        "Bulgaria",
        "Spain",
        "Hungary"
      ],
      "enrollment": 393,
      "conditions": [
        "Early Breast Cancer"
      ],
      "Start Date": "2021-08-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT04622319",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "NSABP Foundation Inc",
        "German Breast Group",
        "AstraZeneca",
        "Spanish Breast Cancer Research Group (SOLTI)"
      ],
      "interventions": [
        "Trastuzumab deruxtecan (T-DXd)",
        "T-DM1",
        "DS-8201a",
        "Trastuzumab emtansine (T-DM1)"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Ireland",
        "Denmark",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Israel",
        "Argentina",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 1600,
      "conditions": [
        "HER2-Positive Primary Breast Cancer",
        "Residual Invasive Breast Cancer"
      ],
      "Start Date": "2020-12-04",
      "Max Phase": "3"
    },
    {
      "id": "NCT04404283",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "Rituximab",
        "Placebo",
        "Lenalidomide"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Switzerland",
        "Germany",
        "Denmark",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 240,
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": "2020-08-20",
      "Max Phase": "3"
    },
    {
      "id": "NCT04182204",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Mabthera; Rituxan",
        "Gemcitabine",
        "Oxaliplatin",
        "Polatuzumab Vedotin",
        "Rituximab"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Mexico",
        "Finland",
        "China",
        "Ireland",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "India",
        "Turkey",
        "Spain",
        "Greece",
        "France",
        "United States"
      ],
      "enrollment": 270,
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2020-02-07",
      "Max Phase": "3"
    },
    {
      "id": "NCT03742102",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Oleclumab",
        "Capivasertib",
        "Paclitaxel",
        "MEDI9447",
        "DS-8201a",
        "AZD5363",
        "Dato-DXd; DS-1062a",
        "Durvalumab",
        "Trastuzumab deruxtecan",
        "Datopotamab deruxtecan",
        "MEDI4736"
      ],
      "locations": [
        "Canada",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "United States"
      ],
      "enrollment": 240,
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "Start Date": "2018-12-21",
      "Max Phase": "2"
    },
    {
      "id": "NCT06324357",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Boehringer Ingelheim"
      ],
      "collaborators": [],
      "interventions": [
        "BI 1810631",
        "Zongertinib",
        "Trastuzumab deruxtecan",
        "T-DM1; Kadcyla\u00ae",
        "T-DXd; Enhertu\u00ae",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 240,
      "conditions": [
        "Esophageal Adenocarcinoma",
        "Metastatic Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2024-05-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT06313086",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "trastuzumab emtansine",
        "T -DM1",
        "DP303c"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 442,
      "conditions": [
        "HER2-positive Breast Cancer"
      ],
      "Start Date": "2024-03-13",
      "Max Phase": "3"
    },
    {
      "id": "NCT06126640",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Jiangsu HengRui Medicine Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "SHR-A1811",
        "Trastuzumab Emtansine"
      ],
      "locations": [],
      "enrollment": 1200,
      "conditions": [
        "HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy"
      ],
      "Start Date": "2023-11-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05904106",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Technische Universit\u00e4t Dresden"
      ],
      "collaborators": [
        "AbbVie",
        "University Hospital Heidelberg"
      ],
      "interventions": [
        "standard of care chemotherapy plus gemtuzumab ozogamicin",
        "Venetoclax plus Azacitidine"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": 146,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2023-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05840211",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Taxol\u00ae",
        "Xeloda\u00ae",
        "Paclitaxel",
        "IMMU-132",
        "Sacituzumab Govitecan-hziy",
        "GS-0132",
        "Abraxane\u00ae",
        "Nab-paclitaxel",
        "Trodelvy\u2122",
        "Capecitabine"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "United States",
        "Canada",
        "Chile",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Malaysia",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 654,
      "conditions": [
        "Locally Advanced or Unresectable Metastatic Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "Start Date": "2023-05-08",
      "Max Phase": "3"
    },
    {
      "id": "NCT05650879",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Enliven Therapeutics"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1",
        "T-DXd",
        "Enhertu",
        "Kadcyla",
        "Fam-Trastuzumab Deruxtecan-Nxki",
        "Trastuzumab emtansine",
        "ELVN-002"
      ],
      "locations": [
        "Italy",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 198,
      "conditions": [
        "HER2 Mutant Non-small Cell Lung Cancer",
        "HER2-positive Metastatic Breast Cancer",
        "HER2 Gene Mutation",
        "HER2 Amplification"
      ],
      "Start Date": "2023-03-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT05633654",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Alliance Foundation Trials, LLC.",
        "NSABP Foundation Inc"
      ],
      "interventions": [
        "Pembrolizumab",
        "Xeloda",
        "IMMU-132",
        "GS-0132",
        "Sacituzumab govitecan-hziy (SG)",
        "Trodelvy\u2122",
        "Capecitabine",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 1514,
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2022-12-12",
      "Max Phase": "3"
    },
    {
      "id": "NCT05593094",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Suzhou Zanrong Pharma Limited"
      ],
      "collaborators": [],
      "interventions": [
        "ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c",
        "ZN-A-1041 1000mg BID",
        "ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c",
        "ZN-A-1041 200mg BID",
        "ZN-A-1041 100mg BID",
        "ZN-A-1041 400mg BID",
        "ZN-A-1041 800mg BID",
        "ZN-A-1041 50mg BID",
        "ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b",
        "ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c",
        "ZN-A-1041 600mg BID",
        "ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b",
        "ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b",
        "ZN-A-1041 Enteric Capsules"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 210,
      "conditions": [
        "Advanced Solid Tumors",
        "HER2-positive Breast Cancer"
      ],
      "Start Date": "2020-10-15",
      "Max Phase": "1"
    },
    {
      "id": "NCT05415215",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Herceptin\u00ae",
        "Pertuzumab, Trastuzumab, and rHuPH20",
        "RG6264",
        "RO5304020",
        "PHESGO\u00ae",
        "RO0452317",
        "T-DM1",
        "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
        "Kadcyla\u00ae",
        "Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)",
        "ado-trastuzumab emtansine",
        "Investigator's Choice of Chemotherapy",
        "Radiotherapy",
        "Pertuzumab IV",
        "RO7198574",
        "Trastuzumab IV",
        "Surgery",
        "RO4368451",
        "Trastuzumab Emtansine",
        "Perjeta\u00ae"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Mexico",
        "Kenya",
        "Singapore",
        "Chile",
        "Bosnia and Herzegovina",
        "Argentina",
        "Peru",
        "Turkey",
        "Korea, Republic of",
        "Bulgaria",
        "Croatia",
        "India",
        "Costa Rica",
        "Spain",
        "South Africa"
      ],
      "enrollment": 347,
      "conditions": [
        "Early Breast Cancer",
        "Inflammatory Breast Cancer",
        "Locally Advanced Breast Cancer"
      ],
      "Start Date": "2022-07-05",
      "Max Phase": "3"
    },
    {
      "id": "NCT05382299",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "IMMU-132",
        "Sacituzumab Govitecan-hziy",
        "GS-0132",
        "Gemcitabine",
        "Trodelvy\u2122",
        "Carboplatin",
        "Abraxane\u00ae",
        "nab-Paclitaxel"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Germany",
        "France",
        "Puerto Rico",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 540,
      "conditions": [
        "Triple Negative Breast Cancer",
        "PD-L1 Negative"
      ],
      "Start Date": "2022-07-20",
      "Max Phase": "3"
    },
    {
      "id": "NCT05274048",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fox Chase Cancer Center"
      ],
      "collaborators": [
        "National Comprehensive Cancer Network",
        "Puma Biotechnology, Inc."
      ],
      "interventions": [
        "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)",
        "Neratinib Pill"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": "2022-06-24",
      "Max Phase": "1"
    },
    {
      "id": "NCT02639091",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "BAY 94-9343",
        "Pemetrexed",
        "Cisplatin"
      ],
      "locations": [
        "Italy",
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "Medical Oncology"
      ],
      "Start Date": "2016-02-03",
      "Max Phase": "1"
    },
    {
      "id": "NCT02467946",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Centre Antoine Lacassagne"
      ],
      "collaborators": [
        "Millennium: The Takeda Oncology Company"
      ],
      "interventions": [
        "Adcetris-Levact",
        "Bendamustine",
        "Brentuximab Vedotin"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 60,
      "conditions": [
        "Clinical Efficacy",
        "Safety"
      ],
      "Start Date": "2016-01-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT04893109",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "trastuzumab-emtansine",
        "T-DM1",
        "Paclitaxel",
        "Herceptin Hylecta",
        "Trastuzumab SC",
        "Kadcyla",
        "Onxal",
        "Taxol"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 500,
      "conditions": [
        "HER2-positive Breast Cancer",
        "Breast Cancer"
      ],
      "Start Date": "2021-06-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT01565200",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jules Bordet Institute"
      ],
      "collaborators": [
        "Roche Pharma AG"
      ],
      "interventions": [
        "89Zr-trastuzumab",
        "T-DM1",
        "Zirconium 89 labelled trastuzumab",
        "Trastuzumab-DM1"
      ],
      "locations": [
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 90,
      "conditions": [
        "HER-2 Positive Breast Cancer"
      ],
      "Start Date": "2012-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03901339",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Vinorelbine",
        "Eribulin",
        "IMMU-132",
        "Sacituzumab Govitecan-hziy",
        "GS-0132",
        "Gemcitabine",
        "Capecitabine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 543,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2019-05-08",
      "Max Phase": "3"
    },
    {
      "id": "NCT03547973",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Merck KGaA, Darmstadt, Germany"
      ],
      "interventions": [
        "Zimberelimab",
        "Pembrolizumab",
        "IMMU-132",
        "Avelumab",
        "Sacituzumab Govitecan-hziy",
        "Domvanalimab",
        "Gemcitabine",
        "Trodelvy\u2122",
        "Cisplatin",
        "Carboplatin",
        "BAVENCIO\u00ae",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Italy",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Greece",
        "France",
        "United States"
      ],
      "enrollment": 643,
      "conditions": [
        "Metastatic Urothelial Cancer"
      ],
      "Start Date": "2018-08-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT00932373",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "trastuzumab-MCC-DM1"
      ],
      "locations": [],
      "enrollment": 54,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2006-04-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00928330",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab",
        "GDC-0941",
        "trastuzumab-MCC-DM1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 57,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2009-07-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT03153163",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "RO5304020",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 11,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2017-06-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT03102320",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [
        "MorphoSys AG",
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Anetumab ravtansine (BAY94-9343)",
        "Gemcitabine",
        "Cisplatin"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Singapore",
        "Switzerland",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 173,
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": "2017-05-26",
      "Max Phase": "1"
    },
    {
      "id": "NCT02999672",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Kadcyla",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "Spain",
        "Slovakia",
        "Italy",
        "Netherlands"
      ],
      "enrollment": 20,
      "conditions": [
        "Cholangiocellular Carcinoma",
        "Bladder Cancer",
        "Pancreas Cancer"
      ],
      "Start Date": "2016-12-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT02675829",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "ado-trastuzumab emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 140,
      "conditions": [
        "Bladder Cancer",
        "Solid Tumor Cancers",
        "Urinary Tract Cancers",
        "Lung Cancer"
      ],
      "Start Date": "2016-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT02658734",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine"
      ],
      "locations": [
        "India"
      ],
      "enrollment": 70,
      "conditions": [
        "HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer"
      ],
      "Start Date": "2016-11-01",
      "Max Phase": "4"
    },
    {
      "id": "NCT02616965",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Fox Chase Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Celgene Corporation"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Romidepsin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 16,
      "conditions": [
        "Cutaneous T-cell Lymphoma (CTCL)"
      ],
      "Start Date": "2017-02-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT02574455",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [],
      "interventions": [
        "Xeloda",
        "Vinorelbine",
        "Eribulin",
        "IMMU-132",
        "Sacituzumab govitecan",
        "Halaven",
        "Navelbine",
        "Gemcitabine",
        "Trodelvy\u00ae",
        "Gemzar",
        "Capecitabine"
      ],
      "locations": [
        "Canada",
        "Germany",
        "United Kingdom",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 529,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2017-11-07",
      "Max Phase": "3"
    },
    {
      "id": "NCT02420873",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "Lorvotuzumab Mertansine (IMGN901)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 9,
      "conditions": [
        "Leukemia"
      ],
      "Start Date": "2015-05-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT02390427",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Otto Metzger, MD"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "T-DM1",
        "Taselisib",
        "Paclitaxel",
        "GCD-0032",
        "Kadcyla",
        "Perjeta",
        "Trastuzumab",
        "Onxal",
        "Pertuzumab",
        "Herceptin",
        "Trastuzumab emtansine",
        "Taxol"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 68,
      "conditions": [
        "Recurrent Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2015-04-20",
      "Max Phase": "1"
    },
    {
      "id": "NCT02289833",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Kadcyla, T-DM1",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "Italy",
        "Switzerland",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "Spain",
        "United States"
      ],
      "enrollment": 49,
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2014-12-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT02254018",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Boehringer Ingelheim"
      ],
      "collaborators": [],
      "interventions": [
        "bivatuzumab mertansine"
      ],
      "locations": [],
      "enrollment": 31,
      "conditions": [
        "Head and Neck Neoplasms"
      ],
      "Start Date": "2002-09-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02254005",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Boehringer Ingelheim"
      ],
      "collaborators": [],
      "interventions": [
        "bivatuzumab mertansine"
      ],
      "locations": [],
      "enrollment": 24,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2002-10-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT02131064",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Herceptin\u00ae",
        "Kadcyla\u00ae, RO5304020",
        "Perjeta\u00ae, RO4368451",
        "Trastuzumab",
        "Carboplatin",
        "Trastuzumab Emtansine",
        "Pertuzumab",
        "Docetaxel"
      ],
      "locations": [
        "Canada",
        "Ukraine",
        "Germany",
        "Korea, Republic of",
        "Taiwan",
        "Spain",
        "Russian Federation",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 444,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2014-06-25",
      "Max Phase": "3"
    },
    {
      "id": "NCT01904903",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Medstar Health Research Institute"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Kadcyla",
        "Ado Trastuzumab Emtansine",
        "Trastuzumab",
        "Pertuzumab",
        "Herceptin",
        "Perjeta"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 31,
      "conditions": [
        "Left Ventricular Function Systolic Dysfunction",
        "HER2 Positive Breast Cancer"
      ],
      "Start Date": "2013-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04379596",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo"
      ],
      "interventions": [
        "Fluorouracil (5-FU)",
        "AZD2936",
        "Volrustomig",
        "MEDI5752",
        "Trastuzumab",
        "Trastuzumab deruxtecan",
        "Biological: Rilvegostomig",
        "Oxaliplatin",
        "Drug: Cisplatin",
        "DS-8201a",
        "Drug: Trastuzumab deruxtecan",
        "Drug: Fluorouracil (5-FU)",
        "Capecitabine",
        "Rilvegostomig",
        "Biological: Trastuzumab",
        "Biological: Volrustomig",
        "Biological: Durvalumab",
        "Biological: Pembrolizumab",
        "Pembrolizumab",
        "Durvalumab",
        "Cisplatin",
        "Drug: Capecitabine",
        "MEDI4736",
        "Drug: Oxaliplatin"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Netherlands",
        "China",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Germany",
        "Russian Federation",
        "Taiwan",
        "Spain",
        "Japan",
        "United States"
      ],
      "enrollment": 413,
      "conditions": [
        "Gastric Cancer"
      ],
      "Start Date": "2020-05-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT01772472",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "NSABP Foundation Inc",
        "German Breast Group"
      ],
      "interventions": [
        "trastuzumab emtansine",
        "trastuzumab"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "China",
        "Sweden",
        "Ireland",
        "Panama",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Belgium",
        "Israel",
        "Argentina",
        "Austria",
        "Taiwan",
        "United States",
        "Canada",
        "Guatemala",
        "Peru",
        "United Kingdom",
        "Colombia",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Turkey",
        "Spain",
        "Serbia",
        "South Africa"
      ],
      "enrollment": 1487,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2013-04-03",
      "Max Phase": "3"
    },
    {
      "id": "NCT01702571",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "RO5304020, T-DM1, Kadcyla",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "Mexico",
        "Indonesia",
        "China",
        "Sweden",
        "Iceland",
        "Denmark",
        "Ireland",
        "Panama",
        "Bulgaria",
        "Germany",
        "Greece",
        "France",
        "United Arab Emirates",
        "Italy",
        "Thailand",
        "Finland",
        "Dominican Republic",
        "Luxembourg",
        "Argentina",
        "Ecuador",
        "Slovenia",
        "Croatia",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "Norway",
        "Canada",
        "Guatemala",
        "Portugal",
        "Venezuela",
        "Peru",
        "Poland",
        "United Kingdom",
        "Brazil",
        "Hong Kong",
        "Slovakia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Estonia"
      ],
      "enrollment": 2185,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2012-11-27",
      "Max Phase": "3"
    },
    {
      "id": "NCT01513083",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "trastuzumab emtansine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 28,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2012-02-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT01419197",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Treatment of physician's choice",
        "T-DM1",
        "Kadcyla",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Sweden",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Czech Republic",
        "Italy",
        "Thailand",
        "Israel",
        "Hungary",
        "Norway",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Brazil",
        "Slovakia",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 602,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2011-09-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT06486441",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Paclitaxel",
        "GS-0132",
        "Sacituzumab govitecan-hziy",
        "Trodelvy\u2122",
        "Doxorubicin",
        "Adriamycin",
        "Taxol"
      ],
      "locations": [],
      "enrollment": 520,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2024-09-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT01196052",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Italy",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "Russian Federation",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 153,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2010-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01120184",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "pertuzumab",
        "trastuzumab emtansine",
        "pertuzumab-placebo",
        "paclitaxel",
        "docetaxel",
        "trastuzumab [Herceptin]"
      ],
      "locations": [
        "Mexico",
        "North Macedonia",
        "Czechia",
        "Bosnia and Herzegovina",
        "Sweden",
        "Denmark",
        "Panama",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "New Zealand",
        "United States",
        "Canada",
        "Guatemala",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Switzerland",
        "Malaysia",
        "Bahamas",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 1095,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2010-07-31",
      "Max Phase": "3"
    },
    {
      "id": "NCT03552471",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Ohio State University Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Clovis Oncology, Inc.",
        "ImmunoGen, Inc."
      ],
      "interventions": [
        "PK Study",
        "8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt",
        "M9346A-sulfo-SPDB-DM4",
        "Rucaparib Camsylate",
        "Mirvetuximab Soravtansine",
        "IMGN853",
        "Rucaparib Phosphate",
        "Pharmacokinetic Study",
        "Rubraca",
        "Laboratory Biomarker Analysis",
        "PHARMACOKINETIC",
        "C0-338"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "BRCA2 Gene Mutation",
        "BRCA1 Gene Mutation",
        "Recurrent Uterine Corpus Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Uterine Serous Carcinoma",
        "Recurrent Uterine Carcinosarcoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Platinum Resistant Ovarian Cancer",
        "Folate Receptor Alpha Positive"
      ],
      "Start Date": "2018-07-12",
      "Max Phase": "1"
    },
    {
      "id": "NCT00991562",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "ImmunoGen, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "BB-10901",
        "huN901-DM1",
        "IMGN901"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2009-12-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT00951665",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "pertuzumab [Perjeta]",
        "trastuzumab emtansine [Kadcyla]",
        "paclitaxel"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 107,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2009-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00943670",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "pertuzumab",
        "T-DM1",
        "Trastuzumab emtansine [Kadcyla]",
        "PERJETA\u2122",
        "trastuzumab-MCC-DM1"
      ],
      "locations": [],
      "enrollment": 51,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2009-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00934856",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1",
        "Pertuzumab",
        "Docetaxel",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "France",
        "United States"
      ],
      "enrollment": 98,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2009-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00882102",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Eisai Inc."
      ],
      "interventions": [
        "Dacogen\u00ae",
        "Decitabine",
        "Mylotarg\u00ae",
        "Gemtuzumab ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 43,
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myelogenous Leukemia"
      ],
      "Start Date": "2009-04-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00875979",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Roche Pharma AG"
      ],
      "interventions": [
        "T-DM1",
        "Trastuzumab emtansine [Kadcyla] 3.6 mg/kg",
        "trastuzumab-DM1",
        "Pertuzumab 420 mg",
        "Trastuzumab emtansine [Kadcyla] 3.0 mg/kg",
        "trastuzumab-MCC-DM1",
        "Perjeta"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 67,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2009-05-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03334617",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [],
      "interventions": [
        "Drug: AZD6738 (ceralasertib) 7 days monotherapy",
        "Drug: AZD9150",
        "Drug: Vistusertib",
        "AZD9150",
        "AZD6738",
        "Oleclumab",
        "Drug: cediranib",
        "Drug: AZD6738 (ceralasertib) (240 mg or 160 mg)",
        "trastuzumab deruxtecan",
        "Drug: Durvalumab",
        "cediranib",
        "AZD6738 (ceralasertib) 7 days monotherapy",
        "AZD6738 (ceralasertib)",
        "Olaparib",
        "Drug: AZD6738",
        "Drug: Oleclumab",
        "AZD6738 (ceralasertib) (240 mg or 160 mg)",
        "Vistusertib",
        "Drug: AZD6738 (ceralasertib)",
        "Durvalumab",
        "Drug: Olaparib",
        "Drug: trastuzumab deruxtecan"
      ],
      "locations": [
        "Canada",
        "Israel",
        "Austria",
        "Germany",
        "Korea, Republic of",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 531,
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2017-09-22",
      "Max Phase": "2"
    },
    {
      "id": "NCT00766116",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "University of California, San Diego"
      ],
      "collaborators": [
        "Pfizer",
        "Celgene Corporation"
      ],
      "interventions": [
        "Vidaz",
        "5-Azacitidine",
        "Mylotarg",
        "Gemtuzumab ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2005-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00679341",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "T-DM1",
        "Trastuzumab emtansine [Kadcyla]",
        "Herceptin",
        "trastuzumab-DM1",
        "Trastuzumab",
        "trastuzumab-MCC-DM1",
        "Docetaxel",
        "Taxotere"
      ],
      "locations": [],
      "enrollment": 137,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2008-09-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00679211",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine [Kadcyla]",
        "T-DM1",
        "Trastuzumab-MCC-DM1"
      ],
      "locations": [],
      "enrollment": 110,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2008-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00509769",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Trastuzumab emtansine [Kadcyla]",
        "T-DM1",
        "trastuzumab-DM1",
        "trastuzumab-MCC-DM1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 112,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2007-07-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03032107",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "T-DM1",
        "Keytruda",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 27,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2017-02-17",
      "Max Phase": "1"
    },
    {
      "id": "NCT02927769",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Nivolumab",
        "bendamustine",
        "Opdivo",
        "brentuximab vedotin",
        "BMS-936558"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Ireland",
        "Germany",
        "Poland",
        "United Kingdom",
        "Spain",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 72,
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": "2017-03-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT04873362",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Atezolizumab",
        "Tecentriq, RO5541267, MPDL3280A",
        "Trastuzumab",
        "Placebo",
        "Trastuzumab Emtansine",
        "Kadcyla, T-DM1, RO5304020",
        "Herceptin"
      ],
      "locations": [
        "Mexico",
        "Kenya",
        "Czechia",
        "Singapore",
        "China",
        "Denmark",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Thailand",
        "South Africa",
        "Dominican Republic",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "New Zealand",
        "United States",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium",
        "Vietnam",
        "Uganda"
      ],
      "enrollment": 1150,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2021-05-04",
      "Max Phase": "3"
    },
    {
      "id": "NCT04740918",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Atezolizumab",
        "Tecentriq, RO5541267, MPDL3280A",
        "Placebo",
        "Trastuzumab Emtansine",
        "Kadcyla, T-DM1, RO5304020"
      ],
      "locations": [
        "China",
        "Greece",
        "Russian Federation",
        "France",
        "Italy",
        "Finland",
        "Slovenia",
        "Croatia",
        "Norway",
        "United States",
        "Canada",
        "Portugal",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia"
      ],
      "enrollment": 96,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2021-06-07",
      "Max Phase": "3"
    },
    {
      "id": "NCT05673928",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Genentech, Inc."
      ],
      "interventions": [
        "T-DM1",
        "Trastuzumab-MCC-DM1",
        "Kadcyla",
        "ado-trastuzumab emtansine",
        "ONT-380",
        "ARRY-380",
        "Tucatinib",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 30,
      "conditions": [
        "Metastatic Solid Tumor",
        "Brain Metastases"
      ],
      "Start Date": "2023-05-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT02924883",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Atezolizumab",
        "Tecentriq, RO5541267, MPDL3280A",
        "Kadcyla\u00ae, T-DM1, RO5304020",
        "Placebo",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "United States"
      ],
      "enrollment": 202,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2016-09-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT05323955",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Carey Anders, M.D."
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Trastuzumab Emtansine (T-DM1)",
        "Pertuzumab",
        "Trastuzumab",
        "Tukysa",
        "Tucatinib",
        "Herceptin",
        "Perjeta"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 48,
      "conditions": [
        "Advanced Breast Cancer",
        "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast",
        "Brain Metastases"
      ],
      "Start Date": "2023-03-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT02751918",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Pegylated Liposomal Doxorubicin",
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Spain",
        "Belgium",
        "Moldova, Republic of",
        "United States"
      ],
      "enrollment": 65,
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "Start Date": "2016-06-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT05183035",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "LLS PedAL Initiative, LLC"
      ],
      "collaborators": [
        "EuPAL",
        "Roche-Genentech",
        "AbbVie",
        "Princess Maxima Center for Pediatric Oncology (European Sponsor)"
      ],
      "interventions": [
        "Azacitidine",
        "Fludarabine",
        "Gemtuzumab Ozogamicin",
        "Venetoclax",
        "Cytarabine"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Finland",
        "Spain",
        "Switzerland",
        "Israel",
        "France",
        "Portugal",
        "Sweden",
        "Denmark",
        "Austria",
        "Australia",
        "Belgium",
        "Netherlands",
        "Norway",
        "New Zealand",
        "United States"
      ],
      "enrollment": 98,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2022-10-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05048797",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Pembrolizumab",
        "Pemetrexed",
        "DS-8201a; T-DXd",
        "Carboplatin",
        "Cisplatin",
        "Trastuzumab Deruxtecan"
      ],
      "locations": [
        "Mexico",
        "China",
        "Denmark",
        "India",
        "Germany",
        "France",
        "Italy",
        "Austria",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Belgium"
      ],
      "enrollment": 450,
      "conditions": [
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      ],
      "Start Date": "2021-10-28",
      "Max Phase": "3"
    },
    {
      "id": "NCT04833114",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "GWT-TUD GmbH"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Polatuzumab Vedotin",
        "Ifosfamide",
        "Mabthera",
        "Carboplatin",
        "Etoposide"
      ],
      "locations": [
        "Spain",
        "United Kingdom",
        "Germany",
        "Austria"
      ],
      "enrollment": 334,
      "conditions": [
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Relapsed Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": "2021-04-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT04457596",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Alliance for Clinical Trials in Oncology"
      ],
      "collaborators": [
        "Seagen Inc.",
        "National Cancer Institute (NCI)"
      ],
      "interventions": [
        "Questionnaire Administration",
        "Quality-of-Life Assessment",
        "Trastuzumab Emtansine",
        "Tucatinib",
        "Placebo Administration"
      ],
      "locations": [
        "Canada",
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 1031,
      "conditions": [
        "Prognostic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIA Breast Cancer AJCC v8",
        "Synchronous Bilateral Breast Carcinoma",
        "Prognostic Stage IIA Breast Cancer AJCC v8",
        "Anatomic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Multifocal Breast Carcinoma",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "HER2 Positive Breast Carcinoma",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IA Breast Cancer AJCC v8",
        "Prognostic Stage IIB Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage IIB Breast Cancer AJCC v8"
      ],
      "Start Date": "2021-01-06",
      "Max Phase": "3"
    },
    {
      "id": "NCT01976169",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Texas Southwestern Medical Center"
      ],
      "collaborators": [
        "Pfizer",
        "University of Pennsylvania"
      ],
      "interventions": [
        "Palbociclib=PD-0332991",
        "PD-0332991 and T-DM1",
        "KADCYLA=T-DM1"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 29,
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "Start Date": "2014-01-24",
      "Max Phase": "1"
    },
    {
      "id": "NCT01562990",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "The Lymphoma Academic Research Organisation"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Rituximab, CMC544, Gemcitabine and Oxaliplatine"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "enrollment": 11,
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2012-12-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT06389006",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "RemeGen Co., Ltd."
      ],
      "collaborators": [],
      "interventions": [
        "JS001",
        "Disitamab Vedotin for Injection",
        "Toripalimab",
        "Epirubicin",
        "CTX",
        "Cyclophosphamide",
        "RC48"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 79,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2024-04-29",
      "Max Phase": "2"
    },
    {
      "id": "NCT06100705",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Yale University"
      ],
      "collaborators": [
        "Dendreon"
      ],
      "interventions": [
        "Provenge",
        "Testosterone Cypionate",
        "DEPO-Testosterone",
        "Sipuleucel-T"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 26,
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "Start Date": "2023-12-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT00781612",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Kadcyla; T-DM1",
        "Paclitaxel",
        "Atezolizumab",
        "Herceptin",
        "Tecentriq",
        "Trastuzumab",
        "Trastuzumab Emtansine",
        "Pertuzumab",
        "Docetaxel",
        "Perjeta"
      ],
      "locations": [
        "Mexico",
        "North Macedonia",
        "Singapore",
        "Czechia",
        "China",
        "Sweden",
        "Denmark",
        "Panama",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Thailand",
        "Israel",
        "Slovenia",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "New Zealand",
        "Norway",
        "United States",
        "Canada",
        "Guatemala",
        "Chile",
        "Portugal",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 720,
      "conditions": [
        "Neoplasm Metastasis"
      ],
      "Start Date": "2008-10-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT05382286",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Taxol\u00ae",
        "Paclitaxel",
        "IMMU-132",
        "Sacituzumab Govitecan-hziy",
        "GS-0132",
        "Gemcitabine",
        "Trodelvy\u2122",
        "Carboplatin",
        "Abraxane\u00ae",
        "Gemzar",
        "nab-Paclitaxel",
        "KEYTRUDA\u00ae"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Germany",
        "France",
        "Puerto Rico",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Malaysia",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 440,
      "conditions": [
        "PD-L1 Positive",
        "Triple Negative Breast Cancer"
      ],
      "Start Date": "2022-07-25",
      "Max Phase": "3"
    },
    {
      "id": "NCT02686346",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "The Lymphoma Academic Research Organisation"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "SGN35",
        "BV",
        "Brentuximab Vedotin",
        "Carboplatine",
        "Ifosfamide",
        "Etoposide"
      ],
      "locations": [
        "Belgium",
        "France"
      ],
      "enrollment": 53,
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": "2016-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT00037596",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Wyeth is now a wholly owned subsidiary of Pfizer"
      ],
      "collaborators": [],
      "interventions": [
        "cytarabine.",
        "Gemtuzumab Ozogamicin"
      ],
      "locations": [],
      "enrollment": null,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2000-08-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03869190",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas"
      ],
      "interventions": [
        "Niraparib",
        "Atezolizumab",
        "Gemcitabine",
        "Sacituzumab Govitecan",
        "Enfortumab Vedotin",
        "Magrolimab (Hu5F9-G4)",
        "Cisplatin",
        "Tiragolumab",
        "Tocilizumab"
      ],
      "locations": [
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Greece",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 645,
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma"
      ],
      "Start Date": "2019-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT02505269",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Adcetris",
        "Rubex \u00ae",
        "DTIC",
        "Brentuximab Vedotin",
        "Dacarbazine",
        "DIC",
        "DTIC-Dome\u00ae",
        "Imidazole Carboxamide",
        "Doxorubicin",
        "Adriamycin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 34,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2015-08-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT04704934",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "collaborators": [
        "AstraZeneca"
      ],
      "interventions": [
        "DS-8201a",
        "Paclitaxel",
        "ENHERTU\u00ae",
        "T-DXd",
        "CYRAMZA\u00ae",
        "Drug: Trastuzumab deruxtecan",
        "Drug: Ramucirumab",
        "Drug: Paclitaxel",
        "Trastuzumab deruxtecan",
        "Ramucirumab"
      ],
      "locations": [
        "Singapore",
        "China",
        "Ireland",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Israel",
        "Argentina",
        "Taiwan",
        "Hungary",
        "Chile",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Belgium"
      ],
      "enrollment": 490,
      "conditions": [
        "Gastric Cancer, Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "Start Date": "2021-05-21",
      "Max Phase": "3"
    },
    {
      "id": "NCT04274426",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AGO Research GmbH"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "Pegylated liposomal doxorubicin (PLD)",
        "Mirvetuximab Soravtansine",
        "Gemcitabine",
        "Carboplatin"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": 136,
      "conditions": [
        "Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma"
      ],
      "Start Date": "2021-10-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05922904",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "M.D. Anderson Cancer Center"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Seagen Inc."
      ],
      "interventions": [
        "Pembrolizumab",
        "Brentuximab vedotin",
        "SGN-35",
        "Adcetris",
        "Dacarbazine",
        "Rubex\u00ae",
        "DTIC-Dome\u00ae",
        "Adriamycin PFS\u00ae",
        "Adriamycin\u00ae",
        "Doxorubicin Hydrochloride",
        "Adriamycin RDF\u2122"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2023-12-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT03839446",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Robert Redner, MD"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "mitoxantrone + etoposide + gemtuzumab ozogamicin"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 16,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2019-02-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT05633667",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Gilead Sciences"
      ],
      "collaborators": [
        "Arcus Biosciences, Inc."
      ],
      "interventions": [
        "Pemetrexed",
        "Etrumadenant (ETRUMA)",
        "AB122",
        "GS-0132",
        "Sacituzumab govitecan-hziy (SG)",
        "GS-0122",
        "Zimberelimab (ZIM)",
        "Carboplatin",
        "GS-0154",
        "Nab-paclitaxel",
        "Nivolumab",
        "Paclitaxel",
        "IMMU-132",
        "GS-0928",
        "AB154",
        "Cisplatin",
        "Domvanalimab (DOM)",
        "Docetaxel",
        "AB928"
      ],
      "locations": [
        "Hong Kong",
        "Israel",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "United States"
      ],
      "enrollment": 397,
      "conditions": [
        "Resectable Non-Small-Cell Lung Cancer",
        "Advanced or Metastatic Non-Small-Cell Lung Cancer",
        "Lung Cancer"
      ],
      "Start Date": "2023-03-16",
      "Max Phase": "2"
    },
    {
      "id": "NCT05558124",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "collaborators": [
        "Jazz Pharmaceuticals"
      ],
      "interventions": [
        "Mylotarg",
        "Gemtuzumab Ozogamicin",
        "CPX-351",
        "daunorubicin-cytarabine",
        "Vyxeos"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2023-02-16",
      "Max Phase": "1"
    },
    {
      "id": "NCT04685616",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Takeda",
        "University of Miami",
        "Seagen Inc.",
        "Canadian Cancer Trials Group",
        "European Organisation for Research and Treatment of Cancer - EORTC",
        "Australasian Leukaemia and Lymphoma Group"
      ],
      "interventions": [
        "Brentuximab vedotin",
        "Bleomycin",
        "Filgrastim",
        "Dacarbazine",
        "Involved site radiotherapy",
        "G-CSF",
        "Haematopoietic growth factor",
        "Doxorubicin",
        "Pegfilgrastim",
        "Vinblastine"
      ],
      "locations": [
        "United Kingdom",
        "Spain",
        "Australia",
        "Belgium",
        "New Zealand",
        "United States"
      ],
      "enrollment": 1042,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2022-04-14",
      "Max Phase": "3"
    },
    {
      "id": "NCT02314481",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "T-DM1",
        "Atezolizumab",
        "Zelboraf",
        "Kadcyla",
        "Alectinib",
        "Vemurafenib",
        "MPDL3280A",
        "Alecensa",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": 50,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2017-05-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT03084939",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Lapatinib",
        "Capecitabine",
        "Kadcyla",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 351,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2017-04-24",
      "Max Phase": "3"
    },
    {
      "id": "NCT02979522",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Brentuximab vedotin",
        "Adcetris",
        "Dacarbazine",
        "Doxorubicin",
        "Adriamycin",
        "Vinblastine"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "Japan",
        "United States"
      ],
      "enrollment": 59,
      "conditions": [
        "Hodgkin Disease"
      ],
      "Start Date": "2017-09-06",
      "Max Phase": "2"
    },
    {
      "id": "NCT05016947",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "AbbVie"
      ],
      "interventions": [
        "Maxidex",
        "Inotuzumab Ozogamicin",
        "Diodex",
        "Besponsa",
        "Decadron",
        "Venetoclax",
        "Dexasone",
        "Hexadrol",
        "Venclexta",
        "Dexamethasone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 26,
      "conditions": [
        "B-Cell Lymphoma",
        "ALL",
        "B-cell Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2021-09-24",
      "Max Phase": "1"
    },
    {
      "id": "NCT04632992",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "MTIG7192A",
        "Atezolizumab",
        "GAVRETO\u2122",
        "RG6058",
        "RG6264",
        "Rozlytrek\u2122",
        "GDC-0068",
        "RO5304020",
        "RO7102122",
        "RG7853",
        "Alecensa\u00ae",
        "RO5541267",
        "RO7092284",
        "RG7440",
        "RG3502",
        "RG6396",
        "RO7499790",
        "RG6268",
        "Alectinib",
        "Tecentriq\u00ae",
        "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
        "Ipatasertib",
        "Tiragolumab",
        "Tucatinib",
        "RG7446",
        "Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously",
        "RO5424802",
        "GDC-0077",
        "Kadcyla\u00ae",
        "PHESGO\u2122",
        "Tukysa\u2122",
        "RG6114",
        "Inavolisib",
        "Investigator's Choice of Chemotherapy",
        "RO7113755",
        "Pralsetinib",
        "RO7198574",
        "Paclitaxel",
        "PH FDC SC",
        "Entrectinib",
        "RO5532961",
        "Trastuzumab Emtansine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 252,
      "conditions": [
        "Advanced Unresectable or Metastatic Solid Malignancy"
      ],
      "Start Date": "2021-01-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT04589845",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Belvarafenib",
        "GDC-0077",
        "GDC-6036",
        "Atezolizumab",
        "Idasanutlin",
        "Entrectinib",
        "Kadcyla",
        "Alectinib",
        "Inavolisib",
        "Tecentriq",
        "Pralsetinib",
        "Ipatasertib",
        "Camonsertib",
        "Gavreto (US)",
        "Rozlytrek",
        "Alecensa",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Singapore",
        "China",
        "Denmark",
        "Germany",
        "France",
        "Puerto Rico",
        "Italy",
        "Belgium",
        "Israel",
        "Taiwan",
        "Netherlands",
        "New Zealand",
        "United States",
        "Canada",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "South Africa"
      ],
      "enrollment": 920,
      "conditions": [
        "Solid Tumors"
      ],
      "Start Date": "2021-01-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT02292979",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Lymphoma Academic Research Organisation"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Bleomycin",
        "Brentuximab Vedotin",
        "Dacarbazine",
        "Doxorubicin",
        "Vinblastine"
      ],
      "locations": [
        "Denmark",
        "Croatia",
        "Belgium",
        "France",
        "Netherlands"
      ],
      "enrollment": 170,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2015-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04385290",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Technische Universit\u00e4t Dresden"
      ],
      "collaborators": [
        "Pfizer",
        "Novartis Pharmaceuticals"
      ],
      "interventions": [
        "Rydapt",
        "MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO",
        "Mylotarg",
        "MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO",
        "MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin",
        "MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO",
        "MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": 214,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2020-09-04",
      "Max Phase": "2"
    },
    {
      "id": "NCT01868451",
      "phases": [],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Stanford University",
        "University of Rochester",
        "City of Hope Medical Center"
      ],
      "interventions": [
        "consolidation volume RT (CVRT)",
        "Doxorubicin HCL",
        "Interim PET",
        "Dacarbazine",
        "Brentuximab vedotin (SGN-35)",
        "Vinblastine Sulfate",
        "Involved-Site Radiation Therapy (ISRT)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 118,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2013-05-01",
      "Max Phase": null
    },
    {
      "id": "NCT02257567",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Bendamustine",
        "DCDS4501A",
        "Polatuzumab vedotin (Lyophilized)",
        "Rituximab",
        "Rituxan; MabThera",
        "GA101; Gazyva; Gazyvaro",
        "Treanda; Ribomustin; Levact",
        "Polatuzumab vedotin (Liquid)",
        "DCDS4501S"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Australia",
        "Hungary",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 331,
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": "2014-10-15",
      "Max Phase": "2"
    },
    {
      "id": "NCT01534078",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Massachusetts General Hospital"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Beth Israel Deaconess Medical Center",
        "Dana-Farber Cancer Institute",
        "H. Lee Moffitt Cancer Center and Research Institute"
      ],
      "interventions": [
        "SGN35",
        "SGN-35",
        "Adcetris",
        "DTIC",
        "Brentuximab Vedotin",
        "Velban",
        "Doxorubicin",
        "Adriamycin, vinblastine, and dacarbazine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 34,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2012-03-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT01494662",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Dana-Farber Cancer Institute"
      ],
      "collaborators": [
        "Puma Biotechnology, Inc.",
        "Translational Breast Cancer Research Consortium"
      ],
      "interventions": [
        "Ado-Trastuzumab Emtansine",
        "Neratinib",
        "Xeloda",
        "T-DM1",
        "HKI-272",
        "Biopsy",
        "Surgical Resection",
        "Capecitabine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 140,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2012-02-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05404945",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Virginia"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC"
      ],
      "interventions": [
        "Pembrolizumab",
        "Brentuximab vedotin",
        "Dacarbazine",
        "Doxorubicin",
        "Adriamycin",
        "Vinblastine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 44,
      "conditions": [
        "Classical Hodgkin Lymphoma"
      ],
      "Start Date": "2022-07-26",
      "Max Phase": "2"
    },
    {
      "id": "NCT00829166",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Xeloda",
        "T-DM1",
        "Trastuzumab-MCC-DM1",
        "Tyverb",
        "RO5304020",
        "Lapatinib",
        "Tykerb",
        "Capecitabine",
        "Trastuzumab emtansine"
      ],
      "locations": [
        "Mexico",
        "Singapore",
        "Bosnia and Herzegovina",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Finland",
        "Slovenia",
        "Taiwan",
        "New Zealand",
        "United States",
        "Canada",
        "Portugal",
        "Philippines",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain"
      ],
      "enrollment": 991,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2009-02-01",
      "Max Phase": "3"
    },
    {
      "id": "NCT05113251",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca"
      ],
      "collaborators": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Onxol",
        "Adriamycin",
        "Rubex",
        "Paclitaxel",
        "T-DXd",
        "Enhertu",
        "Cytoxan",
        "Herzuma",
        "Trastuzumab",
        "Neosar",
        "cyclophosphamide",
        "Trastuzumab Deruxtecan",
        "Pertuzumab",
        "Herceptin",
        "Doxorubicin",
        "Perjeta",
        "Taxol"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Thailand",
        "China",
        "Philippines",
        "Germany",
        "Peru",
        "Poland",
        "Korea, Republic of",
        "Bulgaria",
        "India",
        "Spain",
        "Saudi Arabia",
        "Russian Federation",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "enrollment": 912,
      "conditions": [
        "Breast Cancer",
        "HER2-positive Early Breast Cancer",
        "Breast Neoplasms"
      ],
      "Start Date": "2021-10-25",
      "Max Phase": "3"
    },
    {
      "id": "NCT04341181",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Ulrik Lassen"
      ],
      "collaborators": [
        "Roche Pharma AG",
        "Pfizer",
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Atezolizumab",
        "Avelumab",
        "Erlotinib",
        "Tarceva",
        "Bavencio",
        "Kadcyla",
        "Alectinib",
        "Vemurafenib plus Cobimetinib (combination)",
        "Axitinib",
        "Vismodegib",
        "Trastuzumab emtansine",
        "Herceptin plus Perjeta (combination)",
        "Alecensa",
        "Niraparib",
        "Erivedge",
        "Inlyta",
        "Tecentriq",
        "Zejula",
        "Trastuzumab plus Pertuzumab (combination)",
        "Zelboraf plus Cotellic (combination)"
      ],
      "locations": [
        "Denmark"
      ],
      "enrollment": 300,
      "conditions": [
        "Neoplasms",
        "Neoplasia",
        "Cancer",
        "Tumors"
      ],
      "Start Date": "2020-08-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT03646123",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "vinblastine",
        "Adcetris",
        "SGN-35",
        "Opdivo",
        "brentuximab vedotin",
        "filgrastim",
        "pegfilgrastim",
        "dacarbazine",
        "doxorubicin",
        "nivolumab",
        "G-CSF"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Poland",
        "Spain",
        "Australia",
        "United States"
      ],
      "enrollment": 255,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2019-01-28",
      "Max Phase": "2"
    },
    {
      "id": "NCT03061812",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "collaborators": [],
      "interventions": [
        "Rovalpituzumab tesirine",
        "Rova-T",
        "Dexamethasone",
        "Topotecan"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Croatia",
        "Belarus",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Latvia",
        "Japan",
        "Romania",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Serbia",
        "Belgium"
      ],
      "enrollment": 444,
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "Start Date": "2017-04-11",
      "Max Phase": "3"
    },
    {
      "id": "NCT06377566",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Memorial Sloan Kettering Cancer Center"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Pembrolizumab",
        "Brentuximab vedotin",
        "Vinorelbine",
        "Dacarbazine",
        "Gemcitabine",
        "FDG-PET/CT scan",
        "Doxorubicin",
        "Vinblastine"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 71,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2024-04-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT04844866",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Miltenyi Biomedicine GmbH"
      ],
      "collaborators": [
        "ICON plc"
      ],
      "interventions": [
        "Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab",
        "R-GemOx or BR plus polatuzumab vedotin",
        "MB-CART2019.1"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Hungary",
        "Lithuania",
        "France",
        "Sweden",
        "Germany",
        "Poland",
        "Austria",
        "Belgium",
        "Spain",
        "Netherlands"
      ],
      "enrollment": 168,
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": "2021-08-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT03726879",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Chugai Pharmaceutical"
      ],
      "interventions": [
        "Paclitaxel",
        "Atezolizumab",
        "Kadcyla",
        "Cytoxan",
        "Perjeta",
        "Tecentriq",
        "Cyclophosphamide",
        "Trastuzumab",
        "Neosar",
        "Placebo",
        "Trastuzumab Emtansine",
        "Pertuzumab",
        "Herceptin",
        "Doxorubicin",
        "Adriamycin",
        "Taxol"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Czechia",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "Spain",
        "Russian Federation",
        "Taiwan",
        "Japan",
        "United States"
      ],
      "enrollment": 454,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2019-01-11",
      "Max Phase": "3"
    },
    {
      "id": "NCT01578499",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Bexarotene",
        "Brentuximab Vedotin",
        "SGN-35",
        "Methotrexate"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "Switzerland",
        "France",
        "Germany",
        "Poland",
        "United Kingdom",
        "Austria",
        "Australia",
        "Belgium",
        "Spain",
        "United States"
      ],
      "enrollment": 131,
      "conditions": [
        "Cutaneous T-Cell Lymphoma",
        "Mycosis Fungoides",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma"
      ],
      "Start Date": "2012-06-11",
      "Max Phase": "3"
    },
    {
      "id": "NCT05498220",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "UNC Lineberger Comprehensive Cancer Center"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Polatuzumab vedotin (PV)",
        "Dexamethasone",
        "GCSF",
        "Gemcitabine",
        "Cisplatin",
        "Rituximab",
        "Hyaluronidase"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 44,
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "Start Date": "2023-02-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT03274492",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Vincristine Placebo",
        "DCDS4501A; anti-CD79b-VC-MMAE",
        "Vincristine",
        "Cyclophosphamide",
        "Polatuzumab vedotin Placebo",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "Czechia",
        "China",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Austria",
        "Taiwan",
        "New Zealand",
        "United States",
        "Canada",
        "Ukraine",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 1000,
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2017-11-16",
      "Max Phase": "3"
    },
    {
      "id": "NCT02605915",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Atezolizumab",
        "RO5304020",
        "Cyclophosphamide",
        "Trastuzumab",
        "Tecentriq, RO5541267",
        "RO4368451",
        "Carboplatin",
        "Pertuzumab",
        "Docetaxel",
        "Doxorubicin",
        "Trastuzumab emtansine",
        "RO0452317"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 98,
      "conditions": [
        "Locally Advanced or Early Breast Cancer",
        "HER2-Positive Metastatic Breast Cancer",
        "HER2-Negative Metastatic Breast Cancer"
      ],
      "Start Date": "2015-12-31",
      "Max Phase": "1"
    },
    {
      "id": "NCT06047080",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Polatuzumab vedotin",
        "Cyclophosphamide",
        "Glofitamab",
        "Rituximab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "Mexico",
        "China",
        "Denmark",
        "Germany",
        "France",
        "Italy",
        "Argentina",
        "Taiwan",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 1130,
      "conditions": [
        "Large B-Cell Lymphoma"
      ],
      "Start Date": "2023-09-18",
      "Max Phase": "3"
    },
    {
      "id": "NCT01564784",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "cytarabine and mitoxantrone",
        "HIDAC (high dose cytarabine)",
        "inotuzumab ozogamicin",
        "FLAG (fludarabine, cytarabine and G-CSF)"
      ],
      "locations": [
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Germany",
        "France",
        "Italy",
        "Finland",
        "Argentina",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Korea, Republic of",
        "Spain",
        "Australia"
      ],
      "enrollment": 326,
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2012-08-02",
      "Max Phase": "3"
    },
    {
      "id": "NCT04790903",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "Venetoclax",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "Spain",
        "Italy",
        "France",
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Lymphoma, Large B-Cell, Diffuse"
      ],
      "Start Date": "2021-07-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT04594798",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Rochester"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Polatuzumab vedotin",
        "Cyclophosphamide",
        "Rituximab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 39,
      "conditions": [
        "DLBCL",
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2021-09-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT01966471",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Paclitaxel",
        "Herceptin",
        "Epirubicin",
        "Kadcyla",
        "Cyclophosphamide",
        "Trastuzumab",
        "5-Fluorouracil",
        "Trastuzumab Emtansine",
        "Pertuzumab",
        "Docetaxel",
        "Doxorubicin",
        "Perjeta"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "Bosnia and Herzegovina",
        "Sweden",
        "Panama",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "Thailand",
        "Israel",
        "Georgia",
        "El Salvador",
        "Hungary",
        "Taiwan",
        "Norway",
        "United States",
        "Canada",
        "Guatemala",
        "Chile",
        "Ukraine",
        "Philippines",
        "Peru",
        "Poland",
        "United Kingdom",
        "Colombia",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 1846,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2014-01-31",
      "Max Phase": "3"
    },
    {
      "id": "NCT05673785",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Takeda"
      ],
      "collaborators": [],
      "interventions": [
        "Cyclophosphamide",
        "Brentuximab Vedotin",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 52,
      "conditions": [
        "Lymphoma"
      ],
      "Start Date": "2023-02-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT05180097",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Canadian Cancer Trials Group"
      ],
      "collaborators": [
        "Merck Sharp & Dohme LLC",
        "Seagen Inc."
      ],
      "interventions": [
        "Pembrolizumab",
        "Brentuximab vedotin",
        "Gemcitabine",
        "Cisplatin",
        "Dexamethasone"
      ],
      "locations": [
        "Canada"
      ],
      "enrollment": 84,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2022-11-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT04679012",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Weill Medical College of Cornell University"
      ],
      "collaborators": [
        "Genentech, Inc."
      ],
      "interventions": [
        "Orasone",
        "Cyclophosphamide",
        "VP-16",
        "etopophos",
        "Cortan",
        "toposar",
        "Paracort",
        "Rituxan",
        "Hydroxydoxorubicin Hydrochloride",
        "cytoxan",
        "Polatuzumab Vedotin",
        "Prednisone",
        "chimeric anti-CD20 monoclonal antibody",
        "Polivy",
        "Deltasone",
        "Rituximab",
        "Hydroxydaunomycin",
        "VePesid",
        "Doxorubicin Hydrochloride",
        "Etoposide"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 20,
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Richter Syndrome"
      ],
      "Start Date": "2021-09-24",
      "Max Phase": "2"
    },
    {
      "id": "NCT04569032",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "collaborators": [],
      "interventions": [
        "prednisone",
        "brentuximab vedotin",
        "cyclophosphamide",
        "doxorubicin",
        "ADCETRIS"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "United Kingdom",
        "Spain",
        "France",
        "United States"
      ],
      "enrollment": 82,
      "conditions": [
        "Peripheral T-cell Lymphoma"
      ],
      "Start Date": "2020-11-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT01992653",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Genentech, Inc."
      ],
      "collaborators": [],
      "interventions": [
        "Obinutuzumab",
        "Prednisolone",
        "MabThera/Rituxan",
        "DCDS4501A",
        "Gazyva/Gazyvaro",
        "Cyclophosphamide",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "France",
        "United States"
      ],
      "enrollment": 85,
      "conditions": [
        "Lymphoma, Non Hodgkin"
      ],
      "Start Date": "2013-11-29",
      "Max Phase": "2"
    },
    {
      "id": "NCT02824042",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Bayer"
      ],
      "collaborators": [],
      "interventions": [
        "Itraconazole",
        "Anetumab ravtansine (BAY94-9343)"
      ],
      "locations": [
        "Spain",
        "Australia",
        "Belgium",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 63,
      "conditions": [
        "Medical Oncology"
      ],
      "Start Date": "2016-09-07",
      "Max Phase": "1"
    },
    {
      "id": "NCT02734771",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Patrick Reagan"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "Adasone",
        "Adcetris",
        "Orasone",
        "Cyclophosphamide",
        "Deltacortisone",
        "cAC10-vcMMAE",
        "Endoxan",
        "Myocet",
        "Prednisonum",
        "Rituxan",
        "Cycloblastin",
        "Revimmune",
        "Neosar",
        "Caelyx",
        "Prednisone",
        "SGN-35",
        "Doxil",
        "Procytox",
        "Mabthera",
        "Deltasone",
        "Rituximab",
        "Doxorubicin",
        "Adriamycin",
        "Lyophilizedcytoxan",
        "Brentuximab vedotin",
        "Cytoxan"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "Start Date": "2016-06-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT05955261",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "AbbVie"
      ],
      "interventions": [
        "IMI-30",
        "ABT-99",
        "Fludarabine Phosphate",
        "Cytosar-U\u00ae",
        "Idarubicin Hydrochloride",
        "Gemtuzumab Ozogamicin",
        "Venetoclax",
        "Venclextra",
        "VP-16",
        "Ara-C",
        "Xospata",
        "Neotalem",
        "Vepesid\u00ae",
        "Cytarabine",
        "Gilteritinib",
        "SH T 586",
        "Novantrone",
        "Mylosar",
        "Daunorubicin Hydrochloride",
        "Zavedos",
        "Azacitidine",
        "L-lyxo-Hexopyranoside",
        "Mitoxantrone Hydrochloride",
        "Mylotarg",
        "Vidaza",
        "Pralifan",
        "Etoposide",
        "FI-6339"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 70,
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "Start Date": "2023-07-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT03677141",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Vincristine",
        "Tocilizumab",
        "Cyclophosphamide",
        "Rituxumab",
        "Polatuzumab Vedotin",
        "Mosunetuzumab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "Spain",
        "Poland",
        "Korea, Republic of",
        "Austria",
        "France",
        "United States"
      ],
      "enrollment": 117,
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2019-03-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT03971409",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hope Rugo, MD"
      ],
      "collaborators": [
        "Gilead Sciences",
        "Translational Breast Cancer Research Consortium",
        "Array BioPharma",
        "Breast Cancer Research Foundation",
        "Pfizer",
        "Johns Hopkins University",
        "Hoosier Cancer Research Network"
      ],
      "interventions": [
        "Avelumab",
        "ARRY-162",
        "PF 05082566",
        "PF 5082566",
        "Trodelvy",
        "Bavencio",
        "MEK162",
        "Sacituzumab Govitecan-hziy",
        "MSB0010718C",
        "PF-05082566",
        "Sacituzumab Govitecan",
        "PF-04518600",
        "Caelyx",
        "Anti-OX40 Antibody PF-04518600",
        "PF-2566",
        "ARRY-438162",
        "MSB-0010718C",
        "Lipodox",
        "Utomilumab",
        "Liposomal Doxorubicin",
        "Binimetinib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 150,
      "conditions": [
        "Triple-Negative Breast Carcinoma",
        "Stage IV Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Recurrent Breast Carcinoma",
        "Stage IIIB Breast Cancer",
        "Invasive Breast Carcinoma",
        "Stage III Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Unresectable Breast Carcinoma"
      ],
      "Start Date": "2019-07-08",
      "Max Phase": "2"
    },
    {
      "id": "NCT01920932",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "Seagen Inc."
      ],
      "interventions": [
        "irradiation",
        "Cytoxan(R)",
        "Dimethyl Triazeno Imidazole Carboximide (DTIC)",
        "VP-16",
        "radiation therapy",
        "prednisone",
        "prednisolone",
        "etoposide",
        "doxorubicin",
        "Vepesid(R)",
        "Dacarbazine(R)",
        "SGN-35",
        "brentuximab vedotin",
        "quality of life assessment",
        "cyclophosphamide",
        "radiation",
        "Adcetris(R)",
        "Neupogen(R)",
        "radiotherapy",
        "filgrastim",
        "Adriamycin(R)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 77,
      "conditions": [
        "Stage III Childhood Hodgkin Lymphoma",
        "Stage IV Childhood Hodgkin Lymphoma",
        "Stage II Childhood Hodgkin Lymphoma"
      ],
      "Start Date": "2013-08-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT04914741",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Peter MacCallum Cancer Centre, Australia"
      ],
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Prednisolone",
        "Vincristine",
        "Polatuzumab vedotin",
        "Cyclophosphamide",
        "CD20-TCB",
        "Glofitamab",
        "RO7082859",
        "Rituximab",
        "Doxorubicin"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 80,
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma"
      ],
      "Start Date": "2021-06-29",
      "Max Phase": "2"
    },
    {
      "id": "NCT04884035",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Celgene"
      ],
      "collaborators": [],
      "interventions": [
        "BMS-986382",
        "Prednisolone",
        "Vincristine",
        "CC-220",
        "Polatuzumab vedotin",
        "Iberdomide",
        "BMS-986369",
        "CC-99282",
        "Cyclophosphamide",
        "Rituximab",
        "Doxorubicin",
        "Prednisone"
      ],
      "locations": [
        "Poland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Greece",
        "Taiwan",
        "United States"
      ],
      "enrollment": 174,
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2021-09-15",
      "Max Phase": "1"
    },
    {
      "id": "NCT03467373",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Rituximab (R)",
        "Gazyva",
        "Vincristine",
        "Rituxan",
        "Polatuzumab vedotin",
        "Oncovin",
        "Actemra",
        "Cyclophosphamide",
        "Glofitamab",
        "RO7082859",
        "Obinutuzumab (G)",
        "Doxorubicin",
        "Prednisone",
        "Tocilizumab"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "Denmark",
        "United Kingdom",
        "Spain",
        "Australia",
        "France",
        "United States"
      ],
      "enrollment": 172,
      "conditions": [
        "B-Cell Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2018-03-13",
      "Max Phase": "1"
    },
    {
      "id": "NCT03755804",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Teva Pharmaceuticals USA"
      ],
      "interventions": [
        "Adcetris",
        "irradiation",
        "Prednisolone",
        "Oncovin (R)",
        "Cyclophosphamide",
        "VP-16",
        "radiation therapy",
        "Filgrastim",
        "Neupogen (R)",
        "DACARBAZINE (R)",
        "TREANDA (R)",
        "Prednisone",
        "Vinblastine",
        "Blenoxane (R)",
        "Bleomycin",
        "DTIC",
        "Velban (R)",
        "Quality of Life Measurements (QOL)",
        "Radiotherapy",
        "Doxorubicin",
        "bendamustine",
        "Adriamycin (R)",
        "Cytoxan (R)",
        "Vincristine",
        "Brentuximab Vedotin",
        "Dimethyl Triazeno Imidazole Carboximide",
        "Etoposide",
        "Vepeside",
        "Quality of Life Measurements"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 250,
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "Start Date": "2018-12-12",
      "Max Phase": "2"
    },
    {
      "id": "NCT03424005",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "Seagen Inc.",
        "Gilead Sciences"
      ],
      "interventions": [
        "Fulvestrant",
        "SGN-LIV1A",
        "Atezolizumab",
        "Bevacizumab",
        "Inavolisib (6 mg)",
        "Sacituzumab Govitecan",
        "Inavolisib",
        "Chemotherapy (Gemcitabine + Carboplatin or Eribulin)",
        "GDC-0077, RO7113755",
        "Nab-Paclitaxel",
        "Ipatasertib",
        "Selicrelumab",
        "Capecitabine",
        "Trastuzumab Deruxtecan",
        "Ribociclib",
        "Inavolisib (9 mg)",
        "Tocilizumab",
        "Abemaciclib"
      ],
      "locations": [
        "Israel",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "France",
        "United States"
      ],
      "enrollment": 242,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2018-04-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT01679119",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University College, London"
      ],
      "collaborators": [
        "Pfizer",
        "Cancer Research UK"
      ],
      "interventions": [
        "Inotuzumab Ozogamicin",
        "Prednisolone",
        "Vincristine",
        "MabThera",
        "Gemcitabine",
        "Cyclophosphamide",
        "Rituximab"
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": 129,
      "conditions": [
        "Diffuse Large B Cell Lymphoma"
      ],
      "Start Date": "2013-10-01",
      "Max Phase": "2"
    },
    {
      "id": "NCT03991884",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Washington"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "22-Oxovincaleukoblastine",
        "Prednilonga",
        "Cyclophosphamide",
        "VP-16",
        "Prednicort",
        "Paracort",
        "23214-92-8",
        "Genoxal",
        "Cycloblastin",
        "Cyclophosphamid monohydrate",
        "VP 16-213",
        "LEUROCRISTINE",
        "Adriablastin",
        "Prednisone",
        "SK-Prednisone",
        "2-Dehydrocortisone",
        "Prednitone",
        "Hydroxydaunomycin",
        "Rayos",
        "Predniment",
        "Cyclophosphan",
        "Besponsa",
        "Lastet",
        "Adasone",
        "Predicorten",
        "Hydroxyldaunorubicin",
        "Predicor",
        "Prednisonum",
        "Syklofosfamid",
        "CMC-544",
        "Dacortin",
        "Vincrystine",
        "Prednisone Intensol",
        "Clafen",
        "Carloxan",
        "Doxorubicin",
        "VP16",
        "Cyclophospham",
        "Hydroxyl Daunorubicin",
        "Cytoxan",
        "Etoposide",
        "Ciclofosfamide",
        "Ofisolona",
        "VCR",
        "Orasone",
        "Decortisyl",
        "CP monohydrate",
        "Cyclostin",
        "Toposar",
        "Servisone",
        "635715-01-4",
        "VP 16",
        "Ledoxina",
        "Cycloblastine",
        "Metacortandracin",
        "EPEG",
        "Cicloxal",
        "Decorton",
        "Vepesid",
        "Fosfaseron",
        "Vincristine",
        "Demethyl Epipodophyllotoxin Ethylidine Glucoside",
        "141540",
        "CTX",
        "Delta-Dome",
        "Genuxal",
        "Delta 1-Cortisone",
        "WAY-207294",
        "DeCortin",
        "Cyclophosphamidum",
        "Way 207294",
        "VP-16-213",
        "Revimmune",
        "Neosar",
        "Prednidib",
        "33419-42-0",
        "Cortancyl",
        "Ciclofosfamida",
        "Claphene",
        "14-Hydroxydaunomycin",
        "Cyclophosphane",
        "Mitoxan",
        "Inotuzumab Ozogamicin",
        "Cyclostine",
        "Promifen",
        "WR- 138719"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 24,
      "conditions": [
        "Recurrent B Lymphoblastic Lymphoma",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Refractory B Lymphoblastic Lymphoma",
        "Refractory B Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2019-09-24",
      "Max Phase": "1"
    },
    {
      "id": "NCT02243436",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Grupo Espa\u00f1ol de Linfomas y Transplante Aut\u00f3logo de M\u00e9dula \u00d3sea"
      ],
      "collaborators": [
        "Millennium Pharmaceuticals, Inc."
      ],
      "interventions": [
        "Brentuximab Vedotin",
        "Ara C",
        "Methylprednisolone",
        "Soludomerin",
        "Cisplatin",
        "Cytarabine",
        "Etoposide",
        "ADCETRIS"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 67,
      "conditions": [
        "CLASSICAL HODGKIN LYMPHOMA"
      ],
      "Start Date": "2014-11-11",
      "Max Phase": "2"
    },
    {
      "id": "NCT05283720",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Genmab"
      ],
      "collaborators": [
        "AbbVie"
      ],
      "interventions": [
        "Ibrutinib",
        "GDC-0199",
        "Epcoritamab",
        "Imbruvica",
        "ABBV-GMAB-3013;",
        "Venclexta;",
        "CC-99282",
        "Cyclophosphamide",
        "Venetoclax",
        "ABT-199",
        "Polatuzumab Vedotin",
        "Rituximab",
        "Doxorubicin Hydrochloride [HCl]",
        "Prednisone",
        "Lenalidomide"
      ],
      "locations": [
        "Czechia",
        "Israel",
        "Hungary",
        "Japan",
        "Germany",
        "Denmark",
        "Korea, Republic of",
        "Spain",
        "Taiwan",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 394,
      "conditions": [
        "Non-Hodgkin Lymphoma"
      ],
      "Start Date": "2022-06-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT04486352",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Alliance Foundation Trials, LLC."
      ],
      "collaborators": [
        "Genentech, Inc.",
        "Pfizer",
        "Eli Lilly and Company",
        "Foundation Medicine"
      ],
      "interventions": [
        "GDC-9545",
        "L01XX60",
        "GDC-0068",
        "Letrozole",
        "L01XC32",
        "Atezolizumab - 28 Day Cycle",
        "T-DM1",
        "Avastin",
        "RG7440",
        "Kadcyla",
        "Femara",
        "Ipatasertib",
        "Tiragolumab",
        "Trastuzumab emtansine",
        "Talzenna",
        "Giredestrant",
        "GDC-0077",
        "Bevacizumab",
        "Atezolizumab - 21 Day Cycle",
        "Inavolisib",
        "Verzenio",
        "L01XC07",
        "Tecentriq",
        "Talazoparib",
        "Abemaciclib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 148,
      "conditions": [
        "Endometrial Cancer"
      ],
      "Start Date": "2021-10-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT01055496",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Pfizer"
      ],
      "collaborators": [
        "UCB Pharma"
      ],
      "interventions": [
        "inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone",
        "inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone",
        "CMC-544"
      ],
      "locations": [
        "Canada",
        "Hong Kong",
        "Singapore",
        "Korea, Republic of",
        "United Kingdom",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 103,
      "conditions": [
        "Lymphoma, B-Cell"
      ],
      "Start Date": "2010-03-01",
      "Max Phase": "1"
    },
    {
      "id": "NCT04307576",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Mats Heyman"
      ],
      "collaborators": [
        "Karolinska Institutet",
        "Belgium Health Care Knowledge Centre",
        "The Swedish Childhood Cancer Foundation",
        "Amgen",
        "German Society for Pediatric Oncology and Hematology GPOH gGmbH",
        "The Swedish Research Council",
        "NordForsk",
        "Grupo Portugu\u00eas De Leucemias Pedi\u00e1tricas",
        "Pfizer",
        "Clinical Trial Center North (CTC North GmbH & Co. KG)",
        "Funda\u00e7\u00e3o Rui Os\u00f3rio de Castro",
        "Cancer Research UK",
        "Direction G\u00e9n\u00e9rale de l'Offre de Soins",
        "Acreditar - Associa\u00e7\u00e3o de Pais e Amigos das Crian\u00e7as com Cancro",
        "Aamu Pediatric Cancer Foundation",
        "Assistance Publique - H\u00f4pitaux de Paris",
        "Servier",
        "Nova Laboratories Limited",
        "Danish Cancer Society",
        "The Novo Nordic Foundation",
        "Danish Child Cancer Foundation"
      ],
      "interventions": [
        "Omitted Doxorubicin",
        "Blincyto",
        "6-tioguanine+Standard Maintenance Therapy",
        "Omitted Vincristine+Dexamethasone pulses",
        "Imatinib",
        "Blinatumomab",
        "Inotuzumab Ozogamicin+Standard Maintenance Therapy",
        "Besponsa+Maintenance Therapy"
      ],
      "locations": [
        "Finland",
        "Lithuania",
        "Estonia",
        "Portugal",
        "Sweden",
        "Ireland",
        "Denmark",
        "Iceland",
        "United Kingdom",
        "Germany",
        "Belgium",
        "France",
        "Netherlands",
        "Norway"
      ],
      "enrollment": 6430,
      "conditions": [
        "Leukemia, Acute Lymphoblastic"
      ],
      "Start Date": "2020-07-13",
      "Max Phase": "3"
    },
    {
      "id": "NCT04931342",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [
        "European Network of Gynaecological Oncological Trial Groups (ENGOT)",
        "GOG Foundation"
      ],
      "interventions": [
        "Atezolizumab",
        "RO5304020",
        "Cyclophosphamide",
        "Palbociclib",
        "RO5514041",
        "Letrozole",
        "Cobimetinib",
        "RO4876646, Avastin",
        "Ipatasertib",
        "Giredestrant",
        "Bevacizumab",
        "Trastuzumab Emtansine",
        "Olaparib",
        "Inavolisib",
        "Paclitaxel",
        "RO5541267, Tecentriq",
        "RO5532961",
        "Luteinizing Hormone-Releasing Hormone (LHRH) Agonists",
        "Abemaciclib"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Czechia",
        "Switzerland",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Australia",
        "Russian Federation",
        "France",
        "United States"
      ],
      "enrollment": 176,
      "conditions": [
        "Ovarian Cancer"
      ],
      "Start Date": "2021-10-07",
      "Max Phase": "2"
    },
    {
      "id": "NCT03962465",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University of Virginia"
      ],
      "collaborators": [
        "University of Wisconsin, Madison",
        "Pfizer",
        "Vanderbilt University",
        "Virginia Commonwealth University"
      ],
      "interventions": [
        "rubidomycin",
        "Cytosar-U",
        "Amethopterin",
        "Prednisone Pill",
        "Vincasar",
        "Ara-C",
        "Trexall",
        "Pegaspargase",
        "Cytarabine",
        "Otrexup",
        "Oncovin",
        "Leurocristine",
        "Daunorubicin",
        "Rheumatrex",
        "Deltasone",
        "daunomycin",
        "Oncospar",
        "Methotrexate",
        "Inotuzumab ozogamicin",
        "Cerubidine",
        "Vincristine",
        "Rasuvo",
        "Besponsa",
        "MTX"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 36,
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2022-07-22",
      "Max Phase": "1"
    },
    {
      "id": "NCT03337698",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Hoffmann-La Roche"
      ],
      "collaborators": [],
      "interventions": [
        "Pemetrexed",
        "Atezolizumab",
        "Cobimetinib",
        "Linagliptin",
        "XL092",
        "Gemcitabine",
        "Sacituzumab Govitecan",
        "Ipatasertib",
        "Carboplatin",
        "Tiragolumab",
        "Camonsertib",
        "Evolocumab",
        "Bevacizumab",
        "CPI-444",
        "RO6958688",
        "Radiation",
        "Zanzalintinib",
        "Docetaxel",
        "Tocilizumab"
      ],
      "locations": [
        "Israel",
        "Korea, Republic of",
        "United Kingdom",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 675,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "Start Date": "2018-01-02",
      "Max Phase": "2"
    },
    {
      "id": "NCT03913559",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "St. Jude Children's Research Hospital"
      ],
      "collaborators": [
        "Pfizer"
      ],
      "interventions": [
        "Hydrocortisone",
        "Acetaminophen",
        "CMC-544",
        "Methylprednisolone",
        "Inotuzumab ozogamicin",
        "Cortisol",
        "Besponsa",
        "Diphenhydramine",
        "Trexall\u00ae",
        "Benadryl",
        "Tylenol",
        "Solu-Medrol",
        "Cytarabine",
        "Ara-C",
        "Methotrexate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 32,
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "Start Date": "2019-05-14",
      "Max Phase": "2"
    },
    {
      "id": "CTIS2023-508832-68-00",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: HuMax-TF-ADC,Product Code: PRD952264,Pharmaceutical Form: SOLUTION FOR INFUSION,Other descriptive name: ,Strength: Tisotumab Vedotin 10mg,Product Code: SCP10337134,Pharmaceutical Form: ,Other descriptive name: ,Product Code: SCP6094344,Pharmaceutical Form: ,Other descriptive name: ,Product Code: SCP29096188,Pharmaceutical Form: ,Other descriptive name:"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Ireland",
        "Spain",
        "Belgium",
        "Netherlands"
      ],
      "enrollment": 143,
      "conditions": [
        "Recurrent or stage IVB cervical cancer  MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "MedDRA version: 21.1Level: PTClassification code: 10008342Term: Cervix carcinomaSystem Organ Class: 100000004864",
        "Therapeutic area: Diseases [C] - Neoplasms [C04]"
      ],
      "Start Date": "2024-02-26",
      "Max Phase": "3"
    },
    {
      "id": "CTRI/2024/01/061671",
      "phases": [
        "Phase 4"
      ],
      "sponsor": [
        "ESIC Dental College"
      ],
      "interventions": [
        "Intervention1: Local Application of Ozone oil ( ADC INCLUSIVE DENT OZONE INDIA, OZONOINDS) at tooth extraction site.: Normal tooth extraction, ozone oil is locally applied at extraction site for 5 min and then mouth is rinsed. then patient to apply ozone oil 3 times a day locally at extraction site for 3 days. Control Intervention1: Local application of Glycerin at tooth extraction site as a placebo.: Normal tooth extraction, Glycerin is locally applied at extraction site for 5 min and then mouth is rinsed. then patient to apply glycerin 3 times a day locally at extraction site for 3 days."
      ],
      "locations": [
        "India"
      ],
      "enrollment": 82,
      "conditions": [
        "Health Condition 1: K069- Disorder of gingiva and edentulousalveolar ridge, unspecified"
      ],
      "Start Date": "2024-01-19",
      "Max Phase": "4"
    },
    {
      "id": "JPRN-jRCT2031230569",
      "phases": [],
      "sponsor": [
        "Hibi Kazushige"
      ],
      "interventions": [
        "Drug: AZD0901 Antibody-drug conjugate/Biologic Other Name: CMG901"
      ],
      "locations": [
        "Canada",
        "Singapore",
        "United States of America",
        "Malaysia",
        "Georgia",
        "Republic of Moldova",
        "Poland",
        "United Kingdom",
        "Republic of Korea",
        "Australia",
        "Taiwan",
        "Spain",
        "Japan"
      ],
      "enrollment": 186,
      "conditions": [
        "Gastric cancer, Gastroesophageal junction cancer"
      ],
      "Start Date": "2024-01-16",
      "Max Phase": null
    },
    {
      "id": "NL-OMON56595",
      "phases": [],
      "sponsor": [
        "Amsterdam UMC"
      ],
      "interventions": [
        "Supramarginal resection will be guided by ADC/FET. To make sure that the  standard treatment is always guaranteed, T1c MRI abnormalities will be included  in the surgical target."
      ],
      "locations": [
        "Netherlands"
      ],
      "enrollment": 30,
      "conditions": [
        "10009720",
        "10029211",
        "brain tumor  glioblastoma"
      ],
      "Start Date": "2023-12-22",
      "Max Phase": null
    },
    {
      "id": "NCT06178601",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shanxi Province Cancer Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: AK104"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 36,
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": "2023-12-12",
      "Max Phase": "2"
    },
    {
      "id": "ChiCTR2300077064",
      "phases": [],
      "sponsor": [
        "Hu'nan Cancer Hospital"
      ],
      "interventions": [
        "",
        "Anatomic imaging group (control group):The standard radiotherapy dose of 70.0Gy was given to the target volume PGTV, with a fractional dose of 2.0Gy/F.",
        "DWI guided DP-RT group (DWI group):The target volume GTV-DWI is defined as the area <ADC mean within the GTV. Radiation dose to GTV-DWI is escalated to 77Gy, and the fractional dose is escalated to 2.2 Gy/F."
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "head and neck squamous cell carcinoma"
      ],
      "Start Date": "2023-10-27",
      "Max Phase": null
    },
    {
      "id": "NCT06121557",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"
      ],
      "interventions": [
        "Procedure: Surgery for harvesting tumor-draining lymph nodes",
        "Biological: Interleukin-2",
        "Biological: Camrelizumab",
        "Drug: Cyclophosphamide",
        "Drug: Fludarabine",
        "Drug: Chemotherapeutic drug, ADC or PARP inhibitor",
        "Biological: Tumor-draining lymph node-derived lymphocyte (LNL)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 24,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2023-10-26",
      "Max Phase": "1"
    },
    {
      "id": "NCT06112041",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Second Affiliated Hospital of Soochow University"
      ],
      "interventions": [
        "Drug: ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 29,
      "conditions": [
        "Solid Tumor",
        "Carcinoma"
      ],
      "Start Date": "2023-10-23",
      "Max Phase": "2"
    },
    {
      "id": "NCT06074484",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: AK104"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 36,
      "conditions": [
        "Muscle Invasive Bladder Carcinoma"
      ],
      "Start Date": "2023-08-22",
      "Max Phase": "2"
    },
    {
      "id": "PER-062-22",
      "phases": [],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Participants in the Dato-DXd in combination with durvalumab and carboplatin group will receive Dato-DXd 6.0 mg/kg plus durvalumab 1120 mg plus carboplatin AUC 5 mg/mL/minute as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with Dato-DXd 6.0 mg/kg plus durvalumab 1120 mg as i.v. infusions Q3W on Day 1 of every subsequent cycle. Dato-DXd must be administered prior to durvalumab at each cycle. Carboplatin must be administered after durvalumab at each of the first 4 cycles.  -                      Participants in the histology-specific therapy group will receive either: ? Regimen 1 (participants with non-squamous NSCLC): Pembrolizumab 200 mg plus pemetrexed 500 mg/m2 plus platinum chemotherapy (carboplatin AUC 5 mg/mL/minute or cisplatin75 mg/m2) as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with pembrolizumab 200 mg (with or without pemetrexed 500 mg/m2) as i.v. infusions Q3W on Day 1 of every subsequent cycle",
        " or ? Regimen 2 (participants with squamous NSCLC): Pembrolizumab 200 mg plus paclitaxel 200 mg/m2 plus carboplatin (AUC 5 or 6 mg/mL/minute) as i.v. infusions Q3W on Day 1 of the first 4 cycles, followed by maintenance therapy with pembrolizumab 200 mg monotherapy as an i.v. infusion Q3W on Day 1 of every subsequent cycle. For both regimens in the control arm, pembrolizumab must be administered first and platinum chemotherapy (carboplatin or cisplatin) last. Paclitaxel or pemetrexed must be administered after pembrolizumab, and carboplatin or cisplatin must be administered after paclitaxel or pemetrexed."
      ],
      "locations": [
        "Mexico",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "India",
        "Germany",
        "Greece",
        "France",
        "Italy",
        "Austria",
        "Taiwan",
        "United States",
        "Canada",
        "United Kindgdom",
        "Korea South",
        "Peru",
        "Poland",
        "Japan",
        "Brazil",
        "Hungaria",
        "Turkey",
        "Spain",
        "Vietnam"
      ],
      "enrollment": 1000,
      "conditions": [
        "C349 Bronchus or lung, unspecified  Bronchus or lung, unspecified",
        "C349"
      ],
      "Start Date": "2023-08-08",
      "Max Phase": null
    },
    {
      "id": "NCT05955209",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Peking University Cancer Hospital & Institute"
      ],
      "interventions": [
        "Drug: Disitamab Vedotin(RC48-ADC)"
      ],
      "locations": [
        ""
      ],
      "enrollment": 40,
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "Start Date": "2023-07-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05917158",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jinling Hospital, China"
      ],
      "interventions": [
        "Drug: RC48-ADC and JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 30,
      "conditions": [
        "Upper Tract Urothelial Carcinoma",
        "Carcinoma",
        "UTUC"
      ],
      "Start Date": "2023-06-15",
      "Max Phase": "2"
    },
    {
      "id": "ChiCTR2300071941",
      "phases": [],
      "sponsor": [
        "General Hospital of Northern Theater Command"
      ],
      "interventions": [
        "",
        "Gold Standard:Postoperative pathological results or stereotactic intracranial electroencephalogram (SEEG) results ",
        "Index test:3D-T1WI sequence: gray matter volume (GMV), gray matter concentration (GMC), cortical thickness  DTI sequence: fractional anisotropy (FA), mean diffusivity (MD), apparent diffusion coefficient (ADC)  BOLD sequence: amplitude of low-frequency fluctuation (ALFF), ratio amplitude of low-frequency fluctuation (fALFF)  PET image:Standardized uptake value ratio ( SUVr)  "
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "Drug-refractory epilepsy"
      ],
      "Start Date": "2023-05-30",
      "Max Phase": null
    },
    {
      "id": "NCT05785325",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Second Affiliated Hospital, School of Medicine, Zhejiang University"
      ],
      "interventions": [
        "Drug: RC48-ADC plus Bevacizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 30,
      "conditions": [
        "Colorectal Cancer"
      ],
      "Start Date": "2023-03-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05824325",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: SHR-A1811",
        "Drug: TROP2 ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 56,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2023-05-03",
      "Max Phase": "2"
    },
    {
      "id": "NCT05749588",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: D2: TROP2 ADC with BP102",
        "Drug: B1: TROP2 ADC",
        "Drug: C2: SHR-A1811 with BP102",
        "Drug: B2: TROP2 ADC with Camrelizumab",
        "Drug: H1: TROP2 ADC",
        "Drug: E1: SHR-A1811",
        "Drug: A1: SHR-A1811",
        "Drug: F1: TROP2 ADC",
        "Drug: A2: SHR-A1811 with Camrelizumab",
        "Drug: C1: SHR-A1811",
        "Drug: G1: SHR-A1811",
        "Drug: D1: TROP2 ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 120,
      "conditions": [
        "Triple-negative Breast Cancer"
      ],
      "Start Date": "2023-02-19",
      "Max Phase": "2"
    },
    {
      "id": "RBR-23dgvk8",
      "phases": [],
      "sponsor": [
        "Escuela de Osteopatia de Madri - Brasil Ltda"
      ],
      "interventions": [
        "It is a two-arm, double-blind, randomized controlled clinical trial. The selected patients will be referred by the collaborating neurologists to perform the Nuclear Magnetic Resonance (MRI) with diffusion at Centro Hospitalar Unimed Joinville (imaging department). After performing MRI with apparent diffusion coefficient (ADC) and diffusion-weighted imaging (DWI) and undergoing rehabilitation in a clinic chosen by the volunteers, all will be submitted to assessments of Basic Automatic Reactions (RAB), Functional Independence Measure (MIF), Dynamic Balance Test (Timed Up and Go  TUGt), Fugl-Meyer Scale (EFM), Barthel Index (IB) and Quality of Life Questionnaire (SF-36). For the calculated sample size (n=16), the blinding of the research will be done by the evaluation and intervention, in which researcher 1 will carry out the evaluation and researcher 2 will apply the intervention. Double blinding will be performed using the Randomizer program (www.random.org) and allocated to an experimental group (EG) and a control group (CG). The EG (n=8) will be treated with Osteopathic Manipulative Techniques. The control group (GP) (n=8) will not be treated with Osteopathic Manipulative Techniques. The EG will be undergoing treatment with the OMT proposed by the researchers in 12 (twelve) osteopathic physiotherapeutic consultations, distributed in 1 (one) weekly consultation, totaling 12 (twelve) weeks and with an estimated duration of 60 (sixty) minutes per Query. You will be interviewed via telephone weekly to complete the Barthel functional scale, sleep guidelines and ensure that they are undergoing neurofunctional rehabilitation. The CG will be interviewed weekly by telephone to complete the Barthel functional scale, sleep guidelines and ensure that they are undergoing neurofunc",
        "E02.190.599.280"
      ],
      "locations": [
        "Brazil"
      ],
      "enrollment": null,
      "conditions": [
        "C23.550.470.544",
        "Ischemic Stroke"
      ],
      "Start Date": "2023-01-23",
      "Max Phase": null
    },
    {
      "id": "EUCTR2022-002680-30-DE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Datopotamab Deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN:  Datopotamab Deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Trade Name: Pembrolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Pembrolizumab CAS Number: 1374853-91-4  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "China",
        "Sweden",
        "Argentina",
        "Denmark",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "Spain",
        "Greece",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 1075,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Stage I-III triple-negative breast cancer with residual invasive disease after neoadjuvant therapy.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2022-10-11",
      "Max Phase": "3"
    },
    {
      "id": "NCT05601401",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Peking Union Medical College Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 10,
      "conditions": [
        "Salivary Gland Tumors"
      ],
      "Start Date": "2022-10-17",
      "Max Phase": "2"
    },
    {
      "id": "NCT05594095",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: Dalpiciclib",
        "Drug: Everolimus",
        "Drug: Aromatase Inhibitors or Fulvestrant",
        "Drug: SHR-A1811",
        "Drug: Goserelin",
        "Drug: TPC",
        "Drug: Fluzoparib",
        "Drug: AKT inhibitor",
        "Drug: TROP2 ADC",
        "Drug: Carrelizumab",
        "Drug: Famitinib",
        "Drug: RTK Inhibitor",
        "Drug: PIK3CA inhibitor"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 140,
      "conditions": [
        "Advanced Breast Cancer",
        "Breast Neoplasm",
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "Hormone Receptor Positive Tumor"
      ],
      "Start Date": "2022-10-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT05578287",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Sun Yat-sen University"
      ],
      "interventions": [
        "Drug: Anti-HER2 ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 29,
      "conditions": [
        "Colorectal Cancer"
      ],
      "Start Date": "2022-08-10",
      "Max Phase": "2"
    },
    {
      "id": "NCT05571618",
      "phases": [],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 100,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2022-05-10",
      "Max Phase": null
    },
    {
      "id": "NCT05582499",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Fudan University"
      ],
      "interventions": [
        "Drug: Dalpiciclib",
        "Drug: Letrozole",
        "Drug: Nab paclitaxel",
        "Drug: HER2 ADC",
        "Drug: Carboplatin",
        "Drug: SHR-A1811",
        "Drug: Goserelin",
        "Drug: Fluzoparib",
        "Drug: SHR-1316",
        "Drug: Trastuzumab",
        "Drug: Epirubicin",
        "Drug: Cyclophosphamide",
        "Drug: Pyrotinib",
        "Drug: Pertuzumab",
        "Drug: Trophoblast cell-surface antigen 2 (TROP2) ADC",
        "Drug: Camrelizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 716,
      "conditions": [
        "Hormone Receptor Positive Tumor",
        "Hormone Receptor Negative Tumor",
        "Triple-Negative Breast Cancer (TNBC)",
        "Locally Advanced Breast Cancer",
        "Early-stage Breast Cancer",
        "Breast Neoplasm",
        "HER2-positive Breast Cancer",
        "Breast Cancer",
        "Breast Tumors",
        "HER2-negative Breast Cancer"
      ],
      "Start Date": "2022-09-25",
      "Max Phase": "2"
    },
    {
      "id": "ChiCTR2200063088",
      "phases": [],
      "sponsor": [
        "Jinshazhou Hospital, Guangzhou University of Chinese Medicine"
      ],
      "interventions": [
        "",
        "Interest&#32",
        "Maximum&#32",
        "machine&#32",
        "in&#32",
        "used&#32",
        "with&#32",
        "patients&#32",
        "ADC&#32",
        "Index test:All&#32",
        "coeffici",
        "examined&#32",
        "for&#32",
        "standard&#32",
        "to&#32",
        "PET-MR&#32",
        "True&#32",
        "prostate&#32",
        "Regions&#32",
        "Siemens&#32",
        "diffusion&#32",
        "minimum&#32",
        "lesions&#32",
        "apparent&#32",
        "by&#32",
        "Germany.&#32",
        "D&#32",
        "Gold Standard:All patients met the relevant diagnostic criteria for PC in the European Society of Urogenital Radiology. All patients were diagnosed as PC by pathological puncture, and the tumor was visible and clearly displayed.",
        "was&#32",
        "workstation&#32",
        "maps,&#32",
        "values&#32",
        "(SUVmax)&#32",
        "integrate&#32",
        "of&#32",
        "integrated&#32",
        "were&#32",
        "and&#32",
        "localized&#32",
        "uptake&#32",
        "(ROI)&#32",
        "PET&#32",
        "Syngo&#32",
        "selected.&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "PET-MR"
      ],
      "Start Date": "2022-08-30",
      "Max Phase": null
    },
    {
      "id": "EUCTR2022-000776-19-PL",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Code: AZD5305 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: N/A CAS Number: 2589531-76-8 Current Sponsor code: AZD5305 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-  Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Datopotamab deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Product Name: Flourouracil (5-FU) Pharmaceutical Form: Solution for injection INN or Proposed INN: fluorouracil CAS Number: 51-21-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Bevacizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bevacizumab CAS Number: 216974-75-3 Current Sponsor code: FKB238 Other descriptive name: A recombinant, humanized IgG1 mAb specific for VEGF Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-  Product Name: Carboplatin Pharmaceutical Form: Concen"
      ],
      "locations": [
        "Italy",
        "Canada",
        "Switzerland",
        "China",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Taiwan",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 540,
      "conditions": [
        "various Advanced/Metastatic solid tumour types  - Endometrial Cancer  - Gastric Cancer  - Ovarian Cancer - Metastatic castration-resistant prostate cancer - Colorectal cancer  MedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2022-08-29",
      "Max Phase": "3"
    },
    {
      "id": "ChiCTR2200062091",
      "phases": [],
      "sponsor": [
        "West China Hospital,Sichuan University"
      ],
      "interventions": [
        "value",
        "",
        "T1&#32",
        "Index test:Fat&#32",
        "fraction",
        "Gold Standard:Results of routine large magnetic resonance quantitative examination of liver fat",
        "&#32",
        "ADC&#32",
        "T2&#32",
        "value."
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "liver disease"
      ],
      "Start Date": "2022-07-21",
      "Max Phase": null
    },
    {
      "id": "ChiCTR2200061944",
      "phases": [],
      "sponsor": [
        "The First Hospital of Jiaxing"
      ],
      "interventions": [
        "",
        "(D,&#32",
        "f&#32",
        "exponential&#32",
        "double-exponential,&#32",
        "single-exponential,&#32",
        "DWI&#32",
        "double&#32",
        "a&#32",
        "D*,&#32",
        "Gold Standard:Histopathological diagnosis",
        "multi-modal&#32",
        "multi-parameter&#32",
        "indicators. Indicators&#32",
        "to&#32",
        "obtain&#32",
        "stretched-exponential&#32",
        "include:&#32",
        "single&#32",
        "models,&#32",
        "value),&",
        "including&#32",
        "models&#32",
        "parameters&#32",
        "Index test:Construct&#32",
        "value),&#32",
        "stretched&#32",
        "(ADC&#32",
        "and&#32",
        "distribution&#32",
        "model&#32",
        "non-Gaussian&#32",
        "(DDC&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "thyroid nodules"
      ],
      "Start Date": "2022-07-12",
      "Max Phase": null
    },
    {
      "id": "NCT05417230",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Jiangsu Cancer Institute & Hospital"
      ],
      "interventions": [
        "Drug: Envafolimab",
        "Drug: RC48-ADC"
      ],
      "locations": [
        ""
      ],
      "enrollment": 29,
      "conditions": [
        "Biliary Tract Cancer"
      ],
      "Start Date": "2022-09-06",
      "Max Phase": "2"
    },
    {
      "id": "CTRI/2022/05/042713",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "GlaxoSmithKline Research  Development Limited"
      ],
      "interventions": [
        "Intervention1: Single-Agent Belantamab Mafodotin (GSK2857916): GSK2857916 for injection, 100 mg, Biologic/drug (antibody-drug conjugate) ,Lyophilized powder in single-use vial for reconstitution, 100 mg/vial, IV infusion over at least 30 minutes  Intervention2: Single-Agent Belantamab Mafodotin (GSK2857916: The study has 5 arms: Arm A, a control arm (2.5 mg/kg Q3W) Intervention3: Single-Agent Belantamab Mafodotin (GSK2857916): Arms B through D, 3 arms with dosing alternatives Intervention4: Single-Agent Belantamab Mafodotin (GSK2857916): Arm E, a fifth exploratory arm to evaluate the feasibility of dosing 1.9 mg/kg every 6 weeks (Q6W) based on ocular symptoms (patient-reported symptoms using the OSDI), visual acuity assessments (Snellen chart or equivalent), and corneal findings (KVA scale). Control Intervention1: There is no comparator agent in the study and this monotherapy study.: There is no comparator agent in the study and this monotherapy study."
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Thailand",
        "Spain",
        "United States of America",
        "Republic of Korea",
        "Argentina",
        "Ireland",
        "Poland",
        "United Kingdom",
        "India",
        "Taiwan",
        "Germany",
        "Australia",
        "Greece",
        "Russian Federation",
        "France"
      ],
      "enrollment": 288,
      "conditions": [
        "Health Condition 1: -  Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs Health Condition 3: D758- Other specified diseases of bloodand blood-forming organs"
      ],
      "Start Date": "2022-05-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT05403242",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Chinese PLA General Hospital"
      ],
      "interventions": [
        "Drug: S-1",
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 42,
      "conditions": [
        "Advanced Gastroesophageal Adenocarcinoma"
      ],
      "Start Date": "2022-06-05",
      "Max Phase": "2"
    },
    {
      "id": "NCT05349383",
      "phases": [],
      "sponsor": [
        "Central South University"
      ],
      "interventions": [
        "Drug: Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate",
        "Drug: Antibody-Drug Conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 24618,
      "conditions": [
        "Agranulocytosis",
        "Sepsis (SMQ)",
        "Opportunistic Infections"
      ],
      "Start Date": "2022-04-21",
      "Max Phase": null
    },
    {
      "id": "NCT05356351",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Tianjin Medical University Cancer Institute and Hospital"
      ],
      "interventions": [
        "Drug: RC48- ADC"
      ],
      "locations": [
        ""
      ],
      "enrollment": 30,
      "conditions": [
        "Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance"
      ],
      "Start Date": "2022-04-18",
      "Max Phase": "2"
    },
    {
      "id": "NCT05331326",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
      ],
      "interventions": [
        "Drug: RC48-ADC"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 64,
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2022-08-04",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2021-005223-21-IT",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "ASTRAZENECA AB"
      ],
      "interventions": [
        "Trade Name: Carbo-Cell 10 mg/ml concentrate for solution for infusion Product Name: Carboplatin Product Code: [Carboplatin] Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: CARBOPLATINO CAS Number: 41575-94-4 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Product Name: Eribulin mesylate Product Code: [Eribulin mesylate] Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: ERIBULINA CAS Number: 441045-17-6 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-  Product Name: Nab-paclitaxel Product Code: [Nab-paclitaxel] Pharmaceutical Form: Powder for suspension for injection INN or Proposed INN: PACLITAXEL ALBUMINA CAS Number: 153212-75-1 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Glucocorticoids Product Code: [Glucocorticoids] Pharmaceutical Form: Powder and solvent for solution for injection Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Abraxane 5 mg/ml powder for dispersion for infusion Product Name: Nab-paclitaxel Product Code: [Nab-paclitaxel] Pharmaceutical Form: Dispersion for infusion INN or Proposed INN: PACLITAXEL ALBUMINA CAS Number: 153212-75-1 Current Sponsor code: n/a Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: HALAVEN 0.44 mg/ml solution for injection Product Name: Eribulin mesylate Product Code: [Eribulin mesylate] Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: ERIBULINA CAS Number: 441045-17-6 Current Sponsor code: n/a Concentr"
      ],
      "locations": [
        "Mexico",
        "Singapore",
        "China",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Thailand",
        "Italy",
        "South Africa",
        "Argentina",
        "Taiwan",
        "Hungary",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Belgium"
      ],
      "enrollment": 600,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2022-03-24",
      "Max Phase": "3"
    },
    {
      "id": "NCT05320380",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Children's Oncology Group"
      ],
      "interventions": [
        "Drug: Hydrocortisone Sodium Succinate",
        "Drug: Anti-CD123 ADC IMGN632",
        "Procedure: Bone Marrow Aspiration and Biopsy",
        "Drug: Liposome-encapsulated Daunorubicin-Cytarabine",
        "Drug: Methotrexate",
        "Drug: Cytarabine",
        "Drug: Fludarabine Phosphate",
        "Drug: Prednisolone"
      ],
      "locations": [
        ""
      ],
      "enrollment": null,
      "conditions": [
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Mixed Phenotype Acute Leukemia",
        "Refractory T Acute Lymphoblastic Leukemia",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Recurrent Acute Myeloid Leukemia"
      ],
      "Start Date": "2022-03-22",
      "Max Phase": "2"
    },
    {
      "id": "ACTRN12622000080729",
      "phases": [],
      "sponsor": [
        "St. Vincent's Private Hospital"
      ],
      "interventions": [
        "  \tNo use of Endo-rectal coils or MR Spectroscopy as per current guidelines \tDedicated MRI physicists present for all scans to optimise protocols \tApproximate scan time 30minutes.",
        " \tDynamic Contrast Enhanced imaging (DCE) with automatically-delivered IV gadolinium DTPA bolus 10ml at 3ml/ second followed by rapid sequences with temporal resolution of between 4-7 seconds between scans",
        " \tDetailed quantitative analysis of DCEI imaging using K-trans colour maps and curve analysis according to PIRADS DCEI analytic guidelines",
        " \tT2-weighted imaging in 3 planes with sagittal, coronal, axial and TSE images",
        " \t Diffusion-Weighted Imaging with software derived Apparent Diffusion Co-efficient (ADC) quantitative analysis maps, and multiple B-values (0, 400, 800, 1400)",
        "Multi-parametric MRI scans will be performed as per standard of care for patients on active surveillance and assessed as per this protocol at Baseline, 1 year, 2 years and 3 years including follow-up up to 7 years consistent with the highest standards of prostate MRI: \t3-Tesla magnet field strength \t32-channel system with 14-channel spine coil and 18-channel pelvic phased array coil arrangement \tT1-weighted gradient spine echo sequence to identify biopsy haemorrhage artifact \tT2-weighted, high spatial resolution, anatomical imaging to identify and precisely localise areas of suspicion, and direct MRI-guided biopsy where performed"
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 300,
      "conditions": [
        "  Prostate Cancer",
        "Prostate Cancer",
        "Cancer - Prostate"
      ],
      "Start Date": "2022-01-21",
      "Max Phase": null
    },
    {
      "id": "ChiCTR2200055827",
      "phases": [],
      "sponsor": [
        "Department of Biotherapy, Tumor Center, West China Hospital, Sichuan University"
      ],
      "interventions": [
        "",
        "Experimental group:Videsetuzumab for injection (RC48-ADC)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "HER2-expressing locally advanced or metastatic malignant solid tumor"
      ],
      "Start Date": "2022-01-20",
      "Max Phase": null
    },
    {
      "id": "EUCTR2021-005873-25-ES",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "SOTIO Biotech a.s."
      ],
      "interventions": [
        "Product Name: SOT102 Product Code: SOT102 Pharmaceutical Form: Solution for infusion INN or Proposed INN: antibody-drug conjugate of an anti-CLDN18.2 mAb and the cytotoxic drug PNU159682, coupled by a Gly2-EDA linker Current Sponsor code: SOT102 Other descriptive name: SOT102 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Czechia",
        "Spain",
        "Belgium",
        "France",
        "United States"
      ],
      "enrollment": 269,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Gastric and pancreatic adenocarcinoma  MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 100000004864   MedDRA version: 21.1 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864 "
      ],
      "Start Date": "2022-01-17",
      "Max Phase": "3"
    },
    {
      "id": "NCT05115500",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Second Affiliated Hospital of Soochow University"
      ],
      "interventions": [
        "Drug: ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 55,
      "conditions": [
        "Solid Tumor",
        "Carcinoma"
      ],
      "Start Date": "2021-04-11",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2020-005620-12-ES",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Datopotamab deruxtecan Product Code: DS-1062a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Eribulin mesylate Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Eribulin mesylate CAS Number: 441045-17-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.44-  Product Name: Capecitabine Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9  Product Name: Gemcitabine Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Gemcitabine CAS Number: 95058-81-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 38-  Product Name: Vinorelbine Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Vinorelbine CAS Number: 71486-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Mexico",
        "China",
        "India",
        "Germany",
        "Russian Federation",
        "France",
        "Italy",
        "South Africa",
        "Argentina",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Spain",
        "Belgium"
      ],
      "enrollment": 700,
      "conditions": [
        "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy  MedDRA version: 23.0 Level: PT Classification code 10083232 Term: HER2 negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2021-06-10",
      "Max Phase": "3"
    },
    {
      "id": "CTRI/2021/08/035674",
      "phases": [],
      "sponsor": [
        "Tata Memorial Hospital"
      ],
      "interventions": [
        "Intervention1: Adc b 4000: Additional mri sequence to be taken along with adc b 0 and b1000"
      ],
      "locations": [
        "India"
      ],
      "enrollment": 245,
      "conditions": [
        "Health Condition 1: C718- Malignant neoplasm of overlappingsites of brain"
      ],
      "Start Date": "2021-08-16",
      "Max Phase": null
    },
    {
      "id": "NCT05016973",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"
      ],
      "interventions": [
        "Drug: RC48-ADC",
        "Drug: Triplizumab"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 25,
      "conditions": [
        "Bladder Cancer"
      ],
      "Start Date": "2021-07-25",
      "Max Phase": "2"
    },
    {
      "id": "NCT04983121",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Shengjing Hospital"
      ],
      "interventions": [
        "Drug: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 30,
      "conditions": [
        "Breast Neoplasms"
      ],
      "Start Date": "2021-09-07",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2019-004531-22-PL",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: paclitaxel CAS Number: 33069-62-4 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6-  Product Name: Pertuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: pertuzumab CAS Number: 380610-27-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Turkiye",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "India",
        "Spain",
        "Australia",
        "Russian Federation",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 450,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2021-06-28",
      "Max Phase": "3"
    },
    {
      "id": "NCT04928846",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "interventions": [
        "Biological: Telisotuzumab Vedotin",
        "Drug: Docetaxel"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "China",
        "Sweden",
        "Denmark",
        "Bulgaria",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Italy",
        "South Africa",
        "Israel",
        "Argentina",
        "Austria",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "Chile",
        "Ukraine",
        "Portugal",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Slovakia",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 698,
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "Start Date": "2021-06-14",
      "Max Phase": "3"
    },
    {
      "id": "NCT05160714",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "University Hospital Tuebingen"
      ],
      "interventions": [
        "Radiation: Real-time ADC-guided response adaptive Boost in HNC"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": 24,
      "conditions": [
        "Head and Neck Cancer"
      ],
      "Start Date": "2021-01-06",
      "Max Phase": "1"
    },
    {
      "id": "CTRI/2021/03/032107",
      "phases": [],
      "sponsor": [
        "Pacific dental college and hospital"
      ],
      "interventions": [
        "Intervention1: Use of ozone as irrigant in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India used without activation Control Intervention1: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India activated by manual agitation Control Intervention2: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone Ozonator by ADC India activated by ultra-sonic agitation Control Intervention3: Ozone activation in single rooted teeth during endodontic treatment: Ozone irrigation prepared by Dentozone ozonator by ADC India activated by pro agitator tips system (PATS)"
      ],
      "locations": [
        "India"
      ],
      "enrollment": 120,
      "conditions": [
        "Health Condition 1: K041- Necrosis of pulp"
      ],
      "Start Date": "2021-03-18",
      "Max Phase": null
    },
    {
      "id": "EUCTR2020-001574-29-BE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Brazil",
        "Thailand",
        "Italy",
        "Czechia",
        "Canada",
        "Belgium",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "India",
        "Spain",
        "Australia",
        "Russian Federation",
        "Taiwan",
        "Netherlands",
        "United States"
      ],
      "enrollment": 280,
      "conditions": [
        "Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2021-03-16",
      "Max Phase": "3"
    },
    {
      "id": "NCT04814758",
      "phases": [],
      "sponsor": [
        "Federal Research Institute of Pediatric Hematology, Oncology and Immunology"
      ],
      "interventions": [
        "Diagnostic Test: MRI DWI sequence (ADC values)"
      ],
      "locations": [
        "Russian Federation"
      ],
      "enrollment": 230,
      "conditions": [
        "Nephroblastoma (Wilms Tumour)"
      ],
      "Start Date": "2021-04-03",
      "Max Phase": null
    },
    {
      "id": "EUCTR2020-003427-42-NL",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo, Inc."
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan for injection 100 mg Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Japan",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "France",
        "Netherlands",
        "United States"
      ],
      "enrollment": 150,
      "conditions": [
        "HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2021-03-03",
      "Max Phase": "3"
    },
    {
      "id": "NCT04697628",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "interventions": [
        "Drug: topotecan",
        "Drug: irinotecan",
        "Drug: pemetrexed",
        "Drug: vinorelbine",
        "Drug: tisotumab vedotin",
        "Drug: gemcitabine"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Sweden",
        "Ireland",
        "Denmark",
        "Germany",
        "France",
        "Italy",
        "Finland",
        "Argentina",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "Peru",
        "Poland",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Spain",
        "Belgium"
      ],
      "enrollment": 568,
      "conditions": [
        "Cervical Cancer"
      ],
      "Start Date": "2021-04-01",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2020-003427-42-FR",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo, Inc."
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan for injection 100 mg Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "France",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Taiwan",
        "Netherlands",
        "Japan",
        "United States"
      ],
      "enrollment": 150,
      "conditions": [
        "HER2-mutated metastatic Non-Small Cell Lung Cancer (NSCLC)  MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2020-12-24",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2020-005182-14-FR",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Alligator Bioscience AB"
      ],
      "interventions": [
        "Product Name: mitazalimab Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: mitazalimab  Other descriptive name: ADC-1013, JNJ-64457107 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Oxaliplatin Product Code: Eloxatine  Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Leucovorin Product Code: Calcium Folinate Zentiva  Pharmaceutical Form: Solution for injection/infusion  Product Name: Irinotecan Product Code: Campto  Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Flurouracil Product Code: Flurouracil Teva Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Gemcitabine Product Code: Gemcitabine Accord Pharmaceutical Form: Concentrate for solution for infusion  Product Name: Abraxane Product Code: Abraxane Pharmaceutical Form: Powder for solution for injection/infusion"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 80,
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma  MedDRA version: 20.0 Level: PT Classification code 10073364 Term: Ductal adenocarcinoma of pancreas System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2020-12-23",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-004531-22-FR",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: paclitaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: paclitaxel CAS Number: 33069-62-4  Product Name: Pertuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: pertuzumab CAS Number: 380610-27-5"
      ],
      "locations": [
        "Brazil",
        "Canada",
        "Italy",
        "Germany",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "India",
        "Turkey",
        "Spain",
        "Australia",
        "Russian Federation",
        "Taiwan",
        "France",
        "United States"
      ],
      "enrollment": 350,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "HER2-positive Metastatic Breast Cancer  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2020-12-22",
      "Max Phase": "3"
    },
    {
      "id": "NCT04656652",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Drug: DS-1062a",
        "Drug: Docetaxel"
      ],
      "locations": [
        "Mexico",
        "Czechia",
        "Singapore",
        "China",
        "Germany",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Argentina",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Brazil",
        "Hong Kong",
        "Switzerland",
        "Korea, Republic of",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 590,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2020-11-19",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2020-001574-29-PL",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan CAS Number: 1599440-13-7 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Brazil",
        "Thailand",
        "Italy",
        "Czechia",
        "Canada",
        "Belgium",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "India",
        "Spain",
        "Australia",
        "Russian Federation",
        "Taiwan",
        "Netherlands",
        "United States"
      ],
      "enrollment": 280,
      "conditions": [
        "Treatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.  MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2020-11-09",
      "Max Phase": "3"
    },
    {
      "id": "NCT04506333",
      "phases": [],
      "sponsor": [
        "University of Louisiana Monroe"
      ],
      "interventions": [
        "Device: ADC 740-N Manual Sphygmomanometer",
        "Device: A&D UA-651 Blood Pressure Monitor"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 50,
      "conditions": [
        "Blood Pressure"
      ],
      "Start Date": "2020-06-08",
      "Max Phase": null
    },
    {
      "id": "ACTRN12620000773932",
      "phases": [],
      "sponsor": [
        "Arterica, Inc."
      ],
      "interventions": [
        "The device used is the Arterica Closure Device (ACD). The ACD is a medical device used to close large-bore vascular access sites following endovascular or interventional procedures. It is a handheld device operated by a trained clinician or doctor. The device has a handle and a nose with an extended tip. The tip of the device is inserted into the access site where it brings together the surrounding tissue and closes the wound.   The investigational procedure will be performed in an operation room or catherization lab, by an experienced and trained device operator.    The ADC procedure will take approximately 30 minutes.   The device must be used per the Instructions for Use. The sponsor will ensure all device operators are trained."
      ],
      "locations": [
        "New Zealand"
      ],
      "enrollment": 21,
      "conditions": [
        "Surgery - Other surgery",
        "  large-bore common femoral access site",
        "large-bore common femoral access site"
      ],
      "Start Date": "2020-07-28",
      "Max Phase": null
    },
    {
      "id": "ACTRN12620000757910",
      "phases": [],
      "sponsor": [
        "Dr Myo Min"
      ],
      "interventions": [
        "This study will evaluate the feasibility of a diffusion-weighted magnetic resonance imaging (DW-MRI) guided radiotherapy boost for locally advanced rectal cancer.   Patients will undergo pre-treatment MRI in the fortnight prior to commencing radiotherapy (+/- chemotherapy). Boost volume will be defined quantitatively according to intratumoural apparent diffusion coefficient (ADC) value. This volume will be targeted for a single-fraction 5-10Gy boost 3-5 days prior to commencing standard radiotherapy (50Gy delivered in 25 fractions).   Treatment will be administered by the Radiation Oncology department at Sunshine Coast University Hospital (SCUH), Birtinya. Each treatment takes approximately 15 minutes per day. Patients will be reviewed once per week by radiation oncology medical staff as per normal practice. Patients will also be asked to complete a quality of life questionnaire at several timepoints prior to, during and following completion of the treatment course, which will take an additional 5-10 minutes on each occasion."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 30,
      "conditions": [
        "  Rectal cancer",
        "Cancer - Bowel - Back passage (rectum) or large bowel (colon)",
        "Rectal cancer"
      ],
      "Start Date": "2020-07-23",
      "Max Phase": null
    },
    {
      "id": "NCT04484142",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Daiichi Sankyo"
      ],
      "interventions": [
        "Drug: DS-1062a"
      ],
      "locations": [
        "Italy",
        "Netherlands",
        "Spain",
        "Korea, Republic of",
        "Taiwan",
        "Germany",
        "Hungary",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 137,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2020-07-20",
      "Max Phase": "2"
    },
    {
      "id": "NCT04431739",
      "phases": [],
      "sponsor": [
        "Mohamed Ibrahim Abbas"
      ],
      "interventions": [
        "Device: MRI including conventional MRI, DWI with multiple ADC values"
      ],
      "locations": [
        ""
      ],
      "enrollment": 50,
      "conditions": [
        "Vertebral Lesion"
      ],
      "Start Date": "2020-11-06",
      "Max Phase": null
    },
    {
      "id": "ACTRN12620000592943",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Conjugate Light (Australia) Pty Ltd"
      ],
      "interventions": [
        "The name of the drug being administered is GQ1001. GQ1001 is an Antibody-Drug Conjugate used to treat patients with HER2-positive advanced solid tumors. GQ1001 will be administered by the licensed medical staff at the clinical site as a single intravenous dose on Day 1 of a 21-day treatment cycle. Patient medical records, routine safety lab tests and other necessary medical monitoring will be conducted by the investigators and site medical staff during the study.  Eligible patients will be enrolled into one specific dose cohort following the study progress. Intra-patient dose escalation will not be allowed. Dose cohorts planned for the dose escalation are 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg, and 6.0 mg/kg. Eight cycles treatment was planned for each enrolled patient. The safety review by the Safety Review Committee (SRC) will occur on a continual basis through the duration of the study. The SCR will monitor the safety and provide decisions as to dose escalations and exploring intermediate or higher doses. Patients may stay on the study treatment longer, until disease progression occurs, unacceptable toxicity occurs, or voluntarily withdraw the consent."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 13,
      "conditions": [
        "HER2-Positive Advanced Solid Tumors",
        "Cancer - Any cancer",
        "  HER2-Positive Advanced Solid Tumors"
      ],
      "Start Date": "2020-05-21",
      "Max Phase": "1"
    },
    {
      "id": "ACTRN12620000534987",
      "phases": [],
      "sponsor": [
        "Dr Myo Min"
      ],
      "interventions": [
        "This study aims to assess the feasibility of diffusion weighted magnetic resonance imaging (DW-MRI) guided radiation therapy dose escalation in head and neck cancer (HNC). Participants will need to attend an MRI scan at the Sunshine Coast University Hospital within one week prior to their standard radiotherapy planning CT. This scan will be performed with the participant lying in the radiation therapy treatment position with a custom fit immobilisation mask in place and may take up to an hour to perform.   Based on the quantitative information from this scan, a high-risk volume within the tumour will be identified. A boost dose of 5-7Gy in one fraction will be delivered to this tumour subvolume defined by an area of low apparent diffusion coefficient (ADC) value, representative of increased cellular density. This is followed by a 3-5 day break then the standard fractionated radiation therapy schedule of 66-70Gy over 6-7 weeks is delivered. Each individual treatment takes approximately 15 minutes.  The study will be conducted by the Radiation Oncology department at the Sunshine Coast University Hospital in Birtinya, Queensland. The participant will be asked to complete quality of life questionnaires at 5 different timepoints before, during and after the treatment period. These questionnaires may take up to 5mins to complete each time. Patients will be monitored closely by the treating team for any acute or late treatment side effects."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 30,
      "conditions": [
        "Cancer - Head and neck",
        "  Head and Neck Cancer",
        "Head and Neck Cancer"
      ],
      "Start Date": "2020-04-30",
      "Max Phase": null
    },
    {
      "id": "NCT04264936",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Beijing Cancer Hospital"
      ],
      "interventions": [
        "Drug: RC48-ADC and JS001"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 36,
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "Start Date": "2020-01-15",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2019-001655-39-ES",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab Vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Tisotumab Vedotin CAS Number: 1418731-10-8 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Gemcitabine 1000 mg, powder for solution for infusion Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: GEMCITABINE CAS Number: 95058-81-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-  Trade Name: Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: IRINOTECAN CAS Number: 97682-44-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Trade Name: Potactasol (Topotecan Actavis)4 mg Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TOPOTECAN CAS Number: 123948-87-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4-  Trade Name: Vinorelbin Aurobindo 10 mg/ml Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: VINORELBINE CAS Number: 71486-22-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Singapore",
        "Lithuania",
        "Sweden",
        "Ireland",
        "Denmark",
        "Germany",
        "Greece",
        "France",
        "Czech Republic",
        "Italy",
        "Israel",
        "Finland",
        "Argentina",
        "Croatia",
        "Austria",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Norway",
        "Canada",
        "Ukraine",
        "United Kingdom",
        "Japan",
        "Brazil",
        "Korea, Republic of",
        "Spain",
        "Belgium",
        "Estonia"
      ],
      "enrollment": 482,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Second- or Third-Line Recurrent or Metastatic Cervical Cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2019-12-20",
      "Max Phase": "3"
    },
    {
      "id": "NCT04146610",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
      ],
      "interventions": [
        "Drug: an antibody drug conjugate"
      ],
      "locations": [
        "China"
      ],
      "enrollment": 30,
      "conditions": [
        "Neoplasms"
      ],
      "Start Date": "2019-10-28",
      "Max Phase": "1"
    },
    {
      "id": "EUCTR2019-001219-22-IE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Seagen, Inc."
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-  Product Name: Tistotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: TISOTUMAB VEDOTIN CAS Number: 1418731-10-8 Other descriptive name: HuMax-TF-ADC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-"
      ],
      "locations": [
        "Italy",
        "Ireland",
        "Denmark",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 222,
      "conditions": [
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)  MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10080244 Term: Peritoneal cancer index System Organ Class: 10022891 - Investigations ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2019-10-22",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-002991-15-ES",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "SOLTI"
      ],
      "interventions": [
        "Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201A Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Spain"
      ],
      "enrollment": 180,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Her2-positive, unresectable and/or metastatic breast cancer."
      ],
      "Start Date": "2019-04-09",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-001219-22-ES",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Seattle Genetics, Inc."
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin                 Product Code: HuMax-TF-ADC                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: TISOTUMAB VEDOTIN                 CAS Number: 1418628-81-5                 Other descriptive name: HuMax-TF-ADC                 Concentration unit: mg/kg milligram(s)/kilogram                 Concentration type: equal                 Concentration number: 90-                  Product Name: Tisotumab vedotin                 Product Code: HuMax-TF-ADC                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: TISOTUMAB VEDOTIN                 CAS Number: 1418628-81-5                 Other descriptive name: HuMax-TF-ADC                 Concentration unit: mg/kg milligram(s)/kilogram                 Concentration type: equal                 Concentration number: 200-"
      ],
      "locations": [
        "Italy",
        "Ireland",
        "Denmark",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 142,
      "conditions": [
        "Patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (hereafter collectively referred to as platinum-resistant ovarian cancer and abbreviated as PROC)                   MedDRA version: 20.0                 Level: PT                 Classification code 10033128                 Term: Ovarian cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10016180                 Term: Fallopian tube cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10080244                 Term: Peritoneal cancer index                 System Organ Class: 10022891 - Investigations             ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2019-04-09",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2019-001512-34-BE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo Inc."
      ],
      "interventions": [
        "Product Name: DS-8201a Product Code: DS-8201a Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Trastuzumab deruxtecan  Current Sponsor code: DS-8201A Other descriptive name:  Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Italy",
        "United Kingdom",
        "Spain",
        "Belgium",
        "United States"
      ],
      "enrollment": 72,
      "conditions": [
        "Unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma that has progressed on or after a trastuzumab-containing regimen     MedDRA version: 21.1 Level: LLT Classification code 10071114 Term: Metastatic gastric adenocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: LLT Classification code 10066354 Term: Adenocarcinoma of the gastroesophageal junction System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2019-08-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT03859752",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Open Innovation Partners, Inc."
      ],
      "interventions": [
        "Biological: TR1801-ADC"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 15,
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "Start Date": "2019-02-26",
      "Max Phase": "1"
    },
    {
      "id": "EUCTR2018-002816-29-DE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline Research & Development Ltd"
      ],
      "interventions": [
        "Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: belantamab mafodotin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: Pembrolizumab Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: MK-3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-"
      ],
      "locations": [
        "Spain",
        "Canada",
        "Germany",
        "United States"
      ],
      "enrollment": 40,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 "
      ],
      "Start Date": "2019-02-25",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000764-29-PL",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: MEDI9447 CAS Number: NA Current Sponsor code: MEDI9447 Other descriptive name: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 160-200  Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab Deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 Antibody-Drug Conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Product Name: Datopotamab deruxtecan Product Code: Dato-DXd Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Datopotamab deruxtecan CAS Number: 2238831-60-0 Current Sponsor code: DS-1062a Other descriptive name: Anti-trophoblast cell surface protein 2 (TROP2) antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "United States"
      ],
      "enrollment": 320,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2018-12-19",
      "Max Phase": "3"
    },
    {
      "id": "NCT03763370",
      "phases": [],
      "sponsor": [
        "GlaxoSmithKline"
      ],
      "interventions": [
        "Drug: Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate"
      ],
      "locations": [
        ""
      ],
      "enrollment": null,
      "conditions": [
        "Multiple Myeloma"
      ],
      "Start Date": "2018-11-30",
      "Max Phase": null
    },
    {
      "id": "EUCTR2017-004758-40-DK",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Keytruda Product Name: Pembrolizumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PEMBROLIZUMAB Other descriptive name: Keytruda Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-  Trade Name: Carboplatin Product Name: Carboplatin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Carboplatin Other descriptive name: CARBOPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-  Trade Name: Avastin Product Name: Avastin Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-75-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25-"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Ireland",
        "Denmark",
        "United Kingdom",
        "Turkey",
        "Germany",
        "Belgium",
        "Netherlands",
        "Czech Republic",
        "United States"
      ],
      "enrollment": 140,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "recurrent or stage IVB cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2018-11-16",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000764-29-GB",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AstraZeneca AB"
      ],
      "interventions": [
        "Product Name: durvalumab Product Code: MEDI4736 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: durvalumab CAS Number: 1428935-60-7 Current Sponsor code: MEDI4736 Other descriptive name: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Oleclumab Product Code: MEDI9447 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: MEDI9447 CAS Number: NA Current Sponsor code: MEDI9447 Other descriptive name: MEDI9447 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 80-200  Product Name: Capivasertib Product Code: AZD5363 Pharmaceutical Form: Tablet INN or Proposed INN: Capivasertib CAS Number: 1143532-39-1 Current Sponsor code: AZD5363 Other descriptive name: AZD5363 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 160-200  Product Name: Trastuzumab Deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: Trastuzumab Deruxtecan CAS Number: 1826843-81-5 Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 Antibody-Drug Conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Poland",
        "Korea, Republic of",
        "United Kingdom",
        "Taiwan",
        "United States"
      ],
      "enrollment": 191,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.  MedDRA version: 20.0 Level: PT Classification code 10075566 Term: Triple negative breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2018-10-15",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-001772-38-IE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie Deutschland GmbH & Co. KG"
      ],
      "interventions": [
        "Product Name: Telisotuzumab Vedotin Product Code: ABBV-399 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Telisotuzumab Vedotin Current Sponsor code: ABBV-399 Other descriptive name: ABT-700-vcMMAE ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-"
      ],
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Bulgaria",
        "Greece",
        "Russian Federation",
        "France",
        "Czech Republic",
        "Italy",
        "Israel",
        "Taiwan",
        "Hungary",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Australia",
        "Belgium"
      ],
      "enrollment": 270,
      "conditions": [
        "Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-11-10",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-001772-38-HU",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "AbbVie Deutschland GmbH & Co. KG"
      ],
      "interventions": [
        "Product Name: Telisotuzumab Vedotin Product Code: ABBV-399 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Telisotuzumab Vedotin Current Sponsor code: ABBV-399 Other descriptive name: ABT-700-vcMMAE ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-"
      ],
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Bulgaria",
        "Russian Federation",
        "Greece",
        "France",
        "Italy",
        "Israel",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "New Zealand",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Australia",
        "Belgium"
      ],
      "enrollment": 310,
      "conditions": [
        "Non-Small Cell Lung Cancer  MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-09-10",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000221-31-CZ",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo Inc."
      ],
      "interventions": [
        "Product Name: trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: Herceptin Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab CAS Number: 180288-69-1 Other descriptive name: trastuzumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Tyverb Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lapatinib CAS Number: 231277-92-2 Other descriptive name: lapatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Capecitabine Accord Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-  Trade Name: Capecitabine Dr. Reddy's Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "Israel",
        "Germany",
        "Turkey",
        "Korea, Republic of",
        "United Kingdom",
        "Czech Republic",
        "Spain",
        "Australia",
        "Greece",
        "Belgium",
        "France",
        "Japan",
        "United States"
      ],
      "enrollment": 600,
      "conditions": [
        "Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-09-13",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2018-000221-31-BE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Daiichi Sankyo Inc."
      ],
      "interventions": [
        "Product Name: trastuzumab deruxtecan Product Code: DS-8201a Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: trastuzumab deruxtecan Current Sponsor code: DS-8201a Other descriptive name: Anti-HER2 antibody-drug conjugate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-  Trade Name: Herceptin Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trastuzumab CAS Number: 180288-69-1 Other descriptive name: trastuzumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Tyverb Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lapatinib CAS Number: 231277-92-2 Other descriptive name: lapatinib Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250-  Trade Name: Capecitabine Accord Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade Name: Capecitabin cell pharm Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-  Trade Name: Capecitabine Dr. Reddy's Pharmaceutical Form: Film-coated tablet INN or Proposed INN: capecitabine Other descriptive name: capecitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-  Trade"
      ],
      "locations": [
        "Brazil",
        "Italy",
        "Czechia",
        "Netherlands",
        "Israel",
        "Japan",
        "Germany",
        "Korea, Republic of",
        "United Kingdom",
        "Turkey",
        "Spain",
        "Australia",
        "Greece",
        "Belgium",
        "France",
        "Czech Republic",
        "United States"
      ],
      "enrollment": 600,
      "conditions": [
        "Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression  MedDRA version: 20.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 100000004864 ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-11-09",
      "Max Phase": "3"
    },
    {
      "id": "NCT03539536",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "AbbVie"
      ],
      "interventions": [
        "Drug: Telisotuzumab vedotin"
      ],
      "locations": [
        "Czechia",
        "China",
        "Ireland",
        "Bulgaria",
        "Germany",
        "Greece",
        "Russian Federation",
        "France",
        "Puerto Rico",
        "Italy",
        "Israel",
        "Hungary",
        "Taiwan",
        "Netherlands",
        "United States",
        "Canada",
        "Poland",
        "United Kingdom",
        "Japan",
        "Romania",
        "Switzerland",
        "Korea, Republic of",
        "Turkey",
        "Spain",
        "Australia",
        "Belgium"
      ],
      "enrollment": 270,
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "Start Date": "2018-05-17",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2017-004810-25-DE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "GlaxoSmithKline Research & Development Ltd"
      ],
      "interventions": [
        "Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-  Product Name: GSK2857916 Product Code: GSK2857916 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Humanized IgG1 antibody drug conjugate  CAS Number: N/A Current Sponsor code: GSK2857916 Other descriptive name: GSK2857916 for Injection, 100mg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Germany",
        "United Kingdom",
        "Spain",
        "Australia",
        "France",
        "United States"
      ],
      "enrollment": 230,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Relapsed/Refractory Multiple Myeloma  MedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 "
      ],
      "Start Date": "2018-05-14",
      "Max Phase": "3"
    },
    {
      "id": "JPRN-jRCT2080223860",
      "phases": [],
      "sponsor": [
        "DAIICHI SANKYO Co.,Ltd."
      ],
      "interventions": [
        "investigational material(s) Generic name etc : DS-8201a INN of investigational material : trastuzumab deruxtecan Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous  control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code :  Dosage and Administration for Investigational material : -"
      ],
      "locations": [
        "North America",
        "Japan",
        "Europe"
      ],
      "enrollment": 170,
      "conditions": [
        "HER2-over-expressing or HER2-mutated unresectable and/or metastatic non-squamous NSCLC"
      ],
      "Start Date": "2018-09-04",
      "Max Phase": null
    },
    {
      "id": "EUCTR2017-003413-25-IT",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Italy",
        "Sweden",
        "Germany",
        "Denmark",
        "Spain",
        "Belgium",
        "Czech Republic",
        "United States"
      ],
      "enrollment": 100,
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-03-13",
      "Max Phase": "3"
    },
    {
      "id": "NCT03485209",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seagen Inc."
      ],
      "interventions": [
        "Drug: cisplatin",
        "Drug: tisotumab vedotin",
        "Drug: pembrolizumab",
        "Drug: carboplatin"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Spain",
        "United Kingdom",
        "Germany",
        "France",
        "Puerto Rico",
        "United States"
      ],
      "enrollment": 692,
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Colorectal Neoplasms",
        "Exocrine Pancreatic Cancer",
        "Carcinoma, Squamous Cell of Head and Neck"
      ],
      "Start Date": "2018-08-03",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2017-003413-25-DE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Sweden",
        "Germany",
        "Denmark",
        "Spain",
        "Belgium",
        "Czech Republic",
        "United States"
      ],
      "enrollment": 100,
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-01-03",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2017-003413-25-DK",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Italy",
        "Czechia",
        "Sweden",
        "Germany",
        "Denmark",
        "Spain",
        "Belgium",
        "Czech Republic",
        "United States"
      ],
      "enrollment": 100,
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-02-27",
      "Max Phase": "3"
    },
    {
      "id": "EUCTR2017-003413-25-CZ",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin Product Code: HuMax-TF-ADC Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Italy",
        "Sweden",
        "Germany",
        "Denmark",
        "Spain",
        "Belgium",
        "Czech Republic",
        "United States"
      ],
      "enrollment": 100,
      "conditions": [
        "recurrent or metastatic cervical cancer  MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2018-02-27",
      "Max Phase": "3"
    },
    {
      "id": "ChiCTR-DND-17012404",
      "phases": [],
      "sponsor": [
        "Central Hospital of Minhang District,Shanghai"
      ],
      "interventions": [
        "",
        "BRAF&#32",
        "gene",
        "Index test:T1WI,&#32",
        "DWI,&#32",
        "Gold Standard:Pathological diagnosis",
        "TERT&#32",
        "gene,&#32",
        "T2&#32",
        "ADC,&#32",
        "mapping,&#32",
        "K-trans,&#32",
        "T2WI,&#32",
        "DCE,&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "Papillary thyroid carcinoma"
      ],
      "Start Date": "2017-08-18",
      "Max Phase": null
    },
    {
      "id": "NCT03243331",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Kathy Miller"
      ],
      "interventions": [
        "Drug: PTK7-ADC",
        "Drug: Gedatolisib"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 18,
      "conditions": [
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "Start Date": "2017-03-08",
      "Max Phase": "1"
    },
    {
      "id": "NCT03192501",
      "phases": [],
      "sponsor": [
        "Second Affiliated Hospital of Guangzhou Medical University"
      ],
      "interventions": [
        "Drug: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group."
      ],
      "locations": [
        "China"
      ],
      "enrollment": 250,
      "conditions": [
        "Cancer",
        "Gene Abnormality",
        "Lung Cancer",
        "Gene Product Sequence Variation"
      ],
      "Start Date": "2017-06-15",
      "Max Phase": null
    },
    {
      "id": "ChiCTR-DDD-17010744",
      "phases": [],
      "sponsor": [
        "Jinling Hospital"
      ],
      "interventions": [
        "",
        "MK,&#32",
        "Ve,&#32",
        "D*,&#32",
        "D,&#32",
        " B. histologically proven disease.",
        "Index test:Ktrans,&#32",
        "f,&#32",
        "CBF",
        "Gold Standard:Use long-term clinical follow-up results or pathology as gold standard. Within 12 weeks after concurrent chemoradiotherapy was completed, the progress of disease can be diagnosed as following: A.There is new enhancement outside of the radiation field",
        "ADC,&#32",
        "FA,&#32",
        "Kep,&#32",
        "Vp,&#32"
      ],
      "locations": [
        "China"
      ],
      "enrollment": null,
      "conditions": [
        "Glioma"
      ],
      "Start Date": "2017-02-27",
      "Max Phase": null
    },
    {
      "id": "EUCTR2016-004743-37-BE",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: Tisotumab vedotin                 Product Code: IgG1-1015-011-1006                 Pharmaceutical Form: Powder for concentrate for solution for infusion                 INN or Proposed INN: tisotumab vedotin                 CAS Number: 1418731-10-1                 Current Sponsor code: IgG1-1015-011-1006                 Other descriptive name: HUMAX-TF-ADC                 Concentration unit: mg/ml milligram(s)/millilitre                 Concentration type: equal                 Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Sweden",
        "Denmark",
        "United Kingdom",
        "Hungary",
        "United States"
      ],
      "enrollment": 25,
      "conditions": [
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castrationresistant prostate cancer [CRPC]), esophagus, lung (non-small cell lung cancer [NSCLC]), and Squamous cell carcinoma of the head and neck (SCCHN)                   MedDRA version: 20.0                 Level: PT                 Classification code 10060862                 Term: Prostate cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: HLT                 Classification code 10014742                 Term: Endometrial neoplasms malignant                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10008342                 Term: Cervix carcinoma                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10023774                 Term: Large cell lung cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.1                 Level: PT                 Classification code 10062878                 Term: Gastrooesophageal cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: PT                 Classification code 10005003                 Term: Bladder cancer                 System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)                                MedDRA version: 20.0                 Level: SOC        ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2017-01-30",
      "Max Phase": "3"
    },
    {
      "id": "NCT02738424",
      "phases": [],
      "sponsor": [
        "Centre Hospitalier Universitaire de Saint Etienne"
      ],
      "interventions": [
        "Other: Calculate the ADC scores"
      ],
      "locations": [
        "France"
      ],
      "enrollment": 98,
      "conditions": [
        "Low Back Pain"
      ],
      "Start Date": "2016-11-04",
      "Max Phase": null
    },
    {
      "id": "EUCTR2015-001120-29-DK",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: HuMax-TF-ADC Product Code: IgG1-1015-011-1006 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: tisotumab vedotin CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Other descriptive name: HUMAX-TF-ADC Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Belgium",
        "Denmark",
        "United Kingdom",
        "Hungary",
        "United States"
      ],
      "enrollment": 44,
      "conditions": [
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), esophagus or lung (non-small cell lung cancer [NSCLC])  MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2015-07-15",
      "Max Phase": "3"
    },
    {
      "id": "NCT02379741",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Alligator Bioscience AB"
      ],
      "interventions": [
        "Biological: ADC-1013"
      ],
      "locations": [
        "United Kingdom",
        "Sweden",
        "Denmark"
      ],
      "enrollment": 24,
      "conditions": [
        "Neoplasms",
        "Solid Tumors"
      ],
      "Start Date": "2015-02-16",
      "Max Phase": "1"
    },
    {
      "id": "NCT02341625",
      "phases": [
        "Phase 1",
        "Phase 2"
      ],
      "sponsor": [
        "Bristol-Myers Squibb"
      ],
      "interventions": [
        "Drug: BMS-986148",
        "Biological: Nivolumab"
      ],
      "locations": [
        "Canada",
        "Italy",
        "Hong Kong",
        "Korea, Republic of",
        "United Kingdom",
        "Australia",
        "Belgium",
        "Netherlands",
        "United States"
      ],
      "enrollment": 126,
      "conditions": [
        "Advanced Cancer"
      ],
      "Start Date": "2015-01-14",
      "Max Phase": "2"
    },
    {
      "id": "NCT02312037",
      "phases": [],
      "sponsor": [
        "Pfizer"
      ],
      "interventions": [
        "Biological: Antibody Drug Conjugate Chemotherapeutic"
      ],
      "locations": [
        "Spain",
        "United States"
      ],
      "enrollment": null,
      "conditions": [
        "CD33 Positive Acute Myelogenous Leukemia"
      ],
      "Start Date": "2014-04-12",
      "Max Phase": null
    },
    {
      "id": "ISRCTN68413407",
      "phases": [],
      "sponsor": [
        "Wellcome Trust/DBT India Alliance (India)"
      ],
      "interventions": [
        " total 48 tablets).                 2. Distribution of therapeutic IFA (20 mg/day) 20 tablets/month to the mother/care giver of all anemic children for a total duration of 5 months meant for consumption by the anemic child (total 100 tablets).                 3. Monthly education and counselling of mothers of anemic children by the LHW trained for delivery of this intervention covering the following topics regarding:                 3.1. Symptoms and signs of anemia                 3.2. Treatment with IFA and its side effects                 3.3. Education regarding IFA compliance and its monitoring                 3.4. Information about local iron rich foods and dietary diversification                 3.5. Information about personal hygiene and deworming                 The education and counselling with occur either at the ADC or at the mother?s home at the discretion of the LHW.                 4. Ensuring that all children attend the village ADC for retesting at the end of 6 months.                  Control arm (treatment as usual or CA):                 T",
        "Current interventions as of 31/10/2014:                 Cluster definition:                 A cluster in this study is defined as a village in the geographic area of this trial that is randomly allocated to one of the study arms, its ADC or one of its ADCs, the LHW in charge of the selected ADC, all children aged 12 ? 59 months registered in the ADC and the mothers/care givers of these children.                  In particular, the following activities will take place in the intervention group:                 1. Distribution of supplementary IFA (20 mg, 1 tablet taken biweekly) to the mother/care giver of all non anemic children (supplied at 8 tablets/month, for a duration of 6 months of the trial"
      ],
      "locations": [
        "India"
      ],
      "enrollment": 2520,
      "conditions": [
        "Anemia  Haematological Disorders  Anaemia, unspecified"
      ],
      "Start Date": "2013-12-17",
      "Max Phase": null
    },
    {
      "id": "ISRCTN77650947",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "University of Birmingham (UK)"
      ],
      "interventions": [
        "Brentuximab vedotin: Antibody-drug conjugate                 30 patients will be recruited from hospitals across the UK and will receive a maximum of 16 doses over 48 weeks."
      ],
      "locations": [
        "United Kingdom"
      ],
      "enrollment": 30,
      "conditions": [
        " Disease: Lymphoma (Hodgkin's)  Cancer  Hodgkin lymphoma",
        "Topic: National Cancer Research Network",
        " Subtopic: Lymphoma"
      ],
      "Start Date": "2013-10-16",
      "Max Phase": "2"
    },
    {
      "id": "EUCTR2013-001074-15-GB",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Genmab A/S"
      ],
      "interventions": [
        "Product Name: HuMax-TF-ADC Product Code: IgG1-1015-011-1006 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: HuMax-TF-ADC CAS Number: 1418731-10-1 Current Sponsor code: IgG1-1015-011-1006 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-"
      ],
      "locations": [
        "Sweden",
        "Denmark",
        "United Kingdom",
        "Belgium",
        "United States"
      ],
      "enrollment": 217,
      "conditions": [
        "Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (non-small cell lung cancer [NSCLC]  MedDRA version: 20.0 Level: HLT Classification code 10014742 Term: Endometrial neoplasms malignant System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10008342 Term: Cervix carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10023774 Term: Large cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)   MedDRA version: 21.1 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ",
        "Therapeutic area: Diseases [C] - Cancer [C04]"
      ],
      "Start Date": "2013-07-24",
      "Max Phase": "3"
    },
    {
      "id": "RBR-3vwfjs",
      "phases": [],
      "sponsor": [
        "Universidade Federal do Tocantins"
      ],
      "interventions": [
        "D27.505.954.427.080",
        "HP3.073.433.101",
        "Drug",
        "This is a double blind study. Subjects: We wil select individuals with crack cocaine addiction diagnosis, males, and with minimum age of 18 years, and maximum age 50 years old, and capable of consenting. The intervention will be held for 12 weeks. Study groups: 20 individuals who make use of topiramate and 20 individuals who make use of placebo. Randomization: The sample will be randomized by permuted block technique. The total sample will have 40 participants. Patients will be randomly selected from the Psychosocial Care Center of Palmas, Brazil. Randomization will be performed according to a computer generated random list by the method exchanged in blocks. The first five participants will be allocated in the group who use the medication topiramate. The next five in grup that use placebo. Following five in the second group topiramate and so on until the total number of 40 individuals. Medications that will be used: 25 to 200 mg of topiramate (increased at doses every 7 days 25mg) for 12 weeks. Placebo for 12 weeks single capsule. Urine test to confirm the negative use of the drug: Be quantified for each group (arm) the number of individuals testing negative urine after 12 weeks of intervention. The urine test for cocaine is an immunoassay based on the competitive binding between the antibody drug conjugate immobilized on the membrane and the drug or its metabolites which may be present in the urine sample. The test strip has immobilized drug conjugate in the area of test and antibodies conjugated to gold colloidal conjugate to the membrane. During the examination, a urine sample migrates by capillary action. The benzoylecgonine, if the sample Urine below 300 ng / ml did not saturate the binding sites of antibodies conjugated to gold in the test strip. Antibodies conjug"
      ],
      "locations": [
        "Brazil"
      ],
      "enrollment": null,
      "conditions": [
        "D02.145.074.722.388.250",
        "Cocaine crack addiction.",
        "F01.145.527.100.120"
      ],
      "Start Date": "2013-06-13",
      "Max Phase": null
    },
    {
      "id": "DRKS00002954",
      "phases": [],
      "sponsor": [
        "Universitatsklinikum Freiburg"
      ],
      "interventions": [
        "Group 1: Study protocol MRI (3.0 Tesla): 1. Localizer sequence to plan scan orientations 2. high-resolution T2-weighted images in sagittal, coronal and axial orientation 3. diffusion-weighted (DWI) images with different diffusion weighting, to determine apparent diffusion coefficient (ADC) 4. T2-weighted images with different echo times in the axial orientation in order to determine the relaxation time T2. 5. T2 *-weighted images with different echo times in the axial orientation in order to determine the relaxation time T2 *. 6. T1-weighted MR images with different T1-weighted image in order to determine the relaxation time T1 7. Time series (dynamic) T1-weighted MR images before, during and after contrast agent administration in order to evaluate the tissue-perfusion (dynamic contrast-enhancement, DCE)"
      ],
      "locations": [
        "Germany"
      ],
      "enrollment": 20,
      "conditions": [
        "C61",
        "Malignant neoplasm of prostate"
      ],
      "Start Date": "2012-09-05",
      "Max Phase": null
    },
    {
      "id": "EUCTR2010-020729-42-PL",
      "phases": [
        "Phase 1",
        "Phase 2",
        "Phase 3"
      ],
      "sponsor": [
        "Helix BioPharma Corp"
      ],
      "interventions": [
        "Product Name: Lyophilised L-DOS47 Product Code:  L-DOS47 Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Lyophilised L-DOS47 Current Sponsor code: L-DOS47 Other descriptive name: AFAIKL2-urease immunoconjugate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1.7-"
      ],
      "locations": [
        "Poland"
      ],
      "enrollment": 74,
      "conditions": [
        "Therapeutic area: Diseases [C] - Cancer [C04]",
        "Inoperable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer  MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) "
      ],
      "Start Date": "2011-07-19",
      "Max Phase": "3"
    },
    {
      "id": "ACTRN12608000462381",
      "phases": [],
      "sponsor": [
        "The Royal Childrens' Hospital Mebourne"
      ],
      "interventions": [
        "The randomised cross over trial will aim to determine if additional priming of a haemofilter circuit with 5 u/ml heparinised 4% albumin increases circuit life (compared to only 5 u/ml heparinised saline).  This additional priming will be performed before the circuit is connected to the patient. The study will also determine if there is a difference between regional citrate and global heparinised anticoagulation on circuit life.  The dose of citrate (in the form of ADC-A) will be titrated with a calcium chloride infusion to maintain circuit calciums of less than 0.3 mmol/L and a patient calcium of 1.0-1.3 mmol/L. Upon recruitment all participants will be randomly assigned to one of 8 sequences of varying anticoagulation and priming methods as recommended for a four period crossover design with 2 factorial treatments.  Their first 4 circuits will consist of two heparin and two citrate circuits, one of each will be primed with heparinised saline and the other with an additional heparinised albumin prime, with the order of the treatments determined by their pre-assigned randomised sequence. As hemofiltration is necessary to maintain these patients there will be no intentional \"wash out\" period as with holding treatment may be detrimental to the patient. Each circuit will run until TMP (Transmembrane Pressure) reaches 280mmHg, treatment needs to be interrupted for longer than two hours or a significant adverse event occured.  The participant will be in the trial for a maximum of eight circuits."
      ],
      "locations": [
        "Australia"
      ],
      "enrollment": 100,
      "conditions": [
        "  Acute renal failure",
        "Renal and Urogenital - Kidney disease",
        "Acute renal failure"
      ],
      "Start Date": "2008-09-16",
      "Max Phase": null
    },
    {
      "id": "NCT00077493",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "MedImmune LLC"
      ],
      "interventions": [
        "Procedure: immunotoxin therapy",
        "Procedure: monoclonal antibody therapy",
        "Drug: BL22 immunotoxin",
        "Procedure: antibody-drug conjugate therapy"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 95,
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "Start Date": "2004-10-02",
      "Max Phase": "1"
    },
    {
      "id": "NCT00051584",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seattle Genetics, Inc."
      ],
      "interventions": [
        "Drug: Gemzar (Gemcitabine)",
        "Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate)"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": 60,
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "Start Date": "2003-01-13",
      "Max Phase": "2"
    },
    {
      "id": "NCT00028483",
      "phases": [
        "Phase 2"
      ],
      "sponsor": [
        "Seattle Genetics, Inc."
      ],
      "interventions": [
        "Drug: docetaxel",
        "Drug: cBR96-doxorubicin immunoconjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": null,
      "conditions": [
        "Breast Cancer"
      ],
      "Start Date": "2002-04-01",
      "Max Phase": "2"
    },
    {
      "id": "ISRCTN17161961",
      "phases": [],
      "sponsor": [
        "Cardiff University (UK)"
      ],
      "interventions": [
        "1. (R1) Patients with acute promyelocytic leukemia (APL) will be randomised to receive oral retinoic acid together with either MRC H-DAT chemotherapy or the Spanish Intermittent Idarubicin. Following confirmation of remission, patients will continue with the MRC (DAT:MACE:MIDAC) or Spanish chemotherapy but will be randomised to receive CMA-676/Myelotarg (Immunoconjugate) on day 1 of course 3 or not. (Patients will be monitered molecularly by Reverse Transcription (RT) and real time Polymerase Chain Reaction (PCR) to predict relapse. Three quality of life assessments will be made at 3, 6 and 9 months and resource use information will be collected for cost benefit analysis.)                 2. (R2) Non-APL patients will be randomised to receive induction cources 1 and 2 with H-Dat (Daunorbicin:Ara-C, Thioguanine) or FLA_G IDA (Fludarabine, Ara C, G-CSF, Idarubicin) and to receive CMA-676 (Myelotarg) on day 1 of course 1 or not.                 3. Following the first course of chemotherapy the risk profile of each patient will be determined (based on cytogenetics, blast clearance after course 1). Good risk patients (15%) will leave AML15 and will enter the MRC AML High Risk Trial.                 4. (R3)(R4) Patients who have completed course 2 and are allocated to the chemotherapy comparisons will be randomised to receive CMA-676 (Myelotarg) on day 1 of course 3.                 5. (R5) All patients allocated to allogenic transplant up to 35 years will receive standard conditioning (Cyclophosphamide/TBI) with stem cells obtained from peripheral blood or bone marrow as course 3. For patients 36-50 investigators may choose a conventional transplant or a non-ablative transplant. Patients over 50 years will receive a non-ablative transplant. The non-ablative"
      ],
      "locations": [
        "United Kingdom",
        "Wales"
      ],
      "enrollment": 3000,
      "conditions": [
        "Leukaemia  Cancer  Leukaemia"
      ],
      "Start Date": "2001-02-05",
      "Max Phase": null
    },
    {
      "id": "NCT00004858",
      "phases": [
        "Phase 1"
      ],
      "sponsor": [
        "Parker Hughes Cancer Center"
      ],
      "interventions": [
        "Biological: B43-genistein immunoconjugate"
      ],
      "locations": [
        "United States"
      ],
      "enrollment": null,
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "Start Date": "2000-07-03",
      "Max Phase": "1"
    },
    {
      "id": "NCT00002163",
      "phases": [
        "Phase 3"
      ],
      "sponsor": [
        "Glaxo Wellcome"
      ],
      "interventions": [
        "Drug: Abacavir sulfate"
      ],
      "locations": [
        "Canada",
        "United States"
      ],
      "enrollment": null,
      "conditions": [
        "HIV Infections",
        "AIDS Dementia Complex"
      ],
      "Start Date": "1999-02-11",
      "Max Phase": "3"
    }
  ]
}